0	Treatment	_	_	B-Claim
1	with	_	_	I-Claim
2	cisplatin-based	_	_	I-Claim
3	chemotherapy	_	_	I-Claim
4	provides	_	_	I-Claim
5	a	_	_	I-Claim
6	modest	_	_	I-Claim
7	survival	_	_	I-Claim
8	advantage	_	_	I-Claim
9	over	_	_	I-Claim
10	supportive	_	_	I-Claim
11	care	_	_	I-Claim
12	alone	_	_	I-Claim
13	in	_	_	I-Claim
14	advanced	_	_	I-Claim
15	non-small-cell	_	_	I-Claim
16	lung	_	_	I-Claim
17	cancer	_	_	I-Claim
18	(	_	_	I-Claim
19	NSCLC	_	_	I-Claim
20	)	_	_	I-Claim
21	.	_	_	I-Claim

22	To	_	_	O
23	determine	_	_	O
24	whether	_	_	O
25	a	_	_	O
26	new	_	_	O
27	agent	_	_	O
28	,	_	_	O
29	paclitaxel	_	_	O
30	,	_	_	O
31	would	_	_	O
32	further	_	_	O
33	improve	_	_	O
34	survival	_	_	O
35	in	_	_	O
36	NSCLC	_	_	O
37	,	_	_	O
38	the	_	_	O
39	Eastern	_	_	O
40	Cooperative	_	_	O
41	Oncology	_	_	O
42	Group	_	_	O
43	conducted	_	_	O
44	a	_	_	O
45	randomized	_	_	O
46	trial	_	_	O
47	comparing	_	_	O
48	paclitaxel	_	_	O
49	plus	_	_	O
50	cisplatin	_	_	O
51	to	_	_	O
52	a	_	_	O
53	standard	_	_	O
54	chemotherapy	_	_	O
55	regimen	_	_	O
56	consisting	_	_	O
57	of	_	_	O
58	cisplatin	_	_	O
59	and	_	_	O
60	etoposide	_	_	O
61	.	_	_	O

62	The	_	_	O
63	study	_	_	O
64	was	_	_	O
65	carried	_	_	O
66	out	_	_	O
67	by	_	_	O
68	a	_	_	O
69	multi-institutional	_	_	O
70	cooperative	_	_	O
71	group	_	_	O
72	in	_	_	O
73	chemotherapy-naive	_	_	O
74	stage	_	_	O
75	IIIB	_	_	O
76	to	_	_	O
77	IV	_	_	O
78	NSCLC	_	_	O
79	patients	_	_	O
80	randomized	_	_	O
81	to	_	_	O
82	receive	_	_	O
83	paclitaxel	_	_	O
84	plus	_	_	O
85	cisplatin	_	_	O
86	or	_	_	O
87	etoposide	_	_	O
88	plus	_	_	O
89	cisplatin	_	_	O
90	.	_	_	O

91	Paclitaxel	_	_	O
92	was	_	_	O
93	administered	_	_	O
94	at	_	_	O
95	two	_	_	O
96	different	_	_	O
97	dose	_	_	O
98	levels	_	_	O
99	(	_	_	O
100	135	_	_	O
101	mg/m	_	_	O
102	(	_	_	O
103	2	_	_	O
104	)	_	_	O
105	and	_	_	O
106	250	_	_	O
107	mg/m	_	_	O
108	(	_	_	O
109	2	_	_	O
110	)	_	_	O
111	)	_	_	O
112	,	_	_	O
113	and	_	_	O
114	etoposide	_	_	O
115	was	_	_	O
116	given	_	_	O
117	at	_	_	O
118	a	_	_	O
119	dose	_	_	O
120	of	_	_	O
121	100	_	_	O
122	mg/m	_	_	O
123	(	_	_	O
124	2	_	_	O
125	)	_	_	O
126	daily	_	_	O
127	on	_	_	O
128	days	_	_	O
129	1	_	_	O
130	to	_	_	O
131	3	_	_	O
132	.	_	_	O

133	Each	_	_	O
134	regimen	_	_	O
135	was	_	_	O
136	repeated	_	_	O
137	every	_	_	O
138	21	_	_	O
139	days	_	_	O
140	and	_	_	O
141	each	_	_	O
142	included	_	_	O
143	cisplatin	_	_	O
144	(	_	_	O
145	75	_	_	O
146	mg/m	_	_	O
147	(	_	_	O
148	2	_	_	O
149	)	_	_	O
150	)	_	_	O
151	.	_	_	O

152	The	_	_	O
153	characteristics	_	_	O
154	of	_	_	O
155	the	_	_	O
156	599	_	_	O
157	patients	_	_	O
158	were	_	_	O
159	well-balanced	_	_	O
160	across	_	_	O
161	the	_	_	O
162	three	_	_	O
163	treatment	_	_	O
164	groups	_	_	O
165	.	_	_	O

166	Superior	_	_	B-Premise
167	survival	_	_	I-Premise
168	was	_	_	I-Premise
169	observed	_	_	I-Premise
170	with	_	_	I-Premise
171	the	_	_	I-Premise
172	combined	_	_	I-Premise
173	paclitaxel	_	_	I-Premise
174	regimens	_	_	I-Premise
175	(	_	_	I-Premise
176	median	_	_	I-Premise
177	survival	_	_	I-Premise
178	time	_	_	I-Premise
179	,	_	_	I-Premise
180	9.9	_	_	I-Premise
181	months	_	_	I-Premise
182	;	_	_	I-Premise
183	1-year	_	_	I-Premise
184	survival	_	_	I-Premise
185	rate	_	_	I-Premise
186	,	_	_	I-Premise
187	38.9	_	_	I-Premise
188	%	_	_	I-Premise
189	)	_	_	I-Premise
190	compared	_	_	I-Premise
191	with	_	_	I-Premise
192	etoposide	_	_	I-Premise
193	plus	_	_	I-Premise
194	cisplatin	_	_	I-Premise
195	(	_	_	I-Premise
196	median	_	_	I-Premise
197	survival	_	_	I-Premise
198	time	_	_	I-Premise
199	,	_	_	I-Premise
200	7.6	_	_	I-Premise
201	months	_	_	I-Premise
202	;	_	_	I-Premise
203	1-year	_	_	I-Premise
204	survival	_	_	I-Premise
205	rate	_	_	I-Premise
206	,	_	_	I-Premise
207	31.8	_	_	I-Premise
208	%	_	_	I-Premise
209	;	_	_	I-Premise
210	P	_	_	I-Premise
211	=	_	_	I-Premise
212	.	_	_	I-Premise

213	048	_	_	I-Premise
214	)	_	_	I-Premise
215	.	_	_	I-Premise

216	Comparing	_	_	B-Premise
217	survival	_	_	I-Premise
218	for	_	_	I-Premise
219	the	_	_	I-Premise
220	two	_	_	I-Premise
221	dose	_	_	I-Premise
222	levels	_	_	I-Premise
223	of	_	_	I-Premise
224	paclitaxel	_	_	I-Premise
225	revealed	_	_	I-Premise
226	no	_	_	I-Premise
227	significant	_	_	I-Premise
228	difference	_	_	I-Premise
229	.	_	_	I-Premise

230	The	_	_	B-Premise
231	median	_	_	I-Premise
232	survival	_	_	I-Premise
233	duration	_	_	I-Premise
234	for	_	_	I-Premise
235	the	_	_	I-Premise
236	stage	_	_	I-Premise
237	IIIB	_	_	I-Premise
238	subgroup	_	_	I-Premise
239	was	_	_	I-Premise
240	7.9	_	_	I-Premise
241	months	_	_	I-Premise
242	for	_	_	I-Premise
243	etoposide	_	_	I-Premise
244	plus	_	_	I-Premise
245	cisplatin	_	_	I-Premise
246	patients	_	_	I-Premise
247	versus	_	_	I-Premise
248	13.1	_	_	I-Premise
249	months	_	_	I-Premise
250	for	_	_	I-Premise
251	all	_	_	I-Premise
252	paclitaxel	_	_	I-Premise
253	patients	_	_	I-Premise
254	(	_	_	I-Premise
255	P	_	_	I-Premise
256	=.152	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	For	_	_	B-Premise
260	the	_	_	I-Premise
261	stage	_	_	I-Premise
262	IV	_	_	I-Premise
263	subgroup	_	_	I-Premise
264	,	_	_	I-Premise
265	the	_	_	I-Premise
266	median	_	_	I-Premise
267	survival	_	_	I-Premise
268	time	_	_	I-Premise
269	for	_	_	I-Premise
270	etoposide	_	_	I-Premise
271	plus	_	_	I-Premise
272	cisplatin	_	_	I-Premise
273	was	_	_	I-Premise
274	7.6	_	_	I-Premise
275	months	_	_	I-Premise
276	compared	_	_	I-Premise
277	with	_	_	I-Premise
278	8.9	_	_	I-Premise
279	months	_	_	I-Premise
280	for	_	_	I-Premise
281	paclitaxel	_	_	I-Premise
282	(	_	_	I-Premise
283	P	_	_	I-Premise
284	=.246	_	_	I-Premise
285	)	_	_	I-Premise
286	.	_	_	I-Premise

287	With	_	_	B-Premise
288	the	_	_	I-Premise
289	exceptions	_	_	I-Premise
290	of	_	_	I-Premise
291	increased	_	_	I-Premise
292	granulocytopenia	_	_	I-Premise
293	on	_	_	I-Premise
294	the	_	_	I-Premise
295	low-dose	_	_	I-Premise
296	paclitaxel	_	_	I-Premise
297	regimen	_	_	I-Premise
298	and	_	_	I-Premise
299	increased	_	_	I-Premise
300	myalgias	_	_	I-Premise
301	,	_	_	I-Premise
302	neurotoxicity	_	_	I-Premise
303	,	_	_	I-Premise
304	and	_	_	I-Premise
305	,	_	_	I-Premise
306	possibly	_	_	I-Premise
307	,	_	_	I-Premise
308	increased	_	_	I-Premise
309	treatment-related	_	_	I-Premise
310	cardiac	_	_	I-Premise
311	events	_	_	I-Premise
312	with	_	_	I-Premise
313	high-dose	_	_	I-Premise
314	paclitaxel	_	_	I-Premise
315	,	_	_	I-Premise
316	toxicity	_	_	I-Premise
317	was	_	_	I-Premise
318	similar	_	_	I-Premise
319	across	_	_	I-Premise
320	all	_	_	I-Premise
321	three	_	_	I-Premise
322	arms	_	_	I-Premise
323	.	_	_	I-Premise

324	Quality	_	_	B-Premise
325	of	_	_	I-Premise
326	life	_	_	I-Premise
327	(	_	_	I-Premise
328	QOL	_	_	I-Premise
329	)	_	_	I-Premise
330	declined	_	_	I-Premise
331	significantly	_	_	I-Premise
332	over	_	_	I-Premise
333	the	_	_	I-Premise
334	6	_	_	I-Premise
335	months	_	_	I-Premise
336	.	_	_	I-Premise

337	However	_	_	O
338	,	_	_	O
339	QOL	_	_	B-Claim
340	scores	_	_	I-Claim
341	were	_	_	I-Claim
342	not	_	_	I-Claim
343	significantly	_	_	I-Claim
344	different	_	_	I-Claim
345	among	_	_	I-Claim
346	the	_	_	I-Claim
347	regimens	_	_	I-Claim
348	.	_	_	I-Claim

349	As	_	_	O
350	a	_	_	O
351	result	_	_	O
352	of	_	_	O
353	these	_	_	O
354	observations	_	_	O
355	,	_	_	O
356	paclitaxel	_	_	B-Claim
357	(	_	_	I-Claim
358	135	_	_	I-Claim
359	mg/m	_	_	I-Claim
360	(	_	_	I-Claim
361	2	_	_	I-Claim
362	)	_	_	I-Claim
363	)	_	_	I-Claim
364	combined	_	_	I-Claim
365	with	_	_	I-Claim
366	cisplatin	_	_	I-Claim
367	has	_	_	I-Claim
368	replaced	_	_	I-Claim
369	etoposide	_	_	I-Claim
370	plus	_	_	I-Claim
371	cisplatin	_	_	I-Claim
372	as	_	_	I-Claim
373	the	_	_	I-Claim
374	reference	_	_	I-Claim
375	regimen	_	_	I-Claim
376	in	_	_	I-Claim
377	our	_	_	I-Claim
378	recently	_	_	I-Claim
379	completed	_	_	I-Claim
380	phase	_	_	I-Claim
381	III	_	_	I-Claim
382	trial	_	_	I-Claim
383	.	_	_	I-Claim


0	Menopausal	_	_	B-Claim
1	symptoms	_	_	I-Claim
2	(	_	_	I-Claim
3	e.g.	_	_	I-Claim
4	,	_	_	I-Claim
5	hot	_	_	I-Claim
6	flashes	_	_	I-Claim
7	,	_	_	I-Claim
8	vaginal	_	_	I-Claim
9	dryness	_	_	I-Claim
10	,	_	_	I-Claim
11	and	_	_	I-Claim
12	stress	_	_	I-Claim
13	urinary	_	_	I-Claim
14	incontinence	_	_	I-Claim
15	)	_	_	I-Claim
16	are	_	_	I-Claim
17	very	_	_	I-Claim
18	common	_	_	I-Claim
19	in	_	_	I-Claim
20	breast	_	_	I-Claim
21	cancer	_	_	I-Claim
22	survivors	_	_	I-Claim
23	and	_	_	I-Claim
24	can	_	_	I-Claim
25	not	_	_	I-Claim
26	be	_	_	I-Claim
27	managed	_	_	I-Claim
28	with	_	_	I-Claim
29	standard	_	_	I-Claim
30	estrogen	_	_	I-Claim
31	replacement	_	_	I-Claim
32	therapy	_	_	I-Claim
33	(	_	_	I-Claim
34	ERT	_	_	I-Claim
35	)	_	_	I-Claim
36	in	_	_	I-Claim
37	these	_	_	I-Claim
38	patients	_	_	I-Claim
39	.	_	_	I-Claim

40	The	_	_	O
41	purpose	_	_	O
42	of	_	_	O
43	this	_	_	O
44	study	_	_	O
45	was	_	_	O
46	to	_	_	O
47	test	_	_	O
48	the	_	_	O
49	efficacy	_	_	O
50	of	_	_	O
51	a	_	_	O
52	comprehensive	_	_	O
53	menopausal	_	_	O
54	assessment	_	_	O
55	(	_	_	O
56	CMA	_	_	O
57	)	_	_	O
58	intervention	_	_	O
59	program	_	_	O
60	in	_	_	O
61	achieving	_	_	O
62	relief	_	_	O
63	of	_	_	O
64	symptoms	_	_	O
65	,	_	_	O
66	the	_	_	O
67	improvement	_	_	O
68	in	_	_	O
69	quality	_	_	O
70	of	_	_	O
71	life	_	_	O
72	(	_	_	O
73	QOL	_	_	O
74	)	_	_	O
75	,	_	_	O
76	and	_	_	O
77	sexual	_	_	O
78	functioning	_	_	O
79	in	_	_	O
80	breast	_	_	O
81	cancer	_	_	O
82	survivors	_	_	O
83	.	_	_	O

84	Using	_	_	O
85	a	_	_	O
86	two-group	_	_	O
87	,	_	_	O
88	randomized	_	_	O
89	controlled	_	_	O
90	design	_	_	O
91	,	_	_	O
92	we	_	_	O
93	assigned	_	_	O
94	76	_	_	O
95	postmenopausal	_	_	O
96	breast	_	_	O
97	cancer	_	_	O
98	survivors	_	_	O
99	with	_	_	O
100	at	_	_	O
101	least	_	_	O
102	one	_	_	O
103	severe	_	_	O
104	target	_	_	O
105	symptom	_	_	O
106	either	_	_	O
107	to	_	_	O
108	the	_	_	O
109	intervention	_	_	O
110	group	_	_	O
111	or	_	_	O
112	to	_	_	O
113	a	_	_	O
114	usual-care	_	_	O
115	group	_	_	O
116	.	_	_	O

117	Seventy-two	_	_	O
118	women	_	_	O
119	were	_	_	O
120	evaluable	_	_	O
121	at	_	_	O
122	the	_	_	O
123	end	_	_	O
124	of	_	_	O
125	the	_	_	O
126	study	_	_	O
127	period	_	_	O
128	.	_	_	O

129	The	_	_	O
130	CMA	_	_	O
131	intervention	_	_	O
132	,	_	_	O
133	delivered	_	_	O
134	by	_	_	O
135	a	_	_	O
136	nurse	_	_	O
137	practitioner	_	_	O
138	,	_	_	O
139	focused	_	_	O
140	on	_	_	O
141	symptom	_	_	O
142	assessment	_	_	O
143	,	_	_	O
144	education	_	_	O
145	,	_	_	O
146	counseling	_	_	O
147	and	_	_	O
148	,	_	_	O
149	as	_	_	O
150	appropriate	_	_	O
151	,	_	_	O
152	specific	_	_	O
153	pharmacologic	_	_	O
154	and	_	_	O
155	behavioral	_	_	O
156	interventions	_	_	O
157	for	_	_	O
158	each	_	_	O
159	of	_	_	O
160	the	_	_	O
161	three	_	_	O
162	target	_	_	O
163	symptoms	_	_	O
164	.	_	_	O

165	Psychosocial	_	_	O
166	symptoms	_	_	O
167	were	_	_	O
168	assessed	_	_	O
169	with	_	_	O
170	the	_	_	O
171	use	_	_	O
172	of	_	_	O
173	a	_	_	O
174	self-report	_	_	O
175	screening	_	_	O
176	instrument	_	_	O
177	,	_	_	O
178	and	_	_	O
179	distressed	_	_	O
180	women	_	_	O
181	were	_	_	O
182	referred	_	_	O
183	for	_	_	O
184	counseling	_	_	O
185	if	_	_	O
186	needed	_	_	O
187	.	_	_	O

188	The	_	_	O
189	intervention	_	_	O
190	took	_	_	O
191	place	_	_	O
192	over	_	_	O
193	a	_	_	O
194	4-month	_	_	O
195	period	_	_	O
196	.	_	_	O

197	Outcomes	_	_	O
198	measured	_	_	O
199	were	_	_	O
200	scores	_	_	O
201	on	_	_	O
202	a	_	_	O
203	composite	_	_	O
204	menopausal	_	_	O
205	symptom	_	_	O
206	scale	_	_	O
207	,	_	_	O
208	the	_	_	O
209	RAND	_	_	O
210	Short	_	_	O
211	Form	_	_	O
212	Health	_	_	O
213	Survey	_	_	O
214	Vitality	_	_	O
215	Scale	_	_	O
216	,	_	_	O
217	and	_	_	O
218	the	_	_	O
219	Cancer	_	_	O
220	Rehabilitation	_	_	O
221	Evaluation	_	_	O
222	System	_	_	O
223	(	_	_	O
224	CARES	_	_	O
225	)	_	_	O
226	Sexual	_	_	O
227	Functioning	_	_	O
228	Scale	_	_	O
229	at	_	_	O
230	baseline	_	_	O
231	and	_	_	O
232	at	_	_	O
233	4-month	_	_	O
234	follow-up	_	_	O
235	.	_	_	O

236	All	_	_	O
237	statistical	_	_	O
238	tests	_	_	O
239	were	_	_	O
240	two-sided	_	_	O
241	and	_	_	O
242	were	_	_	O
243	performed	_	_	O
244	at	_	_	O
245	the	_	_	O
246	alpha	_	_	O
247	=	_	_	O
248	.	_	_	O

249	05	_	_	O
250	significance	_	_	O
251	level	_	_	O
252	.	_	_	O

253	Patients	_	_	B-Premise
254	receiving	_	_	I-Premise
255	the	_	_	I-Premise
256	intervention	_	_	I-Premise
257	demonstrated	_	_	I-Premise
258	statistically	_	_	I-Premise
259	significant	_	_	I-Premise
260	improvement	_	_	I-Premise
261	(	_	_	I-Premise
262	P	_	_	I-Premise
263	=.0004	_	_	I-Premise
264	)	_	_	I-Premise
265	in	_	_	I-Premise
266	menopausal	_	_	I-Premise
267	symptoms	_	_	I-Premise
268	but	_	_	I-Premise
269	no	_	_	I-Premise
270	significant	_	_	I-Premise
271	change	_	_	I-Premise
272	in	_	_	I-Premise
273	vitality	_	_	I-Premise
274	(	_	_	I-Premise
275	P	_	_	I-Premise
276	=.77	_	_	I-Premise
277	)	_	_	I-Premise
278	.	_	_	I-Premise

279	Sexual	_	_	B-Premise
280	functioning	_	_	I-Premise
281	was	_	_	I-Premise
282	statistically	_	_	I-Premise
283	significantly	_	_	I-Premise
284	improved	_	_	I-Premise
285	(	_	_	I-Premise
286	P	_	_	I-Premise
287	=.04	_	_	I-Premise
288	)	_	_	I-Premise
289	in	_	_	I-Premise
290	the	_	_	I-Premise
291	treatment	_	_	I-Premise
292	group	_	_	I-Premise
293	compared	_	_	I-Premise
294	with	_	_	I-Premise
295	the	_	_	I-Premise
296	usual-care	_	_	I-Premise
297	group	_	_	I-Premise
298	.	_	_	I-Premise

299	A	_	_	B-Claim
300	clinical	_	_	I-Claim
301	assessment	_	_	I-Claim
302	and	_	_	I-Claim
303	intervention	_	_	I-Claim
304	program	_	_	I-Claim
305	for	_	_	I-Claim
306	menopausal	_	_	I-Claim
307	symptom	_	_	I-Claim
308	management	_	_	I-Claim
309	in	_	_	I-Claim
310	breast	_	_	I-Claim
311	cancer	_	_	I-Claim
312	survivors	_	_	I-Claim
313	is	_	_	I-Claim
314	feasible	_	_	I-Claim
315	and	_	_	I-Claim
316	acceptable	_	_	I-Claim
317	to	_	_	I-Claim
318	patients	_	_	I-Claim
319	,	_	_	I-Claim
320	leading	_	_	I-Claim
321	to	_	_	I-Claim
322	reduction	_	_	I-Claim
323	in	_	_	I-Claim
324	symptoms	_	_	I-Claim
325	and	_	_	I-Claim
326	improvement	_	_	I-Claim
327	in	_	_	I-Claim
328	sexual	_	_	I-Claim
329	functioning	_	_	I-Claim
330	.	_	_	I-Claim

331	Measurable	_	_	B-Claim
332	improvement	_	_	I-Claim
333	in	_	_	I-Claim
334	a	_	_	I-Claim
335	general	_	_	I-Claim
336	QOL	_	_	I-Claim
337	measure	_	_	I-Claim
338	was	_	_	I-Claim
339	not	_	_	I-Claim
340	demonstrated	_	_	I-Claim
341	.	_	_	I-Claim


0	A	_	_	O
1	randomized	_	_	O
2	phase	_	_	O
3	III	_	_	O
4	trial	_	_	O
5	was	_	_	O
6	conducted	_	_	O
7	to	_	_	O
8	determine	_	_	O
9	whether	_	_	O
10	combination	_	_	O
11	therapy	_	_	O
12	with	_	_	O
13	13-cis-retinoic	_	_	O
14	acid	_	_	O
15	(	_	_	O
16	13-CRA	_	_	O
17	)	_	_	O
18	plus	_	_	O
19	interferon	_	_	O
20	alfa-2a	_	_	O
21	(	_	_	O
22	IFNalpha2a	_	_	O
23	)	_	_	O
24	is	_	_	O
25	superior	_	_	O
26	to	_	_	O
27	IFNalpha2a	_	_	O
28	alone	_	_	O
29	in	_	_	O
30	patients	_	_	O
31	with	_	_	O
32	advanced	_	_	O
33	renal	_	_	O
34	cell	_	_	O
35	carcinoma	_	_	O
36	(	_	_	O
37	RCC	_	_	O
38	)	_	_	O
39	.	_	_	O

40	Two	_	_	O
41	hundred	_	_	O
42	eighty-four	_	_	O
43	patients	_	_	O
44	were	_	_	O
45	randomized	_	_	O
46	to	_	_	O
47	treatment	_	_	O
48	with	_	_	O
49	IFNalpha2a	_	_	O
50	plus	_	_	O
51	13-CRA	_	_	O
52	or	_	_	O
53	treatment	_	_	O
54	with	_	_	O
55	IFNalpha2a	_	_	O
56	alone	_	_	O
57	.	_	_	O

58	IFNalpha2a	_	_	O
59	was	_	_	O
60	given	_	_	O
61	daily	_	_	O
62	subcutaneously	_	_	O
63	,	_	_	O
64	starting	_	_	O
65	at	_	_	O
66	a	_	_	O
67	dose	_	_	O
68	of	_	_	O
69	3	_	_	O
70	million	_	_	O
71	units	_	_	O
72	(	_	_	O
73	MU	_	_	O
74	)	_	_	O
75	.	_	_	O

76	The	_	_	O
77	dose	_	_	O
78	was	_	_	O
79	escalated	_	_	O
80	every	_	_	O
81	7	_	_	O
82	days	_	_	O
83	from	_	_	O
84	3	_	_	O
85	to	_	_	O
86	9	_	_	O
87	MU	_	_	O
88	(	_	_	O
89	by	_	_	O
90	increments	_	_	O
91	of	_	_	O
92	3	_	_	O
93	MU	_	_	O
94	)	_	_	O
95	,	_	_	O
96	unless	_	_	O
97	>	_	_	O
98	/=	_	_	O
99	grade	_	_	O
100	2	_	_	O
101	toxicity	_	_	O
102	occurred	_	_	O
103	,	_	_	O
104	in	_	_	O
105	which	_	_	O
106	case	_	_	O
107	dose	_	_	O
108	escalation	_	_	O
109	was	_	_	O
110	stopped	_	_	O
111	.	_	_	O

112	Patients	_	_	O
113	randomized	_	_	O
114	to	_	_	O
115	combination	_	_	O
116	therapy	_	_	O
117	were	_	_	O
118	given	_	_	O
119	oral	_	_	O
120	13-CRA	_	_	O
121	1	_	_	O
122	mg/kg/d	_	_	O
123	plus	_	_	O
124	IFNalpha2a	_	_	O
125	.	_	_	O

126	Quality	_	_	O
127	of	_	_	O
128	life	_	_	O
129	(	_	_	O
130	QOL	_	_	O
131	)	_	_	O
132	was	_	_	O
133	assessed	_	_	O
134	.	_	_	O

135	Complete	_	_	B-Premise
136	or	_	_	I-Premise
137	partial	_	_	I-Premise
138	responses	_	_	I-Premise
139	were	_	_	I-Premise
140	achieved	_	_	I-Premise
141	by	_	_	I-Premise
142	12	_	_	I-Premise
143	%	_	_	I-Premise
144	of	_	_	I-Premise
145	patients	_	_	I-Premise
146	treated	_	_	I-Premise
147	with	_	_	I-Premise
148	IFNalpha2a	_	_	I-Premise
149	plus	_	_	I-Premise
150	13-CRA	_	_	I-Premise
151	and	_	_	I-Premise
152	6	_	_	I-Premise
153	%	_	_	I-Premise
154	of	_	_	I-Premise
155	patients	_	_	I-Premise
156	treated	_	_	I-Premise
157	with	_	_	I-Premise
158	IFNalpha2a	_	_	I-Premise
159	(	_	_	I-Premise
160	P	_	_	I-Premise
161	=.14	_	_	I-Premise
162	)	_	_	I-Premise
163	.	_	_	I-Premise

164	Median	_	_	B-Premise
165	duration	_	_	I-Premise
166	of	_	_	I-Premise
167	response	_	_	I-Premise
168	(	_	_	I-Premise
169	complete	_	_	I-Premise
170	and	_	_	I-Premise
171	partial	_	_	I-Premise
172	combined	_	_	I-Premise
173	)	_	_	I-Premise
174	in	_	_	I-Premise
175	the	_	_	I-Premise
176	group	_	_	I-Premise
177	treated	_	_	I-Premise
178	with	_	_	I-Premise
179	the	_	_	I-Premise
180	combination	_	_	I-Premise
181	was	_	_	I-Premise
182	33	_	_	I-Premise
183	months	_	_	I-Premise
184	(	_	_	I-Premise
185	range	_	_	I-Premise
186	,	_	_	I-Premise
187	9	_	_	I-Premise
188	to	_	_	I-Premise
189	50	_	_	I-Premise
190	months	_	_	I-Premise
191	)	_	_	I-Premise
192	,	_	_	I-Premise
193	versus	_	_	I-Premise
194	22	_	_	I-Premise
195	months	_	_	I-Premise
196	(	_	_	I-Premise
197	range	_	_	I-Premise
198	,	_	_	I-Premise
199	5	_	_	I-Premise
200	to	_	_	I-Premise
201	38	_	_	I-Premise
202	months	_	_	I-Premise
203	)	_	_	I-Premise
204	for	_	_	I-Premise
205	the	_	_	I-Premise
206	second	_	_	I-Premise
207	group	_	_	I-Premise
208	(	_	_	I-Premise
209	P	_	_	I-Premise
210	=.03	_	_	I-Premise
211	)	_	_	I-Premise
212	.	_	_	I-Premise

213	Nineteen	_	_	B-Premise
214	percent	_	_	I-Premise
215	of	_	_	I-Premise
216	patients	_	_	I-Premise
217	treated	_	_	I-Premise
218	with	_	_	I-Premise
219	IFNalpha2a	_	_	I-Premise
220	plus	_	_	I-Premise
221	13-CRA	_	_	I-Premise
222	were	_	_	I-Premise
223	progression-free	_	_	I-Premise
224	at	_	_	I-Premise
225	24	_	_	I-Premise
226	months	_	_	I-Premise
227	,	_	_	I-Premise
228	compared	_	_	I-Premise
229	with	_	_	I-Premise
230	10	_	_	I-Premise
231	%	_	_	I-Premise
232	of	_	_	I-Premise
233	patients	_	_	I-Premise
234	treated	_	_	I-Premise
235	with	_	_	I-Premise
236	IFNalpha2a	_	_	I-Premise
237	alone	_	_	I-Premise
238	(	_	_	I-Premise
239	P	_	_	I-Premise
240	=.05	_	_	I-Premise
241	)	_	_	I-Premise
242	.	_	_	I-Premise

243	Median	_	_	B-Premise
244	survival	_	_	I-Premise
245	time	_	_	I-Premise
246	for	_	_	I-Premise
247	all	_	_	I-Premise
248	patients	_	_	I-Premise
249	was	_	_	I-Premise
250	15	_	_	I-Premise
251	months	_	_	I-Premise
252	,	_	_	I-Premise
253	with	_	_	I-Premise
254	no	_	_	I-Premise
255	difference	_	_	I-Premise
256	in	_	_	I-Premise
257	survival	_	_	I-Premise
258	between	_	_	I-Premise
259	the	_	_	I-Premise
260	two	_	_	I-Premise
261	treatment	_	_	I-Premise
262	arms	_	_	I-Premise
263	(	_	_	I-Premise
264	P	_	_	I-Premise
265	=.26	_	_	I-Premise
266	)	_	_	I-Premise
267	.	_	_	I-Premise

268	QOL	_	_	B-Premise
269	decreased	_	_	I-Premise
270	during	_	_	I-Premise
271	the	_	_	I-Premise
272	first	_	_	I-Premise
273	8	_	_	I-Premise
274	weeks	_	_	I-Premise
275	of	_	_	I-Premise
276	treatment	_	_	I-Premise
277	,	_	_	I-Premise
278	and	_	_	I-Premise
279	a	_	_	I-Premise
280	partial	_	_	I-Premise
281	recovery	_	_	I-Premise
282	followed	_	_	I-Premise
283	.	_	_	I-Premise

284	Lower	_	_	B-Premise
285	scores	_	_	I-Premise
286	were	_	_	I-Premise
287	associated	_	_	I-Premise
288	with	_	_	I-Premise
289	the	_	_	I-Premise
290	combination	_	_	I-Premise
291	therapy	_	_	I-Premise
292	.	_	_	I-Premise

293	Response	_	_	B-Claim
294	proportion	_	_	I-Claim
295	and	_	_	I-Claim
296	survival	_	_	I-Claim
297	did	_	_	I-Claim
298	not	_	_	I-Claim
299	improve	_	_	I-Claim
300	significantly	_	_	I-Claim
301	with	_	_	I-Claim
302	the	_	_	I-Claim
303	addition	_	_	I-Claim
304	of	_	_	I-Claim
305	13-CRA	_	_	I-Claim
306	to	_	_	I-Claim
307	IFNalpha2a	_	_	I-Claim
308	therapy	_	_	I-Claim
309	in	_	_	I-Claim
310	patients	_	_	I-Claim
311	with	_	_	I-Claim
312	advanced	_	_	I-Claim
313	RCC	_	_	I-Claim
314	.	_	_	I-Claim

315	13-CRA	_	_	B-Claim
316	may	_	_	I-Claim
317	lengthen	_	_	I-Claim
318	response	_	_	I-Claim
319	to	_	_	I-Claim
320	IFNalpha2a	_	_	I-Claim
321	therapy	_	_	I-Claim
322	in	_	_	I-Claim
323	patients	_	_	I-Claim
324	with	_	_	I-Claim
325	IFNalpha2a-sensitive	_	_	I-Claim
326	tumors	_	_	I-Claim
327	.	_	_	I-Claim

328	Treatment	_	_	B-Claim
329	,	_	_	I-Claim
330	particularly	_	_	I-Claim
331	the	_	_	I-Claim
332	combination	_	_	I-Claim
333	therapy	_	_	I-Claim
334	,	_	_	I-Claim
335	was	_	_	I-Claim
336	associated	_	_	I-Claim
337	with	_	_	I-Claim
338	a	_	_	I-Claim
339	decrease	_	_	I-Claim
340	in	_	_	I-Claim
341	QOL	_	_	I-Claim
342	.	_	_	I-Claim


0	In	_	_	B-Claim
1	the	_	_	I-Claim
2	context	_	_	I-Claim
3	of	_	_	I-Claim
4	chronic	_	_	I-Claim
5	physical	_	_	I-Claim
6	illness	_	_	I-Claim
7	,	_	_	I-Claim
8	such	_	_	I-Claim
9	as	_	_	I-Claim
10	breast	_	_	I-Claim
11	cancer	_	_	I-Claim
12	,	_	_	I-Claim
13	depression	_	_	I-Claim
14	is	_	_	I-Claim
15	associated	_	_	I-Claim
16	with	_	_	I-Claim
17	increased	_	_	I-Claim
18	morbidity	_	_	I-Claim
19	,	_	_	I-Claim
20	longer	_	_	I-Claim
21	periods	_	_	I-Claim
22	of	_	_	I-Claim
23	hospitalization	_	_	I-Claim
24	,	_	_	I-Claim
25	and	_	_	I-Claim
26	greater	_	_	I-Claim
27	overall	_	_	I-Claim
28	disability	_	_	I-Claim
29	.	_	_	I-Claim

30	Prompt	_	_	B-Claim
31	diagnosis	_	_	I-Claim
32	and	_	_	I-Claim
33	effective	_	_	I-Claim
34	treatment	_	_	I-Claim
35	is	_	_	I-Claim
36	,	_	_	I-Claim
37	therefore	_	_	I-Claim
38	,	_	_	I-Claim
39	essential	_	_	I-Claim
40	.	_	_	I-Claim

41	Several	_	_	O
42	small	_	_	O
43	studies	_	_	O
44	have	_	_	O
45	established	_	_	O
46	the	_	_	O
47	efficacy	_	_	O
48	of	_	_	O
49	tricyclic	_	_	O
50	antidepressants	_	_	O
51	(	_	_	O
52	TCAs	_	_	O
53	)	_	_	O
54	in	_	_	O
55	this	_	_	O
56	setting	_	_	O
57	,	_	_	O
58	and	_	_	O
59	the	_	_	O
60	selective	_	_	O
61	serotonin	_	_	O
62	reuptake	_	_	O
63	inhibitors	_	_	O
64	(	_	_	O
65	SSRIs	_	_	O
66	)	_	_	O
67	would	_	_	O
68	appear	_	_	O
69	to	_	_	O
70	be	_	_	O
71	an	_	_	O
72	alternative	_	_	O
73	therapeutic	_	_	O
74	option	_	_	O
75	because	_	_	O
76	of	_	_	O
77	their	_	_	O
78	established	_	_	O
79	efficacy	_	_	O
80	and	_	_	O
81	better	_	_	O
82	tolerability	_	_	O
83	profile	_	_	O
84	.	_	_	O

85	This	_	_	O
86	was	_	_	O
87	a	_	_	O
88	multicenter	_	_	O
89	.	_	_	O

90	double-blind	_	_	O
91	,	_	_	O
92	parallel-group	_	_	O
93	study	_	_	O
94	in	_	_	O
95	which	_	_	O
96	179	_	_	O
97	women	_	_	O
98	with	_	_	O
99	breast	_	_	O
100	cancer	_	_	O
101	were	_	_	O
102	randomized	_	_	O
103	to	_	_	O
104	treatment	_	_	O
105	with	_	_	O
106	either	_	_	O
107	the	_	_	O
108	SSRI	_	_	O
109	paroxetine	_	_	O
110	(	_	_	O
111	20-40	_	_	O
112	mg/day	_	_	O
113	)	_	_	O
114	,	_	_	O
115	or	_	_	O
116	the	_	_	O
117	TCA	_	_	O
118	,	_	_	O
119	amitriptyline	_	_	O
120	(	_	_	O
121	75-150	_	_	O
122	mg/day	_	_	O
123	)	_	_	O
124	.	_	_	O

125	After	_	_	B-Premise
126	8-weeks	_	_	I-Premise
127	treatment	_	_	I-Premise
128	,	_	_	I-Premise
129	depressive	_	_	I-Premise
130	symptomatology	_	_	I-Premise
131	had	_	_	I-Premise
132	improved	_	_	I-Premise
133	markedly	_	_	I-Premise
134	and	_	_	I-Premise
135	to	_	_	I-Premise
136	a	_	_	I-Premise
137	similar	_	_	I-Premise
138	extent	_	_	I-Premise
139	in	_	_	I-Premise
140	both	_	_	I-Premise
141	groups	_	_	I-Premise
142	on	_	_	I-Premise
143	the	_	_	I-Premise
144	Montgomery	_	_	I-Premise
145	Asberg	_	_	I-Premise
146	Depression	_	_	I-Premise
147	Rating	_	_	I-Premise
148	Scale	_	_	I-Premise
149	.	_	_	I-Premise

150	Clinical	_	_	B-Premise
151	global	_	_	I-Premise
152	impression	_	_	I-Premise
153	(	_	_	I-Premise
154	CGI	_	_	I-Premise
155	)	_	_	I-Premise
156	Global	_	_	I-Premise
157	improvement	_	_	I-Premise
158	and	_	_	I-Premise
159	Patient	_	_	I-Premise
160	global	_	_	I-Premise
161	evaluation	_	_	I-Premise
162	scales	_	_	I-Premise
163	indicated	_	_	I-Premise
164	that	_	_	I-Premise
165	patients	_	_	I-Premise
166	were	_	_	I-Premise
167	minimally	_	_	I-Premise
168	to	_	_	I-Premise
169	much	_	_	I-Premise
170	improved	_	_	I-Premise
171	at	_	_	I-Premise
172	study	_	_	I-Premise
173	endpoint	_	_	I-Premise
174	:	_	_	I-Premise
175	a	_	_	I-Premise
176	change	_	_	I-Premise
177	from	_	_	I-Premise
178	moderately/mildly	_	_	I-Premise
179	ill	_	_	I-Premise
180	to	_	_	I-Premise
181	borderline	_	_	I-Premise
182	ill	_	_	I-Premise
183	on	_	_	I-Premise
184	the	_	_	I-Premise
185	CGI	_	_	I-Premise
186	severity	_	_	I-Premise
187	of	_	_	I-Premise
188	Illness	_	_	I-Premise
189	scale	_	_	I-Premise
190	.	_	_	I-Premise

191	A	_	_	B-Claim
192	steady	_	_	I-Claim
193	improvement	_	_	I-Claim
194	in	_	_	I-Claim
195	quality	_	_	I-Claim
196	of	_	_	I-Claim
197	life	_	_	I-Claim
198	was	_	_	I-Claim
199	also	_	_	I-Claim
200	observed	_	_	I-Claim
201	in	_	_	I-Claim
202	both	_	_	I-Claim
203	groups	_	_	I-Claim
204	.	_	_	I-Claim

205	There	_	_	B-Premise
206	were	_	_	I-Premise
207	no	_	_	I-Premise
208	clinically	_	_	I-Premise
209	significant	_	_	I-Premise
210	differences	_	_	I-Premise
211	between	_	_	I-Premise
212	the	_	_	I-Premise
213	groups	_	_	I-Premise
214	.	_	_	I-Premise

215	In	_	_	B-Premise
216	total	_	_	I-Premise
217	,	_	_	I-Premise
218	47	_	_	I-Premise
219	(	_	_	I-Premise
220	53.4	_	_	I-Premise
221	%	_	_	I-Premise
222	)	_	_	I-Premise
223	patients	_	_	I-Premise
224	in	_	_	I-Premise
225	the	_	_	I-Premise
226	paroxetine	_	_	I-Premise
227	group	_	_	I-Premise
228	and	_	_	I-Premise
229	53	_	_	I-Premise
230	(	_	_	I-Premise
231	59.6	_	_	I-Premise
232	%	_	_	I-Premise
233	)	_	_	I-Premise
234	patients	_	_	I-Premise
235	in	_	_	I-Premise
236	the	_	_	I-Premise
237	amitriptyline	_	_	I-Premise
238	group	_	_	I-Premise
239	had	_	_	I-Premise
240	adverse	_	_	I-Premise
241	experiences	_	_	I-Premise
242	,	_	_	I-Premise
243	the	_	_	I-Premise
244	most	_	_	I-Premise
245	common	_	_	I-Premise
246	of	_	_	I-Premise
247	which	_	_	I-Premise
248	were	_	_	I-Premise
249	the	_	_	I-Premise
250	well-recognized	_	_	I-Premise
251	side-effects	_	_	I-Premise
252	of	_	_	I-Premise
253	the	_	_	I-Premise
254	antidepressant	_	_	I-Premise
255	medications	_	_	I-Premise
256	or	_	_	I-Premise
257	chemotherapy	_	_	I-Premise
258	.	_	_	I-Premise

259	Anticholinergic	_	_	B-Premise
260	effects	_	_	I-Premise
261	were	_	_	I-Premise
262	almost	_	_	I-Premise
263	twice	_	_	I-Premise
264	as	_	_	I-Premise
265	frequent	_	_	I-Premise
266	in	_	_	I-Premise
267	the	_	_	I-Premise
268	amitriptyline	_	_	I-Premise
269	group	_	_	I-Premise
270	(	_	_	I-Premise
271	19.1	_	_	I-Premise
272	%	_	_	I-Premise
273	)	_	_	I-Premise
274	compared	_	_	I-Premise
275	with	_	_	I-Premise
276	paroxetine	_	_	I-Premise
277	(	_	_	I-Premise
278	11.4	_	_	I-Premise
279	%	_	_	I-Premise
280	)	_	_	I-Premise
281	.	_	_	I-Premise

282	This	_	_	O
283	study	_	_	O
284	has	_	_	O
285	demonstrated	_	_	O
286	that	_	_	O
287	paroxetine	_	_	B-Claim
288	is	_	_	I-Claim
289	a	_	_	I-Claim
290	suitable	_	_	I-Claim
291	alternative	_	_	I-Claim
292	to	_	_	I-Claim
293	amitriptyline	_	_	I-Claim
294	for	_	_	I-Claim
295	the	_	_	I-Claim
296	treatment	_	_	I-Claim
297	of	_	_	I-Claim
298	depression	_	_	I-Claim
299	in	_	_	I-Claim
300	patients	_	_	I-Claim
301	with	_	_	I-Claim
302	breast	_	_	I-Claim
303	cancer	_	_	I-Claim
304	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	the	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	assess	_	_	O
8	response	_	_	O
9	rate	_	_	O
10	,	_	_	O
11	clinical	_	_	O
12	outcome	_	_	O
13	,	_	_	O
14	organ/function	_	_	O
15	preservation	_	_	O
16	and	_	_	O
17	toxicity	_	_	O
18	in	_	_	O
19	head	_	_	O
20	and	_	_	O
21	neck	_	_	O
22	cancer	_	_	O
23	patients	_	_	O
24	treated	_	_	O
25	with	_	_	O
26	induction	_	_	O
27	chemotherapy	_	_	O
28	followed	_	_	O
29	by	_	_	O
30	concomitant	_	_	O
31	chemoradiotherapy	_	_	O
32	and	_	_	O
33	,	_	_	O
34	when	_	_	O
35	necessary	_	_	O
36	,	_	_	O
37	limited	_	_	O
38	surgery	_	_	O
39	.	_	_	O

40	The	_	_	O
41	study	_	_	O
42	design	_	_	O
43	was	_	_	O
44	a	_	_	O
45	phase	_	_	O
46	II	_	_	O
47	non-randomized	_	_	O
48	trial	_	_	O
49	in	_	_	O
50	hospitalized	_	_	O
51	patients	_	_	O
52	setting	_	_	O
53	.	_	_	O

54	The	_	_	O
55	treatment	_	_	O
56	plan	_	_	O
57	consisted	_	_	O
58	of	_	_	O
59	3	_	_	O
60	cycles	_	_	O
61	of	_	_	O
62	induction	_	_	O
63	chemotherapy	_	_	O
64	with	_	_	O
65	cisplatin	_	_	O
66	,	_	_	O
67	fluorouracil	_	_	O
68	(	_	_	O
69	5-FU	_	_	O
70	)	_	_	O
71	,	_	_	O
72	l-leucovorin	_	_	O
73	and	_	_	O
74	interferon	_	_	O
75	alpha2b	_	_	O
76	(	_	_	O
77	PFL-IFN	_	_	O
78	)	_	_	O
79	followed	_	_	O
80	by	_	_	O
81	7	_	_	O
82	cycles	_	_	O
83	of	_	_	O
84	5-FU	_	_	O
85	,	_	_	O
86	hydroxyurea	_	_	O
87	and	_	_	O
88	concomitant	_	_	O
89	radiation	_	_	O
90	for	_	_	O
91	5	_	_	O
92	days	_	_	O
93	(	_	_	O
94	FHX	_	_	O
95	)	_	_	O
96	for	_	_	O
97	a	_	_	O
98	total	_	_	O
99	radiation	_	_	O
100	dose	_	_	O
101	of	_	_	O
102	70	_	_	O
103	Gy	_	_	O
104	.	_	_	O

105	13	_	_	O
106	Cis-retinoic	_	_	O
107	acid	_	_	O
108	was	_	_	O
109	added	_	_	O
110	to	_	_	O
111	treatment	_	_	O
112	regimen	_	_	O
113	for	_	_	O
114	chemoprevention	_	_	O
115	and	_	_	O
116	a	_	_	O
117	systematic	_	_	O
118	prophylaxis	_	_	O
119	of	_	_	O
120	mucositis	_	_	O
121	was	_	_	O
122	administered	_	_	O
123	to	_	_	O
124	all	_	_	O
125	patients	_	_	O
126	during	_	_	O
127	FHX	_	_	O
128	.	_	_	O

129	Conservative	_	_	O
130	surgical	_	_	O
131	resection	_	_	O
132	was	_	_	O
133	reserved	_	_	O
134	to	_	_	O
135	patients	_	_	O
136	with	_	_	O
137	no	_	_	O
138	optimal	_	_	O
139	response	_	_	O
140	(	_	_	O
141	PR	_	_	O
142	>	_	_	O
143	or	_	_	O
144	=70	_	_	O
145	%	_	_	O
146	)	_	_	O
147	,	_	_	O
148	whereas	_	_	O
149	radical	_	_	O
150	surgery	_	_	O
151	was	_	_	O
152	performed	_	_	O
153	as	_	_	O
154	salvage	_	_	O
155	treatment	_	_	O
156	.	_	_	O

157	Twenty-six	_	_	O
158	patients	_	_	O
159	were	_	_	O
160	treated	_	_	O
161	at	_	_	O
162	one	_	_	O
163	institution	_	_	O
164	:	_	_	O
165	more	_	_	O
166	than	_	_	O
167	90	_	_	O
168	%	_	_	O
169	had	_	_	O
170	stage	_	_	O
171	IV	_	_	O
172	disease	_	_	O
173	and	_	_	O
174	only	_	_	O
175	19.2	_	_	O
176	%	_	_	O
177	had	_	_	O
178	laryngeal	_	_	O
179	cancer	_	_	O
180	.	_	_	O

181	Eighty-one	_	_	O
182	percent	_	_	O
183	of	_	_	O
184	patients	_	_	O
185	had	_	_	O
186	performance	_	_	O
187	status	_	_	O
188	0	_	_	O
189	and	_	_	O
190	23.1	_	_	O
191	%	_	_	O
192	of	_	_	O
193	patients	_	_	O
194	had	_	_	O
195	>	_	_	O
196	5	_	_	O
197	%	_	_	O
198	weight	_	_	O
199	loss	_	_	O
200	at	_	_	O
201	the	_	_	O
202	start	_	_	O
203	of	_	_	O
204	treatment	_	_	O
205	.	_	_	O

206	Nineteen	_	_	O
207	patients	_	_	O
208	were	_	_	O
209	analyzed	_	_	O
210	for	_	_	O
211	response	_	_	O
212	to	_	_	O
213	PFL-IFN	_	_	O
214	:	_	_	O
215	3/19	_	_	O
216	(	_	_	O
217	15.8	_	_	O
218	%	_	_	O
219	)	_	_	O
220	patients	_	_	O
221	achieved	_	_	O
222	a	_	_	O
223	CR	_	_	O
224	and	_	_	O
225	7/19	_	_	O
226	(	_	_	O
227	36.8	_	_	O
228	%	_	_	O
229	)	_	_	O
230	achieved	_	_	O
231	a	_	_	O
232	PR	_	_	O
233	for	_	_	O
234	an	_	_	O
235	ORR	_	_	O
236	of	_	_	O
237	52.6	_	_	O
238	%	_	_	O
239	.	_	_	O

240	FHX	_	_	O
241	was	_	_	O
242	administered	_	_	O
243	on	_	_	O
244	protocol	_	_	O
245	to	_	_	O
246	12	_	_	O
247	patients	_	_	O
248	:	_	_	O
249	6	_	_	O
250	patients	_	_	O
251	(	_	_	O
252	50	_	_	O
253	%	_	_	O
254	)	_	_	O
255	had	_	_	O
256	CR	_	_	O
257	,	_	_	O
258	1	_	_	O
259	patient	_	_	O
260	(	_	_	O
261	8.3	_	_	O
262	%	_	_	O
263	)	_	_	O
264	had	_	_	O
265	PR	_	_	O
266	for	_	_	O
267	an	_	_	O
268	ORR	_	_	O
269	of	_	_	O
270	58.3	_	_	O
271	%	_	_	O
272	,	_	_	O
273	2	_	_	O
274	patients	_	_	O
275	(	_	_	O
276	16.7	_	_	O
277	%	_	_	O
278	)	_	_	O
279	had	_	_	O
280	SD	_	_	O
281	and	_	_	O
282	3	_	_	O
283	patients	_	_	O
284	(	_	_	O
285	25	_	_	O
286	%	_	_	O
287	)	_	_	O
288	had	_	_	O
289	PD	_	_	O
290	.	_	_	O

291	At	_	_	O
292	the	_	_	O
293	completion	_	_	O
294	of	_	_	O
295	FHX	_	_	O
296	,	_	_	O
297	no	_	_	O
298	patient	_	_	O
299	underwent	_	_	O
300	local	_	_	O
301	therapy	_	_	O
302	according	_	_	O
303	to	_	_	O
304	treatment	_	_	O
305	plan	_	_	O
306	.	_	_	O

307	At	_	_	B-Premise
308	a	_	_	I-Premise
309	median	_	_	I-Premise
310	follow-up	_	_	I-Premise
311	time	_	_	I-Premise
312	of	_	_	I-Premise
313	13.5	_	_	I-Premise
314	months	_	_	I-Premise
315	(	_	_	I-Premise
316	range	_	_	I-Premise
317	1-28+	_	_	I-Premise
318	)	_	_	I-Premise
319	at	_	_	I-Premise
320	June	_	_	I-Premise
321	2001	_	_	I-Premise
322	,	_	_	I-Premise
323	among	_	_	I-Premise
324	26	_	_	I-Premise
325	patients	_	_	I-Premise
326	enrolled	_	_	I-Premise
327	12	_	_	I-Premise
328	(	_	_	I-Premise
329	46.1	_	_	I-Premise
330	%	_	_	I-Premise
331	)	_	_	I-Premise
332	were	_	_	I-Premise
333	still	_	_	I-Premise
334	alive	_	_	I-Premise
335	and	_	_	I-Premise
336	9	_	_	I-Premise
337	(	_	_	I-Premise
338	75	_	_	I-Premise
339	%	_	_	I-Premise
340	)	_	_	I-Premise
341	of	_	_	I-Premise
342	them	_	_	I-Premise
343	were	_	_	I-Premise
344	progression-free	_	_	I-Premise
345	.	_	_	I-Premise

346	The	_	_	B-Premise
347	median	_	_	I-Premise
348	duration	_	_	I-Premise
349	of	_	_	I-Premise
350	response	_	_	I-Premise
351	was	_	_	I-Premise
352	9	_	_	I-Premise
353	months	_	_	I-Premise
354	(	_	_	I-Premise
355	range	_	_	I-Premise
356	0-25+	_	_	I-Premise
357	)	_	_	I-Premise
358	,	_	_	I-Premise
359	the	_	_	I-Premise
360	median	_	_	I-Premise
361	progression-free	_	_	I-Premise
362	survival	_	_	I-Premise
363	was	_	_	I-Premise
364	10.5	_	_	I-Premise
365	months	_	_	I-Premise
366	(	_	_	I-Premise
367	range	_	_	I-Premise
368	0-28+	_	_	I-Premise
369	)	_	_	I-Premise
370	,	_	_	I-Premise
371	the	_	_	I-Premise
372	median	_	_	I-Premise
373	overall	_	_	I-Premise
374	survival	_	_	I-Premise
375	time	_	_	I-Premise
376	was	_	_	I-Premise
377	9	_	_	I-Premise
378	months	_	_	I-Premise
379	(	_	_	I-Premise
380	range	_	_	I-Premise
381	1-22	_	_	I-Premise
382	)	_	_	I-Premise
383	.	_	_	I-Premise

384	The	_	_	B-Premise
385	toxicity	_	_	I-Premise
386	was	_	_	I-Premise
387	significant	_	_	I-Premise
388	and	_	_	I-Premise
389	consisted	_	_	I-Premise
390	mainly	_	_	I-Premise
391	of	_	_	I-Premise
392	mucositis	_	_	I-Premise
393	and	_	_	I-Premise
394	,	_	_	I-Premise
395	to	_	_	I-Premise
396	a	_	_	I-Premise
397	lesser	_	_	I-Premise
398	extent	_	_	I-Premise
399	,	_	_	I-Premise
400	neutropenia/thrombocytopenia	_	_	I-Premise
401	.	_	_	I-Premise

402	In	_	_	O
403	the	_	_	O
404	present	_	_	O
405	study	_	_	O
406	,	_	_	O
407	the	_	_	B-Claim
408	low	_	_	I-Claim
409	serum	_	_	I-Claim
410	levels	_	_	I-Claim
411	of	_	_	I-Claim
412	leptin	_	_	I-Claim
413	and	_	_	I-Claim
414	the	_	_	I-Claim
415	high	_	_	I-Claim
416	serum	_	_	I-Claim
417	levels	_	_	I-Claim
418	of	_	_	I-Claim
419	proinflammatory	_	_	I-Claim
420	cytokines	_	_	I-Claim
421	in	_	_	I-Claim
422	advanced	_	_	I-Claim
423	stage	_	_	I-Claim
424	cancer	_	_	I-Claim
425	patients	_	_	I-Claim
426	were	_	_	I-Claim
427	confirmed	_	_	I-Claim
428	.	_	_	I-Claim

429	In	_	_	O
430	conclusion	_	_	O
431	,	_	_	O
432	this	_	_	B-Claim
433	sequential	_	_	I-Claim
434	induction	_	_	I-Claim
435	chemotherapy	_	_	I-Claim
436	and	_	_	I-Claim
437	chemoradiotherapy	_	_	I-Claim
438	program	_	_	I-Claim
439	has	_	_	I-Claim
440	been	_	_	I-Claim
441	found	_	_	I-Claim
442	moderately	_	_	I-Claim
443	active	_	_	I-Claim
444	and	_	_	I-Claim
445	significantly	_	_	I-Claim
446	toxic	_	_	I-Claim
447	;	_	_	I-Claim
448	moreover	_	_	O
449	,	_	_	O
450	the	_	_	O
451	long	_	_	O
452	overall	_	_	O
453	treatment	_	_	O
454	duration	_	_	O
455	must	_	_	O
456	be	_	_	O
457	taken	_	_	O
458	into	_	_	O
459	consideration	_	_	O
460	.	_	_	O

461	For	_	_	O
462	these	_	_	O
463	reasons	_	_	O
464	,	_	_	O
465	this	_	_	B-Claim
466	regimen	_	_	I-Claim
467	could	_	_	I-Claim
468	not	_	_	I-Claim
469	be	_	_	I-Claim
470	recommended	_	_	I-Claim
471	for	_	_	I-Claim
472	a	_	_	I-Claim
473	phase	_	_	I-Claim
474	III	_	_	I-Claim
475	randomized	_	_	I-Claim
476	study	_	_	I-Claim
477	.	_	_	I-Claim


0	The	_	_	O
1	study	_	_	O
2	was	_	_	O
3	designed	_	_	O
4	to	_	_	O
5	compare	_	_	O
6	the	_	_	O
7	effects	_	_	O
8	of	_	_	O
9	treatment	_	_	O
10	with	_	_	O
11	a	_	_	O
12	combination	_	_	O
13	of	_	_	O
14	trastuzumab	_	_	O
15	(	_	_	O
16	Herceptin	_	_	O
17	;	_	_	O
18	Genentech	_	_	O
19	,	_	_	O
20	Inc	_	_	O
21	,	_	_	O
22	South	_	_	O
23	San	_	_	O
24	Francisco	_	_	O
25	,	_	_	O
26	CA	_	_	O
27	)	_	_	O
28	and	_	_	O
29	chemotherapy	_	_	O
30	versus	_	_	O
31	chemotherapy	_	_	O
32	alone	_	_	O
33	on	_	_	O
34	health-related	_	_	O
35	quality	_	_	O
36	of	_	_	O
37	life	_	_	O
38	(	_	_	O
39	HRQL	_	_	O
40	)	_	_	O
41	in	_	_	O
42	patients	_	_	O
43	with	_	_	O
44	HER-2/neu	_	_	O
45	overexpressing	_	_	O
46	,	_	_	O
47	metastatic	_	_	O
48	breast	_	_	O
49	cancer	_	_	O
50	.	_	_	O

51	A	_	_	O
52	sample	_	_	O
53	of	_	_	O
54	400	_	_	O
55	patients	_	_	O
56	,	_	_	O
57	not	_	_	O
58	previously	_	_	O
59	treated	_	_	O
60	for	_	_	O
61	metastatic	_	_	O
62	disease	_	_	O
63	and	_	_	O
64	randomized	_	_	O
65	to	_	_	O
66	receive	_	_	O
67	either	_	_	O
68	trastuzumab	_	_	O
69	plus	_	_	O
70	chemotherapy	_	_	O
71	(	_	_	O
72	208	_	_	O
73	patients	_	_	O
74	)	_	_	O
75	or	_	_	O
76	chemotherapy	_	_	O
77	alone	_	_	O
78	(	_	_	O
79	192	_	_	O
80	patients	_	_	O
81	)	_	_	O
82	,	_	_	O
83	completed	_	_	O
84	the	_	_	O
85	European	_	_	O
86	Organization	_	_	O
87	for	_	_	O
88	Research	_	_	O
89	and	_	_	O
90	Treatment	_	_	O
91	Care	_	_	O
92	Quality	_	_	O
93	of	_	_	O
94	Life	_	_	O
95	Questionnaire	_	_	O
96	at	_	_	O
97	baseline	_	_	O
98	and	_	_	O
99	on	_	_	O
100	at	_	_	O
101	least	_	_	O
102	one	_	_	O
103	subsequent	_	_	O
104	occasion	_	_	O
105	at	_	_	O
106	8	_	_	O
107	,	_	_	O
108	20	_	_	O
109	,	_	_	O
110	32	_	_	O
111	,	_	_	O
112	44	_	_	O
113	,	_	_	O
114	and	_	_	O
115	56	_	_	O
116	weeks	_	_	O
117	.	_	_	O

118	HRQL	_	_	O
119	improvement	_	_	O
120	or	_	_	O
121	worsening	_	_	O
122	was	_	_	O
123	defined	_	_	O
124	as	_	_	O
125	a	_	_	O
126	>	_	_	O
127	or=	_	_	O
128	10-point	_	_	O
129	change	_	_	O
130	(	_	_	O
131	range	_	_	O
132	,	_	_	O
133	0	_	_	O
134	to	_	_	O
135	100	_	_	O
136	points	_	_	O
137	)	_	_	O
138	in	_	_	O
139	the	_	_	O
140	scores	_	_	O
141	of	_	_	O
142	six	_	_	O
143	preselected	_	_	O
144	domains	_	_	O
145	(	_	_	O
146	global	_	_	O
147	quality	_	_	O
148	of	_	_	O
149	life	_	_	O
150	[	_	_	O
151	QOL	_	_	O
152	]	_	_	O
153	,	_	_	O
154	physical	_	_	O
155	,	_	_	O
156	role	_	_	O
157	,	_	_	O
158	social	_	_	O
159	,	_	_	O
160	and	_	_	O
161	emotional	_	_	O
162	functioning	_	_	O
163	,	_	_	O
164	and	_	_	O
165	fatigue	_	_	O
166	)	_	_	O
167	.	_	_	O

168	Stable	_	_	O
169	HRQL	_	_	O
170	was	_	_	O
171	defined	_	_	O
172	as	_	_	O
173	a	_	_	O
174	change	_	_	O
175	of	_	_	O
176	less	_	_	O
177	than	_	_	O
178	10	_	_	O
179	.	_	_	O

180	A	_	_	O
181	Bonferroni	_	_	O
182	correction	_	_	O
183	was	_	_	O
184	applied	_	_	O
185	for	_	_	O
186	multiple	_	_	O
187	testing	_	_	O
188	.	_	_	O

189	After	_	_	B-Premise
190	completion	_	_	I-Premise
191	of	_	_	I-Premise
192	chemotherapy	_	_	I-Premise
193	,	_	_	I-Premise
194	patients	_	_	I-Premise
195	treated	_	_	I-Premise
196	with	_	_	I-Premise
197	trastuzumab	_	_	I-Premise
198	and	_	_	I-Premise
199	chemotherapy	_	_	I-Premise
200	reported	_	_	I-Premise
201	significant	_	_	I-Premise
202	improvement	_	_	I-Premise
203	in	_	_	I-Premise
204	fatigue	_	_	I-Premise
205	(	_	_	I-Premise
206	P	_	_	I-Premise
207	<	_	_	I-Premise
208	.05	_	_	I-Premise
209	)	_	_	I-Premise
210	as	_	_	I-Premise
211	compared	_	_	I-Premise
212	with	_	_	I-Premise
213	their	_	_	I-Premise
214	baseline	_	_	I-Premise
215	scores	_	_	I-Premise
216	.	_	_	I-Premise

217	Higher	_	_	B-Premise
218	proportions	_	_	I-Premise
219	of	_	_	I-Premise
220	patients	_	_	I-Premise
221	receiving	_	_	I-Premise
222	the	_	_	I-Premise
223	combined	_	_	I-Premise
224	therapy	_	_	I-Premise
225	achieved	_	_	I-Premise
226	improvement	_	_	I-Premise
227	in	_	_	I-Premise
228	global	_	_	I-Premise
229	QOL	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	<	_	_	I-Premise
233	.05	_	_	I-Premise
234	)	_	_	I-Premise
235	than	_	_	I-Premise
236	did	_	_	I-Premise
237	patients	_	_	I-Premise
238	treated	_	_	I-Premise
239	with	_	_	I-Premise
240	chemotherapy	_	_	I-Premise
241	alone	_	_	I-Premise
242	.	_	_	I-Premise

243	Higher	_	_	B-Premise
244	proportions	_	_	I-Premise
245	of	_	_	I-Premise
246	the	_	_	I-Premise
247	combined	_	_	I-Premise
248	therapy	_	_	I-Premise
249	group	_	_	I-Premise
250	also	_	_	I-Premise
251	achieved	_	_	I-Premise
252	improvement	_	_	I-Premise
253	in	_	_	I-Premise
254	physical	_	_	I-Premise
255	and	_	_	I-Premise
256	role	_	_	I-Premise
257	functioning	_	_	I-Premise
258	and	_	_	I-Premise
259	in	_	_	I-Premise
260	fatigue	_	_	I-Premise
261	as	_	_	I-Premise
262	compared	_	_	I-Premise
263	with	_	_	I-Premise
264	the	_	_	I-Premise
265	chemotherapy	_	_	I-Premise
266	group	_	_	I-Premise
267	,	_	_	I-Premise
268	but	_	_	B-Premise
269	the	_	_	I-Premise
270	differences	_	_	I-Premise
271	were	_	_	I-Premise
272	not	_	_	I-Premise
273	statistically	_	_	I-Premise
274	significant	_	_	I-Premise
275	.	_	_	I-Premise

276	There	_	_	B-Premise
277	were	_	_	I-Premise
278	no	_	_	I-Premise
279	differences	_	_	I-Premise
280	in	_	_	I-Premise
281	the	_	_	I-Premise
282	proportions	_	_	I-Premise
283	of	_	_	I-Premise
284	patients	_	_	I-Premise
285	in	_	_	I-Premise
286	the	_	_	I-Premise
287	two	_	_	I-Premise
288	groups	_	_	I-Premise
289	that	_	_	I-Premise
290	reported	_	_	I-Premise
291	worsening	_	_	I-Premise
292	.	_	_	I-Premise

293	Statistically	_	_	B-Claim
294	significantly	_	_	I-Claim
295	higher	_	_	I-Claim
296	proportions	_	_	I-Claim
297	of	_	_	I-Claim
298	patients	_	_	I-Claim
299	treated	_	_	I-Claim
300	with	_	_	I-Claim
301	a	_	_	I-Claim
302	combination	_	_	I-Claim
303	of	_	_	I-Claim
304	trastuzumab	_	_	I-Claim
305	and	_	_	I-Claim
306	chemotherapy	_	_	I-Claim
307	reported	_	_	I-Claim
308	improved	_	_	I-Claim
309	global	_	_	I-Claim
310	QOL	_	_	I-Claim
311	than	_	_	I-Claim
312	did	_	_	I-Claim
313	patients	_	_	I-Claim
314	treated	_	_	I-Claim
315	by	_	_	I-Claim
316	chemotherapy	_	_	I-Claim
317	alone	_	_	I-Claim
318	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	a	_	_	O
6	novel	_	_	O
7	coloplasty	_	_	O
8	colonic	_	_	O
9	pouch	_	_	O
10	design	_	_	O
11	in	_	_	O
12	optimizing	_	_	O
13	bowel	_	_	O
14	function	_	_	O
15	after	_	_	O
16	ultralow	_	_	O
17	anterior	_	_	O
18	resection	_	_	O
19	.	_	_	O

20	A	_	_	B-Claim
21	colonic	_	_	I-Claim
22	J-pouch	_	_	I-Claim
23	may	_	_	I-Claim
24	reduce	_	_	I-Claim
25	excessive	_	_	I-Claim
26	stool	_	_	I-Claim
27	frequency	_	_	I-Claim
28	and	_	_	I-Claim
29	incontinence	_	_	I-Claim
30	after	_	_	I-Claim
31	anterior	_	_	I-Claim
32	resection	_	_	I-Claim
33	,	_	_	I-Claim
34	but	_	_	I-Claim
35	at	_	_	I-Claim
36	the	_	_	I-Claim
37	risk	_	_	I-Claim
38	of	_	_	I-Claim
39	evacuation	_	_	I-Claim
40	problems	_	_	I-Claim
41	.	_	_	I-Claim

42	Experimental	_	_	B-Claim
43	surgery	_	_	I-Claim
44	on	_	_	I-Claim
45	pigs	_	_	I-Claim
46	has	_	_	I-Claim
47	suggested	_	_	I-Claim
48	that	_	_	I-Claim
49	a	_	_	I-Claim
50	coloplasty	_	_	I-Claim
51	pouch	_	_	I-Claim
52	(	_	_	I-Claim
53	CP	_	_	I-Claim
54	)	_	_	I-Claim
55	may	_	_	I-Claim
56	be	_	_	I-Claim
57	a	_	_	I-Claim
58	useful	_	_	I-Claim
59	alternative	_	_	I-Claim
60	.	_	_	O

61	Although	_	_	O
62	CP	_	_	O
63	has	_	_	O
64	recently	_	_	O
65	been	_	_	O
66	shown	_	_	O
67	to	_	_	O
68	be	_	_	O
69	feasible	_	_	O
70	in	_	_	O
71	patients	_	_	O
72	,	_	_	O
73	there	_	_	O
74	is	_	_	O
75	no	_	_	O
76	randomized	_	_	O
77	controlled	_	_	O
78	trial	_	_	O
79	comparing	_	_	O
80	bowel	_	_	O
81	function	_	_	O
82	with	_	_	O
83	the	_	_	O
84	J-pouch	_	_	O
85	.	_	_	O

86	After	_	_	O
87	anterior	_	_	O
88	resection	_	_	O
89	for	_	_	O
90	cancer	_	_	O
91	,	_	_	O
92	patients	_	_	O
93	were	_	_	O
94	allocated	_	_	O
95	to	_	_	O
96	either	_	_	O
97	J-pouch	_	_	O
98	or	_	_	O
99	CP-anal	_	_	O
100	anastomoses	_	_	O
101	.	_	_	O

102	Continence	_	_	O
103	scoring	_	_	O
104	,	_	_	O
105	anorectal	_	_	O
106	manometry	_	_	O
107	,	_	_	O
108	and	_	_	O
109	endoanal	_	_	O
110	ultrasound	_	_	O
111	assessments	_	_	O
112	were	_	_	O
113	made	_	_	O
114	before	_	_	O
115	surgery	_	_	O
116	.	_	_	O

117	All	_	_	O
118	complications	_	_	O
119	were	_	_	O
120	recorded	_	_	O
121	,	_	_	O
122	and	_	_	O
123	these	_	_	O
124	preoperative	_	_	O
125	assessments	_	_	O
126	were	_	_	O
127	repeated	_	_	O
128	at	_	_	O
129	4	_	_	O
130	months	_	_	O
131	.	_	_	O

132	The	_	_	O
133	assessments	_	_	O
134	were	_	_	O
135	repeated	_	_	O
136	again	_	_	O
137	at	_	_	O
138	1	_	_	O
139	year	_	_	O
140	,	_	_	O
141	and	_	_	O
142	a	_	_	O
143	quality	_	_	O
144	of	_	_	O
145	life	_	_	O
146	questionnaire	_	_	O
147	was	_	_	O
148	added	_	_	O
149	.	_	_	O

150	Eighty-eight	_	_	O
151	patients	_	_	O
152	were	_	_	O
153	recruited	_	_	O
154	from	_	_	O
155	October	_	_	O
156	1998	_	_	O
157	to	_	_	O
158	April	_	_	O
159	2000	_	_	O
160	.	_	_	O

161	Both	_	_	O
162	groups	_	_	O
163	were	_	_	O
164	well	_	_	O
165	matched	_	_	O
166	for	_	_	O
167	age	_	_	O
168	,	_	_	O
169	gender	_	_	O
170	,	_	_	O
171	staging	_	_	O
172	,	_	_	O
173	adjuvant	_	_	O
174	therapy	_	_	O
175	,	_	_	O
176	and	_	_	O
177	mean	_	_	O
178	follow-up	_	_	O
179	.	_	_	O

180	There	_	_	O
181	were	_	_	O
182	no	_	_	O
183	differences	_	_	O
184	in	_	_	O
185	the	_	_	O
186	intraoperative	_	_	O
187	time	_	_	O
188	and	_	_	O
189	hospital	_	_	O
190	stay	_	_	O
191	.	_	_	O

192	CP	_	_	B-Premise
193	resulted	_	_	I-Premise
194	in	_	_	I-Premise
195	more	_	_	I-Premise
196	anastomotic	_	_	I-Premise
197	leaks	_	_	I-Premise
198	.	_	_	I-Premise

199	At	_	_	B-Premise
200	4	_	_	I-Premise
201	months	_	_	I-Premise
202	,	_	_	I-Premise
203	J-pouch	_	_	I-Premise
204	patients	_	_	I-Premise
205	had	_	_	I-Premise
206	10.3	_	_	I-Premise
207	%	_	_	I-Premise
208	less	_	_	I-Premise
209	stool	_	_	I-Premise
210	fragmentation	_	_	I-Premise
211	but	_	_	I-Premise
212	poorer	_	_	I-Premise
213	stool	_	_	I-Premise
214	deferment	_	_	I-Premise
215	and	_	_	I-Premise
216	more	_	_	I-Premise
217	nocturnal	_	_	I-Premise
218	leakage	_	_	I-Premise
219	.	_	_	I-Premise

220	However	_	_	O
221	,	_	_	O
222	there	_	_	B-Premise
223	were	_	_	I-Premise
224	no	_	_	I-Premise
225	differences	_	_	I-Premise
226	in	_	_	I-Premise
227	the	_	_	I-Premise
228	bowel	_	_	I-Premise
229	function	_	_	I-Premise
230	,	_	_	I-Premise
231	continence	_	_	I-Premise
232	score	_	_	I-Premise
233	,	_	_	I-Premise
234	and	_	_	I-Premise
235	quality	_	_	I-Premise
236	of	_	_	I-Premise
237	life	_	_	I-Premise
238	at	_	_	I-Premise
239	1	_	_	I-Premise
240	year	_	_	I-Premise
241	.	_	_	I-Premise

242	There	_	_	B-Premise
243	were	_	_	I-Premise
244	no	_	_	I-Premise
245	differences	_	_	I-Premise
246	in	_	_	I-Premise
247	the	_	_	I-Premise
248	anorectal	_	_	I-Premise
249	manometry	_	_	I-Premise
250	and	_	_	I-Premise
251	endoanal	_	_	I-Premise
252	ultrasound	_	_	I-Premise
253	findings	_	_	I-Premise
254	.	_	_	I-Premise

255	Coloplasty	_	_	B-Claim
256	pouches	_	_	I-Claim
257	resulted	_	_	I-Claim
258	in	_	_	I-Claim
259	more	_	_	I-Claim
260	anastomotic	_	_	I-Claim
261	leaks	_	_	I-Claim
262	and	_	_	I-Claim
263	minimal	_	_	I-Claim
264	differences	_	_	I-Claim
265	in	_	_	I-Claim
266	bowel	_	_	I-Claim
267	function	_	_	I-Claim
268	.	_	_	I-Claim

269	At	_	_	O
270	present	_	_	O
271	,	_	_	O
272	the	_	_	B-Claim
273	J-pouch	_	_	I-Claim
274	remains	_	_	I-Claim
275	the	_	_	I-Claim
276	benchmark	_	_	I-Claim
277	for	_	_	I-Claim
278	routine	_	_	I-Claim
279	clinical	_	_	I-Claim
280	practice	_	_	I-Claim
281	,	_	_	I-Claim
282	and	_	_	O
283	due	_	_	B-Claim
284	care	_	_	I-Claim
285	(	_	_	I-Claim
286	including	_	_	I-Claim
287	defunctioning	_	_	I-Claim
288	stoma	_	_	I-Claim
289	)	_	_	I-Claim
290	should	_	_	I-Claim
291	be	_	_	I-Claim
292	exercised	_	_	I-Claim
293	in	_	_	I-Claim
294	situations	_	_	I-Claim
295	requiring	_	_	I-Claim
296	CP	_	_	I-Claim
297	.	_	_	I-Claim


0	Bone	_	_	B-Claim
1	metastases	_	_	I-Claim
2	are	_	_	I-Claim
3	a	_	_	I-Claim
4	common	_	_	I-Claim
5	cause	_	_	I-Claim
6	of	_	_	I-Claim
7	morbidity	_	_	I-Claim
8	in	_	_	I-Claim
9	patients	_	_	I-Claim
10	with	_	_	I-Claim
11	prostate	_	_	I-Claim
12	carcinoma	_	_	I-Claim
13	.	_	_	I-Claim

14	We	_	_	O
15	studied	_	_	O
16	the	_	_	O
17	effect	_	_	O
18	of	_	_	O
19	a	_	_	O
20	new	_	_	O
21	bisphosphonate	_	_	O
22	,	_	_	O
23	zoledronic	_	_	O
24	acid	_	_	O
25	,	_	_	O
26	which	_	_	O
27	blocks	_	_	O
28	bone	_	_	O
29	destruction	_	_	O
30	,	_	_	O
31	on	_	_	O
32	skeletal	_	_	O
33	complications	_	_	O
34	in	_	_	O
35	prostate	_	_	O
36	cancer	_	_	O
37	patients	_	_	O
38	with	_	_	O
39	bone	_	_	O
40	metastases	_	_	O
41	.	_	_	O

42	Patients	_	_	O
43	with	_	_	O
44	hormone-refractory	_	_	O
45	prostate	_	_	O
46	cancer	_	_	O
47	and	_	_	O
48	a	_	_	O
49	history	_	_	O
50	of	_	_	O
51	bone	_	_	O
52	metastases	_	_	O
53	were	_	_	O
54	randomly	_	_	O
55	assigned	_	_	O
56	to	_	_	O
57	a	_	_	O
58	double-blind	_	_	O
59	treatment	_	_	O
60	regimen	_	_	O
61	of	_	_	O
62	intravenous	_	_	O
63	zoledronic	_	_	O
64	acid	_	_	O
65	at	_	_	O
66	4	_	_	O
67	mg	_	_	O
68	(	_	_	O
69	N	_	_	O
70	=	_	_	O
71	214	_	_	O
72	)	_	_	O
73	,	_	_	O
74	zoledronic	_	_	O
75	acid	_	_	O
76	at	_	_	O
77	8	_	_	O
78	mg	_	_	O
79	(	_	_	O
80	subsequently	_	_	O
81	reduced	_	_	O
82	to	_	_	O
83	4	_	_	O
84	mg	_	_	O
85	;	_	_	O
86	8/4	_	_	O
87	)	_	_	O
88	(	_	_	O
89	N	_	_	O
90	=	_	_	O
91	221	_	_	O
92	)	_	_	O
93	,	_	_	O
94	or	_	_	O
95	placebo	_	_	O
96	(	_	_	O
97	N	_	_	O
98	=	_	_	O
99	208	_	_	O
100	)	_	_	O
101	every	_	_	O
102	3	_	_	O
103	weeks	_	_	O
104	for	_	_	O
105	15	_	_	O
106	months	_	_	O
107	.	_	_	O

108	Proportions	_	_	O
109	of	_	_	O
110	patients	_	_	O
111	with	_	_	O
112	skeletal-related	_	_	O
113	events	_	_	O
114	,	_	_	O
115	time	_	_	O
116	to	_	_	O
117	the	_	_	O
118	first	_	_	O
119	skeletal-related	_	_	O
120	event	_	_	O
121	,	_	_	O
122	skeletal	_	_	O
123	morbidity	_	_	O
124	rate	_	_	O
125	,	_	_	O
126	pain	_	_	O
127	and	_	_	O
128	analgesic	_	_	O
129	scores	_	_	O
130	,	_	_	O
131	disease	_	_	O
132	progression	_	_	O
133	,	_	_	O
134	and	_	_	O
135	safety	_	_	O
136	were	_	_	O
137	assessed	_	_	O
138	.	_	_	O

139	All	_	_	O
140	statistical	_	_	O
141	tests	_	_	O
142	were	_	_	O
143	two-sided	_	_	O
144	.	_	_	O

145	Approximately	_	_	O
146	38	_	_	O
147	%	_	_	O
148	of	_	_	O
149	patients	_	_	O
150	who	_	_	O
151	received	_	_	O
152	zoledronic	_	_	O
153	acid	_	_	O
154	at	_	_	O
155	4	_	_	O
156	mg	_	_	O
157	,	_	_	O
158	28	_	_	O
159	%	_	_	O
160	who	_	_	O
161	received	_	_	O
162	zoledronic	_	_	O
163	acid	_	_	O
164	at	_	_	O
165	8/4	_	_	O
166	mg	_	_	O
167	,	_	_	O
168	and	_	_	O
169	31	_	_	O
170	%	_	_	O
171	who	_	_	O
172	received	_	_	O
173	placebo	_	_	O
174	completed	_	_	O
175	the	_	_	O
176	study	_	_	O
177	.	_	_	O

178	A	_	_	B-Premise
179	greater	_	_	I-Premise
180	proportion	_	_	I-Premise
181	of	_	_	I-Premise
182	patients	_	_	I-Premise
183	who	_	_	I-Premise
184	received	_	_	I-Premise
185	placebo	_	_	I-Premise
186	had	_	_	I-Premise
187	skeletal-related	_	_	I-Premise
188	events	_	_	I-Premise
189	than	_	_	I-Premise
190	those	_	_	I-Premise
191	who	_	_	I-Premise
192	received	_	_	I-Premise
193	zoledronic	_	_	I-Premise
194	acid	_	_	I-Premise
195	at	_	_	I-Premise
196	4	_	_	I-Premise
197	mg	_	_	I-Premise
198	(	_	_	I-Premise
199	44.2	_	_	I-Premise
200	%	_	_	I-Premise
201	versus	_	_	I-Premise
202	33.2	_	_	I-Premise
203	%	_	_	I-Premise
204	;	_	_	I-Premise
205	difference	_	_	I-Premise
206	=	_	_	I-Premise
207	-11.0	_	_	I-Premise
208	%	_	_	I-Premise
209	,	_	_	I-Premise
210	95	_	_	I-Premise
211	%	_	_	I-Premise
212	confidence	_	_	I-Premise
213	interval	_	_	I-Premise
214	[	_	_	I-Premise
215	CI	_	_	I-Premise
216	]	_	_	I-Premise
217	=	_	_	I-Premise
218	-20.3	_	_	I-Premise
219	%	_	_	I-Premise
220	to	_	_	I-Premise
221	-1.8	_	_	I-Premise
222	%	_	_	I-Premise
223	;	_	_	I-Premise
224	P	_	_	I-Premise
225	=.021	_	_	I-Premise
226	)	_	_	I-Premise
227	or	_	_	I-Premise
228	those	_	_	I-Premise
229	who	_	_	I-Premise
230	received	_	_	I-Premise
231	zoledronic	_	_	I-Premise
232	acid	_	_	I-Premise
233	at	_	_	I-Premise
234	8/4	_	_	I-Premise
235	mg	_	_	I-Premise
236	(	_	_	I-Premise
237	38.5	_	_	I-Premise
238	%	_	_	I-Premise
239	;	_	_	I-Premise
240	difference	_	_	I-Premise
241	versus	_	_	I-Premise
242	placebo	_	_	I-Premise
243	=	_	_	I-Premise
244	-5.8	_	_	I-Premise
245	%	_	_	I-Premise
246	,	_	_	I-Premise
247	95	_	_	I-Premise
248	%	_	_	I-Premise
249	CI	_	_	I-Premise
250	=	_	_	I-Premise
251	-15.1	_	_	I-Premise
252	%	_	_	I-Premise
253	to	_	_	I-Premise
254	3.6	_	_	I-Premise
255	%	_	_	I-Premise
256	;	_	_	I-Premise
257	P	_	_	I-Premise
258	=.222	_	_	I-Premise
259	)	_	_	I-Premise
260	.	_	_	I-Premise

261	Median	_	_	B-Premise
262	time	_	_	I-Premise
263	to	_	_	I-Premise
264	first	_	_	I-Premise
265	skeletal-related	_	_	I-Premise
266	event	_	_	I-Premise
267	was	_	_	I-Premise
268	321	_	_	I-Premise
269	days	_	_	I-Premise
270	for	_	_	I-Premise
271	patients	_	_	I-Premise
272	who	_	_	I-Premise
273	received	_	_	I-Premise
274	placebo	_	_	I-Premise
275	,	_	_	I-Premise
276	was	_	_	I-Premise
277	not	_	_	I-Premise
278	reached	_	_	I-Premise
279	for	_	_	I-Premise
280	patients	_	_	I-Premise
281	who	_	_	I-Premise
282	received	_	_	I-Premise
283	zoledronic	_	_	I-Premise
284	acid	_	_	I-Premise
285	at	_	_	I-Premise
286	4	_	_	I-Premise
287	mg	_	_	I-Premise
288	(	_	_	I-Premise
289	P	_	_	I-Premise
290	=.011	_	_	I-Premise
291	versus	_	_	I-Premise
292	placebo	_	_	I-Premise
293	)	_	_	I-Premise
294	,	_	_	I-Premise
295	and	_	_	I-Premise
296	was	_	_	I-Premise
297	363	_	_	I-Premise
298	days	_	_	I-Premise
299	for	_	_	I-Premise
300	those	_	_	I-Premise
301	who	_	_	I-Premise
302	received	_	_	I-Premise
303	zoledronic	_	_	I-Premise
304	acid	_	_	I-Premise
305	at	_	_	I-Premise
306	8/4	_	_	I-Premise
307	mg	_	_	I-Premise
308	(	_	_	I-Premise
309	P	_	_	I-Premise
310	=.491	_	_	I-Premise
311	versus	_	_	I-Premise
312	placebo	_	_	I-Premise
313	)	_	_	I-Premise
314	.	_	_	I-Premise

315	Compared	_	_	B-Premise
316	with	_	_	I-Premise
317	urinary	_	_	I-Premise
318	markers	_	_	I-Premise
319	in	_	_	I-Premise
320	patients	_	_	I-Premise
321	who	_	_	I-Premise
322	received	_	_	I-Premise
323	placebo	_	_	I-Premise
324	,	_	_	I-Premise
325	urinary	_	_	I-Premise
326	markers	_	_	I-Premise
327	of	_	_	I-Premise
328	bone	_	_	I-Premise
329	resorption	_	_	I-Premise
330	were	_	_	I-Premise
331	statistically	_	_	I-Premise
332	significantly	_	_	I-Premise
333	decreased	_	_	I-Premise
334	in	_	_	I-Premise
335	patients	_	_	I-Premise
336	who	_	_	I-Premise
337	received	_	_	I-Premise
338	zoledronic	_	_	I-Premise
339	acid	_	_	I-Premise
340	at	_	_	I-Premise
341	either	_	_	I-Premise
342	dose	_	_	I-Premise
343	(	_	_	I-Premise
344	P	_	_	I-Premise
345	=.001	_	_	I-Premise
346	)	_	_	I-Premise
347	.	_	_	I-Premise

348	Pain	_	_	B-Premise
349	and	_	_	I-Premise
350	analgesic	_	_	I-Premise
351	scores	_	_	I-Premise
352	increased	_	_	I-Premise
353	more	_	_	I-Premise
354	in	_	_	I-Premise
355	patients	_	_	I-Premise
356	who	_	_	I-Premise
357	received	_	_	I-Premise
358	placebo	_	_	I-Premise
359	than	_	_	I-Premise
360	in	_	_	I-Premise
361	patients	_	_	I-Premise
362	who	_	_	I-Premise
363	received	_	_	I-Premise
364	zoledronic	_	_	I-Premise
365	acid	_	_	I-Premise
366	,	_	_	I-Premise
367	but	_	_	O
368	there	_	_	B-Premise
369	were	_	_	I-Premise
370	no	_	_	I-Premise
371	differences	_	_	I-Premise
372	in	_	_	I-Premise
373	disease	_	_	I-Premise
374	progression	_	_	I-Premise
375	,	_	_	I-Premise
376	performance	_	_	I-Premise
377	status	_	_	I-Premise
378	,	_	_	I-Premise
379	or	_	_	I-Premise
380	quality-of-life	_	_	I-Premise
381	scores	_	_	I-Premise
382	among	_	_	I-Premise
383	the	_	_	I-Premise
384	groups	_	_	I-Premise
385	.	_	_	I-Premise

386	Zoledronic	_	_	B-Claim
387	acid	_	_	I-Claim
388	at	_	_	I-Claim
389	4	_	_	I-Claim
390	mg	_	_	I-Claim
391	given	_	_	I-Claim
392	as	_	_	I-Claim
393	a	_	_	I-Claim
394	15-minute	_	_	I-Claim
395	infusion	_	_	I-Claim
396	was	_	_	I-Claim
397	well	_	_	I-Claim
398	tolerated	_	_	I-Claim
399	,	_	_	I-Claim
400	but	_	_	O
401	the	_	_	B-Claim
402	8-mg	_	_	I-Claim
403	dose	_	_	I-Claim
404	was	_	_	I-Claim
405	associated	_	_	I-Claim
406	with	_	_	I-Claim
407	renal	_	_	I-Claim
408	function	_	_	I-Claim
409	deterioration	_	_	I-Claim
410	.	_	_	I-Claim

411	Zoledronic	_	_	B-Claim
412	acid	_	_	I-Claim
413	at	_	_	I-Claim
414	4	_	_	I-Claim
415	mg	_	_	I-Claim
416	reduced	_	_	I-Claim
417	skeletal-related	_	_	I-Claim
418	events	_	_	I-Claim
419	in	_	_	I-Claim
420	prostate	_	_	I-Claim
421	cancer	_	_	I-Claim
422	patients	_	_	I-Claim
423	with	_	_	I-Claim
424	bone	_	_	I-Claim
425	metastases	_	_	I-Claim
426	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	in	_	_	O
3	a	_	_	O
4	phase	_	_	O
5	III	_	_	O
6	study	_	_	O
7	the	_	_	O
8	safety	_	_	O
9	and	_	_	O
10	efficacy	_	_	O
11	of	_	_	O
12	fludarabine	_	_	O
13	to	_	_	O
14	that	_	_	O
15	of	_	_	O
16	cyclophosphamide	_	_	O
17	,	_	_	O
18	vincristine	_	_	O
19	,	_	_	O
20	and	_	_	O
21	prednisone	_	_	O
22	(	_	_	O
23	CVP	_	_	O
24	)	_	_	O
25	in	_	_	O
26	recurrent	_	_	O
27	,	_	_	O
28	low-grade	_	_	O
29	,	_	_	O
30	non-Hodgkin	_	_	O
31	's	_	_	O
32	lymphoma	_	_	O
33	after	_	_	O
34	previous	_	_	O
35	response	_	_	O
36	to	_	_	O
37	systemic	_	_	O
38	treatment	_	_	O
39	.	_	_	O

40	Patients	_	_	O
41	were	_	_	O
42	randomized	_	_	O
43	to	_	_	O
44	fludarabine	_	_	O
45	(	_	_	O
46	25	_	_	O
47	mg/m	_	_	O
48	(	_	_	O
49	2	_	_	O
50	)	_	_	O
51	intravenously	_	_	O
52	on	_	_	O
53	days	_	_	O
54	1	_	_	O
55	to	_	_	O
56	5	_	_	O
57	,	_	_	O
58	every	_	_	O
59	28	_	_	O
60	days	_	_	O
61	)	_	_	O
62	or	_	_	O
63	CVP	_	_	O
64	(	_	_	O
65	cyclophosphamide	_	_	O
66	750	_	_	O
67	mg/m	_	_	O
68	(	_	_	O
69	2	_	_	O
70	)	_	_	O
71	and	_	_	O
72	vincristine	_	_	O
73	1.2	_	_	O
74	mg/m	_	_	O
75	(	_	_	O
76	2	_	_	O
77	)	_	_	O
78	both	_	_	O
79	intravenously	_	_	O
80	on	_	_	O
81	day	_	_	O
82	1	_	_	O
83	and	_	_	O
84	prednisone	_	_	O
85	40	_	_	O
86	mg/m	_	_	O
87	(	_	_	O
88	2	_	_	O
89	)	_	_	O
90	orally	_	_	O
91	on	_	_	O
92	days	_	_	O
93	1	_	_	O
94	to	_	_	O
95	5	_	_	O
96	,	_	_	O
97	every	_	_	O
98	21	_	_	O
99	days	_	_	O
100	)	_	_	O
101	.	_	_	O

102	The	_	_	O
103	primary	_	_	O
104	outcome	_	_	O
105	assessed	_	_	O
106	was	_	_	O
107	progression-free	_	_	O
108	survival	_	_	O
109	(	_	_	O
110	PFS	_	_	O
111	)	_	_	O
112	;	_	_	O
113	secondary	_	_	O
114	outcomes	_	_	O
115	included	_	_	O
116	treatment-free	_	_	O
117	survival	_	_	O
118	(	_	_	O
119	TFS	_	_	O
120	)	_	_	O
121	,	_	_	O
122	overall	_	_	O
123	survival	_	_	O
124	(	_	_	O
125	OS	_	_	O
126	)	_	_	O
127	,	_	_	O
128	treatment-related	_	_	O
129	toxicity	_	_	O
130	,	_	_	O
131	and	_	_	O
132	quality	_	_	O
133	of	_	_	O
134	life	_	_	O
135	(	_	_	O
136	QoL	_	_	O
137	)	_	_	O
138	according	_	_	O
139	to	_	_	O
140	the	_	_	O
141	European	_	_	O
142	Organization	_	_	O
143	for	_	_	O
144	Research	_	_	O
145	and	_	_	O
146	Treatment	_	_	O
147	of	_	_	O
148	Cancer	_	_	O
149	's	_	_	O
150	Quality	_	_	O
151	of	_	_	O
152	Life	_	_	O
153	Questionnaire	_	_	O
154	C-30	_	_	O
155	version	_	_	O
156	1.0	_	_	O
157	instrument	_	_	O
158	.	_	_	O

159	Ninety-one	_	_	O
160	patients	_	_	O
161	were	_	_	O
162	randomized	_	_	O
163	,	_	_	O
164	47	_	_	O
165	to	_	_	O
166	fludarabine	_	_	O
167	and	_	_	O
168	44	_	_	O
169	to	_	_	O
170	CVP	_	_	O
171	.	_	_	O

172	There	_	_	B-Premise
173	was	_	_	I-Premise
174	no	_	_	I-Premise
175	difference	_	_	I-Premise
176	in	_	_	I-Premise
177	response	_	_	I-Premise
178	rates	_	_	I-Premise
179	,	_	_	I-Premise
180	with	_	_	I-Premise
181	64	_	_	I-Premise
182	%	_	_	I-Premise
183	(	_	_	I-Premise
184	complete	_	_	I-Premise
185	response	_	_	I-Premise
186	[	_	_	I-Premise
187	CR	_	_	I-Premise
188	]	_	_	I-Premise
189	,	_	_	I-Premise
190	9	_	_	I-Premise
191	%	_	_	I-Premise
192	)	_	_	I-Premise
193	for	_	_	I-Premise
194	fludarabine	_	_	I-Premise
195	versus	_	_	I-Premise
196	52	_	_	I-Premise
197	%	_	_	I-Premise
198	(	_	_	I-Premise
199	CR	_	_	I-Premise
200	,	_	_	I-Premise
201	7	_	_	I-Premise
202	%	_	_	I-Premise
203	)	_	_	I-Premise
204	for	_	_	I-Premise
205	CVP	_	_	I-Premise
206	(	_	_	I-Premise
207	P	_	_	I-Premise
208	=.72	_	_	I-Premise
209	)	_	_	I-Premise
210	.	_	_	I-Premise

211	With	_	_	B-Premise
212	a	_	_	I-Premise
213	median	_	_	I-Premise
214	follow-up	_	_	I-Premise
215	of	_	_	I-Premise
216	42	_	_	I-Premise
217	months	_	_	I-Premise
218	,	_	_	I-Premise
219	median	_	_	I-Premise
220	PFS	_	_	I-Premise
221	(	_	_	I-Premise
222	11	_	_	I-Premise
223	months	_	_	I-Premise
224	v	_	_	I-Premise
225	9.1	_	_	I-Premise
226	months	_	_	I-Premise
227	;	_	_	I-Premise
228	P	_	_	I-Premise
229	=.03	_	_	I-Premise
230	)	_	_	I-Premise
231	and	_	_	I-Premise
232	TFS	_	_	I-Premise
233	(	_	_	I-Premise
234	15	_	_	I-Premise
235	months	_	_	I-Premise
236	v	_	_	I-Premise
237	11	_	_	I-Premise
238	months	_	_	I-Premise
239	;	_	_	I-Premise
240	P	_	_	I-Premise
241	=.02	_	_	I-Premise
242	)	_	_	I-Premise
243	were	_	_	I-Premise
244	superior	_	_	I-Premise
245	in	_	_	I-Premise
246	patients	_	_	I-Premise
247	receiving	_	_	I-Premise
248	fludarabine	_	_	I-Premise
249	.	_	_	I-Premise

250	No	_	_	B-Premise
251	difference	_	_	I-Premise
252	in	_	_	I-Premise
253	median	_	_	I-Premise
254	overall	_	_	I-Premise
255	survival	_	_	I-Premise
256	was	_	_	I-Premise
257	detected	_	_	I-Premise
258	(	_	_	I-Premise
259	57	_	_	I-Premise
260	months	_	_	I-Premise
261	for	_	_	I-Premise
262	fludarabine	_	_	I-Premise
263	v	_	_	I-Premise
264	44	_	_	I-Premise
265	months	_	_	I-Premise
266	for	_	_	I-Premise
267	CVP	_	_	I-Premise
268	;	_	_	I-Premise
269	P	_	_	I-Premise
270	=.95	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	Three	_	_	B-Premise
274	patients	_	_	I-Premise
275	receiving	_	_	I-Premise
276	fludarabine	_	_	I-Premise
277	died	_	_	I-Premise
278	of	_	_	I-Premise
279	treatment-related	_	_	I-Premise
280	toxicity	_	_	I-Premise
281	compared	_	_	I-Premise
282	with	_	_	I-Premise
283	none	_	_	I-Premise
284	of	_	_	I-Premise
285	the	_	_	I-Premise
286	patients	_	_	I-Premise
287	receiving	_	_	I-Premise
288	CVP	_	_	I-Premise
289	.	_	_	I-Premise

290	Peripheral	_	_	B-Premise
291	neuropathy	_	_	I-Premise
292	and	_	_	I-Premise
293	alopecia	_	_	I-Premise
294	were	_	_	I-Premise
295	more	_	_	I-Premise
296	common	_	_	I-Premise
297	with	_	_	I-Premise
298	CVP	_	_	I-Premise
299	.	_	_	I-Premise

300	Patients	_	_	B-Premise
301	receiving	_	_	I-Premise
302	fludarabine	_	_	I-Premise
303	had	_	_	I-Premise
304	higher	_	_	I-Premise
305	scores	_	_	I-Premise
306	for	_	_	I-Premise
307	social	_	_	I-Premise
308	function	_	_	I-Premise
309	(	_	_	I-Premise
310	P	_	_	I-Premise
311	=.008	_	_	I-Premise
312	)	_	_	I-Premise
313	;	_	_	I-Premise
314	no	_	_	B-Premise
315	other	_	_	I-Premise
316	differences	_	_	I-Premise
317	in	_	_	I-Premise
318	QoL	_	_	I-Premise
319	were	_	_	I-Premise
320	detected	_	_	I-Premise
321	.	_	_	I-Premise

322	In	_	_	B-Claim
323	recurrent	_	_	I-Claim
324	low-grade	_	_	I-Claim
325	lymphoma	_	_	I-Claim
326	,	_	_	I-Claim
327	fludarabine	_	_	I-Claim
328	improves	_	_	I-Claim
329	PFS	_	_	I-Claim
330	,	_	_	I-Claim
331	TFS	_	_	I-Claim
332	,	_	_	I-Claim
333	and	_	_	I-Claim
334	social	_	_	I-Claim
335	function	_	_	I-Claim
336	scores	_	_	I-Claim
337	in	_	_	I-Claim
338	comparison	_	_	I-Claim
339	with	_	_	I-Claim
340	CVP	_	_	I-Claim
341	but	_	_	I-Claim
342	does	_	_	I-Claim
343	not	_	_	I-Claim
344	improve	_	_	I-Claim
345	OS	_	_	I-Claim
346	.	_	_	I-Claim


0	Anemia	_	_	B-Claim
1	,	_	_	I-Claim
2	highly	_	_	I-Claim
3	common	_	_	I-Claim
4	among	_	_	I-Claim
5	cancer	_	_	I-Claim
6	patients	_	_	I-Claim
7	,	_	_	I-Claim
8	is	_	_	I-Claim
9	often	_	_	I-Claim
10	an	_	_	I-Claim
11	underlying	_	_	I-Claim
12	cause	_	_	I-Claim
13	of	_	_	I-Claim
14	cancer-related	_	_	I-Claim
15	fatigue	_	_	I-Claim
16	and	_	_	I-Claim
17	other	_	_	I-Claim
18	quality-of-life	_	_	I-Claim
19	(	_	_	I-Claim
20	QOL	_	_	I-Claim
21	)	_	_	I-Claim
22	deficits	_	_	I-Claim
23	.	_	_	I-Claim

24	Although	_	_	O
25	randomized	_	_	O
26	clinical	_	_	O
27	trials	_	_	O
28	have	_	_	O
29	shown	_	_	O
30	that	_	_	O
31	treatment	_	_	O
32	with	_	_	O
33	epoetin	_	_	O
34	alfa	_	_	O
35	increases	_	_	O
36	hemoglobin	_	_	O
37	levels	_	_	O
38	,	_	_	O
39	reduces	_	_	O
40	fatigue	_	_	O
41	,	_	_	O
42	lessens	_	_	O
43	transfusion	_	_	O
44	requirements	_	_	O
45	,	_	_	O
46	and	_	_	O
47	improves	_	_	O
48	overall	_	_	O
49	QOL	_	_	O
50	,	_	_	O
51	cancer-related	_	_	O
52	anemia	_	_	O
53	and	_	_	O
54	fatigue	_	_	O
55	remain	_	_	O
56	undertreated	_	_	O
57	.	_	_	O

58	This	_	_	O
59	is	_	_	O
60	,	_	_	O
61	in	_	_	O
62	part	_	_	O
63	,	_	_	O
64	because	_	_	O
65	scales	_	_	O
66	and	_	_	O
67	measures	_	_	O
68	of	_	_	O
69	QOL	_	_	O
70	are	_	_	O
71	still	_	_	O
72	relatively	_	_	O
73	unfamiliar	_	_	O
74	to	_	_	O
75	most	_	_	O
76	clinicians	_	_	O
77	and	_	_	O
78	because	_	_	O
79	population-based	_	_	O
80	reference	_	_	O
81	ranges	_	_	O
82	are	_	_	O
83	lacking	_	_	O
84	,	_	_	O
85	thus	_	_	O
86	making	_	_	O
87	clinical	_	_	O
88	trial	_	_	O
89	results	_	_	O
90	difficult	_	_	O
91	to	_	_	O
92	interpret	_	_	O
93	.	_	_	O

94	To	_	_	O
95	aid	_	_	O
96	in	_	_	O
97	the	_	_	O
98	interpretation	_	_	O
99	of	_	_	O
100	QOL	_	_	O
101	results	_	_	O
102	from	_	_	O
103	clinical	_	_	O
104	trials	_	_	O
105	,	_	_	O
106	we	_	_	O
107	administered	_	_	O
108	the	_	_	O
109	Functional	_	_	O
110	Assessment	_	_	O
111	of	_	_	O
112	Cancer	_	_	O
113	Therapy-Anemia	_	_	O
114	(	_	_	O
115	FACT-An	_	_	O
116	)	_	_	O
117	QOL	_	_	O
118	instrument	_	_	O
119	to	_	_	O
120	a	_	_	O
121	nationally	_	_	O
122	representative	_	_	O
123	sample	_	_	O
124	of	_	_	O
125	1,400	_	_	O
126	people	_	_	O
127	using	_	_	O
128	an	_	_	O
129	Internet	_	_	O
130	survey	_	_	O
131	panel	_	_	O
132	in	_	_	O
133	the	_	_	O
134	United	_	_	O
135	States	_	_	O
136	.	_	_	O

137	We	_	_	O
138	then	_	_	O
139	compared	_	_	O
140	the	_	_	O
141	FACT-An	_	_	O
142	data	_	_	O
143	from	_	_	O
144	the	_	_	O
145	Internet	_	_	O
146	survey	_	_	O
147	with	_	_	O
148	the	_	_	O
149	QOL	_	_	O
150	data	_	_	O
151	of	_	_	O
152	a	_	_	O
153	375-patient	_	_	O
154	randomized	_	_	O
155	,	_	_	O
156	double-blind	_	_	O
157	clinical	_	_	O
158	trial	_	_	O
159	evaluating	_	_	O
160	epoetin	_	_	O
161	alfa	_	_	O
162	versus	_	_	O
163	placebo	_	_	O
164	in	_	_	O
165	anemic	_	_	O
166	cancer	_	_	O
167	patients	_	_	O
168	.	_	_	O

169	FACT-An	_	_	O
170	,	_	_	O
171	as	_	_	O
172	administered	_	_	O
173	to	_	_	O
174	the	_	_	O
175	survey	_	_	O
176	population	_	_	O
177	,	_	_	O
178	displayed	_	_	O
179	good	_	_	O
180	psychometric	_	_	O
181	properties	_	_	O
182	and	_	_	O
183	was	_	_	O
184	able	_	_	O
185	to	_	_	O
186	discriminate	_	_	O
187	between	_	_	O
188	respondents	_	_	O
189	with	_	_	O
190	histories	_	_	O
191	of	_	_	O
192	specified	_	_	O
193	illnesses	_	_	O
194	,	_	_	O
195	including	_	_	O
196	anemia	_	_	O
197	and	_	_	O
198	cancer	_	_	O
199	,	_	_	O
200	and	_	_	O
201	those	_	_	O
202	without	_	_	O
203	.	_	_	O

204	Comparison	_	_	B-Premise
205	of	_	_	I-Premise
206	the	_	_	I-Premise
207	population	_	_	I-Premise
208	norm	_	_	I-Premise
209	and	_	_	I-Premise
210	clinical	_	_	I-Premise
211	trial	_	_	I-Premise
212	data	_	_	I-Premise
213	showed	_	_	I-Premise
214	that	_	_	I-Premise
215	treatment	_	_	I-Premise
216	with	_	_	I-Premise
217	epoetin	_	_	I-Premise
218	alfa	_	_	I-Premise
219	resulted	_	_	I-Premise
220	in	_	_	I-Premise
221	clinically	_	_	I-Premise
222	meaningful	_	_	I-Premise
223	as	_	_	I-Premise
224	well	_	_	I-Premise
225	as	_	_	I-Premise
226	statistically	_	_	I-Premise
227	significant	_	_	I-Premise
228	improvements	_	_	I-Premise
229	in	_	_	I-Premise
230	QOL	_	_	I-Premise
231	(	_	_	I-Premise
232	P	_	_	I-Premise
233	<	_	_	I-Premise
234	.01	_	_	I-Premise
235	)	_	_	I-Premise
236	.	_	_	I-Premise

237	Reliable	_	_	O
238	population	_	_	O
239	norm	_	_	O
240	data	_	_	O
241	are	_	_	O
242	now	_	_	O
243	available	_	_	O
244	to	_	_	O
245	aid	_	_	O
246	in	_	_	O
247	the	_	_	O
248	interpretation	_	_	O
249	of	_	_	O
250	clinical	_	_	O
251	trial	_	_	O
252	results	_	_	O
253	where	_	_	O
254	the	_	_	O
255	FACT-An	_	_	O
256	questionnaire	_	_	O
257	is	_	_	O
258	administered	_	_	O
259	.	_	_	O

260	In	_	_	B-Claim
261	the	_	_	I-Claim
262	clinical	_	_	I-Claim
263	trial	_	_	I-Claim
264	,	_	_	I-Claim
265	treatment	_	_	I-Claim
266	with	_	_	I-Claim
267	epoetin	_	_	I-Claim
268	alfa	_	_	I-Claim
269	overcame	_	_	I-Claim
270	much	_	_	I-Claim
271	of	_	_	I-Claim
272	the	_	_	I-Claim
273	QOL	_	_	I-Claim
274	deficit	_	_	I-Claim
275	seen	_	_	I-Claim
276	in	_	_	I-Claim
277	anemic	_	_	I-Claim
278	cancer	_	_	I-Claim
279	patients	_	_	I-Claim
280	compared	_	_	I-Claim
281	with	_	_	I-Claim
282	the	_	_	I-Claim
283	norm	_	_	I-Claim
284	population	_	_	I-Claim
285	sample	_	_	I-Claim
286	.	_	_	I-Claim


0	We	_	_	O
1	compared	_	_	O
2	the	_	_	O
3	clinical	_	_	O
4	effects	_	_	O
5	and	_	_	O
6	impact	_	_	O
7	on	_	_	O
8	quality	_	_	O
9	of	_	_	O
10	life	_	_	O
11	(	_	_	O
12	QOL	_	_	O
13	)	_	_	O
14	of	_	_	O
15	patients	_	_	O
16	who	_	_	O
17	received	_	_	O
18	a	_	_	O
19	3-month	_	_	O
20	course	_	_	O
21	of	_	_	O
22	flutamide	_	_	O
23	monotherapy	_	_	O
24	before	_	_	O
25	radical	_	_	O
26	prostatectomy	_	_	O
27	with	_	_	O
28	those	_	_	O
29	who	_	_	O
30	received	_	_	O
31	a	_	_	O
32	3-month	_	_	O
33	course	_	_	O
34	of	_	_	O
35	luteinizing	_	_	O
36	hormone-releasing	_	_	O
37	hormone	_	_	O
38	(	_	_	O
39	LHRH	_	_	O
40	)	_	_	O
41	agonist	_	_	O
42	monotherapy	_	_	O
43	.	_	_	O

44	Thirty-seven	_	_	O
45	patients	_	_	O
46	with	_	_	O
47	non-metastatic	_	_	O
48	prostate	_	_	O
49	cancer	_	_	O
50	were	_	_	O
51	enrolled	_	_	O
52	in	_	_	O
53	this	_	_	O
54	study	_	_	O
55	(	_	_	O
56	19	_	_	O
57	,	_	_	O
58	flutamide	_	_	O
59	;	_	_	O
60	18	_	_	O
61	,	_	_	O
62	LHRH	_	_	O
63	agonist	_	_	O
64	)	_	_	O
65	.	_	_	O

66	The	_	_	O
67	rates	_	_	O
68	of	_	_	O
69	change	_	_	O
70	of	_	_	O
71	serum	_	_	O
72	prostate-specific	_	_	O
73	antigen	_	_	O
74	(	_	_	O
75	PSA	_	_	O
76	)	_	_	O
77	and	_	_	O
78	testosterone	_	_	O
79	levels	_	_	O
80	,	_	_	O
81	downsizing	_	_	O
82	of	_	_	O
83	prostate	_	_	O
84	volume	_	_	O
85	,	_	_	O
86	the	_	_	O
87	rate	_	_	O
88	of	_	_	O
89	organ	_	_	O
90	confined	_	_	O
91	disease	_	_	O
92	,	_	_	O
93	adverse	_	_	O
94	effects	_	_	O
95	and	_	_	O
96	perioperative	_	_	O
97	scores	_	_	O
98	measured	_	_	O
99	using	_	_	O
100	the	_	_	O
101	European	_	_	O
102	Organization	_	_	O
103	for	_	_	O
104	Research	_	_	O
105	and	_	_	O
106	Treatment	_	_	O
107	of	_	_	O
108	Cancer	_	_	O
109	Prostate	_	_	O
110	Cancer	_	_	O
111	Quality	_	_	O
112	of	_	_	O
113	Life	_	_	O
114	Questionnaire	_	_	O
115	(	_	_	O
116	EORTC-P	_	_	O
117	)	_	_	O
118	and	_	_	O
119	the	_	_	O
120	Sapporo	_	_	O
121	Medical	_	_	O
122	University	_	_	O
123	Sexual	_	_	O
124	Function	_	_	O
125	Questionnaire	_	_	O
126	(	_	_	O
127	SMUF	_	_	O
128	)	_	_	O
129	were	_	_	O
130	analyzed	_	_	O
131	.	_	_	O

132	At	_	_	B-Premise
133	radical	_	_	I-Premise
134	prostatectomy	_	_	I-Premise
135	,	_	_	I-Premise
136	pathological	_	_	I-Premise
137	variables	_	_	I-Premise
138	were	_	_	I-Premise
139	not	_	_	I-Premise
140	significantly	_	_	I-Premise
141	different	_	_	I-Premise
142	in	_	_	I-Premise
143	the	_	_	I-Premise
144	two	_	_	I-Premise
145	groups	_	_	I-Premise
146	.	_	_	I-Premise

147	Serum	_	_	B-Premise
148	testosterone	_	_	I-Premise
149	level	_	_	I-Premise
150	was	_	_	I-Premise
151	significantly	_	_	I-Premise
152	higher	_	_	I-Premise
153	(	_	_	I-Premise
154	mean	_	_	I-Premise
155	359.2	_	_	I-Premise
156	compared	_	_	I-Premise
157	to	_	_	I-Premise
158	10.5	_	_	I-Premise
159	,	_	_	I-Premise
160	P	_	_	I-Premise
161	<	_	_	I-Premise
162	0.001	_	_	I-Premise
163	)	_	_	I-Premise
164	,	_	_	I-Premise
165	complete	_	_	B-Premise
166	response	_	_	I-Premise
167	rate	_	_	I-Premise
168	of	_	_	I-Premise
169	PSA	_	_	I-Premise
170	(	_	_	I-Premise
171	13	_	_	I-Premise
172	%	_	_	I-Premise
173	compared	_	_	I-Premise
174	to	_	_	I-Premise
175	57	_	_	I-Premise
176	%	_	_	I-Premise
177	,	_	_	I-Premise
178	P	_	_	I-Premise
179	=	_	_	I-Premise
180	0.028	_	_	I-Premise
181	)	_	_	I-Premise
182	and	_	_	I-Premise
183	rate	_	_	I-Premise
184	of	_	_	I-Premise
185	downsizing	_	_	I-Premise
186	of	_	_	I-Premise
187	prostate	_	_	I-Premise
188	volume	_	_	I-Premise
189	(	_	_	I-Premise
190	mean	_	_	I-Premise
191	,	_	_	I-Premise
192	-17.7	_	_	I-Premise
193	%	_	_	I-Premise
194	compared	_	_	I-Premise
195	to	_	_	I-Premise
196	-35.4	_	_	I-Premise
197	%	_	_	I-Premise
198	,	_	_	I-Premise
199	P	_	_	I-Premise
200	=	_	_	I-Premise
201	0.038	_	_	I-Premise
202	)	_	_	I-Premise
203	were	_	_	I-Premise
204	significantly	_	_	I-Premise
205	lower	_	_	I-Premise
206	in	_	_	I-Premise
207	the	_	_	I-Premise
208	flutamide	_	_	I-Premise
209	group	_	_	I-Premise
210	than	_	_	I-Premise
211	in	_	_	I-Premise
212	the	_	_	I-Premise
213	LHRH	_	_	I-Premise
214	group	_	_	I-Premise
215	.	_	_	I-Premise

216	After	_	_	B-Premise
217	neoadjuvant	_	_	I-Premise
218	hormone	_	_	I-Premise
219	therapy	_	_	I-Premise
220	,	_	_	I-Premise
221	the	_	_	I-Premise
222	scores	_	_	I-Premise
223	on	_	_	I-Premise
224	the	_	_	I-Premise
225	sexual	_	_	I-Premise
226	problem	_	_	I-Premise
227	domain	_	_	I-Premise
228	of	_	_	I-Premise
229	EORTC-P	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	=	_	_	I-Premise
233	0.033	_	_	I-Premise
234	)	_	_	I-Premise
235	and	_	_	I-Premise
236	sexual	_	_	I-Premise
237	desire	_	_	I-Premise
238	score	_	_	I-Premise
239	of	_	_	I-Premise
240	SMUF	_	_	I-Premise
241	(	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	0.021	_	_	I-Premise
245	)	_	_	I-Premise
246	were	_	_	I-Premise
247	significantly	_	_	I-Premise
248	higher	_	_	I-Premise
249	in	_	_	I-Premise
250	the	_	_	I-Premise
251	flutamide	_	_	I-Premise
252	group	_	_	I-Premise
253	than	_	_	I-Premise
254	in	_	_	I-Premise
255	the	_	_	I-Premise
256	LHRH	_	_	I-Premise
257	group	_	_	I-Premise
258	.	_	_	I-Premise

259	At	_	_	B-Premise
260	a	_	_	I-Premise
261	median	_	_	I-Premise
262	follow-up	_	_	I-Premise
263	of	_	_	I-Premise
264	34	_	_	I-Premise
265	months	_	_	I-Premise
266	after	_	_	I-Premise
267	prostatectomy	_	_	I-Premise
268	,	_	_	I-Premise
269	biochemical	_	_	I-Premise
270	failure-free	_	_	I-Premise
271	survival	_	_	I-Premise
272	rate	_	_	I-Premise
273	in	_	_	I-Premise
274	the	_	_	I-Premise
275	flutamide	_	_	I-Premise
276	group	_	_	I-Premise
277	did	_	_	I-Premise
278	not	_	_	I-Premise
279	differ	_	_	I-Premise
280	from	_	_	I-Premise
281	that	_	_	I-Premise
282	in	_	_	I-Premise
283	the	_	_	I-Premise
284	LHRH	_	_	I-Premise
285	group	_	_	I-Premise
286	.	_	_	I-Premise

287	This	_	_	B-Claim
288	study	_	_	I-Claim
289	suggests	_	_	I-Claim
290	that	_	_	I-Claim
291	flutamide	_	_	I-Claim
292	monotherapy	_	_	I-Claim
293	can	_	_	I-Claim
294	be	_	_	I-Claim
295	an	_	_	I-Claim
296	acceptable	_	_	I-Claim
297	modality	_	_	I-Claim
298	as	_	_	I-Claim
299	an	_	_	I-Claim
300	option	_	_	I-Claim
301	for	_	_	I-Claim
302	neoadjuvant	_	_	I-Claim
303	hormone	_	_	I-Claim
304	therapy	_	_	I-Claim
305	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	tolerability	_	_	O
6	of	_	_	O
7	two	_	_	O
8	doses	_	_	O
9	of	_	_	O
10	gefitinib	_	_	O
11	(	_	_	O
12	Iressa	_	_	O
13	[	_	_	O
14	ZD1839	_	_	O
15	]	_	_	O
16	;	_	_	O
17	AstraZeneca	_	_	O
18	,	_	_	O
19	Wilmington	_	_	O
20	,	_	_	O
21	DE	_	_	O
22	)	_	_	O
23	,	_	_	O
24	a	_	_	O
25	novel	_	_	O
26	epidermal	_	_	O
27	growth	_	_	O
28	factor	_	_	O
29	receptor	_	_	O
30	tyrosine	_	_	O
31	kinase	_	_	O
32	inhibitor	_	_	O
33	,	_	_	O
34	in	_	_	O
35	patients	_	_	O
36	with	_	_	O
37	pretreated	_	_	O
38	advanced	_	_	O
39	non-small-cell	_	_	O
40	lung	_	_	O
41	cancer	_	_	O
42	(	_	_	O
43	NSCLC	_	_	O
44	)	_	_	O
45	.	_	_	O

46	This	_	_	O
47	was	_	_	O
48	a	_	_	O
49	randomized	_	_	O
50	,	_	_	O
51	double-blind	_	_	O
52	,	_	_	O
53	parallel-group	_	_	O
54	,	_	_	O
55	multicenter	_	_	O
56	phase	_	_	O
57	II	_	_	O
58	trial	_	_	O
59	.	_	_	O

60	Two	_	_	O
61	hundred	_	_	O
62	ten	_	_	O
63	patients	_	_	O
64	with	_	_	O
65	advanced	_	_	O
66	NSCLC	_	_	O
67	who	_	_	O
68	were	_	_	O
69	previously	_	_	O
70	treated	_	_	O
71	with	_	_	O
72	one	_	_	O
73	or	_	_	O
74	two	_	_	O
75	chemotherapy	_	_	O
76	regimens	_	_	O
77	(	_	_	O
78	at	_	_	O
79	least	_	_	O
80	one	_	_	O
81	containing	_	_	O
82	platinum	_	_	O
83	)	_	_	O
84	were	_	_	O
85	randomly	_	_	O
86	assigned	_	_	O
87	to	_	_	O
88	receive	_	_	O
89	either	_	_	O
90	250-mg	_	_	O
91	or	_	_	O
92	500-mg	_	_	O
93	oral	_	_	O
94	doses	_	_	O
95	of	_	_	O
96	gefitinib	_	_	O
97	once	_	_	O
98	daily	_	_	O
99	.	_	_	O

100	Efficacy	_	_	B-Premise
101	was	_	_	I-Premise
102	similar	_	_	I-Premise
103	for	_	_	I-Premise
104	the	_	_	I-Premise
105	250-	_	_	I-Premise
106	and	_	_	I-Premise
107	500-mg/d	_	_	I-Premise
108	groups	_	_	I-Premise
109	.	_	_	I-Premise

110	Objective	_	_	B-Premise
111	tumor	_	_	I-Premise
112	response	_	_	I-Premise
113	rates	_	_	I-Premise
114	were	_	_	I-Premise
115	18.4	_	_	I-Premise
116	%	_	_	I-Premise
117	(	_	_	I-Premise
118	95	_	_	I-Premise
119	%	_	_	I-Premise
120	confidence	_	_	I-Premise
121	interval	_	_	I-Premise
122	[	_	_	I-Premise
123	CI	_	_	I-Premise
124	]	_	_	I-Premise
125	,	_	_	I-Premise
126	11.5	_	_	I-Premise
127	to	_	_	I-Premise
128	27.3	_	_	I-Premise
129	)	_	_	I-Premise
130	and	_	_	I-Premise
131	19.0	_	_	I-Premise
132	%	_	_	I-Premise
133	(	_	_	I-Premise
134	95	_	_	I-Premise
135	%	_	_	I-Premise
136	CI	_	_	I-Premise
137	,	_	_	I-Premise
138	12.1	_	_	I-Premise
139	to	_	_	I-Premise
140	27.9	_	_	I-Premise
141	)	_	_	I-Premise
142	;	_	_	I-Premise
143	among	_	_	I-Premise
144	evaluable	_	_	I-Premise
145	patients	_	_	I-Premise
146	,	_	_	I-Premise
147	symptom	_	_	I-Premise
148	improvement	_	_	I-Premise
149	rates	_	_	I-Premise
150	were	_	_	I-Premise
151	40.3	_	_	I-Premise
152	%	_	_	I-Premise
153	(	_	_	I-Premise
154	95	_	_	I-Premise
155	%	_	_	I-Premise
156	CI	_	_	I-Premise
157	,	_	_	I-Premise
158	28.5	_	_	I-Premise
159	to	_	_	I-Premise
160	53.0	_	_	I-Premise
161	)	_	_	I-Premise
162	and	_	_	I-Premise
163	37.0	_	_	I-Premise
164	%	_	_	I-Premise
165	(	_	_	I-Premise
166	95	_	_	I-Premise
167	%	_	_	I-Premise
168	CI	_	_	I-Premise
169	,	_	_	I-Premise
170	26.0	_	_	I-Premise
171	to	_	_	I-Premise
172	49.1	_	_	I-Premise
173	)	_	_	I-Premise
174	;	_	_	I-Premise
175	median	_	_	I-Premise
176	progression-free	_	_	I-Premise
177	survival	_	_	I-Premise
178	times	_	_	I-Premise
179	were	_	_	I-Premise
180	2.7	_	_	I-Premise
181	and	_	_	I-Premise
182	2.8	_	_	I-Premise
183	months	_	_	I-Premise
184	;	_	_	I-Premise
185	and	_	_	I-Premise
186	median	_	_	I-Premise
187	overall	_	_	I-Premise
188	survival	_	_	I-Premise
189	times	_	_	I-Premise
190	were	_	_	I-Premise
191	7.6	_	_	I-Premise
192	and	_	_	I-Premise
193	8.0	_	_	I-Premise
194	months	_	_	I-Premise
195	,	_	_	I-Premise
196	respectively	_	_	I-Premise
197	.	_	_	I-Premise

198	Symptom	_	_	B-Premise
199	improvements	_	_	I-Premise
200	were	_	_	I-Premise
201	recorded	_	_	I-Premise
202	for	_	_	I-Premise
203	69.2	_	_	I-Premise
204	%	_	_	I-Premise
205	(	_	_	I-Premise
206	250	_	_	I-Premise
207	mg/d	_	_	I-Premise
208	)	_	_	I-Premise
209	and	_	_	I-Premise
210	85.7	_	_	I-Premise
211	%	_	_	I-Premise
212	(	_	_	I-Premise
213	500	_	_	I-Premise
214	mg/d	_	_	I-Premise
215	)	_	_	I-Premise
216	of	_	_	I-Premise
217	patients	_	_	I-Premise
218	with	_	_	I-Premise
219	a	_	_	I-Premise
220	tumor	_	_	I-Premise
221	response	_	_	I-Premise
222	.	_	_	I-Premise

223	Adverse	_	_	B-Premise
224	events	_	_	I-Premise
225	(	_	_	I-Premise
226	AEs	_	_	I-Premise
227	)	_	_	I-Premise
228	at	_	_	I-Premise
229	both	_	_	I-Premise
230	dose	_	_	I-Premise
231	levels	_	_	I-Premise
232	were	_	_	I-Premise
233	generally	_	_	I-Premise
234	mild	_	_	I-Premise
235	(	_	_	I-Premise
236	grade	_	_	I-Premise
237	1	_	_	I-Premise
238	or	_	_	I-Premise
239	2	_	_	I-Premise
240	)	_	_	I-Premise
241	and	_	_	I-Premise
242	consisted	_	_	I-Premise
243	mainly	_	_	I-Premise
244	of	_	_	I-Premise
245	skin	_	_	I-Premise
246	reactions	_	_	I-Premise
247	and	_	_	I-Premise
248	diarrhea	_	_	I-Premise
249	.	_	_	I-Premise

250	Drug-related	_	_	B-Premise
251	toxicities	_	_	I-Premise
252	were	_	_	I-Premise
253	more	_	_	I-Premise
254	frequent	_	_	I-Premise
255	in	_	_	I-Premise
256	the	_	_	I-Premise
257	higher-dose	_	_	I-Premise
258	group	_	_	I-Premise
259	.	_	_	I-Premise

260	Withdrawal	_	_	B-Premise
261	due	_	_	I-Premise
262	to	_	_	I-Premise
263	drug-related	_	_	I-Premise
264	AEs	_	_	I-Premise
265	was	_	_	I-Premise
266	1.9	_	_	I-Premise
267	%	_	_	I-Premise
268	and	_	_	I-Premise
269	9.4	_	_	I-Premise
270	%	_	_	I-Premise
271	for	_	_	I-Premise
272	patients	_	_	I-Premise
273	receiving	_	_	I-Premise
274	gefitinib	_	_	I-Premise
275	250	_	_	I-Premise
276	and	_	_	I-Premise
277	500	_	_	I-Premise
278	mg/d	_	_	I-Premise
279	,	_	_	I-Premise
280	respectively	_	_	I-Premise
281	.	_	_	I-Premise

282	Gefitinib	_	_	B-Claim
283	showed	_	_	I-Claim
284	clinically	_	_	I-Claim
285	meaningful	_	_	I-Claim
286	antitumor	_	_	I-Claim
287	activity	_	_	I-Claim
288	and	_	_	I-Claim
289	provided	_	_	I-Claim
290	symptom	_	_	I-Claim
291	relief	_	_	I-Claim
292	as	_	_	I-Claim
293	second-	_	_	I-Claim
294	and	_	_	I-Claim
295	third-line	_	_	I-Claim
296	treatment	_	_	I-Claim
297	in	_	_	I-Claim
298	these	_	_	I-Claim
299	patients	_	_	I-Claim
300	.	_	_	I-Claim

301	At	_	_	B-Claim
302	250	_	_	I-Claim
303	mg/d	_	_	I-Claim
304	,	_	_	I-Claim
305	gefitinib	_	_	I-Claim
306	had	_	_	I-Claim
307	a	_	_	I-Claim
308	favorable	_	_	I-Claim
309	AE	_	_	I-Claim
310	profile	_	_	I-Claim
311	.	_	_	I-Claim

312	Gefitinib	_	_	B-Claim
313	250	_	_	I-Claim
314	mg/d	_	_	I-Claim
315	is	_	_	I-Claim
316	an	_	_	I-Claim
317	important	_	_	I-Claim
318	,	_	_	I-Claim
319	novel	_	_	I-Claim
320	treatment	_	_	I-Claim
321	option	_	_	I-Claim
322	for	_	_	I-Claim
323	patients	_	_	I-Claim
324	with	_	_	I-Claim
325	pretreated	_	_	I-Claim
326	advanced	_	_	I-Claim
327	NSCLC	_	_	I-Claim
328	.	_	_	I-Claim


0	The	_	_	O
1	standard	_	_	O
2	treatment	_	_	O
3	for	_	_	O
4	patients	_	_	O
5	with	_	_	O
6	clinically	_	_	O
7	resectable	_	_	O
8	rectal	_	_	O
9	cancer	_	_	O
10	is	_	_	O
11	surgery	_	_	O
12	.	_	_	O

13	Postoperative	_	_	B-Claim
14	radiochemotherapy	_	_	I-Claim
15	(	_	_	I-Claim
16	RCT	_	_	I-Claim
17	)	_	_	I-Claim
18	is	_	_	I-Claim
19	recommended	_	_	I-Claim
20	for	_	_	I-Claim
21	advanced	_	_	I-Claim
22	disease	_	_	I-Claim
23	(	_	_	I-Claim
24	pT3/4	_	_	I-Claim
25	or	_	_	I-Claim
26	pN+	_	_	I-Claim
27	)	_	_	I-Claim
28	.	_	_	I-Claim

29	In	_	_	O
30	recent	_	_	O
31	years	_	_	O
32	,	_	_	O
33	encouraging	_	_	O
34	results	_	_	O
35	of	_	_	O
36	pre-operative	_	_	O
37	radiotherapy	_	_	O
38	have	_	_	O
39	been	_	_	O
40	reported	_	_	O
41	.	_	_	O

42	This	_	_	O
43	prospective	_	_	O
44	randomized	_	_	O
45	phase-III-trial	_	_	O
46	(	_	_	O
47	CAO/ARO/AIO-94	_	_	O
48	)	_	_	O
49	compares	_	_	O
50	the	_	_	O
51	efficacy	_	_	O
52	of	_	_	O
53	neoadjuvant	_	_	O
54	RCT	_	_	O
55	to	_	_	O
56	standard	_	_	O
57	postoperative	_	_	O
58	RCT	_	_	O
59	.	_	_	O

60	We	_	_	O
61	report	_	_	O
62	on	_	_	O
63	the	_	_	O
64	design	_	_	O
65	of	_	_	O
66	the	_	_	O
67	study	_	_	O
68	and	_	_	O
69	first	_	_	O
70	results	_	_	O
71	with	_	_	O
72	regard	_	_	O
73	to	_	_	O
74	toxicity	_	_	O
75	of	_	_	O
76	RCT	_	_	O
77	and	_	_	O
78	postoperative	_	_	O
79	morbidity	_	_	O
80	.	_	_	O

81	Patients	_	_	O
82	with	_	_	O
83	locally	_	_	O
84	advanced	_	_	O
85	operable	_	_	O
86	rectal	_	_	O
87	cancer	_	_	O
88	(	_	_	O
89	uT3/4	_	_	O
90	or	_	_	O
91	uN+	_	_	O
92	,	_	_	O
93	Mason	_	_	O
94	CS	_	_	O
95	III/IV	_	_	O
96	)	_	_	O
97	were	_	_	O
98	randomly	_	_	O
99	assigned	_	_	O
100	to	_	_	O
101	pre	_	_	O
102	or	_	_	O
103	postoperative	_	_	O
104	RCT	_	_	O
105	:	_	_	O
106	A	_	_	O
107	total	_	_	O
108	dose	_	_	O
109	of	_	_	O
110	50.4	_	_	O
111	Gy	_	_	O
112	(	_	_	O
113	single	_	_	O
114	dose	_	_	O
115	1.8	_	_	O
116	Gy	_	_	O
117	)	_	_	O
118	was	_	_	O
119	applied	_	_	O
120	to	_	_	O
121	the	_	_	O
122	tumour	_	_	O
123	and	_	_	O
124	the	_	_	O
125	pelvic	_	_	O
126	lymph	_	_	O
127	nodes	_	_	O
128	.	_	_	O

129	5-FU	_	_	O
130	(	_	_	O
131	1000	_	_	O
132	mg/m2/d	_	_	O
133	)	_	_	O
134	was	_	_	O
135	administered	_	_	O
136	concomitantly	_	_	O
137	in	_	_	O
138	the	_	_	O
139	1th	_	_	O
140	and	_	_	O
141	5th	_	_	O
142	week	_	_	O
143	of	_	_	O
144	radiation	_	_	O
145	as	_	_	O
146	120	_	_	O
147	h-continuous	_	_	O
148	infusion	_	_	O
149	.	_	_	O

150	Four	_	_	O
151	additional	_	_	O
152	cycles	_	_	O
153	of	_	_	O
154	5-FU-chemotherapy	_	_	O
155	(	_	_	O
156	500	_	_	O
157	mg/m2/d	_	_	O
158	,	_	_	O
159	i.v.-bolus	_	_	O
160	)	_	_	O
161	were	_	_	O
162	applied	_	_	O
163	.	_	_	O

164	RCT	_	_	O
165	was	_	_	O
166	identical	_	_	O
167	in	_	_	O
168	both	_	_	O
169	arms	_	_	O
170	except	_	_	O
171	for	_	_	O
172	a	_	_	O
173	small-volume	_	_	O
174	boost	_	_	O
175	of	_	_	O
176	5.4	_	_	O
177	Gy	_	_	O
178	postoperatively	_	_	O
179	.	_	_	O

180	The	_	_	O
181	time	_	_	O
182	interval	_	_	O
183	between	_	_	O
184	RCT	_	_	O
185	and	_	_	O
186	surgery	_	_	O
187	was	_	_	O
188	4-6	_	_	O
189	weeks	_	_	O
190	in	_	_	O
191	both	_	_	O
192	arms	_	_	O
193	.	_	_	O

194	Techniques	_	_	O
195	of	_	_	O
196	surgery	_	_	O
197	were	_	_	O
198	standardized	_	_	O
199	and	_	_	O
200	included	_	_	O
201	total	_	_	O
202	mesorectal	_	_	O
203	excision	_	_	O
204	.	_	_	O

205	Primary	_	_	O
206	endpoints	_	_	O
207	of	_	_	O
208	the	_	_	O
209	study	_	_	O
210	are	_	_	O
211	5-year	_	_	O
212	survival	_	_	O
213	and	_	_	O
214	local	_	_	O
215	and	_	_	O
216	distant	_	_	O
217	control	_	_	O
218	.	_	_	O

219	Secondary	_	_	O
220	endpoints	_	_	O
221	include	_	_	O
222	the	_	_	O
223	rate	_	_	O
224	of	_	_	O
225	curative	_	_	O
226	(	_	_	O
227	R0	_	_	O
228	)	_	_	O
229	resection	_	_	O
230	and	_	_	O
231	sphincter	_	_	O
232	saving	_	_	O
233	procedures	_	_	O
234	,	_	_	O
235	toxicity	_	_	O
236	of	_	_	O
237	RCT	_	_	O
238	,	_	_	O
239	surgical	_	_	O
240	complications	_	_	O
241	and	_	_	O
242	quality	_	_	O
243	of	_	_	O
244	life	_	_	O
245	.	_	_	O

246	As	_	_	O
247	of	_	_	O
248	July	_	_	O
249	2002	_	_	O
250	,	_	_	O
251	805	_	_	O
252	patients	_	_	O
253	were	_	_	O
254	randomized	_	_	O
255	from	_	_	O
256	26	_	_	O
257	participating	_	_	O
258	institutions	_	_	O
259	.	_	_	O

260	Acute	_	_	B-Premise
261	toxicity	_	_	I-Premise
262	(	_	_	I-Premise
263	WHO	_	_	I-Premise
264	)	_	_	I-Premise
265	of	_	_	I-Premise
266	RCT	_	_	I-Premise
267	was	_	_	I-Premise
268	low	_	_	I-Premise
269	,	_	_	I-Premise
270	with	_	_	I-Premise
271	less	_	_	I-Premise
272	than	_	_	I-Premise
273	15	_	_	I-Premise
274	%	_	_	I-Premise
275	of	_	_	I-Premise
276	patients	_	_	I-Premise
277	experiencing	_	_	I-Premise
278	grade	_	_	I-Premise
279	3	_	_	I-Premise
280	or	_	_	I-Premise
281	higher	_	_	I-Premise
282	toxicity	_	_	I-Premise
283	:	_	_	O
284	The	_	_	B-Premise
285	principal	_	_	I-Premise
286	toxicity	_	_	I-Premise
287	was	_	_	I-Premise
288	diarrhea	_	_	I-Premise
289	,	_	_	I-Premise
290	with	_	_	I-Premise
291	12	_	_	I-Premise
292	%	_	_	I-Premise
293	in	_	_	I-Premise
294	the	_	_	I-Premise
295	postoperative	_	_	I-Premise
296	RCT-arm	_	_	I-Premise
297	and	_	_	I-Premise
298	11	_	_	I-Premise
299	%	_	_	I-Premise
300	in	_	_	I-Premise
301	the	_	_	I-Premise
302	pre-operative	_	_	I-Premise
303	RCT-arm	_	_	I-Premise
304	having	_	_	I-Premise
305	grade	_	_	I-Premise
306	3-	_	_	I-Premise
307	,	_	_	I-Premise
308	and	_	_	I-Premise
309	1	_	_	I-Premise
310	%	_	_	I-Premise
311	in	_	_	I-Premise
312	either	_	_	I-Premise
313	arm	_	_	I-Premise
314	having	_	_	I-Premise
315	grade	_	_	I-Premise
316	4-diarrhea	_	_	I-Premise
317	.	_	_	I-Premise

318	Erythema	_	_	B-Premise
319	,	_	_	I-Premise
320	nausea	_	_	I-Premise
321	and	_	_	I-Premise
322	leukopenia	_	_	I-Premise
323	were	_	_	I-Premise
324	the	_	_	I-Premise
325	next	_	_	I-Premise
326	common	_	_	I-Premise
327	toxicities	_	_	I-Premise
328	,	_	_	I-Premise
329	with	_	_	I-Premise
330	less	_	_	I-Premise
331	than	_	_	I-Premise
332	3	_	_	I-Premise
333	%	_	_	I-Premise
334	of	_	_	I-Premise
335	patients	_	_	I-Premise
336	in	_	_	I-Premise
337	either	_	_	I-Premise
338	arm	_	_	I-Premise
339	suffering	_	_	I-Premise
340	grade	_	_	I-Premise
341	3	_	_	I-Premise
342	or	_	_	I-Premise
343	greater	_	_	I-Premise
344	leukopenia	_	_	I-Premise
345	or	_	_	I-Premise
346	nausea	_	_	I-Premise
347	.	_	_	I-Premise

348	Postoperative	_	_	B-Premise
349	complication	_	_	I-Premise
350	rates	_	_	I-Premise
351	were	_	_	I-Premise
352	similar	_	_	I-Premise
353	in	_	_	I-Premise
354	both	_	_	I-Premise
355	arms	_	_	I-Premise
356	,	_	_	I-Premise
357	with	_	_	I-Premise
358	12	_	_	I-Premise
359	%	_	_	I-Premise
360	(	_	_	I-Premise
361	postop	_	_	I-Premise
362	.	_	_	I-Premise

363	RCT	_	_	I-Premise
364	)	_	_	I-Premise
365	and	_	_	I-Premise
366	12	_	_	I-Premise
367	%	_	_	I-Premise
368	(	_	_	I-Premise
369	pre-op	_	_	I-Premise
370	.	_	_	I-Premise

371	RCT	_	_	I-Premise
372	)	_	_	I-Premise
373	of	_	_	I-Premise
374	patients	_	_	I-Premise
375	,	_	_	I-Premise
376	respectively	_	_	I-Premise
377	,	_	_	I-Premise
378	suffering	_	_	I-Premise
379	from	_	_	I-Premise
380	anastomotic	_	_	I-Premise
381	leakage	_	_	I-Premise
382	,	_	_	I-Premise
383	3	_	_	I-Premise
384	%	_	_	I-Premise
385	(	_	_	I-Premise
386	postop	_	_	I-Premise
387	.	_	_	I-Premise

388	RCT	_	_	I-Premise
389	)	_	_	I-Premise
390	and	_	_	I-Premise
391	3	_	_	I-Premise
392	%	_	_	I-Premise
393	(	_	_	I-Premise
394	pre-op	_	_	I-Premise
395	.	_	_	I-Premise

396	RCT	_	_	I-Premise
397	)	_	_	I-Premise
398	from	_	_	I-Premise
399	postoperative	_	_	I-Premise
400	bleeding	_	_	I-Premise
401	,	_	_	I-Premise
402	and	_	_	I-Premise
403	6	_	_	I-Premise
404	%	_	_	I-Premise
405	(	_	_	I-Premise
406	postop	_	_	I-Premise
407	.	_	_	I-Premise

408	RCT	_	_	I-Premise
409	)	_	_	I-Premise
410	and	_	_	I-Premise
411	4	_	_	I-Premise
412	%	_	_	I-Premise
413	(	_	_	I-Premise
414	pre-op	_	_	I-Premise
415	.	_	_	I-Premise

416	RCT	_	_	I-Premise
417	)	_	_	I-Premise
418	from	_	_	I-Premise
419	delayed	_	_	I-Premise
420	wound	_	_	I-Premise
421	healing	_	_	I-Premise
422	.	_	_	I-Premise

423	The	_	_	B-Claim
424	patient	_	_	I-Claim
425	accrual	_	_	I-Claim
426	to	_	_	I-Claim
427	the	_	_	I-Claim
428	trial	_	_	I-Claim
429	is	_	_	I-Claim
430	satisfactory	_	_	I-Claim
431	.	_	_	O

432	Neoadjuvant	_	_	B-Claim
433	RCT	_	_	I-Claim
434	is	_	_	I-Claim
435	well	_	_	I-Claim
436	tolerated	_	_	I-Claim
437	and	_	_	I-Claim
438	bears	_	_	I-Claim
439	no	_	_	I-Claim
440	higher	_	_	I-Claim
441	risk	_	_	I-Claim
442	for	_	_	I-Claim
443	postoperative	_	_	I-Claim
444	morbidity	_	_	I-Claim
445	.	_	_	I-Claim


0	Despite	_	_	B-Claim
1	considerable	_	_	I-Claim
2	improvement	_	_	I-Claim
3	in	_	_	I-Claim
4	the	_	_	I-Claim
5	treatment	_	_	I-Claim
6	of	_	_	I-Claim
7	advanced	_	_	I-Claim
8	ovarian	_	_	I-Claim
9	cancer	_	_	I-Claim
10	,	_	_	I-Claim
11	the	_	_	I-Claim
12	optimization	_	_	I-Claim
13	of	_	_	I-Claim
14	efficacy	_	_	I-Claim
15	and	_	_	I-Claim
16	tolerability	_	_	I-Claim
17	remains	_	_	I-Claim
18	an	_	_	I-Claim
19	important	_	_	I-Claim
20	issue	_	_	I-Claim
21	.	_	_	I-Claim

22	Therefore	_	_	O
23	,	_	_	O
24	we	_	_	O
25	performed	_	_	O
26	a	_	_	O
27	randomized	_	_	O
28	,	_	_	O
29	phase	_	_	O
30	III	_	_	O
31	non-inferiority	_	_	O
32	trial	_	_	O
33	comparing	_	_	O
34	paclitaxel	_	_	O
35	plus	_	_	O
36	cisplatin	_	_	O
37	(	_	_	O
38	PT	_	_	O
39	)	_	_	O
40	with	_	_	O
41	paclitaxel	_	_	O
42	plus	_	_	O
43	carboplatin	_	_	O
44	(	_	_	O
45	TC	_	_	O
46	)	_	_	O
47	in	_	_	O
48	patients	_	_	O
49	with	_	_	O
50	advanced	_	_	O
51	ovarian	_	_	O
52	cancer	_	_	O
53	.	_	_	O

54	A	_	_	O
55	total	_	_	O
56	of	_	_	O
57	798	_	_	O
58	patients	_	_	O
59	with	_	_	O
60	International	_	_	O
61	Federation	_	_	O
62	of	_	_	O
63	Gynecology	_	_	O
64	and	_	_	O
65	Obstetrics	_	_	O
66	stage	_	_	O
67	IIB-IV	_	_	O
68	were	_	_	O
69	randomly	_	_	O
70	assigned	_	_	O
71	to	_	_	O
72	receive	_	_	O
73	six	_	_	O
74	courses	_	_	O
75	of	_	_	O
76	either	_	_	O
77	PT	_	_	O
78	or	_	_	O
79	TC	_	_	O
80	at	_	_	O
81	3-week	_	_	O
82	intervals	_	_	O
83	.	_	_	O

84	The	_	_	O
85	primary	_	_	O
86	endpoint	_	_	O
87	was	_	_	O
88	the	_	_	O
89	proportion	_	_	O
90	of	_	_	O
91	patients	_	_	O
92	without	_	_	O
93	progression	_	_	O
94	at	_	_	O
95	2	_	_	O
96	years	_	_	O
97	.	_	_	O

98	Secondary	_	_	O
99	endpoints	_	_	O
100	included	_	_	O
101	toxicity	_	_	O
102	,	_	_	O
103	response	_	_	O
104	to	_	_	O
105	treatment	_	_	O
106	,	_	_	O
107	quality	_	_	O
108	of	_	_	O
109	life	_	_	O
110	,	_	_	O
111	and	_	_	O
112	overall	_	_	O
113	and	_	_	O
114	progression-free	_	_	O
115	survival	_	_	O
116	time	_	_	O
117	.	_	_	O

118	Quality	_	_	O
119	of	_	_	O
120	life	_	_	O
121	was	_	_	O
122	evaluated	_	_	O
123	using	_	_	O
124	the	_	_	O
125	European	_	_	O
126	Organization	_	_	O
127	for	_	_	O
128	Research	_	_	O
129	and	_	_	O
130	Treatment	_	_	O
131	of	_	_	O
132	Cancer	_	_	O
133	quality-of-life	_	_	O
134	questionnaire	_	_	O
135	(	_	_	O
136	QLQ	_	_	O
137	)	_	_	O
138	-C30	_	_	O
139	,	_	_	O
140	version	_	_	O
141	2.0	_	_	O
142	.	_	_	O

143	Survival	_	_	O
144	curves	_	_	O
145	were	_	_	O
146	calculated	_	_	O
147	using	_	_	O
148	the	_	_	O
149	Kaplan-Meier	_	_	O
150	method	_	_	O
151	,	_	_	O
152	and	_	_	O
153	hazard	_	_	O
154	ratios	_	_	O
155	were	_	_	O
156	estimated	_	_	O
157	using	_	_	O
158	the	_	_	O
159	Cox	_	_	O
160	proportional	_	_	O
161	hazards	_	_	O
162	model	_	_	O
163	.	_	_	O

164	The	_	_	B-Premise
165	proportion	_	_	I-Premise
166	of	_	_	I-Premise
167	patients	_	_	I-Premise
168	without	_	_	I-Premise
169	progression	_	_	I-Premise
170	at	_	_	I-Premise
171	2	_	_	I-Premise
172	years	_	_	I-Premise
173	was	_	_	I-Premise
174	not	_	_	I-Premise
175	statistically	_	_	I-Premise
176	significantly	_	_	I-Premise
177	different	_	_	I-Premise
178	between	_	_	I-Premise
179	the	_	_	I-Premise
180	two	_	_	I-Premise
181	treatment	_	_	I-Premise
182	arms	_	_	I-Premise
183	(	_	_	I-Premise
184	40.0	_	_	I-Premise
185	%	_	_	I-Premise
186	for	_	_	I-Premise
187	PT	_	_	I-Premise
188	versus	_	_	I-Premise
189	37.5	_	_	I-Premise
190	%	_	_	I-Premise
191	for	_	_	I-Premise
192	TC	_	_	I-Premise
193	,	_	_	I-Premise
194	difference	_	_	I-Premise
195	=	_	_	I-Premise
196	2.5	_	_	I-Premise
197	%	_	_	I-Premise
198	,	_	_	I-Premise
199	one-sided	_	_	I-Premise
200	95	_	_	I-Premise
201	%	_	_	I-Premise
202	confidence	_	_	I-Premise
203	interval	_	_	I-Premise
204	[	_	_	I-Premise
205	CI	_	_	I-Premise
206	]	_	_	I-Premise
207	=	_	_	I-Premise
208	-	_	_	I-Premise
209	infinity	_	_	I-Premise
210	to	_	_	I-Premise
211	8.2	_	_	I-Premise
212	%	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	Median	_	_	B-Premise
216	progression-free	_	_	I-Premise
217	survival	_	_	I-Premise
218	time	_	_	I-Premise
219	in	_	_	I-Premise
220	the	_	_	I-Premise
221	TC	_	_	I-Premise
222	arm	_	_	I-Premise
223	(	_	_	I-Premise
224	17.2	_	_	I-Premise
225	months	_	_	I-Premise
226	,	_	_	I-Premise
227	95	_	_	I-Premise
228	%	_	_	I-Premise
229	CI	_	_	I-Premise
230	=	_	_	I-Premise
231	15.2	_	_	I-Premise
232	to	_	_	I-Premise
233	19.3	_	_	I-Premise
234	months	_	_	I-Premise
235	)	_	_	I-Premise
236	and	_	_	I-Premise
237	the	_	_	I-Premise
238	PT	_	_	I-Premise
239	arm	_	_	I-Premise
240	(	_	_	I-Premise
241	19.1	_	_	I-Premise
242	months	_	_	I-Premise
243	,	_	_	I-Premise
244	95	_	_	I-Premise
245	%	_	_	I-Premise
246	CI	_	_	I-Premise
247	=	_	_	I-Premise
248	16.7	_	_	I-Premise
249	to	_	_	I-Premise
250	21.5	_	_	I-Premise
251	months	_	_	I-Premise
252	)	_	_	I-Premise
253	were	_	_	I-Premise
254	also	_	_	I-Premise
255	not	_	_	I-Premise
256	statistically	_	_	I-Premise
257	significantly	_	_	I-Premise
258	different	_	_	I-Premise
259	;	_	_	I-Premise
260	the	_	_	B-Premise
261	same	_	_	I-Premise
262	was	_	_	I-Premise
263	true	_	_	I-Premise
264	of	_	_	I-Premise
265	median	_	_	I-Premise
266	overall	_	_	I-Premise
267	survival	_	_	I-Premise
268	time	_	_	I-Premise
269	(	_	_	I-Premise
270	43.3	_	_	I-Premise
271	months	_	_	I-Premise
272	,	_	_	I-Premise
273	95	_	_	I-Premise
274	%	_	_	I-Premise
275	CI	_	_	I-Premise
276	=	_	_	I-Premise
277	37.2	_	_	I-Premise
278	to	_	_	I-Premise
279	47.8	_	_	I-Premise
280	months	_	_	I-Premise
281	versus	_	_	I-Premise
282	44.1	_	_	I-Premise
283	months	_	_	I-Premise
284	,	_	_	I-Premise
285	95	_	_	I-Premise
286	%	_	_	I-Premise
287	CI	_	_	I-Premise
288	=	_	_	I-Premise
289	40.2	_	_	I-Premise
290	to	_	_	I-Premise
291	49.4	_	_	I-Premise
292	months	_	_	I-Premise
293	,	_	_	I-Premise
294	for	_	_	I-Premise
295	the	_	_	I-Premise
296	TC	_	_	I-Premise
297	and	_	_	I-Premise
298	PT	_	_	I-Premise
299	arms	_	_	I-Premise
300	,	_	_	I-Premise
301	respectively	_	_	I-Premise
302	)	_	_	I-Premise
303	.	_	_	I-Premise

304	The	_	_	B-Premise
305	TC	_	_	I-Premise
306	regimen	_	_	I-Premise
307	was	_	_	I-Premise
308	associated	_	_	I-Premise
309	with	_	_	I-Premise
310	a	_	_	I-Premise
311	higher	_	_	I-Premise
312	frequency	_	_	I-Premise
313	of	_	_	I-Premise
314	hematologic	_	_	I-Premise
315	toxicity	_	_	I-Premise
316	,	_	_	I-Premise
317	but	_	_	B-Premise
318	a	_	_	I-Premise
319	lower	_	_	I-Premise
320	frequency	_	_	I-Premise
321	of	_	_	I-Premise
322	gastrointestinal	_	_	I-Premise
323	and	_	_	I-Premise
324	neurologic	_	_	I-Premise
325	toxicity	_	_	I-Premise
326	,	_	_	I-Premise
327	than	_	_	I-Premise
328	the	_	_	I-Premise
329	PT	_	_	I-Premise
330	regimen	_	_	I-Premise
331	.	_	_	I-Premise

332	Mean	_	_	B-Premise
333	global	_	_	I-Premise
334	quality-of-life	_	_	I-Premise
335	scores	_	_	I-Premise
336	at	_	_	I-Premise
337	the	_	_	I-Premise
338	end	_	_	I-Premise
339	of	_	_	I-Premise
340	treatment	_	_	I-Premise
341	were	_	_	I-Premise
342	statistically	_	_	I-Premise
343	significantly	_	_	I-Premise
344	better	_	_	I-Premise
345	in	_	_	I-Premise
346	the	_	_	I-Premise
347	TC	_	_	I-Premise
348	arm	_	_	I-Premise
349	than	_	_	I-Premise
350	in	_	_	I-Premise
351	the	_	_	I-Premise
352	PT	_	_	I-Premise
353	arm	_	_	I-Premise
354	(	_	_	I-Premise
355	65.25	_	_	I-Premise
356	versus	_	_	I-Premise
357	51.97	_	_	I-Premise
358	,	_	_	I-Premise
359	respectively	_	_	I-Premise
360	;	_	_	I-Premise
361	difference	_	_	I-Premise
362	=	_	_	I-Premise
363	-13.28	_	_	I-Premise
364	,	_	_	I-Premise
365	95	_	_	I-Premise
366	%	_	_	I-Premise
367	CI	_	_	I-Premise
368	=	_	_	I-Premise
369	-18.88	_	_	I-Premise
370	to	_	_	I-Premise
371	-7.68	_	_	I-Premise
372	)	_	_	I-Premise
373	.	_	_	I-Premise

374	The	_	_	B-Claim
375	TC	_	_	I-Claim
376	regimen	_	_	I-Claim
377	achieved	_	_	I-Claim
378	comparable	_	_	I-Claim
379	efficacy	_	_	I-Claim
380	to	_	_	I-Claim
381	the	_	_	I-Claim
382	PT	_	_	I-Claim
383	regimen	_	_	I-Claim
384	but	_	_	I-Claim
385	was	_	_	I-Claim
386	associated	_	_	I-Claim
387	with	_	_	I-Claim
388	better	_	_	I-Claim
389	tolerability	_	_	I-Claim
390	and	_	_	I-Claim
391	quality	_	_	I-Claim
392	of	_	_	I-Claim
393	life	_	_	I-Claim
394	,	_	_	I-Claim
395	and	_	_	I-Claim
396	should	_	_	I-Claim
397	,	_	_	I-Claim
398	therefore	_	_	I-Claim
399	,	_	_	I-Claim
400	be	_	_	I-Claim
401	considered	_	_	I-Claim
402	as	_	_	I-Claim
403	an	_	_	I-Claim
404	important	_	_	I-Claim
405	alternative	_	_	I-Claim
406	for	_	_	I-Claim
407	standard	_	_	I-Claim
408	first-line	_	_	I-Claim
409	chemotherapy	_	_	I-Claim
410	in	_	_	I-Claim
411	patients	_	_	I-Claim
412	with	_	_	I-Claim
413	advanced	_	_	I-Claim
414	ovarian	_	_	I-Claim
415	cancer	_	_	I-Claim
416	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	patient-reported	_	_	O
3	prostate	_	_	O
4	cancer-specific	_	_	O
5	quality	_	_	O
6	of	_	_	O
7	life	_	_	O
8	2	_	_	O
9	and	_	_	O
10	3	_	_	O
11	years	_	_	O
12	after	_	_	O
13	radiotherapy	_	_	O
14	to	_	_	O
15	the	_	_	O
16	prostate	_	_	O
17	in	_	_	O
18	a	_	_	O
19	randomized	_	_	O
20	dose-escalation	_	_	O
21	trial	_	_	O
22	of	_	_	O
23	70	_	_	O
24	versus	_	_	O
25	78	_	_	O
26	Gy	_	_	O
27	conducted	_	_	O
28	from	_	_	O
29	1993	_	_	O
30	to	_	_	O
31	1998	_	_	O
32	.	_	_	O

33	Two	_	_	O
34	years	_	_	O
35	after	_	_	O
36	completing	_	_	O
37	radiotherapy	_	_	O
38	,	_	_	O
39	a	_	_	O
40	questionnaire	_	_	O
41	that	_	_	O
42	assessed	_	_	O
43	bladder	_	_	O
44	,	_	_	O
45	rectal	_	_	O
46	,	_	_	O
47	and	_	_	O
48	sexual	_	_	O
49	function	_	_	O
50	was	_	_	O
51	sent	_	_	O
52	to	_	_	O
53	301	_	_	O
54	patients	_	_	O
55	in	_	_	O
56	the	_	_	O
57	study	_	_	O
58	.	_	_	O

59	Three	_	_	O
60	years	_	_	O
61	after	_	_	O
62	treatment	_	_	O
63	,	_	_	O
64	a	_	_	O
65	second	_	_	O
66	questionnaire	_	_	O
67	was	_	_	O
68	sent	_	_	O
69	to	_	_	O
70	the	_	_	O
71	175	_	_	O
72	patients	_	_	O
73	with	_	_	O
74	adequate	_	_	O
75	follow-up	_	_	O
76	.	_	_	O

77	Three	_	_	B-Premise
78	years	_	_	I-Premise
79	after	_	_	I-Premise
80	radiotherapy	_	_	I-Premise
81	,	_	_	I-Premise
82	urinary	_	_	I-Premise
83	incontinence	_	_	I-Premise
84	was	_	_	I-Premise
85	reported	_	_	I-Premise
86	by	_	_	I-Premise
87	35	_	_	I-Premise
88	%	_	_	I-Premise
89	of	_	_	I-Premise
90	patients	_	_	I-Premise
91	,	_	_	I-Premise
92	but	_	_	I-Premise
93	only	_	_	I-Premise
94	6	_	_	I-Premise
95	%	_	_	I-Premise
96	required	_	_	I-Premise
97	the	_	_	I-Premise
98	use	_	_	I-Premise
99	of	_	_	I-Premise
100	a	_	_	I-Premise
101	pad	_	_	I-Premise
102	or	_	_	I-Premise
103	other	_	_	I-Premise
104	protective	_	_	I-Premise
105	device	_	_	I-Premise
106	.	_	_	I-Premise

107	Patients	_	_	B-Premise
108	reported	_	_	I-Premise
109	increased	_	_	I-Premise
110	leakage	_	_	I-Premise
111	with	_	_	I-Premise
112	a	_	_	I-Premise
113	full	_	_	I-Premise
114	bladder	_	_	I-Premise
115	(	_	_	I-Premise
116	urge	_	_	I-Premise
117	incontinence	_	_	I-Premise
118	)	_	_	I-Premise
119	between	_	_	I-Premise
120	the	_	_	I-Premise
121	2	_	_	I-Premise
122	and	_	_	I-Premise
123	3-year	_	_	I-Premise
124	questionnaires	_	_	I-Premise
125	(	_	_	I-Premise
126	42	_	_	I-Premise
127	%	_	_	I-Premise
128	versus	_	_	I-Premise
129	50	_	_	I-Premise
130	%	_	_	I-Premise
131	;	_	_	I-Premise
132	P	_	_	I-Premise
133	=	_	_	I-Premise
134	0.03	_	_	I-Premise
135	)	_	_	I-Premise
136	.	_	_	I-Premise

137	At	_	_	B-Premise
138	3	_	_	I-Premise
139	years	_	_	I-Premise
140	,	_	_	I-Premise
141	33	_	_	I-Premise
142	%	_	_	I-Premise
143	of	_	_	I-Premise
144	patients	_	_	I-Premise
145	reported	_	_	I-Premise
146	rectal	_	_	I-Premise
147	bleeding	_	_	I-Premise
148	compared	_	_	I-Premise
149	with	_	_	I-Premise
150	47	_	_	I-Premise
151	%	_	_	I-Premise
152	at	_	_	I-Premise
153	2	_	_	I-Premise
154	years	_	_	I-Premise
155	(	_	_	I-Premise
156	P	_	_	I-Premise
157	=	_	_	I-Premise
158	0.006	_	_	I-Premise
159	)	_	_	I-Premise
160	.	_	_	I-Premise

161	Patients	_	_	B-Premise
162	in	_	_	I-Premise
163	the	_	_	I-Premise
164	78-Gy	_	_	I-Premise
165	arm	_	_	I-Premise
166	reported	_	_	I-Premise
167	more	_	_	I-Premise
168	frequent	_	_	I-Premise
169	bowel	_	_	I-Premise
170	movements	_	_	I-Premise
171	at	_	_	I-Premise
172	3	_	_	I-Premise
173	years	_	_	I-Premise
174	and	_	_	I-Premise
175	less	_	_	I-Premise
176	change	_	_	I-Premise
177	in	_	_	I-Premise
178	bowel	_	_	I-Premise
179	function	_	_	I-Premise
180	at	_	_	I-Premise
181	2	_	_	I-Premise
182	years	_	_	I-Premise
183	than	_	_	I-Premise
184	patients	_	_	I-Premise
185	in	_	_	I-Premise
186	the	_	_	I-Premise
187	70-Gy	_	_	I-Premise
188	arm	_	_	I-Premise
189	.	_	_	I-Premise

190	Before	_	_	B-Premise
191	radiotherapy	_	_	I-Premise
192	,	_	_	I-Premise
193	84	_	_	I-Premise
194	%	_	_	I-Premise
195	of	_	_	I-Premise
196	patients	_	_	I-Premise
197	reported	_	_	I-Premise
198	erections	_	_	I-Premise
199	adequate	_	_	I-Premise
200	for	_	_	I-Premise
201	intercourse	_	_	I-Premise
202	at	_	_	I-Premise
203	least	_	_	I-Premise
204	a	_	_	I-Premise
205	few	_	_	I-Premise
206	times	_	_	I-Premise
207	during	_	_	I-Premise
208	the	_	_	I-Premise
209	previous	_	_	I-Premise
210	year	_	_	I-Premise
211	.	_	_	I-Premise

212	After	_	_	B-Premise
213	2	_	_	I-Premise
214	and	_	_	I-Premise
215	3	_	_	I-Premise
216	years	_	_	I-Premise
217	,	_	_	I-Premise
218	this	_	_	I-Premise
219	had	_	_	I-Premise
220	decreased	_	_	I-Premise
221	to	_	_	I-Premise
222	49	_	_	I-Premise
223	%	_	_	I-Premise
224	and	_	_	I-Premise
225	41	_	_	I-Premise
226	%	_	_	I-Premise
227	,	_	_	I-Premise
228	respectively	_	_	I-Premise
229	(	_	_	I-Premise
230	P	_	_	I-Premise
231	<	_	_	I-Premise
232	0.02	_	_	I-Premise
233	)	_	_	I-Premise
234	.	_	_	I-Premise

235	By	_	_	B-Claim
236	patient-reported	_	_	I-Claim
237	questionnaire	_	_	I-Claim
238	,	_	_	I-Claim
239	78	_	_	I-Claim
240	Gy	_	_	I-Claim
241	produced	_	_	I-Claim
242	an	_	_	I-Claim
243	increase	_	_	I-Claim
244	in	_	_	I-Claim
245	bowel	_	_	I-Claim
246	movement	_	_	I-Claim
247	frequency	_	_	I-Claim
248	and	_	_	I-Claim
249	no	_	_	I-Claim
250	increase	_	_	I-Claim
251	in	_	_	I-Claim
252	bladder	_	_	I-Claim
253	or	_	_	I-Claim
254	sexual	_	_	I-Claim
255	side	_	_	I-Claim
256	effects	_	_	I-Claim
257	at	_	_	I-Claim
258	3	_	_	I-Claim
259	years	_	_	I-Claim
260	compared	_	_	I-Claim
261	with	_	_	I-Claim
262	70	_	_	I-Claim
263	Gy	_	_	I-Claim
264	.	_	_	I-Claim

265	Comparing	_	_	B-Claim
266	the	_	_	I-Claim
267	results	_	_	I-Claim
268	2	_	_	I-Claim
269	and	_	_	I-Claim
270	3	_	_	I-Claim
271	years	_	_	I-Claim
272	after	_	_	I-Claim
273	radiotherapy	_	_	I-Claim
274	,	_	_	I-Claim
275	the	_	_	I-Claim
276	symptoms	_	_	I-Claim
277	of	_	_	I-Claim
278	rectal	_	_	I-Claim
279	bleeding	_	_	I-Claim
280	had	_	_	I-Claim
281	improved	_	_	I-Claim
282	,	_	_	I-Claim
283	erectile	_	_	I-Claim
284	function	_	_	I-Claim
285	had	_	_	I-Claim
286	decreased	_	_	I-Claim
287	,	_	_	I-Claim
288	and	_	_	I-Claim
289	urinary	_	_	I-Claim
290	urge	_	_	I-Claim
291	incontinence	_	_	I-Claim
292	had	_	_	I-Claim
293	increased	_	_	I-Claim
294	.	_	_	I-Claim


0	N	_	_	O
1	,	_	_	O
2	N-diethyl-2-	_	_	O
3	[	_	_	O
4	4-	_	_	O
5	(	_	_	O
6	phenylmethyl	_	_	O
7	)	_	_	O
8	phenoxy	_	_	O
9	]	_	_	O
10	ethanamine	_	_	O
11	(	_	_	O
12	DPPE	_	_	O
13	;	_	_	O
14	tesmilifene	_	_	O
15	)	_	_	O
16	is	_	_	O
17	a	_	_	O
18	novel	_	_	O
19	agent	_	_	O
20	that	_	_	O
21	augments	_	_	O
22	chemotherapy	_	_	O
23	cytotoxicity	_	_	O
24	in	_	_	O
25	vitro	_	_	O
26	and	_	_	O
27	in	_	_	O
28	vivo	_	_	O
29	.	_	_	O

30	A	_	_	O
31	phase	_	_	O
32	II	_	_	O
33	trial	_	_	O
34	combining	_	_	O
35	DPPE	_	_	O
36	and	_	_	O
37	doxorubicin	_	_	O
38	(	_	_	O
39	DOX	_	_	O
40	)	_	_	O
41	in	_	_	O
42	metastatic	_	_	O
43	breast	_	_	O
44	carcinoma	_	_	O
45	showed	_	_	O
46	increased	_	_	O
47	response	_	_	O
48	over	_	_	O
49	that	_	_	O
50	expected	_	_	O
51	with	_	_	O
52	DOX	_	_	O
53	.	_	_	O

54	We	_	_	O
55	report	_	_	O
56	a	_	_	O
57	phase	_	_	O
58	III	_	_	O
59	trial	_	_	O
60	comparing	_	_	O
61	DOX	_	_	O
62	with	_	_	O
63	DPPE	_	_	O
64	plus	_	_	O
65	DOX	_	_	O
66	in	_	_	O
67	metastatic	_	_	O
68	or	_	_	O
69	recurrent	_	_	O
70	breast	_	_	O
71	cancer	_	_	O
72	.	_	_	O

73	Anthracycline-naive	_	_	O
74	women	_	_	O
75	with	_	_	O
76	measurable	_	_	O
77	metastatic	_	_	O
78	disease	_	_	O
79	were	_	_	O
80	randomly	_	_	O
81	assigned	_	_	O
82	to	_	_	O
83	receive	_	_	O
84	,	_	_	O
85	every	_	_	O
86	21	_	_	O
87	days	_	_	O
88	,	_	_	O
89	either	_	_	O
90	DOX	_	_	O
91	60	_	_	O
92	mg/m	_	_	O
93	(	_	_	O
94	2	_	_	O
95	)	_	_	O
96	intravenously	_	_	O
97	or	_	_	O
98	DOX	_	_	O
99	during	_	_	O
100	the	_	_	O
101	last	_	_	O
102	20	_	_	O
103	minutes	_	_	O
104	of	_	_	O
105	an	_	_	O
106	80-minute	_	_	O
107	infusion	_	_	O
108	of	_	_	O
109	DPPE	_	_	O
110	(	_	_	O
111	5.3	_	_	O
112	mg/kg	_	_	O
113	)	_	_	O
114	,	_	_	O
115	in	_	_	O
116	both	_	_	O
117	cases	_	_	O
118	to	_	_	O
119	cumulative	_	_	O
120	DOX	_	_	O
121	doses	_	_	O
122	of	_	_	O
123	450	_	_	O
124	mg/m	_	_	O
125	(	_	_	O
126	2	_	_	O
127	)	_	_	O
128	.	_	_	O

129	Patients	_	_	O
130	receiving	_	_	O
131	DPPE	_	_	O
132	were	_	_	O
133	aggressively	_	_	O
134	premedicated	_	_	O
135	to	_	_	O
136	ameliorate	_	_	O
137	toxicity	_	_	O
138	.	_	_	O

139	End	_	_	O
140	points	_	_	O
141	included	_	_	O
142	progression-free	_	_	O
143	survival	_	_	O
144	(	_	_	O
145	PFS	_	_	O
146	)	_	_	O
147	,	_	_	O
148	response	_	_	O
149	rate	_	_	O
150	(	_	_	O
151	RR	_	_	O
152	)	_	_	O
153	,	_	_	O
154	and	_	_	O
155	response	_	_	O
156	duration	_	_	O
157	(	_	_	O
158	RD	_	_	O
159	)	_	_	O
160	,	_	_	O
161	quality	_	_	O
162	of	_	_	O
163	life	_	_	O
164	(	_	_	O
165	QOL	_	_	O
166	)	_	_	O
167	,	_	_	O
168	toxicity	_	_	O
169	,	_	_	O
170	and	_	_	O
171	overall	_	_	O
172	survival	_	_	O
173	(	_	_	O
174	OS	_	_	O
175	)	_	_	O
176	.	_	_	O

177	A	_	_	O
178	planned	_	_	O
179	interim	_	_	O
180	analysis	_	_	O
181	failed	_	_	O
182	to	_	_	O
183	detect	_	_	O
184	an	_	_	O
185	RR	_	_	O
186	difference	_	_	O
187	more	_	_	O
188	than	_	_	O
189	5	_	_	O
190	%	_	_	O
191	.	_	_	O

192	The	_	_	O
193	study	_	_	O
194	was	_	_	O
195	closed	_	_	O
196	to	_	_	O
197	additional	_	_	O
198	accrual	_	_	O
199	and	_	_	O
200	all	_	_	O
201	DPPE	_	_	O
202	was	_	_	O
203	discontinued	_	_	O
204	.	_	_	O

205	The	_	_	O
206	final	_	_	O
207	analysis	_	_	O
208	was	_	_	O
209	conducted	_	_	O
210	as	_	_	O
211	planned	_	_	O
212	after	_	_	O
213	256	_	_	O
214	progression	_	_	O
215	events	_	_	O
216	(	_	_	O
217	median	_	_	O
218	follow-up	_	_	O
219	,	_	_	O
220	20.5	_	_	O
221	months	_	_	O
222	)	_	_	O
223	.	_	_	O

224	There	_	_	B-Premise
225	was	_	_	I-Premise
226	no	_	_	I-Premise
227	significant	_	_	I-Premise
228	difference	_	_	I-Premise
229	in	_	_	I-Premise
230	RR	_	_	I-Premise
231	,	_	_	I-Premise
232	RD	_	_	I-Premise
233	,	_	_	I-Premise
234	or	_	_	I-Premise
235	PFS	_	_	I-Premise
236	between	_	_	I-Premise
237	arms	_	_	I-Premise
238	.	_	_	I-Premise

239	DPPE	_	_	B-Premise
240	plus	_	_	I-Premise
241	DOX	_	_	I-Premise
242	was	_	_	I-Premise
243	statistically	_	_	I-Premise
244	superior	_	_	I-Premise
245	to	_	_	I-Premise
246	DOX	_	_	I-Premise
247	in	_	_	I-Premise
248	OS	_	_	I-Premise
249	(	_	_	I-Premise
250	hazard	_	_	I-Premise
251	ratio	_	_	I-Premise
252	,	_	_	I-Premise
253	0.66	_	_	I-Premise
254	;	_	_	I-Premise
255	95	_	_	I-Premise
256	%	_	_	I-Premise
257	CI	_	_	I-Premise
258	,	_	_	I-Premise
259	0.48	_	_	I-Premise
260	to	_	_	I-Premise
261	0.91	_	_	I-Premise
262	;	_	_	I-Premise
263	P	_	_	I-Premise
264	=.021	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	DPPE	_	_	B-Premise
268	plus	_	_	I-Premise
269	DOX	_	_	I-Premise
270	was	_	_	I-Premise
271	associated	_	_	I-Premise
272	with	_	_	I-Premise
273	more	_	_	I-Premise
274	gastrointestinal	_	_	I-Premise
275	and	_	_	I-Premise
276	CNS	_	_	I-Premise
277	toxicity	_	_	I-Premise
278	.	_	_	I-Premise

279	No	_	_	B-Premise
280	consistent	_	_	I-Premise
281	influence	_	_	I-Premise
282	on	_	_	I-Premise
283	QOL	_	_	I-Premise
284	was	_	_	I-Premise
285	detected	_	_	I-Premise
286	.	_	_	I-Premise

287	This	_	_	B-Claim
288	study	_	_	I-Claim
289	demonstrated	_	_	I-Claim
290	no	_	_	I-Claim
291	advantage	_	_	I-Claim
292	in	_	_	I-Claim
293	RR	_	_	I-Claim
294	,	_	_	I-Claim
295	RD	_	_	I-Claim
296	,	_	_	I-Claim
297	or	_	_	I-Claim
298	PFS	_	_	I-Claim
299	but	_	_	I-Claim
300	significantly	_	_	I-Claim
301	superior	_	_	I-Claim
302	OS	_	_	I-Claim
303	for	_	_	I-Claim
304	DPPE	_	_	I-Claim
305	plus	_	_	I-Claim
306	DOX	_	_	I-Claim
307	.	_	_	I-Claim

308	Additional	_	_	B-Claim
309	studies	_	_	I-Claim
310	of	_	_	I-Claim
311	DPPE	_	_	I-Claim
312	are	_	_	I-Claim
313	warranted	_	_	I-Claim
314	.	_	_	I-Claim


0	Fatigue	_	_	O
1	is	_	_	O
2	a	_	_	O
3	frequent	_	_	O
4	problem	_	_	O
5	after	_	_	O
6	surgical	_	_	O
7	treatment	_	_	O
8	of	_	_	O
9	solid	_	_	O
10	tumours	_	_	O
11	.	_	_	O

12	Aerobic	_	_	B-Claim
13	exercise	_	_	I-Claim
14	and	_	_	I-Claim
15	psychosocial	_	_	I-Claim
16	interventions	_	_	I-Claim
17	have	_	_	I-Claim
18	been	_	_	I-Claim
19	shown	_	_	I-Claim
20	to	_	_	I-Claim
21	reduce	_	_	I-Claim
22	the	_	_	I-Claim
23	severity	_	_	I-Claim
24	of	_	_	I-Claim
25	this	_	_	I-Claim
26	symptom	_	_	I-Claim
27	in	_	_	I-Claim
28	cancer	_	_	I-Claim
29	patients	_	_	I-Claim
30	.	_	_	I-Claim

31	Therefore	_	_	O
32	,	_	_	O
33	we	_	_	O
34	compared	_	_	O
35	the	_	_	O
36	effect	_	_	O
37	of	_	_	O
38	the	_	_	O
39	two	_	_	O
40	therapies	_	_	O
41	on	_	_	O
42	fatigue	_	_	O
43	in	_	_	O
44	a	_	_	O
45	randomised	_	_	O
46	controlled	_	_	O
47	study	_	_	O
48	.	_	_	O

49	Seventy-two	_	_	O
50	patients	_	_	O
51	who	_	_	O
52	underwent	_	_	O
53	surgery	_	_	O
54	for	_	_	O
55	lung	_	_	O
56	(	_	_	O
57	n=27	_	_	O
58	)	_	_	O
59	or	_	_	O
60	gastrointestinal	_	_	O
61	tumours	_	_	O
62	(	_	_	O
63	n=42	_	_	O
64	)	_	_	O
65	were	_	_	O
66	assigned	_	_	O
67	to	_	_	O
68	an	_	_	O
69	aerobic	_	_	O
70	exercise	_	_	O
71	group	_	_	O
72	(	_	_	O
73	stationary	_	_	O
74	biking	_	_	O
75	30	_	_	O
76	min	_	_	O
77	five	_	_	O
78	times	_	_	O
79	weekly	_	_	O
80	)	_	_	O
81	or	_	_	O
82	a	_	_	O
83	progressive	_	_	O
84	relaxation	_	_	O
85	training	_	_	O
86	group	_	_	O
87	(	_	_	O
88	45	_	_	O
89	min	_	_	O
90	three	_	_	O
91	times	_	_	O
92	per	_	_	O
93	week	_	_	O
94	)	_	_	O
95	.	_	_	O

96	Both	_	_	O
97	interventions	_	_	O
98	were	_	_	O
99	carried	_	_	O
100	out	_	_	O
101	for	_	_	O
102	3	_	_	O
103	weeks	_	_	O
104	.	_	_	O

105	At	_	_	O
106	the	_	_	O
107	beginning	_	_	O
108	and	_	_	O
109	the	_	_	O
110	end	_	_	O
111	of	_	_	O
112	the	_	_	O
113	study	_	_	O
114	,	_	_	O
115	we	_	_	O
116	evaluated	_	_	O
117	physical	_	_	O
118	,	_	_	O
119	cognitive	_	_	O
120	and	_	_	O
121	emotional	_	_	O
122	status	_	_	O
123	and	_	_	O
124	somatic	_	_	O
125	complaints	_	_	O
126	with	_	_	O
127	the	_	_	O
128	European	_	_	O
129	Organization	_	_	O
130	for	_	_	O
131	Research	_	_	O
132	and	_	_	O
133	Treatment	_	_	O
134	of	_	_	O
135	Cancer	_	_	O
136	Quality	_	_	O
137	of	_	_	O
138	Life	_	_	O
139	Questionnaire	_	_	O
140	Core	_	_	O
141	Module	_	_	O
142	(	_	_	O
143	EORTC-QLQ-30	_	_	O
144	)	_	_	O
145	questionnaire	_	_	O
146	,	_	_	O
147	and	_	_	O
148	maximal	_	_	O
149	physical	_	_	O
150	performance	_	_	O
151	with	_	_	O
152	an	_	_	O
153	ergometric	_	_	O
154	stress	_	_	O
155	test	_	_	O
156	.	_	_	O

157	Physical	_	_	B-Premise
158	performance	_	_	I-Premise
159	of	_	_	I-Premise
160	the	_	_	I-Premise
161	training	_	_	I-Premise
162	group	_	_	I-Premise
163	improved	_	_	I-Premise
164	significantly	_	_	I-Premise
165	during	_	_	I-Premise
166	the	_	_	I-Premise
167	programme	_	_	I-Premise
168	(	_	_	I-Premise
169	9.4+/-20	_	_	I-Premise
170	watts	_	_	I-Premise
171	,	_	_	I-Premise
172	p=0.01	_	_	I-Premise
173	)	_	_	I-Premise
174	but	_	_	I-Premise
175	remained	_	_	I-Premise
176	unchanged	_	_	I-Premise
177	in	_	_	I-Premise
178	the	_	_	I-Premise
179	relaxation	_	_	I-Premise
180	group	_	_	I-Premise
181	(	_	_	I-Premise
182	1.5+/-14.8	_	_	I-Premise
183	watts	_	_	I-Premise
184	,	_	_	I-Premise
185	p=0.37	_	_	I-Premise
186	)	_	_	I-Premise
187	.	_	_	I-Premise

188	Fatigue	_	_	B-Premise
189	and	_	_	I-Premise
190	global	_	_	I-Premise
191	health	_	_	I-Premise
192	scores	_	_	I-Premise
193	improved	_	_	I-Premise
194	in	_	_	I-Premise
195	both	_	_	I-Premise
196	groups	_	_	I-Premise
197	during	_	_	I-Premise
198	the	_	_	I-Premise
199	intervention	_	_	I-Premise
200	(	_	_	I-Premise
201	fatigue	_	_	I-Premise
202	:	_	_	I-Premise
203	training	_	_	I-Premise
204	group	_	_	I-Premise
205	21	_	_	I-Premise
206	%	_	_	I-Premise
207	,	_	_	I-Premise
208	relaxation	_	_	I-Premise
209	group	_	_	I-Premise
210	19	_	_	I-Premise
211	%	_	_	I-Premise
212	;	_	_	I-Premise
213	global	_	_	I-Premise
214	health	_	_	I-Premise
215	of	_	_	I-Premise
216	both	_	_	I-Premise
217	groups	_	_	I-Premise
218	19	_	_	I-Premise
219	%	_	_	I-Premise
220	,	_	_	I-Premise
221	p	_	_	I-Premise
222	for	_	_	I-Premise
223	all	_	_	I-Premise
224	<	_	_	I-Premise
225	or	_	_	I-Premise
226	=0.01	_	_	I-Premise
227	)	_	_	I-Premise
228	;	_	_	I-Premise
229	however	_	_	B-Premise
230	,	_	_	I-Premise
231	there	_	_	I-Premise
232	was	_	_	I-Premise
233	no	_	_	I-Premise
234	significant	_	_	I-Premise
235	difference	_	_	I-Premise
236	between	_	_	I-Premise
237	changes	_	_	I-Premise
238	in	_	_	I-Premise
239	the	_	_	I-Premise
240	scores	_	_	I-Premise
241	of	_	_	I-Premise
242	both	_	_	I-Premise
243	groups	_	_	I-Premise
244	(	_	_	I-Premise
245	p=0.67	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	We	_	_	B-Claim
249	conclude	_	_	I-Claim
250	that	_	_	I-Claim
251	a	_	_	I-Claim
252	structured	_	_	I-Claim
253	aerobic	_	_	I-Claim
254	training	_	_	I-Claim
255	programme	_	_	I-Claim
256	improves	_	_	I-Claim
257	the	_	_	I-Claim
258	physical	_	_	I-Claim
259	performance	_	_	I-Claim
260	of	_	_	I-Claim
261	patients	_	_	I-Claim
262	recovering	_	_	I-Claim
263	from	_	_	I-Claim
264	surgery	_	_	I-Claim
265	for	_	_	I-Claim
266	solid	_	_	I-Claim
267	tumours	_	_	I-Claim
268	.	_	_	I-Claim

269	However	_	_	B-Claim
270	,	_	_	I-Claim
271	exercise	_	_	I-Claim
272	is	_	_	I-Claim
273	not	_	_	I-Claim
274	better	_	_	I-Claim
275	than	_	_	I-Claim
276	progressive	_	_	I-Claim
277	relaxation	_	_	I-Claim
278	training	_	_	I-Claim
279	for	_	_	I-Claim
280	the	_	_	I-Claim
281	treatment	_	_	I-Claim
282	of	_	_	I-Claim
283	fatigue	_	_	I-Claim
284	in	_	_	I-Claim
285	this	_	_	I-Claim
286	setting	_	_	I-Claim
287	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	whether	_	_	O
3	weekly	_	_	O
4	epoetin	_	_	O
5	alfa	_	_	O
6	could	_	_	O
7	improve	_	_	O
8	hemoglobin	_	_	O
9	(	_	_	O
10	HgB	_	_	O
11	)	_	_	O
12	levels	_	_	O
13	,	_	_	O
14	reduce	_	_	O
15	RBC	_	_	O
16	transfusions	_	_	O
17	,	_	_	O
18	and	_	_	O
19	improve	_	_	O
20	quality	_	_	O
21	of	_	_	O
22	life	_	_	O
23	(	_	_	O
24	QOL	_	_	O
25	)	_	_	O
26	in	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	advanced	_	_	O
30	cancer	_	_	O
31	and	_	_	O
32	with	_	_	O
33	anemia	_	_	O
34	after	_	_	O
35	receiving	_	_	O
36	myelosuppressive	_	_	O
37	chemotherapy	_	_	O
38	.	_	_	O

39	This	_	_	O
40	double-blind	_	_	O
41	,	_	_	O
42	placebo-controlled	_	_	O
43	study	_	_	O
44	randomly	_	_	O
45	assigned	_	_	O
46	patients	_	_	O
47	to	_	_	O
48	placebo	_	_	O
49	or	_	_	O
50	epoetin	_	_	O
51	alfa	_	_	O
52	(	_	_	O
53	Ortho	_	_	O
54	Biotech	_	_	O
55	,	_	_	O
56	Bridgewater	_	_	O
57	,	_	_	O
58	NJ	_	_	O
59	)	_	_	O
60	40,000	_	_	O
61	U	_	_	O
62	subcutaneous	_	_	O
63	weekly	_	_	O
64	for	_	_	O
65	16	_	_	O
66	weeks	_	_	O
67	.	_	_	O

68	QOL	_	_	O
69	,	_	_	O
70	HgB	_	_	O
71	,	_	_	O
72	and	_	_	O
73	RBC	_	_	O
74	transfusions	_	_	O
75	were	_	_	O
76	measured	_	_	O
77	pretreatment	_	_	O
78	and	_	_	O
79	monthly	_	_	O
80	.	_	_	O

81	The	_	_	O
82	study	_	_	O
83	accrued	_	_	O
84	344	_	_	O
85	patients	_	_	O
86	;	_	_	O
87	330	_	_	O
88	were	_	_	O
89	assessable	_	_	O
90	for	_	_	O
91	efficacy	_	_	O
92	and	_	_	O
93	305	_	_	O
94	were	_	_	O
95	assessable	_	_	O
96	for	_	_	O
97	QOL	_	_	O
98	.	_	_	O

99	Placebo-treated	_	_	B-Premise
100	patients	_	_	I-Premise
101	had	_	_	I-Premise
102	a	_	_	I-Premise
103	mean	_	_	I-Premise
104	increase	_	_	I-Premise
105	in	_	_	I-Premise
106	HgB	_	_	I-Premise
107	of	_	_	I-Premise
108	0.9	_	_	I-Premise
109	g/dL	_	_	I-Premise
110	(	_	_	I-Premise
111	range	_	_	I-Premise
112	,	_	_	I-Premise
113	-3.8	_	_	I-Premise
114	to	_	_	I-Premise
115	+5.3	_	_	I-Premise
116	)	_	_	I-Premise
117	compared	_	_	I-Premise
118	with	_	_	I-Premise
119	2.8	_	_	I-Premise
120	g/dL	_	_	I-Premise
121	(	_	_	I-Premise
122	range	_	_	I-Premise
123	,	_	_	I-Premise
124	-2.2	_	_	I-Premise
125	to	_	_	I-Premise
126	+7.5	_	_	I-Premise
127	)	_	_	I-Premise
128	for	_	_	I-Premise
129	epoetin-treated	_	_	I-Premise
130	patients	_	_	I-Premise
131	(	_	_	I-Premise
132	P	_	_	I-Premise
133	<	_	_	I-Premise
134	.0001	_	_	I-Premise
135	)	_	_	I-Premise
136	.	_	_	I-Premise

137	During	_	_	B-Premise
138	the	_	_	I-Premise
139	study	_	_	I-Premise
140	,	_	_	I-Premise
141	31.7	_	_	I-Premise
142	%	_	_	I-Premise
143	of	_	_	I-Premise
144	placebo-treated	_	_	I-Premise
145	patients	_	_	I-Premise
146	achieved	_	_	I-Premise
147	a	_	_	I-Premise
148	>	_	_	I-Premise
149	or	_	_	I-Premise
150	=	_	_	I-Premise
151	2	_	_	I-Premise
152	g/dL	_	_	I-Premise
153	HgB	_	_	I-Premise
154	increase	_	_	I-Premise
155	compared	_	_	I-Premise
156	with	_	_	I-Premise
157	72.7	_	_	I-Premise
158	%	_	_	I-Premise
159	of	_	_	I-Premise
160	epoetin-treated	_	_	I-Premise
161	patients	_	_	I-Premise
162	(	_	_	I-Premise
163	P	_	_	I-Premise
164	<	_	_	I-Premise
165	.0001	_	_	I-Premise
166	)	_	_	I-Premise
167	.	_	_	I-Premise

168	The	_	_	B-Premise
169	incidence	_	_	I-Premise
170	of	_	_	I-Premise
171	RBC	_	_	I-Premise
172	transfusion	_	_	I-Premise
173	for	_	_	I-Premise
174	placebo	_	_	I-Premise
175	and	_	_	I-Premise
176	epoetin	_	_	I-Premise
177	treatment	_	_	I-Premise
178	arms	_	_	I-Premise
179	was	_	_	I-Premise
180	39.6	_	_	I-Premise
181	%	_	_	I-Premise
182	and	_	_	I-Premise
183	25.3	_	_	I-Premise
184	%	_	_	I-Premise
185	(	_	_	I-Premise
186	P	_	_	I-Premise
187	=	_	_	I-Premise
188	.005	_	_	I-Premise
189	)	_	_	I-Premise
190	,	_	_	I-Premise
191	respectively	_	_	I-Premise
192	.	_	_	I-Premise

193	The	_	_	O
194	placebo	_	_	O
195	group	_	_	O
196	received	_	_	O
197	256	_	_	O
198	units	_	_	O
199	of	_	_	O
200	RBCs	_	_	O
201	compared	_	_	O
202	with	_	_	O
203	127	_	_	O
204	units	_	_	O
205	in	_	_	O
206	the	_	_	O
207	epoetin	_	_	O
208	group	_	_	O
209	(	_	_	O
210	P	_	_	O
211	<	_	_	O
212	.0001	_	_	O
213	)	_	_	O
214	.	_	_	O

215	The	_	_	B-Premise
216	incidence	_	_	I-Premise
217	of	_	_	I-Premise
218	toxicity	_	_	I-Premise
219	in	_	_	I-Premise
220	the	_	_	I-Premise
221	groups	_	_	I-Premise
222	was	_	_	I-Premise
223	similar	_	_	I-Premise
224	.	_	_	I-Premise

225	Changes	_	_	B-Premise
226	in	_	_	I-Premise
227	the	_	_	I-Premise
228	average	_	_	I-Premise
229	QOL	_	_	I-Premise
230	scores	_	_	I-Premise
231	from	_	_	I-Premise
232	baseline	_	_	I-Premise
233	to	_	_	I-Premise
234	the	_	_	I-Premise
235	end	_	_	I-Premise
236	of	_	_	I-Premise
237	the	_	_	I-Premise
238	study	_	_	I-Premise
239	were	_	_	I-Premise
240	similar	_	_	I-Premise
241	in	_	_	I-Premise
242	the	_	_	I-Premise
243	two	_	_	I-Premise
244	groups	_	_	I-Premise
245	(	_	_	I-Premise
246	P	_	_	I-Premise
247	=	_	_	I-Premise
248	not	_	_	I-Premise
249	significant	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	The	_	_	B-Premise
253	HgB	_	_	I-Premise
254	responders	_	_	I-Premise
255	(	_	_	I-Premise
256	irrespective	_	_	I-Premise
257	of	_	_	I-Premise
258	treatment	_	_	I-Premise
259	arm	_	_	I-Premise
260	)	_	_	I-Premise
261	had	_	_	I-Premise
262	a	_	_	I-Premise
263	mean	_	_	I-Premise
264	change	_	_	I-Premise
265	in	_	_	I-Premise
266	Functional	_	_	I-Premise
267	Assessment	_	_	I-Premise
268	of	_	_	I-Premise
269	Cancer	_	_	I-Premise
270	Therapy	_	_	I-Premise
271	(	_	_	I-Premise
272	FACT	_	_	I-Premise
273	)	_	_	I-Premise
274	fatigue	_	_	I-Premise
275	score	_	_	I-Premise
276	from	_	_	I-Premise
277	a	_	_	I-Premise
278	baseline	_	_	I-Premise
279	of	_	_	I-Premise
280	+5.1	_	_	I-Premise
281	compared	_	_	I-Premise
282	with	_	_	I-Premise
283	-2.1	_	_	I-Premise
284	for	_	_	I-Premise
285	the	_	_	I-Premise
286	nonresponders	_	_	I-Premise
287	(	_	_	I-Premise
288	P	_	_	I-Premise
289	=	_	_	I-Premise
290	.006	_	_	I-Premise
291	)	_	_	I-Premise
292	.	_	_	I-Premise

293	Epoetin	_	_	B-Claim
294	alfa	_	_	I-Claim
295	significantly	_	_	I-Claim
296	improved	_	_	I-Claim
297	HgB	_	_	I-Claim
298	and	_	_	I-Claim
299	reduced	_	_	I-Claim
300	transfusions	_	_	I-Claim
301	in	_	_	I-Claim
302	this	_	_	I-Claim
303	patient	_	_	I-Claim
304	population	_	_	I-Claim
305	.	_	_	I-Claim

306	These	_	_	B-Claim
307	results	_	_	I-Claim
308	support	_	_	I-Claim
309	the	_	_	I-Claim
310	use	_	_	I-Claim
311	of	_	_	I-Claim
312	weekly	_	_	I-Claim
313	epoetin	_	_	I-Claim
314	alfa	_	_	I-Claim
315	as	_	_	I-Claim
316	an	_	_	I-Claim
317	ameliorative	_	_	I-Claim
318	agent	_	_	I-Claim
319	for	_	_	I-Claim
320	cancer-related	_	_	I-Claim
321	anemia	_	_	I-Claim
322	.	_	_	I-Claim


0	Kaposi	_	_	O
1	's	_	_	O
2	sarcoma	_	_	O
3	is	_	_	O
4	currently	_	_	O
5	the	_	_	O
6	most	_	_	O
7	common	_	_	O
8	tumor	_	_	O
9	in	_	_	O
10	Zimbabwe	_	_	O
11	.	_	_	O

12	The	_	_	O
13	purpose	_	_	O
14	of	_	_	O
15	our	_	_	O
16	study	_	_	O
17	is	_	_	O
18	to	_	_	O
19	compare	_	_	O
20	the	_	_	O
21	effectiveness	_	_	O
22	of	_	_	O
23	supportive	_	_	O
24	care	_	_	O
25	vs.	_	_	O
26	3	_	_	O
27	intervention	_	_	O
28	approaches	_	_	O
29	,	_	_	O
30	namely	_	_	O
31	oral	_	_	O
32	Etoposide	_	_	O
33	,	_	_	O
34	a	_	_	O
35	3-drug	_	_	O
36	combination	_	_	O
37	,	_	_	O
38	and	_	_	O
39	radiotherapy	_	_	O
40	using	_	_	O
41	quality	_	_	O
42	of	_	_	O
43	life	_	_	O
44	(	_	_	O
45	QOL	_	_	O
46	)	_	_	O
47	as	_	_	O
48	the	_	_	O
49	primary	_	_	O
50	measure	_	_	O
51	of	_	_	O
52	success	_	_	O
53	.	_	_	O

54	In	_	_	O
55	addition	_	_	O
56	,	_	_	O
57	our	_	_	O
58	study	_	_	O
59	was	_	_	O
60	to	_	_	O
61	determine	_	_	O
62	whether	_	_	O
63	a	_	_	O
64	disease-specific	_	_	O
65	module	_	_	O
66	has	_	_	O
67	greater	_	_	O
68	sensitivity	_	_	O
69	to	_	_	O
70	group	_	_	O
71	differences	_	_	O
72	than	_	_	O
73	a	_	_	O
74	generic	_	_	O
75	QOL	_	_	O
76	questionnaire	_	_	O
77	and	_	_	O
78	to	_	_	O
79	determine	_	_	O
80	the	_	_	O
81	most	_	_	O
82	pragmatic	_	_	O
83	approach	_	_	O
84	to	_	_	O
85	treating	_	_	O
86	epidemic	_	_	O
87	Kaposi	_	_	O
88	's	_	_	O
89	sarcoma	_	_	O
90	(	_	_	O
91	EKS	_	_	O
92	)	_	_	O
93	in	_	_	O
94	Zimbabwe	_	_	O
95	.	_	_	O

96	Histologically	_	_	O
97	confirmed	_	_	O
98	HIV-positive	_	_	O
99	patients	_	_	O
100	with	_	_	O
101	Kaposi	_	_	O
102	's	_	_	O
103	sarcoma	_	_	O
104	were	_	_	O
105	randomized	_	_	O
106	to	_	_	O
107	receive	_	_	O
108	supportive	_	_	O
109	care	_	_	O
110	only	_	_	O
111	or	_	_	O
112	supportive	_	_	O
113	care	_	_	O
114	plus	_	_	O
115	either	_	_	O
116	radiotherapy	_	_	O
117	,	_	_	O
118	oral	_	_	O
119	Etoposide	_	_	O
120	or	_	_	O
121	a	_	_	O
122	3-drug	_	_	O
123	combination	_	_	O
124	consisting	_	_	O
125	of	_	_	O
126	actinomycin-D	_	_	O
127	,	_	_	O
128	vincristine	_	_	O
129	and	_	_	O
130	bleomycin	_	_	O
131	.	_	_	O

132	No	_	_	O
133	patient	_	_	O
134	received	_	_	O
135	antiretroviral	_	_	O
136	therapy	_	_	O
137	.	_	_	O

138	The	_	_	O
139	primary	_	_	O
140	outcome	_	_	O
141	was	_	_	O
142	QOL	_	_	O
143	measured	_	_	O
144	by	_	_	O
145	the	_	_	O
146	functional	_	_	O
147	living	_	_	O
148	index-cancer	_	_	O
149	(	_	_	O
150	FLI-C	_	_	O
151	)	_	_	O
152	and	_	_	O
153	supplemented	_	_	O
154	by	_	_	O
155	the	_	_	O
156	Kaposi	_	_	O
157	's	_	_	O
158	sarcoma	_	_	O
159	module	_	_	O
160	(	_	_	O
161	KSM	_	_	O
162	)	_	_	O
163	.	_	_	O

164	From	_	_	O
165	1994-1999	_	_	O
166	,	_	_	O
167	495	_	_	O
168	EKS	_	_	O
169	patients	_	_	O
170	were	_	_	O
171	accrued	_	_	O
172	,	_	_	O
173	and	_	_	O
174	470	_	_	O
175	were	_	_	O
176	evaluable	_	_	O
177	.	_	_	O

178	Of	_	_	O
179	these	_	_	O
180	,	_	_	O
181	433	_	_	O
182	are	_	_	O
183	known	_	_	O
184	to	_	_	O
185	be	_	_	O
186	dead	_	_	O
187	,	_	_	O
188	26	_	_	O
189	are	_	_	O
190	lost	_	_	O
191	to	_	_	O
192	follow-up	_	_	O
193	and	_	_	O
194	11	_	_	O
195	are	_	_	O
196	still	_	_	O
197	alive	_	_	O
198	.	_	_	O

199	The	_	_	B-Premise
200	group	_	_	I-Premise
201	treated	_	_	I-Premise
202	with	_	_	I-Premise
203	oral	_	_	I-Premise
204	Etoposide	_	_	I-Premise
205	had	_	_	I-Premise
206	a	_	_	I-Premise
207	significantly	_	_	I-Premise
208	better	_	_	I-Premise
209	QOL	_	_	I-Premise
210	than	_	_	I-Premise
211	the	_	_	I-Premise
212	radiotherapy	_	_	I-Premise
213	group	_	_	I-Premise
214	for	_	_	I-Premise
215	the	_	_	I-Premise
216	total	_	_	I-Premise
217	FLI-C	_	_	I-Premise
218	score	_	_	I-Premise
219	(	_	_	I-Premise
220	adjusted	_	_	I-Premise
221	mean	_	_	I-Premise
222	plus	_	_	I-Premise
223	standard	_	_	I-Premise
224	error	_	_	I-Premise
225	at	_	_	I-Premise
226	3-months	_	_	I-Premise
227	89	_	_	I-Premise
228	+/-	_	_	I-Premise
229	3	_	_	I-Premise
230	vs.	_	_	I-Premise
231	76	_	_	I-Premise
232	+/-	_	_	I-Premise
233	3	_	_	I-Premise
234	;	_	_	I-Premise
235	p	_	_	I-Premise
236	=	_	_	I-Premise
237	0.004	_	_	I-Premise
238	)	_	_	I-Premise
239	and	_	_	I-Premise
240	for	_	_	I-Premise
241	the	_	_	I-Premise
242	hardship	_	_	I-Premise
243	(	_	_	I-Premise
244	11	_	_	I-Premise
245	+/-	_	_	I-Premise
246	0.4	_	_	I-Premise
247	vs.	_	_	I-Premise
248	9	_	_	I-Premise
249	+/-	_	_	I-Premise
250	0.4	_	_	I-Premise
251	;	_	_	I-Premise
252	p	_	_	I-Premise
253	=	_	_	I-Premise
254	0.001	_	_	I-Premise
255	)	_	_	I-Premise
256	;	_	_	I-Premise
257	social	_	_	I-Premise
258	(	_	_	I-Premise
259	10	_	_	I-Premise
260	+/-	_	_	I-Premise
261	0.4	_	_	I-Premise
262	vs.	_	_	I-Premise
263	8	_	_	I-Premise
264	+/-	_	_	I-Premise
265	0.4	_	_	I-Premise
266	;	_	_	I-Premise
267	p	_	_	I-Premise
268	=	_	_	I-Premise
269	0.001	_	_	I-Premise
270	)	_	_	I-Premise
271	and	_	_	I-Premise
272	nausea	_	_	I-Premise
273	(	_	_	I-Premise
274	9	_	_	I-Premise
275	+/-	_	_	I-Premise
276	0.4	_	_	I-Premise
277	vs.	_	_	I-Premise
278	8	_	_	I-Premise
279	+/-	_	_	I-Premise
280	0.4	_	_	I-Premise
281	;	_	_	I-Premise
282	p	_	_	I-Premise
283	=	_	_	I-Premise
284	0.002	_	_	I-Premise
285	)	_	_	I-Premise
286	subscales	_	_	I-Premise
287	.	_	_	I-Premise

288	In	_	_	B-Premise
289	addition	_	_	I-Premise
290	,	_	_	I-Premise
291	on	_	_	I-Premise
292	the	_	_	I-Premise
293	physical	_	_	I-Premise
294	and	_	_	I-Premise
295	psychological	_	_	I-Premise
296	subscales	_	_	I-Premise
297	,	_	_	I-Premise
298	the	_	_	I-Premise
299	Etoposide	_	_	I-Premise
300	group	_	_	I-Premise
301	had	_	_	I-Premise
302	a	_	_	I-Premise
303	significantly	_	_	I-Premise
304	better	_	_	I-Premise
305	QOL	_	_	I-Premise
306	than	_	_	I-Premise
307	the	_	_	I-Premise
308	other	_	_	I-Premise
309	3	_	_	I-Premise
310	treatment	_	_	I-Premise
311	groups	_	_	I-Premise
312	(	_	_	I-Premise
313	p	_	_	I-Premise
314	<	_	_	I-Premise
315	0.04	_	_	I-Premise
316	)	_	_	I-Premise
317	.	_	_	I-Premise

318	The	_	_	B-Premise
319	3-drug	_	_	I-Premise
320	combination	_	_	I-Premise
321	,	_	_	I-Premise
322	supportive	_	_	I-Premise
323	care	_	_	I-Premise
324	and	_	_	I-Premise
325	radiotherapy	_	_	I-Premise
326	groups	_	_	I-Premise
327	did	_	_	I-Premise
328	not	_	_	I-Premise
329	differ	_	_	I-Premise
330	significantly	_	_	I-Premise
331	from	_	_	I-Premise
332	each	_	_	I-Premise
333	other	_	_	I-Premise
334	with	_	_	I-Premise
335	respect	_	_	I-Premise
336	to	_	_	I-Premise
337	the	_	_	I-Premise
338	total	_	_	I-Premise
339	FLI-C	_	_	I-Premise
340	score	_	_	I-Premise
341	or	_	_	I-Premise
342	its	_	_	I-Premise
343	subscales	_	_	I-Premise
344	.	_	_	I-Premise

345	There	_	_	B-Premise
346	were	_	_	I-Premise
347	no	_	_	I-Premise
348	group	_	_	I-Premise
349	differences	_	_	I-Premise
350	with	_	_	I-Premise
351	respect	_	_	I-Premise
352	to	_	_	I-Premise
353	survival	_	_	I-Premise
354	.	_	_	I-Premise

355	Oral	_	_	B-Claim
356	Etoposide	_	_	I-Claim
357	therapy	_	_	I-Claim
358	resulted	_	_	I-Claim
359	in	_	_	I-Claim
360	better	_	_	I-Claim
361	total	_	_	I-Claim
362	FLI-C	_	_	I-Claim
363	QOL	_	_	I-Claim
364	score	_	_	I-Claim
365	than	_	_	I-Claim
366	radiotherapy	_	_	I-Claim
367	.	_	_	I-Claim

368	As	_	_	O
369	well	_	_	O
370	,	_	_	O
371	Etoposide	_	_	B-Claim
372	resulted	_	_	I-Claim
373	in	_	_	I-Claim
374	better	_	_	I-Claim
375	physical	_	_	I-Claim
376	and	_	_	I-Claim
377	psychological	_	_	I-Claim
378	subscale	_	_	I-Claim
379	scores	_	_	I-Claim
380	than	_	_	I-Claim
381	radiotherapy	_	_	I-Claim
382	,	_	_	I-Claim
383	3-drugs	_	_	I-Claim
384	and	_	_	I-Claim
385	supportive	_	_	I-Claim
386	care	_	_	I-Claim
387	.	_	_	I-Claim

388	Thus	_	_	B-Claim
389	,	_	_	I-Claim
390	funds	_	_	I-Claim
391	permitting	_	_	I-Claim
392	,	_	_	I-Claim
393	oral	_	_	I-Claim
394	Etoposide	_	_	I-Claim
395	is	_	_	I-Claim
396	a	_	_	I-Claim
397	pragmatic	_	_	I-Claim
398	approach	_	_	I-Claim
399	to	_	_	I-Claim
400	treating	_	_	I-Claim
401	EKS	_	_	I-Claim
402	in	_	_	I-Claim
403	an	_	_	I-Claim
404	environment	_	_	I-Claim
405	where	_	_	I-Claim
406	antiretroviral	_	_	I-Claim
407	drugs	_	_	I-Claim
408	are	_	_	I-Claim
409	not	_	_	I-Claim
410	universally	_	_	I-Claim
411	available	_	_	I-Claim
412	.	_	_	I-Claim

413	The	_	_	B-Claim
414	study	_	_	I-Claim
415	underscores	_	_	I-Claim
416	the	_	_	I-Claim
417	value	_	_	I-Claim
418	of	_	_	I-Claim
419	undertaking	_	_	I-Claim
420	studies	_	_	I-Claim
421	in	_	_	I-Claim
422	areas	_	_	I-Claim
423	of	_	_	I-Claim
424	disease	_	_	I-Claim
425	prevalence	_	_	I-Claim
426	and	_	_	I-Claim
427	the	_	_	I-Claim
428	necessity	_	_	I-Claim
429	of	_	_	I-Claim
430	selecting	_	_	I-Claim
431	appropriate	_	_	I-Claim
432	outcome	_	_	I-Claim
433	measures	_	_	I-Claim
434	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	a	_	_	O
8	biweekly	_	_	O
9	regimen	_	_	O
10	of	_	_	O
11	leucovorin	_	_	O
12	(	_	_	O
13	LV	_	_	O
14	)	_	_	O
15	plus	_	_	O
16	fluorouracil	_	_	O
17	(	_	_	O
18	FU	_	_	O
19	)	_	_	O
20	alone	_	_	O
21	or	_	_	O
22	in	_	_	O
23	combination	_	_	O
24	with	_	_	O
25	cisplatin	_	_	O
26	or	_	_	O
27	irinotecan	_	_	O
28	in	_	_	O
29	patients	_	_	O
30	with	_	_	O
31	previously	_	_	O
32	untreated	_	_	O
33	metastatic	_	_	O
34	gastric	_	_	O
35	adenocarcinoma	_	_	O
36	and	_	_	O
37	to	_	_	O
38	select	_	_	O
39	the	_	_	O
40	best	_	_	O
41	arm	_	_	O
42	for	_	_	O
43	a	_	_	O
44	phase	_	_	O
45	III	_	_	O
46	study	_	_	O
47	.	_	_	O

48	One	_	_	O
49	hundred	_	_	O
50	thirty-six	_	_	O
51	patients	_	_	O
52	(	_	_	O
53	two	_	_	O
54	were	_	_	O
55	ineligible	_	_	O
56	)	_	_	O
57	were	_	_	O
58	enrolled	_	_	O
59	onto	_	_	O
60	the	_	_	O
61	randomized	_	_	O
62	multicenter	_	_	O
63	phase	_	_	O
64	II	_	_	O
65	trial	_	_	O
66	.	_	_	O

67	Patients	_	_	O
68	received	_	_	O
69	LV	_	_	O
70	200	_	_	O
71	mg/m	_	_	O
72	(	_	_	O
73	2	_	_	O
74	)	_	_	O
75	(	_	_	O
76	2-hour	_	_	O
77	infusion	_	_	O
78	)	_	_	O
79	followed	_	_	O
80	by	_	_	O
81	FU	_	_	O
82	400	_	_	O
83	mg/m	_	_	O
84	(	_	_	O
85	2	_	_	O
86	)	_	_	O
87	(	_	_	O
88	bolus	_	_	O
89	)	_	_	O
90	and	_	_	O
91	FU	_	_	O
92	600	_	_	O
93	mg/m	_	_	O
94	(	_	_	O
95	2	_	_	O
96	)	_	_	O
97	(	_	_	O
98	22-hour	_	_	O
99	continuous	_	_	O
100	infusion	_	_	O
101	)	_	_	O
102	on	_	_	O
103	days	_	_	O
104	1	_	_	O
105	and	_	_	O
106	2	_	_	O
107	every	_	_	O
108	14	_	_	O
109	days	_	_	O
110	(	_	_	O
111	LV5FU2	_	_	O
112	;	_	_	O
113	arm	_	_	O
114	A	_	_	O
115	)	_	_	O
116	,	_	_	O
117	LV5FU2	_	_	O
118	plus	_	_	O
119	cisplatin	_	_	O
120	50	_	_	O
121	mg/m	_	_	O
122	(	_	_	O
123	2	_	_	O
124	)	_	_	O
125	(	_	_	O
126	1-hour	_	_	O
127	infusion	_	_	O
128	)	_	_	O
129	on	_	_	O
130	day	_	_	O
131	1	_	_	O
132	or	_	_	O
133	2	_	_	O
134	(	_	_	O
135	arm	_	_	O
136	B	_	_	O
137	)	_	_	O
138	,	_	_	O
139	or	_	_	O
140	LV5FU2	_	_	O
141	plus	_	_	O
142	irinotecan	_	_	O
143	180	_	_	O
144	mg/m	_	_	O
145	(	_	_	O
146	2	_	_	O
147	)	_	_	O
148	(	_	_	O
149	2-hour	_	_	O
150	infusion	_	_	O
151	)	_	_	O
152	on	_	_	O
153	day	_	_	O
154	1	_	_	O
155	(	_	_	O
156	arm	_	_	O
157	C	_	_	O
158	)	_	_	O
159	.	_	_	O

160	The	_	_	B-Premise
161	overall	_	_	I-Premise
162	response	_	_	I-Premise
163	rates	_	_	I-Premise
164	,	_	_	I-Premise
165	which	_	_	I-Premise
166	were	_	_	I-Premise
167	confirmed	_	_	I-Premise
168	by	_	_	I-Premise
169	an	_	_	I-Premise
170	independent	_	_	I-Premise
171	expert	_	_	I-Premise
172	panel	_	_	I-Premise
173	,	_	_	I-Premise
174	were	_	_	I-Premise
175	13	_	_	I-Premise
176	%	_	_	I-Premise
177	(	_	_	I-Premise
178	95	_	_	I-Premise
179	%	_	_	I-Premise
180	CI	_	_	I-Premise
181	,	_	_	I-Premise
182	3.4	_	_	I-Premise
183	%	_	_	I-Premise
184	to	_	_	I-Premise
185	23.3	_	_	I-Premise
186	%	_	_	I-Premise
187	)	_	_	I-Premise
188	,	_	_	I-Premise
189	27	_	_	I-Premise
190	%	_	_	I-Premise
191	(	_	_	I-Premise
192	95	_	_	I-Premise
193	%	_	_	I-Premise
194	CI	_	_	I-Premise
195	,	_	_	I-Premise
196	14.1	_	_	I-Premise
197	%	_	_	I-Premise
198	to	_	_	I-Premise
199	40.4	_	_	I-Premise
200	%	_	_	I-Premise
201	)	_	_	I-Premise
202	,	_	_	I-Premise
203	and	_	_	I-Premise
204	40	_	_	I-Premise
205	%	_	_	I-Premise
206	(	_	_	I-Premise
207	95	_	_	I-Premise
208	%	_	_	I-Premise
209	CI	_	_	I-Premise
210	,	_	_	I-Premise
211	25.7	_	_	I-Premise
212	%	_	_	I-Premise
213	to	_	_	I-Premise
214	54.3	_	_	I-Premise
215	%	_	_	I-Premise
216	)	_	_	I-Premise
217	for	_	_	I-Premise
218	arms	_	_	I-Premise
219	A	_	_	I-Premise
220	,	_	_	I-Premise
221	B	_	_	I-Premise
222	,	_	_	I-Premise
223	and	_	_	I-Premise
224	C	_	_	I-Premise
225	,	_	_	I-Premise
226	respectively	_	_	I-Premise
227	.	_	_	I-Premise

228	Median	_	_	B-Premise
229	progression-free	_	_	I-Premise
230	survival	_	_	I-Premise
231	and	_	_	I-Premise
232	overall	_	_	I-Premise
233	survival	_	_	I-Premise
234	times	_	_	I-Premise
235	were	_	_	I-Premise
236	3.2	_	_	I-Premise
237	months	_	_	I-Premise
238	(	_	_	I-Premise
239	95	_	_	I-Premise
240	%	_	_	I-Premise
241	CI	_	_	I-Premise
242	,	_	_	I-Premise
243	1.8	_	_	I-Premise
244	to	_	_	I-Premise
245	4.6	_	_	I-Premise
246	months	_	_	I-Premise
247	)	_	_	I-Premise
248	and	_	_	I-Premise
249	6.8	_	_	I-Premise
250	months	_	_	I-Premise
251	(	_	_	I-Premise
252	95	_	_	I-Premise
253	%	_	_	I-Premise
254	CI	_	_	I-Premise
255	,	_	_	I-Premise
256	2.6	_	_	I-Premise
257	to	_	_	I-Premise
258	11.1	_	_	I-Premise
259	months	_	_	I-Premise
260	)	_	_	I-Premise
261	with	_	_	I-Premise
262	LV5FU2	_	_	I-Premise
263	,	_	_	I-Premise
264	respectively	_	_	I-Premise
265	;	_	_	I-Premise
266	4.9	_	_	I-Premise
267	months	_	_	I-Premise
268	(	_	_	I-Premise
269	95	_	_	I-Premise
270	%	_	_	I-Premise
271	CI	_	_	I-Premise
272	,	_	_	I-Premise
273	3.5	_	_	I-Premise
274	to	_	_	I-Premise
275	6.3	_	_	I-Premise
276	months	_	_	I-Premise
277	)	_	_	I-Premise
278	and	_	_	I-Premise
279	9.5	_	_	I-Premise
280	months	_	_	I-Premise
281	(	_	_	I-Premise
282	95	_	_	I-Premise
283	%	_	_	I-Premise
284	CI	_	_	I-Premise
285	,	_	_	I-Premise
286	6.9	_	_	I-Premise
287	to	_	_	I-Premise
288	12.2	_	_	I-Premise
289	months	_	_	I-Premise
290	)	_	_	I-Premise
291	with	_	_	I-Premise
292	LV5FU2-cisplatin	_	_	I-Premise
293	,	_	_	I-Premise
294	respectively	_	_	I-Premise
295	;	_	_	I-Premise
296	and	_	_	I-Premise
297	6.9	_	_	I-Premise
298	months	_	_	I-Premise
299	(	_	_	I-Premise
300	95	_	_	I-Premise
301	%	_	_	I-Premise
302	CI	_	_	I-Premise
303	,	_	_	I-Premise
304	5.5	_	_	I-Premise
305	to	_	_	I-Premise
306	8.3	_	_	I-Premise
307	months	_	_	I-Premise
308	)	_	_	I-Premise
309	and	_	_	I-Premise
310	11.3	_	_	I-Premise
311	months	_	_	I-Premise
312	(	_	_	I-Premise
313	95	_	_	I-Premise
314	%	_	_	I-Premise
315	CI	_	_	I-Premise
316	,	_	_	I-Premise
317	9.3	_	_	I-Premise
318	to	_	_	I-Premise
319	13.3	_	_	I-Premise
320	months	_	_	I-Premise
321	)	_	_	I-Premise
322	with	_	_	I-Premise
323	LV5FU2-irinotecan	_	_	I-Premise
324	,	_	_	I-Premise
325	respectively	_	_	I-Premise
326	.	_	_	I-Premise

327	Of	_	_	B-Claim
328	the	_	_	I-Claim
329	three	_	_	I-Claim
330	regimens	_	_	I-Claim
331	tested	_	_	I-Claim
332	,	_	_	I-Claim
333	the	_	_	I-Claim
334	combination	_	_	I-Claim
335	of	_	_	I-Claim
336	LV5FU2-irinotecan	_	_	I-Claim
337	is	_	_	I-Claim
338	the	_	_	I-Claim
339	most	_	_	I-Claim
340	promising	_	_	I-Claim
341	and	_	_	I-Claim
342	will	_	_	I-Claim
343	be	_	_	I-Claim
344	assessed	_	_	I-Claim
345	in	_	_	I-Claim
346	a	_	_	I-Claim
347	phase	_	_	I-Claim
348	III	_	_	I-Claim
349	trial	_	_	I-Claim
350	.	_	_	I-Claim


0	Treatment-induced	_	_	O
1	arm	_	_	O
2	lymphoedema	_	_	O
3	is	_	_	O
4	a	_	_	O
5	common	_	_	O
6	and	_	_	O
7	distressing	_	_	O
8	complication	_	_	O
9	of	_	_	O
10	curative	_	_	O
11	surgery	_	_	O
12	and	_	_	O
13	radiotherapy	_	_	O
14	for	_	_	O
15	early	_	_	O
16	breast	_	_	O
17	cancer	_	_	O
18	.	_	_	O

19	A	_	_	O
20	number	_	_	O
21	of	_	_	O
22	studies	_	_	O
23	testing	_	_	O
24	alpha-tocopherol	_	_	O
25	(	_	_	O
26	vitamin	_	_	O
27	E	_	_	O
28	)	_	_	O
29	and	_	_	O
30	pentoxifylline	_	_	O
31	suggest	_	_	O
32	evidence	_	_	O
33	of	_	_	O
34	clinical	_	_	O
35	regression	_	_	O
36	of	_	_	O
37	superficial	_	_	O
38	radiation-induced	_	_	O
39	fibrosis	_	_	O
40	but	_	_	O
41	there	_	_	O
42	is	_	_	O
43	only	_	_	O
44	very	_	_	O
45	limited	_	_	O
46	evidence	_	_	O
47	from	_	_	O
48	randomised	_	_	O
49	trials	_	_	O
50	.	_	_	O

51	Arm	_	_	O
52	lymphoedema	_	_	O
53	after	_	_	O
54	lymphatic	_	_	O
55	radiotherapy	_	_	O
56	and	_	_	O
57	surgery	_	_	O
58	has	_	_	O
59	been	_	_	O
60	used	_	_	O
61	in	_	_	O
62	the	_	_	O
63	present	_	_	O
64	study	_	_	O
65	as	_	_	O
66	a	_	_	O
67	clinical	_	_	O
68	system	_	_	O
69	for	_	_	O
70	testing	_	_	O
71	these	_	_	O
72	drugs	_	_	O
73	in	_	_	O
74	a	_	_	O
75	double-blind	_	_	O
76	placebo-controlled	_	_	O
77	randomised	_	_	O
78	phase	_	_	O
79	II	_	_	O
80	trial	_	_	O
81	.	_	_	O

82	Sixty-eight	_	_	O
83	eligible	_	_	O
84	research	_	_	O
85	volunteers	_	_	O
86	with	_	_	O
87	a	_	_	O
88	minimum	_	_	O
89	20	_	_	O
90	%	_	_	O
91	increase	_	_	O
92	in	_	_	O
93	arm	_	_	O
94	volume	_	_	O
95	at	_	_	O
96	a	_	_	O
97	median	_	_	O
98	15.5	_	_	O
99	years	_	_	O
100	(	_	_	O
101	range	_	_	O
102	2-41	_	_	O
103	)	_	_	O
104	after	_	_	O
105	axillary/supraclavicular	_	_	O
106	radiotherapy	_	_	O
107	(	_	_	O
108	plus	_	_	O
109	axillary	_	_	O
110	surgery	_	_	O
111	in	_	_	O
112	51/68	_	_	O
113	(	_	_	O
114	75	_	_	O
115	%	_	_	O
116	)	_	_	O
117	cases	_	_	O
118	)	_	_	O
119	were	_	_	O
120	randomised	_	_	O
121	to	_	_	O
122	active	_	_	O
123	drugs	_	_	O
124	or	_	_	O
125	placebo	_	_	O
126	.	_	_	O

127	All	_	_	O
128	volunteers	_	_	O
129	were	_	_	O
130	given	_	_	O
131	dl-alpha	_	_	O
132	tocopheryl	_	_	O
133	acetate	_	_	O
134	500	_	_	O
135	mg	_	_	O
136	twice	_	_	O
137	a	_	_	O
138	day	_	_	O
139	orally	_	_	O
140	plus	_	_	O
141	pentoxifylline	_	_	O
142	400	_	_	O
143	mg	_	_	O
144	twice	_	_	O
145	a	_	_	O
146	day	_	_	O
147	orally	_	_	O
148	,	_	_	O
149	or	_	_	O
150	corresponding	_	_	O
151	placebos	_	_	O
152	,	_	_	O
153	for	_	_	O
154	6	_	_	O
155	months	_	_	O
156	.	_	_	O

157	The	_	_	O
158	primary	_	_	O
159	endpoint	_	_	O
160	was	_	_	O
161	volume	_	_	O
162	of	_	_	O
163	the	_	_	O
164	ipsilateral	_	_	O
165	limb	_	_	O
166	measured	_	_	O
167	opto-electronically	_	_	O
168	using	_	_	O
169	a	_	_	O
170	perometer	_	_	O
171	and	_	_	O
172	expressed	_	_	O
173	as	_	_	O
174	a	_	_	O
175	percentage	_	_	O
176	of	_	_	O
177	the	_	_	O
178	contralateral	_	_	O
179	limb	_	_	O
180	volume	_	_	O
181	.	_	_	O

182	At	_	_	B-Premise
183	12	_	_	I-Premise
184	months	_	_	I-Premise
185	post-randomisation	_	_	I-Premise
186	,	_	_	I-Premise
187	there	_	_	I-Premise
188	was	_	_	I-Premise
189	no	_	_	I-Premise
190	significant	_	_	I-Premise
191	difference	_	_	I-Premise
192	between	_	_	I-Premise
193	treatment	_	_	I-Premise
194	and	_	_	I-Premise
195	control	_	_	I-Premise
196	groups	_	_	I-Premise
197	in	_	_	I-Premise
198	terms	_	_	I-Premise
199	of	_	_	I-Premise
200	arm	_	_	I-Premise
201	volume	_	_	I-Premise
202	.	_	_	I-Premise

203	Absolute	_	_	B-Premise
204	change	_	_	I-Premise
205	in	_	_	I-Premise
206	arm	_	_	I-Premise
207	volume	_	_	I-Premise
208	at	_	_	I-Premise
209	12	_	_	I-Premise
210	months	_	_	I-Premise
211	was	_	_	I-Premise
212	2.5	_	_	I-Premise
213	%	_	_	I-Premise
214	(	_	_	I-Premise
215	95	_	_	I-Premise
216	%	_	_	I-Premise
217	CI	_	_	I-Premise
218	-0.40	_	_	I-Premise
219	to	_	_	I-Premise
220	5.3	_	_	I-Premise
221	)	_	_	I-Premise
222	in	_	_	I-Premise
223	the	_	_	I-Premise
224	treatment	_	_	I-Premise
225	group	_	_	I-Premise
226	compared	_	_	I-Premise
227	to	_	_	I-Premise
228	1.2	_	_	I-Premise
229	%	_	_	I-Premise
230	(	_	_	I-Premise
231	95	_	_	I-Premise
232	%	_	_	I-Premise
233	CI	_	_	I-Premise
234	-2.8	_	_	I-Premise
235	to	_	_	I-Premise
236	5.1	_	_	I-Premise
237	)	_	_	I-Premise
238	in	_	_	I-Premise
239	the	_	_	I-Premise
240	placebo	_	_	I-Premise
241	group	_	_	I-Premise
242	.	_	_	I-Premise

243	The	_	_	B-Premise
244	difference	_	_	I-Premise
245	in	_	_	I-Premise
246	mean	_	_	I-Premise
247	volume	_	_	I-Premise
248	change	_	_	I-Premise
249	between	_	_	I-Premise
250	randomisation	_	_	I-Premise
251	groups	_	_	I-Premise
252	at	_	_	I-Premise
253	12	_	_	I-Premise
254	months	_	_	I-Premise
255	was	_	_	I-Premise
256	not	_	_	I-Premise
257	statistically	_	_	I-Premise
258	significant	_	_	I-Premise
259	(	_	_	I-Premise
260	P	_	_	I-Premise
261	=	_	_	I-Premise
262	0.6	_	_	I-Premise
263	)	_	_	I-Premise
264	,	_	_	I-Premise
265	-1.3	_	_	I-Premise
266	%	_	_	I-Premise
267	(	_	_	I-Premise
268	95	_	_	I-Premise
269	%	_	_	I-Premise
270	CI	_	_	I-Premise
271	-6.1	_	_	I-Premise
272	to	_	_	I-Premise
273	3.5	_	_	I-Premise
274	)	_	_	I-Premise
275	,	_	_	I-Premise
276	nor	_	_	I-Premise
277	was	_	_	I-Premise
278	there	_	_	I-Premise
279	a	_	_	I-Premise
280	significant	_	_	I-Premise
281	difference	_	_	I-Premise
282	in	_	_	I-Premise
283	response	_	_	I-Premise
284	at	_	_	I-Premise
285	6	_	_	I-Premise
286	months	_	_	I-Premise
287	(	_	_	I-Premise
288	P	_	_	I-Premise
289	=	_	_	I-Premise
290	0.7	_	_	I-Premise
291	)	_	_	I-Premise
292	,	_	_	I-Premise
293	where	_	_	I-Premise
294	mean	_	_	I-Premise
295	change	_	_	I-Premise
296	in	_	_	I-Premise
297	arm	_	_	I-Premise
298	volume	_	_	I-Premise
299	from	_	_	I-Premise
300	baseline	_	_	I-Premise
301	in	_	_	I-Premise
302	the	_	_	I-Premise
303	treatment	_	_	I-Premise
304	and	_	_	I-Premise
305	placebo	_	_	I-Premise
306	groups	_	_	I-Premise
307	was	_	_	I-Premise
308	-2.3	_	_	I-Premise
309	%	_	_	I-Premise
310	(	_	_	I-Premise
311	95	_	_	I-Premise
312	%	_	_	I-Premise
313	CI	_	_	I-Premise
314	-7.9	_	_	I-Premise
315	to	_	_	I-Premise
316	3.4	_	_	I-Premise
317	)	_	_	I-Premise
318	and	_	_	I-Premise
319	-1.1	_	_	I-Premise
320	%	_	_	I-Premise
321	(	_	_	I-Premise
322	95	_	_	I-Premise
323	%	_	_	I-Premise
324	CI	_	_	I-Premise
325	-3.9	_	_	I-Premise
326	to	_	_	I-Premise
327	1.7	_	_	I-Premise
328	)	_	_	I-Premise
329	,	_	_	I-Premise
330	respectively	_	_	I-Premise
331	.	_	_	I-Premise

332	There	_	_	B-Premise
333	were	_	_	I-Premise
334	no	_	_	I-Premise
335	significant	_	_	I-Premise
336	differences	_	_	I-Premise
337	between	_	_	I-Premise
338	randomised	_	_	I-Premise
339	groups	_	_	I-Premise
340	in	_	_	I-Premise
341	terms	_	_	I-Premise
342	of	_	_	I-Premise
343	secondary	_	_	I-Premise
344	endpoints	_	_	I-Premise
345	,	_	_	I-Premise
346	including	_	_	I-Premise
347	tissue	_	_	I-Premise
348	induration	_	_	I-Premise
349	(	_	_	I-Premise
350	fibrosis	_	_	I-Premise
351	)	_	_	I-Premise
352	in	_	_	I-Premise
353	the	_	_	I-Premise
354	irradiated	_	_	I-Premise
355	breast	_	_	I-Premise
356	or	_	_	I-Premise
357	chest	_	_	I-Premise
358	wall	_	_	I-Premise
359	,	_	_	I-Premise
360	pectoral	_	_	I-Premise
361	fold	_	_	I-Premise
362	or	_	_	I-Premise
363	supraclavicular	_	_	I-Premise
364	fossa	_	_	I-Premise
365	,	_	_	I-Premise
366	change	_	_	I-Premise
367	in	_	_	I-Premise
368	photographic	_	_	I-Premise
369	breast/chest	_	_	I-Premise
370	wall	_	_	I-Premise
371	appearance	_	_	I-Premise
372	or	_	_	I-Premise
373	patient	_	_	I-Premise
374	self-assessment	_	_	I-Premise
375	of	_	_	I-Premise
376	function	_	_	I-Premise
377	and	_	_	I-Premise
378	Quality	_	_	I-Premise
379	of	_	_	I-Premise
380	Life	_	_	I-Premise
381	at	_	_	I-Premise
382	either	_	_	I-Premise
383	6	_	_	I-Premise
384	or	_	_	I-Premise
385	12	_	_	I-Premise
386	months	_	_	I-Premise
387	.	_	_	I-Premise

388	The	_	_	B-Claim
389	study	_	_	I-Claim
390	fails	_	_	I-Claim
391	to	_	_	I-Claim
392	demonstrate	_	_	I-Claim
393	efficacy	_	_	I-Claim
394	of	_	_	I-Claim
395	dl-alpha	_	_	I-Claim
396	tocopheryl	_	_	I-Claim
397	acetate	_	_	I-Claim
398	plus	_	_	I-Claim
399	pentoxifylline	_	_	I-Claim
400	in	_	_	I-Claim
401	patients	_	_	I-Claim
402	with	_	_	I-Claim
403	arm	_	_	I-Claim
404	lymphoedema	_	_	I-Claim
405	following	_	_	I-Claim
406	axillary	_	_	I-Claim
407	surgery	_	_	I-Claim
408	and	_	_	I-Claim
409	lymphatic	_	_	I-Claim
410	radiotherapy	_	_	I-Claim
411	,	_	_	I-Claim
412	nor	_	_	I-Claim
413	does	_	_	I-Claim
414	it	_	_	I-Claim
415	suggest	_	_	I-Claim
416	any	_	_	I-Claim
417	benefits	_	_	I-Claim
418	of	_	_	I-Claim
419	these	_	_	I-Claim
420	drugs	_	_	I-Claim
421	in	_	_	I-Claim
422	radiation-induced	_	_	I-Claim
423	induration	_	_	I-Claim
424	(	_	_	I-Claim
425	fibrosis	_	_	I-Claim
426	)	_	_	I-Claim
427	in	_	_	I-Claim
428	the	_	_	I-Claim
429	breast	_	_	I-Claim
430	,	_	_	I-Claim
431	chest	_	_	I-Claim
432	wall	_	_	I-Claim
433	,	_	_	I-Claim
434	pectoral	_	_	I-Claim
435	fold	_	_	I-Claim
436	,	_	_	I-Claim
437	axilla	_	_	I-Claim
438	or	_	_	I-Claim
439	supraclavicular	_	_	I-Claim
440	fossa	_	_	I-Claim
441	.	_	_	I-Claim


0	Approximately	_	_	O
1	40	_	_	O
2	%	_	_	O
3	of	_	_	O
4	patients	_	_	O
5	with	_	_	O
6	glaucoma	_	_	O
7	are	_	_	O
8	concomitantly	_	_	O
9	prescribed	_	_	O
10	>	_	_	O
11	or=2	_	_	O
12	different	_	_	O
13	intraocular	_	_	O
14	pressure	_	_	O
15	(	_	_	O
16	IOP	_	_	O
17	)	_	_	O
18	-lowering	_	_	O
19	medications	_	_	O
20	.	_	_	O

21	An	_	_	O
22	effective	_	_	O
23	and	_	_	O
24	well-tolerated	_	_	O
25	fixed	_	_	O
26	combination	_	_	O
27	of	_	_	O
28	agents	_	_	O
29	requiring	_	_	O
30	once-daily	_	_	O
31	instillation	_	_	O
32	may	_	_	O
33	improve	_	_	O
34	patient	_	_	O
35	compliance	_	_	O
36	.	_	_	O

37	The	_	_	O
38	purpose	_	_	O
39	of	_	_	O
40	this	_	_	O
41	study	_	_	O
42	was	_	_	O
43	to	_	_	O
44	compare	_	_	O
45	the	_	_	O
46	efficacy	_	_	O
47	and	_	_	O
48	safety	_	_	O
49	profile	_	_	O
50	of	_	_	O
51	the	_	_	O
52	fixed	_	_	O
53	combination	_	_	O
54	latanoprost	_	_	O
55	0.005	_	_	O
56	%	_	_	O
57	+	_	_	O
58	timolol	_	_	O
59	maleate	_	_	O
60	0.5	_	_	O
61	%	_	_	O
62	QD	_	_	O
63	with	_	_	O
64	those	_	_	O
65	of	_	_	O
66	latanoprost	_	_	O
67	0.005	_	_	O
68	%	_	_	O
69	monotherapy	_	_	O
70	QD	_	_	O
71	in	_	_	O
72	patients	_	_	O
73	whose	_	_	O
74	elevated	_	_	O
75	IOP	_	_	O
76	(	_	_	O
77	>	_	_	O
78	or=21	_	_	O
79	mm	_	_	O
80	Hg	_	_	O
81	)	_	_	O
82	was	_	_	O
83	inadequately	_	_	O
84	controlled	_	_	O
85	by	_	_	O
86	latanoprost	_	_	O
87	.	_	_	O

88	This	_	_	O
89	21-day	_	_	O
90	,	_	_	O
91	randomized	_	_	O
92	,	_	_	O
93	double-masked	_	_	O
94	,	_	_	O
95	active-control	_	_	O
96	study	_	_	O
97	was	_	_	O
98	conducted	_	_	O
99	at	_	_	O
100	49	_	_	O
101	study	_	_	O
102	sites	_	_	O
103	in	_	_	O
104	Argentina	_	_	O
105	,	_	_	O
106	Brazil	_	_	O
107	,	_	_	O
108	Colombia	_	_	O
109	,	_	_	O
110	Mexico	_	_	O
111	,	_	_	O
112	Peru	_	_	O
113	,	_	_	O
114	the	_	_	O
115	United	_	_	O
116	States	_	_	O
117	,	_	_	O
118	and	_	_	O
119	Venezuela	_	_	O
120	.	_	_	O

121	Adults	_	_	O
122	with	_	_	O
123	glaucoma	_	_	O
124	or	_	_	O
125	ocular	_	_	O
126	hypertension	_	_	O
127	who	_	_	O
128	had	_	_	O
129	failed	_	_	O
130	to	_	_	O
131	reach	_	_	O
132	an	_	_	O
133	IOP	_	_	O
134	of	_	_	O
135	<	_	_	O
136	21	_	_	O
137	mm	_	_	O
138	Hg	_	_	O
139	while	_	_	O
140	receiving	_	_	O
141	latanoprost	_	_	O
142	for	_	_	O
143	at	_	_	O
144	least	_	_	O
145	28	_	_	O
146	days	_	_	O
147	were	_	_	O
148	enrolled	_	_	O
149	.	_	_	O

150	After	_	_	O
151	an	_	_	O
152	additional	_	_	O
153	28	_	_	O
154	days	_	_	O
155	of	_	_	O
156	latanoprost	_	_	O
157	run-in	_	_	O
158	,	_	_	O
159	patients	_	_	O
160	were	_	_	O
161	randomly	_	_	O
162	assigned	_	_	O
163	to	_	_	O
164	continue	_	_	O
165	latanoprost	_	_	O
166	monotherapy	_	_	O
167	or	_	_	O
168	to	_	_	O
169	switch	_	_	O
170	to	_	_	O
171	the	_	_	O
172	fixed	_	_	O
173	combination	_	_	O
174	for	_	_	O
175	21	_	_	O
176	days	_	_	O
177	.	_	_	O

178	The	_	_	O
179	intent-to-treat	_	_	O
180	(	_	_	O
181	ITT	_	_	O
182	)	_	_	O
183	population	_	_	O
184	included	_	_	O
185	all	_	_	O
186	patients	_	_	O
187	who	_	_	O
188	received	_	_	O
189	at	_	_	O
190	least	_	_	O
191	1	_	_	O
192	dose	_	_	O
193	of	_	_	O
194	double-masked	_	_	O
195	study	_	_	O
196	medication	_	_	O
197	;	_	_	O
198	the	_	_	O
199	per-protocol	_	_	O
200	(	_	_	O
201	PP	_	_	O
202	)	_	_	O
203	analysis	_	_	O
204	included	_	_	O
205	patients	_	_	O
206	who	_	_	O
207	completed	_	_	O
208	the	_	_	O
209	study	_	_	O
210	without	_	_	O
211	a	_	_	O
212	major	_	_	O
213	protocol	_	_	O
214	violation	_	_	O
215	and	_	_	O
216	who	_	_	O
217	had	_	_	O
218	IOP	_	_	O
219	measurements	_	_	O
220	both	_	_	O
221	at	_	_	O
222	baseline	_	_	O
223	and	_	_	O
224	at	_	_	O
225	day	_	_	O
226	21	_	_	O
227	.	_	_	O

228	The	_	_	O
229	primary	_	_	O
230	end	_	_	O
231	point	_	_	O
232	was	_	_	O
233	the	_	_	O
234	proportion	_	_	O
235	of	_	_	O
236	patients	_	_	O
237	whose	_	_	O
238	IOP	_	_	O
239	was	_	_	O
240	decreased	_	_	O
241	>	_	_	O
242	or=2	_	_	O
243	mm	_	_	O
244	Hg	_	_	O
245	from	_	_	O
246	the	_	_	O
247	baseline	_	_	O
248	level	_	_	O
249	on	_	_	O
250	day	_	_	O
251	21	_	_	O
252	.	_	_	O

253	Proportions	_	_	O
254	of	_	_	O
255	patients	_	_	O
256	demonstrating	_	_	O
257	IOP	_	_	O
258	decreases	_	_	O
259	>	_	_	O
260	or=3	_	_	O
261	,	_	_	O
262	>	_	_	O
263	or=4	_	_	O
264	,	_	_	O
265	or	_	_	O
266	>	_	_	O
267	or=5	_	_	O
268	mm	_	_	O
269	Hg	_	_	O
270	from	_	_	O
271	the	_	_	O
272	baseline	_	_	O
273	level	_	_	O
274	and	_	_	O
275	of	_	_	O
276	patients	_	_	O
277	reaching	_	_	O
278	an	_	_	O
279	10P	_	_	O
280	<	_	_	O
281	or=18	_	_	O
282	mm	_	_	O
283	Hg	_	_	O
284	were	_	_	O
285	evaluated	_	_	O
286	.	_	_	O

287	Adverse	_	_	O
288	events	_	_	O
289	(	_	_	O
290	AEs	_	_	O
291	)	_	_	O
292	were	_	_	O
293	also	_	_	O
294	assessed	_	_	O
295	.	_	_	O

296	A	_	_	O
297	total	_	_	O
298	of	_	_	O
299	350	_	_	O
300	patients	_	_	O
301	were	_	_	O
302	enrolled	_	_	O
303	.	_	_	O

304	In	_	_	O
305	all	_	_	O
306	,	_	_	O
307	348	_	_	O
308	patients	_	_	O
309	were	_	_	O
310	included	_	_	O
311	in	_	_	O
312	the	_	_	O
313	ITT	_	_	O
314	and	_	_	O
315	tolerability	_	_	O
316	analyses	_	_	O
317	(	_	_	O
318	fixed	_	_	O
319	combination	_	_	O
320	,	_	_	O
321	n	_	_	O
322	=	_	_	O
323	175	_	_	O
324	;	_	_	O
325	latanoprost	_	_	O
326	,	_	_	O
327	n	_	_	O
328	=	_	_	O
329	173	_	_	O
330	;	_	_	O
331	mean	_	_	O
332	[	_	_	O
333	SD	_	_	O
334	]	_	_	O
335	age	_	_	O
336	,	_	_	O
337	64.4	_	_	O
338	[	_	_	O
339	13.2	_	_	O
340	]	_	_	O
341	and	_	_	O
342	63.2	_	_	O
343	[	_	_	O
344	14.0	_	_	O
345	]	_	_	O
346	years	_	_	O
347	,	_	_	O
348	respectively	_	_	O
349	;	_	_	O
350	103	_	_	O
351	women	_	_	O
352	in	_	_	O
353	each	_	_	O
354	group	_	_	O
355	)	_	_	O
356	.	_	_	O

357	Baseline	_	_	O
358	demographic	_	_	O
359	and	_	_	O
360	clinical	_	_	O
361	characteristics	_	_	O
362	were	_	_	O
363	similar	_	_	O
364	between	_	_	O
365	groups	_	_	O
366	.	_	_	O

367	A	_	_	B-Premise
368	higher	_	_	I-Premise
369	percentage	_	_	I-Premise
370	of	_	_	I-Premise
371	patients	_	_	I-Premise
372	receiving	_	_	I-Premise
373	the	_	_	I-Premise
374	fixed	_	_	I-Premise
375	combination	_	_	I-Premise
376	had	_	_	I-Premise
377	IOP	_	_	I-Premise
378	decreases	_	_	I-Premise
379	of	_	_	I-Premise
380	2	_	_	I-Premise
381	mm	_	_	I-Premise
382	Hg	_	_	I-Premise
383	on	_	_	I-Premise
384	day	_	_	I-Premise
385	21	_	_	I-Premise
386	relative	_	_	I-Premise
387	to	_	_	I-Premise
388	baseline	_	_	I-Premise
389	compared	_	_	I-Premise
390	with	_	_	I-Premise
391	latanoprost-treated	_	_	I-Premise
392	patients	_	_	I-Premise
393	(	_	_	I-Premise
394	79.4	_	_	I-Premise
395	%	_	_	I-Premise
396	vs	_	_	I-Premise
397	51.4	_	_	I-Premise
398	%	_	_	I-Premise
399	,	_	_	I-Premise
400	respectively	_	_	I-Premise
401	;	_	_	I-Premise
402	P	_	_	I-Premise
403	<	_	_	I-Premise
404	0.001	_	_	I-Premise
405	)	_	_	I-Premise
406	.	_	_	I-Premise

407	PP	_	_	B-Premise
408	analyses	_	_	I-Premise
409	found	_	_	I-Premise
410	that	_	_	I-Premise
411	more	_	_	I-Premise
412	patients	_	_	I-Premise
413	in	_	_	I-Premise
414	the	_	_	I-Premise
415	fixed-combination	_	_	I-Premise
416	group	_	_	I-Premise
417	had	_	_	I-Premise
418	IOP	_	_	I-Premise
419	decreases	_	_	I-Premise
420	>	_	_	I-Premise
421	or=3	_	_	I-Premise
422	,	_	_	I-Premise
423	>	_	_	I-Premise
424	or=4	_	_	I-Premise
425	,	_	_	I-Premise
426	or	_	_	I-Premise
427	>	_	_	I-Premise
428	or=5	_	_	I-Premise
429	mm	_	_	I-Premise
430	Hg	_	_	I-Premise
431	(	_	_	I-Premise
432	for	_	_	I-Premise
433	each	_	_	I-Premise
434	target	_	_	I-Premise
435	level	_	_	I-Premise
436	,	_	_	I-Premise
437	P	_	_	I-Premise
438	<	_	_	I-Premise
439	0.001	_	_	I-Premise
440	vs	_	_	I-Premise
441	latanoprost	_	_	I-Premise
442	group	_	_	I-Premise
443	)	_	_	I-Premise
444	or	_	_	I-Premise
445	final	_	_	I-Premise
446	IOP	_	_	I-Premise
447	18	_	_	I-Premise
448	mm	_	_	I-Premise
449	Hg	_	_	I-Premise
450	(	_	_	I-Premise
451	fixed	_	_	I-Premise
452	-combination	_	_	I-Premise
453	,	_	_	I-Premise
454	35.1	_	_	I-Premise
455	%	_	_	I-Premise
456	;	_	_	I-Premise
457	latanoprost	_	_	I-Premise
458	,	_	_	I-Premise
459	17.8	_	_	I-Premise
460	%	_	_	I-Premise
461	;	_	_	I-Premise
462	P	_	_	I-Premise
463	<	_	_	I-Premise
464	0.001	_	_	I-Premise
465	)	_	_	I-Premise
466	.	_	_	I-Premise

467	Both	_	_	B-Claim
468	treatments	_	_	I-Claim
469	were	_	_	I-Claim
470	well	_	_	I-Claim
471	tolerated	_	_	I-Claim
472	.	_	_	I-Claim

473	Similar	_	_	B-Premise
474	proportions	_	_	I-Premise
475	of	_	_	I-Premise
476	patients	_	_	I-Premise
477	in	_	_	I-Premise
478	the	_	_	I-Premise
479	fixed-combination	_	_	I-Premise
480	and	_	_	I-Premise
481	latanoprost	_	_	I-Premise
482	groups	_	_	I-Premise
483	reported	_	_	I-Premise
484	at	_	_	I-Premise
485	least	_	_	I-Premise
486	1	_	_	I-Premise
487	treatment-emergent	_	_	I-Premise
488	AE	_	_	I-Premise
489	(	_	_	I-Premise
490	10.9	_	_	I-Premise
491	%	_	_	I-Premise
492	and	_	_	I-Premise
493	12.1	_	_	I-Premise
494	%	_	_	I-Premise
495	,	_	_	I-Premise
496	respectively	_	_	I-Premise
497	)	_	_	I-Premise
498	.	_	_	I-Premise

499	In	_	_	O
500	this	_	_	O
501	selected	_	_	O
502	population	_	_	O
503	of	_	_	O
504	patients	_	_	B-Claim
505	with	_	_	I-Claim
506	an	_	_	I-Claim
507	inadequate	_	_	I-Claim
508	initial	_	_	I-Claim
509	IOP	_	_	I-Claim
510	response	_	_	I-Claim
511	to	_	_	I-Claim
512	latanoprost	_	_	I-Claim
513	,	_	_	I-Claim
514	switching	_	_	I-Claim
515	to	_	_	I-Claim
516	fixed-combination	_	_	I-Claim
517	latanoprosttimolol	_	_	I-Claim
518	resulted	_	_	I-Claim
519	in	_	_	I-Claim
520	a	_	_	I-Claim
521	greater	_	_	I-Claim
522	decrease	_	_	I-Claim
523	in	_	_	I-Claim
524	IOP	_	_	I-Claim
525	and	_	_	I-Claim
526	similar	_	_	I-Claim
527	tolerability	_	_	I-Claim
528	compared	_	_	I-Claim
529	with	_	_	I-Claim
530	continuing	_	_	I-Claim
531	latanoprost	_	_	I-Claim
532	therapy	_	_	I-Claim
533	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	,	_	_	O
5	impact	_	_	O
6	on	_	_	O
7	quality-of-life	_	_	O
8	(	_	_	O
9	QoL	_	_	O
10	)	_	_	O
11	and	_	_	O
12	tolerability	_	_	O
13	of	_	_	O
14	two	_	_	O
15	different	_	_	O
16	irinotecan	_	_	O
17	administration	_	_	O
18	schedules	_	_	O
19	in	_	_	O
20	combination	_	_	O
21	with	_	_	O
22	capecitabine	_	_	O
23	as	_	_	O
24	first-line	_	_	O
25	treatment	_	_	O
26	of	_	_	O
27	metastatic	_	_	O
28	colorectal	_	_	O
29	cancer	_	_	O
30	.	_	_	O

31	We	_	_	O
32	carried	_	_	O
33	out	_	_	O
34	a	_	_	O
35	randomized	_	_	O
36	phase	_	_	O
37	II	_	_	O
38	trial	_	_	O
39	to	_	_	O
40	select	_	_	O
41	one	_	_	O
42	of	_	_	O
43	the	_	_	O
44	following	_	_	O
45	treatment	_	_	O
46	regimens	_	_	O
47	for	_	_	O
48	further	_	_	O
49	investigation	_	_	O
50	:	_	_	O
51	weekly	_	_	O
52	irinotecan	_	_	O
53	at	_	_	O
54	a	_	_	O
55	dose	_	_	O
56	of	_	_	O
57	70	_	_	O
58	mg/m	_	_	O
59	(	_	_	O
60	2	_	_	O
61	)	_	_	O
62	days	_	_	O
63	1	_	_	O
64	,	_	_	O
65	8	_	_	O
66	,	_	_	O
67	15	_	_	O
68	,	_	_	O
69	22	_	_	O
70	,	_	_	O
71	29	_	_	O
72	(	_	_	O
73	arm	_	_	O
74	A	_	_	O
75	)	_	_	O
76	or	_	_	O
77	3-weekly	_	_	O
78	irinotecan	_	_	O
79	at	_	_	O
80	a	_	_	O
81	dose	_	_	O
82	of	_	_	O
83	300/240	_	_	O
84	mg/m	_	_	O
85	(	_	_	O
86	2	_	_	O
87	)	_	_	O
88	day	_	_	O
89	1	_	_	O
90	and	_	_	O
91	days	_	_	O
92	22	_	_	O
93	(	_	_	O
94	arm	_	_	O
95	B	_	_	O
96	)	_	_	O
97	in	_	_	O
98	combination	_	_	O
99	with	_	_	O
100	capecitabine	_	_	O
101	1000	_	_	O
102	mg/m	_	_	O
103	(	_	_	O
104	2	_	_	O
105	)	_	_	O
106	twice	_	_	O
107	daily	_	_	O
108	days	_	_	O
109	1-14	_	_	O
110	and	_	_	O
111	days	_	_	O
112	22-35	_	_	O
113	every	_	_	O
114	6	_	_	O
115	weeks	_	_	O
116	.	_	_	O

117	Seventy-five	_	_	O
118	patients	_	_	O
119	with	_	_	O
120	good	_	_	O
121	performance	_	_	O
122	status	_	_	O
123	entered	_	_	O
124	the	_	_	O
125	trial	_	_	O
126	.	_	_	O

127	The	_	_	O
128	two	_	_	O
129	arms	_	_	O
130	were	_	_	O
131	well	_	_	O
132	balanced	_	_	O
133	for	_	_	O
134	relevant	_	_	O
135	patient	_	_	O
136	and	_	_	O
137	disease	_	_	O
138	characteristics	_	_	O
139	.	_	_	O

140	The	_	_	B-Premise
141	most	_	_	I-Premise
142	frequent	_	_	I-Premise
143	toxic	_	_	I-Premise
144	effects	_	_	I-Premise
145	were	_	_	I-Premise
146	grade	_	_	I-Premise
147	3/4	_	_	I-Premise
148	diarrhea	_	_	I-Premise
149	(	_	_	I-Premise
150	arm	_	_	I-Premise
151	A	_	_	I-Premise
152	:	_	_	I-Premise
153	34	_	_	I-Premise
154	%	_	_	I-Premise
155	,	_	_	I-Premise
156	B	_	_	I-Premise
157	:	_	_	I-Premise
158	19	_	_	I-Premise
159	%	_	_	I-Premise
160	)	_	_	I-Premise
161	,	_	_	I-Premise
162	grade	_	_	I-Premise
163	3/4	_	_	I-Premise
164	neutropenia	_	_	I-Premise
165	(	_	_	I-Premise
166	A	_	_	I-Premise
167	:	_	_	I-Premise
168	5	_	_	I-Premise
169	%	_	_	I-Premise
170	,	_	_	I-Premise
171	B	_	_	I-Premise
172	:	_	_	I-Premise
173	19	_	_	I-Premise
174	%	_	_	I-Premise
175	)	_	_	I-Premise
176	and	_	_	I-Premise
177	grade	_	_	I-Premise
178	2/3	_	_	I-Premise
179	alopecia	_	_	I-Premise
180	(	_	_	I-Premise
181	A	_	_	I-Premise
182	:	_	_	I-Premise
183	26	_	_	I-Premise
184	%	_	_	I-Premise
185	,	_	_	I-Premise
186	B	_	_	I-Premise
187	:	_	_	I-Premise
188	65	_	_	I-Premise
189	%	_	_	I-Premise
190	)	_	_	I-Premise
191	.	_	_	I-Premise

192	Other	_	_	B-Premise
193	grade	_	_	I-Premise
194	3/4	_	_	I-Premise
195	toxic	_	_	I-Premise
196	effects	_	_	I-Premise
197	were	_	_	I-Premise
198	rare	_	_	I-Premise
199	(	_	_	I-Premise
200	<	_	_	I-Premise
201	5	_	_	I-Premise
202	%	_	_	I-Premise
203	)	_	_	I-Premise
204	.	_	_	I-Premise

205	Response	_	_	B-Premise
206	rates	_	_	I-Premise
207	were	_	_	I-Premise
208	34	_	_	I-Premise
209	%	_	_	I-Premise
210	[	_	_	I-Premise
211	95	_	_	I-Premise
212	%	_	_	I-Premise
213	confidence	_	_	I-Premise
214	interval	_	_	I-Premise
215	(	_	_	I-Premise
216	CI	_	_	I-Premise
217	)	_	_	I-Premise
218	20	_	_	I-Premise
219	%	_	_	I-Premise
220	to	_	_	I-Premise
221	51	_	_	I-Premise
222	%	_	_	I-Premise
223	]	_	_	I-Premise
224	in	_	_	I-Premise
225	arm	_	_	I-Premise
226	A	_	_	I-Premise
227	and	_	_	I-Premise
228	35	_	_	I-Premise
229	%	_	_	I-Premise
230	(	_	_	I-Premise
231	95	_	_	I-Premise
232	%	_	_	I-Premise
233	CI	_	_	I-Premise
234	:	_	_	I-Premise
235	20	_	_	I-Premise
236	%	_	_	I-Premise
237	to	_	_	I-Premise
238	53	_	_	I-Premise
239	%	_	_	I-Premise
240	)	_	_	I-Premise
241	in	_	_	I-Premise
242	arm	_	_	I-Premise
243	B	_	_	I-Premise
244	.	_	_	I-Premise

245	Median	_	_	B-Premise
246	time	_	_	I-Premise
247	to	_	_	I-Premise
248	progression	_	_	I-Premise
249	was	_	_	I-Premise
250	6.9	_	_	I-Premise
251	(	_	_	I-Premise
252	4.6-10.1	_	_	I-Premise
253	)	_	_	I-Premise
254	and	_	_	I-Premise
255	9.2	_	_	I-Premise
256	(	_	_	I-Premise
257	7.9-11.5	_	_	I-Premise
258	)	_	_	I-Premise
259	months	_	_	I-Premise
260	and	_	_	I-Premise
261	median	_	_	I-Premise
262	overall	_	_	I-Premise
263	survival	_	_	I-Premise
264	was	_	_	I-Premise
265	17.4	_	_	I-Premise
266	(	_	_	I-Premise
267	12.6-23.0+	_	_	I-Premise
268	)	_	_	I-Premise
269	and	_	_	I-Premise
270	24.7	_	_	I-Premise
271	(	_	_	I-Premise
272	16.3-26.4+	_	_	I-Premise
273	)	_	_	I-Premise
274	months	_	_	I-Premise
275	.	_	_	I-Premise

276	Patients	_	_	B-Premise
277	with	_	_	I-Premise
278	an	_	_	I-Premise
279	objective	_	_	I-Premise
280	tumor	_	_	I-Premise
281	response	_	_	I-Premise
282	reported	_	_	I-Premise
283	better	_	_	I-Premise
284	physical	_	_	I-Premise
285	well-being	_	_	I-Premise
286	(	_	_	I-Premise
287	P	_	_	I-Premise
288	<	_	_	I-Premise
289	0.01	_	_	I-Premise
290	)	_	_	I-Premise
291	,	_	_	I-Premise
292	mood	_	_	I-Premise
293	(	_	_	I-Premise
294	P	_	_	I-Premise
295	<	_	_	I-Premise
296	0.05	_	_	I-Premise
297	)	_	_	I-Premise
298	,	_	_	I-Premise
299	functional	_	_	I-Premise
300	performance	_	_	I-Premise
301	(	_	_	I-Premise
302	P	_	_	I-Premise
303	<	_	_	I-Premise
304	0.05	_	_	I-Premise
305	)	_	_	I-Premise
306	and	_	_	I-Premise
307	less	_	_	I-Premise
308	effort	_	_	I-Premise
309	to	_	_	I-Premise
310	cope	_	_	I-Premise
311	(	_	_	I-Premise
312	P	_	_	I-Premise
313	<	_	_	I-Premise
314	0.05	_	_	I-Premise
315	)	_	_	I-Premise
316	compared	_	_	I-Premise
317	with	_	_	I-Premise
318	the	_	_	I-Premise
319	non-responders	_	_	I-Premise
320	and	_	_	I-Premise
321	stable	_	_	I-Premise
322	disease	_	_	I-Premise
323	patients	_	_	I-Premise
324	.	_	_	I-Premise

325	The	_	_	O
326	primary	_	_	O
327	end	_	_	O
328	point	_	_	O
329	of	_	_	O
330	this	_	_	O
331	study	_	_	O
332	was	_	_	O
333	the	_	_	O
334	objective	_	_	O
335	response	_	_	O
336	rate	_	_	O
337	and	_	_	O
338	based	_	_	O
339	on	_	_	O
340	the	_	_	O
341	statistical	_	_	O
342	design	_	_	O
343	of	_	_	O
344	the	_	_	O
345	trial	_	_	O
346	,	_	_	O
347	the	_	_	O
348	3-weekly	_	_	O
349	irinotecan	_	_	O
350	schedule	_	_	O
351	was	_	_	O
352	selected	_	_	O
353	over	_	_	O
354	weekly	_	_	O
355	irinotecan	_	_	O
356	administration	_	_	O
357	.	_	_	O

358	The	_	_	B-Claim
359	3-weekly	_	_	I-Claim
360	irinotecan	_	_	I-Claim
361	schedule	_	_	I-Claim
362	also	_	_	I-Claim
363	seemed	_	_	I-Claim
364	advantageous	_	_	I-Claim
365	in	_	_	I-Claim
366	terms	_	_	I-Claim
367	of	_	_	I-Claim
368	grade	_	_	I-Claim
369	3/4	_	_	I-Claim
370	diarrhea	_	_	I-Claim
371	,	_	_	I-Claim
372	time	_	_	I-Claim
373	to	_	_	I-Claim
374	progression	_	_	I-Claim
375	,	_	_	I-Claim
376	overall	_	_	I-Claim
377	survival	_	_	I-Claim
378	and	_	_	I-Claim
379	patient	_	_	I-Claim
380	convenience	_	_	I-Claim
381	,	_	_	I-Claim
382	but	_	_	B-Claim
383	the	_	_	I-Claim
384	study	_	_	I-Claim
385	was	_	_	I-Claim
386	not	_	_	I-Claim
387	designed	_	_	I-Claim
388	to	_	_	I-Claim
389	detect	_	_	I-Claim
390	differences	_	_	I-Claim
391	in	_	_	I-Claim
392	these	_	_	I-Claim
393	parameters	_	_	I-Claim
394	.	_	_	I-Claim

395	In	_	_	O
396	addition	_	_	O
397	,	_	_	O
398	tumor	_	_	B-Claim
399	response	_	_	I-Claim
400	was	_	_	I-Claim
401	shown	_	_	I-Claim
402	to	_	_	I-Claim
403	have	_	_	I-Claim
404	a	_	_	I-Claim
405	beneficial	_	_	I-Claim
406	effect	_	_	I-Claim
407	on	_	_	I-Claim
408	QoL	_	_	I-Claim
409	indicators	_	_	I-Claim
410	.	_	_	I-Claim


0	This	_	_	O
1	randomized	_	_	O
2	phase	_	_	O
3	II	_	_	O
4	study	_	_	O
5	compared	_	_	O
6	two	_	_	O
7	treatment	_	_	O
8	schedules	_	_	O
9	of	_	_	O
10	gemcitabine	_	_	O
11	in	_	_	O
12	patients	_	_	O
13	with	_	_	O
14	non-small-cell	_	_	O
15	lung	_	_	O
16	cancer	_	_	O
17	(	_	_	O
18	NSCLC	_	_	O
19	)	_	_	O
20	and	_	_	O
21	impaired	_	_	O
22	Karnofsky	_	_	O
23	performance	_	_	O
24	status	_	_	O
25	(	_	_	O
26	KP	_	_	O
27	)	_	_	O
28	.	_	_	O

29	Primary	_	_	O
30	objectives	_	_	O
31	were	_	_	O
32	to	_	_	O
33	record	_	_	O
34	changes	_	_	O
35	from	_	_	O
36	baseline	_	_	O
37	KP	_	_	O
38	and	_	_	O
39	to	_	_	O
40	assess	_	_	O
41	symptom	_	_	O
42	palliation	_	_	O
43	.	_	_	O

44	Secondary	_	_	O
45	objectives	_	_	O
46	were	_	_	O
47	overall	_	_	O
48	survival	_	_	O
49	,	_	_	O
50	tumor	_	_	O
51	response	_	_	O
52	,	_	_	O
53	and	_	_	O
54	toxicity	_	_	O
55	.	_	_	O

56	Patients	_	_	O
57	with	_	_	O
58	stage	_	_	O
59	IIIb	_	_	O
60	and	_	_	O
61	IV	_	_	O
62	NSCLC	_	_	O
63	and	_	_	O
64	KP	_	_	O
65	<	_	_	O
66	/=	_	_	O
67	70	_	_	O
68	were	_	_	O
69	randomly	_	_	O
70	assigned	_	_	O
71	to	_	_	O
72	receive	_	_	O
73	gemcitabine	_	_	O
74	1,000	_	_	O
75	mg/m	_	_	O
76	(	_	_	O
77	2	_	_	O
78	)	_	_	O
79	on	_	_	O
80	days	_	_	O
81	1	_	_	O
82	,	_	_	O
83	8	_	_	O
84	,	_	_	O
85	and	_	_	O
86	15	_	_	O
87	of	_	_	O
88	each	_	_	O
89	28-day	_	_	O
90	cycle	_	_	O
91	(	_	_	O
92	3w4	_	_	O
93	)	_	_	O
94	or	_	_	O
95	gemcitabine	_	_	O
96	1,500	_	_	O
97	mg/m	_	_	O
98	(	_	_	O
99	2	_	_	O
100	)	_	_	O
101	on	_	_	O
102	days	_	_	O
103	1	_	_	O
104	and	_	_	O
105	8	_	_	O
106	of	_	_	O
107	each	_	_	O
108	21-day	_	_	O
109	cycle	_	_	O
110	(	_	_	O
111	2w3	_	_	O
112	)	_	_	O
113	,	_	_	O
114	both	_	_	O
115	for	_	_	O
116	up	_	_	O
117	to	_	_	O
118	six	_	_	O
119	cycles	_	_	O
120	.	_	_	O

121	KP	_	_	O
122	,	_	_	O
123	toxicity	_	_	O
124	,	_	_	O
125	and	_	_	O
126	SS14	_	_	O
127	lung	_	_	O
128	cancer	_	_	O
129	specific	_	_	O
130	questions	_	_	O
131	were	_	_	O
132	recorded	_	_	O
133	before	_	_	O
134	each	_	_	O
135	cycle	_	_	O
136	of	_	_	O
137	treatment	_	_	O
138	.	_	_	O

139	Response	_	_	O
140	was	_	_	O
141	evaluated	_	_	O
142	4	_	_	O
143	weeks	_	_	O
144	after	_	_	O
145	the	_	_	O
146	last	_	_	O
147	cycle	_	_	O
148	.	_	_	O

149	One	_	_	O
150	hundred	_	_	O
151	seventy-four	_	_	O
152	patients	_	_	O
153	were	_	_	O
154	enrolled	_	_	O
155	.	_	_	O

156	There	_	_	B-Premise
157	was	_	_	I-Premise
158	significant	_	_	I-Premise
159	early	_	_	I-Premise
160	attrition	_	_	I-Premise
161	due	_	_	I-Premise
162	to	_	_	I-Premise
163	disease	_	_	I-Premise
164	progression	_	_	I-Premise
165	;	_	_	I-Premise
166	only	_	_	I-Premise
167	61.5	_	_	I-Premise
168	%	_	_	I-Premise
169	of	_	_	I-Premise
170	patients	_	_	I-Premise
171	were	_	_	I-Premise
172	alive	_	_	I-Premise
173	at	_	_	I-Premise
174	2	_	_	I-Premise
175	months	_	_	I-Premise
176	.	_	_	I-Premise

177	There	_	_	B-Premise
178	was	_	_	I-Premise
179	a	_	_	I-Premise
180	significant	_	_	I-Premise
181	improvement	_	_	I-Premise
182	in	_	_	I-Premise
183	KP	_	_	I-Premise
184	from	_	_	I-Premise
185	baseline	_	_	I-Premise
186	to	_	_	I-Premise
187	pre-cycle	_	_	I-Premise
188	3	_	_	I-Premise
189	in	_	_	I-Premise
190	both	_	_	I-Premise
191	arms	_	_	I-Premise
192	,	_	_	I-Premise
193	with	_	_	I-Premise
194	a	_	_	I-Premise
195	trend	_	_	I-Premise
196	in	_	_	I-Premise
197	favor	_	_	I-Premise
198	of	_	_	I-Premise
199	the	_	_	I-Premise
200	3w4	_	_	I-Premise
201	regimen	_	_	I-Premise
202	for	_	_	I-Premise
203	duration	_	_	I-Premise
204	and	_	_	I-Premise
205	faster	_	_	I-Premise
206	onset	_	_	I-Premise
207	of	_	_	I-Premise
208	improvement	_	_	I-Premise
209	.	_	_	I-Premise

210	Eight	_	_	B-Premise
211	of	_	_	I-Premise
212	the	_	_	I-Premise
213	17	_	_	I-Premise
214	quality-of-life	_	_	I-Premise
215	(	_	_	I-Premise
216	QOL	_	_	I-Premise
217	)	_	_	I-Premise
218	variables	_	_	I-Premise
219	assessed	_	_	I-Premise
220	showed	_	_	I-Premise
221	an	_	_	I-Premise
222	improvement	_	_	I-Premise
223	of	_	_	I-Premise
224	more	_	_	I-Premise
225	than	_	_	I-Premise
226	10	_	_	I-Premise
227	%	_	_	I-Premise
228	between	_	_	I-Premise
229	baseline	_	_	I-Premise
230	and	_	_	I-Premise
231	the	_	_	I-Premise
232	start	_	_	I-Premise
233	of	_	_	I-Premise
234	the	_	_	I-Premise
235	third	_	_	I-Premise
236	cycle	_	_	I-Premise
237	of	_	_	I-Premise
238	treatment	_	_	I-Premise
239	.	_	_	I-Premise

240	Response	_	_	B-Premise
241	rate	_	_	I-Premise
242	,	_	_	I-Premise
243	survival	_	_	I-Premise
244	,	_	_	I-Premise
245	and	_	_	I-Premise
246	duration	_	_	I-Premise
247	were	_	_	I-Premise
248	similar	_	_	I-Premise
249	in	_	_	I-Premise
250	both	_	_	I-Premise
251	arms	_	_	I-Premise
252	.	_	_	I-Premise

253	There	_	_	B-Claim
254	was	_	_	I-Claim
255	no	_	_	I-Claim
256	significant	_	_	I-Claim
257	difference	_	_	I-Claim
258	between	_	_	I-Claim
259	the	_	_	I-Claim
260	two	_	_	I-Claim
261	schedules	_	_	I-Claim
262	examined	_	_	I-Claim
263	in	_	_	I-Claim
264	terms	_	_	I-Claim
265	of	_	_	I-Claim
266	improvement	_	_	I-Claim
267	in	_	_	I-Claim
268	KP	_	_	I-Claim
269	or	_	_	I-Claim
270	QOL	_	_	I-Claim
271	,	_	_	I-Claim
272	but	_	_	I-Claim
273	there	_	_	I-Claim
274	seemed	_	_	I-Claim
275	to	_	_	I-Claim
276	be	_	_	I-Claim
277	a	_	_	I-Claim
278	trend	_	_	I-Claim
279	in	_	_	I-Claim
280	favor	_	_	I-Claim
281	of	_	_	I-Claim
282	the	_	_	I-Claim
283	3w4	_	_	I-Claim
284	schedule	_	_	I-Claim
285	.	_	_	I-Claim


0	Bevacizumab	_	_	B-Claim
1	,	_	_	I-Claim
2	a	_	_	I-Claim
3	monoclonal	_	_	I-Claim
4	antibody	_	_	I-Claim
5	against	_	_	I-Claim
6	vascular	_	_	I-Claim
7	endothelial	_	_	I-Claim
8	growth	_	_	I-Claim
9	factor	_	_	I-Claim
10	,	_	_	I-Claim
11	increases	_	_	I-Claim
12	survival	_	_	I-Claim
13	when	_	_	I-Claim
14	combined	_	_	I-Claim
15	with	_	_	I-Claim
16	irinotecan-based	_	_	I-Claim
17	chemotherapy	_	_	I-Claim
18	in	_	_	I-Claim
19	first-line	_	_	I-Claim
20	treatment	_	_	I-Claim
21	of	_	_	I-Claim
22	metastatic	_	_	I-Claim
23	colorectal	_	_	I-Claim
24	cancer	_	_	I-Claim
25	(	_	_	I-Claim
26	CRC	_	_	I-Claim
27	)	_	_	I-Claim
28	.	_	_	I-Claim

29	This	_	_	O
30	randomized	_	_	O
31	,	_	_	O
32	phase	_	_	O
33	II	_	_	O
34	trial	_	_	O
35	compared	_	_	O
36	bevacizumab	_	_	O
37	plus	_	_	O
38	fluorouracil	_	_	O
39	and	_	_	O
40	leucovorin	_	_	O
41	(	_	_	O
42	FU/LV	_	_	O
43	)	_	_	O
44	versus	_	_	O
45	placebo	_	_	O
46	plus	_	_	O
47	FU/LV	_	_	O
48	as	_	_	O
49	first-line	_	_	O
50	therapy	_	_	O
51	in	_	_	O
52	patients	_	_	O
53	considered	_	_	O
54	nonoptimal	_	_	O
55	candidates	_	_	O
56	for	_	_	O
57	first-line	_	_	O
58	irinotecan	_	_	O
59	.	_	_	O

60	Patients	_	_	O
61	had	_	_	O
62	metastatic	_	_	O
63	CRC	_	_	O
64	and	_	_	O
65	one	_	_	O
66	of	_	_	O
67	the	_	_	O
68	following	_	_	O
69	characteristics	_	_	O
70	:	_	_	O
71	age	_	_	O
72	>	_	_	O
73	or	_	_	O
74	=	_	_	O
75	65	_	_	O
76	years	_	_	O
77	,	_	_	O
78	Eastern	_	_	O
79	Cooperative	_	_	O
80	Oncology	_	_	O
81	Group	_	_	O
82	performance	_	_	O
83	status	_	_	O
84	1	_	_	O
85	or	_	_	O
86	2	_	_	O
87	,	_	_	O
88	serum	_	_	O
89	albumin	_	_	O
90	<	_	_	O
91	or	_	_	O
92	=	_	_	O
93	3.5	_	_	O
94	g/dL	_	_	O
95	,	_	_	O
96	or	_	_	O
97	prior	_	_	O
98	abdominal/pelvic	_	_	O
99	radiotherapy	_	_	O
100	.	_	_	O

101	Patients	_	_	O
102	were	_	_	O
103	randomly	_	_	O
104	assigned	_	_	O
105	to	_	_	O
106	FU/LV/placebo	_	_	O
107	(	_	_	O
108	n	_	_	O
109	=	_	_	O
110	105	_	_	O
111	)	_	_	O
112	or	_	_	O
113	FU/LV/bevacizumab	_	_	O
114	(	_	_	O
115	n	_	_	O
116	=	_	_	O
117	104	_	_	O
118	)	_	_	O
119	.	_	_	O

120	The	_	_	O
121	primary	_	_	O
122	end	_	_	O
123	point	_	_	O
124	was	_	_	O
125	overall	_	_	O
126	survival	_	_	O
127	.	_	_	O

128	Secondary	_	_	O
129	end	_	_	O
130	points	_	_	O
131	were	_	_	O
132	progression-free	_	_	O
133	survival	_	_	O
134	,	_	_	O
135	response	_	_	O
136	rate	_	_	O
137	,	_	_	O
138	response	_	_	O
139	duration	_	_	O
140	,	_	_	O
141	and	_	_	O
142	quality	_	_	O
143	of	_	_	O
144	life	_	_	O
145	.	_	_	O

146	Safety	_	_	O
147	was	_	_	O
148	also	_	_	O
149	assessed	_	_	O
150	.	_	_	O

151	Median	_	_	B-Premise
152	survival	_	_	I-Premise
153	was	_	_	I-Premise
154	16.6	_	_	I-Premise
155	months	_	_	I-Premise
156	for	_	_	I-Premise
157	the	_	_	I-Premise
158	FU/LV/bevacizumab	_	_	I-Premise
159	group	_	_	I-Premise
160	and	_	_	I-Premise
161	12.9	_	_	I-Premise
162	months	_	_	I-Premise
163	for	_	_	I-Premise
164	the	_	_	I-Premise
165	FU/LV/placebo	_	_	I-Premise
166	group	_	_	I-Premise
167	(	_	_	I-Premise
168	hazard	_	_	I-Premise
169	ratio	_	_	I-Premise
170	,	_	_	I-Premise
171	0.79	_	_	I-Premise
172	;	_	_	I-Premise
173	P	_	_	I-Premise
174	=	_	_	I-Premise
175	.16	_	_	I-Premise
176	)	_	_	I-Premise
177	.	_	_	I-Premise

178	Median	_	_	B-Premise
179	progression-free	_	_	I-Premise
180	survival	_	_	I-Premise
181	was	_	_	I-Premise
182	9.2	_	_	I-Premise
183	months	_	_	I-Premise
184	(	_	_	I-Premise
185	FU/LV/bevacizumab	_	_	I-Premise
186	)	_	_	I-Premise
187	and	_	_	I-Premise
188	5.5	_	_	I-Premise
189	months	_	_	I-Premise
190	(	_	_	I-Premise
191	FU/LV/placebo	_	_	I-Premise
192	)	_	_	I-Premise
193	;	_	_	I-Premise
194	hazard	_	_	B-Premise
195	ratio	_	_	I-Premise
196	was	_	_	I-Premise
197	0.50	_	_	I-Premise
198	;	_	_	I-Premise
199	P	_	_	I-Premise
200	=	_	_	I-Premise
201	.0002	_	_	I-Premise
202	.	_	_	O

203	Response	_	_	B-Premise
204	rates	_	_	I-Premise
205	were	_	_	I-Premise
206	26.0	_	_	I-Premise
207	%	_	_	I-Premise
208	(	_	_	I-Premise
209	FU/LV/bevacizumab	_	_	I-Premise
210	)	_	_	I-Premise
211	and	_	_	I-Premise
212	15.2	_	_	I-Premise
213	%	_	_	I-Premise
214	(	_	_	I-Premise
215	FU/LV/placebo	_	_	I-Premise
216	)	_	_	I-Premise
217	(	_	_	I-Premise
218	P	_	_	I-Premise
219	=	_	_	I-Premise
220	.055	_	_	I-Premise
221	)	_	_	I-Premise
222	;	_	_	I-Premise
223	duration	_	_	B-Premise
224	of	_	_	I-Premise
225	response	_	_	I-Premise
226	was	_	_	I-Premise
227	9.2	_	_	I-Premise
228	months	_	_	I-Premise
229	(	_	_	I-Premise
230	FU/LV/bevacizumab	_	_	I-Premise
231	)	_	_	I-Premise
232	and	_	_	I-Premise
233	6.8	_	_	I-Premise
234	months	_	_	I-Premise
235	(	_	_	I-Premise
236	FU/LV/placebo	_	_	I-Premise
237	)	_	_	I-Premise
238	;	_	_	I-Premise
239	hazard	_	_	B-Premise
240	ratio	_	_	I-Premise
241	was	_	_	I-Premise
242	0.42	_	_	I-Premise
243	;	_	_	I-Premise
244	P	_	_	I-Premise
245	=	_	_	I-Premise
246	.088	_	_	I-Premise
247	.	_	_	I-Premise

248	Grade	_	_	B-Premise
249	3	_	_	I-Premise
250	hypertension	_	_	I-Premise
251	was	_	_	I-Premise
252	more	_	_	I-Premise
253	common	_	_	I-Premise
254	with	_	_	I-Premise
255	bevacizumab	_	_	I-Premise
256	treatment	_	_	I-Premise
257	(	_	_	I-Premise
258	16	_	_	I-Premise
259	%	_	_	I-Premise
260	v	_	_	I-Premise
261	3	_	_	I-Premise
262	%	_	_	I-Premise
263	)	_	_	I-Premise
264	but	_	_	B-Premise
265	was	_	_	I-Premise
266	controlled	_	_	I-Premise
267	with	_	_	I-Premise
268	oral	_	_	I-Premise
269	medication	_	_	I-Premise
270	and	_	_	I-Premise
271	did	_	_	I-Premise
272	not	_	_	I-Premise
273	cause	_	_	I-Premise
274	study	_	_	I-Premise
275	drug	_	_	I-Premise
276	discontinuation	_	_	I-Premise
277	.	_	_	I-Premise

278	Addition	_	_	B-Claim
279	of	_	_	I-Claim
280	bevacizumab	_	_	I-Claim
281	to	_	_	I-Claim
282	FU/LV	_	_	I-Claim
283	as	_	_	I-Claim
284	first-line	_	_	I-Claim
285	therapy	_	_	I-Claim
286	in	_	_	I-Claim
287	CRC	_	_	I-Claim
288	patients	_	_	I-Claim
289	who	_	_	I-Claim
290	were	_	_	I-Claim
291	not	_	_	I-Claim
292	considered	_	_	I-Claim
293	optimal	_	_	I-Claim
294	candidates	_	_	I-Claim
295	for	_	_	I-Claim
296	first-line	_	_	I-Claim
297	irinotecan	_	_	I-Claim
298	treatment	_	_	I-Claim
299	provided	_	_	I-Claim
300	clinically	_	_	I-Claim
301	significant	_	_	I-Claim
302	patient	_	_	I-Claim
303	benefit	_	_	I-Claim
304	,	_	_	I-Claim
305	including	_	_	I-Claim
306	statistically	_	_	I-Claim
307	significant	_	_	I-Claim
308	improvement	_	_	I-Claim
309	in	_	_	I-Claim
310	progression-free	_	_	I-Claim
311	survival	_	_	I-Claim
312	.	_	_	I-Claim


0	Proinflammatory	_	_	O
1	cytokines	_	_	O
2	,	_	_	O
3	especially	_	_	O
4	tumour	_	_	O
5	necrosis	_	_	O
6	factor	_	_	O
7	alpha	_	_	O
8	(	_	_	O
9	TNF-alpha	_	_	O
10	)	_	_	O
11	,	_	_	O
12	play	_	_	O
13	a	_	_	O
14	prominent	_	_	O
15	role	_	_	O
16	in	_	_	O
17	the	_	_	O
18	pathogenesis	_	_	O
19	of	_	_	O
20	cancer	_	_	O
21	cachexia	_	_	O
22	.	_	_	O

23	Thalidomide	_	_	B-Claim
24	,	_	_	I-Claim
25	which	_	_	I-Claim
26	is	_	_	I-Claim
27	an	_	_	I-Claim
28	inhibitor	_	_	I-Claim
29	of	_	_	I-Claim
30	TNF-alpha	_	_	I-Claim
31	synthesis	_	_	I-Claim
32	,	_	_	I-Claim
33	may	_	_	I-Claim
34	represent	_	_	I-Claim
35	a	_	_	I-Claim
36	novel	_	_	I-Claim
37	and	_	_	I-Claim
38	rational	_	_	I-Claim
39	approach	_	_	I-Claim
40	to	_	_	I-Claim
41	the	_	_	I-Claim
42	treatment	_	_	I-Claim
43	of	_	_	I-Claim
44	cancer	_	_	I-Claim
45	cachexia	_	_	I-Claim
46	.	_	_	I-Claim

47	To	_	_	O
48	assess	_	_	O
49	the	_	_	O
50	safety	_	_	O
51	and	_	_	O
52	efficacy	_	_	O
53	of	_	_	O
54	thalidomide	_	_	O
55	in	_	_	O
56	attenuating	_	_	O
57	weight	_	_	O
58	loss	_	_	O
59	in	_	_	O
60	patients	_	_	O
61	with	_	_	O
62	cachexia	_	_	O
63	secondary	_	_	O
64	to	_	_	O
65	advanced	_	_	O
66	pancreatic	_	_	O
67	cancer	_	_	O
68	.	_	_	O

69	Fifty	_	_	O
70	patients	_	_	O
71	with	_	_	O
72	advanced	_	_	O
73	pancreatic	_	_	O
74	cancer	_	_	O
75	who	_	_	O
76	had	_	_	O
77	lost	_	_	O
78	at	_	_	O
79	least	_	_	O
80	10	_	_	O
81	%	_	_	O
82	of	_	_	O
83	their	_	_	O
84	body	_	_	O
85	weight	_	_	O
86	were	_	_	O
87	randomised	_	_	O
88	to	_	_	O
89	receive	_	_	O
90	thalidomide	_	_	O
91	200	_	_	O
92	mg	_	_	O
93	daily	_	_	O
94	or	_	_	O
95	placebo	_	_	O
96	for	_	_	O
97	24	_	_	O
98	weeks	_	_	O
99	in	_	_	O
100	a	_	_	O
101	single	_	_	O
102	centre	_	_	O
103	,	_	_	O
104	double	_	_	O
105	blind	_	_	O
106	,	_	_	O
107	randomised	_	_	O
108	controlled	_	_	O
109	trial	_	_	O
110	.	_	_	O

111	The	_	_	O
112	primary	_	_	O
113	outcome	_	_	O
114	was	_	_	O
115	change	_	_	O
116	in	_	_	O
117	weight	_	_	O
118	and	_	_	O
119	nutritional	_	_	O
120	status	_	_	O
121	.	_	_	O

122	Thirty	_	_	O
123	three	_	_	O
124	patients	_	_	O
125	(	_	_	O
126	16	_	_	O
127	control	_	_	O
128	,	_	_	O
129	17	_	_	O
130	thalidomide	_	_	O
131	)	_	_	O
132	were	_	_	O
133	evaluated	_	_	O
134	at	_	_	O
135	four	_	_	O
136	weeks	_	_	O
137	,	_	_	O
138	and	_	_	O
139	20	_	_	O
140	patients	_	_	O
141	(	_	_	O
142	eight	_	_	O
143	control	_	_	O
144	,	_	_	O
145	12	_	_	O
146	thalidomide	_	_	O
147	)	_	_	O
148	at	_	_	O
149	eight	_	_	O
150	weeks	_	_	O
151	.	_	_	O

152	At	_	_	B-Premise
153	four	_	_	I-Premise
154	weeks	_	_	I-Premise
155	,	_	_	I-Premise
156	patients	_	_	I-Premise
157	who	_	_	I-Premise
158	received	_	_	I-Premise
159	thalidomide	_	_	I-Premise
160	had	_	_	I-Premise
161	gained	_	_	I-Premise
162	on	_	_	I-Premise
163	average	_	_	I-Premise
164	0.37	_	_	I-Premise
165	kg	_	_	I-Premise
166	in	_	_	I-Premise
167	weight	_	_	I-Premise
168	and	_	_	I-Premise
169	1.0	_	_	I-Premise
170	cm	_	_	I-Premise
171	(	_	_	I-Premise
172	3	_	_	I-Premise
173	)	_	_	I-Premise
174	in	_	_	I-Premise
175	arm	_	_	I-Premise
176	muscle	_	_	I-Premise
177	mass	_	_	I-Premise
178	(	_	_	I-Premise
179	AMA	_	_	I-Premise
180	)	_	_	I-Premise
181	compared	_	_	I-Premise
182	with	_	_	I-Premise
183	a	_	_	I-Premise
184	loss	_	_	I-Premise
185	of	_	_	I-Premise
186	2.21	_	_	I-Premise
187	kg	_	_	I-Premise
188	(	_	_	I-Premise
189	absolute	_	_	I-Premise
190	difference	_	_	I-Premise
191	-2.59	_	_	I-Premise
192	kg	_	_	I-Premise
193	(	_	_	I-Premise
194	95	_	_	I-Premise
195	%	_	_	I-Premise
196	confidence	_	_	I-Premise
197	interval	_	_	I-Premise
198	(	_	_	I-Premise
199	CI	_	_	I-Premise
200	)	_	_	I-Premise
201	-4.3	_	_	I-Premise
202	to	_	_	I-Premise
203	-0.8	_	_	I-Premise
204	)	_	_	I-Premise
205	;	_	_	I-Premise
206	p	_	_	I-Premise
207	=	_	_	I-Premise
208	0.005	_	_	I-Premise
209	)	_	_	I-Premise
210	and	_	_	I-Premise
211	4.46	_	_	I-Premise
212	cm	_	_	I-Premise
213	(	_	_	I-Premise
214	3	_	_	I-Premise
215	)	_	_	I-Premise
216	(	_	_	I-Premise
217	absolute	_	_	I-Premise
218	difference	_	_	I-Premise
219	-5.6	_	_	I-Premise
220	cm	_	_	I-Premise
221	(	_	_	I-Premise
222	3	_	_	I-Premise
223	)	_	_	I-Premise
224	(	_	_	I-Premise
225	95	_	_	I-Premise
226	%	_	_	I-Premise
227	CI	_	_	I-Premise
228	-8.9	_	_	I-Premise
229	to	_	_	I-Premise
230	-2.2	_	_	I-Premise
231	)	_	_	I-Premise
232	;	_	_	I-Premise
233	p	_	_	I-Premise
234	=	_	_	I-Premise
235	0.002	_	_	I-Premise
236	)	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	placebo	_	_	I-Premise
240	group	_	_	I-Premise
241	.	_	_	I-Premise

242	At	_	_	B-Premise
243	eight	_	_	I-Premise
244	weeks	_	_	I-Premise
245	,	_	_	I-Premise
246	patients	_	_	I-Premise
247	in	_	_	I-Premise
248	the	_	_	I-Premise
249	thalidomide	_	_	I-Premise
250	group	_	_	I-Premise
251	had	_	_	I-Premise
252	lost	_	_	I-Premise
253	0.06	_	_	I-Premise
254	kg	_	_	I-Premise
255	in	_	_	I-Premise
256	weight	_	_	I-Premise
257	and	_	_	I-Premise
258	0.5	_	_	I-Premise
259	cm	_	_	I-Premise
260	(	_	_	I-Premise
261	3	_	_	I-Premise
262	)	_	_	I-Premise
263	in	_	_	I-Premise
264	AMA	_	_	I-Premise
265	compared	_	_	I-Premise
266	with	_	_	I-Premise
267	a	_	_	I-Premise
268	loss	_	_	I-Premise
269	of	_	_	I-Premise
270	3.62	_	_	I-Premise
271	kg	_	_	I-Premise
272	(	_	_	I-Premise
273	absolute	_	_	I-Premise
274	difference	_	_	I-Premise
275	-3.57	_	_	I-Premise
276	kg	_	_	I-Premise
277	(	_	_	I-Premise
278	95	_	_	I-Premise
279	%	_	_	I-Premise
280	CI	_	_	I-Premise
281	-6.8	_	_	I-Premise
282	to	_	_	I-Premise
283	-0.3	_	_	I-Premise
284	)	_	_	I-Premise
285	;	_	_	I-Premise
286	p	_	_	I-Premise
287	=	_	_	I-Premise
288	0.034	_	_	I-Premise
289	)	_	_	I-Premise
290	and	_	_	I-Premise
291	8.4	_	_	I-Premise
292	cm	_	_	I-Premise
293	(	_	_	I-Premise
294	3	_	_	I-Premise
295	)	_	_	I-Premise
296	(	_	_	I-Premise
297	absolute	_	_	I-Premise
298	difference	_	_	I-Premise
299	-7.9	_	_	I-Premise
300	cm	_	_	I-Premise
301	(	_	_	I-Premise
302	3	_	_	I-Premise
303	)	_	_	I-Premise
304	(	_	_	I-Premise
305	95	_	_	I-Premise
306	%	_	_	I-Premise
307	CI	_	_	I-Premise
308	-14.0	_	_	I-Premise
309	to	_	_	I-Premise
310	-1.8	_	_	I-Premise
311	)	_	_	I-Premise
312	;	_	_	I-Premise
313	p	_	_	I-Premise
314	=	_	_	I-Premise
315	0.014	_	_	I-Premise
316	)	_	_	I-Premise
317	in	_	_	I-Premise
318	the	_	_	I-Premise
319	placebo	_	_	I-Premise
320	group	_	_	I-Premise
321	.	_	_	I-Premise

322	Improvement	_	_	B-Premise
323	in	_	_	I-Premise
324	physical	_	_	I-Premise
325	functioning	_	_	I-Premise
326	correlated	_	_	I-Premise
327	positively	_	_	I-Premise
328	with	_	_	I-Premise
329	weight	_	_	I-Premise
330	gain	_	_	I-Premise
331	(	_	_	I-Premise
332	r	_	_	I-Premise
333	=	_	_	I-Premise
334	0.56	_	_	I-Premise
335	,	_	_	I-Premise
336	p	_	_	I-Premise
337	=	_	_	I-Premise
338	0.001	_	_	I-Premise
339	)	_	_	I-Premise
340	.	_	_	I-Premise

341	Thalidomide	_	_	B-Claim
342	was	_	_	I-Claim
343	well	_	_	I-Claim
344	tolerated	_	_	I-Claim
345	and	_	_	I-Claim
346	effective	_	_	I-Claim
347	at	_	_	I-Claim
348	attenuating	_	_	I-Claim
349	loss	_	_	I-Claim
350	of	_	_	I-Claim
351	weight	_	_	I-Claim
352	and	_	_	I-Claim
353	lean	_	_	I-Claim
354	body	_	_	I-Claim
355	mass	_	_	I-Claim
356	in	_	_	I-Claim
357	patients	_	_	I-Claim
358	with	_	_	I-Claim
359	cachexia	_	_	I-Claim
360	due	_	_	I-Claim
361	to	_	_	I-Claim
362	advanced	_	_	I-Claim
363	pancreatic	_	_	I-Claim
364	cancer	_	_	I-Claim
365	.	_	_	I-Claim


0	To	_	_	O
1	test	_	_	O
2	the	_	_	O
3	ability	_	_	O
4	of	_	_	O
5	the	_	_	O
6	cytoprotectant	_	_	O
7	,	_	_	O
8	amifostine	_	_	O
9	,	_	_	O
10	to	_	_	O
11	reduce	_	_	O
12	chemoradiotherapy-induced	_	_	O
13	esophagitis	_	_	O
14	and	_	_	O
15	evaluate	_	_	O
16	its	_	_	O
17	influence	_	_	O
18	on	_	_	O
19	quality	_	_	O
20	of	_	_	O
21	life	_	_	O
22	(	_	_	O
23	QOL	_	_	O
24	)	_	_	O
25	and	_	_	O
26	swallowing	_	_	O
27	symptoms	_	_	O
28	.	_	_	O

29	A	_	_	O
30	total	_	_	O
31	of	_	_	O
32	243	_	_	O
33	patients	_	_	O
34	with	_	_	O
35	stage	_	_	O
36	II	_	_	O
37	to	_	_	O
38	IIIA/B	_	_	O
39	non-small-cell	_	_	O
40	lung	_	_	O
41	cancer	_	_	O
42	received	_	_	O
43	induction	_	_	O
44	paclitaxel	_	_	O
45	225	_	_	O
46	mg/m	_	_	O
47	(	_	_	O
48	2	_	_	O
49	)	_	_	O
50	intravenously	_	_	O
51	(	_	_	O
52	IV	_	_	O
53	)	_	_	O
54	days	_	_	O
55	1	_	_	O
56	and	_	_	O
57	22	_	_	O
58	and	_	_	O
59	carboplatin	_	_	O
60	area	_	_	O
61	under	_	_	O
62	the	_	_	O
63	curve	_	_	O
64	(	_	_	O
65	AUC	_	_	O
66	)	_	_	O
67	days	_	_	O
68	1	_	_	O
69	and	_	_	O
70	22	_	_	O
71	,	_	_	O
72	followed	_	_	O
73	by	_	_	O
74	concurrent	_	_	O
75	weekly	_	_	O
76	paclitaxel	_	_	O
77	(	_	_	O
78	50	_	_	O
79	mg/m	_	_	O
80	(	_	_	O
81	2	_	_	O
82	)	_	_	O
83	IV	_	_	O
84	)	_	_	O
85	and	_	_	O
86	carboplatin	_	_	O
87	(	_	_	O
88	AUC	_	_	O
89	2	_	_	O
90	)	_	_	O
91	,	_	_	O
92	and	_	_	O
93	hyperfractionated	_	_	O
94	radiation	_	_	O
95	therapy	_	_	O
96	(	_	_	O
97	69.6	_	_	O
98	Gy	_	_	O
99	at	_	_	O
100	1.2	_	_	O
101	Gy	_	_	O
102	bid	_	_	O
103	)	_	_	O
104	.	_	_	O

105	Patients	_	_	O
106	were	_	_	O
107	randomly	_	_	O
108	assigned	_	_	O
109	at	_	_	O
110	registration	_	_	O
111	to	_	_	O
112	amifostine	_	_	O
113	(	_	_	O
114	AM	_	_	O
115	)	_	_	O
116	500	_	_	O
117	mg	_	_	O
118	IV	_	_	O
119	four	_	_	O
120	times	_	_	O
121	per	_	_	O
122	week	_	_	O
123	or	_	_	O
124	no	_	_	O
125	AM	_	_	O
126	during	_	_	O
127	chemoradiotherapy	_	_	O
128	.	_	_	O

129	Beyond	_	_	O
130	standard	_	_	O
131	toxicity	_	_	O
132	end	_	_	O
133	points	_	_	O
134	,	_	_	O
135	physician	_	_	O
136	dysphagia	_	_	O
137	logs	_	_	O
138	(	_	_	O
139	PDLs	_	_	O
140	)	_	_	O
141	,	_	_	O
142	daily	_	_	O
143	patient	_	_	O
144	swallowing	_	_	O
145	diaries	_	_	O
146	,	_	_	O
147	and	_	_	O
148	QOL	_	_	O
149	(	_	_	O
150	EORTC	_	_	O
151	QLQ-C30/LC-13	_	_	O
152	)	_	_	O
153	were	_	_	O
154	also	_	_	O
155	collected	_	_	O
156	.	_	_	O

157	Swallowing	_	_	O
158	AUC	_	_	O
159	analyses	_	_	O
160	were	_	_	O
161	calculated	_	_	O
162	from	_	_	O
163	patient	_	_	O
164	diaries	_	_	O
165	and	_	_	O
166	PDLs	_	_	O
167	.	_	_	O

168	A	_	_	O
169	total	_	_	O
170	of	_	_	O
171	120	_	_	O
172	patients	_	_	O
173	were	_	_	O
174	randomly	_	_	O
175	assigned	_	_	O
176	to	_	_	O
177	receive	_	_	O
178	AM	_	_	O
179	,	_	_	O
180	and	_	_	O
181	122	_	_	O
182	,	_	_	O
183	to	_	_	O
184	receive	_	_	O
185	no	_	_	O
186	AM	_	_	O
187	(	_	_	O
188	one	_	_	O
189	patient	_	_	O
190	was	_	_	O
191	ineligible	_	_	O
192	)	_	_	O
193	;	_	_	O
194	72	_	_	O
195	%	_	_	O
196	received	_	_	O
197	AM	_	_	O
198	per	_	_	O
199	protocol	_	_	O
200	or	_	_	O
201	with	_	_	O
202	a	_	_	O
203	minor	_	_	O
204	deviation	_	_	O
205	.	_	_	O

206	AM	_	_	B-Premise
207	was	_	_	I-Premise
208	associated	_	_	I-Premise
209	with	_	_	I-Premise
210	higher	_	_	I-Premise
211	rates	_	_	I-Premise
212	of	_	_	I-Premise
213	acute	_	_	I-Premise
214	nausea	_	_	I-Premise
215	(	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	.03	_	_	I-Premise
219	)	_	_	I-Premise
220	,	_	_	I-Premise
221	vomiting	_	_	I-Premise
222	(	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	.007	_	_	I-Premise
226	)	_	_	I-Premise
227	,	_	_	I-Premise
228	cardiovascular	_	_	I-Premise
229	toxicity	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	=	_	_	I-Premise
233	.0001	_	_	I-Premise
234	)	_	_	I-Premise
235	,	_	_	I-Premise
236	and	_	_	I-Premise
237	infection	_	_	I-Premise
238	or	_	_	I-Premise
239	febrile	_	_	I-Premise
240	neutropenia	_	_	I-Premise
241	(	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	.03	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	The	_	_	B-Premise
248	rate	_	_	I-Premise
249	of	_	_	I-Premise
250	>	_	_	I-Premise
251	/=	_	_	I-Premise
252	grade	_	_	I-Premise
253	3	_	_	I-Premise
254	esophagitis	_	_	I-Premise
255	was	_	_	I-Premise
256	30	_	_	I-Premise
257	%	_	_	I-Premise
258	with	_	_	I-Premise
259	AM	_	_	I-Premise
260	versus	_	_	I-Premise
261	34	_	_	I-Premise
262	%	_	_	I-Premise
263	without	_	_	I-Premise
264	AM	_	_	I-Premise
265	(	_	_	I-Premise
266	P	_	_	I-Premise
267	=	_	_	I-Premise
268	.9	_	_	I-Premise
269	)	_	_	I-Premise
270	.	_	_	I-Premise

271	Patient	_	_	B-Premise
272	diaries	_	_	I-Premise
273	demonstrated	_	_	I-Premise
274	lower	_	_	I-Premise
275	swallowing	_	_	I-Premise
276	dysfunction	_	_	I-Premise
277	AUC	_	_	I-Premise
278	with	_	_	I-Premise
279	amifostine	_	_	I-Premise
280	(	_	_	I-Premise
281	z	_	_	I-Premise
282	test	_	_	I-Premise
283	P	_	_	I-Premise
284	=	_	_	I-Premise
285	.025	_	_	I-Premise
286	)	_	_	I-Premise
287	.	_	_	I-Premise

288	QOL	_	_	B-Premise
289	was	_	_	I-Premise
290	not	_	_	I-Premise
291	significantly	_	_	I-Premise
292	different	_	_	I-Premise
293	between	_	_	I-Premise
294	the	_	_	I-Premise
295	two	_	_	I-Premise
296	arms	_	_	I-Premise
297	,	_	_	I-Premise
298	except	_	_	I-Premise
299	for	_	_	I-Premise
300	pain	_	_	I-Premise
301	,	_	_	I-Premise
302	which	_	_	I-Premise
303	showed	_	_	I-Premise
304	more	_	_	I-Premise
305	clinically	_	_	I-Premise
306	meaningful	_	_	I-Premise
307	improvement	_	_	I-Premise
308	and	_	_	I-Premise
309	less	_	_	I-Premise
310	deterioration	_	_	I-Premise
311	at	_	_	I-Premise
312	6	_	_	I-Premise
313	weeks	_	_	I-Premise
314	follow-up	_	_	I-Premise
315	(	_	_	I-Premise
316	v	_	_	I-Premise
317	pretreatment	_	_	I-Premise
318	)	_	_	I-Premise
319	in	_	_	I-Premise
320	the	_	_	I-Premise
321	AM	_	_	I-Premise
322	arm	_	_	I-Premise
323	(	_	_	I-Premise
324	P	_	_	I-Premise
325	=	_	_	I-Premise
326	.003	_	_	I-Premise
327	)	_	_	I-Premise
328	.	_	_	I-Premise

329	The	_	_	B-Premise
330	median	_	_	I-Premise
331	survival	_	_	I-Premise
332	rates	_	_	I-Premise
333	for	_	_	I-Premise
334	both	_	_	I-Premise
335	arms	_	_	I-Premise
336	were	_	_	I-Premise
337	comparable	_	_	I-Premise
338	(	_	_	I-Premise
339	AM	_	_	I-Premise
340	,	_	_	I-Premise
341	17.3	_	_	I-Premise
342	v	_	_	I-Premise
343	no	_	_	I-Premise
344	AM	_	_	I-Premise
345	,	_	_	I-Premise
346	17.9	_	_	I-Premise
347	months	_	_	I-Premise
348	;	_	_	I-Premise
349	P	_	_	I-Premise
350	=	_	_	I-Premise
351	.87	_	_	I-Premise
352	)	_	_	I-Premise
353	.	_	_	I-Premise

354	AM	_	_	B-Claim
355	did	_	_	I-Claim
356	not	_	_	I-Claim
357	significantly	_	_	I-Claim
358	reduce	_	_	I-Claim
359	esophagitis	_	_	I-Claim
360	>	_	_	I-Claim
361	/=	_	_	I-Claim
362	grade	_	_	I-Claim
363	3	_	_	I-Claim
364	in	_	_	I-Claim
365	patients	_	_	I-Claim
366	receiving	_	_	I-Claim
367	hyperfractionated	_	_	I-Claim
368	radiation	_	_	I-Claim
369	and	_	_	I-Claim
370	chemotherapy	_	_	I-Claim
371	.	_	_	I-Claim

372	However	_	_	B-Claim
373	,	_	_	I-Claim
374	patient	_	_	I-Claim
375	self-assessments	_	_	I-Claim
376	suggested	_	_	I-Claim
377	a	_	_	I-Claim
378	possible	_	_	I-Claim
379	advantage	_	_	I-Claim
380	to	_	_	I-Claim
381	AM	_	_	I-Claim
382	that	_	_	I-Claim
383	is	_	_	I-Claim
384	being	_	_	I-Claim
385	explored	_	_	I-Claim
386	with	_	_	I-Claim
387	modified	_	_	I-Claim
388	dosing	_	_	I-Claim
389	route	_	_	I-Claim
390	strategies	_	_	I-Claim
391	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	investigate	_	_	O
8	whether	_	_	O
9	specialized	_	_	O
10	supportive	_	_	O
11	enteral	_	_	O
12	and	_	_	O
13	parenteral	_	_	O
14	feeding	_	_	O
15	have	_	_	O
16	superior	_	_	O
17	effects	_	_	O
18	compared	_	_	O
19	to	_	_	O
20	oral	_	_	O
21	nutrition	_	_	O
22	on	_	_	O
23	recovery	_	_	O
24	during	_	_	O
25	long-term	_	_	O
26	postoperative	_	_	O
27	treatment	_	_	O
28	of	_	_	O
29	cancer	_	_	O
30	patients	_	_	O
31	with	_	_	O
32	preoperative	_	_	O
33	weight	_	_	O
34	loss	_	_	O
35	and	_	_	O
36	reduced	_	_	O
37	maximum	_	_	O
38	exercise	_	_	O
39	capacity	_	_	O
40	.	_	_	O

41	One	_	_	O
42	hundred	_	_	O
43	twenty-six	_	_	O
44	patients	_	_	O
45	referred	_	_	O
46	for	_	_	O
47	resection	_	_	O
48	of	_	_	O
49	the	_	_	O
50	esophagus	_	_	O
51	(	_	_	O
52	n	_	_	O
53	=	_	_	O
54	48	_	_	O
55	)	_	_	O
56	,	_	_	O
57	stomach	_	_	O
58	(	_	_	O
59	n	_	_	O
60	=	_	_	O
61	28	_	_	O
62	)	_	_	O
63	,	_	_	O
64	or	_	_	O
65	pancreas	_	_	O
66	(	_	_	O
67	n	_	_	O
68	=	_	_	O
69	50	_	_	O
70	)	_	_	O
71	were	_	_	O
72	considered	_	_	O
73	to	_	_	O
74	be	_	_	O
75	included	_	_	O
76	before	_	_	O
77	operation	_	_	O
78	.	_	_	O

79	Included	_	_	O
80	patients	_	_	O
81	(	_	_	O
82	n	_	_	O
83	=	_	_	O
84	80	_	_	O
85	)	_	_	O
86	received	_	_	O
87	supportive	_	_	O
88	enteral	_	_	O
89	or	_	_	O
90	parenteral	_	_	O
91	nutrition	_	_	O
92	postoperatively	_	_	O
93	at	_	_	O
94	home	_	_	O
95	corresponding	_	_	O
96	to	_	_	O
97	1000	_	_	O
98	kcal/d	_	_	O
99	until	_	_	O
100	the	_	_	O
101	patients	_	_	O
102	did	_	_	O
103	not	_	_	O
104	wish	_	_	O
105	to	_	_	O
106	continue	_	_	O
107	with	_	_	O
108	artificial	_	_	O
109	nutrition	_	_	O
110	for	_	_	O
111	any	_	_	O
112	reason	_	_	O
113	.	_	_	O

114	Patients	_	_	O
115	randomized	_	_	O
116	to	_	_	O
117	oral	_	_	O
118	nutrition	_	_	O
119	only	_	_	O
120	served	_	_	O
121	as	_	_	O
122	control	_	_	O
123	subjects	_	_	O
124	.	_	_	O

125	Caloric	_	_	O
126	intake	_	_	O
127	,	_	_	O
128	body	_	_	O
129	composition	_	_	O
130	(	_	_	O
131	dual-energy	_	_	O
132	x-ray	_	_	O
133	absorptiometry	_	_	O
134	)	_	_	O
135	,	_	_	O
136	and	_	_	O
137	respiratory	_	_	O
138	gas	_	_	O
139	exchanges	_	_	O
140	at	_	_	O
141	rest	_	_	O
142	and	_	_	O
143	during	_	_	O
144	exercise	_	_	O
145	were	_	_	O
146	measured	_	_	O
147	including	_	_	O
148	health-related	_	_	O
149	quality	_	_	O
150	of	_	_	O
151	life	_	_	O
152	.	_	_	O

153	Survival	_	_	B-Premise
154	and	_	_	I-Premise
155	hospital	_	_	I-Premise
156	stay	_	_	I-Premise
157	did	_	_	I-Premise
158	not	_	_	I-Premise
159	differ	_	_	I-Premise
160	among	_	_	I-Premise
161	the	_	_	I-Premise
162	groups	_	_	I-Premise
163	,	_	_	I-Premise
164	whereas	_	_	I-Premise
165	overall	_	_	I-Premise
166	complications	_	_	I-Premise
167	were	_	_	I-Premise
168	higher	_	_	I-Premise
169	on	_	_	I-Premise
170	artificial	_	_	I-Premise
171	nutrition	_	_	I-Premise
172	(	_	_	I-Premise
173	P	_	_	I-Premise
174	<	_	_	I-Premise
175	.05	_	_	I-Premise
176	)	_	_	I-Premise
177	.	_	_	I-Premise

178	Changes	_	_	B-Premise
179	in	_	_	I-Premise
180	resting	_	_	I-Premise
181	energy	_	_	I-Premise
182	expenditure	_	_	I-Premise
183	and	_	_	I-Premise
184	biochemical	_	_	I-Premise
185	tests	_	_	I-Premise
186	did	_	_	I-Premise
187	not	_	_	I-Premise
188	differ	_	_	I-Premise
189	during	_	_	I-Premise
190	follow-up	_	_	I-Premise
191	among	_	_	I-Premise
192	the	_	_	I-Premise
193	groups	_	_	I-Premise
194	.	_	_	I-Premise

195	Body	_	_	B-Premise
196	weight	_	_	I-Premise
197	and	_	_	I-Premise
198	whole	_	_	I-Premise
199	body	_	_	I-Premise
200	fat	_	_	I-Premise
201	declined	_	_	I-Premise
202	similarly	_	_	I-Premise
203	over	_	_	I-Premise
204	time	_	_	I-Premise
205	in	_	_	I-Premise
206	all	_	_	I-Premise
207	groups	_	_	I-Premise
208	(	_	_	I-Premise
209	P	_	_	I-Premise
210	<	_	_	I-Premise
211	.005	_	_	I-Premise
212	)	_	_	I-Premise
213	,	_	_	I-Premise
214	whereas	_	_	O
215	lean	_	_	B-Premise
216	body	_	_	I-Premise
217	mass	_	_	I-Premise
218	was	_	_	I-Premise
219	unchanged	_	_	I-Premise
220	during	_	_	I-Premise
221	follow-up	_	_	I-Premise
222	compared	_	_	I-Premise
223	to	_	_	I-Premise
224	preoperative	_	_	I-Premise
225	values	_	_	I-Premise
226	.	_	_	I-Premise

227	Maximum	_	_	B-Premise
228	exercise	_	_	I-Premise
229	capacity	_	_	I-Premise
230	and	_	_	I-Premise
231	maximum	_	_	I-Premise
232	oxygen	_	_	I-Premise
233	consumption	_	_	I-Premise
234	were	_	_	I-Premise
235	normalized	_	_	I-Premise
236	within	_	_	I-Premise
237	6	_	_	I-Premise
238	months	_	_	I-Premise
239	postoperatively	_	_	I-Premise
240	in	_	_	I-Premise
241	all	_	_	I-Premise
242	groups	_	_	I-Premise
243	.	_	_	I-Premise

244	There	_	_	B-Premise
245	was	_	_	I-Premise
246	no	_	_	I-Premise
247	difference	_	_	I-Premise
248	in	_	_	I-Premise
249	recovery	_	_	I-Premise
250	of	_	_	I-Premise
251	food	_	_	I-Premise
252	intake	_	_	I-Premise
253	among	_	_	I-Premise
254	the	_	_	I-Premise
255	groups	_	_	I-Premise
256	.	_	_	I-Premise

257	Parenteral	_	_	B-Claim
258	feeding	_	_	I-Claim
259	was	_	_	I-Claim
260	associated	_	_	I-Claim
261	with	_	_	I-Claim
262	the	_	_	I-Claim
263	highest	_	_	I-Claim
264	rate	_	_	I-Claim
265	of	_	_	I-Claim
266	nutrition-related	_	_	I-Claim
267	complications	_	_	I-Claim
268	,	_	_	I-Claim
269	whereas	_	_	O
270	enteral	_	_	B-Claim
271	feeding	_	_	I-Claim
272	reduced	_	_	I-Claim
273	quality	_	_	I-Claim
274	of	_	_	I-Claim
275	life	_	_	I-Claim
276	most	_	_	I-Claim
277	extensively	_	_	I-Claim
278	.	_	_	I-Claim

279	After	_	_	B-Claim
280	major	_	_	I-Claim
281	surgery	_	_	I-Claim
282	,	_	_	I-Claim
283	specialized	_	_	I-Claim
284	supportive	_	_	I-Claim
285	enteral	_	_	I-Claim
286	and	_	_	I-Claim
287	parenteral	_	_	I-Claim
288	nutrition	_	_	I-Claim
289	are	_	_	I-Claim
290	not	_	_	I-Claim
291	superior	_	_	I-Claim
292	to	_	_	I-Claim
293	oral	_	_	I-Claim
294	nutrition	_	_	I-Claim
295	only	_	_	I-Claim
296	when	_	_	I-Claim
297	guided	_	_	I-Claim
298	by	_	_	I-Claim
299	a	_	_	I-Claim
300	dietitian	_	_	I-Claim
301	.	_	_	I-Claim


0	This	_	_	O
1	is	_	_	O
2	a	_	_	O
3	randomized	_	_	O
4	phase	_	_	O
5	II	_	_	O
6	study	_	_	O
7	designed	_	_	O
8	to	_	_	O
9	compare	_	_	O
10	the	_	_	O
11	toxicity	_	_	O
12	profile	_	_	O
13	of	_	_	O
14	a	_	_	O
15	non-platinum-based	_	_	O
16	with	_	_	O
17	a	_	_	O
18	platinum-based	_	_	O
19	regimen	_	_	O
20	in	_	_	O
21	the	_	_	O
22	treatment	_	_	O
23	of	_	_	O
24	advanced	_	_	O
25	non-small	_	_	O
26	cell	_	_	O
27	lung	_	_	O
28	cancer	_	_	O
29	.	_	_	O

30	Eighty-nine	_	_	O
31	chemotherapy-naïve	_	_	O
32	patients	_	_	O
33	were	_	_	O
34	randomized	_	_	O
35	either	_	_	O
36	to	_	_	O
37	gemcitabine	_	_	O
38	(	_	_	O
39	1,000	_	_	O
40	mg/m2	_	_	O
41	,	_	_	O
42	30-min	_	_	O
43	infusion	_	_	O
44	on	_	_	O
45	days	_	_	O
46	1	_	_	O
47	,	_	_	O
48	8	_	_	O
49	and	_	_	O
50	15	_	_	O
51	)	_	_	O
52	and	_	_	O
53	oral	_	_	O
54	etoposide	_	_	O
55	(	_	_	O
56	50	_	_	O
57	mg	_	_	O
58	,	_	_	O
59	days	_	_	O
60	1-14	_	_	O
61	;	_	_	O
62	GE	_	_	O
63	group	_	_	O
64	)	_	_	O
65	or	_	_	O
66	gemcitabine	_	_	O
67	at	_	_	O
68	the	_	_	O
69	same	_	_	O
70	schedule	_	_	O
71	and	_	_	O
72	cisplatin	_	_	O
73	(	_	_	O
74	75	_	_	O
75	mg/m2	_	_	O
76	on	_	_	O
77	day	_	_	O
78	15	_	_	O
79	;	_	_	O
80	GP	_	_	O
81	group	_	_	O
82	)	_	_	O
83	.	_	_	O

84	The	_	_	O
85	primary	_	_	O
86	endpoint	_	_	O
87	is	_	_	O
88	toxicity	_	_	O
89	,	_	_	O
90	and	_	_	O
91	secondary	_	_	O
92	endpoints	_	_	O
93	include	_	_	O
94	response	_	_	O
95	rate	_	_	O
96	,	_	_	O
97	survival	_	_	O
98	outcome	_	_	O
99	and	_	_	O
100	quality	_	_	O
101	of	_	_	O
102	life	_	_	O
103	(	_	_	O
104	QOL	_	_	O
105	)	_	_	O
106	.	_	_	O

107	The	_	_	B-Premise
108	incidence	_	_	I-Premise
109	of	_	_	I-Premise
110	WHO	_	_	I-Premise
111	grade	_	_	I-Premise
112	3	_	_	I-Premise
113	or	_	_	I-Premise
114	4	_	_	I-Premise
115	anemia	_	_	I-Premise
116	,	_	_	I-Premise
117	neutropenia	_	_	I-Premise
118	and	_	_	I-Premise
119	thrombocytopenia	_	_	I-Premise
120	was	_	_	I-Premise
121	29	_	_	I-Premise
122	,	_	_	I-Premise
123	44	_	_	I-Premise
124	and	_	_	I-Premise
125	22	_	_	I-Premise
126	%	_	_	I-Premise
127	(	_	_	I-Premise
128	GE	_	_	I-Premise
129	group	_	_	I-Premise
130	)	_	_	I-Premise
131	,	_	_	I-Premise
132	and	_	_	I-Premise
133	28	_	_	I-Premise
134	,	_	_	I-Premise
135	49	_	_	I-Premise
136	and	_	_	I-Premise
137	23	_	_	I-Premise
138	%	_	_	I-Premise
139	(	_	_	I-Premise
140	GP	_	_	I-Premise
141	group	_	_	I-Premise
142	)	_	_	I-Premise
143	,	_	_	I-Premise
144	respectively	_	_	I-Premise
145	(	_	_	I-Premise
146	p	_	_	I-Premise
147	=	_	_	I-Premise
148	0.75	_	_	I-Premise
149	,	_	_	I-Premise
150	0.95	_	_	I-Premise
151	and	_	_	I-Premise
152	0.87	_	_	I-Premise
153	,	_	_	I-Premise
154	respectively	_	_	I-Premise
155	)	_	_	I-Premise
156	.	_	_	I-Premise

157	The	_	_	B-Premise
158	rate	_	_	I-Premise
159	of	_	_	I-Premise
160	grade	_	_	I-Premise
161	2	_	_	I-Premise
162	or	_	_	I-Premise
163	above	_	_	I-Premise
164	nausea	_	_	I-Premise
165	was	_	_	I-Premise
166	numerically	_	_	I-Premise
167	higher	_	_	I-Premise
168	in	_	_	I-Premise
169	the	_	_	I-Premise
170	GP	_	_	I-Premise
171	arm	_	_	I-Premise
172	,	_	_	I-Premise
173	but	_	_	B-Premise
174	the	_	_	I-Premise
175	difference	_	_	I-Premise
176	was	_	_	I-Premise
177	not	_	_	I-Premise
178	statistically	_	_	I-Premise
179	significant	_	_	I-Premise
180	(	_	_	I-Premise
181	GE	_	_	I-Premise
182	15.5	_	_	I-Premise
183	%	_	_	I-Premise
184	,	_	_	I-Premise
185	GP	_	_	I-Premise
186	27.7	_	_	I-Premise
187	%	_	_	I-Premise
188	,	_	_	I-Premise
189	p	_	_	I-Premise
190	=	_	_	I-Premise
191	0.20	_	_	I-Premise
192	)	_	_	I-Premise
193	.	_	_	I-Premise

194	The	_	_	B-Premise
195	rate	_	_	I-Premise
196	of	_	_	I-Premise
197	vomiting	_	_	I-Premise
198	in	_	_	I-Premise
199	the	_	_	I-Premise
200	GE	_	_	I-Premise
201	and	_	_	I-Premise
202	GP	_	_	I-Premise
203	arms	_	_	I-Premise
204	was	_	_	I-Premise
205	20.0	_	_	I-Premise
206	and	_	_	I-Premise
207	20.5	_	_	I-Premise
208	%	_	_	I-Premise
209	,	_	_	I-Premise
210	respectively	_	_	I-Premise
211	(	_	_	I-Premise
212	p	_	_	I-Premise
213	=	_	_	I-Premise
214	0.96	_	_	I-Premise
215	)	_	_	I-Premise
216	.	_	_	I-Premise

217	However	_	_	B-Premise
218	,	_	_	I-Premise
219	subjective	_	_	I-Premise
220	changes	_	_	I-Premise
221	in	_	_	I-Premise
222	QOL	_	_	I-Premise
223	scores	_	_	I-Premise
224	on	_	_	I-Premise
225	nausea	_	_	I-Premise
226	and	_	_	I-Premise
227	vomiting	_	_	I-Premise
228	were	_	_	I-Premise
229	significantly	_	_	I-Premise
230	higher	_	_	I-Premise
231	in	_	_	I-Premise
232	the	_	_	I-Premise
233	GP	_	_	I-Premise
234	arm	_	_	I-Premise
235	(	_	_	I-Premise
236	p	_	_	I-Premise
237	=	_	_	I-Premise
238	0.001	_	_	I-Premise
239	)	_	_	I-Premise
240	.	_	_	I-Premise

241	Other	_	_	B-Premise
242	symptoms	_	_	I-Premise
243	including	_	_	I-Premise
244	sore	_	_	I-Premise
245	mouth	_	_	I-Premise
246	and	_	_	I-Premise
247	hair	_	_	I-Premise
248	loss	_	_	I-Premise
249	were	_	_	I-Premise
250	significantly	_	_	I-Premise
251	higher	_	_	I-Premise
252	in	_	_	I-Premise
253	the	_	_	I-Premise
254	GE	_	_	I-Premise
255	arm	_	_	I-Premise
256	(	_	_	I-Premise
257	p	_	_	I-Premise
258	=	_	_	I-Premise
259	0.003	_	_	I-Premise
260	and	_	_	I-Premise
261	0.007	_	_	I-Premise
262	,	_	_	I-Premise
263	respectively	_	_	I-Premise
264	)	_	_	I-Premise
265	.	_	_	I-Premise

266	There	_	_	B-Premise
267	were	_	_	I-Premise
268	also	_	_	I-Premise
269	significant	_	_	I-Premise
270	differences	_	_	I-Premise
271	observed	_	_	I-Premise
272	in	_	_	I-Premise
273	emotional	_	_	I-Premise
274	(	_	_	I-Premise
275	p	_	_	I-Premise
276	=	_	_	I-Premise
277	0.014	_	_	I-Premise
278	)	_	_	I-Premise
279	,	_	_	I-Premise
280	cognitive	_	_	I-Premise
281	(	_	_	I-Premise
282	p	_	_	I-Premise
283	=	_	_	I-Premise
284	0.028	_	_	I-Premise
285	)	_	_	I-Premise
286	and	_	_	I-Premise
287	social	_	_	I-Premise
288	functioning	_	_	I-Premise
289	(	_	_	I-Premise
290	p	_	_	I-Premise
291	=	_	_	I-Premise
292	0.034	_	_	I-Premise
293	)	_	_	I-Premise
294	in	_	_	I-Premise
295	favor	_	_	I-Premise
296	of	_	_	I-Premise
297	GP	_	_	I-Premise
298	.	_	_	I-Premise

299	The	_	_	B-Premise
300	differences	_	_	I-Premise
301	in	_	_	I-Premise
302	tumor	_	_	I-Premise
303	response	_	_	I-Premise
304	(	_	_	I-Premise
305	35.5	_	_	I-Premise
306	and	_	_	I-Premise
307	46.5	_	_	I-Premise
308	%	_	_	I-Premise
309	for	_	_	I-Premise
310	GE	_	_	I-Premise
311	and	_	_	I-Premise
312	GP	_	_	I-Premise
313	,	_	_	I-Premise
314	respectively	_	_	I-Premise
315	)	_	_	I-Premise
316	were	_	_	I-Premise
317	not	_	_	I-Premise
318	significantly	_	_	I-Premise
319	different	_	_	I-Premise
320	.	_	_	I-Premise

321	Median	_	_	B-Premise
322	time	_	_	I-Premise
323	to	_	_	I-Premise
324	disease	_	_	I-Premise
325	progression	_	_	I-Premise
326	(	_	_	I-Premise
327	33.8	_	_	I-Premise
328	and	_	_	I-Premise
329	40.7	_	_	I-Premise
330	weeks	_	_	I-Premise
331	,	_	_	I-Premise
332	respectively	_	_	I-Premise
333	)	_	_	I-Premise
334	and	_	_	I-Premise
335	overall	_	_	I-Premise
336	survival	_	_	I-Premise
337	(	_	_	I-Premise
338	41.4	_	_	I-Premise
339	and	_	_	I-Premise
340	57.3	_	_	I-Premise
341	weeks	_	_	I-Premise
342	,	_	_	I-Premise
343	respectively	_	_	I-Premise
344	)	_	_	I-Premise
345	were	_	_	I-Premise
346	of	_	_	I-Premise
347	borderline	_	_	I-Premise
348	significance	_	_	I-Premise
349	in	_	_	I-Premise
350	favor	_	_	I-Premise
351	of	_	_	I-Premise
352	the	_	_	I-Premise
353	GP	_	_	I-Premise
354	arm	_	_	I-Premise
355	(	_	_	I-Premise
356	p	_	_	I-Premise
357	=	_	_	I-Premise
358	0.055	_	_	I-Premise
359	)	_	_	I-Premise
360	.	_	_	I-Premise

361	This	_	_	B-Claim
362	toxicity	_	_	I-Claim
363	profile	_	_	I-Claim
364	of	_	_	I-Claim
365	GE	_	_	I-Claim
366	is	_	_	I-Claim
367	similar	_	_	I-Claim
368	to	_	_	I-Claim
369	GP	_	_	I-Claim
370	,	_	_	I-Claim
371	but	_	_	B-Claim
372	the	_	_	I-Claim
373	apparent	_	_	I-Claim
374	inferior	_	_	I-Claim
375	efficacy	_	_	I-Claim
376	may	_	_	I-Claim
377	discourage	_	_	I-Claim
378	further	_	_	I-Claim
379	investigation	_	_	I-Claim
380	.	_	_	O


0	A	_	_	O
1	multidimensional	_	_	O
2	rehabilitation	_	_	O
3	program	_	_	O
4	for	_	_	O
5	cancer	_	_	O
6	survivors	_	_	O
7	was	_	_	O
8	developed	_	_	O
9	to	_	_	O
10	overcome	_	_	O
11	cancer-related	_	_	O
12	problems	_	_	O
13	and	_	_	O
14	to	_	_	O
15	improve	_	_	O
16	quality	_	_	O
17	of	_	_	O
18	life	_	_	O
19	.	_	_	O

20	The	_	_	O
21	two	_	_	O
22	purposes	_	_	O
23	of	_	_	O
24	the	_	_	O
25	study	_	_	O
26	were	_	_	O
27	to	_	_	O
28	describe	_	_	O
29	the	_	_	O
30	effectiveness	_	_	O
31	of	_	_	O
32	the	_	_	O
33	program	_	_	O
34	and	_	_	O
35	to	_	_	O
36	obtain	_	_	O
37	information	_	_	O
38	about	_	_	O
39	patient	_	_	O
40	preferences	_	_	O
41	for	_	_	O
42	multi	_	_	O
43	or	_	_	O
44	mono	_	_	O
45	dimensional	_	_	O
46	rehabilitation	_	_	O
47	programs	_	_	O
48	.	_	_	O

49	cancer	_	_	O
50	survivors	_	_	O
51	with	_	_	O
52	different	_	_	O
53	diagnoses	_	_	O
54	,	_	_	O
55	and	_	_	O
56	cancer-related	_	_	O
57	physical	_	_	O
58	and	_	_	O
59	psychosocial	_	_	O
60	problems	_	_	O
61	.	_	_	O

62	a	_	_	O
63	15-week	_	_	O
64	rehabilitation	_	_	O
65	program	_	_	O
66	including	_	_	O
67	individual	_	_	O
68	exercise	_	_	O
69	,	_	_	O
70	sports	_	_	O
71	,	_	_	O
72	psycho-education	_	_	O
73	,	_	_	O
74	and	_	_	O
75	information	_	_	O
76	.	_	_	O

77	Group-wise	_	_	O
78	randomization	_	_	O
79	was	_	_	O
80	implemented	_	_	O
81	by	_	_	O
82	assigning	_	_	O
83	one	_	_	O
84	half	_	_	O
85	of	_	_	O
86	the	_	_	O
87	patients	_	_	O
88	to	_	_	O
89	the	_	_	O
90	complete	_	_	O
91	program	_	_	O
92	while	_	_	O
93	the	_	_	O
94	other	_	_	O
95	half	_	_	O
96	were	_	_	O
97	allowed	_	_	O
98	to	_	_	O
99	choose	_	_	O
100	which	_	_	O
101	program	_	_	O
102	components	_	_	O
103	they	_	_	O
104	considered	_	_	O
105	relevant	_	_	O
106	.	_	_	O

107	Health-Related	_	_	O
108	Quality	_	_	O
109	of	_	_	O
110	Life	_	_	O
111	[	_	_	O
112	RAND-36	_	_	O
113	and	_	_	O
114	Rotterdam	_	_	O
115	Symptom	_	_	O
116	Check	_	_	O
117	List	_	_	O
118	(	_	_	O
119	RSCL	_	_	O
120	)	_	_	O
121	]	_	_	O
122	,	_	_	O
123	exercise	_	_	O
124	capacity	_	_	O
125	(	_	_	O
126	symptom	_	_	O
127	limited	_	_	O
128	bicycle	_	_	O
129	ergometry	_	_	O
130	)	_	_	O
131	,	_	_	O
132	muscle	_	_	O
133	force	_	_	O
134	(	_	_	O
135	hand-held	_	_	O
136	dynamometry	_	_	O
137	)	_	_	O
138	,	_	_	O
139	and	_	_	O
140	patient	_	_	O
141	preferences	_	_	O
142	.	_	_	O

143	Measurements	_	_	O
144	were	_	_	O
145	performed	_	_	O
146	before	_	_	O
147	(	_	_	O
148	T0	_	_	O
149	)	_	_	O
150	and	_	_	O
151	after	_	_	O
152	the	_	_	O
153	rehabilitation	_	_	O
154	program	_	_	O
155	(	_	_	O
156	T1	_	_	O
157	)	_	_	O
158	,	_	_	O
159	and	_	_	O
160	at	_	_	O
161	a	_	_	O
162	3-month	_	_	O
163	follow-up	_	_	O
164	(	_	_	O
165	T2	_	_	O
166	)	_	_	O
167	.	_	_	O

168	After	_	_	B-Premise
169	the	_	_	I-Premise
170	rehabilitation	_	_	I-Premise
171	program	_	_	I-Premise
172	,	_	_	I-Premise
173	cancer	_	_	I-Premise
174	survivors	_	_	I-Premise
175	(	_	_	I-Premise
176	n=63	_	_	I-Premise
177	)	_	_	I-Premise
178	displayed	_	_	I-Premise
179	statistically	_	_	I-Premise
180	significant	_	_	I-Premise
181	improvements	_	_	I-Premise
182	on	_	_	I-Premise
183	health-related	_	_	I-Premise
184	quality	_	_	I-Premise
185	of	_	_	I-Premise
186	life	_	_	I-Premise
187	with	_	_	I-Premise
188	effect	_	_	I-Premise
189	sizes	_	_	I-Premise
190	(	_	_	I-Premise
191	ES	_	_	I-Premise
192	)	_	_	I-Premise
193	varying	_	_	I-Premise
194	from	_	_	I-Premise
195	0.38	_	_	I-Premise
196	to	_	_	I-Premise
197	0.99	_	_	I-Premise
198	(	_	_	I-Premise
199	RAND-36	_	_	I-Premise
200	)	_	_	I-Premise
201	and	_	_	I-Premise
202	from	_	_	I-Premise
203	-0.34	_	_	I-Premise
204	to	_	_	I-Premise
205	-0.57	_	_	I-Premise
206	(	_	_	I-Premise
207	RSCL	_	_	I-Premise
208	)	_	_	I-Premise
209	,	_	_	I-Premise
210	most	_	_	I-Premise
211	persistent	_	_	I-Premise
212	at	_	_	I-Premise
213	3-month	_	_	I-Premise
214	follow-up	_	_	I-Premise
215	.	_	_	I-Premise

216	Furthermore	_	_	B-Premise
217	,	_	_	I-Premise
218	statistically	_	_	I-Premise
219	significant	_	_	I-Premise
220	improvements	_	_	I-Premise
221	in	_	_	I-Premise
222	exercise	_	_	I-Premise
223	capacity	_	_	I-Premise
224	and	_	_	I-Premise
225	muscle	_	_	I-Premise
226	force	_	_	I-Premise
227	of	_	_	I-Premise
228	upper	_	_	I-Premise
229	and	_	_	I-Premise
230	lower	_	_	I-Premise
231	extremities	_	_	I-Premise
232	were	_	_	I-Premise
233	displayed	_	_	I-Premise
234	after	_	_	I-Premise
235	rehabilitation	_	_	I-Premise
236	.	_	_	I-Premise

237	If	_	_	B-Premise
238	offered	_	_	I-Premise
239	a	_	_	I-Premise
240	choice	_	_	I-Premise
241	,	_	_	I-Premise
242	80	_	_	I-Premise
243	%	_	_	I-Premise
244	of	_	_	I-Premise
245	the	_	_	I-Premise
246	patients	_	_	I-Premise
247	prior	_	_	I-Premise
248	to	_	_	I-Premise
249	start	_	_	I-Premise
250	and	_	_	I-Premise
251	58	_	_	I-Premise
252	%	_	_	I-Premise
253	of	_	_	I-Premise
254	the	_	_	I-Premise
255	patients	_	_	I-Premise
256	after	_	_	I-Premise
257	completion	_	_	I-Premise
258	of	_	_	I-Premise
259	the	_	_	I-Premise
260	program	_	_	I-Premise
261	indicated	_	_	I-Premise
262	that	_	_	I-Premise
263	they	_	_	I-Premise
264	preferred	_	_	I-Premise
265	the	_	_	I-Premise
266	entire	_	_	I-Premise
267	multidimensional	_	_	I-Premise
268	program	_	_	I-Premise
269	.	_	_	I-Premise

270	A	_	_	B-Claim
271	multidimensional	_	_	I-Claim
272	rehabilitation	_	_	I-Claim
273	program	_	_	I-Claim
274	has	_	_	I-Claim
275	statistically	_	_	I-Claim
276	and	_	_	I-Claim
277	clinically	_	_	I-Claim
278	relevant	_	_	I-Claim
279	beneficial	_	_	I-Claim
280	effects	_	_	I-Claim
281	on	_	_	I-Claim
282	health-related	_	_	I-Claim
283	quality	_	_	I-Claim
284	of	_	_	I-Claim
285	life	_	_	I-Claim
286	,	_	_	I-Claim
287	exercise	_	_	I-Claim
288	capacity	_	_	I-Claim
289	,	_	_	I-Claim
290	and	_	_	I-Claim
291	muscle	_	_	I-Claim
292	force	_	_	I-Claim
293	in	_	_	I-Claim
294	cancer	_	_	I-Claim
295	patients	_	_	I-Claim
296	with	_	_	I-Claim
297	different	_	_	I-Claim
298	diagnoses	_	_	I-Claim
299	.	_	_	I-Claim

300	Furthermore	_	_	O
301	,	_	_	O
302	if	_	_	B-Claim
303	offered	_	_	I-Claim
304	the	_	_	I-Claim
305	choice	_	_	I-Claim
306	,	_	_	I-Claim
307	the	_	_	I-Claim
308	majority	_	_	I-Claim
309	of	_	_	I-Claim
310	cancer	_	_	I-Claim
311	survivors	_	_	I-Claim
312	seem	_	_	I-Claim
313	to	_	_	I-Claim
314	prefer	_	_	I-Claim
315	multidimensional	_	_	I-Claim
316	programs	_	_	I-Claim
317	to	_	_	I-Claim
318	programs	_	_	I-Claim
319	with	_	_	I-Claim
320	only	_	_	I-Claim
321	one	_	_	I-Claim
322	component	_	_	I-Claim
323	.	_	_	I-Claim


0	Evidence	_	_	B-Claim
1	suggests	_	_	I-Claim
2	that	_	_	I-Claim
3	the	_	_	I-Claim
4	re-entry	_	_	I-Claim
5	phase	_	_	I-Claim
6	(	_	_	I-Claim
7	ie	_	_	I-Claim
8	,	_	_	I-Claim
9	early	_	_	I-Claim
10	period	_	_	I-Claim
11	after	_	_	I-Claim
12	medical	_	_	I-Claim
13	treatment	_	_	I-Claim
14	completion	_	_	I-Claim
15	)	_	_	I-Claim
16	presents	_	_	I-Claim
17	distinct	_	_	I-Claim
18	challenges	_	_	I-Claim
19	for	_	_	I-Claim
20	cancer	_	_	I-Claim
21	patients	_	_	I-Claim
22	.	_	_	I-Claim

23	To	_	_	O
24	facilitate	_	_	O
25	the	_	_	O
26	transition	_	_	O
27	to	_	_	O
28	recovery	_	_	O
29	,	_	_	O
30	we	_	_	O
31	conducted	_	_	O
32	the	_	_	O
33	Moving	_	_	O
34	Beyond	_	_	O
35	Cancer	_	_	O
36	(	_	_	O
37	MBC	_	_	O
38	)	_	_	O
39	trial	_	_	O
40	,	_	_	O
41	a	_	_	O
42	multisite	_	_	O
43	,	_	_	O
44	randomized	_	_	O
45	,	_	_	O
46	controlled	_	_	O
47	trial	_	_	O
48	of	_	_	O
49	psychoeducational	_	_	O
50	interventions	_	_	O
51	for	_	_	O
52	breast	_	_	O
53	cancer	_	_	O
54	patients	_	_	O
55	.	_	_	O

56	Breast	_	_	O
57	cancer	_	_	O
58	patients	_	_	O
59	were	_	_	O
60	registered	_	_	O
61	within	_	_	O
62	6	_	_	O
63	weeks	_	_	O
64	after	_	_	O
65	surgery	_	_	O
66	.	_	_	O

67	After	_	_	O
68	medical	_	_	O
69	treatment	_	_	O
70	,	_	_	O
71	they	_	_	O
72	completed	_	_	O
73	baseline	_	_	O
74	measures	_	_	O
75	and	_	_	O
76	were	_	_	O
77	randomly	_	_	O
78	assigned	_	_	O
79	to	_	_	O
80	standard	_	_	O
81	National	_	_	O
82	Cancer	_	_	O
83	Institute	_	_	O
84	print	_	_	O
85	material	_	_	O
86	(	_	_	O
87	CTL	_	_	O
88	)	_	_	O
89	;	_	_	O
90	standard	_	_	O
91	print	_	_	O
92	material	_	_	O
93	and	_	_	O
94	peer-modeling	_	_	O
95	videotape	_	_	O
96	(	_	_	O
97	VID	_	_	O
98	)	_	_	O
99	;	_	_	O
100	or	_	_	O
101	standard	_	_	O
102	print	_	_	O
103	material	_	_	O
104	,	_	_	O
105	videotape	_	_	O
106	,	_	_	O
107	two	_	_	O
108	sessions	_	_	O
109	with	_	_	O
110	a	_	_	O
111	trained	_	_	O
112	cancer	_	_	O
113	educator	_	_	O
114	,	_	_	O
115	and	_	_	O
116	informational	_	_	O
117	workbook	_	_	O
118	(	_	_	O
119	EDU	_	_	O
120	)	_	_	O
121	.	_	_	O

122	Two	_	_	O
123	primary	_	_	O
124	end	_	_	O
125	points	_	_	O
126	were	_	_	O
127	examined	_	_	O
128	:	_	_	O
129	energy/fatigue	_	_	O
130	and	_	_	O
131	cancer-specific	_	_	O
132	distress	_	_	O
133	.	_	_	O

134	Secondary	_	_	O
135	end	_	_	O
136	points	_	_	O
137	were	_	_	O
138	depressive	_	_	O
139	symptoms	_	_	O
140	and	_	_	O
141	post-traumatic	_	_	O
142	growth	_	_	O
143	.	_	_	O

144	Perceived	_	_	O
145	preparedness	_	_	O
146	for	_	_	O
147	re-entry	_	_	O
148	was	_	_	O
149	analyzed	_	_	O
150	as	_	_	O
151	a	_	_	O
152	moderator	_	_	O
153	of	_	_	O
154	effects	_	_	O
155	.	_	_	O

156	Of	_	_	O
157	558	_	_	O
158	women	_	_	O
159	randomly	_	_	O
160	assigned	_	_	O
161	to	_	_	O
162	treatment	_	_	O
163	,	_	_	O
164	418	_	_	O
165	completed	_	_	O
166	the	_	_	O
167	6-month	_	_	O
168	assessment	_	_	O
169	and	_	_	O
170	399	_	_	O
171	completed	_	_	O
172	the	_	_	O
173	12-month	_	_	O
174	assessment	_	_	O
175	.	_	_	O

176	In	_	_	B-Premise
177	analyses	_	_	I-Premise
178	controlling	_	_	I-Premise
179	for	_	_	I-Premise
180	study	_	_	I-Premise
181	site	_	_	I-Premise
182	and	_	_	I-Premise
183	baseline	_	_	I-Premise
184	depressive	_	_	I-Premise
185	symptoms	_	_	I-Premise
186	,	_	_	I-Premise
187	VID	_	_	I-Premise
188	produced	_	_	I-Premise
189	significant	_	_	I-Premise
190	improvement	_	_	I-Premise
191	in	_	_	I-Premise
192	energy/fatigue	_	_	I-Premise
193	at	_	_	I-Premise
194	6	_	_	I-Premise
195	months	_	_	I-Premise
196	relative	_	_	I-Premise
197	to	_	_	I-Premise
198	CTL	_	_	I-Premise
199	,	_	_	I-Premise
200	particularly	_	_	I-Premise
201	among	_	_	I-Premise
202	women	_	_	I-Premise
203	who	_	_	I-Premise
204	felt	_	_	I-Premise
205	less	_	_	I-Premise
206	prepared	_	_	I-Premise
207	for	_	_	I-Premise
208	re-entry	_	_	I-Premise
209	at	_	_	I-Premise
210	baseline	_	_	I-Premise
211	.	_	_	I-Premise

212	No	_	_	B-Premise
213	significant	_	_	I-Premise
214	main	_	_	I-Premise
215	effect	_	_	I-Premise
216	of	_	_	I-Premise
217	the	_	_	I-Premise
218	interventions	_	_	I-Premise
219	emerged	_	_	I-Premise
220	on	_	_	I-Premise
221	cancer-specific	_	_	I-Premise
222	distress	_	_	I-Premise
223	,	_	_	I-Premise
224	but	_	_	B-Premise
225	EDU	_	_	I-Premise
226	prompted	_	_	I-Premise
227	greater	_	_	I-Premise
228	reduction	_	_	I-Premise
229	in	_	_	I-Premise
230	this	_	_	I-Premise
231	outcome	_	_	I-Premise
232	relative	_	_	I-Premise
233	to	_	_	I-Premise
234	CTL	_	_	I-Premise
235	at	_	_	I-Premise
236	6	_	_	I-Premise
237	months	_	_	I-Premise
238	for	_	_	I-Premise
239	patients	_	_	I-Premise
240	who	_	_	I-Premise
241	felt	_	_	I-Premise
242	more	_	_	I-Premise
243	prepared	_	_	I-Premise
244	for	_	_	I-Premise
245	re-entry	_	_	I-Premise
246	.	_	_	I-Premise

247	Between-group	_	_	B-Premise
248	differences	_	_	I-Premise
249	in	_	_	I-Premise
250	the	_	_	I-Premise
251	primary	_	_	I-Premise
252	outcomes	_	_	I-Premise
253	were	_	_	I-Premise
254	not	_	_	I-Premise
255	significant	_	_	I-Premise
256	at	_	_	I-Premise
257	12	_	_	I-Premise
258	months	_	_	I-Premise
259	,	_	_	I-Premise
260	and	_	_	B-Premise
261	no	_	_	I-Premise
262	significant	_	_	I-Premise
263	effects	_	_	I-Premise
264	emerged	_	_	I-Premise
265	on	_	_	I-Premise
266	the	_	_	I-Premise
267	secondary	_	_	I-Premise
268	end	_	_	I-Premise
269	points	_	_	I-Premise
270	.	_	_	I-Premise

271	A	_	_	B-Claim
272	peer-modeling	_	_	I-Claim
273	videotape	_	_	I-Claim
274	can	_	_	I-Claim
275	accelerate	_	_	I-Claim
276	the	_	_	I-Claim
277	recovery	_	_	I-Claim
278	of	_	_	I-Claim
279	energy	_	_	I-Claim
280	during	_	_	I-Claim
281	the	_	_	I-Claim
282	re-entry	_	_	I-Claim
283	phase	_	_	I-Claim
284	in	_	_	I-Claim
285	women	_	_	I-Claim
286	treated	_	_	I-Claim
287	for	_	_	I-Claim
288	breast	_	_	I-Claim
289	cancer	_	_	I-Claim
290	,	_	_	I-Claim
291	particularly	_	_	I-Claim
292	among	_	_	I-Claim
293	those	_	_	I-Claim
294	who	_	_	I-Claim
295	feel	_	_	I-Claim
296	less	_	_	I-Claim
297	prepared	_	_	I-Claim
298	for	_	_	I-Claim
299	re-entry	_	_	I-Claim
300	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	is	_	_	O
3	the	_	_	O
4	first	_	_	O
5	large	_	_	O
6	prospective	_	_	O
7	RCT	_	_	O
8	of	_	_	O
9	sentinel	_	_	O
10	node	_	_	O
11	biopsy	_	_	O
12	(	_	_	O
13	SNB	_	_	O
14	)	_	_	O
15	compared	_	_	O
16	with	_	_	O
17	standard	_	_	O
18	axillary	_	_	O
19	treatment	_	_	O
20	(	_	_	O
21	level	_	_	O
22	I-III	_	_	O
23	axillary	_	_	O
24	lymph	_	_	O
25	node	_	_	O
26	dissection	_	_	O
27	or	_	_	O
28	four	_	_	O
29	node	_	_	O
30	sampling	_	_	O
31	)	_	_	O
32	,	_	_	O
33	which	_	_	O
34	includes	_	_	O
35	comprehensive	_	_	O
36	and	_	_	O
37	repeated	_	_	O
38	quality	_	_	O
39	of	_	_	O
40	life	_	_	O
41	(	_	_	O
42	QOL	_	_	O
43	)	_	_	O
44	assessments	_	_	O
45	over	_	_	O
46	18	_	_	O
47	months	_	_	O
48	.	_	_	O

49	Patients	_	_	O
50	(	_	_	O
51	n	_	_	O
52	=	_	_	O
53	829	_	_	O
54	)	_	_	O
55	completed	_	_	O
56	the	_	_	O
57	Functional	_	_	O
58	Assessment	_	_	O
59	of	_	_	O
60	Cancer	_	_	O
61	Therapy	_	_	O
62	-	_	_	O
63	Breast	_	_	O
64	(	_	_	O
65	FACT-B+4	_	_	O
66	)	_	_	O
67	and	_	_	O
68	the	_	_	O
69	Spielberger	_	_	O
70	State/Trait	_	_	O
71	Anxiety	_	_	O
72	Inventory	_	_	O
73	(	_	_	O
74	STAI	_	_	O
75	)	_	_	O
76	at	_	_	O
77	baseline	_	_	O
78	(	_	_	O
79	pre-surgery	_	_	O
80	)	_	_	O
81	and	_	_	O
82	at	_	_	O
83	1	_	_	O
84	,	_	_	O
85	3	_	_	O
86	,	_	_	O
87	6	_	_	O
88	,	_	_	O
89	12	_	_	O
90	,	_	_	O
91	and	_	_	O
92	18	_	_	O
93	months	_	_	O
94	post-surgery	_	_	O
95	.	_	_	O

96	There	_	_	B-Claim
97	were	_	_	I-Claim
98	significant	_	_	I-Claim
99	differences	_	_	I-Claim
100	between	_	_	I-Claim
101	treatment	_	_	I-Claim
102	groups	_	_	I-Claim
103	favouring	_	_	I-Claim
104	the	_	_	I-Claim
105	SNB	_	_	I-Claim
106	group	_	_	I-Claim
107	throughout	_	_	I-Claim
108	the	_	_	I-Claim
109	18	_	_	I-Claim
110	months	_	_	I-Claim
111	assessment	_	_	I-Claim
112	.	_	_	I-Claim

113	Patients	_	_	B-Premise
114	in	_	_	I-Premise
115	the	_	_	I-Premise
116	standard	_	_	I-Premise
117	treatment	_	_	I-Premise
118	group	_	_	I-Premise
119	showed	_	_	I-Premise
120	a	_	_	I-Premise
121	greater	_	_	I-Premise
122	decline	_	_	I-Premise
123	in	_	_	I-Premise
124	Trial	_	_	I-Premise
125	Outcome	_	_	I-Premise
126	Index	_	_	I-Premise
127	(	_	_	I-Premise
128	TOI	_	_	I-Premise
129	)	_	_	I-Premise
130	scores	_	_	I-Premise
131	(	_	_	I-Premise
132	physical	_	_	I-Premise
133	well-being	_	_	I-Premise
134	,	_	_	I-Premise
135	functional	_	_	I-Premise
136	well-being	_	_	I-Premise
137	and	_	_	I-Premise
138	breast	_	_	I-Premise
139	cancer	_	_	I-Premise
140	concerns	_	_	I-Premise
141	subscales	_	_	I-Premise
142	in	_	_	I-Premise
143	FACT-B+4	_	_	I-Premise
144	)	_	_	I-Premise
145	and	_	_	I-Premise
146	recovered	_	_	I-Premise
147	more	_	_	I-Premise
148	slowly	_	_	I-Premise
149	than	_	_	I-Premise
150	patients	_	_	I-Premise
151	in	_	_	I-Premise
152	the	_	_	I-Premise
153	SNB	_	_	I-Premise
154	group	_	_	I-Premise
155	(	_	_	I-Premise
156	p	_	_	I-Premise
157	<	_	_	I-Premise
158	0.01	_	_	I-Premise
159	)	_	_	I-Premise
160	.	_	_	I-Premise

161	The	_	_	B-Premise
162	change	_	_	I-Premise
163	in	_	_	I-Premise
164	total	_	_	I-Premise
165	FACT-B+4	_	_	I-Premise
166	scores	_	_	I-Premise
167	(	_	_	I-Premise
168	measuring	_	_	I-Premise
169	global	_	_	I-Premise
170	QOL	_	_	I-Premise
171	)	_	_	I-Premise
172	closely	_	_	I-Premise
173	resembled	_	_	I-Premise
174	the	_	_	I-Premise
175	TOI	_	_	I-Premise
176	results	_	_	I-Premise
177	.	_	_	I-Premise

178	18	_	_	B-Premise
179	months	_	_	I-Premise
180	post-surgery	_	_	I-Premise
181	approximately	_	_	I-Premise
182	twice	_	_	I-Premise
183	as	_	_	I-Premise
184	many	_	_	I-Premise
185	patients	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	standard	_	_	I-Premise
189	group	_	_	I-Premise
190	compared	_	_	I-Premise
191	with	_	_	I-Premise
192	the	_	_	I-Premise
193	SNB	_	_	I-Premise
194	group	_	_	I-Premise
195	reported	_	_	I-Premise
196	substantial	_	_	I-Premise
197	arm	_	_	I-Premise
198	swelling	_	_	I-Premise
199	(	_	_	I-Premise
200	14	_	_	I-Premise
201	%	_	_	I-Premise
202	versus	_	_	I-Premise
203	7	_	_	I-Premise
204	%	_	_	I-Premise
205	)	_	_	I-Premise
206	(	_	_	I-Premise
207	p	_	_	I-Premise
208	=	_	_	I-Premise
209	0.002	_	_	I-Premise
210	)	_	_	I-Premise
211	or	_	_	I-Premise
212	numbness	_	_	I-Premise
213	(	_	_	I-Premise
214	19	_	_	I-Premise
215	%	_	_	I-Premise
216	versus	_	_	I-Premise
217	8.7	_	_	I-Premise
218	%	_	_	I-Premise
219	)	_	_	I-Premise
220	(	_	_	I-Premise
221	p	_	_	I-Premise
222	<	_	_	I-Premise
223	0.001	_	_	I-Premise
224	)	_	_	I-Premise
225	.	_	_	I-Premise

226	Despite	_	_	O
227	the	_	_	O
228	uncertainty	_	_	O
229	about	_	_	O
230	undergoing	_	_	O
231	a	_	_	O
232	relatively	_	_	O
233	new	_	_	O
234	procedure	_	_	O
235	and	_	_	O
236	the	_	_	O
237	possible	_	_	O
238	need	_	_	O
239	for	_	_	O
240	further	_	_	O
241	surgery	_	_	O
242	,	_	_	O
243	there	_	_	B-Premise
244	was	_	_	I-Premise
245	no	_	_	I-Premise
246	evidence	_	_	I-Premise
247	of	_	_	I-Premise
248	increased	_	_	I-Premise
249	anxiety	_	_	I-Premise
250	amongst	_	_	I-Premise
251	patients	_	_	I-Premise
252	randomised	_	_	I-Premise
253	to	_	_	I-Premise
254	SNB	_	_	I-Premise
255	(	_	_	I-Premise
256	p	_	_	I-Premise
257	>	_	_	I-Premise
258	0.05	_	_	I-Premise
259	)	_	_	I-Premise
260	.	_	_	I-Premise

261	For	_	_	B-Premise
262	6	_	_	I-Premise
263	months	_	_	I-Premise
264	post-surgery	_	_	I-Premise
265	younger	_	_	I-Premise
266	patients	_	_	I-Premise
267	reported	_	_	I-Premise
268	less	_	_	I-Premise
269	favourable	_	_	I-Premise
270	QOL	_	_	I-Premise
271	scores	_	_	I-Premise
272	(	_	_	I-Premise
273	p	_	_	I-Premise
274	<	_	_	I-Premise
275	0.001	_	_	I-Premise
276	)	_	_	I-Premise
277	and	_	_	I-Premise
278	greater	_	_	I-Premise
279	levels	_	_	I-Premise
280	of	_	_	I-Premise
281	anxiety	_	_	I-Premise
282	(	_	_	I-Premise
283	p	_	_	I-Premise
284	<	_	_	I-Premise
285	0.01	_	_	I-Premise
286	)	_	_	I-Premise
287	.	_	_	I-Premise

288	In	_	_	B-Claim
289	view	_	_	I-Claim
290	of	_	_	I-Claim
291	the	_	_	I-Claim
292	benefits	_	_	I-Claim
293	regarding	_	_	I-Claim
294	arm	_	_	I-Claim
295	functioning	_	_	I-Claim
296	and	_	_	I-Claim
297	quality	_	_	I-Claim
298	of	_	_	I-Claim
299	life	_	_	I-Claim
300	,	_	_	I-Claim
301	the	_	_	I-Claim
302	data	_	_	I-Claim
303	from	_	_	I-Claim
304	this	_	_	I-Claim
305	randomised	_	_	I-Claim
306	study	_	_	I-Claim
307	support	_	_	I-Claim
308	the	_	_	I-Claim
309	use	_	_	I-Claim
310	of	_	_	I-Claim
311	SNB	_	_	I-Claim
312	in	_	_	I-Claim
313	patients	_	_	I-Claim
314	with	_	_	I-Claim
315	clinically	_	_	I-Claim
316	node	_	_	I-Claim
317	negative	_	_	I-Claim
318	breast	_	_	I-Claim
319	cancer	_	_	I-Claim
320	.	_	_	I-Claim


0	To	_	_	O
1	describe	_	_	O
2	the	_	_	O
3	Food	_	_	O
4	and	_	_	O
5	Drug	_	_	O
6	Administration	_	_	O
7	(	_	_	O
8	FDA	_	_	O
9	)	_	_	O
10	review	_	_	O
11	and	_	_	O
12	approval	_	_	O
13	of	_	_	O
14	erlotinib	_	_	O
15	(	_	_	O
16	Tarceva	_	_	O
17	,	_	_	O
18	OSI	_	_	O
19	Pharmaceuticals	_	_	O
20	,	_	_	O
21	Melville	_	_	O
22	,	_	_	O
23	NY	_	_	O
24	)	_	_	O
25	for	_	_	O
26	treatment	_	_	O
27	of	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	locally	_	_	O
31	advanced	_	_	O
32	or	_	_	O
33	metastatic	_	_	O
34	non-small	_	_	O
35	cell	_	_	O
36	lung	_	_	O
37	cancer	_	_	O
38	(	_	_	O
39	NSCLC	_	_	O
40	)	_	_	O
41	after	_	_	O
42	failure	_	_	O
43	of	_	_	O
44	at	_	_	O
45	least	_	_	O
46	one	_	_	O
47	prior	_	_	O
48	chemotherapy	_	_	O
49	regimen	_	_	O
50	.	_	_	O

51	The	_	_	O
52	FDA	_	_	O
53	reviewed	_	_	O
54	raw	_	_	O
55	data	_	_	O
56	in	_	_	O
57	electronic	_	_	O
58	format	_	_	O
59	from	_	_	O
60	a	_	_	O
61	randomized	_	_	O
62	controlled	_	_	O
63	clinical	_	_	O
64	trial	_	_	O
65	comparing	_	_	O
66	erlotinib	_	_	O
67	with	_	_	O
68	placebo	_	_	O
69	in	_	_	O
70	patients	_	_	O
71	with	_	_	O
72	locally	_	_	O
73	advanced	_	_	O
74	or	_	_	O
75	metastatic	_	_	O
76	NSCLC	_	_	O
77	after	_	_	O
78	failure	_	_	O
79	of	_	_	O
80	at	_	_	O
81	least	_	_	O
82	one	_	_	O
83	prior	_	_	O
84	chemotherapy	_	_	O
85	regimen	_	_	O
86	.	_	_	O

87	Patients	_	_	O
88	were	_	_	O
89	randomized	_	_	O
90	in	_	_	O
91	a	_	_	O
92	2:1	_	_	O
93	ratio	_	_	O
94	(	_	_	O
95	erlotinib	_	_	O
96	,	_	_	O
97	n	_	_	O
98	=	_	_	O
99	488	_	_	O
100	and	_	_	O
101	placebo	_	_	O
102	,	_	_	O
103	n	_	_	O
104	=	_	_	O
105	243	_	_	O
106	)	_	_	O
107	.	_	_	O

108	Erlotinib	_	_	B-Claim
109	was	_	_	I-Claim
110	superior	_	_	I-Claim
111	to	_	_	I-Claim
112	placebo	_	_	I-Claim
113	for	_	_	I-Claim
114	survival	_	_	I-Claim
115	,	_	_	I-Claim
116	progression-free	_	_	I-Claim
117	survival	_	_	I-Claim
118	,	_	_	I-Claim
119	and	_	_	I-Claim
120	tumor	_	_	I-Claim
121	response	_	_	I-Claim
122	rate	_	_	I-Claim
123	.	_	_	I-Claim

124	Exploratory	_	_	B-Claim
125	analyses	_	_	I-Claim
126	indicate	_	_	I-Claim
127	that	_	_	I-Claim
128	epidermal	_	_	I-Claim
129	growth	_	_	I-Claim
130	factor	_	_	I-Claim
131	receptor	_	_	I-Claim
132	status	_	_	I-Claim
133	may	_	_	I-Claim
134	be	_	_	I-Claim
135	an	_	_	I-Claim
136	important	_	_	I-Claim
137	predictor	_	_	I-Claim
138	of	_	_	I-Claim
139	the	_	_	I-Claim
140	erlotinib	_	_	I-Claim
141	survival	_	_	I-Claim
142	effect	_	_	I-Claim
143	.	_	_	I-Claim

144	Rash	_	_	B-Premise
145	(	_	_	I-Premise
146	75	_	_	I-Premise
147	%	_	_	I-Premise
148	versus	_	_	I-Premise
149	17	_	_	I-Premise
150	%	_	_	I-Premise
151	)	_	_	I-Premise
152	and	_	_	I-Premise
153	diarrhea	_	_	I-Premise
154	(	_	_	I-Premise
155	54	_	_	I-Premise
156	%	_	_	I-Premise
157	versus	_	_	I-Premise
158	18	_	_	I-Premise
159	%	_	_	I-Premise
160	)	_	_	I-Premise
161	in	_	_	I-Premise
162	the	_	_	I-Premise
163	erlotnib	_	_	I-Premise
164	and	_	_	I-Premise
165	placebo	_	_	I-Premise
166	group	_	_	I-Premise
167	respectively	_	_	I-Premise
168	were	_	_	I-Premise
169	the	_	_	I-Premise
170	most	_	_	I-Premise
171	common	_	_	I-Premise
172	adverse	_	_	I-Premise
173	events	_	_	I-Premise
174	.	_	_	I-Premise

175	Severe	_	_	B-Premise
176	rash	_	_	I-Premise
177	occurred	_	_	I-Premise
178	in	_	_	I-Premise
179	9	_	_	I-Premise
180	%	_	_	I-Premise
181	and	_	_	I-Premise
182	severe	_	_	I-Premise
183	diarrhea	_	_	I-Premise
184	in	_	_	I-Premise
185	6	_	_	I-Premise
186	%	_	_	I-Premise
187	of	_	_	I-Premise
188	erlotinib-treated	_	_	I-Premise
189	patients	_	_	I-Premise
190	and	_	_	I-Premise
191	each	_	_	I-Premise
192	resulted	_	_	I-Premise
193	in	_	_	I-Premise
194	study	_	_	I-Premise
195	discontinuation	_	_	I-Premise
196	in	_	_	I-Premise
197	1	_	_	I-Premise
198	%	_	_	I-Premise
199	of	_	_	I-Premise
200	patients	_	_	I-Premise
201	.	_	_	I-Premise

202	Dose	_	_	B-Premise
203	reductions	_	_	I-Premise
204	were	_	_	I-Premise
205	required	_	_	I-Premise
206	for	_	_	I-Premise
207	10	_	_	I-Premise
208	%	_	_	I-Premise
209	of	_	_	I-Premise
210	patients	_	_	I-Premise
211	with	_	_	I-Premise
212	rash	_	_	I-Premise
213	and	_	_	I-Premise
214	4	_	_	I-Premise
215	%	_	_	I-Premise
216	of	_	_	I-Premise
217	patients	_	_	I-Premise
218	with	_	_	I-Premise
219	diarrhea	_	_	I-Premise
220	.	_	_	I-Premise

221	On	_	_	O
222	November	_	_	O
223	18	_	_	O
224	,	_	_	O
225	2004	_	_	O
226	,	_	_	O
227	the	_	_	O
228	FDA	_	_	O
229	granted	_	_	O
230	erlotinib	_	_	O
231	regular	_	_	O
232	approval	_	_	O
233	for	_	_	O
234	treatment	_	_	O
235	of	_	_	O
236	patients	_	_	O
237	with	_	_	O
238	locally	_	_	O
239	advanced	_	_	O
240	or	_	_	O
241	metastatic	_	_	O
242	NSCLC	_	_	O
243	after	_	_	O
244	failure	_	_	O
245	of	_	_	O
246	at	_	_	O
247	least	_	_	O
248	one	_	_	O
249	prior	_	_	O
250	chemotherapy	_	_	O
251	regimen	_	_	O
252	.	_	_	O

253	The	_	_	O
254	applicant	_	_	O
255	has	_	_	O
256	committed	_	_	O
257	to	_	_	O
258	conduct	_	_	O
259	post-marketing	_	_	O
260	clinical	_	_	O
261	trials	_	_	O
262	to	_	_	O
263	assess	_	_	O
264	further	_	_	O
265	the	_	_	O
266	effect	_	_	O
267	of	_	_	O
268	epidermal	_	_	O
269	growth	_	_	O
270	factor	_	_	O
271	receptor	_	_	O
272	expression	_	_	O
273	,	_	_	O
274	measured	_	_	O
275	with	_	_	O
276	immunohistochemical	_	_	O
277	staining	_	_	O
278	,	_	_	O
279	on	_	_	O
280	erlotinib	_	_	O
281	treatment	_	_	O
282	effect	_	_	O
283	.	_	_	O


0	We	_	_	O
1	investigated	_	_	O
2	the	_	_	O
3	role	_	_	O
4	of	_	_	O
5	tamoxifen	_	_	O
6	and	_	_	O
7	radiotherapy	_	_	O
8	(	_	_	O
9	RT	_	_	O
10	)	_	_	O
11	for	_	_	O
12	the	_	_	O
13	prevention	_	_	O
14	and	_	_	O
15	treatment	_	_	O
16	of	_	_	O
17	gynecomastia	_	_	O
18	and	_	_	O
19	breast	_	_	O
20	pain	_	_	O
21	during	_	_	O
22	adjuvant	_	_	O
23	bicalutamide	_	_	O
24	monotherapy	_	_	O
25	after	_	_	O
26	radical	_	_	O
27	prostatectomy	_	_	O
28	(	_	_	O
29	RP	_	_	O
30	)	_	_	O
31	in	_	_	O
32	patients	_	_	O
33	with	_	_	O
34	prostate	_	_	O
35	cancer	_	_	O
36	.	_	_	O

37	Also	_	_	O
38	,	_	_	O
39	we	_	_	O
40	evaluated	_	_	O
41	their	_	_	O
42	effects	_	_	O
43	on	_	_	O
44	patient	_	_	O
45	hormonal	_	_	O
46	status	_	_	O
47	,	_	_	O
48	quality	_	_	O
49	of	_	_	O
50	life	_	_	O
51	(	_	_	O
52	QOL	_	_	O
53	)	_	_	O
54	,	_	_	O
55	sexual	_	_	O
56	function	_	_	O
57	and	_	_	O
58	prostate	_	_	O
59	specific	_	_	O
60	antigen	_	_	O
61	relapse-free	_	_	O
62	survival	_	_	O
63	.	_	_	O

64	This	_	_	O
65	was	_	_	O
66	a	_	_	O
67	multicenter	_	_	O
68	prospective	_	_	O
69	trial	_	_	O
70	.	_	_	O

71	From	_	_	O
72	January	_	_	O
73	2002	_	_	O
74	to	_	_	O
75	February	_	_	O
76	2004	_	_	O
77	,	_	_	O
78	102	_	_	O
79	patients	_	_	O
80	who	_	_	O
81	had	_	_	O
82	undergone	_	_	O
83	RP	_	_	O
84	for	_	_	O
85	localized	_	_	O
86	or	_	_	O
87	locally	_	_	O
88	advanced	_	_	O
89	prostate	_	_	O
90	cancer	_	_	O
91	were	_	_	O
92	recruited	_	_	O
93	and	_	_	O
94	randomized	_	_	O
95	into	_	_	O
96	3	_	_	O
97	groups	_	_	O
98	,	_	_	O
99	namely	_	_	O
100	group	_	_	O
101	1-those	_	_	O
102	receiving	_	_	O
103	only	_	_	O
104	150	_	_	O
105	mg	_	_	O
106	bicalutamide	_	_	O
107	as	_	_	O
108	adjuvant	_	_	O
109	hormonal	_	_	O
110	therapy	_	_	O
111	,	_	_	O
112	group	_	_	O
113	2-those	_	_	O
114	receiving	_	_	O
115	bicalutamide	_	_	O
116	and	_	_	O
117	10	_	_	O
118	mg	_	_	O
119	tamoxifen	_	_	O
120	,	_	_	O
121	and	_	_	O
122	group	_	_	O
123	3-those	_	_	O
124	receiving	_	_	O
125	bicalutamide	_	_	O
126	and	_	_	O
127	RT	_	_	O
128	.	_	_	O

129	Patients	_	_	O
130	in	_	_	O
131	group	_	_	O
132	1	_	_	O
133	in	_	_	O
134	whom	_	_	O
135	gynecomastia	_	_	O
136	or	_	_	O
137	breast	_	_	O
138	pain	_	_	O
139	developed	_	_	O
140	were	_	_	O
141	subsequently	_	_	O
142	randomized	_	_	O
143	to	_	_	O
144	receive	_	_	O
145	tamoxifen	_	_	O
146	or	_	_	O
147	RT	_	_	O
148	soon	_	_	O
149	after	_	_	O
150	symptoms	_	_	O
151	started	_	_	O
152	.	_	_	O

153	Gynecomastia	_	_	O
154	,	_	_	O
155	breast	_	_	O
156	pain	_	_	O
157	,	_	_	O
158	prostate	_	_	O
159	specific	_	_	O
160	antigen	_	_	O
161	,	_	_	O
162	QOL	_	_	O
163	,	_	_	O
164	sexual	_	_	O
165	function	_	_	O
166	and	_	_	O
167	hormonal	_	_	O
168	levels	_	_	O
169	were	_	_	O
170	assessed	_	_	O
171	.	_	_	O

172	Minimum	_	_	O
173	followup	_	_	O
174	was	_	_	O
175	12	_	_	O
176	months	_	_	O
177	.	_	_	O

178	Of	_	_	B-Premise
179	group	_	_	I-Premise
180	1	_	_	I-Premise
181	patients	_	_	I-Premise
182	67	_	_	I-Premise
183	%	_	_	I-Premise
184	had	_	_	I-Premise
185	gynecomastia	_	_	I-Premise
186	compared	_	_	I-Premise
187	with	_	_	I-Premise
188	8	_	_	I-Premise
189	%	_	_	I-Premise
190	in	_	_	I-Premise
191	group	_	_	I-Premise
192	2	_	_	I-Premise
193	and	_	_	I-Premise
194	34	_	_	I-Premise
195	%	_	_	I-Premise
196	in	_	_	I-Premise
197	group	_	_	I-Premise
198	3	_	_	I-Premise
199	.	_	_	I-Premise

200	Breast	_	_	B-Premise
201	pain	_	_	I-Premise
202	was	_	_	I-Premise
203	more	_	_	I-Premise
204	frequent	_	_	I-Premise
205	in	_	_	I-Premise
206	group	_	_	I-Premise
207	1	_	_	I-Premise
208	than	_	_	I-Premise
209	in	_	_	I-Premise
210	groups	_	_	I-Premise
211	2	_	_	I-Premise
212	and	_	_	I-Premise
213	3	_	_	I-Premise
214	(	_	_	I-Premise
215	58	_	_	I-Premise
216	%	_	_	I-Premise
217	vs	_	_	I-Premise
218	7	_	_	I-Premise
219	%	_	_	I-Premise
220	and	_	_	I-Premise
221	30	_	_	I-Premise
222	%	_	_	I-Premise
223	,	_	_	I-Premise
224	respectively	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	Differences	_	_	B-Premise
228	were	_	_	I-Premise
229	significant	_	_	I-Premise
230	between	_	_	I-Premise
231	groups	_	_	I-Premise
232	1	_	_	I-Premise
233	and	_	_	I-Premise
234	2	_	_	I-Premise
235	(	_	_	I-Premise
236	OR	_	_	I-Premise
237	0.12	_	_	I-Premise
238	p	_	_	I-Premise
239	<	_	_	I-Premise
240	0.001	_	_	I-Premise
241	)	_	_	I-Premise
242	,	_	_	I-Premise
243	and	_	_	I-Premise
244	groups	_	_	I-Premise
245	1	_	_	I-Premise
246	and	_	_	I-Premise
247	3	_	_	I-Premise
248	(	_	_	I-Premise
249	OR	_	_	I-Premise
250	0.52	_	_	I-Premise
251	p	_	_	I-Premise
252	<	_	_	I-Premise
253	0.01	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	In	_	_	B-Premise
257	patients	_	_	I-Premise
258	in	_	_	I-Premise
259	group	_	_	I-Premise
260	1	_	_	I-Premise
261	who	_	_	I-Premise
262	had	_	_	I-Premise
263	gynecomastia	_	_	I-Premise
264	or	_	_	I-Premise
265	breast	_	_	I-Premise
266	pain	_	_	I-Premise
267	a	_	_	I-Premise
268	significant	_	_	I-Premise
269	decrease	_	_	I-Premise
270	in	_	_	I-Premise
271	symptoms	_	_	I-Premise
272	was	_	_	I-Premise
273	achieved	_	_	I-Premise
274	in	_	_	I-Premise
275	those	_	_	I-Premise
276	receiving	_	_	I-Premise
277	tamoxifen	_	_	I-Premise
278	(	_	_	I-Premise
279	p	_	_	I-Premise
280	<	_	_	I-Premise
281	0.05	_	_	I-Premise
282	)	_	_	I-Premise
283	.	_	_	I-Premise

284	Treatments	_	_	B-Premise
285	were	_	_	I-Premise
286	well	_	_	I-Premise
287	tolerated	_	_	I-Premise
288	in	_	_	I-Premise
289	the	_	_	I-Premise
290	3	_	_	I-Premise
291	groups	_	_	I-Premise
292	.	_	_	I-Premise

293	No	_	_	B-Premise
294	differences	_	_	I-Premise
295	in	_	_	I-Premise
296	QOL	_	_	I-Premise
297	between	_	_	I-Premise
298	groups	_	_	I-Premise
299	2	_	_	I-Premise
300	and	_	_	I-Premise
301	3	_	_	I-Premise
302	were	_	_	I-Premise
303	found	_	_	I-Premise
304	.	_	_	I-Premise

305	At	_	_	B-Premise
306	a	_	_	I-Premise
307	median	_	_	I-Premise
308	followup	_	_	I-Premise
309	of	_	_	I-Premise
310	26	_	_	I-Premise
311	months	_	_	I-Premise
312	we	_	_	I-Premise
313	observed	_	_	I-Premise
314	12	_	_	I-Premise
315	biochemical	_	_	I-Premise
316	relapses	_	_	I-Premise
317	.	_	_	I-Premise

318	Gynecomastia	_	_	B-Claim
319	and	_	_	I-Claim
320	breast	_	_	I-Claim
321	pain	_	_	I-Claim
322	induced	_	_	I-Claim
323	by	_	_	I-Claim
324	bicalutamide	_	_	I-Claim
325	monotherapy	_	_	I-Claim
326	after	_	_	I-Claim
327	RP	_	_	I-Claim
328	can	_	_	I-Claim
329	be	_	_	I-Claim
330	prevented	_	_	I-Claim
331	and	_	_	I-Claim
332	treated	_	_	I-Claim
333	.	_	_	I-Claim

334	Tamoxifen	_	_	B-Claim
335	has	_	_	I-Claim
336	been	_	_	I-Claim
337	shown	_	_	I-Claim
338	to	_	_	I-Claim
339	be	_	_	I-Claim
340	more	_	_	I-Claim
341	effective	_	_	I-Claim
342	and	_	_	I-Claim
343	safe	_	_	I-Claim
344	than	_	_	I-Claim
345	RT	_	_	I-Claim
346	in	_	_	I-Claim
347	this	_	_	I-Claim
348	setting	_	_	I-Claim
349	.	_	_	I-Claim

350	QOL	_	_	B-Claim
351	and	_	_	I-Claim
352	sexual	_	_	I-Claim
353	function	_	_	I-Claim
354	are	_	_	I-Claim
355	not	_	_	I-Claim
356	negatively	_	_	I-Claim
357	influenced	_	_	I-Claim
358	by	_	_	I-Claim
359	these	_	_	I-Claim
360	2	_	_	I-Claim
361	treatment	_	_	I-Claim
362	options	_	_	I-Claim
363	.	_	_	O


0	Axillary	_	_	B-Claim
1	clearance	_	_	I-Claim
2	in	_	_	I-Claim
3	early	_	_	I-Claim
4	breast	_	_	I-Claim
5	cancer	_	_	I-Claim
6	aims	_	_	I-Claim
7	to	_	_	I-Claim
8	improve	_	_	I-Claim
9	locoregional	_	_	I-Claim
10	control	_	_	I-Claim
11	and	_	_	I-Claim
12	provide	_	_	I-Claim
13	staging	_	_	I-Claim
14	information	_	_	I-Claim
15	but	_	_	O
16	is	_	_	O
17	associated	_	_	O
18	with	_	_	O
19	undesirable	_	_	O
20	morbidity	_	_	O
21	.	_	_	O

22	We	_	_	O
23	therefore	_	_	O
24	investigated	_	_	O
25	whether	_	_	O
26	avoiding	_	_	O
27	axillary	_	_	O
28	surgery	_	_	O
29	in	_	_	O
30	older	_	_	O
31	women	_	_	O
32	would	_	_	O
33	result	_	_	O
34	in	_	_	O
35	improved	_	_	O
36	quality	_	_	O
37	of	_	_	O
38	life	_	_	O
39	(	_	_	O
40	QL	_	_	O
41	)	_	_	O
42	with	_	_	O
43	similar	_	_	O
44	disease-free	_	_	O
45	survival	_	_	O
46	(	_	_	O
47	DFS	_	_	O
48	)	_	_	O
49	and	_	_	O
50	overall	_	_	O
51	survival	_	_	O
52	(	_	_	O
53	OS	_	_	O
54	)	_	_	O
55	.	_	_	O

56	Between	_	_	O
57	1993	_	_	O
58	and	_	_	O
59	2002	_	_	O
60	,	_	_	O
61	women	_	_	O
62	>	_	_	O
63	or	_	_	O
64	=	_	_	O
65	60	_	_	O
66	years	_	_	O
67	old	_	_	O
68	with	_	_	O
69	clinically	_	_	O
70	node-negative	_	_	O
71	operable	_	_	O
72	breast	_	_	O
73	cancer	_	_	O
74	in	_	_	O
75	whom	_	_	O
76	adjuvant	_	_	O
77	tamoxifen	_	_	O
78	was	_	_	O
79	considered	_	_	O
80	indicated	_	_	O
81	regardless	_	_	O
82	of	_	_	O
83	pathologic	_	_	O
84	nodal	_	_	O
85	status	_	_	O
86	were	_	_	O
87	randomly	_	_	O
88	assigned	_	_	O
89	to	_	_	O
90	primary	_	_	O
91	surgery	_	_	O
92	plus	_	_	O
93	axillary	_	_	O
94	clearance	_	_	O
95	(	_	_	O
96	Sx	_	_	O
97	+	_	_	O
98	Ax	_	_	O
99	)	_	_	O
100	followed	_	_	O
101	by	_	_	O
102	tamoxifen	_	_	O
103	(	_	_	O
104	Tam	_	_	O
105	)	_	_	O
106	versus	_	_	O
107	Sx	_	_	O
108	without	_	_	O
109	Ax	_	_	O
110	followed	_	_	O
111	by	_	_	O
112	Tam	_	_	O
113	for	_	_	O
114	5	_	_	O
115	consecutive	_	_	O
116	years	_	_	O
117	.	_	_	O

118	The	_	_	O
119	primary	_	_	O
120	end	_	_	O
121	point	_	_	O
122	was	_	_	O
123	QL	_	_	O
124	reported	_	_	O
125	by	_	_	O
126	the	_	_	O
127	patient	_	_	O
128	and	_	_	O
129	by	_	_	O
130	physician	_	_	O
131	assessment	_	_	O
132	.	_	_	O

133	A	_	_	O
134	total	_	_	O
135	of	_	_	O
136	473	_	_	O
137	patients	_	_	O
138	(	_	_	O
139	234	_	_	O
140	to	_	_	O
141	Sx	_	_	O
142	+	_	_	O
143	Ax	_	_	O
144	,	_	_	O
145	239	_	_	O
146	to	_	_	O
147	Sx	_	_	O
148	)	_	_	O
149	were	_	_	O
150	randomly	_	_	O
151	assigned	_	_	O
152	.	_	_	O

153	The	_	_	O
154	median	_	_	O
155	age	_	_	O
156	was	_	_	O
157	74	_	_	O
158	years	_	_	O
159	;	_	_	O
160	80	_	_	O
161	%	_	_	O
162	had	_	_	O
163	estrogen	_	_	O
164	receptor-positive	_	_	O
165	disease	_	_	O
166	.	_	_	O

167	In	_	_	B-Premise
168	both	_	_	I-Premise
169	the	_	_	I-Premise
170	patients	_	_	I-Premise
171	'	_	_	I-Premise
172	subjective	_	_	I-Premise
173	assessment	_	_	I-Premise
174	of	_	_	I-Premise
175	their	_	_	I-Premise
176	QL	_	_	I-Premise
177	and	_	_	I-Premise
178	the	_	_	I-Premise
179	physicians	_	_	I-Premise
180	'	_	_	I-Premise
181	perception	_	_	I-Premise
182	of	_	_	I-Premise
183	the	_	_	I-Premise
184	patients	_	_	I-Premise
185	'	_	_	I-Premise
186	QL	_	_	I-Premise
187	,	_	_	I-Premise
188	the	_	_	I-Premise
189	largest	_	_	I-Premise
190	adverse	_	_	I-Premise
191	QL	_	_	I-Premise
192	effects	_	_	I-Premise
193	of	_	_	I-Premise
194	Ax	_	_	I-Premise
195	were	_	_	I-Premise
196	observed	_	_	I-Premise
197	from	_	_	I-Premise
198	baseline	_	_	I-Premise
199	to	_	_	I-Premise
200	the	_	_	I-Premise
201	first	_	_	I-Premise
202	postoperative	_	_	I-Premise
203	assessment	_	_	I-Premise
204	,	_	_	I-Premise
205	but	_	_	B-Premise
206	the	_	_	I-Premise
207	differences	_	_	I-Premise
208	tended	_	_	I-Premise
209	to	_	_	I-Premise
210	disappear	_	_	I-Premise
211	in	_	_	I-Premise
212	6	_	_	I-Premise
213	to	_	_	I-Premise
214	12	_	_	I-Premise
215	months	_	_	I-Premise
216	.	_	_	I-Premise

217	At	_	_	B-Premise
218	a	_	_	I-Premise
219	median	_	_	I-Premise
220	follow-up	_	_	I-Premise
221	of	_	_	I-Premise
222	6.6	_	_	I-Premise
223	years	_	_	I-Premise
224	,	_	_	I-Premise
225	results	_	_	I-Premise
226	for	_	_	I-Premise
227	Sx	_	_	I-Premise
228	+	_	_	I-Premise
229	Ax	_	_	I-Premise
230	and	_	_	I-Premise
231	Sx	_	_	I-Premise
232	yielded	_	_	I-Premise
233	similar	_	_	I-Premise
234	DFS	_	_	I-Premise
235	(	_	_	I-Premise
236	6-year	_	_	I-Premise
237	DFS	_	_	I-Premise
238	,	_	_	I-Premise
239	67	_	_	I-Premise
240	%	_	_	I-Premise
241	v	_	_	I-Premise
242	66	_	_	I-Premise
243	%	_	_	I-Premise
244	;	_	_	I-Premise
245	hazard	_	_	I-Premise
246	ratio	_	_	I-Premise
247	[	_	_	I-Premise
248	HR	_	_	I-Premise
249	]	_	_	I-Premise
250	Sx	_	_	I-Premise
251	+	_	_	I-Premise
252	Ax/Sx	_	_	I-Premise
253	,	_	_	I-Premise
254	1.06	_	_	I-Premise
255	;	_	_	I-Premise
256	95	_	_	I-Premise
257	%	_	_	I-Premise
258	CI	_	_	I-Premise
259	,	_	_	I-Premise
260	0.79	_	_	I-Premise
261	to	_	_	I-Premise
262	1.42	_	_	I-Premise
263	;	_	_	I-Premise
264	P	_	_	I-Premise
265	=	_	_	I-Premise
266	.69	_	_	I-Premise
267	)	_	_	I-Premise
268	and	_	_	I-Premise
269	OS	_	_	I-Premise
270	(	_	_	I-Premise
271	6-year	_	_	I-Premise
272	OS	_	_	I-Premise
273	,	_	_	I-Premise
274	75	_	_	I-Premise
275	%	_	_	I-Premise
276	v	_	_	I-Premise
277	73	_	_	I-Premise
278	%	_	_	I-Premise
279	;	_	_	I-Premise
280	HR	_	_	I-Premise
281	Sx	_	_	I-Premise
282	+	_	_	I-Premise
283	Ax/Sx	_	_	I-Premise
284	,	_	_	I-Premise
285	1.05	_	_	I-Premise
286	;	_	_	I-Premise
287	95	_	_	I-Premise
288	%	_	_	I-Premise
289	CI	_	_	I-Premise
290	,	_	_	I-Premise
291	0.76	_	_	I-Premise
292	to	_	_	I-Premise
293	1.46	_	_	I-Premise
294	;	_	_	I-Premise
295	P	_	_	I-Premise
296	=	_	_	I-Premise
297	.77	_	_	I-Premise
298	)	_	_	I-Premise
299	.	_	_	I-Premise

300	Avoiding	_	_	B-Claim
301	axillary	_	_	I-Claim
302	clearance	_	_	I-Claim
303	for	_	_	I-Claim
304	women	_	_	I-Claim
305	>	_	_	I-Claim
306	or	_	_	I-Claim
307	=	_	_	I-Claim
308	60	_	_	I-Claim
309	years	_	_	I-Claim
310	old	_	_	I-Claim
311	who	_	_	I-Claim
312	have	_	_	I-Claim
313	clinically	_	_	I-Claim
314	node-negative	_	_	I-Claim
315	disease	_	_	I-Claim
316	and	_	_	I-Claim
317	receive	_	_	I-Claim
318	Tam	_	_	I-Claim
319	for	_	_	I-Claim
320	endocrine-responsive	_	_	I-Claim
321	disease	_	_	I-Claim
322	yields	_	_	I-Claim
323	similar	_	_	I-Claim
324	efficacy	_	_	I-Claim
325	with	_	_	I-Claim
326	better	_	_	I-Claim
327	early	_	_	I-Claim
328	QL	_	_	I-Claim
329	.	_	_	I-Claim


0	Fatigue	_	_	B-Claim
1	has	_	_	I-Claim
2	a	_	_	I-Claim
3	significant	_	_	I-Claim
4	impact	_	_	I-Claim
5	on	_	_	I-Claim
6	the	_	_	I-Claim
7	quality	_	_	I-Claim
8	of	_	_	I-Claim
9	life	_	_	I-Claim
10	(	_	_	I-Claim
11	QOL	_	_	I-Claim
12	)	_	_	I-Claim
13	of	_	_	I-Claim
14	cancer	_	_	I-Claim
15	patients	_	_	I-Claim
16	.	_	_	I-Claim

17	Recent	_	_	B-Claim
18	research	_	_	I-Claim
19	has	_	_	I-Claim
20	suggested	_	_	I-Claim
21	that	_	_	I-Claim
22	physical	_	_	I-Claim
23	activity	_	_	I-Claim
24	can	_	_	I-Claim
25	reduce	_	_	I-Claim
26	fatigue	_	_	I-Claim
27	in	_	_	I-Claim
28	patients	_	_	I-Claim
29	receiving	_	_	I-Claim
30	active	_	_	I-Claim
31	cancer	_	_	I-Claim
32	treatment	_	_	I-Claim
33	.	_	_	I-Claim

34	In	_	_	O
35	this	_	_	O
36	project	_	_	O
37	,	_	_	O
38	we	_	_	O
39	examined	_	_	O
40	the	_	_	O
41	impact	_	_	O
42	that	_	_	O
43	participation	_	_	O
44	in	_	_	O
45	a	_	_	O
46	randomized	_	_	O
47	controlled	_	_	O
48	trial	_	_	O
49	of	_	_	O
50	a	_	_	O
51	multidisciplinary	_	_	O
52	intervention	_	_	O
53	designed	_	_	O
54	to	_	_	O
55	impact	_	_	O
56	overall	_	_	O
57	QOL	_	_	O
58	had	_	_	O
59	on	_	_	O
60	fatigue	_	_	O
61	for	_	_	O
62	advanced	_	_	O
63	cancer	_	_	O
64	patients	_	_	O
65	actively	_	_	O
66	receiving	_	_	O
67	treatment	_	_	O
68	.	_	_	O

69	Patients	_	_	O
70	with	_	_	O
71	newly	_	_	O
72	diagnosed	_	_	O
73	cancer	_	_	O
74	were	_	_	O
75	randomly	_	_	O
76	assigned	_	_	O
77	to	_	_	O
78	an	_	_	O
79	8-session	_	_	O
80	structured	_	_	O
81	multidisciplinary	_	_	O
82	intervention	_	_	O
83	or	_	_	O
84	a	_	_	O
85	standard-care	_	_	O
86	arm	_	_	O
87	at	_	_	O
88	the	_	_	O
89	beginning	_	_	O
90	of	_	_	O
91	their	_	_	O
92	course	_	_	O
93	of	_	_	O
94	radiotherapy	_	_	O
95	(	_	_	O
96	RT	_	_	O
97	)	_	_	O
98	designed	_	_	O
99	to	_	_	O
100	impact	_	_	O
101	QOL	_	_	O
102	.	_	_	O

103	Ninety-minute	_	_	O
104	sessions	_	_	O
105	were	_	_	O
106	led	_	_	O
107	by	_	_	O
108	either	_	_	O
109	a	_	_	O
110	psychiatrist	_	_	O
111	or	_	_	O
112	psychologist	_	_	O
113	,	_	_	O
114	collaborating	_	_	O
115	with	_	_	O
116	a	_	_	O
117	nurse	_	_	O
118	,	_	_	O
119	physical	_	_	O
120	therapist	_	_	O
121	,	_	_	O
122	chaplain	_	_	O
123	,	_	_	O
124	or	_	_	O
125	social	_	_	O
126	worker	_	_	O
127	,	_	_	O
128	depending	_	_	O
129	on	_	_	O
130	the	_	_	O
131	session	_	_	O
132	's	_	_	O
133	theme	_	_	O
134	.	_	_	O

135	The	_	_	O
136	fatigue	_	_	O
137	assessments	_	_	O
138	used	_	_	O
139	in	_	_	O
140	this	_	_	O
141	trial	_	_	O
142	included	_	_	O
143	the	_	_	O
144	Linear	_	_	O
145	Analogue	_	_	O
146	Self	_	_	O
147	Assessment	_	_	O
148	(	_	_	O
149	LASA	_	_	O
150	)	_	_	O
151	,	_	_	O
152	the	_	_	O
153	Profile	_	_	O
154	of	_	_	O
155	Mood	_	_	O
156	States	_	_	O
157	(	_	_	O
158	POMS	_	_	O
159	)	_	_	O
160	,	_	_	O
161	Spielberger	_	_	O
162	's	_	_	O
163	State-Trait	_	_	O
164	Anxiety	_	_	O
165	Inventory	_	_	O
166	(	_	_	O
167	STAI	_	_	O
168	)	_	_	O
169	,	_	_	O
170	and	_	_	O
171	the	_	_	O
172	Symptom	_	_	O
173	Distress	_	_	O
174	Scale	_	_	O
175	(	_	_	O
176	SDS	_	_	O
177	)	_	_	O
178	.	_	_	O

179	There	_	_	O
180	were	_	_	O
181	115	_	_	O
182	participants	_	_	O
183	enrolled	_	_	O
184	and	_	_	O
185	the	_	_	O
186	2	_	_	O
187	randomization	_	_	O
188	arms	_	_	O
189	were	_	_	O
190	well	_	_	O
191	balanced	_	_	O
192	in	_	_	O
193	terms	_	_	O
194	of	_	_	O
195	baseline	_	_	O
196	characteristics	_	_	O
197	and	_	_	O
198	treatment	_	_	O
199	received	_	_	O
200	except	_	_	O
201	for	_	_	O
202	increased	_	_	O
203	commuting	_	_	O
204	distance	_	_	O
205	for	_	_	O
206	the	_	_	O
207	patients	_	_	O
208	in	_	_	O
209	the	_	_	O
210	intervention	_	_	O
211	arm	_	_	O
212	(	_	_	O
213	P	_	_	O
214	=	_	_	O
215	0.042	_	_	O
216	)	_	_	O
217	.	_	_	O

218	Most	_	_	B-Premise
219	of	_	_	I-Premise
220	scores	_	_	I-Premise
221	indicated	_	_	I-Premise
222	less	_	_	I-Premise
223	fatigue	_	_	I-Premise
224	(	_	_	I-Premise
225	higher	_	_	I-Premise
226	score	_	_	I-Premise
227	)	_	_	I-Premise
228	in	_	_	I-Premise
229	the	_	_	I-Premise
230	standard	_	_	I-Premise
231	treatment	_	_	I-Premise
232	group	_	_	I-Premise
233	,	_	_	I-Premise
234	but	_	_	B-Premise
235	there	_	_	I-Premise
236	were	_	_	I-Premise
237	no	_	_	I-Premise
238	statistically	_	_	I-Premise
239	significant	_	_	I-Premise
240	differences	_	_	I-Premise
241	found	_	_	I-Premise
242	at	_	_	I-Premise
243	baseline	_	_	I-Premise
244	and	_	_	I-Premise
245	weeks	_	_	I-Premise
246	4	_	_	I-Premise
247	,	_	_	I-Premise
248	8	_	_	I-Premise
249	,	_	_	I-Premise
250	and	_	_	I-Premise
251	27	_	_	I-Premise
252	except	_	_	I-Premise
253	for	_	_	I-Premise
254	SDS	_	_	I-Premise
255	at	_	_	I-Premise
256	week	_	_	I-Premise
257	8	_	_	I-Premise
258	(	_	_	I-Premise
259	P	_	_	I-Premise
260	=	_	_	I-Premise
261	0.018	_	_	I-Premise
262	)	_	_	I-Premise
263	with	_	_	I-Premise
264	less	_	_	I-Premise
265	patients	_	_	I-Premise
266	reporting	_	_	I-Premise
267	significant	_	_	I-Premise
268	fatigue	_	_	I-Premise
269	in	_	_	I-Premise
270	the	_	_	I-Premise
271	standard	_	_	I-Premise
272	treatment	_	_	I-Premise
273	arm	_	_	I-Premise
274	.	_	_	I-Premise

275	For	_	_	B-Premise
276	the	_	_	I-Premise
277	entire	_	_	I-Premise
278	participant	_	_	I-Premise
279	population	_	_	I-Premise
280	,	_	_	I-Premise
281	fatigue	_	_	I-Premise
282	levels	_	_	I-Premise
283	initially	_	_	I-Premise
284	worsened	_	_	I-Premise
285	with	_	_	I-Premise
286	radiotherapy	_	_	I-Premise
287	,	_	_	I-Premise
288	stabilized	_	_	I-Premise
289	at	_	_	I-Premise
290	week	_	_	I-Premise
291	8	_	_	I-Premise
292	,	_	_	I-Premise
293	and	_	_	I-Premise
294	returned	_	_	I-Premise
295	to	_	_	I-Premise
296	baseline	_	_	I-Premise
297	by	_	_	I-Premise
298	week	_	_	I-Premise
299	27	_	_	I-Premise
300	.	_	_	I-Premise

301	Disease	_	_	B-Premise
302	site	_	_	I-Premise
303	,	_	_	I-Premise
304	chemotherapy	_	_	I-Premise
305	use	_	_	I-Premise
306	,	_	_	I-Premise
307	and	_	_	I-Premise
308	radiotherapy	_	_	I-Premise
309	dose	_	_	I-Premise
310	did	_	_	I-Premise
311	not	_	_	I-Premise
312	have	_	_	I-Premise
313	a	_	_	I-Premise
314	significant	_	_	I-Premise
315	impact	_	_	I-Premise
316	on	_	_	I-Premise
317	fatigue	_	_	I-Premise
318	levels	_	_	I-Premise
319	.	_	_	I-Premise

320	Radiotherapy	_	_	B-Premise
321	initially	_	_	I-Premise
322	caused	_	_	I-Premise
323	a	_	_	I-Premise
324	worsening	_	_	I-Premise
325	of	_	_	I-Premise
326	fatigue	_	_	I-Premise
327	but	_	_	I-Premise
328	with	_	_	I-Premise
329	time	_	_	I-Premise
330	fatigue	_	_	I-Premise
331	levels	_	_	I-Premise
332	returned	_	_	I-Premise
333	to	_	_	I-Premise
334	baseline	_	_	I-Premise
335	.	_	_	O

336	Clinically	_	_	B-Claim
337	,	_	_	I-Claim
338	this	_	_	I-Claim
339	structured	_	_	I-Claim
340	multidisciplinary	_	_	I-Claim
341	intervention	_	_	I-Claim
342	had	_	_	I-Claim
343	no	_	_	I-Claim
344	impact	_	_	I-Claim
345	on	_	_	I-Claim
346	fatigue	_	_	I-Claim
347	,	_	_	I-Claim
348	and	_	_	O
349	there	_	_	B-Claim
350	was	_	_	I-Claim
351	the	_	_	I-Claim
352	suggestion	_	_	I-Claim
353	the	_	_	I-Claim
354	multiple	_	_	I-Claim
355	sessions	_	_	I-Claim
356	may	_	_	I-Claim
357	have	_	_	I-Claim
358	contributed	_	_	I-Claim
359	to	_	_	I-Claim
360	worse	_	_	I-Claim
361	fatigue	_	_	I-Claim
362	during	_	_	I-Claim
363	active	_	_	I-Claim
364	cancer	_	_	I-Claim
365	treatment	_	_	I-Claim
366	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	epoetin	_	_	O
6	alfa	_	_	O
7	on	_	_	O
8	quality	_	_	O
9	of	_	_	O
10	life	_	_	O
11	(	_	_	O
12	QOL	_	_	O
13	)	_	_	O
14	in	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	solid	_	_	O
18	tumors	_	_	O
19	and	_	_	O
20	mild-to-moderate	_	_	O
21	anemia	_	_	O
22	receiving	_	_	O
23	platinum-based	_	_	O
24	chemotherapy	_	_	O
25	relative	_	_	O
26	to	_	_	O
27	population	_	_	O
28	norms	_	_	O
29	.	_	_	O

30	In	_	_	O
31	the	_	_	O
32	original	_	_	O
33	study	_	_	O
34	,	_	_	O
35	patients	_	_	O
36	(	_	_	O
37	n	_	_	O
38	=	_	_	O
39	316	_	_	O
40	)	_	_	O
41	with	_	_	O
42	hemoglobin	_	_	O
43	(	_	_	O
44	Hb	_	_	O
45	)	_	_	O
46	levels	_	_	O
47	<	_	_	O
48	or	_	_	O
49	=12.1	_	_	O
50	g/dl	_	_	O
51	were	_	_	O
52	randomized	_	_	O
53	2:1	_	_	O
54	to	_	_	O
55	receive	_	_	O
56	either	_	_	O
57	epoetin	_	_	O
58	alfa	_	_	O
59	at	_	_	O
60	a	_	_	O
61	dose	_	_	O
62	of	_	_	O
63	10,000	_	_	O
64	U	_	_	O
65	thrice	_	_	O
66	weekly	_	_	O
67	s.c.	_	_	O
68	or	_	_	O
69	best	_	_	O
70	supportive	_	_	O
71	care	_	_	O
72	(	_	_	O
73	BSC	_	_	O
74	)	_	_	O
75	to	_	_	O
76	compare	_	_	O
77	the	_	_	O
78	effects	_	_	O
79	on	_	_	O
80	transfusion	_	_	O
81	use	_	_	O
82	,	_	_	O
83	hematologic	_	_	O
84	response	_	_	O
85	,	_	_	O
86	and	_	_	O
87	QOL	_	_	O
88	(	_	_	O
89	measured	_	_	O
90	by	_	_	O
91	the	_	_	O
92	Functional	_	_	O
93	Assessment	_	_	O
94	of	_	_	O
95	Cancer	_	_	O
96	Therapy-Anemia	_	_	O
97	[	_	_	O
98	FACT-An	_	_	O
99	]	_	_	O
100	and	_	_	O
101	Cancer	_	_	O
102	Linear	_	_	O
103	Analogue	_	_	O
104	Scale	_	_	O
105	[	_	_	O
106	CLAS	_	_	O
107	]	_	_	O
108	)	_	_	O
109	.	_	_	O

110	The	_	_	O
111	QOL	_	_	O
112	data	_	_	O
113	from	_	_	O
114	this	_	_	O
115	previously	_	_	O
116	reported	_	_	O
117	trial	_	_	O
118	were	_	_	O
119	reanalyzed	_	_	O
120	here	_	_	O
121	relative	_	_	O
122	to	_	_	O
123	population	_	_	O
124	norms	_	_	O
125	.	_	_	O

126	Mean	_	_	O
127	baseline	_	_	O
128	QOL	_	_	O
129	scores	_	_	O
130	were	_	_	O
131	similar	_	_	O
132	between	_	_	O
133	groups	_	_	O
134	.	_	_	O

135	At	_	_	O
136	study	_	_	O
137	completion	_	_	O
138	,	_	_	O
139	mean	_	_	O
140	CLAS	_	_	O
141	,	_	_	O
142	FACT-An	_	_	O
143	,	_	_	O
144	FACT-An	_	_	O
145	Anemia	_	_	O
146	subscale	_	_	O
147	,	_	_	O
148	and	_	_	O
149	FACT-An	_	_	O
150	Fatigue	_	_	O
151	subscale	_	_	O
152	scores	_	_	O
153	were	_	_	O
154	significantly	_	_	O
155	higher	_	_	O
156	for	_	_	O
157	patients	_	_	O
158	given	_	_	O
159	epoetin	_	_	O
160	alfa	_	_	O
161	than	_	_	O
162	for	_	_	O
163	those	_	_	O
164	treated	_	_	O
165	with	_	_	O
166	BSC	_	_	O
167	.	_	_	O

168	Compared	_	_	O
169	with	_	_	O
170	population	_	_	O
171	norms	_	_	O
172	,	_	_	O
173	both	_	_	O
174	groups	_	_	O
175	had	_	_	O
176	impaired	_	_	O
177	QOL	_	_	O
178	at	_	_	O
179	baseline	_	_	O
180	.	_	_	O

181	Differences	_	_	B-Premise
182	in	_	_	I-Premise
183	mean	_	_	I-Premise
184	QOL	_	_	I-Premise
185	change	_	_	I-Premise
186	scores	_	_	I-Premise
187	from	_	_	I-Premise
188	baseline	_	_	I-Premise
189	to	_	_	I-Premise
190	study	_	_	I-Premise
191	end	_	_	I-Premise
192	for	_	_	I-Premise
193	epoetin	_	_	I-Premise
194	alfa	_	_	I-Premise
195	versus	_	_	I-Premise
196	BSC	_	_	I-Premise
197	were	_	_	I-Premise
198	3.17	_	_	I-Premise
199	points	_	_	I-Premise
200	for	_	_	I-Premise
201	the	_	_	I-Premise
202	FACT-General	_	_	I-Premise
203	Total	_	_	I-Premise
204	,	_	_	I-Premise
205	9.90	_	_	I-Premise
206	for	_	_	I-Premise
207	the	_	_	I-Premise
208	FACT-An	_	_	I-Premise
209	Fatigue	_	_	I-Premise
210	subscale	_	_	I-Premise
211	,	_	_	I-Premise
212	and	_	_	I-Premise
213	7.30	_	_	I-Premise
214	for	_	_	I-Premise
215	the	_	_	I-Premise
216	FACT-An	_	_	I-Premise
217	Anemia	_	_	I-Premise
218	subscale	_	_	I-Premise
219	.	_	_	I-Premise

220	This	_	_	B-Premise
221	was	_	_	I-Premise
222	equivalent	_	_	I-Premise
223	to	_	_	I-Premise
224	corrections	_	_	I-Premise
225	in	_	_	I-Premise
226	QOL	_	_	I-Premise
227	deficits	_	_	I-Premise
228	attributable	_	_	I-Premise
229	to	_	_	I-Premise
230	epoetin	_	_	I-Premise
231	alfa	_	_	I-Premise
232	of	_	_	I-Premise
233	97.3	_	_	I-Premise
234	%	_	_	I-Premise
235	,	_	_	I-Premise
236	40.7	_	_	I-Premise
237	%	_	_	I-Premise
238	,	_	_	I-Premise
239	and	_	_	I-Premise
240	38.0	_	_	I-Premise
241	%	_	_	I-Premise
242	for	_	_	I-Premise
243	the	_	_	I-Premise
244	FACT-General	_	_	I-Premise
245	Total	_	_	I-Premise
246	,	_	_	I-Premise
247	FACT-An	_	_	I-Premise
248	Fatigue	_	_	I-Premise
249	,	_	_	I-Premise
250	and	_	_	I-Premise
251	FACT-An	_	_	I-Premise
252	Anemia	_	_	I-Premise
253	subscale	_	_	I-Premise
254	scores	_	_	I-Premise
255	,	_	_	I-Premise
256	respectively	_	_	I-Premise
257	,	_	_	I-Premise
258	versus	_	_	I-Premise
259	BSC	_	_	I-Premise
260	.	_	_	I-Premise

261	A	_	_	B-Premise
262	somewhat	_	_	I-Premise
263	greater	_	_	I-Premise
264	QOL	_	_	I-Premise
265	benefit	_	_	I-Premise
266	was	_	_	I-Premise
267	observed	_	_	I-Premise
268	for	_	_	I-Premise
269	the	_	_	I-Premise
270	FACT-An	_	_	I-Premise
271	Fatigue	_	_	I-Premise
272	and	_	_	I-Premise
273	FACT-An	_	_	I-Premise
274	Anemia	_	_	I-Premise
275	subscales	_	_	I-Premise
276	in	_	_	I-Premise
277	the	_	_	I-Premise
278	subset	_	_	I-Premise
279	of	_	_	I-Premise
280	patients	_	_	I-Premise
281	with	_	_	I-Premise
282	baseline	_	_	I-Premise
283	Hb	_	_	I-Premise
284	levels	_	_	I-Premise
285	>	_	_	I-Premise
286	10.5	_	_	I-Premise
287	g/dl	_	_	I-Premise
288	.	_	_	I-Premise

289	Patients	_	_	B-Premise
290	in	_	_	I-Premise
291	this	_	_	I-Premise
292	study	_	_	I-Premise
293	had	_	_	I-Premise
294	impaired	_	_	I-Premise
295	QOL	_	_	I-Premise
296	compared	_	_	I-Premise
297	with	_	_	I-Premise
298	population	_	_	I-Premise
299	norms	_	_	I-Premise
300	.	_	_	I-Premise

301	Early	_	_	B-Claim
302	treatment	_	_	I-Claim
303	with	_	_	I-Claim
304	epoetin	_	_	I-Claim
305	alfa	_	_	I-Claim
306	to	_	_	I-Claim
307	correct	_	_	I-Claim
308	anemia	_	_	I-Claim
309	improved	_	_	I-Claim
310	QOL	_	_	I-Claim
311	in	_	_	I-Claim
312	a	_	_	I-Claim
313	statistically	_	_	I-Claim
314	significant	_	_	I-Claim
315	and	_	_	I-Claim
316	clinically	_	_	I-Claim
317	meaningful	_	_	I-Claim
318	way	_	_	I-Claim
319	,	_	_	I-Claim
320	and	_	_	I-Claim
321	improvements	_	_	I-Claim
322	were	_	_	I-Claim
323	greater	_	_	I-Claim
324	in	_	_	I-Claim
325	patients	_	_	I-Claim
326	with	_	_	I-Claim
327	baseline	_	_	I-Claim
328	Hb	_	_	I-Claim
329	levels	_	_	I-Claim
330	>	_	_	I-Claim
331	10.5	_	_	I-Claim
332	g/dl	_	_	I-Claim
333	.	_	_	I-Claim


0	This	_	_	O
1	analysis	_	_	O
2	of	_	_	O
3	the	_	_	O
4	results	_	_	O
5	of	_	_	O
6	a	_	_	O
7	randomized	_	_	O
8	,	_	_	O
9	controlled	_	_	O
10	trial	_	_	O
11	evaluating	_	_	O
12	the	_	_	O
13	effects	_	_	O
14	of	_	_	O
15	epoetin	_	_	O
16	alfa	_	_	O
17	(	_	_	O
18	EPO	_	_	O
19	)	_	_	O
20	therapy	_	_	O
21	on	_	_	O
22	transfusion	_	_	O
23	requirements	_	_	O
24	,	_	_	O
25	hemoglobin	_	_	O
26	(	_	_	O
27	Hb	_	_	O
28	)	_	_	O
29	,	_	_	O
30	and	_	_	O
31	quality	_	_	O
32	of	_	_	O
33	life	_	_	O
34	(	_	_	O
35	QOL	_	_	O
36	)	_	_	O
37	in	_	_	O
38	patients	_	_	O
39	with	_	_	O
40	cancer	_	_	O
41	receiving	_	_	O
42	platinum-based	_	_	O
43	chemotherapy	_	_	O
44	was	_	_	O
45	conducted	_	_	O
46	to	_	_	O
47	evaluate	_	_	O
48	the	_	_	O
49	effect	_	_	O
50	of	_	_	O
51	initial	_	_	O
52	Hb	_	_	O
53	level	_	_	O
54	on	_	_	O
55	study	_	_	O
56	outcomes	_	_	O
57	.	_	_	O

58	Patients	_	_	O
59	with	_	_	O
60	Hb	_	_	O
61	levels	_	_	O
62	<	_	_	O
63	or	_	_	O
64	=12.1	_	_	O
65	g/dl	_	_	O
66	were	_	_	O
67	randomized	_	_	O
68	2:1	_	_	O
69	to	_	_	O
70	receive	_	_	O
71	EPO	_	_	O
72	,	_	_	O
73	10,000	_	_	O
74	U	_	_	O
75	three	_	_	O
76	times	_	_	O
77	weekly	_	_	O
78	s.c.	_	_	O
79	or	_	_	O
80	best	_	_	O
81	supportive	_	_	O
82	care	_	_	O
83	(	_	_	O
84	BSC	_	_	O
85	)	_	_	O
86	until	_	_	O
87	4	_	_	O
88	weeks	_	_	O
89	after	_	_	O
90	their	_	_	O
91	last	_	_	O
92	chemotherapy	_	_	O
93	cycle	_	_	O
94	.	_	_	O

95	For	_	_	O
96	this	_	_	O
97	analysis	_	_	O
98	,	_	_	O
99	patients	_	_	O
100	were	_	_	O
101	stratified	_	_	O
102	by	_	_	O
103	baseline	_	_	O
104	Hb	_	_	O
105	level	_	_	O
106	(	_	_	O
107	<	_	_	O
108	or	_	_	O
109	=9.7	_	_	O
110	g/dl	_	_	O
111	,	_	_	O
112	>	_	_	O
113	9.7	_	_	O
114	g/dl	_	_	O
115	to	_	_	O
116	<	_	_	O
117	or	_	_	O
118	=10.5	_	_	O
119	g/dl	_	_	O
120	,	_	_	O
121	>	_	_	O
122	10.5	_	_	O
123	g/dl	_	_	O
124	to	_	_	O
125	<	_	_	O
126	or	_	_	O
127	=11.3	_	_	O
128	g/dl	_	_	O
129	,	_	_	O
130	and	_	_	O
131	>	_	_	O
132	11.3	_	_	O
133	g/dl	_	_	O
134	to	_	_	O
135	<	_	_	O
136	or	_	_	O
137	=12.1	_	_	O
138	g/dl	_	_	O
139	)	_	_	O
140	,	_	_	O
141	and	_	_	O
142	study	_	_	O
143	results	_	_	O
144	were	_	_	O
145	reanalyzed	_	_	O
146	.	_	_	O

147	Significantly	_	_	B-Premise
148	fewer	_	_	I-Premise
149	EPO	_	_	I-Premise
150	patients	_	_	I-Premise
151	than	_	_	I-Premise
152	BSC	_	_	I-Premise
153	patients	_	_	I-Premise
154	with	_	_	I-Premise
155	initial	_	_	I-Premise
156	Hb	_	_	I-Premise
157	levels	_	_	I-Premise
158	>	_	_	I-Premise
159	9.7	_	_	I-Premise
160	g/dl	_	_	I-Premise
161	to	_	_	I-Premise
162	<	_	_	I-Premise
163	or	_	_	I-Premise
164	=12.1	_	_	I-Premise
165	g/dl	_	_	I-Premise
166	required	_	_	I-Premise
167	transfusions	_	_	I-Premise
168	.	_	_	I-Premise

169	EPO	_	_	B-Premise
170	maintained	_	_	I-Premise
171	Hb	_	_	I-Premise
172	levels	_	_	I-Premise
173	throughout	_	_	I-Premise
174	the	_	_	I-Premise
175	study	_	_	I-Premise
176	for	_	_	I-Premise
177	patients	_	_	I-Premise
178	with	_	_	I-Premise
179	Hb	_	_	I-Premise
180	levels	_	_	I-Premise
181	>	_	_	I-Premise
182	11.3	_	_	I-Premise
183	g/dl	_	_	I-Premise
184	to	_	_	I-Premise
185	<	_	_	I-Premise
186	or	_	_	I-Premise
187	=12.1	_	_	I-Premise
188	g/dl	_	_	I-Premise
189	,	_	_	I-Premise
190	compared	_	_	I-Premise
191	with	_	_	I-Premise
192	a	_	_	I-Premise
193	decrease	_	_	I-Premise
194	with	_	_	I-Premise
195	BSC	_	_	I-Premise
196	.	_	_	I-Premise

197	For	_	_	B-Premise
198	patients	_	_	I-Premise
199	with	_	_	I-Premise
200	baseline	_	_	I-Premise
201	Hb	_	_	I-Premise
202	levels	_	_	I-Premise
203	>	_	_	I-Premise
204	10.5	_	_	I-Premise
205	g/dl	_	_	I-Premise
206	,	_	_	I-Premise
207	for	_	_	I-Premise
208	whom	_	_	I-Premise
209	the	_	_	I-Premise
210	mean	_	_	I-Premise
211	changes	_	_	I-Premise
212	from	_	_	I-Premise
213	baseline	_	_	I-Premise
214	to	_	_	I-Premise
215	last	_	_	I-Premise
216	assessment	_	_	I-Premise
217	were	_	_	I-Premise
218	measured	_	_	I-Premise
219	by	_	_	I-Premise
220	the	_	_	I-Premise
221	Cancer	_	_	I-Premise
222	Linear	_	_	I-Premise
223	Analogue	_	_	I-Premise
224	Scale	_	_	I-Premise
225	assessments	_	_	I-Premise
226	of	_	_	I-Premise
227	energy	_	_	I-Premise
228	and	_	_	I-Premise
229	overall	_	_	I-Premise
230	QOL	_	_	I-Premise
231	as	_	_	I-Premise
232	well	_	_	I-Premise
233	as	_	_	I-Premise
234	by	_	_	I-Premise
235	the	_	_	I-Premise
236	Functional	_	_	I-Premise
237	Assessment	_	_	I-Premise
238	of	_	_	I-Premise
239	Cancer	_	_	I-Premise
240	Therapy	_	_	I-Premise
241	(	_	_	I-Premise
242	FACT	_	_	I-Premise
243	)	_	_	I-Premise
244	-Fatigue	_	_	I-Premise
245	and	_	_	I-Premise
246	FACT-An	_	_	I-Premise
247	Anemia	_	_	I-Premise
248	subscale	_	_	I-Premise
249	,	_	_	I-Premise
250	QOL	_	_	I-Premise
251	scores	_	_	I-Premise
252	were	_	_	I-Premise
253	significantly	_	_	I-Premise
254	greater	_	_	I-Premise
255	with	_	_	I-Premise
256	EPO	_	_	I-Premise
257	than	_	_	I-Premise
258	with	_	_	I-Premise
259	BSC	_	_	I-Premise
260	.	_	_	I-Premise

261	QOL	_	_	B-Premise
262	declined	_	_	I-Premise
263	in	_	_	I-Premise
264	patients	_	_	I-Premise
265	receiving	_	_	I-Premise
266	BSC	_	_	I-Premise
267	,	_	_	I-Premise
268	and	_	_	O
269	the	_	_	B-Premise
270	mean	_	_	I-Premise
271	decreases	_	_	I-Premise
272	in	_	_	I-Premise
273	QOL	_	_	I-Premise
274	scores	_	_	I-Premise
275	were	_	_	I-Premise
276	greater	_	_	I-Premise
277	for	_	_	I-Premise
278	BSC	_	_	I-Premise
279	patients	_	_	I-Premise
280	with	_	_	I-Premise
281	baseline	_	_	I-Premise
282	Hb	_	_	I-Premise
283	levels	_	_	I-Premise
284	>	_	_	I-Premise
285	10.5	_	_	I-Premise
286	g/dl	_	_	I-Premise
287	,	_	_	I-Premise
288	compared	_	_	I-Premise
289	with	_	_	I-Premise
290	the	_	_	I-Premise
291	overall	_	_	I-Premise
292	BSC	_	_	I-Premise
293	group	_	_	I-Premise
294	.	_	_	I-Premise

295	In	_	_	B-Claim
296	patients	_	_	I-Claim
297	with	_	_	I-Claim
298	cancer	_	_	I-Claim
299	receiving	_	_	I-Claim
300	platinum-based	_	_	I-Claim
301	chemotherapy	_	_	I-Claim
302	and	_	_	I-Claim
303	with	_	_	I-Claim
304	baseline	_	_	I-Claim
305	Hb	_	_	I-Claim
306	levels	_	_	I-Claim
307	>	_	_	I-Claim
308	10.5	_	_	I-Claim
309	g/dl	_	_	I-Claim
310	,	_	_	I-Claim
311	early	_	_	I-Claim
312	intervention	_	_	I-Claim
313	with	_	_	I-Claim
314	EPO	_	_	I-Claim
315	reduces	_	_	I-Claim
316	transfusions	_	_	I-Claim
317	,	_	_	I-Claim
318	maintains	_	_	I-Claim
319	Hb	_	_	I-Claim
320	level	_	_	I-Claim
321	,	_	_	I-Claim
322	and	_	_	I-Claim
323	maintains	_	_	I-Claim
324	or	_	_	I-Claim
325	improves	_	_	I-Claim
326	QOL	_	_	I-Claim
327	.	_	_	I-Claim

328	This	_	_	B-Claim
329	study	_	_	I-Claim
330	supports	_	_	I-Claim
331	the	_	_	I-Claim
332	positive	_	_	I-Claim
333	effects	_	_	I-Claim
334	of	_	_	I-Claim
335	early	_	_	I-Claim
336	intervention	_	_	I-Claim
337	when	_	_	I-Claim
338	analyzed	_	_	I-Claim
339	according	_	_	I-Claim
340	to	_	_	I-Claim
341	initial	_	_	I-Claim
342	Hb	_	_	I-Claim
343	value	_	_	I-Claim
344	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	difference	_	_	O
4	of	_	_	O
5	efficacy	_	_	O
6	,	_	_	O
7	side-effects	_	_	O
8	and	_	_	O
9	quality	_	_	O
10	of	_	_	O
11	life	_	_	O
12	in	_	_	O
13	advanced	_	_	O
14	non-small-cell	_	_	O
15	lung	_	_	O
16	cancer	_	_	O
17	(	_	_	O
18	NSCLC	_	_	O
19	)	_	_	O
20	patients	_	_	O
21	treated	_	_	O
22	with	_	_	O
23	oxaliplatin	_	_	O
24	plus	_	_	O
25	vinorelbine	_	_	O
26	or	_	_	O
27	cisplatin	_	_	O
28	plus	_	_	O
29	vinorelbine	_	_	O
30	.	_	_	O

31	Eligible	_	_	O
32	patients	_	_	O
33	were	_	_	O
34	randomly	_	_	O
35	assigned	_	_	O
36	to	_	_	O
37	NL	_	_	O
38	(	_	_	O
39	oxaliplatin	_	_	O
40	+	_	_	O
41	vinorelbine	_	_	O
42	)	_	_	O
43	group	_	_	O
44	and	_	_	O
45	NP	_	_	O
46	(	_	_	O
47	cisplatin	_	_	O
48	+	_	_	O
49	vinorelbine	_	_	O
50	)	_	_	O
51	group	_	_	O
52	in	_	_	O
53	a	_	_	O
54	2:1	_	_	O
55	ratio	_	_	O
56	.	_	_	O

57	In	_	_	O
58	the	_	_	O
59	NL	_	_	O
60	group	_	_	O
61	,	_	_	O
62	70	_	_	O
63	evaluable	_	_	O
64	cases	_	_	O
65	were	_	_	O
66	treated	_	_	O
67	with	_	_	O
68	oxaliplatin	_	_	O
69	130	_	_	O
70	mg/m	_	_	O
71	(	_	_	O
72	2	_	_	O
73	)	_	_	O
74	i.v	_	_	O
75	.	_	_	O

76	on	_	_	O
77	day	_	_	O
78	2	_	_	O
79	,	_	_	O
80	and	_	_	O
81	vinorelbine	_	_	O
82	25	_	_	O
83	mg/m	_	_	O
84	(	_	_	O
85	2	_	_	O
86	)	_	_	O
87	i.v	_	_	O
88	.	_	_	O

89	on	_	_	O
90	days	_	_	O
91	1	_	_	O
92	and	_	_	O
93	8	_	_	O
94	in	_	_	O
95	21	_	_	O
96	days	_	_	O
97	per	_	_	O
98	cycle	_	_	O
99	.	_	_	O

100	In	_	_	O
101	the	_	_	O
102	NP	_	_	O
103	group	_	_	O
104	,	_	_	O
105	32	_	_	O
106	evaluable	_	_	O
107	cases	_	_	O
108	were	_	_	O
109	treated	_	_	O
110	with	_	_	O
111	cisplatin	_	_	O
112	80	_	_	O
113	mg/m	_	_	O
114	(	_	_	O
115	2	_	_	O
116	)	_	_	O
117	i.v	_	_	O
118	.	_	_	O

119	divided	_	_	O
120	to	_	_	O
121	2	_	_	O
122	-	_	_	O
123	3	_	_	O
124	days	_	_	O
125	dosing	_	_	O
126	,	_	_	O
127	21	_	_	O
128	days	_	_	O
129	per	_	_	O
130	cycle	_	_	O
131	,	_	_	O
132	and	_	_	O
133	vinorelbine	_	_	O
134	administered	_	_	O
135	by	_	_	O
136	the	_	_	O
137	same	_	_	O
138	way	_	_	O
139	as	_	_	O
140	in	_	_	O
141	the	_	_	O
142	NL	_	_	O
143	group	_	_	O
144	.	_	_	O

145	The	_	_	O
146	response	_	_	O
147	rate	_	_	O
148	,	_	_	O
149	time	_	_	O
150	to	_	_	O
151	progression	_	_	O
152	(	_	_	O
153	TTP	_	_	O
154	)	_	_	O
155	,	_	_	O
156	one-year	_	_	O
157	survival	_	_	O
158	,	_	_	O
159	side-effects	_	_	O
160	and	_	_	O
161	the	_	_	O
162	quality	_	_	O
163	of	_	_	O
164	life	_	_	O
165	were	_	_	O
166	observed	_	_	O
167	.	_	_	O

168	The	_	_	B-Premise
169	response	_	_	I-Premise
170	rate	_	_	I-Premise
171	was	_	_	I-Premise
172	35.7	_	_	I-Premise
173	%	_	_	I-Premise
174	vs.	_	_	I-Premise
175	43.8	_	_	I-Premise
176	%	_	_	I-Premise
177	(	_	_	I-Premise
178	P	_	_	I-Premise
179	=	_	_	I-Premise
180	0.4	_	_	I-Premise
181	)	_	_	I-Premise
182	,	_	_	I-Premise
183	median	_	_	I-Premise
184	TTP	_	_	I-Premise
185	was	_	_	I-Premise
186	4.7	_	_	I-Premise
187	months	_	_	I-Premise
188	vs.	_	_	I-Premise
189	5.5	_	_	I-Premise
190	months	_	_	I-Premise
191	(	_	_	I-Premise
192	P	_	_	I-Premise
193	=	_	_	I-Premise
194	0.6	_	_	I-Premise
195	)	_	_	I-Premise
196	,	_	_	I-Premise
197	one-year	_	_	I-Premise
198	survival	_	_	I-Premise
199	rate	_	_	I-Premise
200	was	_	_	I-Premise
201	38.5	_	_	I-Premise
202	%	_	_	I-Premise
203	vs.	_	_	I-Premise
204	58.6	_	_	I-Premise
205	%	_	_	I-Premise
206	(	_	_	I-Premise
207	P	_	_	I-Premise
208	=	_	_	I-Premise
209	0.07	_	_	I-Premise
210	)	_	_	I-Premise
211	in	_	_	I-Premise
212	the	_	_	I-Premise
213	NL	_	_	I-Premise
214	and	_	_	I-Premise
215	NP	_	_	I-Premise
216	groups	_	_	I-Premise
217	,	_	_	I-Premise
218	respectively	_	_	I-Premise
219	.	_	_	I-Premise

220	Grade	_	_	B-Premise
221	I-II	_	_	I-Premise
222	neuro-sensory	_	_	I-Premise
223	toxicity	_	_	I-Premise
224	occurred	_	_	I-Premise
225	significantly	_	_	I-Premise
226	more	_	_	I-Premise
227	frequent	_	_	I-Premise
228	in	_	_	I-Premise
229	NL	_	_	I-Premise
230	group	_	_	I-Premise
231	than	_	_	I-Premise
232	in	_	_	I-Premise
233	NP	_	_	I-Premise
234	group	_	_	I-Premise
235	(	_	_	I-Premise
236	68.4	_	_	I-Premise
237	%	_	_	I-Premise
238	vs.	_	_	I-Premise
239	36.4	_	_	I-Premise
240	%	_	_	I-Premise
241	,	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	0.0017	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	However	_	_	B-Premise
248	,	_	_	I-Premise
249	Grade	_	_	I-Premise
250	I-II	_	_	I-Premise
251	granulocytopenia	_	_	I-Premise
252	was	_	_	I-Premise
253	significantly	_	_	I-Premise
254	less	_	_	I-Premise
255	occurred	_	_	I-Premise
256	in	_	_	I-Premise
257	NL	_	_	I-Premise
258	group	_	_	I-Premise
259	than	_	_	I-Premise
260	in	_	_	I-Premise
261	NP	_	_	I-Premise
262	group	_	_	I-Premise
263	(	_	_	I-Premise
264	49.4	_	_	I-Premise
265	%	_	_	I-Premise
266	vs.	_	_	I-Premise
267	70.6	_	_	I-Premise
268	%	_	_	I-Premise
269	,	_	_	I-Premise
270	P	_	_	I-Premise
271	=	_	_	I-Premise
272	0.037	_	_	I-Premise
273	)	_	_	I-Premise
274	.	_	_	I-Premise

275	There	_	_	B-Premise
276	was	_	_	I-Premise
277	no	_	_	I-Premise
278	statistically	_	_	I-Premise
279	difference	_	_	I-Premise
280	between	_	_	I-Premise
281	the	_	_	I-Premise
282	two	_	_	I-Premise
283	groups	_	_	I-Premise
284	regarding	_	_	I-Premise
285	quality	_	_	I-Premise
286	of	_	_	I-Premise
287	life	_	_	I-Premise
288	.	_	_	I-Premise

289	Due	_	_	B-Claim
290	to	_	_	I-Claim
291	good	_	_	I-Claim
292	efficacy	_	_	I-Claim
293	and	_	_	I-Claim
294	tolerability	_	_	I-Claim
295	,	_	_	I-Claim
296	the	_	_	I-Claim
297	NL	_	_	I-Claim
298	regimen	_	_	I-Claim
299	offered	_	_	I-Claim
300	a	_	_	I-Claim
301	new	_	_	I-Claim
302	candidate	_	_	I-Claim
303	for	_	_	I-Claim
304	treating	_	_	I-Claim
305	advanced	_	_	I-Claim
306	NSCLC	_	_	I-Claim
307	.	_	_	I-Claim


0	Morbidity	_	_	B-Claim
1	is	_	_	I-Claim
2	an	_	_	I-Claim
3	important	_	_	I-Claim
4	issue	_	_	I-Claim
5	in	_	_	I-Claim
6	cancer	_	_	I-Claim
7	research	_	_	I-Claim
8	.	_	_	I-Claim

9	The	_	_	B-Claim
10	observer-based	_	_	I-Claim
11	toxicity	_	_	I-Claim
12	scoring	_	_	I-Claim
13	system	_	_	I-Claim
14	used	_	_	I-Claim
15	by	_	_	I-Claim
16	DAHANCA	_	_	I-Claim
17	(	_	_	I-Claim
18	the	_	_	I-Claim
19	Danish	_	_	I-Claim
20	head	_	_	I-Claim
21	and	_	_	I-Claim
22	neck	_	_	I-Claim
23	cancer	_	_	I-Claim
24	study	_	_	I-Claim
25	group	_	_	I-Claim
26	)	_	_	I-Claim
27	has	_	_	I-Claim
28	proved	_	_	I-Claim
29	itself	_	_	I-Claim
30	sensitive	_	_	I-Claim
31	to	_	_	I-Claim
32	differences	_	_	I-Claim
33	in	_	_	I-Claim
34	toxicity	_	_	I-Claim
35	in	_	_	I-Claim
36	a	_	_	I-Claim
37	large	_	_	I-Claim
38	randomised	_	_	I-Claim
39	study	_	_	I-Claim
40	,	_	_	I-Claim
41	but	_	_	B-Claim
42	like	_	_	I-Claim
43	other	_	_	I-Claim
44	toxicity	_	_	I-Claim
45	scoring	_	_	I-Claim
46	systems	_	_	I-Claim
47	it	_	_	I-Claim
48	has	_	_	I-Claim
49	not	_	_	I-Claim
50	been	_	_	I-Claim
51	formally	_	_	I-Claim
52	validated	_	_	I-Claim
53	.	_	_	I-Claim

54	Conversely	_	_	O
55	,	_	_	O
56	the	_	_	O
57	EORTC	_	_	O
58	quality	_	_	O
59	of	_	_	O
60	life	_	_	O
61	questionnaire	_	_	O
62	(	_	_	O
63	QLQ	_	_	O
64	)	_	_	O
65	has	_	_	O
66	been	_	_	O
67	validated	_	_	O
68	as	_	_	O
69	a	_	_	O
70	tool	_	_	O
71	for	_	_	O
72	collecting	_	_	O
73	information	_	_	O
74	about	_	_	O
75	the	_	_	O
76	consequences	_	_	O
77	of	_	_	O
78	disease	_	_	O
79	and	_	_	O
80	treatment	_	_	O
81	on	_	_	O
82	the	_	_	O
83	well	_	_	O
84	being	_	_	O
85	of	_	_	O
86	cancer	_	_	O
87	patients	_	_	O
88	.	_	_	O

89	The	_	_	O
90	purpose	_	_	O
91	of	_	_	O
92	this	_	_	O
93	study	_	_	O
94	was	_	_	O
95	to	_	_	O
96	examine	_	_	O
97	the	_	_	O
98	relationship	_	_	O
99	between	_	_	O
100	the	_	_	O
101	two	_	_	O
102	methods	_	_	O
103	of	_	_	O
104	side	_	_	O
105	effect	_	_	O
106	recording	_	_	O
107	.	_	_	O

108	One	_	_	O
109	hundred	_	_	O
110	and	_	_	O
111	sixteen	_	_	O
112	recurrence	_	_	O
113	free	_	_	O
114	patients	_	_	O
115	with	_	_	O
116	laryngeal	_	_	O
117	(	_	_	O
118	n=44	_	_	O
119	)	_	_	O
120	,	_	_	O
121	pharyngeal	_	_	O
122	(	_	_	O
123	n=34	_	_	O
124	)	_	_	O
125	and	_	_	O
126	oral	_	_	O
127	cavity	_	_	O
128	(	_	_	O
129	n=38	_	_	O
130	)	_	_	O
131	cancer	_	_	O
132	attending	_	_	O
133	follow-up	_	_	O
134	after	_	_	O
135	radiotherapy	_	_	O
136	(	_	_	O
137	n=83	_	_	O
138	)	_	_	O
139	or	_	_	O
140	surgery	_	_	O
141	(	_	_	O
142	n=33	_	_	O
143	)	_	_	O
144	completed	_	_	O
145	EORTC	_	_	O
146	C30	_	_	O
147	,	_	_	O
148	the	_	_	O
149	core	_	_	O
150	questionnaire	_	_	O
151	concerning	_	_	O
152	general	_	_	O
153	symptoms	_	_	O
154	and	_	_	O
155	function	_	_	O
156	and	_	_	O
157	EORTC	_	_	O
158	H	_	_	O
159	&	_	_	O
160	amp	_	_	O
161	;	_	_	O
162	N35	_	_	O
163	the	_	_	O
164	head	_	_	O
165	and	_	_	O
166	neck	_	_	O
167	specific	_	_	O
168	questionnaire	_	_	O
169	.	_	_	O

170	The	_	_	O
171	attending	_	_	O
172	physicians	_	_	O
173	in	_	_	O
174	the	_	_	O
175	follow-up	_	_	O
176	clinic	_	_	O
177	evaluated	_	_	O
178	and	_	_	O
179	recorded	_	_	O
180	DAHANCA	_	_	O
181	toxicity	_	_	O
182	scores	_	_	O
183	on	_	_	O
184	the	_	_	O
185	same	_	_	O
186	patients	_	_	O
187	.	_	_	O

188	The	_	_	B-Premise
189	DAHANCA	_	_	I-Premise
190	toxicity	_	_	I-Premise
191	scoring	_	_	I-Premise
192	system	_	_	I-Premise
193	and	_	_	I-Premise
194	the	_	_	I-Premise
195	EORTC	_	_	I-Premise
196	QLQ	_	_	I-Premise
197	correlated	_	_	I-Premise
198	with	_	_	I-Premise
199	several	_	_	I-Premise
200	clinical	_	_	I-Premise
201	endpoints	_	_	I-Premise
202	.	_	_	I-Premise

203	The	_	_	B-Premise
204	conceptually	_	_	I-Premise
205	similar	_	_	I-Premise
206	endpoints	_	_	I-Premise
207	of	_	_	I-Premise
208	the	_	_	I-Premise
209	two	_	_	I-Premise
210	methods	_	_	I-Premise
211	correlated	_	_	I-Premise
212	significantly	_	_	I-Premise
213	.	_	_	I-Premise

214	The	_	_	B-Premise
215	objective	_	_	I-Premise
216	endpoints	_	_	I-Premise
217	of	_	_	I-Premise
218	the	_	_	I-Premise
219	DAHANCA	_	_	I-Premise
220	scoring	_	_	I-Premise
221	system	_	_	I-Premise
222	were	_	_	I-Premise
223	only	_	_	I-Premise
224	correlated	_	_	I-Premise
225	with	_	_	I-Premise
226	quality	_	_	I-Premise
227	of	_	_	I-Premise
228	life	_	_	I-Premise
229	endpoints	_	_	I-Premise
230	to	_	_	I-Premise
231	a	_	_	I-Premise
232	very	_	_	I-Premise
233	low	_	_	I-Premise
234	degree	_	_	I-Premise
235	.	_	_	I-Premise

236	The	_	_	B-Premise
237	DAHANCA	_	_	I-Premise
238	toxicity	_	_	I-Premise
239	scores	_	_	I-Premise
240	had	_	_	I-Premise
241	a	_	_	I-Premise
242	low	_	_	I-Premise
243	sensitivity	_	_	I-Premise
244	(	_	_	I-Premise
245	0.48-0.74	_	_	I-Premise
246	)	_	_	I-Premise
247	in	_	_	I-Premise
248	detecting	_	_	I-Premise
249	equivalent	_	_	I-Premise
250	subjective	_	_	I-Premise
251	complaints	_	_	I-Premise
252	from	_	_	I-Premise
253	the	_	_	I-Premise
254	questionnaires	_	_	I-Premise
255	and	_	_	I-Premise
256	the	_	_	I-Premise
257	observer-based	_	_	I-Premise
258	scoring	_	_	I-Premise
259	system	_	_	I-Premise
260	severely	_	_	I-Premise
261	underestimated	_	_	I-Premise
262	patient	_	_	I-Premise
263	complaints	_	_	I-Premise
264	.	_	_	I-Premise

265	A	_	_	B-Premise
266	specific	_	_	I-Premise
267	patient	_	_	I-Premise
268	group	_	_	I-Premise
269	where	_	_	I-Premise
270	the	_	_	I-Premise
271	DAHANCA	_	_	I-Premise
272	score	_	_	I-Premise
273	had	_	_	I-Premise
274	a	_	_	I-Premise
275	higher	_	_	I-Premise
276	tendency	_	_	I-Premise
277	to	_	_	I-Premise
278	fail	_	_	I-Premise
279	could	_	_	I-Premise
280	not	_	_	I-Premise
281	be	_	_	I-Premise
282	detected	_	_	I-Premise
283	.	_	_	I-Premise

284	The	_	_	B-Claim
285	DAHANCA	_	_	I-Claim
286	toxicity	_	_	I-Claim
287	score	_	_	I-Claim
288	is	_	_	I-Claim
289	an	_	_	I-Claim
290	effective	_	_	I-Claim
291	instrument	_	_	I-Claim
292	in	_	_	I-Claim
293	assessing	_	_	I-Claim
294	objective	_	_	I-Claim
295	treatment	_	_	I-Claim
296	induced	_	_	I-Claim
297	toxicity	_	_	I-Claim
298	in	_	_	I-Claim
299	head	_	_	I-Claim
300	and	_	_	I-Claim
301	neck	_	_	I-Claim
302	cancer	_	_	I-Claim
303	patients	_	_	I-Claim
304	but	_	_	I-Claim
305	insensitive	_	_	I-Claim
306	and	_	_	I-Claim
307	non-specific	_	_	I-Claim
308	with	_	_	I-Claim
309	regard	_	_	I-Claim
310	to	_	_	I-Claim
311	patient	_	_	I-Claim
312	assessed	_	_	I-Claim
313	subjective	_	_	I-Claim
314	endpoints	_	_	I-Claim
315	.	_	_	I-Claim

316	This	_	_	B-Claim
317	weakness	_	_	I-Claim
318	seems	_	_	I-Claim
319	inherent	_	_	I-Claim
320	in	_	_	I-Claim
321	an	_	_	I-Claim
322	observer-based	_	_	I-Claim
323	scoring	_	_	I-Claim
324	system	_	_	I-Claim
325	,	_	_	I-Claim
326	and	_	_	I-Claim
327	will	_	_	I-Claim
328	probably	_	_	I-Claim
329	also	_	_	I-Claim
330	apply	_	_	I-Claim
331	to	_	_	I-Claim
332	newer	_	_	I-Claim
333	ones	_	_	I-Claim
334	like	_	_	I-Claim
335	CTCAE	_	_	I-Claim
336	3.0	_	_	I-Claim
337	.	_	_	I-Claim


0	DPPE	_	_	B-Claim
1	(	_	_	I-Claim
2	tesmilifene	_	_	I-Claim
3	)	_	_	I-Claim
4	plus	_	_	I-Claim
5	doxorubicin	_	_	I-Claim
6	(	_	_	I-Claim
7	DOX	_	_	I-Claim
8	)	_	_	I-Claim
9	demonstrated	_	_	I-Claim
10	a	_	_	I-Claim
11	significant	_	_	I-Claim
12	improvement	_	_	I-Claim
13	in	_	_	I-Claim
14	survival	_	_	I-Claim
15	versus	_	_	I-Claim
16	DOX	_	_	I-Claim
17	in	_	_	I-Claim
18	a	_	_	I-Claim
19	phase	_	_	I-Claim
20	III	_	_	I-Claim
21	clinical	_	_	I-Claim
22	trial	_	_	I-Claim
23	in	_	_	I-Claim
24	advanced	_	_	I-Claim
25	breast	_	_	I-Claim
26	cancer	_	_	I-Claim
27	.	_	_	I-Claim

28	However	_	_	B-Premise
29	,	_	_	I-Premise
30	DPPE	_	_	I-Premise
31	is	_	_	I-Premise
32	associated	_	_	I-Premise
33	with	_	_	I-Premise
34	unusual	_	_	I-Premise
35	toxicity	_	_	I-Premise
36	in	_	_	I-Premise
37	the	_	_	I-Premise
38	form	_	_	I-Premise
39	of	_	_	I-Premise
40	hallucinations	_	_	I-Premise
41	,	_	_	I-Premise
42	nausea	_	_	I-Premise
43	and	_	_	I-Premise
44	vomiting	_	_	I-Premise
45	which	_	_	I-Premise
46	were	_	_	I-Premise
47	anticipated	_	_	I-Premise
48	to	_	_	I-Premise
49	impact	_	_	I-Premise
50	on	_	_	I-Premise
51	short-term	_	_	I-Premise
52	quality	_	_	I-Premise
53	of	_	_	I-Premise
54	life	_	_	I-Premise
55	(	_	_	I-Premise
56	QOL	_	_	I-Premise
57	)	_	_	I-Premise
58	.	_	_	I-Premise

59	Standard	_	_	O
60	National	_	_	O
61	Cancer	_	_	O
62	Institute	_	_	O
63	of	_	_	O
64	Canada	_	_	O
65	Clinical	_	_	O
66	Trials	_	_	O
67	Group	_	_	O
68	(	_	_	O
69	NCIC	_	_	O
70	CTG	_	_	O
71	)	_	_	O
72	approaches	_	_	O
73	were	_	_	O
74	applied	_	_	O
75	as	_	_	O
76	the	_	_	O
77	primary	_	_	O
78	method	_	_	O
79	to	_	_	O
80	analyze	_	_	O
81	the	_	_	O
82	QOL	_	_	O
83	data	_	_	O
84	from	_	_	O
85	this	_	_	O
86	trial	_	_	O
87	.	_	_	O

88	This	_	_	O
89	includes	_	_	O
90	cross-sectional	_	_	O
91	comparisons	_	_	O
92	,	_	_	O
93	together	_	_	O
94	with	_	_	O
95	a	_	_	O
96	global	_	_	O
97	test	_	_	O
98	for	_	_	O
99	the	_	_	O
100	QOL	_	_	O
101	response	_	_	O
102	rate	_	_	O
103	.	_	_	O

104	Sensitivity	_	_	O
105	analyses	_	_	O
106	were	_	_	O
107	also	_	_	O
108	performed	_	_	O
109	for	_	_	O
110	selected	_	_	O
111	QOL	_	_	O
112	domains	_	_	O
113	and	_	_	O
114	items	_	_	O
115	,	_	_	O
116	using	_	_	O
117	other	_	_	O
118	types	_	_	O
119	of	_	_	O
120	summary	_	_	O
121	measures	_	_	O
122	and	_	_	O
123	statistics	_	_	O
124	.	_	_	O

125	Two	_	_	O
126	hundred	_	_	O
127	seventy	_	_	O
128	one	_	_	O
129	patients	_	_	O
130	(	_	_	O
131	89	_	_	O
132	%	_	_	O
133	of	_	_	O
134	randomized	_	_	O
135	)	_	_	O
136	submitted	_	_	O
137	the	_	_	O
138	baseline	_	_	O
139	QOL	_	_	O
140	questionnaires	_	_	O
141	and	_	_	O
142	were	_	_	O
143	included	_	_	O
144	in	_	_	O
145	the	_	_	O
146	QOL	_	_	O
147	analysis	_	_	O
148	.	_	_	O

149	No	_	_	B-Premise
150	statistically	_	_	I-Premise
151	significant	_	_	I-Premise
152	difference	_	_	I-Premise
153	in	_	_	I-Premise
154	QOL	_	_	I-Premise
155	response	_	_	I-Premise
156	between	_	_	I-Premise
157	treatment	_	_	I-Premise
158	arms	_	_	I-Premise
159	was	_	_	I-Premise
160	found	_	_	I-Premise
161	for	_	_	I-Premise
162	any	_	_	I-Premise
163	domain	_	_	I-Premise
164	or	_	_	I-Premise
165	item	_	_	I-Premise
166	except	_	_	I-Premise
167	nausea	_	_	I-Premise
168	and	_	_	I-Premise
169	vomiting	_	_	I-Premise
170	(	_	_	I-Premise
171	P	_	_	I-Premise
172	=	_	_	I-Premise
173	0.04	_	_	I-Premise
174	)	_	_	I-Premise
175	.	_	_	I-Premise

176	Cross-sectional	_	_	B-Premise
177	comparisons	_	_	I-Premise
178	showed	_	_	I-Premise
179	statistically	_	_	I-Premise
180	significant	_	_	I-Premise
181	differences	_	_	I-Premise
182	for	_	_	I-Premise
183	some	_	_	I-Premise
184	domains/items	_	_	I-Premise
185	at	_	_	I-Premise
186	specific	_	_	I-Premise
187	assessment	_	_	I-Premise
188	times	_	_	I-Premise
189	with	_	_	I-Premise
190	all	_	_	I-Premise
191	differences	_	_	I-Premise
192	favoring	_	_	I-Premise
193	the	_	_	I-Premise
194	DOX	_	_	I-Premise
195	alone	_	_	I-Premise
196	arm	_	_	I-Premise
197	.	_	_	I-Premise

198	Patients	_	_	B-Premise
199	on	_	_	I-Premise
200	DPPE/DOX	_	_	I-Premise
201	arm	_	_	I-Premise
202	were	_	_	I-Premise
203	significantly	_	_	I-Premise
204	worse	_	_	I-Premise
205	in	_	_	I-Premise
206	terms	_	_	I-Premise
207	of	_	_	I-Premise
208	average	_	_	I-Premise
209	and	_	_	I-Premise
210	median	_	_	I-Premise
211	pain	_	_	I-Premise
212	change	_	_	I-Premise
213	scores	_	_	I-Premise
214	.	_	_	I-Premise

215	Different	_	_	B-Claim
216	analyses	_	_	I-Claim
217	yielded	_	_	I-Claim
218	slightly	_	_	I-Claim
219	different	_	_	I-Claim
220	conclusions	_	_	I-Claim
221	but	_	_	O
222	,	_	_	O
223	in	_	_	B-Claim
224	general	_	_	I-Claim
225	,	_	_	I-Claim
226	the	_	_	I-Claim
227	QOL	_	_	I-Claim
228	analyses	_	_	I-Claim
229	were	_	_	I-Claim
230	concordant	_	_	I-Claim
231	and	_	_	I-Claim
232	showed	_	_	I-Claim
233	that	_	_	I-Claim
234	patients	_	_	I-Claim
235	on	_	_	I-Claim
236	DOX	_	_	I-Claim
237	alone	_	_	I-Claim
238	had	_	_	I-Claim
239	fewer	_	_	I-Claim
240	disease	_	_	I-Claim
241	and	_	_	I-Claim
242	treatment	_	_	I-Claim
243	related	_	_	I-Claim
244	adverse	_	_	I-Claim
245	events	_	_	I-Claim
246	and	_	_	I-Claim
247	better	_	_	I-Claim
248	QOL	_	_	I-Claim
249	.	_	_	I-Claim

250	Interestingly	_	_	B-Claim
251	,	_	_	I-Claim
252	the	_	_	I-Claim
253	QOL	_	_	I-Claim
254	response	_	_	I-Claim
255	analysis	_	_	I-Claim
256	also	_	_	I-Claim
257	showed	_	_	I-Claim
258	that	_	_	I-Claim
259	aggressive	_	_	I-Claim
260	premedication	_	_	I-Claim
261	regimens	_	_	I-Claim
262	appear	_	_	I-Claim
263	to	_	_	I-Claim
264	ameliorate	_	_	I-Claim
265	potential	_	_	I-Claim
266	negative	_	_	I-Claim
267	effects	_	_	I-Claim
268	of	_	_	I-Claim
269	DPPE	_	_	I-Claim
270	on	_	_	I-Claim
271	emesis	_	_	I-Claim
272	and	_	_	I-Claim
273	nausea	_	_	I-Claim
274	as	_	_	I-Claim
275	measured	_	_	I-Claim
276	by	_	_	I-Claim
277	patient	_	_	I-Claim
278	assessed	_	_	I-Claim
279	QOL	_	_	I-Claim
280	.	_	_	I-Claim


0	Chemotherapy	_	_	B-Claim
1	prolongs	_	_	I-Claim
2	survival	_	_	I-Claim
3	and	_	_	I-Claim
4	improves	_	_	I-Claim
5	quality	_	_	I-Claim
6	of	_	_	I-Claim
7	life	_	_	I-Claim
8	(	_	_	I-Claim
9	QOL	_	_	I-Claim
10	)	_	_	I-Claim
11	for	_	_	I-Claim
12	good	_	_	I-Claim
13	performance	_	_	I-Claim
14	status	_	_	I-Claim
15	(	_	_	I-Claim
16	PS	_	_	I-Claim
17	)	_	_	I-Claim
18	patients	_	_	I-Claim
19	with	_	_	I-Claim
20	advanced	_	_	I-Claim
21	non-small	_	_	I-Claim
22	cell	_	_	I-Claim
23	lung	_	_	I-Claim
24	cancer	_	_	I-Claim
25	(	_	_	I-Claim
26	NSCLC	_	_	I-Claim
27	)	_	_	I-Claim
28	.	_	_	I-Claim

29	Targeted	_	_	B-Claim
30	therapies	_	_	I-Claim
31	may	_	_	I-Claim
32	improve	_	_	I-Claim
33	chemotherapy	_	_	I-Claim
34	effectiveness	_	_	I-Claim
35	without	_	_	I-Claim
36	worsening	_	_	I-Claim
37	toxicity	_	_	I-Claim
38	.	_	_	I-Claim

39	SGN-15	_	_	O
40	is	_	_	O
41	an	_	_	O
42	antibody-drug	_	_	O
43	conjugate	_	_	O
44	(	_	_	O
45	ADC	_	_	O
46	)	_	_	O
47	,	_	_	O
48	consisting	_	_	O
49	of	_	_	O
50	a	_	_	O
51	chimeric	_	_	O
52	murine	_	_	O
53	monoclonal	_	_	O
54	antibody	_	_	O
55	recognizing	_	_	O
56	the	_	_	O
57	Lewis	_	_	O
58	Y	_	_	O
59	(	_	_	O
60	Le	_	_	O
61	(	_	_	O
62	y	_	_	O
63	)	_	_	O
64	)	_	_	O
65	antigen	_	_	O
66	,	_	_	O
67	conjugated	_	_	O
68	to	_	_	O
69	doxorubicin	_	_	O
70	.	_	_	O

71	Le	_	_	B-Claim
72	(	_	_	I-Claim
73	y	_	_	I-Claim
74	)	_	_	I-Claim
75	is	_	_	I-Claim
76	an	_	_	I-Claim
77	attractive	_	_	I-Claim
78	target	_	_	I-Claim
79	since	_	_	I-Claim
80	it	_	_	I-Claim
81	is	_	_	I-Claim
82	expressed	_	_	I-Claim
83	by	_	_	I-Claim
84	most	_	_	I-Claim
85	NSCLC	_	_	I-Claim
86	.	_	_	I-Claim

87	SGN-15	_	_	B-Premise
88	was	_	_	I-Premise
89	active	_	_	I-Premise
90	against	_	_	I-Premise
91	Le	_	_	I-Premise
92	(	_	_	I-Premise
93	y	_	_	I-Premise
94	)	_	_	I-Premise
95	-positive	_	_	I-Premise
96	tumors	_	_	I-Premise
97	in	_	_	I-Premise
98	early	_	_	I-Premise
99	phase	_	_	I-Premise
100	clinical	_	_	I-Premise
101	trials	_	_	I-Premise
102	and	_	_	I-Premise
103	was	_	_	I-Premise
104	synergistic	_	_	I-Premise
105	with	_	_	I-Premise
106	docetaxel	_	_	I-Premise
107	in	_	_	I-Premise
108	preclinical	_	_	I-Premise
109	experiments	_	_	I-Premise
110	.	_	_	I-Premise

111	This	_	_	O
112	Phase	_	_	O
113	II	_	_	O
114	,	_	_	O
115	open-label	_	_	O
116	study	_	_	O
117	was	_	_	O
118	conducted	_	_	O
119	to	_	_	O
120	confirm	_	_	O
121	the	_	_	O
122	activity	_	_	O
123	of	_	_	O
124	SGN-15	_	_	O
125	plus	_	_	O
126	docetaxel	_	_	O
127	in	_	_	O
128	previously	_	_	O
129	treated	_	_	O
130	NSCLC	_	_	O
131	patients	_	_	O
132	.	_	_	O

133	Sixty-two	_	_	O
134	patients	_	_	O
135	with	_	_	O
136	recurrent	_	_	O
137	or	_	_	O
138	metastatic	_	_	O
139	NSCLC	_	_	O
140	expressing	_	_	O
141	Le	_	_	O
142	(	_	_	O
143	y	_	_	O
144	)	_	_	O
145	,	_	_	O
146	one	_	_	O
147	or	_	_	O
148	two	_	_	O
149	prior	_	_	O
150	chemotherapy	_	_	O
151	regimens	_	_	O
152	,	_	_	O
153	and	_	_	O
154	PS	_	_	O
155	<	_	_	O
156	or	_	_	O
157	=2	_	_	O
158	were	_	_	O
159	randomized	_	_	O
160	2:1	_	_	O
161	to	_	_	O
162	receive	_	_	O
163	SGN-15	_	_	O
164	200	_	_	O
165	mg/m2/week	_	_	O
166	with	_	_	O
167	docetaxel	_	_	O
168	35	_	_	O
169	mg/m2/week	_	_	O
170	(	_	_	O
171	Arm	_	_	O
172	A	_	_	O
173	)	_	_	O
174	or	_	_	O
175	docetaxel	_	_	O
176	35	_	_	O
177	mg/m2/week	_	_	O
178	alone	_	_	O
179	(	_	_	O
180	Arm	_	_	O
181	B	_	_	O
182	)	_	_	O
183	for	_	_	O
184	6	_	_	O
185	of	_	_	O
186	8	_	_	O
187	weeks	_	_	O
188	.	_	_	O

189	Intrapatient	_	_	O
190	dose-escalation	_	_	O
191	of	_	_	O
192	SGN-15	_	_	O
193	to	_	_	O
194	350	_	_	O
195	mg/m2	_	_	O
196	was	_	_	O
197	permitted	_	_	O
198	in	_	_	O
199	the	_	_	O
200	second	_	_	O
201	half	_	_	O
202	of	_	_	O
203	the	_	_	O
204	study	_	_	O
205	.	_	_	O

206	Endpoints	_	_	O
207	were	_	_	O
208	survival	_	_	O
209	,	_	_	O
210	safety	_	_	O
211	,	_	_	O
212	efficacy	_	_	O
213	,	_	_	O
214	and	_	_	O
215	quality	_	_	O
216	of	_	_	O
217	life	_	_	O
218	.	_	_	O

219	Forty	_	_	O
220	patients	_	_	O
221	on	_	_	O
222	Arm	_	_	O
223	A	_	_	O
224	and	_	_	O
225	19	_	_	O
226	on	_	_	O
227	Arm	_	_	O
228	B	_	_	O
229	received	_	_	O
230	at	_	_	O
231	least	_	_	O
232	one	_	_	O
233	treatment	_	_	O
234	.	_	_	O

235	Patients	_	_	B-Premise
236	on	_	_	I-Premise
237	Arms	_	_	I-Premise
238	A	_	_	I-Premise
239	and	_	_	I-Premise
240	B	_	_	I-Premise
241	had	_	_	I-Premise
242	median	_	_	I-Premise
243	survivals	_	_	I-Premise
244	of	_	_	I-Premise
245	31.4	_	_	I-Premise
246	and	_	_	I-Premise
247	25.3	_	_	I-Premise
248	weeks	_	_	I-Premise
249	,	_	_	I-Premise
250	12-month	_	_	I-Premise
251	survivals	_	_	I-Premise
252	of	_	_	I-Premise
253	29	_	_	I-Premise
254	%	_	_	I-Premise
255	and	_	_	I-Premise
256	24	_	_	I-Premise
257	%	_	_	I-Premise
258	,	_	_	I-Premise
259	and	_	_	I-Premise
260	18-month	_	_	I-Premise
261	survivals	_	_	I-Premise
262	of	_	_	I-Premise
263	18	_	_	I-Premise
264	%	_	_	I-Premise
265	and	_	_	I-Premise
266	8	_	_	I-Premise
267	%	_	_	I-Premise
268	,	_	_	I-Premise
269	respectively	_	_	I-Premise
270	.	_	_	O

271	Toxicity	_	_	B-Premise
272	was	_	_	I-Premise
273	mild	_	_	I-Premise
274	in	_	_	I-Premise
275	both	_	_	I-Premise
276	arms	_	_	I-Premise
277	.	_	_	I-Premise

278	QOL	_	_	B-Premise
279	analyses	_	_	I-Premise
280	favored	_	_	I-Premise
281	Arm	_	_	I-Premise
282	A.	_	_	I-Premise
283	SGN-15	_	_	B-Claim
284	plus	_	_	I-Claim
285	docetaxel	_	_	I-Claim
286	is	_	_	I-Claim
287	a	_	_	I-Claim
288	well-tolerated	_	_	I-Claim
289	and	_	_	I-Claim
290	active	_	_	I-Claim
291	second	_	_	I-Claim
292	and	_	_	I-Claim
293	third	_	_	I-Claim
294	line	_	_	I-Claim
295	treatment	_	_	I-Claim
296	for	_	_	I-Claim
297	NSCLC	_	_	I-Claim
298	patients	_	_	I-Claim
299	.	_	_	O

300	Ongoing	_	_	O
301	studies	_	_	O
302	are	_	_	O
303	exploring	_	_	O
304	alternate	_	_	O
305	schedules	_	_	O
306	to	_	_	O
307	maximize	_	_	O
308	synergy	_	_	O
309	between	_	_	O
310	these	_	_	O
311	agents	_	_	O
312	.	_	_	O


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	assess	_	_	O
8	efficacy	_	_	O
9	and	_	_	O
10	safety	_	_	O
11	of	_	_	O
12	association	_	_	O
13	of	_	_	O
14	duloxetine	_	_	O
15	and	_	_	O
16	rehabilitation	_	_	O
17	compared	_	_	O
18	with	_	_	O
19	rehabilitation	_	_	O
20	alone	_	_	O
21	in	_	_	O
22	men	_	_	O
23	with	_	_	O
24	SUI	_	_	O
25	after	_	_	O
26	radical	_	_	O
27	retropubic	_	_	O
28	prostatectomy	_	_	O
29	(	_	_	O
30	RRP	_	_	O
31	)	_	_	O
32	,	_	_	O
33	and	_	_	O
34	to	_	_	O
35	compare	_	_	O
36	continence	_	_	O
37	rate	_	_	O
38	even	_	_	O
39	after	_	_	O
40	planned	_	_	O
41	duloxetine	_	_	O
42	suspension	_	_	O
43	.	_	_	O

44	After	_	_	O
45	catheter	_	_	O
46	removal	_	_	O
47	,	_	_	O
48	112	_	_	O
49	patients	_	_	O
50	were	_	_	O
51	randomized	_	_	O
52	to	_	_	O
53	receive	_	_	O
54	rehabilitation	_	_	O
55	and	_	_	O
56	duloxetine	_	_	O
57	(	_	_	O
58	group	_	_	O
59	A	_	_	O
60	)	_	_	O
61	or	_	_	O
62	rehabilitation	_	_	O
63	alone	_	_	O
64	(	_	_	O
65	group	_	_	O
66	B	_	_	O
67	)	_	_	O
68	,	_	_	O
69	for	_	_	O
70	16	_	_	O
71	wk	_	_	O
72	.	_	_	O

73	postprostatectomy	_	_	O
74	SUI	_	_	O
75	with	_	_	O
76	daily	_	_	O
77	incontinent	_	_	O
78	episodes	_	_	O
79	frequency	_	_	O
80	(	_	_	O
81	IEF	_	_	O
82	)	_	_	O
83	of	_	_	O
84	four	_	_	O
85	or	_	_	O
86	greater	_	_	O
87	.	_	_	O

88	After	_	_	O
89	16	_	_	O
90	wk	_	_	O
91	both	_	_	O
92	groups	_	_	O
93	suspended	_	_	O
94	duloxetine/placebo	_	_	O
95	and	_	_	O
96	continued	_	_	O
97	rehabilitation	_	_	O
98	.	_	_	O

99	All	_	_	O
100	patients	_	_	O
101	completed	_	_	O
102	incontinence	_	_	O
103	quality	_	_	O
104	of	_	_	O
105	life	_	_	O
106	(	_	_	O
107	I-QoL	_	_	O
108	)	_	_	O
109	questionnaire	_	_	O
110	and	_	_	O
111	bladder	_	_	O
112	diary	_	_	O
113	.	_	_	O

114	Wilcoxon	_	_	O
115	test	_	_	O
116	was	_	_	O
117	used	_	_	O
118	to	_	_	O
119	analyse	_	_	O
120	changes	_	_	O
121	in	_	_	O
122	IEF	_	_	O
123	and	_	_	O
124	in	_	_	O
125	I-QoL	_	_	O
126	score	_	_	O
127	;	_	_	O
128	Fisher	_	_	O
129	exact	_	_	O
130	test	_	_	O
131	was	_	_	O
132	used	_	_	O
133	to	_	_	O
134	compare	_	_	O
135	continent	_	_	O
136	patients	_	_	O
137	between	_	_	O
138	the	_	_	O
139	groups	_	_	O
140	.	_	_	O

141	Adverse	_	_	O
142	events	_	_	O
143	for	_	_	O
144	duloxetine	_	_	O
145	was	_	_	O
146	15.2	_	_	O
147	%	_	_	O
148	.	_	_	O

149	102	_	_	O
150	men	_	_	O
151	completed	_	_	O
152	the	_	_	O
153	study	_	_	O
154	.	_	_	O

155	There	_	_	B-Premise
156	was	_	_	I-Premise
157	a	_	_	I-Premise
158	significant	_	_	I-Premise
159	decrease	_	_	I-Premise
160	in	_	_	I-Premise
161	pad	_	_	I-Premise
162	use	_	_	I-Premise
163	in	_	_	I-Premise
164	group	_	_	I-Premise
165	A	_	_	I-Premise
166	.	_	_	I-Premise

167	After	_	_	B-Premise
168	16	_	_	I-Premise
169	wk	_	_	I-Premise
170	,	_	_	I-Premise
171	39	_	_	I-Premise
172	patients	_	_	I-Premise
173	versus	_	_	I-Premise
174	27	_	_	I-Premise
175	were	_	_	I-Premise
176	dry	_	_	I-Premise
177	(	_	_	I-Premise
178	p=0.007	_	_	I-Premise
179	)	_	_	I-Premise
180	.	_	_	I-Premise

181	At	_	_	B-Premise
182	20	_	_	I-Premise
183	wk	_	_	I-Premise
184	,	_	_	I-Premise
185	4	_	_	I-Premise
186	wk	_	_	I-Premise
187	after	_	_	I-Premise
188	planned	_	_	I-Premise
189	interruption	_	_	I-Premise
190	of	_	_	I-Premise
191	duloxetine	_	_	I-Premise
192	,	_	_	I-Premise
193	we	_	_	I-Premise
194	observed	_	_	I-Premise
195	a	_	_	I-Premise
196	U-turn	_	_	I-Premise
197	,	_	_	I-Premise
198	23	_	_	I-Premise
199	patients	_	_	I-Premise
200	were	_	_	I-Premise
201	completely	_	_	I-Premise
202	dry	_	_	I-Premise
203	in	_	_	I-Premise
204	group	_	_	I-Premise
205	A	_	_	I-Premise
206	versus	_	_	I-Premise
207	38	_	_	I-Premise
208	in	_	_	I-Premise
209	group	_	_	I-Premise
210	B	_	_	I-Premise
211	(	_	_	I-Premise
212	p=0.008	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	Whereas	_	_	B-Premise
216	,	_	_	I-Premise
217	after	_	_	I-Premise
218	24	_	_	I-Premise
219	wk	_	_	I-Premise
220	,	_	_	I-Premise
221	31	_	_	I-Premise
222	in	_	_	I-Premise
223	group	_	_	I-Premise
224	A	_	_	I-Premise
225	versus	_	_	I-Premise
226	41	_	_	I-Premise
227	in	_	_	I-Premise
228	group	_	_	I-Premise
229	B	_	_	I-Premise
230	were	_	_	I-Premise
231	dry	_	_	I-Premise
232	(	_	_	I-Premise
233	p=0.08	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	O

236	The	_	_	B-Claim
237	decrease	_	_	I-Claim
238	in	_	_	I-Claim
239	IEF	_	_	I-Claim
240	and	_	_	I-Claim
241	improvements	_	_	I-Claim
242	in	_	_	I-Claim
243	I-QoL	_	_	I-Claim
244	scores	_	_	I-Claim
245	were	_	_	I-Claim
246	significantly	_	_	I-Claim
247	greater	_	_	I-Claim
248	in	_	_	I-Claim
249	group	_	_	I-Claim
250	A	_	_	I-Claim
251	for	_	_	I-Claim
252	the	_	_	I-Claim
253	first	_	_	I-Claim
254	16	_	_	I-Claim
255	wk	_	_	I-Claim
256	.	_	_	I-Claim

257	The	_	_	B-Claim
258	data	_	_	I-Claim
259	suggest	_	_	I-Claim
260	that	_	_	I-Claim
261	combination	_	_	I-Claim
262	therapy	_	_	I-Claim
263	might	_	_	I-Claim
264	provide	_	_	I-Claim
265	another	_	_	I-Claim
266	treatment	_	_	I-Claim
267	option	_	_	I-Claim
268	for	_	_	I-Claim
269	SUI	_	_	I-Claim
270	in	_	_	I-Claim
271	men	_	_	I-Claim
272	that	_	_	I-Claim
273	might	_	_	I-Claim
274	increase	_	_	I-Claim
275	the	_	_	I-Claim
276	percentage	_	_	I-Claim
277	of	_	_	I-Claim
278	early	_	_	I-Claim
279	postsurgery	_	_	I-Claim
280	continence	_	_	I-Claim
281	.	_	_	I-Claim


0	The	_	_	B-Claim
1	impact	_	_	I-Claim
2	of	_	_	I-Claim
3	treatment	_	_	I-Claim
4	on	_	_	I-Claim
5	health-related	_	_	I-Claim
6	quality	_	_	I-Claim
7	of	_	_	I-Claim
8	life	_	_	I-Claim
9	(	_	_	I-Claim
10	HRQoL	_	_	I-Claim
11	)	_	_	I-Claim
12	is	_	_	I-Claim
13	an	_	_	I-Claim
14	important	_	_	I-Claim
15	consideration	_	_	I-Claim
16	in	_	_	I-Claim
17	the	_	_	I-Claim
18	adjuvant	_	_	I-Claim
19	treatment	_	_	I-Claim
20	of	_	_	I-Claim
21	operable	_	_	I-Claim
22	breast	_	_	I-Claim
23	cancer	_	_	I-Claim
24	.	_	_	I-Claim

25	Here	_	_	O
26	we	_	_	O
27	report	_	_	O
28	mature	_	_	O
29	HRQoL	_	_	O
30	outcomes	_	_	O
31	from	_	_	O
32	the	_	_	O
33	ATAC	_	_	O
34	trial	_	_	O
35	,	_	_	O
36	comparing	_	_	O
37	anastrozole	_	_	O
38	with	_	_	O
39	tamoxifen	_	_	O
40	as	_	_	O
41	primary	_	_	O
42	adjuvant	_	_	O
43	therapy	_	_	O
44	for	_	_	O
45	postmenopausal	_	_	O
46	women	_	_	O
47	with	_	_	O
48	localized	_	_	O
49	breast	_	_	O
50	cancer	_	_	O
51	.	_	_	O

52	Patients	_	_	O
53	completed	_	_	O
54	the	_	_	O
55	Functional	_	_	O
56	Assessment	_	_	O
57	of	_	_	O
58	Cancer	_	_	O
59	Therapy-Breast	_	_	O
60	(	_	_	O
61	FACT-B	_	_	O
62	)	_	_	O
63	questionnaire	_	_	O
64	plus	_	_	O
65	endocrine	_	_	O
66	subscale	_	_	O
67	(	_	_	O
68	ES	_	_	O
69	)	_	_	O
70	at	_	_	O
71	baseline	_	_	O
72	,	_	_	O
73	3	_	_	O
74	and	_	_	O
75	6	_	_	O
76	months	_	_	O
77	,	_	_	O
78	and	_	_	O
79	every	_	_	O
80	6	_	_	O
81	months	_	_	O
82	thereafter	_	_	O
83	.	_	_	O

84	Baseline	_	_	O
85	characteristics	_	_	O
86	in	_	_	O
87	the	_	_	O
88	HRQoL	_	_	O
89	sub-protocol	_	_	O
90	were	_	_	O
91	well	_	_	O
92	balanced	_	_	O
93	between	_	_	O
94	the	_	_	O
95	anastrozole	_	_	O
96	(	_	_	O
97	n	_	_	O
98	=	_	_	O
99	335	_	_	O
100	)	_	_	O
101	and	_	_	O
102	tamoxifen	_	_	O
103	(	_	_	O
104	n	_	_	O
105	=	_	_	O
106	347	_	_	O
107	)	_	_	O
108	groups	_	_	O
109	in	_	_	O
110	the	_	_	O
111	primary	_	_	O
112	analysis	_	_	O
113	population	_	_	O
114	.	_	_	O

115	As	_	_	B-Premise
116	with	_	_	I-Premise
117	previously	_	_	I-Premise
118	published	_	_	I-Premise
119	results	_	_	I-Premise
120	at	_	_	I-Premise
121	2	_	_	I-Premise
122	years	_	_	I-Premise
123	,	_	_	I-Premise
124	there	_	_	I-Premise
125	was	_	_	I-Premise
126	no	_	_	I-Premise
127	statistically	_	_	I-Premise
128	significant	_	_	I-Premise
129	difference	_	_	I-Premise
130	in	_	_	I-Premise
131	the	_	_	I-Premise
132	Trial	_	_	I-Premise
133	Outcome	_	_	I-Premise
134	Index	_	_	I-Premise
135	of	_	_	I-Premise
136	the	_	_	I-Premise
137	FACT-B	_	_	I-Premise
138	,	_	_	I-Premise
139	the	_	_	I-Premise
140	primary	_	_	I-Premise
141	endpoint	_	_	I-Premise
142	of	_	_	I-Premise
143	the	_	_	I-Premise
144	study	_	_	I-Premise
145	,	_	_	I-Premise
146	between	_	_	I-Premise
147	treatments	_	_	I-Premise
148	at	_	_	I-Premise
149	5	_	_	I-Premise
150	years	_	_	I-Premise
151	.	_	_	I-Premise

152	There	_	_	B-Premise
153	were	_	_	I-Premise
154	no	_	_	I-Premise
155	statistically	_	_	I-Premise
156	significant	_	_	I-Premise
157	differences	_	_	I-Premise
158	between	_	_	I-Premise
159	treatment	_	_	I-Premise
160	groups	_	_	I-Premise
161	in	_	_	I-Premise
162	ES	_	_	I-Premise
163	total	_	_	I-Premise
164	scores	_	_	I-Premise
165	.	_	_	I-Premise

166	Consistent	_	_	O
167	with	_	_	O
168	the	_	_	O
169	2-year	_	_	O
170	analysis	_	_	O
171	,	_	_	O
172	there	_	_	B-Claim
173	were	_	_	I-Claim
174	differences	_	_	I-Claim
175	between	_	_	I-Claim
176	treatment	_	_	I-Claim
177	groups	_	_	I-Claim
178	in	_	_	I-Claim
179	patient-reported	_	_	I-Claim
180	side	_	_	I-Claim
181	effects	_	_	I-Claim
182	:	_	_	I-Claim
183	diarrhea	_	_	B-Premise
184	(	_	_	I-Premise
185	anastrozole	_	_	I-Premise
186	3.1	_	_	I-Premise
187	%	_	_	I-Premise
188	vs.	_	_	I-Premise
189	tamoxifen	_	_	I-Premise
190	1.3	_	_	I-Premise
191	%	_	_	I-Premise
192	)	_	_	I-Premise
193	,	_	_	I-Premise
194	vaginal	_	_	I-Premise
195	dryness	_	_	I-Premise
196	(	_	_	I-Premise
197	18.5	_	_	I-Premise
198	%	_	_	I-Premise
199	vs.	_	_	I-Premise
200	9.1	_	_	I-Premise
201	%	_	_	I-Premise
202	)	_	_	I-Premise
203	,	_	_	I-Premise
204	diminished	_	_	I-Premise
205	libido	_	_	I-Premise
206	(	_	_	I-Premise
207	34.0	_	_	I-Premise
208	%	_	_	I-Premise
209	vs.	_	_	I-Premise
210	26.1	_	_	I-Premise
211	%	_	_	I-Premise
212	)	_	_	I-Premise
213	,	_	_	I-Premise
214	and	_	_	I-Premise
215	dyspareunia	_	_	I-Premise
216	(	_	_	I-Premise
217	17.3	_	_	I-Premise
218	%	_	_	I-Premise
219	vs.	_	_	I-Premise
220	8.1	_	_	I-Premise
221	%	_	_	I-Premise
222	)	_	_	I-Premise
223	were	_	_	I-Premise
224	significantly	_	_	I-Premise
225	more	_	_	I-Premise
226	frequent	_	_	I-Premise
227	with	_	_	I-Premise
228	anastrozole	_	_	I-Premise
229	compared	_	_	I-Premise
230	to	_	_	I-Premise
231	tamoxifen	_	_	I-Premise
232	.	_	_	I-Premise

233	Dizziness	_	_	B-Premise
234	(	_	_	I-Premise
235	3.1	_	_	I-Premise
236	%	_	_	I-Premise
237	vs.	_	_	I-Premise
238	5.4	_	_	I-Premise
239	%	_	_	I-Premise
240	)	_	_	I-Premise
241	and	_	_	I-Premise
242	vaginal	_	_	I-Premise
243	discharge	_	_	I-Premise
244	(	_	_	I-Premise
245	1.2	_	_	I-Premise
246	%	_	_	I-Premise
247	vs.	_	_	I-Premise
248	5.2	_	_	I-Premise
249	%	_	_	I-Premise
250	)	_	_	I-Premise
251	were	_	_	I-Premise
252	significantly	_	_	I-Premise
253	less	_	_	I-Premise
254	frequent	_	_	I-Premise
255	with	_	_	I-Premise
256	anastrozole	_	_	I-Premise
257	compared	_	_	I-Premise
258	to	_	_	I-Premise
259	tamoxifen	_	_	I-Premise
260	.	_	_	I-Premise

261	In	_	_	B-Claim
262	this	_	_	I-Claim
263	,	_	_	I-Claim
264	the	_	_	I-Claim
265	first	_	_	I-Claim
266	report	_	_	I-Claim
267	of	_	_	I-Claim
268	HRQoL	_	_	I-Claim
269	over	_	_	I-Claim
270	5	_	_	I-Claim
271	years	_	_	I-Claim
272	of	_	_	I-Claim
273	initial	_	_	I-Claim
274	adjuvant	_	_	I-Claim
275	therapy	_	_	I-Claim
276	with	_	_	I-Claim
277	an	_	_	I-Claim
278	aromatase	_	_	I-Claim
279	inhibitor	_	_	I-Claim
280	,	_	_	I-Claim
281	we	_	_	I-Claim
282	conclude	_	_	I-Claim
283	that	_	_	I-Claim
284	anastrozole	_	_	I-Claim
285	and	_	_	I-Claim
286	tamoxifen	_	_	I-Claim
287	had	_	_	I-Claim
288	similar	_	_	I-Claim
289	impacts	_	_	I-Claim
290	on	_	_	I-Claim
291	HRQoL	_	_	I-Claim
292	,	_	_	I-Claim
293	which	_	_	I-Claim
294	was	_	_	I-Claim
295	maintained	_	_	I-Claim
296	or	_	_	I-Claim
297	slightly	_	_	I-Claim
298	improved	_	_	I-Claim
299	during	_	_	I-Claim
300	the	_	_	I-Claim
301	treatment	_	_	I-Claim
302	period	_	_	I-Claim
303	for	_	_	I-Claim
304	both	_	_	I-Claim
305	groups	_	_	I-Claim
306	.	_	_	I-Claim


0	In	_	_	O
1	the	_	_	O
2	randomized	_	_	O
3	,	_	_	O
4	multinational	_	_	O
5	phase	_	_	O
6	II/III	_	_	O
7	trial	_	_	O
8	(	_	_	O
9	V325	_	_	O
10	)	_	_	O
11	of	_	_	O
12	untreated	_	_	O
13	advanced	_	_	O
14	gastric	_	_	O
15	cancer	_	_	O
16	patients	_	_	O
17	,	_	_	O
18	the	_	_	O
19	phase	_	_	O
20	II	_	_	O
21	part	_	_	O
22	selected	_	_	O
23	docetaxel	_	_	O
24	,	_	_	O
25	cisplatin	_	_	O
26	,	_	_	O
27	and	_	_	O
28	fluorouracil	_	_	O
29	(	_	_	O
30	DCF	_	_	O
31	)	_	_	O
32	over	_	_	O
33	docetaxel	_	_	O
34	and	_	_	O
35	cisplatin	_	_	O
36	for	_	_	O
37	comparison	_	_	O
38	against	_	_	O
39	cisplatin	_	_	O
40	and	_	_	O
41	fluorouracil	_	_	O
42	(	_	_	O
43	CF	_	_	O
44	;	_	_	O
45	reference	_	_	O
46	regimen	_	_	O
47	)	_	_	O
48	in	_	_	O
49	the	_	_	O
50	phase	_	_	O
51	III	_	_	O
52	part	_	_	O
53	.	_	_	O

54	Advanced	_	_	O
55	gastric	_	_	O
56	cancer	_	_	O
57	patients	_	_	O
58	were	_	_	O
59	randomly	_	_	O
60	assigned	_	_	O
61	to	_	_	O
62	docetaxel	_	_	O
63	75	_	_	O
64	mg/m2	_	_	O
65	and	_	_	O
66	cisplatin	_	_	O
67	75	_	_	O
68	mg/m2	_	_	O
69	(	_	_	O
70	day	_	_	O
71	1	_	_	O
72	)	_	_	O
73	plus	_	_	O
74	fluorouracil	_	_	O
75	750	_	_	O
76	mg/m2/d	_	_	O
77	(	_	_	O
78	days	_	_	O
79	1	_	_	O
80	to	_	_	O
81	5	_	_	O
82	)	_	_	O
83	every	_	_	O
84	3	_	_	O
85	weeks	_	_	O
86	or	_	_	O
87	cisplatin	_	_	O
88	100	_	_	O
89	mg/m2	_	_	O
90	(	_	_	O
91	day	_	_	O
92	1	_	_	O
93	)	_	_	O
94	plus	_	_	O
95	fluorouracil	_	_	O
96	1,000	_	_	O
97	mg/m2/d	_	_	O
98	(	_	_	O
99	days	_	_	O
100	1	_	_	O
101	to	_	_	O
102	5	_	_	O
103	)	_	_	O
104	every	_	_	O
105	4	_	_	O
106	weeks	_	_	O
107	.	_	_	O

108	The	_	_	O
109	primary	_	_	O
110	end	_	_	O
111	point	_	_	O
112	was	_	_	O
113	time-to-progression	_	_	O
114	(	_	_	O
115	TTP	_	_	O
116	)	_	_	O
117	.	_	_	O

118	In	_	_	O
119	445	_	_	O
120	randomly	_	_	O
121	assigned	_	_	O
122	and	_	_	O
123	treated	_	_	O
124	patients	_	_	O
125	(	_	_	O
126	DCF	_	_	O
127	=	_	_	O
128	221	_	_	O
129	;	_	_	O
130	CF	_	_	O
131	=	_	_	O
132	224	_	_	O
133	)	_	_	O
134	,	_	_	O
135	TTP	_	_	O
136	was	_	_	O
137	longer	_	_	O
138	with	_	_	O
139	DCF	_	_	O
140	versus	_	_	O
141	CF	_	_	O
142	(	_	_	O
143	32	_	_	O
144	%	_	_	O
145	risk	_	_	O
146	reduction	_	_	O
147	;	_	_	O
148	log-rank	_	_	O
149	P	_	_	O
150	<	_	_	O
151	.001	_	_	O
152	)	_	_	O
153	.	_	_	O

154	Overall	_	_	B-Premise
155	survival	_	_	I-Premise
156	was	_	_	I-Premise
157	longer	_	_	I-Premise
158	with	_	_	I-Premise
159	DCF	_	_	I-Premise
160	versus	_	_	I-Premise
161	CF	_	_	I-Premise
162	(	_	_	I-Premise
163	23	_	_	I-Premise
164	%	_	_	I-Premise
165	risk	_	_	I-Premise
166	reduction	_	_	I-Premise
167	;	_	_	I-Premise
168	log-rank	_	_	I-Premise
169	P	_	_	I-Premise
170	=	_	_	I-Premise
171	.02	_	_	I-Premise
172	)	_	_	I-Premise
173	.	_	_	I-Premise

174	Two-year	_	_	B-Premise
175	survival	_	_	I-Premise
176	rate	_	_	I-Premise
177	was	_	_	I-Premise
178	18	_	_	I-Premise
179	%	_	_	I-Premise
180	with	_	_	I-Premise
181	DCF	_	_	I-Premise
182	and	_	_	I-Premise
183	9	_	_	I-Premise
184	%	_	_	I-Premise
185	with	_	_	I-Premise
186	CF	_	_	I-Premise
187	.	_	_	I-Premise

188	Overall	_	_	B-Premise
189	response	_	_	I-Premise
190	rate	_	_	I-Premise
191	was	_	_	I-Premise
192	higher	_	_	I-Premise
193	with	_	_	I-Premise
194	DCF	_	_	I-Premise
195	(	_	_	I-Premise
196	chi2	_	_	I-Premise
197	P	_	_	I-Premise
198	=	_	_	I-Premise
199	.01	_	_	I-Premise
200	)	_	_	I-Premise
201	.	_	_	I-Premise

202	Grade	_	_	B-Premise
203	3	_	_	I-Premise
204	to	_	_	I-Premise
205	4	_	_	I-Premise
206	treatment-related	_	_	I-Premise
207	adverse	_	_	I-Premise
208	events	_	_	I-Premise
209	occurred	_	_	I-Premise
210	in	_	_	I-Premise
211	69	_	_	I-Premise
212	%	_	_	I-Premise
213	(	_	_	I-Premise
214	DCF	_	_	I-Premise
215	)	_	_	I-Premise
216	v	_	_	I-Premise
217	59	_	_	I-Premise
218	%	_	_	I-Premise
219	(	_	_	I-Premise
220	CF	_	_	I-Premise
221	)	_	_	I-Premise
222	of	_	_	I-Premise
223	patients	_	_	I-Premise
224	.	_	_	I-Premise

225	Frequent	_	_	B-Premise
226	grade	_	_	I-Premise
227	3	_	_	I-Premise
228	to	_	_	I-Premise
229	4	_	_	I-Premise
230	toxicities	_	_	I-Premise
231	for	_	_	I-Premise
232	DCF	_	_	I-Premise
233	v	_	_	I-Premise
234	CF	_	_	I-Premise
235	were	_	_	I-Premise
236	:	_	_	I-Premise
237	neutropenia	_	_	I-Premise
238	(	_	_	I-Premise
239	82	_	_	I-Premise
240	%	_	_	I-Premise
241	v	_	_	I-Premise
242	57	_	_	I-Premise
243	%	_	_	I-Premise
244	)	_	_	I-Premise
245	,	_	_	I-Premise
246	stomatitis	_	_	I-Premise
247	(	_	_	I-Premise
248	21	_	_	I-Premise
249	%	_	_	I-Premise
250	v	_	_	I-Premise
251	27	_	_	I-Premise
252	%	_	_	I-Premise
253	)	_	_	I-Premise
254	,	_	_	I-Premise
255	diarrhea	_	_	I-Premise
256	(	_	_	I-Premise
257	19	_	_	I-Premise
258	%	_	_	I-Premise
259	v	_	_	I-Premise
260	8	_	_	I-Premise
261	%	_	_	I-Premise
262	)	_	_	I-Premise
263	,	_	_	I-Premise
264	lethargy	_	_	I-Premise
265	(	_	_	I-Premise
266	19	_	_	I-Premise
267	%	_	_	I-Premise
268	v	_	_	I-Premise
269	14	_	_	I-Premise
270	%	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	Complicated	_	_	B-Premise
274	neutropenia	_	_	I-Premise
275	was	_	_	I-Premise
276	more	_	_	I-Premise
277	frequent	_	_	I-Premise
278	with	_	_	I-Premise
279	DCF	_	_	I-Premise
280	than	_	_	I-Premise
281	CF	_	_	I-Premise
282	(	_	_	I-Premise
283	29	_	_	I-Premise
284	%	_	_	I-Premise
285	v	_	_	I-Premise
286	12	_	_	I-Premise
287	%	_	_	I-Premise
288	)	_	_	I-Premise
289	.	_	_	I-Premise

290	Adding	_	_	B-Claim
291	docetaxel	_	_	I-Claim
292	to	_	_	I-Claim
293	CF	_	_	I-Claim
294	significantly	_	_	I-Claim
295	improved	_	_	I-Claim
296	TTP	_	_	I-Claim
297	,	_	_	I-Claim
298	survival	_	_	I-Claim
299	,	_	_	I-Claim
300	and	_	_	I-Claim
301	response	_	_	I-Claim
302	rate	_	_	I-Claim
303	in	_	_	I-Claim
304	gastric	_	_	I-Claim
305	cancer	_	_	I-Claim
306	patients	_	_	I-Claim
307	,	_	_	I-Claim
308	but	_	_	I-Claim
309	resulted	_	_	I-Claim
310	in	_	_	I-Claim
311	some	_	_	I-Claim
312	increase	_	_	I-Claim
313	in	_	_	I-Claim
314	toxicity	_	_	I-Claim
315	.	_	_	I-Claim

316	Incorporation	_	_	B-Claim
317	of	_	_	I-Claim
318	docetaxel	_	_	I-Claim
319	,	_	_	I-Claim
320	as	_	_	I-Claim
321	in	_	_	I-Claim
322	DCF	_	_	I-Claim
323	or	_	_	I-Claim
324	with	_	_	I-Claim
325	other	_	_	I-Claim
326	active	_	_	I-Claim
327	drug	_	_	I-Claim
328	(	_	_	I-Claim
329	s	_	_	I-Claim
330	)	_	_	I-Claim
331	,	_	_	I-Claim
332	is	_	_	I-Claim
333	a	_	_	I-Claim
334	new	_	_	I-Claim
335	therapy	_	_	I-Claim
336	option	_	_	I-Claim
337	for	_	_	I-Claim
338	patients	_	_	I-Claim
339	with	_	_	I-Claim
340	untreated	_	_	I-Claim
341	advanced	_	_	I-Claim
342	gastric	_	_	I-Claim
343	cancer	_	_	I-Claim
344	.	_	_	I-Claim


0	Surgery	_	_	O
1	and	_	_	O
2	radiotherapy	_	_	O
3	commonly	_	_	O
4	cause	_	_	O
5	adverse	_	_	O
6	musculoskeletal	_	_	O
7	problems	_	_	O
8	,	_	_	O
9	particularly	_	_	O
10	loss	_	_	O
11	of	_	_	O
12	strength	_	_	O
13	and	_	_	O
14	range	_	_	O
15	of	_	_	O
16	motion	_	_	O
17	,	_	_	O
18	in	_	_	O
19	the	_	_	O
20	upper	_	_	O
21	quadrant	_	_	O
22	of	_	_	O
23	breast	_	_	O
24	cancer	_	_	O
25	patients	_	_	O
26	.	_	_	O

27	Few	_	_	O
28	well-designed	_	_	O
29	studies	_	_	O
30	have	_	_	O
31	investigated	_	_	O
32	whether	_	_	O
33	these	_	_	O
34	impairments	_	_	O
35	can	_	_	O
36	be	_	_	O
37	prevented	_	_	O
38	.	_	_	O

39	Stretching	_	_	B-Claim
40	is	_	_	I-Claim
41	an	_	_	I-Claim
42	effective	_	_	I-Claim
43	technique	_	_	I-Claim
44	for	_	_	I-Claim
45	increasing	_	_	I-Claim
46	range	_	_	I-Claim
47	of	_	_	I-Claim
48	motion	_	_	I-Claim
49	,	_	_	I-Claim
50	hence	_	_	O
51	the	_	_	O
52	aim	_	_	O
53	of	_	_	O
54	this	_	_	O
55	study	_	_	O
56	was	_	_	O
57	to	_	_	O
58	investigate	_	_	O
59	whether	_	_	O
60	a	_	_	O
61	stretching	_	_	O
62	program	_	_	O
63	reduced	_	_	O
64	acute	_	_	O
65	musculoskeletal	_	_	O
66	impairments	_	_	O
67	in	_	_	O
68	patients	_	_	O
69	undergoing	_	_	O
70	radiotherapy	_	_	O
71	for	_	_	O
72	breast	_	_	O
73	cancer	_	_	O
74	.	_	_	O

75	Sixty-four	_	_	O
76	women	_	_	O
77	were	_	_	O
78	recruited	_	_	O
79	prior	_	_	O
80	to	_	_	O
81	commencement	_	_	O
82	of	_	_	O
83	radiotherapy	_	_	O
84	following	_	_	O
85	breast	_	_	O
86	cancer	_	_	O
87	surgery	_	_	O
88	.	_	_	O

89	Participants	_	_	O
90	were	_	_	O
91	randomised	_	_	O
92	to	_	_	O
93	either	_	_	O
94	a	_	_	O
95	control	_	_	O
96	or	_	_	O
97	stretch	_	_	O
98	group	_	_	O
99	.	_	_	O

100	Participants	_	_	O
101	in	_	_	O
102	both	_	_	O
103	groups	_	_	O
104	were	_	_	O
105	reviewed	_	_	O
106	by	_	_	O
107	the	_	_	O
108	physical	_	_	O
109	therapist	_	_	O
110	on	_	_	O
111	a	_	_	O
112	weekly	_	_	O
113	basis	_	_	O
114	for	_	_	O
115	approximately	_	_	O
116	6	_	_	O
117	weeks	_	_	O
118	,	_	_	O
119	and	_	_	O
120	were	_	_	O
121	given	_	_	O
122	general	_	_	O
123	information	_	_	O
124	about	_	_	O
125	skin	_	_	O
126	care	_	_	O
127	and	_	_	O
128	lymphedema	_	_	O
129	.	_	_	O

130	The	_	_	O
131	control	_	_	O
132	group	_	_	O
133	received	_	_	O
134	no	_	_	O
135	advice	_	_	O
136	about	_	_	O
137	exercise	_	_	O
138	.	_	_	O

139	The	_	_	O
140	stretch	_	_	O
141	group	_	_	O
142	received	_	_	O
143	instruction	_	_	O
144	on	_	_	O
145	low-load	_	_	O
146	,	_	_	O
147	prolonged	_	_	O
148	pectoral	_	_	O
149	stretches	_	_	O
150	,	_	_	O
151	which	_	_	O
152	were	_	_	O
153	to	_	_	O
154	be	_	_	O
155	performed	_	_	O
156	daily	_	_	O
157	and	_	_	O
158	were	_	_	O
159	checked	_	_	O
160	at	_	_	O
161	weekly	_	_	O
162	visits	_	_	O
163	.	_	_	O

164	Shoulder	_	_	O
165	range	_	_	O
166	of	_	_	O
167	motion	_	_	O
168	,	_	_	O
169	strength	_	_	O
170	,	_	_	O
171	arm	_	_	O
172	circumference	_	_	O
173	,	_	_	O
174	and	_	_	O
175	quality	_	_	O
176	of	_	_	O
177	life	_	_	O
178	measurements	_	_	O
179	were	_	_	O
180	taken	_	_	O
181	prior	_	_	O
182	to	_	_	O
183	,	_	_	O
184	and	_	_	O
185	at	_	_	O
186	completion	_	_	O
187	of	_	_	O
188	radiotherapy	_	_	O
189	,	_	_	O
190	and	_	_	O
191	at	_	_	O
192	7	_	_	O
193	months	_	_	O
194	after	_	_	O
195	radiotherapy	_	_	O
196	.	_	_	O

197	There	_	_	B-Premise
198	was	_	_	I-Premise
199	no	_	_	I-Premise
200	difference	_	_	I-Premise
201	in	_	_	I-Premise
202	any	_	_	I-Premise
203	outcome	_	_	I-Premise
204	between	_	_	I-Premise
205	groups	_	_	I-Premise
206	.	_	_	I-Premise

207	Breast	_	_	B-Premise
208	symptoms	_	_	I-Premise
209	increased	_	_	I-Premise
210	for	_	_	I-Premise
211	both	_	_	I-Premise
212	groups	_	_	I-Premise
213	during	_	_	I-Premise
214	radiotherapy	_	_	I-Premise
215	,	_	_	I-Premise
216	without	_	_	I-Premise
217	loss	_	_	I-Premise
218	of	_	_	I-Premise
219	strength	_	_	I-Premise
220	or	_	_	I-Premise
221	range	_	_	I-Premise
222	of	_	_	I-Premise
223	movement	_	_	I-Premise
224	.	_	_	I-Premise

225	The	_	_	B-Premise
226	incidence	_	_	I-Premise
227	of	_	_	I-Premise
228	lymphedema	_	_	I-Premise
229	during	_	_	I-Premise
230	the	_	_	I-Premise
231	study	_	_	I-Premise
232	was	_	_	I-Premise
233	low	_	_	I-Premise
234	for	_	_	I-Premise
235	both	_	_	I-Premise
236	groups	_	_	I-Premise
237	and	_	_	I-Premise
238	did	_	_	I-Premise
239	not	_	_	I-Premise
240	differ	_	_	I-Premise
241	between	_	_	I-Premise
242	groups	_	_	I-Premise
243	.	_	_	I-Premise

244	The	_	_	B-Premise
245	pectoral	_	_	I-Premise
246	stretching	_	_	I-Premise
247	program	_	_	I-Premise
248	did	_	_	I-Premise
249	not	_	_	I-Premise
250	influence	_	_	I-Premise
251	the	_	_	I-Premise
252	outcomes	_	_	I-Premise
253	measured	_	_	I-Premise
254	because	_	_	I-Premise
255	the	_	_	I-Premise
256	symptoms	_	_	I-Premise
257	reported	_	_	I-Premise
258	by	_	_	I-Premise
259	patients	_	_	I-Premise
260	were	_	_	I-Premise
261	not	_	_	I-Premise
262	a	_	_	I-Premise
263	consequence	_	_	I-Premise
264	of	_	_	I-Premise
265	contracture	_	_	I-Premise
266	.	_	_	I-Premise


0	This	_	_	O
1	study	_	_	O
2	aimed	_	_	O
3	to	_	_	O
4	compare	_	_	O
5	quality	_	_	O
6	of	_	_	O
7	life	_	_	O
8	(	_	_	O
9	QOL	_	_	O
10	)	_	_	O
11	,	_	_	O
12	functional	_	_	O
13	outcome	_	_	O
14	,	_	_	O
15	body	_	_	O
16	image	_	_	O
17	,	_	_	O
18	and	_	_	O
19	cosmesis	_	_	O
20	after	_	_	O
21	hand-assisted	_	_	O
22	laparoscopic	_	_	O
23	(	_	_	O
24	LRP	_	_	O
25	)	_	_	O
26	versus	_	_	O
27	open	_	_	O
28	restorative	_	_	O
29	proctocolectomy	_	_	O
30	(	_	_	O
31	ORP	_	_	O
32	)	_	_	O
33	.	_	_	O

34	The	_	_	O
35	potential	_	_	O
36	long-term	_	_	O
37	advantages	_	_	O
38	of	_	_	O
39	LRP	_	_	O
40	over	_	_	O
41	ORP	_	_	O
42	remain	_	_	O
43	to	_	_	O
44	be	_	_	O
45	determined	_	_	O
46	.	_	_	O

47	The	_	_	O
48	most	_	_	O
49	likely	_	_	O
50	advantage	_	_	O
51	of	_	_	O
52	LRP	_	_	O
53	is	_	_	O
54	the	_	_	O
55	superior	_	_	O
56	cosmetic	_	_	O
57	result	_	_	O
58	.	_	_	O

59	It	_	_	O
60	is	_	_	O
61	,	_	_	O
62	however	_	_	O
63	,	_	_	O
64	unclear	_	_	O
65	whether	_	_	O
66	the	_	_	O
67	size	_	_	O
68	and	_	_	O
69	location	_	_	O
70	of	_	_	O
71	incisions	_	_	O
72	affect	_	_	O
73	body	_	_	O
74	image	_	_	O
75	and	_	_	O
76	QOL	_	_	O
77	.	_	_	O

78	In	_	_	O
79	a	_	_	O
80	previously	_	_	O
81	conducted	_	_	O
82	randomized	_	_	O
83	trial	_	_	O
84	comparing	_	_	O
85	LRP	_	_	O
86	with	_	_	O
87	ORP	_	_	O
88	,	_	_	O
89	60	_	_	O
90	patients	_	_	O
91	were	_	_	O
92	prospectively	_	_	O
93	evaluated	_	_	O
94	.	_	_	O

95	The	_	_	O
96	primary	_	_	O
97	end	_	_	O
98	points	_	_	O
99	were	_	_	O
100	body	_	_	O
101	image	_	_	O
102	and	_	_	O
103	cosmesis	_	_	O
104	.	_	_	O

105	The	_	_	O
106	secondary	_	_	O
107	end	_	_	O
108	points	_	_	O
109	were	_	_	O
110	morbidity	_	_	O
111	,	_	_	O
112	QOL	_	_	O
113	,	_	_	O
114	and	_	_	O
115	functional	_	_	O
116	outcome	_	_	O
117	.	_	_	O

118	A	_	_	O
119	body	_	_	O
120	image	_	_	O
121	questionnaire	_	_	O
122	was	_	_	O
123	used	_	_	O
124	to	_	_	O
125	evaluate	_	_	O
126	body	_	_	O
127	image	_	_	O
128	and	_	_	O
129	cosmesis	_	_	O
130	.	_	_	O

131	The	_	_	O
132	Short	_	_	O
133	Form-36	_	_	O
134	Health	_	_	O
135	Survey	_	_	O
136	and	_	_	O
137	the	_	_	O
138	Gastrointestinal	_	_	O
139	Quality	_	_	O
140	of	_	_	O
141	Life	_	_	O
142	Inventory	_	_	O
143	were	_	_	O
144	used	_	_	O
145	to	_	_	O
146	assess	_	_	O
147	QOL	_	_	O
148	.	_	_	O

149	Body	_	_	O
150	image	_	_	O
151	and	_	_	O
152	QOL	_	_	O
153	also	_	_	O
154	were	_	_	O
155	assessed	_	_	O
156	preoperatively	_	_	O
157	.	_	_	O

158	A	_	_	O
159	total	_	_	O
160	of	_	_	O
161	53	_	_	O
162	patients	_	_	O
163	completed	_	_	O
164	the	_	_	O
165	QOL	_	_	O
166	and	_	_	O
167	functional	_	_	O
168	outcome	_	_	O
169	questionnaires	_	_	O
170	.	_	_	O

171	There	_	_	B-Premise
172	were	_	_	I-Premise
173	no	_	_	I-Premise
174	differences	_	_	I-Premise
175	in	_	_	I-Premise
176	functional	_	_	I-Premise
177	outcome	_	_	I-Premise
178	,	_	_	I-Premise
179	morbidity	_	_	I-Premise
180	,	_	_	I-Premise
181	or	_	_	I-Premise
182	QOL	_	_	I-Premise
183	between	_	_	I-Premise
184	LRP	_	_	I-Premise
185	and	_	_	I-Premise
186	ORP	_	_	I-Premise
187	.	_	_	I-Premise

188	At	_	_	O
189	a	_	_	O
190	median	_	_	O
191	of	_	_	O
192	2.7	_	_	O
193	years	_	_	O
194	after	_	_	O
195	surgery	_	_	O
196	,	_	_	O
197	46	_	_	O
198	patients	_	_	O
199	returned	_	_	O
200	the	_	_	O
201	questionnaires	_	_	O
202	regarding	_	_	O
203	body	_	_	O
204	image	_	_	O
205	,	_	_	O
206	cosmesis	_	_	O
207	,	_	_	O
208	and	_	_	O
209	morbidity	_	_	O
210	.	_	_	O

211	The	_	_	B-Premise
212	body	_	_	I-Premise
213	image	_	_	I-Premise
214	and	_	_	I-Premise
215	cosmesis	_	_	I-Premise
216	scores	_	_	I-Premise
217	of	_	_	I-Premise
218	female	_	_	I-Premise
219	patients	_	_	I-Premise
220	were	_	_	I-Premise
221	significantly	_	_	I-Premise
222	higher	_	_	I-Premise
223	in	_	_	I-Premise
224	the	_	_	I-Premise
225	LRP	_	_	I-Premise
226	group	_	_	I-Premise
227	than	_	_	I-Premise
228	in	_	_	I-Premise
229	the	_	_	I-Premise
230	ORP	_	_	I-Premise
231	group	_	_	I-Premise
232	(	_	_	I-Premise
233	body	_	_	I-Premise
234	image	_	_	I-Premise
235	,	_	_	I-Premise
236	17.4	_	_	I-Premise
237	vs	_	_	I-Premise
238	14.9	_	_	I-Premise
239	;	_	_	I-Premise
240	cosmesis	_	_	I-Premise
241	,	_	_	I-Premise
242	19.1	_	_	I-Premise
243	vs	_	_	I-Premise
244	13.0	_	_	I-Premise
245	,	_	_	I-Premise
246	respectively	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	The	_	_	B-Premise
250	female	_	_	I-Premise
251	patients	_	_	I-Premise
252	in	_	_	I-Premise
253	the	_	_	I-Premise
254	ORP	_	_	I-Premise
255	group	_	_	I-Premise
256	had	_	_	I-Premise
257	significantly	_	_	I-Premise
258	lower	_	_	I-Premise
259	body	_	_	I-Premise
260	image	_	_	I-Premise
261	scores	_	_	I-Premise
262	than	_	_	I-Premise
263	the	_	_	I-Premise
264	male	_	_	I-Premise
265	patients	_	_	I-Premise
266	(	_	_	I-Premise
267	14.9	_	_	I-Premise
268	vs	_	_	I-Premise
269	18.3	_	_	I-Premise
270	)	_	_	I-Premise
271	.	_	_	I-Premise

272	This	_	_	B-Claim
273	study	_	_	I-Claim
274	is	_	_	I-Claim
275	the	_	_	I-Claim
276	first	_	_	I-Claim
277	to	_	_	I-Claim
278	show	_	_	I-Claim
279	that	_	_	I-Claim
280	ORP	_	_	I-Claim
281	has	_	_	I-Claim
282	a	_	_	I-Claim
283	negative	_	_	I-Claim
284	impact	_	_	I-Claim
285	on	_	_	I-Claim
286	body	_	_	I-Claim
287	image	_	_	I-Claim
288	and	_	_	I-Claim
289	cosmesis	_	_	I-Claim
290	as	_	_	I-Claim
291	compared	_	_	I-Claim
292	with	_	_	I-Claim
293	LRP	_	_	I-Claim
294	.	_	_	I-Claim

295	Functional	_	_	B-Claim
296	outcome	_	_	I-Claim
297	,	_	_	I-Claim
298	QOL	_	_	I-Claim
299	,	_	_	I-Claim
300	and	_	_	I-Claim
301	morbidity	_	_	I-Claim
302	are	_	_	I-Claim
303	similar	_	_	I-Claim
304	for	_	_	I-Claim
305	the	_	_	I-Claim
306	two	_	_	I-Claim
307	approaches	_	_	I-Claim
308	.	_	_	I-Claim

309	The	_	_	B-Claim
310	advantages	_	_	I-Claim
311	of	_	_	I-Claim
312	a	_	_	I-Claim
313	long-lasting	_	_	I-Claim
314	improved	_	_	I-Claim
315	body	_	_	I-Claim
316	image	_	_	I-Claim
317	and	_	_	I-Claim
318	cosmesis	_	_	I-Claim
319	for	_	_	I-Claim
320	this	_	_	I-Claim
321	relatively	_	_	I-Claim
322	young	_	_	I-Claim
323	patient	_	_	I-Claim
324	population	_	_	I-Claim
325	may	_	_	I-Claim
326	compensate	_	_	I-Claim
327	for	_	_	I-Claim
328	the	_	_	I-Claim
329	longer	_	_	I-Claim
330	operating	_	_	I-Claim
331	times	_	_	I-Claim
332	and	_	_	I-Claim
333	higher	_	_	I-Claim
334	costs	_	_	I-Claim
335	,	_	_	I-Claim
336	particularly	_	_	I-Claim
337	for	_	_	I-Claim
338	women	_	_	I-Claim
339	.	_	_	I-Claim


0	Depression	_	_	B-Claim
1	,	_	_	I-Claim
2	anxiety	_	_	I-Claim
3	,	_	_	I-Claim
4	fatigue	_	_	I-Claim
5	,	_	_	I-Claim
6	and	_	_	I-Claim
7	impaired	_	_	I-Claim
8	wellbeing	_	_	I-Claim
9	are	_	_	I-Claim
10	common	_	_	I-Claim
11	,	_	_	I-Claim
12	important	_	_	I-Claim
13	,	_	_	I-Claim
14	and	_	_	I-Claim
15	closely	_	_	I-Claim
16	related	_	_	I-Claim
17	in	_	_	I-Claim
18	advanced	_	_	I-Claim
19	cancer	_	_	I-Claim
20	.	_	_	I-Claim

21	We	_	_	O
22	aimed	_	_	O
23	to	_	_	O
24	identify	_	_	O
25	the	_	_	O
26	effects	_	_	O
27	of	_	_	O
28	an	_	_	O
29	established	_	_	O
30	antidepressant	_	_	O
31	on	_	_	O
32	these	_	_	O
33	symptoms	_	_	O
34	and	_	_	O
35	survival	_	_	O
36	in	_	_	O
37	patients	_	_	O
38	with	_	_	O
39	advanced	_	_	O
40	cancer	_	_	O
41	who	_	_	O
42	did	_	_	O
43	not	_	_	O
44	have	_	_	O
45	major	_	_	O
46	depression	_	_	O
47	as	_	_	O
48	assessed	_	_	O
49	by	_	_	O
50	clinicians	_	_	O
51	.	_	_	O

52	Between	_	_	O
53	July	_	_	O
54	,	_	_	O
55	2001	_	_	O
56	,	_	_	O
57	and	_	_	O
58	February	_	_	O
59	,	_	_	O
60	2006	_	_	O
61	,	_	_	O
62	189	_	_	O
63	patients	_	_	O
64	with	_	_	O
65	advanced	_	_	O
66	cancer	_	_	O
67	were	_	_	O
68	randomly	_	_	O
69	assigned	_	_	O
70	sertraline	_	_	O
71	50	_	_	O
72	mg	_	_	O
73	(	_	_	O
74	n=95	_	_	O
75	)	_	_	O
76	,	_	_	O
77	or	_	_	O
78	placebo	_	_	O
79	(	_	_	O
80	n=94	_	_	O
81	)	_	_	O
82	,	_	_	O
83	once	_	_	O
84	per	_	_	O
85	day	_	_	O
86	.	_	_	O

87	The	_	_	O
88	primary	_	_	O
89	outcome	_	_	O
90	was	_	_	O
91	depression	_	_	O
92	as	_	_	O
93	assessed	_	_	O
94	by	_	_	O
95	the	_	_	O
96	Centre	_	_	O
97	for	_	_	O
98	Epidemiologic	_	_	O
99	Studies	_	_	O
100	Depression	_	_	O
101	scale	_	_	O
102	(	_	_	O
103	CES-D	_	_	O
104	)	_	_	O
105	;	_	_	O
106	the	_	_	O
107	main	_	_	O
108	secondary	_	_	O
109	outcomes	_	_	O
110	were	_	_	O
111	:	_	_	O
112	anxiety	_	_	O
113	as	_	_	O
114	assessed	_	_	O
115	by	_	_	O
116	Hospital	_	_	O
117	Anxiety	_	_	O
118	and	_	_	O
119	Depression	_	_	O
120	Scales	_	_	O
121	(	_	_	O
122	HADS-A	_	_	O
123	)	_	_	O
124	;	_	_	O
125	overall	_	_	O
126	quality	_	_	O
127	of	_	_	O
128	life	_	_	O
129	and	_	_	O
130	fatigue	_	_	O
131	as	_	_	O
132	assessed	_	_	O
133	by	_	_	O
134	Functional	_	_	O
135	Assessment	_	_	O
136	of	_	_	O
137	Cancer	_	_	O
138	Therapy	_	_	O
139	General	_	_	O
140	and	_	_	O
141	Fatigue	_	_	O
142	scales	_	_	O
143	(	_	_	O
144	FACT-G	_	_	O
145	and	_	_	O
146	FACT-F	_	_	O
147	,	_	_	O
148	respectively	_	_	O
149	)	_	_	O
150	;	_	_	O
151	and	_	_	O
152	clinicians	_	_	O
153	'	_	_	O
154	ratings	_	_	O
155	of	_	_	O
156	quality	_	_	O
157	of	_	_	O
158	life	_	_	O
159	by	_	_	O
160	use	_	_	O
161	of	_	_	O
162	Spizter	_	_	O
163	's	_	_	O
164	Quality	_	_	O
165	of	_	_	O
166	Life	_	_	O
167	Index	_	_	O
168	(	_	_	O
169	SQLI	_	_	O
170	)	_	_	O
171	.	_	_	O

172	Multiple	_	_	O
173	measures	_	_	O
174	were	_	_	O
175	used	_	_	O
176	for	_	_	O
177	corroboration	_	_	O
178	of	_	_	O
179	the	_	_	O
180	most	_	_	O
181	important	_	_	O
182	outcomes	_	_	O
183	.	_	_	O

184	Primary	_	_	O
185	analyses	_	_	O
186	were	_	_	O
187	done	_	_	O
188	by	_	_	O
189	intention	_	_	O
190	to	_	_	O
191	treat	_	_	O
192	and	_	_	O
193	were	_	_	O
194	based	_	_	O
195	on	_	_	O
196	scale	_	_	O
197	scores	_	_	O
198	at	_	_	O
199	4	_	_	O
200	weeks	_	_	O
201	and	_	_	O
202	8	_	_	O
203	weeks	_	_	O
204	.	_	_	O

205	The	_	_	O
206	benefits	_	_	O
207	of	_	_	O
208	sertraline	_	_	O
209	compared	_	_	O
210	with	_	_	O
211	placebo	_	_	O
212	are	_	_	O
213	expressed	_	_	O
214	on	_	_	O
215	a	_	_	O
216	range	_	_	O
217	from	_	_	O
218	+100	_	_	O
219	(	_	_	O
220	ie	_	_	O
221	,	_	_	O
222	maximum	_	_	O
223	benefit	_	_	O
224	)	_	_	O
225	to	_	_	O
226	-100	_	_	O
227	(	_	_	O
228	ie	_	_	O
229	,	_	_	O
230	maximum	_	_	O
231	harm	_	_	O
232	)	_	_	O
233	;	_	_	O
234	a	_	_	O
235	difference	_	_	O
236	of	_	_	O
237	10	_	_	O
238	was	_	_	O
239	deemed	_	_	O
240	clinically	_	_	O
241	significant	_	_	O
242	.	_	_	O

243	This	_	_	O
244	clinical	_	_	O
245	trial	_	_	O
246	is	_	_	O
247	registered	_	_	O
248	at	_	_	O
249	Current	_	_	O
250	Controlled	_	_	O
251	Trials	_	_	O
252	website	_	_	O
253	http	_	_	O
254	:	_	_	O
255	//www.controlled-trials.com/ISRCTN72466475	_	_	O
256	.	_	_	O

257	Sertraline	_	_	B-Premise
258	had	_	_	I-Premise
259	no	_	_	I-Premise
260	significant	_	_	I-Premise
261	effect	_	_	I-Premise
262	(	_	_	I-Premise
263	scale	_	_	I-Premise
264	,	_	_	I-Premise
265	benefit	_	_	I-Premise
266	over	_	_	I-Premise
267	placebo	_	_	I-Premise
268	[	_	_	I-Premise
269	95	_	_	I-Premise
270	%	_	_	I-Premise
271	CI	_	_	I-Premise
272	]	_	_	I-Premise
273	)	_	_	I-Premise
274	on	_	_	I-Premise
275	depression	_	_	I-Premise
276	(	_	_	I-Premise
277	CES-D	_	_	I-Premise
278	0.4	_	_	I-Premise
279	[	_	_	I-Premise
280	-2.6	_	_	I-Premise
281	to	_	_	I-Premise
282	3.4	_	_	I-Premise
283	]	_	_	I-Premise
284	)	_	_	I-Premise
285	,	_	_	I-Premise
286	anxiety	_	_	I-Premise
287	(	_	_	I-Premise
288	HADS-A	_	_	I-Premise
289	2.0	_	_	I-Premise
290	[	_	_	I-Premise
291	-1.5	_	_	I-Premise
292	to	_	_	I-Premise
293	5.5	_	_	I-Premise
294	]	_	_	I-Premise
295	)	_	_	I-Premise
296	,	_	_	I-Premise
297	fatigue	_	_	I-Premise
298	(	_	_	I-Premise
299	FACT-F	_	_	I-Premise
300	0.3	_	_	I-Premise
301	[	_	_	I-Premise
302	-4.3	_	_	I-Premise
303	to	_	_	I-Premise
304	4.9	_	_	I-Premise
305	]	_	_	I-Premise
306	)	_	_	I-Premise
307	,	_	_	I-Premise
308	overall	_	_	I-Premise
309	quality	_	_	I-Premise
310	of	_	_	I-Premise
311	life	_	_	I-Premise
312	(	_	_	I-Premise
313	FACT-G	_	_	I-Premise
314	1.7	_	_	I-Premise
315	[	_	_	I-Premise
316	-1.3	_	_	I-Premise
317	to	_	_	I-Premise
318	4.7	_	_	I-Premise
319	]	_	_	I-Premise
320	)	_	_	I-Premise
321	,	_	_	I-Premise
322	or	_	_	I-Premise
323	clinicians	_	_	I-Premise
324	'	_	_	I-Premise
325	ratings	_	_	I-Premise
326	(	_	_	I-Premise
327	SQLI	_	_	I-Premise
328	2.0	_	_	I-Premise
329	[	_	_	I-Premise
330	-2.5	_	_	I-Premise
331	to	_	_	I-Premise
332	6.5	_	_	I-Premise
333	]	_	_	I-Premise
334	)	_	_	I-Premise
335	,	_	_	I-Premise
336	and	_	_	I-Premise
337	the	_	_	I-Premise
338	95	_	_	I-Premise
339	%	_	_	I-Premise
340	CI	_	_	I-Premise
341	ruled	_	_	I-Premise
342	out	_	_	I-Premise
343	a	_	_	I-Premise
344	clinically	_	_	I-Premise
345	significant	_	_	I-Premise
346	benefit	_	_	I-Premise
347	for	_	_	I-Premise
348	all	_	_	I-Premise
349	main	_	_	I-Premise
350	outcomes	_	_	I-Premise
351	.	_	_	I-Premise

352	Sertraline	_	_	B-Premise
353	was	_	_	I-Premise
354	discontinued	_	_	I-Premise
355	more	_	_	I-Premise
356	often	_	_	I-Premise
357	and	_	_	I-Premise
358	earlier	_	_	I-Premise
359	than	_	_	I-Premise
360	was	_	_	I-Premise
361	placebo	_	_	I-Premise
362	(	_	_	I-Premise
363	hazard	_	_	I-Premise
364	ratio	_	_	I-Premise
365	1.46	_	_	I-Premise
366	[	_	_	I-Premise
367	1.03-2.06	_	_	I-Premise
368	]	_	_	I-Premise
369	,	_	_	I-Premise
370	p=0.03	_	_	I-Premise
371	)	_	_	I-Premise
372	.	_	_	I-Premise

373	Recruitment	_	_	O
374	was	_	_	O
375	stopped	_	_	O
376	after	_	_	O
377	the	_	_	B-Premise
378	first	_	_	I-Premise
379	planned	_	_	I-Premise
380	interim	_	_	I-Premise
381	analysis	_	_	I-Premise
382	in	_	_	I-Premise
383	February	_	_	I-Premise
384	2006	_	_	I-Premise
385	(	_	_	I-Premise
386	n=150	_	_	I-Premise
387	)	_	_	I-Premise
388	showed	_	_	I-Premise
389	that	_	_	I-Premise
390	survival	_	_	I-Premise
391	was	_	_	I-Premise
392	longer	_	_	I-Premise
393	in	_	_	I-Premise
394	patients	_	_	I-Premise
395	assigned	_	_	I-Premise
396	placebo	_	_	I-Premise
397	than	_	_	I-Premise
398	in	_	_	I-Premise
399	patients	_	_	I-Premise
400	assigned	_	_	I-Premise
401	sertraline	_	_	I-Premise
402	(	_	_	I-Premise
403	unadjusted	_	_	I-Premise
404	hazard	_	_	I-Premise
405	ratio	_	_	I-Premise
406	1.60	_	_	I-Premise
407	[	_	_	I-Premise
408	95	_	_	I-Premise
409	%	_	_	I-Premise
410	CI	_	_	I-Premise
411	1.04-2.45	_	_	I-Premise
412	]	_	_	I-Premise
413	,	_	_	I-Premise
414	log-rank	_	_	I-Premise
415	p=0.04	_	_	I-Premise
416	;	_	_	I-Premise
417	adjusted	_	_	I-Premise
418	hazard	_	_	I-Premise
419	ratio	_	_	I-Premise
420	1.62	_	_	I-Premise
421	[	_	_	I-Premise
422	1.06-2.41	_	_	I-Premise
423	]	_	_	I-Premise
424	,	_	_	I-Premise
425	Cox	_	_	I-Premise
426	model	_	_	I-Premise
427	p=0.02	_	_	I-Premise
428	)	_	_	I-Premise
429	.	_	_	I-Premise

430	However	_	_	B-Premise
431	,	_	_	I-Premise
432	at	_	_	I-Premise
433	the	_	_	I-Premise
434	final	_	_	I-Premise
435	analysis	_	_	I-Premise
436	in	_	_	I-Premise
437	July	_	_	I-Premise
438	2006	_	_	I-Premise
439	of	_	_	I-Premise
440	all	_	_	I-Premise
441	patients	_	_	I-Premise
442	(	_	_	I-Premise
443	n=189	_	_	I-Premise
444	)	_	_	I-Premise
445	and	_	_	I-Premise
446	with	_	_	I-Premise
447	longer	_	_	I-Premise
448	follow-up	_	_	I-Premise
449	,	_	_	I-Premise
450	survival	_	_	I-Premise
451	did	_	_	I-Premise
452	not	_	_	I-Premise
453	differ	_	_	I-Premise
454	significantly	_	_	I-Premise
455	between	_	_	I-Premise
456	the	_	_	I-Premise
457	treatment	_	_	I-Premise
458	groups	_	_	I-Premise
459	(	_	_	I-Premise
460	unadjusted	_	_	I-Premise
461	hazard	_	_	I-Premise
462	ratio	_	_	I-Premise
463	1.35	_	_	I-Premise
464	[	_	_	I-Premise
465	0.95-1.91	_	_	I-Premise
466	]	_	_	I-Premise
467	,	_	_	I-Premise
468	log-rank	_	_	I-Premise
469	p=0.09	_	_	I-Premise
470	;	_	_	I-Premise
471	adjusted	_	_	I-Premise
472	hazard	_	_	I-Premise
473	ratio	_	_	I-Premise
474	1.27	_	_	I-Premise
475	[	_	_	I-Premise
476	0.87-1.84	_	_	I-Premise
477	]	_	_	I-Premise
478	,	_	_	I-Premise
479	Cox	_	_	I-Premise
480	model	_	_	I-Premise
481	p=0.20	_	_	I-Premise
482	)	_	_	I-Premise
483	.	_	_	I-Premise

484	The	_	_	O
485	trial	_	_	O
486	was	_	_	O
487	closed	_	_	O
488	because	_	_	O
489	it	_	_	O
490	had	_	_	O
491	ruled	_	_	O
492	out	_	_	O
493	a	_	_	O
494	significant	_	_	O
495	benefit	_	_	O
496	of	_	_	O
497	sertraline	_	_	O
498	.	_	_	O

499	Sertraline	_	_	B-Claim
500	did	_	_	I-Claim
501	not	_	_	I-Claim
502	improve	_	_	I-Claim
503	symptoms	_	_	I-Claim
504	,	_	_	I-Claim
505	wellbeing	_	_	I-Claim
506	,	_	_	I-Claim
507	or	_	_	I-Claim
508	survival	_	_	I-Claim
509	in	_	_	I-Claim
510	patients	_	_	I-Claim
511	with	_	_	I-Claim
512	advanced	_	_	I-Claim
513	cancer	_	_	I-Claim
514	who	_	_	I-Claim
515	do	_	_	I-Claim
516	not	_	_	I-Claim
517	have	_	_	I-Claim
518	major	_	_	I-Claim
519	depression	_	_	I-Claim
520	,	_	_	I-Claim
521	and	_	_	I-Claim
522	should	_	_	I-Claim
523	be	_	_	I-Claim
524	reserved	_	_	I-Claim
525	for	_	_	I-Claim
526	those	_	_	I-Claim
527	with	_	_	I-Claim
528	a	_	_	I-Claim
529	proven	_	_	I-Claim
530	indication	_	_	I-Claim
531	.	_	_	I-Claim


0	Recently	_	_	B-Claim
1	,	_	_	I-Claim
2	the	_	_	I-Claim
3	treatment	_	_	I-Claim
4	of	_	_	I-Claim
5	advanced	_	_	I-Claim
6	gastric	_	_	I-Claim
7	cancer	_	_	I-Claim
8	by	_	_	I-Claim
9	continuous	_	_	I-Claim
10	infusion	_	_	I-Claim
11	of	_	_	I-Claim
12	5-fluorouracil	_	_	I-Claim
13	(	_	_	I-Claim
14	5-FU	_	_	I-Claim
15	)	_	_	I-Claim
16	with	_	_	I-Claim
17	low-dose	_	_	I-Claim
18	cisplatin	_	_	I-Claim
19	(	_	_	I-Claim
20	CDDP	_	_	I-Claim
21	)	_	_	I-Claim
22	has	_	_	I-Claim
23	improved	_	_	I-Claim
24	efficacy	_	_	I-Claim
25	without	_	_	I-Claim
26	severe	_	_	I-Claim
27	toxicities	_	_	I-Claim
28	.	_	_	I-Claim

29	The	_	_	B-Claim
30	possible	_	_	I-Claim
31	effectiveness	_	_	I-Claim
32	of	_	_	I-Claim
33	5-FU+low-dose	_	_	I-Claim
34	CDDP	_	_	I-Claim
35	for	_	_	I-Claim
36	colorectal	_	_	I-Claim
37	cancer	_	_	I-Claim
38	(	_	_	I-Claim
39	CRC	_	_	I-Claim
40	)	_	_	I-Claim
41	is	_	_	I-Claim
42	intriguing	_	_	I-Claim
43	.	_	_	I-Claim

44	One	_	_	O
45	hundred	_	_	O
46	fifty-five	_	_	O
47	patients	_	_	O
48	with	_	_	O
49	far-advanced	_	_	O
50	CRC	_	_	O
51	including	_	_	O
52	at	_	_	O
53	least	_	_	O
54	one	_	_	O
55	measurable	_	_	O
56	lesion	_	_	O
57	were	_	_	O
58	enrolled	_	_	O
59	in	_	_	O
60	a	_	_	O
61	prospective	_	_	O
62	randomized	_	_	O
63	clinical	_	_	O
64	trial	_	_	O
65	funded	_	_	O
66	by	_	_	O
67	the	_	_	O
68	Japanese	_	_	O
69	Foundation	_	_	O
70	for	_	_	O
71	Multidisciplinary	_	_	O
72	Treatment	_	_	O
73	of	_	_	O
74	Cancer	_	_	O
75	.	_	_	O

76	These	_	_	O
77	patients	_	_	O
78	were	_	_	O
79	assigned	_	_	O
80	to	_	_	O
81	the	_	_	O
82	two	_	_	O
83	arms	_	_	O
84	to	_	_	O
85	assess	_	_	O
86	the	_	_	O
87	value	_	_	O
88	of	_	_	O
89	low-dose	_	_	O
90	CDDP	_	_	O
91	when	_	_	O
92	added	_	_	O
93	to	_	_	O
94	a	_	_	O
95	continuous	_	_	O
96	intravenous	_	_	O
97	infusion	_	_	O
98	of	_	_	O
99	5-FU	_	_	O
100	at	_	_	O
101	a	_	_	O
102	dose	_	_	O
103	of	_	_	O
104	300	_	_	O
105	mg/m	_	_	O
106	(	_	_	O
107	2	_	_	O
108	)	_	_	O
109	/24	_	_	O
110	hrs	_	_	O
111	in	_	_	O
112	a	_	_	O
113	one-week	_	_	O
114	cycle	_	_	O
115	consisting	_	_	O
116	of	_	_	O
117	5	_	_	O
118	days	_	_	O
119	of	_	_	O
120	treatment	_	_	O
121	and	_	_	O
122	2	_	_	O
123	days	_	_	O
124	of	_	_	O
125	rest	_	_	O
126	for	_	_	O
127	at	_	_	O
128	least	_	_	O
129	12	_	_	O
130	weeks	_	_	O
131	.	_	_	O

132	CD-DP	_	_	O
133	was	_	_	O
134	given	_	_	O
135	intravenously	_	_	O
136	at	_	_	O
137	a	_	_	O
138	dose	_	_	O
139	of	_	_	O
140	3	_	_	O
141	mg/m	_	_	O
142	(	_	_	O
143	2	_	_	O
144	)	_	_	O
145	on	_	_	O
146	days	_	_	O
147	1-5	_	_	O
148	and	_	_	O
149	days	_	_	O
150	8-12	_	_	O
151	,	_	_	O
152	and	_	_	O
153	then	_	_	O
154	at	_	_	O
155	a	_	_	O
156	dose	_	_	O
157	of	_	_	O
158	7	_	_	O
159	mg/m	_	_	O
160	(	_	_	O
161	2	_	_	O
162	)	_	_	O
163	twice	_	_	O
164	a	_	_	O
165	week	_	_	O
166	.	_	_	O

167	Three	_	_	O
168	patients	_	_	O
169	were	_	_	O
170	excluded	_	_	O
171	from	_	_	O
172	the	_	_	O
173	trial	_	_	O
174	.	_	_	O

175	The	_	_	B-Premise
176	response	_	_	I-Premise
177	rate	_	_	I-Premise
178	in	_	_	I-Premise
179	the	_	_	I-Premise
180	5-FU+low-dose	_	_	I-Premise
181	CDDP	_	_	I-Premise
182	arm	_	_	I-Premise
183	(	_	_	I-Premise
184	n=75	_	_	I-Premise
185	)	_	_	I-Premise
186	was	_	_	I-Premise
187	significantly	_	_	I-Premise
188	higher	_	_	I-Premise
189	than	_	_	I-Premise
190	that	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	5-FU	_	_	I-Premise
194	arm	_	_	I-Premise
195	(	_	_	I-Premise
196	n=77	_	_	I-Premise
197	)	_	_	I-Premise
198	(	_	_	I-Premise
199	25.3	_	_	I-Premise
200	%	_	_	I-Premise
201	vs.	_	_	I-Premise
202	11.7	_	_	I-Premise
203	%	_	_	I-Premise
204	;	_	_	I-Premise
205	P	_	_	I-Premise
206	=	_	_	I-Premise
207	0.037	_	_	I-Premise
208	)	_	_	I-Premise
209	.	_	_	I-Premise

210	There	_	_	B-Premise
211	was	_	_	I-Premise
212	no	_	_	I-Premise
213	significant	_	_	I-Premise
214	difference	_	_	I-Premise
215	in	_	_	I-Premise
216	the	_	_	I-Premise
217	median	_	_	I-Premise
218	overall	_	_	I-Premise
219	survival	_	_	I-Premise
220	time	_	_	I-Premise
221	between	_	_	I-Premise
222	the	_	_	I-Premise
223	5-FU+low-dose	_	_	I-Premise
224	CDDP	_	_	I-Premise
225	arm	_	_	I-Premise
226	and	_	_	I-Premise
227	the	_	_	I-Premise
228	5-FU	_	_	I-Premise
229	arm	_	_	I-Premise
230	(	_	_	I-Premise
231	479	_	_	I-Premise
232	and	_	_	I-Premise
233	491	_	_	I-Premise
234	days	_	_	I-Premise
235	,	_	_	I-Premise
236	respectively	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	Grades	_	_	B-Premise
240	3/4	_	_	I-Premise
241	toxicities	_	_	I-Premise
242	occurred	_	_	I-Premise
243	infrequently	_	_	I-Premise
244	in	_	_	I-Premise
245	both	_	_	I-Premise
246	arms	_	_	I-Premise
247	.	_	_	I-Premise

248	The	_	_	B-Premise
249	quality	_	_	I-Premise
250	of	_	_	I-Premise
251	life	_	_	I-Premise
252	was	_	_	I-Premise
253	almost	_	_	I-Premise
254	the	_	_	I-Premise
255	same	_	_	I-Premise
256	between	_	_	I-Premise
257	the	_	_	I-Premise
258	arms	_	_	I-Premise
259	.	_	_	O

260	Low-dose	_	_	B-Claim
261	CDDP	_	_	I-Claim
262	improved	_	_	I-Claim
263	the	_	_	I-Claim
264	response	_	_	I-Claim
265	rate	_	_	I-Claim
266	while	_	_	I-Claim
267	keeping	_	_	I-Claim
268	toxicities	_	_	I-Claim
269	within	_	_	I-Claim
270	clinically	_	_	I-Claim
271	acceptable	_	_	I-Claim
272	limits	_	_	I-Claim
273	.	_	_	I-Claim

274	However	_	_	B-Claim
275	,	_	_	I-Claim
276	this	_	_	I-Claim
277	combined	_	_	I-Claim
278	treatment	_	_	I-Claim
279	did	_	_	I-Claim
280	not	_	_	I-Claim
281	confer	_	_	I-Claim
282	a	_	_	I-Claim
283	survival	_	_	I-Claim
284	advantage	_	_	I-Claim
285	over	_	_	I-Claim
286	treatment	_	_	I-Claim
287	with	_	_	I-Claim
288	continuous	_	_	I-Claim
289	infusion	_	_	I-Claim
290	of	_	_	I-Claim
291	5-FU	_	_	I-Claim
292	alone	_	_	I-Claim
293	for	_	_	I-Claim
294	patients	_	_	I-Claim
295	with	_	_	I-Claim
296	far-advanced	_	_	I-Claim
297	CRC	_	_	I-Claim
298	;	_	_	I-Claim
299	that	_	_	I-Claim
300	might	_	_	I-Claim
301	be	_	_	I-Claim
302	attributable	_	_	I-Claim
303	to	_	_	I-Claim
304	the	_	_	I-Claim
305	short	_	_	I-Claim
306	CDDP	_	_	I-Claim
307	administration	_	_	I-Claim
308	setting	_	_	I-Claim
309	of	_	_	I-Claim
310	12	_	_	I-Claim
311	weeks	_	_	I-Claim
312	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	long	_	_	O
4	term	_	_	O
5	risks	_	_	O
6	and	_	_	O
7	benefits	_	_	O
8	of	_	_	O
9	hormone	_	_	O
10	replacement	_	_	O
11	therapy	_	_	O
12	(	_	_	O
13	combined	_	_	O
14	hormone	_	_	O
15	therapy	_	_	O
16	versus	_	_	O
17	placebo	_	_	O
18	,	_	_	O
19	and	_	_	O
20	oestrogen	_	_	O
21	alone	_	_	O
22	versus	_	_	O
23	combined	_	_	O
24	hormone	_	_	O
25	therapy	_	_	O
26	)	_	_	O
27	.	_	_	O

28	Multicentre	_	_	O
29	,	_	_	O
30	randomised	_	_	O
31	,	_	_	O
32	placebo	_	_	O
33	controlled	_	_	O
34	,	_	_	O
35	double	_	_	O
36	blind	_	_	O
37	trial	_	_	O
38	.	_	_	O

39	General	_	_	O
40	practices	_	_	O
41	in	_	_	O
42	UK	_	_	O
43	(	_	_	O
44	384	_	_	O
45	)	_	_	O
46	,	_	_	O
47	Australia	_	_	O
48	(	_	_	O
49	91	_	_	O
50	)	_	_	O
51	,	_	_	O
52	and	_	_	O
53	New	_	_	O
54	Zealand	_	_	O
55	(	_	_	O
56	24	_	_	O
57	)	_	_	O
58	.	_	_	O

59	Postmenopausal	_	_	O
60	women	_	_	O
61	aged	_	_	O
62	50-69	_	_	O
63	years	_	_	O
64	at	_	_	O
65	randomisation	_	_	O
66	.	_	_	O

67	At	_	_	O
68	early	_	_	O
69	closure	_	_	O
70	of	_	_	O
71	the	_	_	O
72	trial	_	_	O
73	,	_	_	O
74	56,583	_	_	O
75	had	_	_	O
76	been	_	_	O
77	screened	_	_	O
78	,	_	_	O
79	8980	_	_	O
80	entered	_	_	O
81	run-in	_	_	O
82	,	_	_	O
83	and	_	_	O
84	5692	_	_	O
85	(	_	_	O
86	26	_	_	O
87	%	_	_	O
88	of	_	_	O
89	target	_	_	O
90	of	_	_	O
91	22,300	_	_	O
92	)	_	_	O
93	started	_	_	O
94	treatment	_	_	O
95	.	_	_	O

96	Oestrogen	_	_	O
97	only	_	_	O
98	therapy	_	_	O
99	(	_	_	O
100	conjugated	_	_	O
101	equine	_	_	O
102	oestrogens	_	_	O
103	0.625	_	_	O
104	mg	_	_	O
105	orally	_	_	O
106	daily	_	_	O
107	)	_	_	O
108	or	_	_	O
109	combined	_	_	O
110	hormone	_	_	O
111	therapy	_	_	O
112	(	_	_	O
113	conjugated	_	_	O
114	equine	_	_	O
115	oestrogens	_	_	O
116	plus	_	_	O
117	medroxyprogesterone	_	_	O
118	acetate	_	_	O
119	2.5/5.0	_	_	O
120	mg	_	_	O
121	orally	_	_	O
122	daily	_	_	O
123	)	_	_	O
124	.	_	_	O

125	Ten	_	_	O
126	years	_	_	O
127	of	_	_	O
128	treatment	_	_	O
129	planned	_	_	O
130	.	_	_	O

131	major	_	_	O
132	cardiovascular	_	_	O
133	disease	_	_	O
134	,	_	_	O
135	osteoporotic	_	_	O
136	fractures	_	_	O
137	,	_	_	O
138	and	_	_	O
139	breast	_	_	O
140	cancer	_	_	O
141	.	_	_	O

142	other	_	_	O
143	cancers	_	_	O
144	,	_	_	O
145	death	_	_	O
146	from	_	_	O
147	all	_	_	O
148	causes	_	_	O
149	,	_	_	O
150	venous	_	_	O
151	thromboembolism	_	_	O
152	,	_	_	O
153	cerebrovascular	_	_	O
154	disease	_	_	O
155	,	_	_	O
156	dementia	_	_	O
157	,	_	_	O
158	and	_	_	O
159	quality	_	_	O
160	of	_	_	O
161	life	_	_	O
162	.	_	_	O

163	The	_	_	O
164	trial	_	_	O
165	was	_	_	O
166	prematurely	_	_	O
167	closed	_	_	O
168	during	_	_	O
169	recruitment	_	_	O
170	,	_	_	O
171	after	_	_	O
172	a	_	_	O
173	median	_	_	O
174	follow-up	_	_	O
175	of	_	_	O
176	11.9	_	_	O
177	months	_	_	O
178	(	_	_	O
179	interquartile	_	_	O
180	range	_	_	O
181	7.1-19.6	_	_	O
182	,	_	_	O
183	total	_	_	O
184	6498	_	_	O
185	women	_	_	O
186	years	_	_	O
187	)	_	_	O
188	in	_	_	O
189	those	_	_	O
190	enrolled	_	_	O
191	,	_	_	O
192	after	_	_	O
193	the	_	_	O
194	publication	_	_	O
195	of	_	_	O
196	early	_	_	O
197	results	_	_	O
198	from	_	_	O
199	the	_	_	O
200	women	_	_	O
201	's	_	_	O
202	health	_	_	O
203	initiative	_	_	O
204	study	_	_	O
205	.	_	_	O

206	The	_	_	O
207	mean	_	_	O
208	age	_	_	O
209	of	_	_	O
210	randomised	_	_	O
211	women	_	_	O
212	was	_	_	O
213	62.8	_	_	O
214	(	_	_	O
215	SD	_	_	O
216	4.8	_	_	O
217	)	_	_	O
218	years	_	_	O
219	.	_	_	O

220	When	_	_	B-Premise
221	combined	_	_	I-Premise
222	hormone	_	_	I-Premise
223	therapy	_	_	I-Premise
224	(	_	_	I-Premise
225	n=2196	_	_	I-Premise
226	)	_	_	I-Premise
227	was	_	_	I-Premise
228	compared	_	_	I-Premise
229	with	_	_	I-Premise
230	placebo	_	_	I-Premise
231	(	_	_	I-Premise
232	n=2189	_	_	I-Premise
233	)	_	_	I-Premise
234	,	_	_	I-Premise
235	there	_	_	I-Premise
236	was	_	_	I-Premise
237	a	_	_	I-Premise
238	significant	_	_	I-Premise
239	increase	_	_	I-Premise
240	in	_	_	I-Premise
241	the	_	_	I-Premise
242	number	_	_	I-Premise
243	of	_	_	I-Premise
244	major	_	_	I-Premise
245	cardiovascular	_	_	I-Premise
246	events	_	_	I-Premise
247	(	_	_	I-Premise
248	7	_	_	I-Premise
249	v	_	_	I-Premise
250	0	_	_	I-Premise
251	,	_	_	I-Premise
252	P=0.016	_	_	I-Premise
253	)	_	_	I-Premise
254	and	_	_	I-Premise
255	venous	_	_	I-Premise
256	thromboembolisms	_	_	I-Premise
257	(	_	_	I-Premise
258	22	_	_	I-Premise
259	v	_	_	I-Premise
260	3	_	_	I-Premise
261	,	_	_	I-Premise
262	hazard	_	_	I-Premise
263	ratio	_	_	I-Premise
264	7.36	_	_	I-Premise
265	(	_	_	I-Premise
266	95	_	_	I-Premise
267	%	_	_	I-Premise
268	CI	_	_	I-Premise
269	2.20	_	_	I-Premise
270	to	_	_	I-Premise
271	24.60	_	_	I-Premise
272	)	_	_	I-Premise
273	)	_	_	I-Premise
274	.	_	_	I-Premise

275	There	_	_	B-Premise
276	were	_	_	I-Premise
277	no	_	_	I-Premise
278	statistically	_	_	I-Premise
279	significant	_	_	I-Premise
280	differences	_	_	I-Premise
281	in	_	_	I-Premise
282	numbers	_	_	I-Premise
283	of	_	_	I-Premise
284	breast	_	_	I-Premise
285	or	_	_	I-Premise
286	other	_	_	I-Premise
287	cancers	_	_	I-Premise
288	(	_	_	I-Premise
289	22	_	_	I-Premise
290	v	_	_	I-Premise
291	25	_	_	I-Premise
292	,	_	_	I-Premise
293	hazard	_	_	I-Premise
294	ratio	_	_	I-Premise
295	0.88	_	_	I-Premise
296	(	_	_	I-Premise
297	0.49	_	_	I-Premise
298	to	_	_	I-Premise
299	1.56	_	_	I-Premise
300	)	_	_	I-Premise
301	)	_	_	I-Premise
302	,	_	_	I-Premise
303	cerebrovascular	_	_	I-Premise
304	events	_	_	I-Premise
305	(	_	_	I-Premise
306	14	_	_	I-Premise
307	v	_	_	I-Premise
308	19	_	_	I-Premise
309	,	_	_	I-Premise
310	0.73	_	_	I-Premise
311	(	_	_	I-Premise
312	0.37	_	_	I-Premise
313	to	_	_	I-Premise
314	1.46	_	_	I-Premise
315	)	_	_	I-Premise
316	)	_	_	I-Premise
317	,	_	_	I-Premise
318	fractures	_	_	I-Premise
319	(	_	_	I-Premise
320	40	_	_	I-Premise
321	v	_	_	I-Premise
322	58	_	_	I-Premise
323	,	_	_	I-Premise
324	0.69	_	_	I-Premise
325	(	_	_	I-Premise
326	0.46	_	_	I-Premise
327	to	_	_	I-Premise
328	1.03	_	_	I-Premise
329	)	_	_	I-Premise
330	)	_	_	I-Premise
331	,	_	_	I-Premise
332	and	_	_	I-Premise
333	overall	_	_	I-Premise
334	deaths	_	_	I-Premise
335	(	_	_	I-Premise
336	8	_	_	I-Premise
337	v	_	_	I-Premise
338	5	_	_	I-Premise
339	,	_	_	I-Premise
340	1.60	_	_	I-Premise
341	(	_	_	I-Premise
342	0.52	_	_	I-Premise
343	to	_	_	I-Premise
344	4.89	_	_	I-Premise
345	)	_	_	I-Premise
346	)	_	_	I-Premise
347	.	_	_	I-Premise

348	Comparison	_	_	B-Premise
349	of	_	_	I-Premise
350	combined	_	_	I-Premise
351	hormone	_	_	I-Premise
352	therapy	_	_	I-Premise
353	(	_	_	I-Premise
354	n=815	_	_	I-Premise
355	)	_	_	I-Premise
356	versus	_	_	I-Premise
357	oestrogen	_	_	I-Premise
358	therapy	_	_	I-Premise
359	(	_	_	I-Premise
360	n=826	_	_	I-Premise
361	)	_	_	I-Premise
362	outcomes	_	_	I-Premise
363	revealed	_	_	I-Premise
364	no	_	_	I-Premise
365	significant	_	_	I-Premise
366	differences	_	_	I-Premise
367	.	_	_	I-Premise

368	Hormone	_	_	B-Claim
369	replacement	_	_	I-Claim
370	therapy	_	_	I-Claim
371	increases	_	_	I-Claim
372	cardiovascular	_	_	I-Claim
373	and	_	_	I-Claim
374	thromboembolic	_	_	I-Claim
375	risk	_	_	I-Claim
376	when	_	_	I-Claim
377	started	_	_	I-Claim
378	many	_	_	I-Claim
379	years	_	_	I-Claim
380	after	_	_	I-Claim
381	the	_	_	I-Claim
382	menopause	_	_	I-Claim
383	.	_	_	I-Claim

384	The	_	_	B-Claim
385	results	_	_	I-Claim
386	are	_	_	I-Claim
387	consistent	_	_	I-Claim
388	with	_	_	I-Claim
389	the	_	_	I-Claim
390	findings	_	_	I-Claim
391	of	_	_	I-Claim
392	the	_	_	I-Claim
393	women	_	_	I-Claim
394	's	_	_	I-Claim
395	health	_	_	I-Claim
396	initiative	_	_	I-Claim
397	study	_	_	I-Claim
398	and	_	_	I-Claim
399	secondary	_	_	I-Claim
400	prevention	_	_	I-Claim
401	studies	_	_	I-Claim
402	.	_	_	I-Claim

403	Research	_	_	B-Claim
404	is	_	_	I-Claim
405	needed	_	_	I-Claim
406	to	_	_	I-Claim
407	assess	_	_	I-Claim
408	the	_	_	I-Claim
409	long	_	_	I-Claim
410	term	_	_	I-Claim
411	risks	_	_	I-Claim
412	and	_	_	I-Claim
413	benefits	_	_	I-Claim
414	of	_	_	I-Claim
415	starting	_	_	I-Claim
416	hormone	_	_	I-Claim
417	replacement	_	_	I-Claim
418	therapy	_	_	I-Claim
419	near	_	_	I-Claim
420	the	_	_	I-Claim
421	menopause	_	_	I-Claim
422	,	_	_	I-Claim
423	when	_	_	I-Claim
424	the	_	_	I-Claim
425	effect	_	_	I-Claim
426	may	_	_	I-Claim
427	be	_	_	I-Claim
428	different	_	_	I-Claim
429	.	_	_	I-Claim


0	It	_	_	B-Claim
1	has	_	_	I-Claim
2	been	_	_	I-Claim
3	shown	_	_	I-Claim
4	that	_	_	I-Claim
5	nonpharmacologic	_	_	I-Claim
6	interventions	_	_	I-Claim
7	are	_	_	I-Claim
8	effective	_	_	I-Claim
9	management	_	_	I-Claim
10	techniques	_	_	I-Claim
11	for	_	_	I-Claim
12	cancer-related	_	_	I-Claim
13	fatigue	_	_	I-Claim
14	(	_	_	I-Claim
15	CRF	_	_	I-Claim
16	)	_	_	I-Claim
17	in	_	_	I-Claim
18	cancer	_	_	I-Claim
19	survivors	_	_	I-Claim
20	.	_	_	I-Claim

21	However	_	_	O
22	,	_	_	O
23	few	_	_	O
24	studies	_	_	O
25	have	_	_	O
26	investigated	_	_	O
27	their	_	_	O
28	effectiveness	_	_	O
29	in	_	_	O
30	patients	_	_	O
31	who	_	_	O
32	are	_	_	O
33	receiving	_	_	O
34	chemotherapy	_	_	O
35	.	_	_	O

36	In	_	_	O
37	this	_	_	O
38	study	_	_	O
39	,	_	_	O
40	the	_	_	O
41	authors	_	_	O
42	tested	_	_	O
43	the	_	_	O
44	effectiveness	_	_	O
45	of	_	_	O
46	a	_	_	O
47	brief	_	_	O
48	behaviorally	_	_	O
49	oriented	_	_	O
50	intervention	_	_	O
51	in	_	_	O
52	reducing	_	_	O
53	CRF	_	_	O
54	and	_	_	O
55	improving	_	_	O
56	physical	_	_	O
57	function	_	_	O
58	and	_	_	O
59	associated	_	_	O
60	distress	_	_	O
61	in	_	_	O
62	individuals	_	_	O
63	who	_	_	O
64	were	_	_	O
65	receiving	_	_	O
66	chemotherapy	_	_	O
67	.	_	_	O

68	For	_	_	O
69	this	_	_	O
70	randomized	_	_	O
71	controlled	_	_	O
72	trial	_	_	O
73	,	_	_	O
74	60	_	_	O
75	patients	_	_	O
76	with	_	_	O
77	cancer	_	_	O
78	were	_	_	O
79	recruited	_	_	O
80	and	_	_	O
81	received	_	_	O
82	either	_	_	O
83	usual	_	_	O
84	care	_	_	O
85	or	_	_	O
86	the	_	_	O
87	intervention	_	_	O
88	.	_	_	O

89	The	_	_	O
90	intervention	_	_	O
91	was	_	_	O
92	delivered	_	_	O
93	on	_	_	O
94	an	_	_	O
95	individual	_	_	O
96	basis	_	_	O
97	on	_	_	O
98	3	_	_	O
99	occasions	_	_	O
100	over	_	_	O
101	a	_	_	O
102	period	_	_	O
103	from	_	_	O
104	9	_	_	O
105	weeks	_	_	O
106	to	_	_	O
107	12	_	_	O
108	weeks	_	_	O
109	,	_	_	O
110	and	_	_	O
111	the	_	_	O
112	objective	_	_	O
113	of	_	_	O
114	the	_	_	O
115	intervention	_	_	O
116	was	_	_	O
117	to	_	_	O
118	alter	_	_	O
119	fatigue-related	_	_	O
120	thoughts	_	_	O
121	and	_	_	O
122	behavior	_	_	O
123	.	_	_	O

124	Primary	_	_	O
125	outcomes	_	_	O
126	were	_	_	O
127	assessed	_	_	O
128	as	_	_	O
129	follows	_	_	O
130	:	_	_	O
131	CRF	_	_	O
132	using	_	_	O
133	the	_	_	O
134	Visual	_	_	O
135	Analogue	_	_	O
136	Scale-Global	_	_	O
137	Fatigue	_	_	O
138	;	_	_	O
139	physical	_	_	O
140	functioning	_	_	O
141	using	_	_	O
142	the	_	_	O
143	European	_	_	O
144	Organization	_	_	O
145	for	_	_	O
146	Research	_	_	O
147	and	_	_	O
148	Treatment	_	_	O
149	of	_	_	O
150	Cancer	_	_	O
151	Quality-of-Life	_	_	O
152	Core	_	_	O
153	30	_	_	O
154	Questionnaire	_	_	O
155	,	_	_	O
156	and	_	_	O
157	CRF-associated	_	_	O
158	distress	_	_	O
159	using	_	_	O
160	the	_	_	O
161	Fatigue	_	_	O
162	Outcome	_	_	O
163	Measure	_	_	O
164	.	_	_	O

165	Assessments	_	_	O
166	were	_	_	O
167	made	_	_	O
168	on	_	_	O
169	4	_	_	O
170	occasions	_	_	O
171	:	_	_	O
172	at	_	_	O
173	baseline	_	_	O
174	(	_	_	O
175	T0	_	_	O
176	)	_	_	O
177	,	_	_	O
178	at	_	_	O
179	the	_	_	O
180	end	_	_	O
181	of	_	_	O
182	chemotherapy	_	_	O
183	(	_	_	O
184	T1	_	_	O
185	)	_	_	O
186	,	_	_	O
187	1	_	_	O
188	month	_	_	O
189	after	_	_	O
190	chemotherapy	_	_	O
191	(	_	_	O
192	T2	_	_	O
193	)	_	_	O
194	,	_	_	O
195	and	_	_	O
196	9	_	_	O
197	months	_	_	O
198	after	_	_	O
199	recruitment	_	_	O
200	(	_	_	O
201	T3	_	_	O
202	)	_	_	O
203	.	_	_	O

204	Normally	_	_	O
205	distributed	_	_	O
206	data	_	_	O
207	were	_	_	O
208	analyzed	_	_	O
209	using	_	_	O
210	t	_	_	O
211	tests	_	_	O
212	and	_	_	O
213	random-slope/random-intercept	_	_	O
214	mixed	_	_	O
215	models	_	_	O
216	.	_	_	O

217	The	_	_	B-Premise
218	intervention	_	_	I-Premise
219	demonstrated	_	_	I-Premise
220	a	_	_	I-Premise
221	trend	_	_	I-Premise
222	toward	_	_	I-Premise
223	improved	_	_	I-Premise
224	CRF	_	_	I-Premise
225	,	_	_	I-Premise
226	although	_	_	B-Premise
227	this	_	_	I-Premise
228	effect	_	_	I-Premise
229	was	_	_	I-Premise
230	reduced	_	_	I-Premise
231	once	_	_	I-Premise
232	confounders	_	_	I-Premise
233	had	_	_	I-Premise
234	been	_	_	I-Premise
235	controlled	_	_	I-Premise
236	statistically	_	_	I-Premise
237	.	_	_	I-Premise

238	There	_	_	B-Premise
239	was	_	_	I-Premise
240	a	_	_	I-Premise
241	significant	_	_	I-Premise
242	improvement	_	_	I-Premise
243	in	_	_	I-Premise
244	physical	_	_	I-Premise
245	functioning	_	_	I-Premise
246	(	_	_	I-Premise
247	coefficient	_	_	I-Premise
248	,	_	_	I-Premise
249	10.0	_	_	I-Premise
250	;	_	_	I-Premise
251	95	_	_	I-Premise
252	%	_	_	I-Premise
253	confidence	_	_	I-Premise
254	interval	_	_	I-Premise
255	,	_	_	I-Premise
256	2.5-17.5	_	_	I-Premise
257	;	_	_	I-Premise
258	P	_	_	I-Premise
259	=	_	_	I-Premise
260	.009	_	_	I-Premise
261	)	_	_	I-Premise
262	,	_	_	I-Premise
263	and	_	_	I-Premise
264	this	_	_	I-Premise
265	effect	_	_	I-Premise
266	remained	_	_	I-Premise
267	once	_	_	I-Premise
268	the	_	_	I-Premise
269	confounding	_	_	I-Premise
270	effects	_	_	I-Premise
271	of	_	_	I-Premise
272	mood	_	_	I-Premise
273	disturbance	_	_	I-Premise
274	and	_	_	I-Premise
275	comorbid	_	_	I-Premise
276	disorders	_	_	I-Premise
277	were	_	_	I-Premise
278	controlled	_	_	I-Premise
279	statistically	_	_	I-Premise
280	.	_	_	I-Premise

281	No	_	_	B-Premise
282	decrease	_	_	I-Premise
283	in	_	_	I-Premise
284	fatigue-related	_	_	I-Premise
285	distress	_	_	I-Premise
286	was	_	_	I-Premise
287	detected	_	_	I-Premise
288	.	_	_	I-Premise

289	The	_	_	B-Claim
290	behaviorally	_	_	I-Claim
291	oriented	_	_	I-Claim
292	intervention	_	_	I-Claim
293	brought	_	_	I-Claim
294	about	_	_	I-Claim
295	significant	_	_	I-Claim
296	improvements	_	_	I-Claim
297	in	_	_	I-Claim
298	physical	_	_	I-Claim
299	functioning	_	_	I-Claim
300	,	_	_	I-Claim
301	indicated	_	_	I-Claim
302	a	_	_	I-Claim
303	trend	_	_	I-Claim
304	toward	_	_	I-Claim
305	improved	_	_	I-Claim
306	CRF	_	_	I-Claim
307	,	_	_	I-Claim
308	but	_	_	I-Claim
309	detected	_	_	I-Claim
310	no	_	_	I-Claim
311	effect	_	_	I-Claim
312	for	_	_	I-Claim
313	fatigue-related	_	_	I-Claim
314	distress	_	_	I-Claim
315	.	_	_	I-Claim


0	Tumor	_	_	B-Claim
1	necrosis	_	_	I-Claim
2	factor-alpha	_	_	I-Claim
3	(	_	_	I-Claim
4	TNF-alpha	_	_	I-Claim
5	)	_	_	I-Claim
6	is	_	_	I-Claim
7	a	_	_	I-Claim
8	putative	_	_	I-Claim
9	mediator	_	_	I-Claim
10	of	_	_	I-Claim
11	the	_	_	I-Claim
12	cancer	_	_	I-Claim
13	anorexia/weight	_	_	I-Claim
14	loss	_	_	I-Claim
15	syndrome	_	_	I-Claim
16	.	_	_	I-Claim

17	The	_	_	O
18	current	_	_	O
19	study	_	_	O
20	was	_	_	O
21	designed	_	_	O
22	to	_	_	O
23	determine	_	_	O
24	whether	_	_	O
25	etanercept	_	_	O
26	(	_	_	O
27	a	_	_	O
28	dimeric	_	_	O
29	fusion	_	_	O
30	protein	_	_	O
31	consisting	_	_	O
32	of	_	_	O
33	the	_	_	O
34	extracellular	_	_	O
35	ligand-binding	_	_	O
36	portion	_	_	O
37	of	_	_	O
38	the	_	_	O
39	human	_	_	O
40	75-kilodalton	_	_	O
41	TNF	_	_	O
42	receptor	_	_	O
43	linked	_	_	O
44	to	_	_	O
45	the	_	_	O
46	Fc	_	_	O
47	portion	_	_	O
48	of	_	_	O
49	human	_	_	O
50	immunoglobulin	_	_	O
51	[	_	_	O
52	Ig	_	_	O
53	]	_	_	O
54	G1	_	_	O
55	)	_	_	O
56	could	_	_	O
57	palliate	_	_	O
58	this	_	_	O
59	syndrome	_	_	O
60	.	_	_	O

61	A	_	_	O
62	total	_	_	O
63	of	_	_	O
64	63	_	_	O
65	evaluable	_	_	O
66	patients	_	_	O
67	were	_	_	O
68	randomly	_	_	O
69	assigned	_	_	O
70	to	_	_	O
71	receive	_	_	O
72	either	_	_	O
73	etanercept	_	_	O
74	at	_	_	O
75	a	_	_	O
76	dose	_	_	O
77	of	_	_	O
78	25	_	_	O
79	mg	_	_	O
80	subcutaneously	_	_	O
81	twice	_	_	O
82	weekly	_	_	O
83	versus	_	_	O
84	a	_	_	O
85	comparably	_	_	O
86	administered	_	_	O
87	placebo	_	_	O
88	.	_	_	O

89	All	_	_	O
90	patients	_	_	O
91	had	_	_	O
92	an	_	_	O
93	incurable	_	_	O
94	malignancy	_	_	O
95	,	_	_	O
96	acknowledged	_	_	O
97	loss	_	_	O
98	of	_	_	O
99	weight	_	_	O
100	and/or	_	_	O
101	appetite	_	_	O
102	as	_	_	O
103	a	_	_	O
104	concern	_	_	O
105	,	_	_	O
106	and	_	_	O
107	reported	_	_	O
108	a	_	_	O
109	weight	_	_	O
110	loss	_	_	O
111	of	_	_	O
112	>	_	_	O
113	2.27	_	_	O
114	kg	_	_	O
115	over	_	_	O
116	2	_	_	O
117	months	_	_	O
118	and/or	_	_	O
119	a	_	_	O
120	daily	_	_	O
121	intake	_	_	O
122	of	_	_	O
123	<	_	_	O
124	20	_	_	O
125	calories/kg	_	_	O
126	body	_	_	O
127	weight	_	_	O
128	.	_	_	O

129	Over	_	_	B-Premise
130	time	_	_	I-Premise
131	,	_	_	I-Premise
132	weight	_	_	I-Premise
133	gain	_	_	I-Premise
134	was	_	_	I-Premise
135	found	_	_	I-Premise
136	to	_	_	I-Premise
137	be	_	_	I-Premise
138	minimal	_	_	I-Premise
139	in	_	_	I-Premise
140	both	_	_	I-Premise
141	treatment	_	_	I-Premise
142	arms	_	_	I-Premise
143	;	_	_	I-Premise
144	no	_	_	I-Premise
145	patient	_	_	I-Premise
146	gained	_	_	I-Premise
147	>	_	_	I-Premise
148	or=10	_	_	I-Premise
149	%	_	_	I-Premise
150	of	_	_	I-Premise
151	their	_	_	I-Premise
152	baseline	_	_	I-Premise
153	weight	_	_	I-Premise
154	.	_	_	I-Premise

155	Previously	_	_	B-Premise
156	validated	_	_	I-Premise
157	appetite	_	_	I-Premise
158	questionnaires	_	_	I-Premise
159	revealed	_	_	I-Premise
160	negligible	_	_	I-Premise
161	improvements	_	_	I-Premise
162	in	_	_	I-Premise
163	both	_	_	I-Premise
164	treatment	_	_	I-Premise
165	arms	_	_	I-Premise
166	.	_	_	I-Premise

167	The	_	_	B-Premise
168	median	_	_	I-Premise
169	survival	_	_	I-Premise
170	was	_	_	I-Premise
171	also	_	_	I-Premise
172	comparable	_	_	I-Premise
173	(	_	_	I-Premise
174	175	_	_	I-Premise
175	days	_	_	I-Premise
176	vs	_	_	I-Premise
177	148	_	_	I-Premise
178	days	_	_	I-Premise
179	in	_	_	I-Premise
180	etanercept-treated	_	_	I-Premise
181	and	_	_	I-Premise
182	placebo-exposed	_	_	I-Premise
183	patients	_	_	I-Premise
184	,	_	_	I-Premise
185	respectively	_	_	I-Premise
186	;	_	_	I-Premise
187	P	_	_	I-Premise
188	=	_	_	I-Premise
189	.82	_	_	I-Premise
190	)	_	_	I-Premise
191	.	_	_	I-Premise

192	Finally	_	_	O
193	,	_	_	O
194	preliminary	_	_	B-Premise
195	data	_	_	I-Premise
196	regarding	_	_	I-Premise
197	adverse	_	_	I-Premise
198	events	_	_	I-Premise
199	demonstrated	_	_	I-Premise
200	that	_	_	I-Premise
201	patients	_	_	I-Premise
202	treated	_	_	I-Premise
203	with	_	_	I-Premise
204	etanercept	_	_	I-Premise
205	had	_	_	I-Premise
206	higher	_	_	I-Premise
207	rates	_	_	I-Premise
208	of	_	_	I-Premise
209	neurotoxicity	_	_	I-Premise
210	(	_	_	I-Premise
211	29	_	_	I-Premise
212	%	_	_	I-Premise
213	vs	_	_	I-Premise
214	0	_	_	I-Premise
215	%	_	_	I-Premise
216	)	_	_	I-Premise
217	but	_	_	I-Premise
218	lower	_	_	I-Premise
219	rates	_	_	I-Premise
220	of	_	_	I-Premise
221	anemia	_	_	I-Premise
222	(	_	_	I-Premise
223	0	_	_	I-Premise
224	%	_	_	I-Premise
225	vs	_	_	I-Premise
226	19	_	_	I-Premise
227	%	_	_	I-Premise
228	)	_	_	I-Premise
229	and	_	_	I-Premise
230	thrombocytopenia	_	_	I-Premise
231	(	_	_	I-Premise
232	0	_	_	I-Premise
233	%	_	_	I-Premise
234	vs	_	_	I-Premise
235	14	_	_	I-Premise
236	%	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	Infection	_	_	B-Premise
240	rates	_	_	I-Premise
241	were	_	_	I-Premise
242	negligible	_	_	I-Premise
243	in	_	_	I-Premise
244	both	_	_	I-Premise
245	groups	_	_	I-Premise
246	.	_	_	I-Premise

247	Genotyping	_	_	B-Premise
248	for	_	_	I-Premise
249	TNF-alpha-238	_	_	I-Premise
250	and	_	_	I-Premise
251	TNF-alpha-308	_	_	I-Premise
252	polymorphisms	_	_	I-Premise
253	revealed	_	_	I-Premise
254	no	_	_	I-Premise
255	clinical	_	_	I-Premise
256	significance	_	_	I-Premise
257	for	_	_	I-Premise
258	these	_	_	I-Premise
259	genotypes	_	_	I-Premise
260	,	_	_	I-Premise
261	except	_	_	I-Premise
262	for	_	_	I-Premise
263	a	_	_	I-Premise
264	preliminary	_	_	I-Premise
265	association	_	_	I-Premise
266	between	_	_	I-Premise
267	presence	_	_	I-Premise
268	of	_	_	I-Premise
269	the	_	_	I-Premise
270	-238	_	_	I-Premise
271	G/A	_	_	I-Premise
272	genotype	_	_	I-Premise
273	and	_	_	I-Premise
274	relatively	_	_	I-Premise
275	less	_	_	I-Premise
276	favorable	_	_	I-Premise
277	survival	_	_	I-Premise
278	.	_	_	I-Premise

279	Etanercept	_	_	B-Claim
280	,	_	_	I-Claim
281	as	_	_	I-Claim
282	prescribed	_	_	I-Claim
283	in	_	_	I-Claim
284	the	_	_	I-Claim
285	current	_	_	I-Claim
286	trial	_	_	I-Claim
287	,	_	_	I-Claim
288	does	_	_	I-Claim
289	not	_	_	I-Claim
290	appear	_	_	I-Claim
291	to	_	_	I-Claim
292	palliate	_	_	I-Claim
293	the	_	_	I-Claim
294	cancer	_	_	I-Claim
295	anorexia/weight	_	_	I-Claim
296	loss	_	_	I-Claim
297	syndrome	_	_	I-Claim
298	in	_	_	I-Claim
299	patients	_	_	I-Claim
300	with	_	_	I-Claim
301	advanced	_	_	I-Claim
302	disease	_	_	I-Claim
303	.	_	_	I-Claim


0	Patients	_	_	B-Claim
1	receiving	_	_	I-Claim
2	chemotherapy	_	_	I-Claim
3	for	_	_	I-Claim
4	cancer	_	_	I-Claim
5	often	_	_	I-Claim
6	develop	_	_	I-Claim
7	anemia	_	_	I-Claim
8	,	_	_	I-Claim
9	which	_	_	I-Claim
10	can	_	_	I-Claim
11	contribute	_	_	I-Claim
12	to	_	_	I-Claim
13	increased	_	_	I-Claim
14	morbidity	_	_	I-Claim
15	and	_	_	I-Claim
16	reduced	_	_	I-Claim
17	quality	_	_	I-Claim
18	of	_	_	I-Claim
19	life	_	_	I-Claim
20	(	_	_	I-Claim
21	QOL	_	_	I-Claim
22	)	_	_	I-Claim
23	.	_	_	I-Claim

24	Chemotherapy-induced	_	_	B-Claim
25	anemia	_	_	I-Claim
26	can	_	_	I-Claim
27	be	_	_	I-Claim
28	successfully	_	_	I-Claim
29	treated	_	_	I-Claim
30	using	_	_	I-Claim
31	recombinant	_	_	I-Claim
32	human	_	_	I-Claim
33	erythropoietin	_	_	I-Claim
34	(	_	_	I-Claim
35	rHuEPO	_	_	I-Claim
36	)	_	_	I-Claim
37	.	_	_	I-Claim

38	To	_	_	O
39	demonstrate	_	_	O
40	the	_	_	O
41	effectiveness	_	_	O
42	of	_	_	O
43	once-weekly	_	_	O
44	(	_	_	O
45	QW	_	_	O
46	)	_	_	O
47	rHuEPO	_	_	O
48	dosing	_	_	O
49	to	_	_	O
50	effect	_	_	O
51	improved	_	_	O
52	hemoglobin	_	_	O
53	levels	_	_	O
54	,	_	_	O
55	decreased	_	_	O
56	transfusion	_	_	O
57	use	_	_	O
58	,	_	_	O
59	and	_	_	O
60	improved	_	_	O
61	functional	_	_	O
62	outcomes	_	_	O
63	and	_	_	O
64	QOL	_	_	O
65	in	_	_	O
66	pediatric	_	_	O
67	leukemic	_	_	O
68	patients	_	_	O
69	(	_	_	O
70	ALL	_	_	O
71	)	_	_	O
72	receiving	_	_	O
73	maintenance	_	_	O
74	chemotherapy	_	_	O
75	.	_	_	O

76	This	_	_	O
77	was	_	_	O
78	a	_	_	O
79	prospective	_	_	O
80	randomized	_	_	O
81	,	_	_	O
82	single-center	_	_	O
83	,	_	_	O
84	open-label	_	_	O
85	,	_	_	O
86	12-week	_	_	O
87	case-control	_	_	O
88	study	_	_	O
89	of	_	_	O
90	epoetin	_	_	O
91	alfa	_	_	O
92	in	_	_	O
93	pediatric	_	_	O
94	patients	_	_	O
95	with	_	_	O
96	acute	_	_	O
97	lymphoblastic	_	_	O
98	leukemia	_	_	O
99	(	_	_	O
100	ALL	_	_	O
101	)	_	_	O
102	in	_	_	O
103	remission	_	_	O
104	receiving	_	_	O
105	maintenance	_	_	O
106	chemotherapy	_	_	O
107	.	_	_	O

108	Sixty	_	_	O
109	patients	_	_	O
110	were	_	_	O
111	randomly	_	_	O
112	assigned	_	_	O
113	to	_	_	O
114	receive	_	_	O
115	either	_	_	O
116	epoetin	_	_	O
117	alfa	_	_	O
118	(	_	_	O
119	rHuEPO	_	_	O
120	group	_	_	O
121	=	_	_	O
122	30	_	_	O
123	cases	_	_	O
124	,	_	_	O
125	17	_	_	O
126	males	_	_	O
127	and	_	_	O
128	13	_	_	O
129	females	_	_	O
130	,	_	_	O
131	age	_	_	O
132	;	_	_	O
133	6.8	_	_	O
134	+/-	_	_	O
135	2.33	_	_	O
136	years	_	_	O
137	)	_	_	O
138	,	_	_	O
139	or	_	_	O
140	no	_	_	O
141	epoetin	_	_	O
142	alfa	_	_	O
143	(	_	_	O
144	control	_	_	O
145	group	_	_	O
146	=	_	_	O
147	30	_	_	O
148	cases	_	_	O
149	,	_	_	O
150	16	_	_	O
151	males	_	_	O
152	and	_	_	O
153	14	_	_	O
154	females	_	_	O
155	,	_	_	O
156	age	_	_	O
157	;	_	_	O
158	6.76	_	_	O
159	+/-	_	_	O
160	2.28	_	_	O
161	years	_	_	O
162	)	_	_	O
163	.	_	_	O

164	Both	_	_	O
165	groups	_	_	O
166	were	_	_	O
167	matched	_	_	O
168	as	_	_	O
169	regard	_	_	O
170	age	_	_	O
171	,	_	_	O
172	sex	_	_	O
173	,	_	_	O
174	baseline	_	_	O
175	Hb	_	_	O
176	concentration	_	_	O
177	,	_	_	O
178	remission	_	_	O
179	state	_	_	O
180	,	_	_	O
181	chemotherapy	_	_	O
182	regimen	_	_	O
183	,	_	_	O
184	numbers	_	_	O
185	and	_	_	O
186	amount	_	_	O
187	of	_	_	O
188	blood	_	_	O
189	transfusion	_	_	O
190	,	_	_	O
191	and	_	_	O
192	leukemia	_	_	O
193	state	_	_	O
194	(	_	_	O
195	both	_	_	O
196	were	_	_	O
197	low	_	_	O
198	and	_	_	O
199	standard	_	_	O
200	risk	_	_	O
201	)	_	_	O
202	.	_	_	O

203	Epoetin	_	_	O
204	alfa	_	_	O
205	was	_	_	O
206	administered	_	_	O
207	at	_	_	O
208	a	_	_	O
209	dose	_	_	O
210	of	_	_	O
211	450	_	_	O
212	IU/kg	_	_	O
213	,	_	_	O
214	once	_	_	O
215	weekly	_	_	O
216	,	_	_	O
217	subcutaneously	_	_	O
218	(	_	_	O
219	s.c.	_	_	O
220	)	_	_	O
221	for	_	_	O
222	12	_	_	O
223	consecutive	_	_	O
224	weeks	_	_	O
225	.	_	_	O

226	Endpoints	_	_	O
227	were	_	_	O
228	changes	_	_	O
229	in	_	_	O
230	hematologic	_	_	O
231	and	_	_	O
232	QOL	_	_	O
233	parameters	_	_	O
234	.	_	_	O

235	Among	_	_	B-Premise
236	the	_	_	I-Premise
237	30	_	_	I-Premise
238	patients	_	_	I-Premise
239	evaluable	_	_	I-Premise
240	for	_	_	I-Premise
241	hematologic	_	_	I-Premise
242	response	_	_	I-Premise
243	,	_	_	I-Premise
244	the	_	_	I-Premise
245	mean	_	_	I-Premise
246	increase	_	_	I-Premise
247	in	_	_	I-Premise
248	Hb	_	_	I-Premise
249	from	_	_	I-Premise
250	baseline	_	_	I-Premise
251	to	_	_	I-Premise
252	time	_	_	I-Premise
253	of	_	_	I-Premise
254	final	_	_	I-Premise
255	evaluation	_	_	I-Premise
256	was	_	_	I-Premise
257	3.08	_	_	I-Premise
258	+/-	_	_	I-Premise
259	1.48	_	_	I-Premise
260	g/dl	_	_	I-Premise
261	(	_	_	I-Premise
262	p	_	_	I-Premise
263	<	_	_	I-Premise
264	0.001	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	An	_	_	B-Premise
268	increase	_	_	I-Premise
269	in	_	_	I-Premise
270	Hb	_	_	I-Premise
271	of	_	_	I-Premise
272	>	_	_	I-Premise
273	or	_	_	I-Premise
274	=	_	_	I-Premise
275	2	_	_	I-Premise
276	g/dl	_	_	I-Premise
277	,	_	_	I-Premise
278	in	_	_	I-Premise
279	the	_	_	I-Premise
280	absence	_	_	I-Premise
281	of	_	_	I-Premise
282	blood	_	_	I-Premise
283	transfusion	_	_	I-Premise
284	,	_	_	I-Premise
285	occurred	_	_	I-Premise
286	in	_	_	I-Premise
287	70	_	_	I-Premise
288	%	_	_	I-Premise
289	of	_	_	I-Premise
290	patients	_	_	I-Premise
291	(	_	_	I-Premise
292	21	_	_	I-Premise
293	of	_	_	I-Premise
294	30	_	_	I-Premise
295	patients	_	_	I-Premise
296	)	_	_	I-Premise
297	who	_	_	I-Premise
298	were	_	_	I-Premise
299	on	_	_	I-Premise
300	the	_	_	I-Premise
301	study	_	_	I-Premise
302	for	_	_	I-Premise
303	>	_	_	I-Premise
304	or	_	_	I-Premise
305	=	_	_	I-Premise
306	30	_	_	I-Premise
307	days	_	_	I-Premise
308	.	_	_	I-Premise

309	The	_	_	B-Premise
310	overall	_	_	I-Premise
311	response	_	_	I-Premise
312	rate	_	_	I-Premise
313	(	_	_	I-Premise
314	Hb	_	_	I-Premise
315	increase	_	_	I-Premise
316	>	_	_	I-Premise
317	or	_	_	I-Premise
318	=	_	_	I-Premise
319	2	_	_	I-Premise
320	g/dl	_	_	I-Premise
321	or	_	_	I-Premise
322	Hb	_	_	I-Premise
323	>	_	_	I-Premise
324	or	_	_	I-Premise
325	=	_	_	I-Premise
326	12	_	_	I-Premise
327	g/dl	_	_	I-Premise
328	in	_	_	I-Premise
329	the	_	_	I-Premise
330	absence	_	_	I-Premise
331	of	_	_	I-Premise
332	blood	_	_	I-Premise
333	transfusion	_	_	I-Premise
334	)	_	_	I-Premise
335	was	_	_	I-Premise
336	90	_	_	I-Premise
337	%	_	_	I-Premise
338	(	_	_	I-Premise
339	27	_	_	I-Premise
340	of	_	_	I-Premise
341	30	_	_	I-Premise
342	patients	_	_	I-Premise
343	)	_	_	I-Premise
344	.	_	_	I-Premise

345	In	_	_	B-Premise
346	30	_	_	I-Premise
347	patients	_	_	I-Premise
348	who	_	_	I-Premise
349	were	_	_	I-Premise
350	evaluable	_	_	I-Premise
351	for	_	_	I-Premise
352	QOL	_	_	I-Premise
353	assessment	_	_	I-Premise
354	,	_	_	I-Premise
355	epoetin-alpha	_	_	I-Premise
356	therapy	_	_	I-Premise
357	was	_	_	I-Premise
358	found	_	_	I-Premise
359	to	_	_	I-Premise
360	significantly	_	_	I-Premise
361	(	_	_	I-Premise
362	p	_	_	I-Premise
363	<	_	_	I-Premise
364	0.001	_	_	I-Premise
365	)	_	_	I-Premise
366	improve	_	_	I-Premise
367	mean	_	_	I-Premise
368	cancer	_	_	I-Premise
369	linear	_	_	I-Premise
370	analog	_	_	I-Premise
371	scale	_	_	I-Premise
372	(	_	_	I-Premise
373	CLAS	_	_	I-Premise
374	)	_	_	I-Premise
375	scores	_	_	I-Premise
376	for	_	_	I-Premise
377	energy	_	_	I-Premise
378	level	_	_	I-Premise
379	,	_	_	I-Premise
380	ability	_	_	I-Premise
381	to	_	_	I-Premise
382	perform	_	_	I-Premise
383	daily	_	_	I-Premise
384	activity	_	_	I-Premise
385	,	_	_	I-Premise
386	and	_	_	I-Premise
387	overall	_	_	I-Premise
388	QOL	_	_	I-Premise
389	from	_	_	I-Premise
390	baseline	_	_	I-Premise
391	to	_	_	I-Premise
392	the	_	_	I-Premise
393	time	_	_	I-Premise
394	of	_	_	I-Premise
395	final	_	_	I-Premise
396	evaluation	_	_	I-Premise
397	.	_	_	I-Premise

398	QW	_	_	B-Premise
399	epoetin-alpha	_	_	I-Premise
400	was	_	_	I-Premise
401	found	_	_	I-Premise
402	to	_	_	I-Premise
403	be	_	_	I-Premise
404	well	_	_	I-Premise
405	tolerated	_	_	I-Premise
406	.	_	_	I-Premise

407	Treatment	_	_	B-Claim
408	with	_	_	I-Claim
409	QW	_	_	I-Claim
410	epoetin-alpha	_	_	I-Claim
411	was	_	_	I-Claim
412	found	_	_	I-Claim
413	to	_	_	I-Claim
414	increase	_	_	I-Claim
415	Hb	_	_	I-Claim
416	levels	_	_	I-Claim
417	,	_	_	I-Claim
418	decrease	_	_	I-Claim
419	transfusion	_	_	I-Claim
420	requirement	_	_	I-Claim
421	,	_	_	I-Claim
422	and	_	_	I-Claim
423	improve	_	_	I-Claim
424	functional	_	_	I-Claim
425	status	_	_	I-Claim
426	and	_	_	I-Claim
427	QOL	_	_	I-Claim
428	in	_	_	I-Claim
429	anemic	_	_	I-Claim
430	patients	_	_	I-Claim
431	with	_	_	I-Claim
432	ALL	_	_	I-Claim
433	in	_	_	I-Claim
434	maintenance	_	_	I-Claim
435	receiving	_	_	I-Claim
436	chemotherapy	_	_	I-Claim
437	.	_	_	I-Claim

438	The	_	_	B-Claim
439	once-weekly	_	_	I-Claim
440	schedule	_	_	I-Claim
441	is	_	_	I-Claim
442	convenient	_	_	I-Claim
443	,	_	_	I-Claim
444	safe	_	_	I-Claim
445	,	_	_	I-Claim
446	and	_	_	I-Claim
447	may	_	_	I-Claim
448	reduce	_	_	I-Claim
449	the	_	_	I-Claim
450	burden	_	_	I-Claim
451	on	_	_	I-Claim
452	patients	_	_	I-Claim
453	,	_	_	I-Claim
454	parents	_	_	I-Claim
455	,	_	_	I-Claim
456	and	_	_	I-Claim
457	their	_	_	I-Claim
458	caregivers	_	_	I-Claim
459	by	_	_	I-Claim
460	reducing	_	_	I-Claim
461	the	_	_	I-Claim
462	number	_	_	I-Claim
463	of	_	_	I-Claim
464	visits	_	_	I-Claim
465	to	_	_	I-Claim
466	the	_	_	I-Claim
467	clinic	_	_	I-Claim
468	.	_	_	I-Claim


0	Studies	_	_	O
1	have	_	_	O
2	shown	_	_	O
3	that	_	_	O
4	there	_	_	O
5	is	_	_	O
6	a	_	_	O
7	high	_	_	O
8	prevalence	_	_	O
9	of	_	_	O
10	depression	_	_	O
11	in	_	_	O
12	cancer	_	_	O
13	patients	_	_	O
14	.	_	_	O

15	Women	_	_	B-Claim
16	with	_	_	I-Claim
17	breast	_	_	I-Claim
18	cancer	_	_	I-Claim
19	may	_	_	I-Claim
20	have	_	_	I-Claim
21	an	_	_	I-Claim
22	even	_	_	I-Claim
23	higher	_	_	I-Claim
24	risk	_	_	I-Claim
25	of	_	_	I-Claim
26	depression	_	_	I-Claim
27	particularly	_	_	I-Claim
28	in	_	_	I-Claim
29	a	_	_	I-Claim
30	postmenopausal	_	_	I-Claim
31	or	_	_	I-Claim
32	estrogen	_	_	I-Claim
33	deficiency	_	_	I-Claim
34	state	_	_	I-Claim
35	.	_	_	I-Claim

36	A	_	_	O
37	small	_	_	O
38	number	_	_	O
39	of	_	_	O
40	randomized	_	_	O
41	controlled	_	_	O
42	trials	_	_	O
43	have	_	_	O
44	examined	_	_	O
45	the	_	_	O
46	efficacy	_	_	O
47	of	_	_	O
48	antidepressants	_	_	O
49	compared	_	_	O
50	to	_	_	O
51	that	_	_	O
52	of	_	_	O
53	a	_	_	O
54	placebo	_	_	O
55	in	_	_	O
56	cancer	_	_	O
57	patients	_	_	O
58	,	_	_	O
59	but	_	_	O
60	some	_	_	O
61	results	_	_	O
62	have	_	_	O
63	been	_	_	O
64	difficult	_	_	O
65	to	_	_	O
66	interpret	_	_	O
67	due	_	_	O
68	to	_	_	O
69	a	_	_	O
70	heterogeneous	_	_	O
71	patient	_	_	O
72	group	_	_	O
73	.	_	_	O

74	In	_	_	O
75	the	_	_	O
76	current	_	_	O
77	investigation	_	_	O
78	,	_	_	O
79	we	_	_	O
80	screened	_	_	O
81	newly	_	_	O
82	diagnosed	_	_	O
83	early	_	_	O
84	stage	_	_	O
85	breast	_	_	O
86	cancer	_	_	O
87	patients	_	_	O
88	for	_	_	O
89	depressive	_	_	O
90	symptoms	_	_	O
91	prior	_	_	O
92	to	_	_	O
93	the	_	_	O
94	initiation	_	_	O
95	of	_	_	O
96	adjuvant	_	_	O
97	therapy	_	_	O
98	and	_	_	O
99	investigated	_	_	O
100	whether	_	_	O
101	the	_	_	O
102	oral	_	_	O
103	antidepressant	_	_	O
104	fluoxetine	_	_	O
105	affected	_	_	O
106	depressive	_	_	O
107	symptoms	_	_	O
108	,	_	_	O
109	completion	_	_	O
110	of	_	_	O
111	adjuvant	_	_	O
112	treatment	_	_	O
113	,	_	_	O
114	and	_	_	O
115	quality	_	_	O
116	of	_	_	O
117	life	_	_	O
118	.	_	_	O

119	Patients	_	_	O
120	with	_	_	O
121	newly	_	_	O
122	diagnosed	_	_	O
123	early	_	_	O
124	stage	_	_	O
125	breast	_	_	O
126	cancer	_	_	O
127	were	_	_	O
128	screened	_	_	O
129	for	_	_	O
130	depressive	_	_	O
131	symptoms	_	_	O
132	prior	_	_	O
133	to	_	_	O
134	the	_	_	O
135	initiation	_	_	O
136	of	_	_	O
137	adjuvant	_	_	O
138	therapy	_	_	O
139	.	_	_	O

140	Patients	_	_	O
141	with	_	_	O
142	depressive	_	_	O
143	symptoms	_	_	O
144	were	_	_	O
145	randomized	_	_	O
146	to	_	_	O
147	a	_	_	O
148	daily	_	_	O
149	oral	_	_	O
150	fluoxetine	_	_	O
151	or	_	_	O
152	a	_	_	O
153	placebo	_	_	O
154	.	_	_	O

155	Patients	_	_	O
156	were	_	_	O
157	then	_	_	O
158	followed	_	_	O
159	for	_	_	O
160	6	_	_	O
161	months	_	_	O
162	and	_	_	O
163	evaluated	_	_	O
164	for	_	_	O
165	quality	_	_	O
166	of	_	_	O
167	life	_	_	O
168	,	_	_	O
169	completion	_	_	O
170	of	_	_	O
171	adjuvant	_	_	O
172	treatment	_	_	O
173	,	_	_	O
174	and	_	_	O
175	depressive	_	_	O
176	symptoms	_	_	O
177	.	_	_	O

178	A	_	_	O
179	high	_	_	O
180	percentage	_	_	O
181	of	_	_	O
182	patients	_	_	O
183	with	_	_	O
184	newly	_	_	O
185	diagnosed	_	_	O
186	early	_	_	O
187	stage	_	_	O
188	breast	_	_	O
189	cancer	_	_	O
190	were	_	_	O
191	found	_	_	O
192	to	_	_	O
193	have	_	_	O
194	depressive	_	_	O
195	symptoms	_	_	O
196	prior	_	_	O
197	to	_	_	O
198	the	_	_	O
199	initiation	_	_	O
200	of	_	_	O
201	adjuvant	_	_	O
202	therapy	_	_	O
203	.	_	_	O

204	The	_	_	B-Premise
205	use	_	_	I-Premise
206	of	_	_	I-Premise
207	fluoxetine	_	_	I-Premise
208	for	_	_	I-Premise
209	6	_	_	I-Premise
210	months	_	_	I-Premise
211	resulted	_	_	I-Premise
212	in	_	_	I-Premise
213	an	_	_	I-Premise
214	improvement	_	_	I-Premise
215	in	_	_	I-Premise
216	quality	_	_	I-Premise
217	of	_	_	I-Premise
218	life	_	_	I-Premise
219	,	_	_	I-Premise
220	a	_	_	I-Premise
221	higher	_	_	I-Premise
222	completion	_	_	I-Premise
223	of	_	_	I-Premise
224	adjuvant	_	_	I-Premise
225	treatment	_	_	I-Premise
226	(	_	_	I-Premise
227	chemotherapy	_	_	I-Premise
228	,	_	_	I-Premise
229	hormonal	_	_	I-Premise
230	therapy	_	_	I-Premise
231	,	_	_	I-Premise
232	chemotherapy	_	_	I-Premise
233	plus	_	_	I-Premise
234	hormonal	_	_	I-Premise
235	therapy	_	_	I-Premise
236	)	_	_	I-Premise
237	,	_	_	I-Premise
238	and	_	_	I-Premise
239	a	_	_	I-Premise
240	reduction	_	_	I-Premise
241	in	_	_	I-Premise
242	depressive	_	_	I-Premise
243	symptoms	_	_	I-Premise
244	compared	_	_	I-Premise
245	to	_	_	I-Premise
246	patients	_	_	I-Premise
247	who	_	_	I-Premise
248	received	_	_	I-Premise
249	placebo	_	_	I-Premise
250	.	_	_	I-Premise

251	An	_	_	B-Claim
252	antidepressant	_	_	I-Claim
253	should	_	_	I-Claim
254	be	_	_	I-Claim
255	considered	_	_	I-Claim
256	for	_	_	I-Claim
257	early	_	_	I-Claim
258	stage	_	_	I-Claim
259	breast	_	_	I-Claim
260	cancer	_	_	I-Claim
261	patients	_	_	I-Claim
262	with	_	_	I-Claim
263	depressive	_	_	I-Claim
264	symptoms	_	_	I-Claim
265	who	_	_	I-Claim
266	are	_	_	I-Claim
267	receiving	_	_	I-Claim
268	adjuvant	_	_	I-Claim
269	treatment	_	_	I-Claim
270	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	quality	_	_	O
10	of	_	_	O
11	life	_	_	O
12	(	_	_	O
13	QOL	_	_	O
14	)	_	_	O
15	of	_	_	O
16	high-risk	_	_	O
17	breast	_	_	O
18	cancer	_	_	O
19	patients	_	_	O
20	included	_	_	O
21	in	_	_	O
22	a	_	_	O
23	randomized	_	_	O
24	clinical	_	_	O
25	trial	_	_	O
26	(	_	_	O
27	PEGASE	_	_	O
28	01	_	_	O
29	)	_	_	O
30	comparing	_	_	O
31	conventional	_	_	O
32	chemotherapy	_	_	O
33	versus	_	_	O
34	adding	_	_	O
35	an	_	_	O
36	additional	_	_	O
37	high-dose	_	_	O
38	chemotherapy	_	_	O
39	(	_	_	O
40	HDC	_	_	O
41	)	_	_	O
42	cycle	_	_	O
43	with	_	_	O
44	blood	_	_	O
45	stem	_	_	O
46	cell	_	_	O
47	support	_	_	O
48	.	_	_	O

49	A	_	_	O
50	total	_	_	O
51	of	_	_	O
52	314	_	_	O
53	patients	_	_	O
54	were	_	_	O
55	included	_	_	O
56	in	_	_	O
57	the	_	_	O
58	clinical	_	_	O
59	trial	_	_	O
60	.	_	_	O

61	QOL	_	_	O
62	evaluations	_	_	O
63	were	_	_	O
64	available	_	_	O
65	for	_	_	O
66	199	_	_	O
67	patients	_	_	O
68	.	_	_	O

69	QOL	_	_	O
70	was	_	_	O
71	assessed	_	_	O
72	over	_	_	O
73	a	_	_	O
74	1-year	_	_	O
75	follow-up	_	_	O
76	period	_	_	O
77	,	_	_	O
78	using	_	_	O
79	the	_	_	O
80	European	_	_	O
81	Organization	_	_	O
82	for	_	_	O
83	Research	_	_	O
84	and	_	_	O
85	Treatment	_	_	O
86	of	_	_	O
87	Cancer	_	_	O
88	Quality	_	_	O
89	of	_	_	O
90	Life	_	_	O
91	Questionnaire	_	_	O
92	C-30	_	_	O
93	.	_	_	O

94	The	_	_	O
95	results	_	_	O
96	were	_	_	O
97	analyzed	_	_	O
98	using	_	_	O
99	a	_	_	O
100	linear	_	_	O
101	mixed-effects	_	_	O
102	model	_	_	O
103	.	_	_	O

104	Toxicity	_	_	B-Premise
105	of	_	_	I-Premise
106	HDC	_	_	I-Premise
107	has	_	_	I-Premise
108	a	_	_	I-Premise
109	strong	_	_	I-Premise
110	negative	_	_	I-Premise
111	impact	_	_	I-Premise
112	on	_	_	I-Premise
113	patients	_	_	I-Premise
114	'	_	_	I-Premise
115	QOL	_	_	I-Premise
116	during	_	_	I-Premise
117	the	_	_	I-Premise
118	treatment	_	_	I-Premise
119	phase	_	_	I-Premise
120	.	_	_	I-Premise

121	This	_	_	B-Premise
122	negative	_	_	I-Premise
123	impact	_	_	I-Premise
124	tended	_	_	I-Premise
125	to	_	_	I-Premise
126	last	_	_	I-Premise
127	longer	_	_	I-Premise
128	in	_	_	I-Premise
129	the	_	_	I-Premise
130	HDC	_	_	I-Premise
131	group	_	_	I-Premise
132	,	_	_	I-Premise
133	as	_	_	I-Premise
134	for	_	_	I-Premise
135	most	_	_	I-Premise
136	of	_	_	I-Premise
137	the	_	_	I-Premise
138	QLQ-C30	_	_	I-Premise
139	scales	_	_	I-Premise
140	,	_	_	I-Premise
141	the	_	_	I-Premise
142	QOL	_	_	I-Premise
143	scores	_	_	I-Premise
144	of	_	_	I-Premise
145	HDC	_	_	I-Premise
146	patients	_	_	I-Premise
147	tend	_	_	I-Premise
148	to	_	_	I-Premise
149	improve	_	_	I-Premise
150	at	_	_	I-Premise
151	a	_	_	I-Premise
152	slower	_	_	I-Premise
153	rate	_	_	I-Premise
154	than	_	_	I-Premise
155	that	_	_	I-Premise
156	of	_	_	I-Premise
157	patients	_	_	I-Premise
158	receiving	_	_	I-Premise
159	standard	_	_	I-Premise
160	chemotherapy	_	_	I-Premise
161	.	_	_	I-Premise

162	In	_	_	O
163	particular	_	_	O
164	,	_	_	O
165	physical	_	_	B-Premise
166	functioning	_	_	I-Premise
167	remains	_	_	I-Premise
168	deteriorated	_	_	I-Premise
169	1	_	_	I-Premise
170	year	_	_	I-Premise
171	after	_	_	I-Premise
172	inclusion	_	_	I-Premise
173	for	_	_	I-Premise
174	HDC	_	_	I-Premise
175	patients	_	_	I-Premise
176	comparatively	_	_	I-Premise
177	to	_	_	I-Premise
178	conventional	_	_	I-Premise
179	chemotherapy	_	_	I-Premise
180	patients	_	_	I-Premise
181	(	_	_	I-Premise
182	85.99	_	_	I-Premise
183	vs.	_	_	I-Premise
184	76.65	_	_	I-Premise
185	,	_	_	I-Premise
186	P	_	_	I-Premise
187	=	_	_	I-Premise
188	0.021	_	_	I-Premise
189	)	_	_	I-Premise
190	,	_	_	O
191	and	_	_	B-Premise
192	the	_	_	I-Premise
193	pain	_	_	I-Premise
194	score	_	_	I-Premise
195	was	_	_	I-Premise
196	still	_	_	I-Premise
197	higher	_	_	I-Premise
198	in	_	_	I-Premise
199	the	_	_	I-Premise
200	HDC	_	_	I-Premise
201	group	_	_	I-Premise
202	at	_	_	I-Premise
203	that	_	_	I-Premise
204	time	_	_	I-Premise
205	(	_	_	I-Premise
206	28.32	_	_	I-Premise
207	vs.	_	_	I-Premise
208	15.97	_	_	I-Premise
209	,	_	_	I-Premise
210	P	_	_	I-Premise
211	=	_	_	I-Premise
212	0.004	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	HDC	_	_	B-Claim
216	has	_	_	I-Claim
217	a	_	_	I-Claim
218	negative	_	_	I-Claim
219	impact	_	_	I-Claim
220	on	_	_	I-Claim
221	QOL	_	_	I-Claim
222	even	_	_	I-Claim
223	after	_	_	I-Claim
224	treatment	_	_	I-Claim
225	phase	_	_	I-Claim
226	.	_	_	I-Claim

227	In	_	_	O
228	the	_	_	O
229	absence	_	_	O
230	of	_	_	O
231	an	_	_	O
232	overall	_	_	O
233	survival	_	_	O
234	benefit	_	_	O
235	of	_	_	O
236	using	_	_	O
237	HDC	_	_	O
238	for	_	_	O
239	high-risk	_	_	O
240	breast	_	_	O
241	cancer	_	_	O
242	patients	_	_	O
243	,	_	_	O
244	QOL	_	_	O
245	studies	_	_	O
246	with	_	_	O
247	a	_	_	O
248	longer	_	_	O
249	follow-up	_	_	O
250	play	_	_	O
251	an	_	_	O
252	important	_	_	O
253	role	_	_	O
254	in	_	_	O
255	informing	_	_	O
256	the	_	_	O
257	complex	_	_	O
258	trade-off	_	_	O
259	implied	_	_	O
260	by	_	_	O
261	HDC	_	_	O
262	between	_	_	O
263	higher	_	_	O
264	toxicity	_	_	O
265	,	_	_	O
266	reduced	_	_	O
267	risk	_	_	O
268	of	_	_	O
269	relapse	_	_	O
270	,	_	_	O
271	and	_	_	O
272	QOL	_	_	O
273	decrease	_	_	O
274	after	_	_	O
275	the	_	_	O
276	active	_	_	O
277	phase	_	_	O
278	of	_	_	O
279	treatment	_	_	O
280	.	_	_	O


0	We	_	_	O
1	aimed	_	_	O
2	at	_	_	O
3	investigating	_	_	O
4	the	_	_	O
5	efficacy	_	_	O
6	,	_	_	O
7	tolerability	_	_	O
8	,	_	_	O
9	and	_	_	O
10	quality	_	_	O
11	of	_	_	O
12	life	_	_	O
13	(	_	_	O
14	QOL	_	_	O
15	)	_	_	O
16	of	_	_	O
17	gemcitabine	_	_	O
18	(	_	_	O
19	GEM	_	_	O
20	)	_	_	O
21	compared	_	_	O
22	with	_	_	O
23	pegylated	_	_	O
24	liposomal	_	_	O
25	doxorubicin	_	_	O
26	(	_	_	O
27	PLD	_	_	O
28	)	_	_	O
29	in	_	_	O
30	the	_	_	O
31	salvage	_	_	O
32	treatment	_	_	O
33	of	_	_	O
34	recurrent	_	_	O
35	ovarian	_	_	O
36	cancer	_	_	O
37	.	_	_	O

38	A	_	_	O
39	phase	_	_	O
40	III	_	_	O
41	randomized	_	_	O
42	multicenter	_	_	O
43	trial	_	_	O
44	was	_	_	O
45	planned	_	_	O
46	to	_	_	O
47	compare	_	_	O
48	GEM	_	_	O
49	(	_	_	O
50	1,000	_	_	O
51	mg/m	_	_	O
52	(	_	_	O
53	2	_	_	O
54	)	_	_	O
55	on	_	_	O
56	days	_	_	O
57	1	_	_	O
58	,	_	_	O
59	8	_	_	O
60	,	_	_	O
61	and	_	_	O
62	15	_	_	O
63	every	_	_	O
64	28	_	_	O
65	days	_	_	O
66	)	_	_	O
67	with	_	_	O
68	PLD	_	_	O
69	(	_	_	O
70	40	_	_	O
71	mg/m	_	_	O
72	(	_	_	O
73	2	_	_	O
74	)	_	_	O
75	every	_	_	O
76	28	_	_	O
77	days	_	_	O
78	)	_	_	O
79	in	_	_	O
80	ovarian	_	_	O
81	cancer	_	_	O
82	patients	_	_	O
83	who	_	_	O
84	experienced	_	_	O
85	treatment	_	_	O
86	failure	_	_	O
87	with	_	_	O
88	only	_	_	O
89	one	_	_	O
90	platinum/paclitaxel	_	_	O
91	regimen	_	_	O
92	and	_	_	O
93	who	_	_	O
94	experienced	_	_	O
95	recurrence	_	_	O
96	or	_	_	O
97	progression	_	_	O
98	within	_	_	O
99	12	_	_	O
100	months	_	_	O
101	after	_	_	O
102	completion	_	_	O
103	of	_	_	O
104	primary	_	_	O
105	treatment	_	_	O
106	.	_	_	O

107	One	_	_	O
108	hundred	_	_	O
109	fifty-three	_	_	O
110	patients	_	_	O
111	were	_	_	O
112	randomly	_	_	O
113	assigned	_	_	O
114	to	_	_	O
115	PLD	_	_	O
116	(	_	_	O
117	n	_	_	O
118	=	_	_	O
119	76	_	_	O
120	)	_	_	O
121	or	_	_	O
122	GEM	_	_	O
123	(	_	_	O
124	n	_	_	O
125	=	_	_	O
126	77	_	_	O
127	)	_	_	O
128	.	_	_	O

129	Treatment	_	_	O
130	arms	_	_	O
131	were	_	_	O
132	well	_	_	O
133	balanced	_	_	O
134	for	_	_	O
135	clinicopathologic	_	_	O
136	characteristics	_	_	O
137	.	_	_	O

138	Grade	_	_	O
139	3	_	_	O
140	or	_	_	O
141	4	_	_	O
142	neutropenia	_	_	O
143	was	_	_	O
144	more	_	_	O
145	frequent	_	_	O
146	in	_	_	O
147	GEM-treated	_	_	O
148	patients	_	_	O
149	versus	_	_	O
150	PLD-treated	_	_	O
151	patients	_	_	O
152	(	_	_	O
153	P	_	_	O
154	=	_	_	O
155	.007	_	_	O
156	)	_	_	O
157	.	_	_	O

158	Grade	_	_	O
159	3	_	_	O
160	or	_	_	O
161	4	_	_	O
162	palmar-plantar	_	_	O
163	erythrodysesthesia	_	_	O
164	was	_	_	O
165	documented	_	_	O
166	in	_	_	O
167	a	_	_	O
168	higher	_	_	O
169	proportion	_	_	O
170	of	_	_	O
171	PLD	_	_	O
172	patients	_	_	O
173	(	_	_	O
174	6	_	_	O
175	%	_	_	O
176	)	_	_	O
177	versus	_	_	O
178	GEM	_	_	O
179	patients	_	_	O
180	(	_	_	O
181	0	_	_	O
182	%	_	_	O
183	;	_	_	O
184	P	_	_	O
185	=	_	_	O
186	.061	_	_	O
187	)	_	_	O
188	.	_	_	O

189	The	_	_	B-Premise
190	overall	_	_	I-Premise
191	response	_	_	I-Premise
192	rate	_	_	I-Premise
193	was	_	_	I-Premise
194	16	_	_	I-Premise
195	%	_	_	I-Premise
196	in	_	_	I-Premise
197	the	_	_	I-Premise
198	PLD	_	_	I-Premise
199	arm	_	_	I-Premise
200	compared	_	_	I-Premise
201	with	_	_	I-Premise
202	29	_	_	I-Premise
203	%	_	_	I-Premise
204	in	_	_	I-Premise
205	the	_	_	I-Premise
206	GEM	_	_	I-Premise
207	arm	_	_	I-Premise
208	(	_	_	I-Premise
209	P	_	_	I-Premise
210	=	_	_	I-Premise
211	.056	_	_	I-Premise
212	)	_	_	I-Premise
213	.	_	_	I-Premise

214	No	_	_	B-Premise
215	statistically	_	_	I-Premise
216	significant	_	_	I-Premise
217	difference	_	_	I-Premise
218	in	_	_	I-Premise
219	time	_	_	I-Premise
220	to	_	_	I-Premise
221	progression	_	_	I-Premise
222	(	_	_	I-Premise
223	TTP	_	_	I-Premise
224	)	_	_	I-Premise
225	curves	_	_	I-Premise
226	according	_	_	I-Premise
227	to	_	_	I-Premise
228	treatment	_	_	I-Premise
229	allocation	_	_	I-Premise
230	was	_	_	I-Premise
231	documented	_	_	I-Premise
232	(	_	_	I-Premise
233	P	_	_	I-Premise
234	=	_	_	I-Premise
235	.411	_	_	I-Premise
236	)	_	_	I-Premise
237	.	_	_	I-Premise

238	However	_	_	B-Premise
239	,	_	_	I-Premise
240	a	_	_	I-Premise
241	trend	_	_	I-Premise
242	for	_	_	I-Premise
243	more	_	_	I-Premise
244	favorable	_	_	I-Premise
245	overall	_	_	I-Premise
246	survival	_	_	I-Premise
247	was	_	_	I-Premise
248	documented	_	_	I-Premise
249	in	_	_	I-Premise
250	the	_	_	I-Premise
251	PLD	_	_	I-Premise
252	arm	_	_	I-Premise
253	compared	_	_	I-Premise
254	with	_	_	I-Premise
255	the	_	_	I-Premise
256	GEM	_	_	I-Premise
257	arm	_	_	I-Premise
258	,	_	_	I-Premise
259	although	_	_	B-Premise
260	the	_	_	I-Premise
261	P	_	_	I-Premise
262	value	_	_	I-Premise
263	was	_	_	I-Premise
264	of	_	_	I-Premise
265	borderline	_	_	I-Premise
266	statistical	_	_	I-Premise
267	significance	_	_	I-Premise
268	(	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	.048	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	Statistically	_	_	B-Premise
275	significantly	_	_	I-Premise
276	higher	_	_	I-Premise
277	global	_	_	I-Premise
278	QOL	_	_	I-Premise
279	scores	_	_	I-Premise
280	were	_	_	I-Premise
281	found	_	_	I-Premise
282	in	_	_	I-Premise
283	PLD-treated	_	_	I-Premise
284	patients	_	_	I-Premise
285	at	_	_	I-Premise
286	the	_	_	I-Premise
287	first	_	_	I-Premise
288	and	_	_	I-Premise
289	second	_	_	I-Premise
290	postbaseline	_	_	I-Premise
291	QOL	_	_	I-Premise
292	assessments	_	_	I-Premise
293	.	_	_	I-Premise

294	GEM	_	_	B-Claim
295	does	_	_	I-Claim
296	not	_	_	I-Claim
297	provide	_	_	I-Claim
298	an	_	_	I-Claim
299	advantage	_	_	I-Claim
300	compared	_	_	I-Claim
301	with	_	_	I-Claim
302	PLD	_	_	I-Claim
303	in	_	_	I-Claim
304	terms	_	_	I-Claim
305	of	_	_	I-Claim
306	TTP	_	_	I-Claim
307	in	_	_	I-Claim
308	ovarian	_	_	I-Claim
309	cancer	_	_	I-Claim
310	patients	_	_	I-Claim
311	who	_	_	I-Claim
312	experience	_	_	I-Claim
313	recurrence	_	_	I-Claim
314	within	_	_	I-Claim
315	12	_	_	I-Claim
316	months	_	_	I-Claim
317	after	_	_	I-Claim
318	primary	_	_	I-Claim
319	treatment	_	_	I-Claim
320	but	_	_	I-Claim
321	should	_	_	I-Claim
322	be	_	_	I-Claim
323	considered	_	_	I-Claim
324	in	_	_	I-Claim
325	the	_	_	I-Claim
326	spectrum	_	_	I-Claim
327	of	_	_	I-Claim
328	drugs	_	_	I-Claim
329	to	_	_	I-Claim
330	be	_	_	I-Claim
331	possibly	_	_	I-Claim
332	used	_	_	I-Claim
333	in	_	_	I-Claim
334	the	_	_	I-Claim
335	salvage	_	_	I-Claim
336	setting	_	_	I-Claim
337	.	_	_	I-Claim


0	To	_	_	O
1	observe	_	_	O
2	the	_	_	O
3	clinical	_	_	O
4	efficacy	_	_	O
5	of	_	_	O
6	Shenqi	_	_	O
7	Fuzheng	_	_	O
8	Injection	_	_	O
9	(	_	_	O
10	SFI	_	_	O
11	)	_	_	O
12	combined	_	_	O
13	with	_	_	O
14	chemotherapy	_	_	O
15	in	_	_	O
16	treating	_	_	O
17	patients	_	_	O
18	with	_	_	O
19	advanced	_	_	O
20	breast	_	_	O
21	cancer	_	_	O
22	.	_	_	O

23	Sixty	_	_	O
24	patients	_	_	O
25	were	_	_	O
26	randomly	_	_	O
27	assigned	_	_	O
28	to	_	_	O
29	two	_	_	O
30	groups	_	_	O
31	by	_	_	O
32	digital	_	_	O
33	table	_	_	O
34	,	_	_	O
35	the	_	_	O
36	control	_	_	O
37	group	_	_	O
38	and	_	_	O
39	the	_	_	O
40	treatment	_	_	O
41	group	_	_	O
42	,	_	_	O
43	30	_	_	O
44	in	_	_	O
45	each	_	_	O
46	group	_	_	O
47	.	_	_	O

48	All	_	_	O
49	patients	_	_	O
50	were	_	_	O
51	treated	_	_	O
52	with	_	_	O
53	the	_	_	O
54	same	_	_	O
55	CTF	_	_	O
56	regimen	_	_	O
57	of	_	_	O
58	chemotherapy	_	_	O
59	for	_	_	O
60	21	_	_	O
61	days	_	_	O
62	as	_	_	O
63	one	_	_	O
64	therapeutic	_	_	O
65	cycle	_	_	O
66	,	_	_	O
67	while	_	_	O
68	those	_	_	O
69	in	_	_	O
70	the	_	_	O
71	treatment	_	_	O
72	group	_	_	O
73	were	_	_	O
74	given	_	_	O
75	SFI	_	_	O
76	additionally	_	_	O
77	in	_	_	O
78	the	_	_	O
79	meanwhite	_	_	O
80	.	_	_	O

81	The	_	_	O
82	therapeutic	_	_	O
83	efficacy	_	_	O
84	was	_	_	O
85	evaluated	_	_	O
86	after	_	_	O
87	2	_	_	O
88	cycles	_	_	O
89	of	_	_	O
90	treatment	_	_	O
91	by	_	_	O
92	observing	_	_	O
93	the	_	_	O
94	changes	_	_	O
95	of	_	_	O
96	short-term	_	_	O
97	efficacy	_	_	O
98	,	_	_	O
99	TCM	_	_	O
100	syndrome	_	_	O
101	,	_	_	O
102	quality	_	_	O
103	of	_	_	O
104	life	_	_	O
105	and	_	_	O
106	immune	_	_	O
107	function	_	_	O
108	,	_	_	O
109	as	_	_	O
110	well	_	_	O
111	as	_	_	O
112	the	_	_	O
113	adverse	_	_	O
114	reaction	_	_	O
115	.	_	_	O

116	The	_	_	B-Premise
117	total	_	_	I-Premise
118	short-term	_	_	I-Premise
119	remission	_	_	I-Premise
120	rate	_	_	I-Premise
121	,	_	_	I-Premise
122	the	_	_	I-Premise
123	improvement	_	_	I-Premise
124	rate	_	_	I-Premise
125	of	_	_	I-Premise
126	clinical	_	_	I-Premise
127	syndrome	_	_	I-Premise
128	and	_	_	I-Premise
129	quality	_	_	I-Premise
130	of	_	_	I-Premise
131	life	_	_	I-Premise
132	was	_	_	I-Premise
133	50.0	_	_	I-Premise
134	%	_	_	I-Premise
135	,	_	_	I-Premise
136	70.0	_	_	I-Premise
137	%	_	_	I-Premise
138	and	_	_	I-Premise
139	76.7	_	_	I-Premise
140	%	_	_	I-Premise
141	in	_	_	I-Premise
142	the	_	_	I-Premise
143	treatment	_	_	I-Premise
144	group	_	_	I-Premise
145	,	_	_	I-Premise
146	and	_	_	I-Premise
147	43.3	_	_	I-Premise
148	%	_	_	I-Premise
149	,	_	_	I-Premise
150	46.7	_	_	I-Premise
151	%	_	_	I-Premise
152	and	_	_	I-Premise
153	50.0	_	_	I-Premise
154	%	_	_	I-Premise
155	in	_	_	I-Premise
156	the	_	_	I-Premise
157	control	_	_	I-Premise
158	group	_	_	I-Premise
159	,	_	_	I-Premise
160	respectively	_	_	I-Premise
161	,	_	_	I-Premise
162	showing	_	_	I-Premise
163	significant	_	_	I-Premise
164	difference	_	_	I-Premise
165	between	_	_	I-Premise
166	the	_	_	I-Premise
167	two	_	_	I-Premise
168	groups	_	_	I-Premise
169	(	_	_	I-Premise
170	all	_	_	I-Premise
171	P	_	_	I-Premise
172	<	_	_	I-Premise
173	0.05	_	_	I-Premise
174	)	_	_	I-Premise
175	.	_	_	I-Premise

176	The	_	_	B-Premise
177	occurrence	_	_	I-Premise
178	of	_	_	I-Premise
179	adverse	_	_	I-Premise
180	reaction	_	_	I-Premise
181	in	_	_	I-Premise
182	the	_	_	I-Premise
183	treatment	_	_	I-Premise
184	group	_	_	I-Premise
185	was	_	_	I-Premise
186	lower	_	_	I-Premise
187	than	_	_	I-Premise
188	that	_	_	I-Premise
189	in	_	_	I-Premise
190	the	_	_	I-Premise
191	control	_	_	I-Premise
192	group	_	_	I-Premise
193	(	_	_	I-Premise
194	P	_	_	I-Premise
195	<	_	_	I-Premise
196	0.05	_	_	I-Premise
197	)	_	_	I-Premise
198	.	_	_	I-Premise

199	The	_	_	B-Premise
200	level	_	_	I-Premise
201	of	_	_	I-Premise
202	CD3+	_	_	I-Premise
203	CD4+	_	_	I-Premise
204	and	_	_	I-Premise
205	CD4+/CD8+	_	_	I-Premise
206	ratio	_	_	I-Premise
207	increased	_	_	I-Premise
208	(	_	_	I-Premise
209	P	_	_	I-Premise
210	<	_	_	I-Premise
211	0.05	_	_	I-Premise
212	)	_	_	I-Premise
213	and	_	_	I-Premise
214	CD8+	_	_	I-Premise
215	decreased	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	treatment	_	_	I-Premise
219	group	_	_	I-Premise
220	(	_	_	I-Premise
221	P	_	_	I-Premise
222	<	_	_	I-Premise
223	0.01	_	_	I-Premise
224	)	_	_	I-Premise
225	,	_	_	I-Premise
226	while	_	_	I-Premise
227	they	_	_	I-Premise
228	showed	_	_	I-Premise
229	insignificant	_	_	I-Premise
230	change	_	_	I-Premise
231	in	_	_	I-Premise
232	the	_	_	I-Premise
233	control	_	_	I-Premise
234	group	_	_	I-Premise
235	.	_	_	I-Premise

236	For	_	_	B-Claim
237	treatment	_	_	I-Claim
238	of	_	_	I-Claim
239	advanced	_	_	I-Claim
240	breast	_	_	I-Claim
241	cancer	_	_	I-Claim
242	,	_	_	I-Claim
243	SFI	_	_	I-Claim
244	can	_	_	I-Claim
245	alleviate	_	_	I-Claim
246	the	_	_	I-Claim
247	bone	_	_	I-Claim
248	marrow	_	_	I-Claim
249	inhibition	_	_	I-Claim
250	caused	_	_	I-Claim
251	by	_	_	I-Claim
252	chemotherapy	_	_	I-Claim
253	,	_	_	I-Claim
254	improve	_	_	I-Claim
255	clinical	_	_	I-Claim
256	symptoms	_	_	I-Claim
257	and	_	_	I-Claim
258	quality	_	_	I-Claim
259	of	_	_	I-Claim
260	life	_	_	I-Claim
261	and	_	_	I-Claim
262	prolong	_	_	I-Claim
263	the	_	_	I-Claim
264	survival	_	_	I-Claim
265	period	_	_	I-Claim
266	by	_	_	I-Claim
267	regulating	_	_	I-Claim
268	cellular	_	_	I-Claim
269	immune	_	_	I-Claim
270	function	_	_	I-Claim
271	of	_	_	I-Claim
272	patients	_	_	I-Claim
273	,	_	_	I-Claim
274	so	_	_	I-Claim
275	as	_	_	I-Claim
276	to	_	_	I-Claim
277	enhance	_	_	I-Claim
278	the	_	_	I-Claim
279	therapeutic	_	_	I-Claim
280	effect	_	_	I-Claim
281	of	_	_	I-Claim
282	chemotherapy	_	_	I-Claim
283	.	_	_	I-Claim


0	To	_	_	O
1	observe	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	TCM	_	_	O
6	therapy	_	_	O
7	for	_	_	O
8	removing	_	_	O
9	toxic	_	_	O
10	substance	_	_	O
11	and	_	_	O
12	unblocking	_	_	O
13	meridians	_	_	O
14	on	_	_	O
15	post-radiation	_	_	O
16	quality	_	_	O
17	of	_	_	O
18	life	_	_	O
19	(	_	_	O
20	QOF	_	_	O
21	)	_	_	O
22	in	_	_	O
23	55	_	_	O
24	patients	_	_	O
25	with	_	_	O
26	lung	_	_	O
27	cancer	_	_	O
28	.	_	_	O

29	All	_	_	O
30	patients	_	_	O
31	were	_	_	O
32	randomly	_	_	O
33	assigned	_	_	O
34	to	_	_	O
35	two	_	_	O
36	groups	_	_	O
37	,	_	_	O
38	the	_	_	O
39	55	_	_	O
40	patients	_	_	O
41	in	_	_	O
42	the	_	_	O
43	treated	_	_	O
44	group	_	_	O
45	were	_	_	O
46	treated	_	_	O
47	with	_	_	O
48	radiotherapy	_	_	O
49	combined	_	_	O
50	with	_	_	O
51	the	_	_	O
52	TCM	_	_	O
53	therapy	_	_	O
54	,	_	_	O
55	and	_	_	O
56	the	_	_	O
57	53	_	_	O
58	in	_	_	O
59	the	_	_	O
60	control	_	_	O
61	group	_	_	O
62	were	_	_	O
63	given	_	_	O
64	radiotherapy	_	_	O
65	alone	_	_	O
66	.	_	_	O

67	The	_	_	O
68	clinical	_	_	O
69	efficacy	_	_	O
70	was	_	_	O
71	evaluated	_	_	O
72	by	_	_	O
73	indexes	_	_	O
74	including	_	_	O
75	KPS	_	_	O
76	scores	_	_	O
77	,	_	_	O
78	QLQ-C30	_	_	O
79	questionnaire	_	_	O
80	,	_	_	O
81	LC13	_	_	O
82	specific	_	_	O
83	scale	_	_	O
84	for	_	_	O
85	lung	_	_	O
86	cancer	_	_	O
87	,	_	_	O
88	evaluation	_	_	O
89	criteria	_	_	O
90	for	_	_	O
91	TCM	_	_	O
92	efficacy	_	_	O
93	,	_	_	O
94	the	_	_	O
95	6-min	_	_	O
96	walking	_	_	O
97	distance	_	_	O
98	,	_	_	O
99	and	_	_	O
100	body	_	_	O
101	weight	_	_	O
102	,	_	_	O
103	etc	_	_	O
104	.	_	_	O

105	The	_	_	B-Premise
106	KPS	_	_	I-Premise
107	score	_	_	I-Premise
108	in	_	_	I-Premise
109	the	_	_	I-Premise
110	treated	_	_	I-Premise
111	group	_	_	I-Premise
112	after	_	_	I-Premise
113	treatment	_	_	I-Premise
114	was	_	_	I-Premise
115	improved	_	_	I-Premise
116	in	_	_	I-Premise
117	13	_	_	I-Premise
118	patients	_	_	I-Premise
119	(	_	_	I-Premise
120	23.6	_	_	I-Premise
121	%	_	_	I-Premise
122	)	_	_	I-Premise
123	,	_	_	I-Premise
124	stabilized	_	_	I-Premise
125	in	_	_	I-Premise
126	27	_	_	I-Premise
127	(	_	_	I-Premise
128	49.6	_	_	I-Premise
129	%	_	_	I-Premise
130	)	_	_	I-Premise
131	and	_	_	I-Premise
132	declined	_	_	I-Premise
133	in	_	_	I-Premise
134	15	_	_	I-Premise
135	(	_	_	I-Premise
136	27.3	_	_	I-Premise
137	%	_	_	I-Premise
138	)	_	_	I-Premise
139	,	_	_	I-Premise
140	while	_	_	I-Premise
141	in	_	_	I-Premise
142	the	_	_	I-Premise
143	control	_	_	I-Premise
144	group	_	_	I-Premise
145	,	_	_	I-Premise
146	it	_	_	I-Premise
147	was	_	_	I-Premise
148	improved	_	_	I-Premise
149	in	_	_	I-Premise
150	7	_	_	I-Premise
151	(	_	_	I-Premise
152	13.2	_	_	I-Premise
153	%	_	_	I-Premise
154	)	_	_	I-Premise
155	,	_	_	I-Premise
156	stabilized	_	_	I-Premise
157	in	_	_	I-Premise
158	21	_	_	I-Premise
159	(	_	_	I-Premise
160	39.6	_	_	I-Premise
161	%	_	_	I-Premise
162	)	_	_	I-Premise
163	and	_	_	I-Premise
164	declined	_	_	I-Premise
165	in	_	_	I-Premise
166	25	_	_	I-Premise
167	(	_	_	I-Premise
168	47.2	_	_	I-Premise
169	%	_	_	I-Premise
170	)	_	_	I-Premise
171	,	_	_	I-Premise
172	the	_	_	I-Premise
173	difference	_	_	I-Premise
174	between	_	_	I-Premise
175	the	_	_	I-Premise
176	two	_	_	I-Premise
177	groups	_	_	I-Premise
178	was	_	_	I-Premise
179	significant	_	_	I-Premise
180	(	_	_	I-Premise
181	P	_	_	I-Premise
182	<	_	_	I-Premise
183	0.05	_	_	I-Premise
184	)	_	_	I-Premise
185	.	_	_	I-Premise

186	The	_	_	B-Premise
187	results	_	_	I-Premise
188	from	_	_	I-Premise
189	evaluation	_	_	I-Premise
190	with	_	_	I-Premise
191	QLQ-C30	_	_	I-Premise
192	questionnaire	_	_	I-Premise
193	and	_	_	I-Premise
194	LC30	_	_	I-Premise
195	scale	_	_	I-Premise
196	in	_	_	I-Premise
197	the	_	_	I-Premise
198	treated	_	_	I-Premise
199	group	_	_	I-Premise
200	was	_	_	I-Premise
201	also	_	_	I-Premise
202	superior	_	_	I-Premise
203	to	_	_	I-Premise
204	those	_	_	I-Premise
205	in	_	_	I-Premise
206	the	_	_	I-Premise
207	control	_	_	I-Premise
208	group	_	_	I-Premise
209	(	_	_	I-Premise
210	P	_	_	I-Premise
211	<	_	_	I-Premise
212	0.05	_	_	I-Premise
213	)	_	_	I-Premise
214	,	_	_	I-Premise
215	respectively	_	_	I-Premise
216	.	_	_	I-Premise

217	The	_	_	B-Premise
218	scores	_	_	I-Premise
219	of	_	_	I-Premise
220	TCM	_	_	I-Premise
221	efficacy	_	_	I-Premise
222	(	_	_	I-Premise
223	24.52	_	_	I-Premise
224	+/-	_	_	I-Premise
225	8.98	_	_	I-Premise
226	vs	_	_	I-Premise
227	29.76	_	_	I-Premise
228	+/-	_	_	I-Premise
229	7.09	_	_	I-Premise
230	,	_	_	I-Premise
231	P	_	_	I-Premise
232	<	_	_	I-Premise
233	0.05	_	_	I-Premise
234	)	_	_	I-Premise
235	and	_	_	I-Premise
236	the	_	_	I-Premise
237	6-min	_	_	I-Premise
238	walking	_	_	I-Premise
239	distance	_	_	I-Premise
240	(	_	_	I-Premise
241	233.4	_	_	I-Premise
242	+/-	_	_	I-Premise
243	29.2	_	_	I-Premise
244	m	_	_	I-Premise
245	vs	_	_	I-Premise
246	205.8	_	_	I-Premise
247	+/-	_	_	I-Premise
248	31.9	_	_	I-Premise
249	m	_	_	I-Premise
250	,	_	_	I-Premise
251	P	_	_	I-Premise
252	<	_	_	I-Premise
253	0.05	_	_	I-Premise
254	)	_	_	I-Premise
255	were	_	_	I-Premise
256	better	_	_	I-Premise
257	in	_	_	I-Premise
258	the	_	_	I-Premise
259	treated	_	_	I-Premise
260	group	_	_	I-Premise
261	.	_	_	I-Premise

262	After	_	_	B-Premise
263	treatment	_	_	I-Premise
264	in	_	_	I-Premise
265	the	_	_	I-Premise
266	treated	_	_	I-Premise
267	group	_	_	I-Premise
268	,	_	_	I-Premise
269	the	_	_	I-Premise
270	body	_	_	I-Premise
271	weight	_	_	I-Premise
272	was	_	_	I-Premise
273	increased	_	_	I-Premise
274	in	_	_	I-Premise
275	11	_	_	I-Premise
276	patients	_	_	I-Premise
277	(	_	_	I-Premise
278	20.0	_	_	I-Premise
279	%	_	_	I-Premise
280	)	_	_	I-Premise
281	,	_	_	I-Premise
282	stabilized	_	_	I-Premise
283	in	_	_	I-Premise
284	28	_	_	I-Premise
285	(	_	_	I-Premise
286	50.9	_	_	I-Premise
287	%	_	_	I-Premise
288	)	_	_	I-Premise
289	and	_	_	I-Premise
290	decreased	_	_	I-Premise
291	in	_	_	I-Premise
292	16	_	_	I-Premise
293	(	_	_	I-Premise
294	29.1	_	_	I-Premise
295	%	_	_	I-Premise
296	)	_	_	I-Premise
297	,	_	_	I-Premise
298	while	_	_	I-Premise
299	in	_	_	I-Premise
300	the	_	_	I-Premise
301	control	_	_	I-Premise
302	group	_	_	I-Premise
303	it	_	_	I-Premise
304	was	_	_	I-Premise
305	increased	_	_	I-Premise
306	in	_	_	I-Premise
307	5	_	_	I-Premise
308	(	_	_	I-Premise
309	9.4	_	_	I-Premise
310	%	_	_	I-Premise
311	)	_	_	I-Premise
312	,	_	_	I-Premise
313	stabilized	_	_	I-Premise
314	in	_	_	I-Premise
315	26	_	_	I-Premise
316	(	_	_	I-Premise
317	49.1	_	_	I-Premise
318	%	_	_	I-Premise
319	)	_	_	I-Premise
320	and	_	_	I-Premise
321	decreased	_	_	I-Premise
322	in	_	_	I-Premise
323	22	_	_	I-Premise
324	(	_	_	I-Premise
325	41.5	_	_	I-Premise
326	%	_	_	I-Premise
327	)	_	_	I-Premise
328	,	_	_	I-Premise
329	difference	_	_	I-Premise
330	between	_	_	I-Premise
331	the	_	_	I-Premise
332	two	_	_	I-Premise
333	groups	_	_	I-Premise
334	was	_	_	I-Premise
335	significant	_	_	I-Premise
336	,	_	_	I-Premise
337	too	_	_	I-Premise
338	(	_	_	I-Premise
339	P	_	_	I-Premise
340	<	_	_	I-Premise
341	0.05	_	_	I-Premise
342	)	_	_	I-Premise
343	.	_	_	I-Premise

344	TCM	_	_	B-Claim
345	therapy	_	_	I-Claim
346	for	_	_	I-Claim
347	removing	_	_	I-Claim
348	toxic	_	_	I-Claim
349	substance	_	_	I-Claim
350	and	_	_	I-Claim
351	unblocking	_	_	I-Claim
352	meridians	_	_	I-Claim
353	can	_	_	I-Claim
354	improve	_	_	I-Claim
355	the	_	_	I-Claim
356	post-radiation	_	_	I-Claim
357	QOL	_	_	I-Claim
358	of	_	_	I-Claim
359	patients	_	_	I-Claim
360	with	_	_	I-Claim
361	lung	_	_	I-Claim
362	cancer	_	_	I-Claim
363	to	_	_	I-Claim
364	some	_	_	I-Claim
365	extent	_	_	I-Claim
366	.	_	_	I-Claim


0	The	_	_	O
1	management	_	_	O
2	of	_	_	O
3	recurrent	_	_	O
4	ovarian	_	_	O
5	cancer	_	_	O
6	remains	_	_	O
7	controversial	_	_	O
8	.	_	_	O

9	Single-agent	_	_	O
10	topotecan	_	_	O
11	is	_	_	O
12	an	_	_	O
13	established	_	_	O
14	treatment	_	_	O
15	option	_	_	O
16	,	_	_	O
17	and	_	_	O
18	preliminary	_	_	O
19	evidence	_	_	O
20	suggests	_	_	O
21	improved	_	_	O
22	tumor	_	_	O
23	control	_	_	O
24	by	_	_	O
25	combining	_	_	O
26	topotecan	_	_	O
27	with	_	_	O
28	etoposide	_	_	O
29	or	_	_	O
30	gemcitabine	_	_	O
31	.	_	_	O

32	Women	_	_	O
33	with	_	_	O
34	relapsed	_	_	O
35	ovarian	_	_	O
36	cancer	_	_	O
37	after	_	_	O
38	primary	_	_	O
39	surgery	_	_	O
40	and	_	_	O
41	platinum-based	_	_	O
42	chemotherapy	_	_	O
43	were	_	_	O
44	randomly	_	_	O
45	assigned	_	_	O
46	to	_	_	O
47	topotecan	_	_	O
48	monotherapy	_	_	O
49	1.25	_	_	O
50	mg/m	_	_	O
51	(	_	_	O
52	2	_	_	O
53	)	_	_	O
54	/d	_	_	O
55	,	_	_	O
56	topotecan	_	_	O
57	1.0	_	_	O
58	mg/m	_	_	O
59	(	_	_	O
60	2	_	_	O
61	)	_	_	O
62	plus	_	_	O
63	oral	_	_	O
64	etoposide	_	_	O
65	50	_	_	O
66	mg/d	_	_	O
67	,	_	_	O
68	or	_	_	O
69	topotecan	_	_	O
70	0.5	_	_	O
71	mg/m	_	_	O
72	(	_	_	O
73	2	_	_	O
74	)	_	_	O
75	/d	_	_	O
76	plus	_	_	O
77	gemcitabine	_	_	O
78	800	_	_	O
79	mg/m	_	_	O
80	(	_	_	O
81	2	_	_	O
82	)	_	_	O
83	on	_	_	O
84	day	_	_	O
85	1	_	_	O
86	and	_	_	O
87	600	_	_	O
88	mg/m	_	_	O
89	(	_	_	O
90	2	_	_	O
91	)	_	_	O
92	on	_	_	O
93	day	_	_	O
94	8	_	_	O
95	every	_	_	O
96	3	_	_	O
97	weeks	_	_	O
98	.	_	_	O

99	Patients	_	_	O
100	were	_	_	O
101	stratified	_	_	O
102	for	_	_	O
103	platinum-refractory	_	_	O
104	and	_	_	O
105	platinum-sensitive	_	_	O
106	disease	_	_	O
107	according	_	_	O
108	to	_	_	O
109	a	_	_	O
110	recurrence-free	_	_	O
111	interval	_	_	O
112	of	_	_	O
113	less	_	_	O
114	or	_	_	O
115	more	_	_	O
116	than	_	_	O
117	12	_	_	O
118	months	_	_	O
119	,	_	_	O
120	respectively	_	_	O
121	.	_	_	O

122	The	_	_	O
123	primary	_	_	O
124	end	_	_	O
125	point	_	_	O
126	was	_	_	O
127	overall	_	_	O
128	survival	_	_	O
129	.	_	_	O

130	Secondary	_	_	O
131	end	_	_	O
132	points	_	_	O
133	included	_	_	O
134	progression-free	_	_	O
135	survival	_	_	O
136	,	_	_	O
137	objective	_	_	O
138	response	_	_	O
139	rates	_	_	O
140	,	_	_	O
141	toxicity	_	_	O
142	,	_	_	O
143	and	_	_	O
144	quality	_	_	O
145	of	_	_	O
146	life	_	_	O
147	(	_	_	O
148	as	_	_	O
149	measured	_	_	O
150	by	_	_	O
151	the	_	_	O
152	European	_	_	O
153	Organisation	_	_	O
154	for	_	_	O
155	Research	_	_	O
156	and	_	_	O
157	Treatment	_	_	O
158	of	_	_	O
159	Cancer	_	_	O
160	[	_	_	O
161	EORTC	_	_	O
162	]	_	_	O
163	30-item	_	_	O
164	Quality-of-Life	_	_	O
165	Questionnaire	_	_	O
166	)	_	_	O
167	.	_	_	O

168	The	_	_	O
169	trial	_	_	O
170	enrolled	_	_	O
171	502	_	_	O
172	patients	_	_	O
173	with	_	_	O
174	a	_	_	O
175	mean	_	_	O
176	age	_	_	O
177	of	_	_	O
178	60.5	_	_	O
179	years	_	_	O
180	(	_	_	O
181	+/-	_	_	O
182	10.2	_	_	O
183	years	_	_	O
184	)	_	_	O
185	,	_	_	O
186	208	_	_	O
187	of	_	_	O
188	whom	_	_	O
189	were	_	_	O
190	platinum	_	_	O
191	resistant	_	_	O
192	.	_	_	O

193	Median	_	_	B-Premise
194	overall	_	_	I-Premise
195	survival	_	_	I-Premise
196	was	_	_	I-Premise
197	17.2	_	_	I-Premise
198	months	_	_	I-Premise
199	(	_	_	I-Premise
200	95	_	_	I-Premise
201	%	_	_	I-Premise
202	CI	_	_	I-Premise
203	,	_	_	I-Premise
204	13.5	_	_	I-Premise
205	to	_	_	I-Premise
206	21.9	_	_	I-Premise
207	months	_	_	I-Premise
208	)	_	_	I-Premise
209	with	_	_	I-Premise
210	topotecan	_	_	I-Premise
211	,	_	_	I-Premise
212	17.8	_	_	I-Premise
213	months	_	_	I-Premise
214	(	_	_	I-Premise
215	95	_	_	I-Premise
216	%	_	_	I-Premise
217	CI	_	_	I-Premise
218	,	_	_	I-Premise
219	13.7	_	_	I-Premise
220	to	_	_	I-Premise
221	20.0	_	_	I-Premise
222	months	_	_	I-Premise
223	)	_	_	I-Premise
224	with	_	_	I-Premise
225	topotecan	_	_	I-Premise
226	plus	_	_	I-Premise
227	etoposide	_	_	I-Premise
228	(	_	_	I-Premise
229	log-rank	_	_	I-Premise
230	P	_	_	I-Premise
231	=	_	_	I-Premise
232	.7647	_	_	I-Premise
233	)	_	_	I-Premise
234	,	_	_	I-Premise
235	and	_	_	I-Premise
236	15.2	_	_	I-Premise
237	months	_	_	I-Premise
238	(	_	_	I-Premise
239	95	_	_	I-Premise
240	%	_	_	I-Premise
241	CI	_	_	I-Premise
242	,	_	_	I-Premise
243	11.3	_	_	I-Premise
244	to	_	_	I-Premise
245	20.9	_	_	I-Premise
246	months	_	_	I-Premise
247	)	_	_	I-Premise
248	with	_	_	I-Premise
249	topotecan	_	_	I-Premise
250	plus	_	_	I-Premise
251	gemcitabine	_	_	I-Premise
252	(	_	_	I-Premise
253	log-rank	_	_	I-Premise
254	P	_	_	I-Premise
255	=	_	_	I-Premise
256	.2344	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	Platinum-sensitive	_	_	B-Premise
260	patients	_	_	I-Premise
261	lived	_	_	I-Premise
262	significantly	_	_	I-Premise
263	longer	_	_	I-Premise
264	than	_	_	I-Premise
265	platinum-refractory	_	_	I-Premise
266	patients	_	_	I-Premise
267	(	_	_	I-Premise
268	21.9	_	_	I-Premise
269	v	_	_	I-Premise
270	10.6	_	_	I-Premise
271	months	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	The	_	_	O
275	median	_	_	O
276	progression-free	_	_	O
277	survival	_	_	O
278	was	_	_	O
279	7.0	_	_	O
280	,	_	_	O
281	7.8	_	_	O
282	,	_	_	O
283	and	_	_	O
284	6.3	_	_	O
285	months	_	_	O
286	,	_	_	O
287	respectively	_	_	O
288	.	_	_	O

289	Objective	_	_	O
290	response	_	_	O
291	rates	_	_	O
292	were	_	_	O
293	27.8	_	_	O
294	%	_	_	O
295	,	_	_	O
296	36.1	_	_	O
297	%	_	_	O
298	,	_	_	O
299	and	_	_	O
300	31.6	_	_	O
301	%	_	_	O
302	,	_	_	O
303	respectively	_	_	O
304	.	_	_	O

305	Patients	_	_	B-Premise
306	under	_	_	I-Premise
307	combined	_	_	I-Premise
308	treatment	_	_	I-Premise
309	were	_	_	I-Premise
310	at	_	_	I-Premise
311	higher	_	_	I-Premise
312	risk	_	_	I-Premise
313	of	_	_	I-Premise
314	severe	_	_	I-Premise
315	thrombocytopenia	_	_	I-Premise
316	.	_	_	I-Premise

317	Nonplatinum	_	_	B-Claim
318	topotecan	_	_	I-Claim
319	combinations	_	_	I-Claim
320	do	_	_	I-Claim
321	not	_	_	I-Claim
322	provide	_	_	I-Claim
323	a	_	_	I-Claim
324	survival	_	_	I-Claim
325	advantage	_	_	I-Claim
326	over	_	_	I-Claim
327	topotecan	_	_	I-Claim
328	alone	_	_	I-Claim
329	in	_	_	I-Claim
330	women	_	_	I-Claim
331	with	_	_	I-Claim
332	relapsed	_	_	I-Claim
333	ovarian	_	_	I-Claim
334	cancer	_	_	I-Claim
335	.	_	_	I-Claim


0	﻿	_	_	O
1	To	_	_	O
2	compare	_	_	O
3	the	_	_	O
4	IOP-lowering	_	_	O
5	efficacy	_	_	O
6	of	_	_	O
7	a.m.-dosed	_	_	O
8	travoprost	_	_	O
9	and	_	_	O
10	latanoprost	_	_	O
11	at	_	_	O
12	24-h	_	_	O
13	post-dose	_	_	O
14	.	_	_	O

15	Open-angle	_	_	O
16	glaucoma	_	_	O
17	patients	_	_	O
18	not	_	_	O
19	naïve	_	_	O
20	to	_	_	O
21	prostaglandin	_	_	O
22	therapy	_	_	O
23	and	_	_	O
24	currently	_	_	O
25	controlled	_	_	O
26	on	_	_	O
27	p.m.-dosed	_	_	O
28	(	_	_	O
29	2100	_	_	O
30	)	_	_	O
31	latanoprost	_	_	O
32	(	_	_	O
33	n	_	_	O
34	=	_	_	O
35	21	_	_	O
36	)	_	_	O
37	or	_	_	O
38	travoprost	_	_	O
39	(	_	_	O
40	n	_	_	O
41	=	_	_	O
42	30	_	_	O
43	)	_	_	O
44	had	_	_	O
45	baseline	_	_	O
46	IOPs	_	_	O
47	measured	_	_	O
48	at	_	_	O
49	0900	_	_	O
50	.	_	_	O

51	In	_	_	O
52	a	_	_	O
53	randomized	_	_	O
54	,	_	_	O
55	single-masked	_	_	O
56	,	_	_	O
57	crossover	_	_	O
58	design	_	_	O
59	,	_	_	O
60	patients	_	_	O
61	received	_	_	O
62	travoprost	_	_	O
63	(	_	_	O
64	Travatan	_	_	O
65	†	_	_	O
66	)	_	_	O
67	or	_	_	O
68	latanoprost	_	_	O
69	(	_	_	O
70	Xalatan	_	_	O
71	‡	_	_	O
72	)	_	_	O
73	at	_	_	O
74	0900	_	_	O
75	for	_	_	O
76	4	_	_	O
77	weeks	_	_	O
78	,	_	_	O
79	then	_	_	O
80	were	_	_	O
81	crossed	_	_	O
82	over	_	_	O
83	to	_	_	O
84	receive	_	_	O
85	the	_	_	O
86	second	_	_	O
87	prostaglandin	_	_	O
88	for	_	_	O
89	another	_	_	O
90	4	_	_	O
91	weeks	_	_	O
92	.	_	_	O

93	Treatment	_	_	O
94	IOP	_	_	O
95	was	_	_	O
96	measured	_	_	O
97	at	_	_	O
98	0900	_	_	O
99	prior	_	_	O
100	to	_	_	O
101	morning	_	_	O
102	dose	_	_	O
103	at	_	_	O
104	both	_	_	O
105	4	_	_	O
106	and	_	_	O
107	8	_	_	O
108	week	_	_	O
109	visits	_	_	O
110	.	_	_	O

111	Patient	_	_	O
112	dosing	_	_	O
113	preference	_	_	O
114	(	_	_	O
115	a.m./p.m	_	_	O
116	.	_	_	O
117	)	_	_	O

118	was	_	_	O
119	surveyed	_	_	O
120	on	_	_	O
121	exit	_	_	O
122	.	_	_	O

123	Main	_	_	O
124	outcome	_	_	O
125	measure	_	_	O
126	:	_	_	O
127	Intraocular	_	_	O
128	pressure	_	_	O
129	(	_	_	O
130	IOP	_	_	O
131	)	_	_	O
132	.	_	_	O

133	†	_	_	O
134	Travatan	_	_	O
135	is	_	_	O
136	a	_	_	O
137	registered	_	_	O
138	trade	_	_	O
139	name	_	_	O
140	of	_	_	O
141	Alcon	_	_	O
142	Laboratories	_	_	O
143	,	_	_	O
144	Inc.	_	_	O
145	,	_	_	O
146	Fort	_	_	O
147	Worth	_	_	O
148	,	_	_	O
149	TX	_	_	O
150	,	_	_	O
151	USA	_	_	O
152	‡	_	_	O
153	Xalatan	_	_	O
154	is	_	_	O
155	a	_	_	O
156	registered	_	_	O
157	trade	_	_	O
158	name	_	_	O
159	of	_	_	O
160	Pfizer	_	_	O
161	,	_	_	O
162	New	_	_	O
163	York	_	_	O
164	,	_	_	O
165	NY	_	_	O
166	,	_	_	O
167	USA	_	_	O
168	.	_	_	O

169	The	_	_	B-Premise
170	mean	_	_	I-Premise
171	IOP	_	_	I-Premise
172	in	_	_	I-Premise
173	the	_	_	I-Premise
174	first	_	_	I-Premise
175	period	_	_	I-Premise
176	when	_	_	I-Premise
177	all	_	_	I-Premise
178	patients	_	_	I-Premise
179	were	_	_	I-Premise
180	dosed	_	_	I-Premise
181	in	_	_	I-Premise
182	the	_	_	I-Premise
183	evening	_	_	I-Premise
184	was	_	_	I-Premise
185	assessed	_	_	I-Premise
186	12	_	_	I-Premise
187	h	_	_	I-Premise
188	after	_	_	I-Premise
189	dosing	_	_	I-Premise
190	at	_	_	I-Premise
191	09:00	_	_	I-Premise
192	and	_	_	I-Premise
193	it	_	_	I-Premise
194	was	_	_	I-Premise
195	similar	_	_	I-Premise
196	in	_	_	I-Premise
197	the	_	_	I-Premise
198	two	_	_	I-Premise
199	treatment	_	_	I-Premise
200	groups	_	_	I-Premise
201	(	_	_	I-Premise
202	mean	_	_	I-Premise
203	+/-	_	_	I-Premise
204	standard	_	_	I-Premise
205	deviation	_	_	I-Premise
206	:	_	_	I-Premise
207	17.9	_	_	I-Premise
208	+/-	_	_	I-Premise
209	2.7	_	_	I-Premise
210	mmHg	_	_	I-Premise
211	for	_	_	I-Premise
212	travoprost	_	_	I-Premise
213	versus	_	_	I-Premise
214	17.7	_	_	I-Premise
215	+/-	_	_	I-Premise
216	2.5	_	_	I-Premise
217	mmHg	_	_	I-Premise
218	for	_	_	I-Premise
219	latanoprost	_	_	I-Premise
220	,	_	_	I-Premise
221	p	_	_	I-Premise
222	=	_	_	I-Premise
223	0.812	_	_	I-Premise
224	)	_	_	I-Premise
225	.	_	_	I-Premise

226	In	_	_	B-Premise
227	the	_	_	I-Premise
228	a.m.-dosing	_	_	I-Premise
229	crossover	_	_	I-Premise
230	comparison	_	_	I-Premise
231	,	_	_	I-Premise
232	the	_	_	I-Premise
233	24-h	_	_	I-Premise
234	post-dose	_	_	I-Premise
235	IOP	_	_	I-Premise
236	was	_	_	I-Premise
237	significantly	_	_	I-Premise
238	lower	_	_	I-Premise
239	(	_	_	I-Premise
240	p	_	_	I-Premise
241	<	_	_	I-Premise
242	0.001	_	_	I-Premise
243	)	_	_	I-Premise
244	on	_	_	I-Premise
245	travoprost	_	_	I-Premise
246	(	_	_	I-Premise
247	16.9	_	_	I-Premise
248	+/-	_	_	I-Premise
249	3.1	_	_	I-Premise
250	mmHg	_	_	I-Premise
251	)	_	_	I-Premise
252	compared	_	_	I-Premise
253	to	_	_	I-Premise
254	latanoprost	_	_	I-Premise
255	(	_	_	I-Premise
256	18.6	_	_	I-Premise
257	+/-	_	_	I-Premise
258	3.3	_	_	I-Premise
259	mmHg	_	_	I-Premise
260	)	_	_	I-Premise
261	.	_	_	I-Premise

262	In	_	_	O
263	the	_	_	O
264	exit	_	_	O
265	survey	_	_	O
266	,	_	_	O
267	51	_	_	O
268	%	_	_	O
269	of	_	_	O
270	patients	_	_	O
271	preferred	_	_	O
272	a.m.-dosing	_	_	O
273	.	_	_	O

274	a.m.-dosed	_	_	B-Claim
275	travoprost	_	_	I-Claim
276	is	_	_	I-Claim
277	superior	_	_	I-Claim
278	to	_	_	I-Claim
279	a.m.-dosed	_	_	I-Claim
280	latanoprost	_	_	I-Claim
281	by	_	_	I-Claim
282	1.7	_	_	I-Claim
283	mmHg	_	_	I-Claim
284	at	_	_	I-Claim
285	24-h	_	_	I-Claim
286	post-dose	_	_	I-Claim
287	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	safety	_	_	O
4	,	_	_	O
5	tolerability	_	_	O
6	and	_	_	O
7	efficacy	_	_	O
8	of	_	_	O
9	abatacept	_	_	O
10	in	_	_	O
11	patients	_	_	O
12	with	_	_	O
13	rheumatoid	_	_	O
14	arthritis	_	_	O
15	(	_	_	O
16	RA	_	_	O
17	)	_	_	O
18	who	_	_	O
19	had	_	_	O
20	failed	_	_	O
21	anti-tumour	_	_	O
22	necrosis	_	_	O
23	factor	_	_	O
24	(	_	_	O
25	TNF	_	_	O
26	)	_	_	O
27	therapy	_	_	O
28	and	_	_	O
29	were	_	_	O
30	switched	_	_	O
31	to	_	_	O
32	abatacept	_	_	O
33	directly	_	_	O
34	or	_	_	O
35	after	_	_	O
36	completing	_	_	O
37	washout	_	_	O
38	.	_	_	O

39	In	_	_	O
40	this	_	_	O
41	international	_	_	O
42	,	_	_	O
43	6-month	_	_	O
44	,	_	_	O
45	open-label	_	_	O
46	trial	_	_	O
47	,	_	_	O
48	patients	_	_	O
49	had	_	_	O
50	active	_	_	O
51	RA	_	_	O
52	,	_	_	O
53	an	_	_	O
54	inadequate	_	_	O
55	response	_	_	O
56	to	_	_	O
57	anti-TNF	_	_	O
58	therapy	_	_	O
59	for	_	_	O
60	3	_	_	O
61	months	_	_	O
62	or	_	_	O
63	longer	_	_	O
64	and	_	_	O
65	a	_	_	O
66	disease	_	_	O
67	activity	_	_	O
68	score	_	_	O
69	in	_	_	O
70	28	_	_	O
71	joints	_	_	O
72	(	_	_	O
73	DAS28	_	_	O
74	(	_	_	O
75	C-reactive	_	_	O
76	protein	_	_	O
77	;	_	_	O
78	CRP	_	_	O
79	)	_	_	O
80	of	_	_	O
81	5.1	_	_	O
82	or	_	_	O
83	greater	_	_	O
84	.	_	_	O

85	Washout	_	_	O
86	patients	_	_	O
87	discontinued	_	_	O
88	anti-TNF	_	_	O
89	therapy	_	_	O
90	2	_	_	O
91	months	_	_	O
92	or	_	_	O
93	longer	_	_	O
94	pre-screening	_	_	O
95	;	_	_	O
96	direct-switch	_	_	O
97	patients	_	_	O
98	began	_	_	O
99	abatacept	_	_	O
100	(	_	_	O
101	approximately	_	_	O
102	10	_	_	O
103	mg/kg	_	_	O
104	)	_	_	O
105	at	_	_	O
106	their	_	_	O
107	next	_	_	O
108	scheduled	_	_	O
109	anti-TNF	_	_	O
110	therapy	_	_	O
111	dose	_	_	O
112	.	_	_	O

113	1046	_	_	O
114	patients	_	_	O
115	were	_	_	O
116	treated	_	_	O
117	(	_	_	O
118	449	_	_	O
119	washout	_	_	O
120	,	_	_	O
121	597	_	_	O
122	direct-switch	_	_	O
123	;	_	_	O
124	baseline	_	_	O
125	characteristics	_	_	O
126	were	_	_	O
127	similar	_	_	O
128	between	_	_	O
129	groups	_	_	O
130	)	_	_	O
131	.	_	_	O

132	At	_	_	B-Premise
133	6	_	_	I-Premise
134	months	_	_	I-Premise
135	,	_	_	I-Premise
136	adverse	_	_	I-Premise
137	events	_	_	I-Premise
138	(	_	_	I-Premise
139	AE	_	_	I-Premise
140	;	_	_	I-Premise
141	78.0	_	_	I-Premise
142	%	_	_	I-Premise
143	vs	_	_	I-Premise
144	79.2	_	_	I-Premise
145	%	_	_	I-Premise
146	)	_	_	I-Premise
147	,	_	_	I-Premise
148	serious	_	_	I-Premise
149	AE	_	_	I-Premise
150	(	_	_	I-Premise
151	11.1	_	_	I-Premise
152	%	_	_	I-Premise
153	vs	_	_	I-Premise
154	9.9	_	_	I-Premise
155	%	_	_	I-Premise
156	)	_	_	I-Premise
157	and	_	_	I-Premise
158	discontinuations	_	_	I-Premise
159	due	_	_	I-Premise
160	to	_	_	I-Premise
161	AE	_	_	I-Premise
162	(	_	_	I-Premise
163	3.8	_	_	I-Premise
164	%	_	_	I-Premise
165	vs	_	_	I-Premise
166	4.0	_	_	I-Premise
167	%	_	_	I-Premise
168	)	_	_	I-Premise
169	and	_	_	I-Premise
170	serious	_	_	I-Premise
171	AE	_	_	I-Premise
172	(	_	_	I-Premise
173	2.0	_	_	I-Premise
174	%	_	_	I-Premise
175	vs	_	_	I-Premise
176	1.3	_	_	I-Premise
177	%	_	_	I-Premise
178	)	_	_	I-Premise
179	were	_	_	I-Premise
180	comparable	_	_	I-Premise
181	in	_	_	I-Premise
182	washout	_	_	I-Premise
183	versus	_	_	I-Premise
184	direct-switch	_	_	I-Premise
185	patients	_	_	I-Premise
186	.	_	_	I-Premise

187	There	_	_	B-Premise
188	were	_	_	I-Premise
189	no	_	_	I-Premise
190	opportunistic	_	_	I-Premise
191	infections	_	_	I-Premise
192	.	_	_	I-Premise

193	At	_	_	B-Premise
194	6	_	_	I-Premise
195	months	_	_	I-Premise
196	,	_	_	I-Premise
197	in	_	_	I-Premise
198	washout	_	_	I-Premise
199	versus	_	_	I-Premise
200	direct-switch	_	_	I-Premise
201	patients	_	_	I-Premise
202	,	_	_	I-Premise
203	similar	_	_	I-Premise
204	clinically	_	_	I-Premise
205	meaningful	_	_	I-Premise
206	improvements	_	_	I-Premise
207	were	_	_	I-Premise
208	seen	_	_	I-Premise
209	in	_	_	I-Premise
210	DAS28	_	_	I-Premise
211	(	_	_	I-Premise
212	CRP	_	_	I-Premise
213	)	_	_	I-Premise
214	(	_	_	I-Premise
215	>	_	_	I-Premise
216	or	_	_	I-Premise
217	=1.2	_	_	I-Premise
218	unit	_	_	I-Premise
219	improvement	_	_	I-Premise
220	,	_	_	I-Premise
221	59.5	_	_	I-Premise
222	%	_	_	I-Premise
223	vs	_	_	I-Premise
224	53.6	_	_	I-Premise
225	%	_	_	I-Premise
226	,	_	_	I-Premise
227	respectively	_	_	I-Premise
228	;	_	_	I-Premise
229	low	_	_	I-Premise
230	disease	_	_	I-Premise
231	activity	_	_	I-Premise
232	state	_	_	I-Premise
233	,	_	_	I-Premise
234	22.5	_	_	I-Premise
235	%	_	_	I-Premise
236	vs	_	_	I-Premise
237	22.3	_	_	I-Premise
238	%	_	_	I-Premise
239	;	_	_	I-Premise
240	DAS28-defined	_	_	I-Premise
241	remission	_	_	I-Premise
242	,	_	_	I-Premise
243	12.0	_	_	I-Premise
244	%	_	_	I-Premise
245	vs	_	_	I-Premise
246	13.7	_	_	I-Premise
247	%	_	_	I-Premise
248	)	_	_	I-Premise
249	,	_	_	I-Premise
250	physical	_	_	I-Premise
251	function	_	_	I-Premise
252	(	_	_	I-Premise
253	health	_	_	I-Premise
254	assessment	_	_	I-Premise
255	questionnaire	_	_	I-Premise
256	disability	_	_	I-Premise
257	index	_	_	I-Premise
258	>	_	_	I-Premise
259	or	_	_	I-Premise
260	=0.22	_	_	I-Premise
261	improvement	_	_	I-Premise
262	;	_	_	I-Premise
263	46.3	_	_	I-Premise
264	%	_	_	I-Premise
265	vs	_	_	I-Premise
266	47.1	_	_	I-Premise
267	%	_	_	I-Premise
268	)	_	_	I-Premise
269	and	_	_	I-Premise
270	health-related	_	_	I-Premise
271	quality	_	_	I-Premise
272	of	_	_	I-Premise
273	life	_	_	I-Premise
274	(	_	_	I-Premise
275	mean	_	_	I-Premise
276	change	_	_	I-Premise
277	in	_	_	I-Premise
278	short-form	_	_	I-Premise
279	36	_	_	I-Premise
280	scores	_	_	I-Premise
281	:	_	_	I-Premise
282	physical	_	_	I-Premise
283	component	_	_	I-Premise
284	summary	_	_	I-Premise
285	,	_	_	I-Premise
286	5.5	_	_	I-Premise
287	vs	_	_	I-Premise
288	6.1	_	_	I-Premise
289	;	_	_	I-Premise
290	mental	_	_	I-Premise
291	component	_	_	I-Premise
292	summary	_	_	I-Premise
293	,	_	_	I-Premise
294	4.8	_	_	I-Premise
295	vs	_	_	I-Premise
296	5.4	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	Abatacept	_	_	B-Claim
300	demonstrated	_	_	I-Claim
301	acceptable	_	_	I-Claim
302	safety	_	_	I-Claim
303	and	_	_	I-Claim
304	tolerability	_	_	I-Claim
305	and	_	_	I-Claim
306	clinically	_	_	I-Claim
307	meaningful	_	_	I-Claim
308	efficacy	_	_	I-Claim
309	over	_	_	I-Claim
310	6	_	_	I-Claim
311	months	_	_	I-Claim
312	in	_	_	I-Claim
313	patients	_	_	I-Claim
314	with	_	_	I-Claim
315	inadequate	_	_	I-Claim
316	response	_	_	I-Claim
317	to	_	_	I-Claim
318	anti-TNF	_	_	I-Claim
319	therapy	_	_	I-Claim
320	.	_	_	I-Claim

321	Results	_	_	B-Claim
322	were	_	_	I-Claim
323	comparable	_	_	I-Claim
324	with	_	_	I-Claim
325	or	_	_	I-Claim
326	without	_	_	I-Claim
327	a	_	_	I-Claim
328	washout	_	_	I-Claim
329	,	_	_	I-Claim
330	supporting	_	_	I-Claim
331	direct	_	_	I-Claim
332	switching	_	_	I-Claim
333	from	_	_	I-Claim
334	anti-TNF	_	_	I-Claim
335	therapy	_	_	I-Claim
336	to	_	_	I-Claim
337	abatacept	_	_	I-Claim
338	as	_	_	I-Claim
339	an	_	_	I-Claim
340	option	_	_	I-Claim
341	in	_	_	I-Claim
342	clinical	_	_	I-Claim
343	practice	_	_	I-Claim
344	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	survival	_	_	O
3	in	_	_	O
4	patients	_	_	O
5	with	_	_	O
6	recurrent	_	_	O
7	or	_	_	O
8	metastatic	_	_	O
9	squamous	_	_	O
10	cell	_	_	O
11	carcinoma	_	_	O
12	of	_	_	O
13	the	_	_	O
14	head	_	_	O
15	and	_	_	O
16	neck	_	_	O
17	(	_	_	O
18	SCCHN	_	_	O
19	)	_	_	O
20	treated	_	_	O
21	with	_	_	O
22	gefitinib	_	_	O
23	250	_	_	O
24	or	_	_	O
25	500	_	_	O
26	mg/day	_	_	O
27	or	_	_	O
28	standard	_	_	O
29	methotrexate	_	_	O
30	.	_	_	O

31	Four	_	_	O
32	hundred	_	_	O
33	eighty-six	_	_	O
34	patients	_	_	O
35	with	_	_	O
36	recurrent	_	_	O
37	SCCHN	_	_	O
38	were	_	_	O
39	randomly	_	_	O
40	assigned	_	_	O
41	to	_	_	O
42	oral	_	_	O
43	gefitinib	_	_	O
44	250	_	_	O
45	mg/day	_	_	O
46	,	_	_	O
47	gefitinib	_	_	O
48	500	_	_	O
49	mg/day	_	_	O
50	,	_	_	O
51	or	_	_	O
52	methotrexate	_	_	O
53	40	_	_	O
54	mg/m	_	_	O
55	(	_	_	O
56	2	_	_	O
57	)	_	_	O
58	intravenously	_	_	O
59	weekly	_	_	O
60	.	_	_	O

61	Primary	_	_	O
62	end	_	_	O
63	point	_	_	O
64	was	_	_	O
65	overall	_	_	O
66	survival	_	_	O
67	,	_	_	O
68	secondary	_	_	O
69	end	_	_	O
70	points	_	_	O
71	were	_	_	O
72	objective	_	_	O
73	response	_	_	O
74	rate	_	_	O
75	(	_	_	O
76	ORR	_	_	O
77	)	_	_	O
78	,	_	_	O
79	safety	_	_	O
80	,	_	_	O
81	symptom	_	_	O
82	improvement	_	_	O
83	,	_	_	O
84	and	_	_	O
85	quality	_	_	O
86	of	_	_	O
87	life	_	_	O
88	(	_	_	O
89	QOL	_	_	O
90	)	_	_	O
91	.	_	_	O

92	Exploratory	_	_	O
93	end	_	_	O
94	points	_	_	O
95	included	_	_	O
96	association	_	_	O
97	of	_	_	O
98	efficacy	_	_	O
99	with	_	_	O
100	epidermal	_	_	O
101	growth	_	_	O
102	factor	_	_	O
103	receptor	_	_	O
104	gene	_	_	O
105	copy	_	_	O
106	number	_	_	O
107	and	_	_	O
108	other	_	_	O
109	biomarkers	_	_	O
110	.	_	_	O

111	Neither	_	_	B-Premise
112	gefitinib	_	_	I-Premise
113	250	_	_	I-Premise
114	nor	_	_	I-Premise
115	500	_	_	I-Premise
116	mg/day	_	_	I-Premise
117	improved	_	_	I-Premise
118	overall	_	_	I-Premise
119	survival	_	_	I-Premise
120	compared	_	_	I-Premise
121	with	_	_	I-Premise
122	methotrexate	_	_	I-Premise
123	(	_	_	I-Premise
124	hazard	_	_	I-Premise
125	ratio	_	_	I-Premise
126	[	_	_	I-Premise
127	HR	_	_	I-Premise
128	]	_	_	I-Premise
129	,	_	_	I-Premise
130	1.22	_	_	I-Premise
131	;	_	_	I-Premise
132	95	_	_	I-Premise
133	%	_	_	I-Premise
134	CI	_	_	I-Premise
135	,	_	_	I-Premise
136	0.95	_	_	I-Premise
137	to	_	_	I-Premise
138	1.57	_	_	I-Premise
139	;	_	_	I-Premise
140	P	_	_	I-Premise
141	=	_	_	I-Premise
142	.12	_	_	I-Premise
143	;	_	_	I-Premise
144	and	_	_	I-Premise
145	HR	_	_	I-Premise
146	,	_	_	I-Premise
147	1.12	_	_	I-Premise
148	;	_	_	I-Premise
149	95	_	_	I-Premise
150	%	_	_	I-Premise
151	CI	_	_	I-Premise
152	,	_	_	I-Premise
153	0.87	_	_	I-Premise
154	to	_	_	I-Premise
155	1.43	_	_	I-Premise
156	;	_	_	I-Premise
157	P	_	_	I-Premise
158	=	_	_	I-Premise
159	.39	_	_	I-Premise
160	,	_	_	I-Premise
161	respectively	_	_	I-Premise
162	)	_	_	I-Premise
163	.	_	_	I-Premise

164	In	_	_	B-Premise
165	the	_	_	I-Premise
166	gefitinib	_	_	I-Premise
167	250	_	_	I-Premise
168	mg/day	_	_	I-Premise
169	,	_	_	I-Premise
170	500	_	_	I-Premise
171	mg/day	_	_	I-Premise
172	,	_	_	I-Premise
173	and	_	_	I-Premise
174	methotrexate	_	_	I-Premise
175	groups	_	_	I-Premise
176	,	_	_	I-Premise
177	respectively	_	_	I-Premise
178	,	_	_	I-Premise
179	median	_	_	I-Premise
180	overall	_	_	I-Premise
181	survival	_	_	I-Premise
182	was	_	_	I-Premise
183	5.6	_	_	I-Premise
184	,	_	_	I-Premise
185	6.0	_	_	I-Premise
186	,	_	_	I-Premise
187	and	_	_	I-Premise
188	6.7	_	_	I-Premise
189	months	_	_	I-Premise
190	;	_	_	I-Premise
191	ORRs	_	_	I-Premise
192	(	_	_	I-Premise
193	Response	_	_	I-Premise
194	Evaluation	_	_	I-Premise
195	Criteria	_	_	I-Premise
196	in	_	_	I-Premise
197	Solid	_	_	I-Premise
198	Tumors	_	_	I-Premise
199	)	_	_	I-Premise
200	were	_	_	I-Premise
201	2.7	_	_	I-Premise
202	%	_	_	I-Premise
203	,	_	_	I-Premise
204	7.6	_	_	I-Premise
205	%	_	_	I-Premise
206	and	_	_	I-Premise
207	3.9	_	_	I-Premise
208	%	_	_	I-Premise
209	,	_	_	I-Premise
210	with	_	_	I-Premise
211	no	_	_	I-Premise
212	statistically	_	_	I-Premise
213	significant	_	_	I-Premise
214	difference	_	_	I-Premise
215	between	_	_	I-Premise
216	either	_	_	I-Premise
217	gefitinib	_	_	I-Premise
218	arm	_	_	I-Premise
219	and	_	_	I-Premise
220	methotrexate	_	_	I-Premise
221	.	_	_	I-Premise

222	No	_	_	B-Premise
223	unexpected	_	_	I-Premise
224	adverse	_	_	I-Premise
225	events	_	_	I-Premise
226	were	_	_	I-Premise
227	observed	_	_	I-Premise
228	,	_	_	I-Premise
229	except	_	_	B-Premise
230	for	_	_	I-Premise
231	tumor	_	_	I-Premise
232	hemorrhage-type	_	_	I-Premise
233	events	_	_	I-Premise
234	with	_	_	I-Premise
235	gefitinib	_	_	I-Premise
236	(	_	_	I-Premise
237	8.9	_	_	I-Premise
238	%	_	_	I-Premise
239	,	_	_	I-Premise
240	gefitinib	_	_	I-Premise
241	250	_	_	I-Premise
242	mg/day	_	_	I-Premise
243	;	_	_	I-Premise
244	11.4	_	_	I-Premise
245	%	_	_	I-Premise
246	,	_	_	I-Premise
247	gefitinib	_	_	I-Premise
248	500	_	_	I-Premise
249	mg/day	_	_	I-Premise
250	;	_	_	I-Premise
251	1.9	_	_	I-Premise
252	%	_	_	I-Premise
253	,	_	_	I-Premise
254	methotrexate	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	QOL	_	_	B-Premise
258	improvement	_	_	I-Premise
259	rates	_	_	I-Premise
260	(	_	_	I-Premise
261	Functional	_	_	I-Premise
262	Assessment	_	_	I-Premise
263	of	_	_	I-Premise
264	Cancer	_	_	I-Premise
265	Therapy-Head	_	_	I-Premise
266	&	_	_	I-Premise
267	amp	_	_	I-Premise
268	;	_	_	I-Premise
269	Neck	_	_	I-Premise
270	total	_	_	I-Premise
271	score	_	_	I-Premise
272	)	_	_	I-Premise
273	were	_	_	I-Premise
274	13.4	_	_	I-Premise
275	%	_	_	I-Premise
276	,	_	_	I-Premise
277	18.0	_	_	I-Premise
278	%	_	_	I-Premise
279	,	_	_	I-Premise
280	and	_	_	I-Premise
281	6.0	_	_	I-Premise
282	%	_	_	I-Premise
283	for	_	_	I-Premise
284	gefitinib	_	_	I-Premise
285	250	_	_	I-Premise
286	mg/day	_	_	I-Premise
287	,	_	_	I-Premise
288	500	_	_	I-Premise
289	mg/day	_	_	I-Premise
290	,	_	_	I-Premise
291	and	_	_	I-Premise
292	methotrexate	_	_	I-Premise
293	,	_	_	I-Premise
294	respectively	_	_	I-Premise
295	.	_	_	I-Premise

296	In	_	_	B-Claim
297	patients	_	_	I-Claim
298	with	_	_	I-Claim
299	recurrent	_	_	I-Claim
300	or	_	_	I-Claim
301	metastatic	_	_	I-Claim
302	SCCHN	_	_	I-Claim
303	,	_	_	I-Claim
304	while	_	_	I-Claim
305	responses	_	_	I-Claim
306	with	_	_	I-Claim
307	gefitinib	_	_	I-Claim
308	were	_	_	I-Claim
309	seen	_	_	I-Claim
310	,	_	_	I-Claim
311	neither	_	_	I-Claim
312	gefitinib	_	_	I-Claim
313	250	_	_	I-Claim
314	nor	_	_	I-Claim
315	500	_	_	I-Claim
316	mg/day	_	_	I-Claim
317	improved	_	_	I-Claim
318	overall	_	_	I-Claim
319	survival	_	_	I-Claim
320	compared	_	_	I-Claim
321	with	_	_	I-Claim
322	methotrexate	_	_	I-Claim
323	.	_	_	I-Claim

324	With	_	_	B-Claim
325	the	_	_	I-Claim
326	exception	_	_	I-Claim
327	of	_	_	I-Claim
328	tumor	_	_	I-Claim
329	hemorrhage-type	_	_	I-Claim
330	events	_	_	I-Claim
331	with	_	_	I-Claim
332	gefitinib	_	_	I-Claim
333	,	_	_	I-Claim
334	the	_	_	I-Claim
335	adverse	_	_	I-Claim
336	event	_	_	I-Claim
337	profiles	_	_	I-Claim
338	were	_	_	I-Claim
339	generally	_	_	I-Claim
340	consistent	_	_	I-Claim
341	with	_	_	I-Claim
342	those	_	_	I-Claim
343	previously	_	_	I-Claim
344	observed	_	_	I-Claim
345	.	_	_	I-Claim


0	The	_	_	O
1	European	_	_	O
2	Study	_	_	O
3	Group	_	_	O
4	for	_	_	O
5	Pancreatic	_	_	O
6	Cancer	_	_	O
7	(	_	_	O
8	ESPAC-1	_	_	O
9	)	_	_	O
10	study	_	_	O
11	is	_	_	O
12	the	_	_	O
13	largest	_	_	O
14	study	_	_	O
15	of	_	_	O
16	adjuvant	_	_	O
17	treatment	_	_	O
18	for	_	_	O
19	pancreatic	_	_	O
20	ductal	_	_	O
21	adenocarcinoma	_	_	O
22	to	_	_	O
23	date	_	_	O
24	and	_	_	O
25	confirmed	_	_	O
26	a	_	_	O
27	survival	_	_	O
28	advantage	_	_	O
29	for	_	_	O
30	adjuvant	_	_	O
31	chemotherapy	_	_	O
32	but	_	_	O
33	not	_	_	O
34	for	_	_	O
35	chemoradiation	_	_	O
36	.	_	_	O

37	The	_	_	O
38	importance	_	_	O
39	of	_	_	O
40	parallel	_	_	O
41	evaluation	_	_	O
42	of	_	_	O
43	survival	_	_	O
44	and	_	_	O
45	quality	_	_	O
46	of	_	_	O
47	life	_	_	O
48	(	_	_	O
49	QoL	_	_	O
50	)	_	_	O
51	has	_	_	O
52	been	_	_	O
53	recognized	_	_	O
54	as	_	_	O
55	fundamental	_	_	O
56	and	_	_	O
57	the	_	_	O
58	aim	_	_	O
59	was	_	_	O
60	to	_	_	O
61	assess	_	_	O
62	QoL	_	_	O
63	and	_	_	O
64	quality	_	_	O
65	adjusted	_	_	O
66	survival	_	_	O
67	.	_	_	O

68	A	_	_	O
69	longitudinal	_	_	O
70	QoL	_	_	O
71	study	_	_	O
72	on	_	_	O
73	a	_	_	O
74	subset	_	_	O
75	of	_	_	O
76	ESPAC-1	_	_	O
77	patients	_	_	O
78	who	_	_	O
79	prospectively	_	_	O
80	completed	_	_	O
81	the	_	_	O
82	EORTC	_	_	O
83	QLQ	_	_	O
84	C-30	_	_	O
85	questionnaire	_	_	O
86	during	_	_	O
87	treatment	_	_	O
88	and	_	_	O
89	follow-up	_	_	O
90	.	_	_	O

91	An	_	_	O
92	integrated	_	_	O
93	quality-survival	_	_	O
94	product	_	_	O
95	method	_	_	O
96	was	_	_	O
97	used	_	_	O
98	to	_	_	O
99	adjust	_	_	O
100	any	_	_	O
101	treatment	_	_	O
102	effect	_	_	O
103	on	_	_	O
104	survival	_	_	O
105	by	_	_	O
106	a	_	_	O
107	function	_	_	O
108	of	_	_	O
109	measured	_	_	O
110	QoL	_	_	O
111	,	_	_	O
112	calculated	_	_	O
113	over	_	_	O
114	a	_	_	O
115	restricted	_	_	O
116	24-month-period	_	_	O
117	(	_	_	O
118	QALM-24	_	_	O
119	)	_	_	O
120	.	_	_	O

121	Three	_	_	O
122	hundred	_	_	O
123	and	_	_	O
124	sixteen	_	_	O
125	patients	_	_	O
126	completed	_	_	O
127	1,201	_	_	O
128	questionnaires	_	_	O
129	.	_	_	O

130	There	_	_	O
131	were	_	_	O
132	no	_	_	O
133	differences	_	_	O
134	between	_	_	O
135	treatment	_	_	O
136	groups	_	_	O
137	in	_	_	O
138	dimension	_	_	O
139	scores	_	_	O
140	at	_	_	O
141	baseline	_	_	O
142	(	_	_	O
143	randomization	_	_	O
144	)	_	_	O
145	.	_	_	O

146	For	_	_	B-Premise
147	the	_	_	I-Premise
148	chemotherapy	_	_	I-Premise
149	group	_	_	I-Premise
150	,	_	_	I-Premise
151	the	_	_	I-Premise
152	mean	_	_	I-Premise
153	Quality	_	_	I-Premise
154	Adjusted	_	_	I-Premise
155	Life	_	_	I-Premise
156	Months	_	_	I-Premise
157	over	_	_	I-Premise
158	24	_	_	I-Premise
159	months	_	_	I-Premise
160	(	_	_	I-Premise
161	QALM-24	_	_	I-Premise
162	)	_	_	I-Premise
163	was	_	_	I-Premise
164	9.6	_	_	I-Premise
165	(	_	_	I-Premise
166	95	_	_	I-Premise
167	%	_	_	I-Premise
168	CI	_	_	I-Premise
169	:	_	_	I-Premise
170	8.7	_	_	I-Premise
171	,	_	_	I-Premise
172	11.2	_	_	I-Premise
173	)	_	_	I-Premise
174	months	_	_	I-Premise
175	compared	_	_	I-Premise
176	with	_	_	I-Premise
177	the	_	_	I-Premise
178	mean	_	_	I-Premise
179	QALM-24	_	_	I-Premise
180	of	_	_	I-Premise
181	8.6	_	_	I-Premise
182	(	_	_	I-Premise
183	95	_	_	I-Premise
184	%	_	_	I-Premise
185	CI	_	_	I-Premise
186	:	_	_	I-Premise
187	7.6	_	_	I-Premise
188	,	_	_	I-Premise
189	10.5	_	_	I-Premise
190	)	_	_	I-Premise
191	months	_	_	I-Premise
192	for	_	_	I-Premise
193	the	_	_	I-Premise
194	no	_	_	I-Premise
195	chemotherapy	_	_	I-Premise
196	group	_	_	I-Premise
197	.	_	_	I-Premise

198	For	_	_	B-Premise
199	the	_	_	I-Premise
200	chemoradiation	_	_	I-Premise
201	group	_	_	I-Premise
202	,	_	_	I-Premise
203	the	_	_	I-Premise
204	mean	_	_	I-Premise
205	QALM-24	_	_	I-Premise
206	was	_	_	I-Premise
207	7.1	_	_	I-Premise
208	(	_	_	I-Premise
209	95	_	_	I-Premise
210	%	_	_	I-Premise
211	CI	_	_	I-Premise
212	:	_	_	I-Premise
213	6.0	_	_	I-Premise
214	,	_	_	I-Premise
215	9.0	_	_	I-Premise
216	)	_	_	I-Premise
217	months	_	_	I-Premise
218	compared	_	_	I-Premise
219	with	_	_	I-Premise
220	the	_	_	I-Premise
221	mean	_	_	I-Premise
222	QALM-24	_	_	I-Premise
223	of	_	_	I-Premise
224	8.1	_	_	I-Premise
225	(	_	_	I-Premise
226	95	_	_	I-Premise
227	%	_	_	I-Premise
228	CI	_	_	I-Premise
229	:	_	_	I-Premise
230	7.0	_	_	I-Premise
231	,	_	_	I-Premise
232	10.0	_	_	I-Premise
233	)	_	_	I-Premise
234	months	_	_	I-Premise
235	for	_	_	I-Premise
236	the	_	_	I-Premise
237	no	_	_	I-Premise
238	chemoradiation	_	_	I-Premise
239	group	_	_	I-Premise
240	.	_	_	I-Premise

241	The	_	_	B-Claim
242	previously	_	_	I-Claim
243	reported	_	_	I-Claim
244	survival	_	_	I-Claim
245	advantage	_	_	I-Claim
246	supporting	_	_	I-Claim
247	the	_	_	I-Claim
248	use	_	_	I-Claim
249	of	_	_	I-Claim
250	adjuvant	_	_	I-Claim
251	chemotherapy	_	_	I-Claim
252	is	_	_	I-Claim
253	maintained	_	_	I-Claim
254	when	_	_	I-Claim
255	adjusted	_	_	I-Claim
256	using	_	_	I-Claim
257	quality	_	_	I-Claim
258	adjusted	_	_	I-Claim
259	survival	_	_	I-Claim
260	methodology	_	_	I-Claim
261	.	_	_	I-Claim

262	Chemotherapy	_	_	B-Claim
263	provided	_	_	I-Claim
264	on	_	_	I-Claim
265	average	_	_	I-Claim
266	an	_	_	I-Claim
267	additional	_	_	I-Claim
268	1.0	_	_	I-Claim
269	quality-adjusted	_	_	I-Claim
270	life	_	_	I-Claim
271	months	_	_	I-Claim
272	within	_	_	I-Claim
273	a	_	_	I-Claim
274	restricted	_	_	I-Claim
275	2-year	_	_	I-Claim
276	time	_	_	I-Claim
277	period	_	_	I-Claim
278	from	_	_	I-Claim
279	the	_	_	I-Claim
280	time	_	_	I-Claim
281	of	_	_	I-Claim
282	resection	_	_	I-Claim
283	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure	_	_	O
5	(	_	_	O
6	IOP	_	_	O
7	)	_	_	O
8	lowering	_	_	O
9	efficacy	_	_	O
10	and	_	_	O
11	side	_	_	O
12	effects	_	_	O
13	of	_	_	O
14	latanoprost	_	_	O
15	0.005	_	_	O
16	%	_	_	O
17	and	_	_	O
18	bimatoprost	_	_	O
19	0.03	_	_	O
20	%	_	_	O
21	in	_	_	O
22	subjects	_	_	O
23	with	_	_	O
24	chronic	_	_	O
25	primary	_	_	O
26	angle	_	_	O
27	closure	_	_	O
28	glaucoma	_	_	O
29	(	_	_	O
30	PACG	_	_	O
31	)	_	_	O
32	.	_	_	O

33	This	_	_	O
34	was	_	_	O
35	an	_	_	O
36	observer-masked	_	_	O
37	randomised	_	_	O
38	crossover	_	_	O
39	study	_	_	O
40	of	_	_	O
41	60	_	_	O
42	PACG	_	_	O
43	subjects	_	_	O
44	who	_	_	O
45	received	_	_	O
46	either	_	_	O
47	latanoprost	_	_	O
48	or	_	_	O
49	bimatoprost	_	_	O
50	for	_	_	O
51	6	_	_	O
52	weeks	_	_	O
53	,	_	_	O
54	after	_	_	O
55	which	_	_	O
56	they	_	_	O
57	were	_	_	O
58	crossed	_	_	O
59	over	_	_	O
60	to	_	_	O
61	the	_	_	O
62	other	_	_	O
63	medication	_	_	O
64	for	_	_	O
65	another	_	_	O
66	6	_	_	O
67	weeks	_	_	O
68	.	_	_	O

69	The	_	_	O
70	IOP-reducing	_	_	O
71	effect	_	_	O
72	of	_	_	O
73	the	_	_	O
74	medications	_	_	O
75	was	_	_	O
76	assessed	_	_	O
77	by	_	_	O
78	the	_	_	O
79	reduction	_	_	O
80	in	_	_	O
81	IOP	_	_	O
82	after	_	_	O
83	6	_	_	O
84	weeks	_	_	O
85	of	_	_	O
86	treatment	_	_	O
87	compared	_	_	O
88	with	_	_	O
89	baseline	_	_	O
90	.	_	_	O

91	Fifty-four	_	_	O
92	subjects	_	_	O
93	(	_	_	O
94	80	_	_	O
95	eyes	_	_	O
96	)	_	_	O
97	completed	_	_	O
98	the	_	_	O
99	study	_	_	O
100	.	_	_	O

101	Latanoprost	_	_	B-Premise
102	reduced	_	_	I-Premise
103	IOP	_	_	I-Premise
104	(	_	_	I-Premise
105	mean	_	_	I-Premise
106	(	_	_	I-Premise
107	SD	_	_	I-Premise
108	)	_	_	I-Premise
109	)	_	_	I-Premise
110	by	_	_	I-Premise
111	8.4	_	_	I-Premise
112	(	_	_	I-Premise
113	3.8	_	_	I-Premise
114	)	_	_	I-Premise
115	mm	_	_	I-Premise
116	Hg	_	_	I-Premise
117	and	_	_	I-Premise
118	bimatoprost	_	_	I-Premise
119	by	_	_	I-Premise
120	8.9	_	_	I-Premise
121	(	_	_	I-Premise
122	3.9	_	_	I-Premise
123	)	_	_	I-Premise
124	mm	_	_	I-Premise
125	Hg	_	_	I-Premise
126	from	_	_	I-Premise
127	a	_	_	I-Premise
128	baseline	_	_	I-Premise
129	of	_	_	I-Premise
130	25.2	_	_	I-Premise
131	(	_	_	I-Premise
132	3.6	_	_	I-Premise
133	)	_	_	I-Premise
134	mm	_	_	I-Premise
135	Hg	_	_	I-Premise
136	and	_	_	I-Premise
137	25.2	_	_	I-Premise
138	(	_	_	I-Premise
139	3.6	_	_	I-Premise
140	)	_	_	I-Premise
141	mm	_	_	I-Premise
142	Hg	_	_	I-Premise
143	respectively	_	_	I-Premise
144	(	_	_	I-Premise
145	p	_	_	I-Premise
146	=	_	_	I-Premise
147	0.23	_	_	I-Premise
148	)	_	_	I-Premise
149	.	_	_	I-Premise

150	Adverse	_	_	B-Premise
151	events	_	_	I-Premise
152	were	_	_	I-Premise
153	mild	_	_	I-Premise
154	in	_	_	I-Premise
155	both	_	_	I-Premise
156	groups	_	_	I-Premise
157	;	_	_	I-Premise
158	however	_	_	B-Premise
159	there	_	_	I-Premise
160	were	_	_	I-Premise
161	twice	_	_	I-Premise
162	as	_	_	I-Premise
163	many	_	_	I-Premise
164	reports	_	_	I-Premise
165	of	_	_	I-Premise
166	an	_	_	I-Premise
167	adverse	_	_	I-Premise
168	event	_	_	I-Premise
169	in	_	_	I-Premise
170	the	_	_	I-Premise
171	bimatoprost	_	_	I-Premise
172	group	_	_	I-Premise
173	(	_	_	I-Premise
174	81	_	_	I-Premise
175	%	_	_	I-Premise
176	)	_	_	I-Premise
177	compared	_	_	I-Premise
178	with	_	_	I-Premise
179	the	_	_	I-Premise
180	latanoprost	_	_	I-Premise
181	group	_	_	I-Premise
182	(	_	_	I-Premise
183	40	_	_	I-Premise
184	%	_	_	I-Premise
185	,	_	_	I-Premise
186	p	_	_	I-Premise
187	<	_	_	I-Premise
188	0.01	_	_	I-Premise
189	)	_	_	I-Premise
190	.	_	_	I-Premise

191	Ocular	_	_	O
192	irritation	_	_	O
193	was	_	_	O
194	the	_	_	O
195	most	_	_	O
196	frequently	_	_	O
197	reported	_	_	O
198	adverse	_	_	O
199	event	_	_	O
200	in	_	_	O
201	both	_	_	O
202	groups	_	_	O
203	;	_	_	O
204	22	_	_	B-Premise
205	subjects	_	_	I-Premise
206	(	_	_	I-Premise
207	37.9	_	_	I-Premise
208	%	_	_	I-Premise
209	)	_	_	I-Premise
210	treated	_	_	I-Premise
211	with	_	_	I-Premise
212	bimatoprost	_	_	I-Premise
213	experienced	_	_	I-Premise
214	ocular	_	_	I-Premise
215	hyperaemia	_	_	I-Premise
216	as	_	_	I-Premise
217	compared	_	_	I-Premise
218	with	_	_	I-Premise
219	13	_	_	I-Premise
220	subjects	_	_	I-Premise
221	(	_	_	I-Premise
222	22.4	_	_	I-Premise
223	%	_	_	I-Premise
224	)	_	_	I-Premise
225	treated	_	_	I-Premise
226	with	_	_	I-Premise
227	latanoprost	_	_	I-Premise
228	(	_	_	I-Premise
229	p	_	_	I-Premise
230	=	_	_	I-Premise
231	0.11	_	_	I-Premise
232	)	_	_	I-Premise
233	.	_	_	I-Premise

234	Bimatoprost	_	_	B-Claim
235	once	_	_	I-Claim
236	daily	_	_	I-Claim
237	was	_	_	I-Claim
238	similarly	_	_	I-Claim
239	effective	_	_	I-Claim
240	in	_	_	I-Claim
241	reducing	_	_	I-Claim
242	IOP	_	_	I-Claim
243	compared	_	_	I-Claim
244	with	_	_	I-Claim
245	latanoprost	_	_	I-Claim
246	once	_	_	I-Claim
247	daily	_	_	I-Claim
248	in	_	_	I-Claim
249	subjects	_	_	I-Claim
250	with	_	_	I-Claim
251	chronic	_	_	I-Claim
252	PACG	_	_	I-Claim
253	.	_	_	I-Claim

254	Both	_	_	B-Claim
255	drugs	_	_	I-Claim
256	were	_	_	I-Claim
257	well	_	_	I-Claim
258	tolerated	_	_	I-Claim
259	with	_	_	I-Claim
260	mild	_	_	I-Claim
261	ocular	_	_	I-Claim
262	adverse	_	_	I-Claim
263	events	_	_	I-Claim
264	.	_	_	I-Claim


0	Therapy	_	_	O
1	for	_	_	O
2	polycystic	_	_	O
3	liver	_	_	O
4	is	_	_	O
5	invasive	_	_	O
6	,	_	_	O
7	expensive	_	_	O
8	,	_	_	O
9	and	_	_	O
10	has	_	_	O
11	disappointing	_	_	O
12	long-term	_	_	O
13	results	_	_	O
14	.	_	_	O

15	Treatment	_	_	O
16	with	_	_	O
17	somatostatin	_	_	O
18	analogues	_	_	O
19	slowed	_	_	O
20	kidney	_	_	O
21	growth	_	_	O
22	in	_	_	O
23	patients	_	_	O
24	with	_	_	O
25	polycystic	_	_	O
26	kidney	_	_	O
27	disease	_	_	O
28	(	_	_	O
29	PKD	_	_	O
30	)	_	_	O
31	and	_	_	O
32	reduced	_	_	O
33	liver	_	_	O
34	and	_	_	O
35	kidney	_	_	O
36	volume	_	_	O
37	in	_	_	O
38	a	_	_	O
39	PKD	_	_	O
40	rodent	_	_	O
41	model	_	_	O
42	.	_	_	O

43	We	_	_	O
44	evaluated	_	_	O
45	the	_	_	O
46	effects	_	_	O
47	of	_	_	O
48	lanreotide	_	_	O
49	,	_	_	O
50	a	_	_	O
51	somatostatin	_	_	O
52	analogue	_	_	O
53	,	_	_	O
54	in	_	_	O
55	patients	_	_	O
56	with	_	_	O
57	polycystic	_	_	O
58	liver	_	_	O
59	because	_	_	O
60	of	_	_	O
61	autosomal-dominant	_	_	O
62	(	_	_	O
63	AD	_	_	O
64	)	_	_	O
65	PKD	_	_	O
66	or	_	_	O
67	autosomal-dominant	_	_	O
68	polycystic	_	_	O
69	liver	_	_	O
70	disease	_	_	O
71	(	_	_	O
72	PCLD	_	_	O
73	)	_	_	O
74	.	_	_	O

75	We	_	_	O
76	performed	_	_	O
77	a	_	_	O
78	randomized	_	_	O
79	,	_	_	O
80	double-blind	_	_	O
81	,	_	_	O
82	placebo-controlled	_	_	O
83	trial	_	_	O
84	in	_	_	O
85	2	_	_	O
86	tertiary	_	_	O
87	referral	_	_	O
88	centers	_	_	O
89	.	_	_	O

90	Patients	_	_	O
91	with	_	_	O
92	polycystic	_	_	O
93	liver	_	_	O
94	(	_	_	O
95	n	_	_	O
96	=	_	_	O
97	54	_	_	O
98	)	_	_	O
99	were	_	_	O
100	randomly	_	_	O
101	assigned	_	_	O
102	to	_	_	O
103	groups	_	_	O
104	given	_	_	O
105	lanreotide	_	_	O
106	(	_	_	O
107	120	_	_	O
108	mg	_	_	O
109	)	_	_	O
110	or	_	_	O
111	placebo	_	_	O
112	,	_	_	O
113	administered	_	_	O
114	every	_	_	O
115	28	_	_	O
116	days	_	_	O
117	for	_	_	O
118	24	_	_	O
119	weeks	_	_	O
120	.	_	_	O

121	The	_	_	O
122	primary	_	_	O
123	end	_	_	O
124	point	_	_	O
125	was	_	_	O
126	the	_	_	O
127	difference	_	_	O
128	in	_	_	O
129	total	_	_	O
130	liver	_	_	O
131	volume	_	_	O
132	,	_	_	O
133	measured	_	_	O
134	by	_	_	O
135	computerized	_	_	O
136	tomography	_	_	O
137	at	_	_	O
138	weeks	_	_	O
139	0	_	_	O
140	and	_	_	O
141	24	_	_	O
142	.	_	_	O

143	Analyses	_	_	O
144	were	_	_	O
145	performed	_	_	O
146	on	_	_	O
147	an	_	_	O
148	intention-to-treat	_	_	O
149	basis	_	_	O
150	.	_	_	O

151	Baseline	_	_	B-Premise
152	characteristics	_	_	I-Premise
153	were	_	_	I-Premise
154	comparable	_	_	I-Premise
155	for	_	_	I-Premise
156	both	_	_	I-Premise
157	groups	_	_	I-Premise
158	,	_	_	I-Premise
159	except	_	_	B-Premise
160	that	_	_	I-Premise
161	more	_	_	I-Premise
162	patients	_	_	I-Premise
163	with	_	_	I-Premise
164	ADPKD	_	_	I-Premise
165	were	_	_	I-Premise
166	assigned	_	_	I-Premise
167	to	_	_	I-Premise
168	the	_	_	I-Premise
169	placebo	_	_	I-Premise
170	group	_	_	I-Premise
171	(	_	_	I-Premise
172	P	_	_	I-Premise
173	=	_	_	I-Premise
174	.03	_	_	I-Premise
175	)	_	_	I-Premise
176	.	_	_	I-Premise

177	The	_	_	B-Premise
178	mean	_	_	I-Premise
179	liver	_	_	I-Premise
180	volume	_	_	I-Premise
181	decreased	_	_	I-Premise
182	2.9	_	_	I-Premise
183	%	_	_	I-Premise
184	,	_	_	I-Premise
185	from	_	_	I-Premise
186	4606	_	_	I-Premise
187	mL	_	_	I-Premise
188	(	_	_	I-Premise
189	95	_	_	I-Premise
190	%	_	_	I-Premise
191	confidence	_	_	I-Premise
192	interval	_	_	I-Premise
193	(	_	_	I-Premise
194	CI	_	_	I-Premise
195	)	_	_	I-Premise
196	:	_	_	I-Premise
197	547-8665	_	_	I-Premise
198	)	_	_	I-Premise
199	to	_	_	I-Premise
200	4471	_	_	I-Premise
201	mL	_	_	I-Premise
202	(	_	_	I-Premise
203	95	_	_	I-Premise
204	%	_	_	I-Premise
205	CI	_	_	I-Premise
206	:	_	_	I-Premise
207	542-8401	_	_	I-Premise
208	mL	_	_	I-Premise
209	)	_	_	I-Premise
210	,	_	_	I-Premise
211	in	_	_	I-Premise
212	patients	_	_	I-Premise
213	given	_	_	I-Premise
214	lanreotide	_	_	I-Premise
215	.	_	_	I-Premise

216	In	_	_	B-Premise
217	the	_	_	I-Premise
218	placebo	_	_	I-Premise
219	group	_	_	I-Premise
220	,	_	_	I-Premise
221	the	_	_	I-Premise
222	mean	_	_	I-Premise
223	liver	_	_	I-Premise
224	volume	_	_	I-Premise
225	increased	_	_	I-Premise
226	1.6	_	_	I-Premise
227	%	_	_	I-Premise
228	,	_	_	I-Premise
229	from	_	_	I-Premise
230	4689	_	_	I-Premise
231	mL	_	_	I-Premise
232	(	_	_	I-Premise
233	95	_	_	I-Premise
234	%	_	_	I-Premise
235	CI	_	_	I-Premise
236	:	_	_	I-Premise
237	613-8765	_	_	I-Premise
238	mL	_	_	I-Premise
239	)	_	_	I-Premise
240	to	_	_	I-Premise
241	4895	_	_	I-Premise
242	mL	_	_	I-Premise
243	(	_	_	I-Premise
244	95	_	_	I-Premise
245	%	_	_	I-Premise
246	CI	_	_	I-Premise
247	:	_	_	I-Premise
248	739-9053	_	_	I-Premise
249	mL	_	_	I-Premise
250	)	_	_	I-Premise
251	(	_	_	I-Premise
252	P	_	_	I-Premise
253	<	_	_	I-Premise
254	.01	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	Post	_	_	B-Premise
258	hoc	_	_	I-Premise
259	stratification	_	_	I-Premise
260	for	_	_	I-Premise
261	patients	_	_	I-Premise
262	with	_	_	I-Premise
263	ADPKD	_	_	I-Premise
264	or	_	_	I-Premise
265	PCLD	_	_	I-Premise
266	revealed	_	_	I-Premise
267	similar	_	_	I-Premise
268	changes	_	_	I-Premise
269	in	_	_	I-Premise
270	liver	_	_	I-Premise
271	volume	_	_	I-Premise
272	,	_	_	I-Premise
273	with	_	_	I-Premise
274	statistically	_	_	I-Premise
275	significant	_	_	I-Premise
276	differences	_	_	I-Premise
277	in	_	_	I-Premise
278	patients	_	_	I-Premise
279	given	_	_	I-Premise
280	lanreotide	_	_	I-Premise
281	(	_	_	I-Premise
282	P	_	_	I-Premise
283	<	_	_	I-Premise
284	.01	_	_	I-Premise
285	for	_	_	I-Premise
286	both	_	_	I-Premise
287	diseases	_	_	I-Premise
288	)	_	_	I-Premise
289	.	_	_	I-Premise

290	In	_	_	B-Claim
291	patients	_	_	I-Claim
292	with	_	_	I-Claim
293	polycystic	_	_	I-Claim
294	liver	_	_	I-Claim
295	,	_	_	I-Claim
296	6	_	_	I-Claim
297	months	_	_	I-Claim
298	of	_	_	I-Claim
299	treatment	_	_	I-Claim
300	with	_	_	I-Claim
301	lanreotide	_	_	I-Claim
302	reduces	_	_	I-Claim
303	liver	_	_	I-Claim
304	volume	_	_	I-Claim
305	.	_	_	I-Claim


0	A	_	_	O
1	randomized	_	_	O
2	controlled	_	_	O
3	trial	_	_	O
4	was	_	_	O
5	performed	_	_	O
6	to	_	_	O
7	assess	_	_	O
8	the	_	_	O
9	outcome	_	_	O
10	of	_	_	O
11	early	_	_	O
12	oral	_	_	O
13	postoperative	_	_	O
14	feeding	_	_	O
15	(	_	_	O
16	EOF	_	_	O
17	)	_	_	O
18	compared	_	_	O
19	with	_	_	O
20	traditional	_	_	O
21	oral	_	_	O
22	feeding	_	_	O
23	(	_	_	O
24	TOF	_	_	O
25	)	_	_	O
26	in	_	_	O
27	gynecologic	_	_	O
28	oncology	_	_	O
29	patients	_	_	O
30	undergoing	_	_	O
31	a	_	_	O
32	complex	_	_	O
33	laparotomy	_	_	O
34	,	_	_	O
35	including	_	_	O
36	upper	_	_	O
37	abdominal	_	_	O
38	surgery	_	_	O
39	.	_	_	O

40	Patients	_	_	O
41	aged	_	_	O
42	18-75	_	_	O
43	years	_	_	O
44	,	_	_	O
45	undergoing	_	_	O
46	an	_	_	O
47	elective	_	_	O
48	laparotomy	_	_	O
49	and	_	_	O
50	with	_	_	O
51	a	_	_	O
52	preoperative	_	_	O
53	suspicion	_	_	O
54	of	_	_	O
55	gynecologic	_	_	O
56	malignancy	_	_	O
57	,	_	_	O
58	were	_	_	O
59	eligible	_	_	O
60	.	_	_	O

61	Exclusion	_	_	O
62	criteria	_	_	O
63	included	_	_	O
64	infectious	_	_	O
65	conditions	_	_	O
66	,	_	_	O
67	intestinal	_	_	O
68	obstruction	_	_	O
69	,	_	_	O
70	severe	_	_	O
71	malnutrition	_	_	O
72	,	_	_	O
73	American	_	_	O
74	Society	_	_	O
75	of	_	_	O
76	Anesthesiologists	_	_	O
77	score	_	_	O
78	C4	_	_	O
79	,	_	_	O
80	intestinal	_	_	O
81	resection	_	_	O
82	,	_	_	O
83	and	_	_	O
84	postoperative	_	_	O
85	stay	_	_	O
86	in	_	_	O
87	the	_	_	O
88	intensive	_	_	O
89	care	_	_	O
90	unit	_	_	O
91	lasting	_	_	O
92	24	_	_	O
93	h.	_	_	O
94	Patients	_	_	O
95	allocated	_	_	O
96	to	_	_	O
97	EOF	_	_	O
98	received	_	_	O
99	liquid	_	_	O
100	diet	_	_	O
101	in	_	_	O
102	the	_	_	O
103	first	_	_	O
104	postoperative	_	_	O
105	day	_	_	O
106	and	_	_	O
107	then	_	_	O
108	regular	_	_	O
109	diet	_	_	O
110	.	_	_	O

111	Patients	_	_	O
112	received	_	_	O
113	traditional	_	_	O
114	feeding	_	_	O
115	scheme	_	_	O
116	until	_	_	O
117	resolution	_	_	O
118	of	_	_	O
119	postoperative	_	_	O
120	ileus	_	_	O
121	to	_	_	O
122	start	_	_	O
123	liquid	_	_	O
124	diet	_	_	O
125	.	_	_	O

126	The	_	_	O
127	primary	_	_	O
128	end-point	_	_	O
129	of	_	_	O
130	the	_	_	O
131	trial	_	_	O
132	was	_	_	O
133	length	_	_	O
134	of	_	_	O
135	hospital	_	_	O
136	stay	_	_	O
137	.	_	_	O

138	Between	_	_	O
139	January	_	_	O
140	1	_	_	O
141	,	_	_	O
142	2007	_	_	O
143	,	_	_	O
144	and	_	_	O
145	November	_	_	O
146	17	_	_	O
147	,	_	_	O
148	2007	_	_	O
149	,	_	_	O
150	a	_	_	O
151	total	_	_	O
152	of	_	_	O
153	143	_	_	O
154	patients	_	_	O
155	were	_	_	O
156	randomized	_	_	O
157	to	_	_	O
158	receive	_	_	O
159	either	_	_	O
160	EOF	_	_	O
161	or	_	_	O
162	TOF	_	_	O
163	.	_	_	O

164	Hospital	_	_	B-Premise
165	stay	_	_	I-Premise
166	for	_	_	I-Premise
167	patients	_	_	I-Premise
168	who	_	_	I-Premise
169	received	_	_	I-Premise
170	EOF	_	_	I-Premise
171	(	_	_	I-Premise
172	n=71	_	_	I-Premise
173	)	_	_	I-Premise
174	was	_	_	I-Premise
175	4.7	_	_	I-Premise
176	vs.	_	_	I-Premise
177	5.8	_	_	I-Premise
178	days	_	_	I-Premise
179	for	_	_	I-Premise
180	the	_	_	I-Premise
181	TOF	_	_	I-Premise
182	group	_	_	I-Premise
183	(	_	_	I-Premise
184	n=72	_	_	I-Premise
185	)	_	_	I-Premise
186	(	_	_	I-Premise
187	P=0.006	_	_	I-Premise
188	)	_	_	I-Premise
189	.	_	_	I-Premise

190	The	_	_	B-Premise
191	mean	_	_	I-Premise
192	level	_	_	I-Premise
193	of	_	_	I-Premise
194	postoperative	_	_	I-Premise
195	satisfaction	_	_	I-Premise
196	was	_	_	I-Premise
197	significantly	_	_	I-Premise
198	higher	_	_	I-Premise
199	in	_	_	I-Premise
200	the	_	_	I-Premise
201	EOF	_	_	I-Premise
202	group	_	_	I-Premise
203	(	_	_	I-Premise
204	82.8	_	_	I-Premise
205	vs.	_	_	I-Premise
206	71.7	_	_	I-Premise
207	mm	_	_	I-Premise
208	,	_	_	I-Premise
209	P	_	_	I-Premise
210	B	_	_	I-Premise
211	0.001	_	_	I-Premise
212	)	_	_	I-Premise
213	.	_	_	I-Premise

214	Patients	_	_	B-Premise
215	who	_	_	I-Premise
216	received	_	_	I-Premise
217	the	_	_	I-Premise
218	TOF	_	_	I-Premise
219	scheme	_	_	I-Premise
220	had	_	_	I-Premise
221	significantly	_	_	I-Premise
222	higher	_	_	I-Premise
223	overall	_	_	I-Premise
224	postoperative	_	_	I-Premise
225	complications	_	_	I-Premise
226	(	_	_	I-Premise
227	39	_	_	I-Premise
228	vs.	_	_	I-Premise
229	17	_	_	I-Premise
230	%	_	_	I-Premise
231	in	_	_	I-Premise
232	EOF	_	_	I-Premise
233	group	_	_	I-Premise
234	,	_	_	I-Premise
235	P=0.003	_	_	I-Premise
236	)	_	_	I-Premise
237	and	_	_	I-Premise
238	infective	_	_	I-Premise
239	complications	_	_	I-Premise
240	(	_	_	I-Premise
241	14	_	_	I-Premise
242	%	_	_	I-Premise
243	in	_	_	I-Premise
244	TOF	_	_	I-Premise
245	group	_	_	I-Premise
246	vs.	_	_	I-Premise
247	3	_	_	I-Premise
248	%	_	_	I-Premise
249	in	_	_	I-Premise
250	EOF	_	_	I-Premise
251	group	_	_	I-Premise
252	,	_	_	I-Premise
253	P=0.017	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	Variables	_	_	B-Premise
257	such	_	_	I-Premise
258	as	_	_	I-Premise
259	nausea	_	_	I-Premise
260	and	_	_	I-Premise
261	vomiting	_	_	I-Premise
262	,	_	_	I-Premise
263	analgesic	_	_	I-Premise
264	and	_	_	I-Premise
265	antiemetic	_	_	I-Premise
266	requirement	_	_	I-Premise
267	as	_	_	I-Premise
268	well	_	_	I-Premise
269	as	_	_	I-Premise
270	level	_	_	I-Premise
271	of	_	_	I-Premise
272	pain	_	_	I-Premise
273	and	_	_	I-Premise
274	quality	_	_	I-Premise
275	of	_	_	I-Premise
276	life	_	_	I-Premise
277	were	_	_	I-Premise
278	not	_	_	I-Premise
279	different	_	_	I-Premise
280	between	_	_	I-Premise
281	groups	_	_	I-Premise
282	.	_	_	I-Premise

283	On	_	_	B-Claim
284	the	_	_	I-Claim
285	basis	_	_	I-Claim
286	of	_	_	I-Claim
287	these	_	_	I-Claim
288	findings	_	_	I-Claim
289	,	_	_	I-Claim
290	the	_	_	I-Claim
291	policy	_	_	I-Claim
292	of	_	_	I-Claim
293	EOF	_	_	I-Claim
294	should	_	_	I-Claim
295	be	_	_	I-Claim
296	used	_	_	I-Claim
297	after	_	_	I-Claim
298	a	_	_	I-Claim
299	complex	_	_	I-Claim
300	gynecologic	_	_	I-Claim
301	oncologic	_	_	I-Claim
302	laparotomy	_	_	I-Claim
303	.	_	_	I-Claim


0	Both	_	_	O
1	gastrojejunostomy	_	_	O
2	(	_	_	O
3	GJJ	_	_	O
4	)	_	_	O
5	and	_	_	O
6	stent	_	_	O
7	placement	_	_	O
8	are	_	_	O
9	commonly	_	_	O
10	used	_	_	O
11	palliative	_	_	O
12	treatments	_	_	O
13	of	_	_	O
14	obstructive	_	_	O
15	symptoms	_	_	O
16	caused	_	_	O
17	by	_	_	O
18	malignant	_	_	O
19	gastric	_	_	O
20	outlet	_	_	O
21	obstruction	_	_	O
22	(	_	_	O
23	GOO	_	_	O
24	)	_	_	O
25	.	_	_	O

26	Compare	_	_	O
27	GJJ	_	_	O
28	and	_	_	O
29	stent	_	_	O
30	placement	_	_	O
31	.	_	_	O

32	Multicenter	_	_	O
33	,	_	_	O
34	randomized	_	_	O
35	trial	_	_	O
36	.	_	_	O

37	Twenty-one	_	_	O
38	centers	_	_	O
39	in	_	_	O
40	The	_	_	O
41	Netherlands	_	_	O
42	.	_	_	O

43	Patients	_	_	O
44	with	_	_	O
45	GOO	_	_	O
46	.	_	_	O

47	GJJ	_	_	O
48	and	_	_	O
49	stent	_	_	O
50	placement	_	_	O
51	.	_	_	O

52	Outcomes	_	_	O
53	were	_	_	O
54	medical	_	_	O
55	effects	_	_	O
56	,	_	_	O
57	quality	_	_	O
58	of	_	_	O
59	life	_	_	O
60	,	_	_	O
61	and	_	_	O
62	costs	_	_	O
63	.	_	_	O

64	Analysis	_	_	O
65	was	_	_	O
66	by	_	_	O
67	intent	_	_	O
68	to	_	_	O
69	treat	_	_	O
70	.	_	_	O

71	Eighteen	_	_	O
72	patients	_	_	O
73	were	_	_	O
74	randomized	_	_	O
75	to	_	_	O
76	GJJ	_	_	O
77	and	_	_	O
78	21	_	_	O
79	to	_	_	O
80	stent	_	_	O
81	placement	_	_	O
82	.	_	_	O

83	Food	_	_	B-Premise
84	intake	_	_	I-Premise
85	improved	_	_	I-Premise
86	more	_	_	I-Premise
87	rapidly	_	_	I-Premise
88	after	_	_	I-Premise
89	stent	_	_	I-Premise
90	placement	_	_	I-Premise
91	than	_	_	I-Premise
92	after	_	_	I-Premise
93	GJJ	_	_	I-Premise
94	(	_	_	I-Premise
95	GOO	_	_	I-Premise
96	Scoring	_	_	I-Premise
97	System	_	_	I-Premise
98	score	_	_	I-Premise
99	>	_	_	I-Premise
100	or	_	_	I-Premise
101	=	_	_	I-Premise
102	2	_	_	I-Premise
103	:	_	_	I-Premise
104	median	_	_	I-Premise
105	5	_	_	I-Premise
106	vs	_	_	I-Premise
107	8	_	_	I-Premise
108	days	_	_	I-Premise
109	,	_	_	I-Premise
110	respectively	_	_	I-Premise
111	;	_	_	I-Premise
112	P	_	_	I-Premise
113	<	_	_	I-Premise
114	.01	_	_	I-Premise
115	)	_	_	I-Premise
116	but	_	_	B-Premise
117	long-term	_	_	I-Premise
118	relief	_	_	I-Premise
119	was	_	_	I-Premise
120	better	_	_	I-Premise
121	after	_	_	I-Premise
122	GJJ	_	_	I-Premise
123	,	_	_	I-Premise
124	with	_	_	I-Premise
125	more	_	_	I-Premise
126	patients	_	_	I-Premise
127	living	_	_	I-Premise
128	more	_	_	I-Premise
129	days	_	_	I-Premise
130	with	_	_	I-Premise
131	a	_	_	I-Premise
132	GOO	_	_	I-Premise
133	Scoring	_	_	I-Premise
134	System	_	_	I-Premise
135	score	_	_	I-Premise
136	of	_	_	I-Premise
137	2	_	_	I-Premise
138	or	_	_	I-Premise
139	more	_	_	I-Premise
140	than	_	_	I-Premise
141	after	_	_	I-Premise
142	stent	_	_	I-Premise
143	placement	_	_	I-Premise
144	(	_	_	I-Premise
145	72	_	_	I-Premise
146	vs	_	_	I-Premise
147	50	_	_	I-Premise
148	days	_	_	I-Premise
149	,	_	_	I-Premise
150	respectively	_	_	I-Premise
151	;	_	_	I-Premise
152	P	_	_	I-Premise
153	=	_	_	I-Premise
154	.05	_	_	I-Premise
155	)	_	_	I-Premise
156	.	_	_	I-Premise

157	More	_	_	B-Premise
158	major	_	_	I-Premise
159	complications	_	_	I-Premise
160	(	_	_	I-Premise
161	stent	_	_	I-Premise
162	:	_	_	I-Premise
163	6	_	_	I-Premise
164	in	_	_	I-Premise
165	4	_	_	I-Premise
166	patients	_	_	I-Premise
167	vs	_	_	I-Premise
168	GJJ	_	_	I-Premise
169	:	_	_	I-Premise
170	0	_	_	I-Premise
171	;	_	_	I-Premise
172	P	_	_	I-Premise
173	=	_	_	I-Premise
174	.02	_	_	I-Premise
175	)	_	_	I-Premise
176	,	_	_	I-Premise
177	recurrent	_	_	I-Premise
178	obstructive	_	_	I-Premise
179	symptoms	_	_	I-Premise
180	(	_	_	I-Premise
181	stent	_	_	I-Premise
182	:	_	_	I-Premise
183	8	_	_	I-Premise
184	in	_	_	I-Premise
185	5	_	_	I-Premise
186	patients	_	_	I-Premise
187	vs	_	_	I-Premise
188	GJJ	_	_	I-Premise
189	:	_	_	I-Premise
190	1	_	_	I-Premise
191	in	_	_	I-Premise
192	1	_	_	I-Premise
193	patient	_	_	I-Premise
194	;	_	_	I-Premise
195	P	_	_	I-Premise
196	=	_	_	I-Premise
197	.02	_	_	I-Premise
198	)	_	_	I-Premise
199	,	_	_	I-Premise
200	and	_	_	I-Premise
201	reinterventions	_	_	I-Premise
202	(	_	_	I-Premise
203	stent	_	_	I-Premise
204	:	_	_	I-Premise
205	10	_	_	I-Premise
206	in	_	_	I-Premise
207	7	_	_	I-Premise
208	patients	_	_	I-Premise
209	vs	_	_	I-Premise
210	GJJ	_	_	I-Premise
211	:	_	_	I-Premise
212	2	_	_	I-Premise
213	in	_	_	I-Premise
214	2	_	_	I-Premise
215	patients	_	_	I-Premise
216	;	_	_	I-Premise
217	P	_	_	I-Premise
218	<	_	_	I-Premise
219	.01	_	_	I-Premise
220	)	_	_	I-Premise
221	were	_	_	I-Premise
222	observed	_	_	I-Premise
223	after	_	_	I-Premise
224	stent	_	_	I-Premise
225	placement	_	_	I-Premise
226	compared	_	_	I-Premise
227	with	_	_	I-Premise
228	GJJ	_	_	I-Premise
229	.	_	_	I-Premise

230	When	_	_	B-Premise
231	stent	_	_	I-Premise
232	obstruction	_	_	I-Premise
233	was	_	_	I-Premise
234	not	_	_	I-Premise
235	regarded	_	_	I-Premise
236	as	_	_	I-Premise
237	a	_	_	I-Premise
238	major	_	_	I-Premise
239	complication	_	_	I-Premise
240	,	_	_	I-Premise
241	no	_	_	I-Premise
242	differences	_	_	I-Premise
243	in	_	_	I-Premise
244	complications	_	_	I-Premise
245	were	_	_	I-Premise
246	found	_	_	I-Premise
247	(	_	_	I-Premise
248	P	_	_	I-Premise
249	=	_	_	I-Premise
250	.4	_	_	I-Premise
251	)	_	_	I-Premise
252	.	_	_	I-Premise

253	There	_	_	B-Premise
254	were	_	_	I-Premise
255	also	_	_	I-Premise
256	no	_	_	I-Premise
257	differences	_	_	I-Premise
258	in	_	_	I-Premise
259	median	_	_	I-Premise
260	survival	_	_	I-Premise
261	(	_	_	I-Premise
262	stent	_	_	I-Premise
263	:	_	_	I-Premise
264	56	_	_	I-Premise
265	days	_	_	I-Premise
266	vs	_	_	I-Premise
267	GJJ	_	_	I-Premise
268	:	_	_	I-Premise
269	78	_	_	I-Premise
270	days	_	_	I-Premise
271	)	_	_	I-Premise
272	and	_	_	I-Premise
273	quality	_	_	I-Premise
274	of	_	_	I-Premise
275	life	_	_	I-Premise
276	.	_	_	I-Premise

277	Mean	_	_	B-Premise
278	total	_	_	I-Premise
279	costs	_	_	I-Premise
280	of	_	_	I-Premise
281	GJJ	_	_	I-Premise
282	were	_	_	I-Premise
283	higher	_	_	I-Premise
284	compared	_	_	I-Premise
285	with	_	_	I-Premise
286	stent	_	_	I-Premise
287	placement	_	_	I-Premise
288	(	_	_	I-Premise
289	$	_	_	I-Premise
290	16,535	_	_	I-Premise
291	vs	_	_	I-Premise
292	$	_	_	I-Premise
293	11,720	_	_	I-Premise
294	,	_	_	I-Premise
295	respectively	_	_	I-Premise
296	;	_	_	I-Premise
297	P	_	_	I-Premise
298	=	_	_	I-Premise
299	.049	_	_	I-Premise
300	[	_	_	I-Premise
301	comparing	_	_	I-Premise
302	medians	_	_	I-Premise
303	]	_	_	I-Premise
304	)	_	_	I-Premise
305	.	_	_	I-Premise

306	Because	_	_	O
307	of	_	_	O
308	the	_	_	O
309	small	_	_	O
310	study	_	_	O
311	population	_	_	O
312	,	_	_	O
313	only	_	_	O
314	initial	_	_	O
315	hospital	_	_	O
316	costs	_	_	O
317	would	_	_	O
318	have	_	_	O
319	been	_	_	O
320	statistically	_	_	O
321	significant	_	_	O
322	if	_	_	O
323	the	_	_	O
324	Bonferroni	_	_	O
325	correction	_	_	O
326	for	_	_	O
327	multiple	_	_	O
328	testing	_	_	O
329	had	_	_	O
330	been	_	_	O
331	applied	_	_	O
332	.	_	_	O

333	Relatively	_	_	O
334	small	_	_	O
335	patient	_	_	O
336	population	_	_	O
337	.	_	_	O

338	Despite	_	_	B-Premise
339	slow	_	_	I-Premise
340	initial	_	_	I-Premise
341	symptom	_	_	I-Premise
342	improvement	_	_	I-Premise
343	,	_	_	I-Premise
344	GJJ	_	_	B-Claim
345	was	_	_	I-Claim
346	associated	_	_	I-Claim
347	with	_	_	I-Claim
348	better	_	_	I-Claim
349	long-term	_	_	I-Claim
350	results	_	_	I-Claim
351	and	_	_	I-Claim
352	is	_	_	I-Claim
353	therefore	_	_	I-Claim
354	the	_	_	I-Claim
355	treatment	_	_	I-Claim
356	of	_	_	I-Claim
357	choice	_	_	I-Claim
358	in	_	_	I-Claim
359	patients	_	_	I-Claim
360	with	_	_	I-Claim
361	a	_	_	I-Claim
362	life	_	_	I-Claim
363	expectancy	_	_	I-Claim
364	of	_	_	I-Claim
365	2	_	_	I-Claim
366	months	_	_	I-Claim
367	or	_	_	I-Claim
368	longer	_	_	I-Claim
369	.	_	_	I-Claim

370	Because	_	_	B-Claim
371	stent	_	_	I-Claim
372	placement	_	_	I-Claim
373	was	_	_	I-Claim
374	associated	_	_	I-Claim
375	with	_	_	I-Claim
376	better	_	_	I-Claim
377	short-term	_	_	I-Claim
378	outcomes	_	_	I-Claim
379	,	_	_	I-Claim
380	this	_	_	B-Claim
381	treatment	_	_	I-Claim
382	is	_	_	I-Claim
383	preferable	_	_	I-Claim
384	for	_	_	I-Claim
385	patients	_	_	I-Claim
386	expected	_	_	I-Claim
387	to	_	_	I-Claim
388	live	_	_	I-Claim
389	less	_	_	I-Claim
390	than	_	_	I-Claim
391	2	_	_	I-Claim
392	months	_	_	I-Claim
393	.	_	_	I-Claim


0	Restoring	_	_	O
1	sensory	_	_	O
2	innervation	_	_	O
3	may	_	_	O
4	be	_	_	O
5	a	_	_	O
6	useful	_	_	O
7	adjunct	_	_	O
8	in	_	_	O
9	free	_	_	O
10	flap	_	_	O
11	head	_	_	O
12	and	_	_	O
13	neck	_	_	O
14	reconstruction	_	_	O
15	but	_	_	O
16	,	_	_	O
17	as	_	_	O
18	yet	_	_	O
19	,	_	_	O
20	has	_	_	O
21	not	_	_	O
22	been	_	_	O
23	shown	_	_	O
24	to	_	_	O
25	improve	_	_	O
26	outcomes	_	_	O
27	of	_	_	O
28	breast	_	_	O
29	reconstruction	_	_	O
30	.	_	_	O

31	The	_	_	O
32	authors	_	_	O
33	'	_	_	O
34	previous	_	_	O
35	study	_	_	O
36	demonstrated	_	_	O
37	objectively	_	_	O
38	improved	_	_	O
39	sensation	_	_	O
40	in	_	_	O
41	a	_	_	O
42	group	_	_	O
43	of	_	_	O
44	innervated	_	_	O
45	transverse	_	_	O
46	rectus	_	_	O
47	abdominis	_	_	O
48	musculocutaneous	_	_	O
49	(	_	_	O
50	TRAM	_	_	O
51	)	_	_	O
52	flap	_	_	O
53	breast	_	_	O
54	reconstruction	_	_	O
55	patients	_	_	O
56	relative	_	_	O
57	to	_	_	O
58	noninnervated	_	_	O
59	flaps	_	_	O
60	.	_	_	O

61	This	_	_	O
62	study	_	_	O
63	compared	_	_	O
64	patient-rated	_	_	O
65	outcomes	_	_	O
66	of	_	_	O
67	free	_	_	O
68	TRAM	_	_	O
69	breast	_	_	O
70	reconstruction	_	_	O
71	in	_	_	O
72	innervated	_	_	O
73	versus	_	_	O
74	noninnervated	_	_	O
75	flaps	_	_	O
76	.	_	_	O

77	Twenty-seven	_	_	O
78	women	_	_	O
79	were	_	_	O
80	randomized	_	_	O
81	prospectively	_	_	O
82	to	_	_	O
83	undergo	_	_	O
84	either	_	_	O
85	innervated	_	_	O
86	or	_	_	O
87	noninnervated	_	_	O
88	free	_	_	O
89	TRAM	_	_	O
90	flap	_	_	O
91	breast	_	_	O
92	reconstruction	_	_	O
93	.	_	_	O

94	For	_	_	O
95	innervated	_	_	O
96	flaps	_	_	O
97	,	_	_	O
98	the	_	_	O
99	T10	_	_	O
100	intercostal	_	_	O
101	nerve	_	_	O
102	was	_	_	O
103	harvested	_	_	O
104	with	_	_	O
105	the	_	_	O
106	TRAM	_	_	O
107	flap	_	_	O
108	and	_	_	O
109	neurotized	_	_	O
110	to	_	_	O
111	the	_	_	O
112	T4	_	_	O
113	sensory	_	_	O
114	nerve	_	_	O
115	at	_	_	O
116	the	_	_	O
117	recipient	_	_	O
118	site	_	_	O
119	.	_	_	O

120	Three	_	_	O
121	validated	_	_	O
122	outcome	_	_	O
123	tools	_	_	O
124	were	_	_	O
125	administered	_	_	O
126	after	_	_	O
127	surgery	_	_	O
128	:	_	_	O
129	the	_	_	O
130	Medical	_	_	O
131	Outcomes	_	_	O
132	Study	_	_	O
133	36-Item	_	_	O
134	Short	_	_	O
135	Form	_	_	O
136	Health	_	_	O
137	Survey	_	_	O
138	,	_	_	O
139	the	_	_	O
140	Body	_	_	O
141	Image	_	_	O
142	after	_	_	O
143	Breast	_	_	O
144	Cancer	_	_	O
145	Questionnaire	_	_	O
146	,	_	_	O
147	and	_	_	O
148	the	_	_	O
149	Functional	_	_	O
150	Assessment	_	_	O
151	of	_	_	O
152	Cancer	_	_	O
153	Therapy-Breast	_	_	O
154	.	_	_	O

155	Results	_	_	B-Premise
156	were	_	_	I-Premise
157	correlated	_	_	I-Premise
158	with	_	_	I-Premise
159	previously	_	_	I-Premise
160	reported	_	_	I-Premise
161	objective	_	_	I-Premise
162	sensibility	_	_	I-Premise
163	outcomes	_	_	I-Premise
164	.	_	_	I-Premise

165	Eighteen	_	_	O
166	of	_	_	O
167	27	_	_	O
168	women	_	_	O
169	returned	_	_	O
170	their	_	_	O
171	questionnaires	_	_	O
172	a	_	_	O
173	mean	_	_	O
174	48	_	_	O
175	months	_	_	O
176	after	_	_	O
177	free	_	_	O
178	TRAM	_	_	O
179	flap	_	_	O
180	reconstruction	_	_	O
181	.	_	_	O

182	Demographic	_	_	O
183	analysis	_	_	O
184	revealed	_	_	O
185	no	_	_	O
186	significant	_	_	O
187	differences	_	_	O
188	in	_	_	O
189	patient	_	_	O
190	age	_	_	O
191	,	_	_	O
192	height	_	_	O
193	,	_	_	O
194	smoking	_	_	O
195	,	_	_	O
196	radiation	_	_	O
197	therapy	_	_	O
198	,	_	_	O
199	and	_	_	O
200	nipple-areola	_	_	O
201	complex	_	_	O
202	reconstruction	_	_	O
203	between	_	_	O
204	randomized	_	_	O
205	patient	_	_	O
206	groups	_	_	O
207	.	_	_	O

208	There	_	_	B-Premise
209	was	_	_	I-Premise
210	a	_	_	I-Premise
211	statistically	_	_	I-Premise
212	significant	_	_	I-Premise
213	improvement	_	_	I-Premise
214	in	_	_	I-Premise
215	all	_	_	I-Premise
216	three	_	_	I-Premise
217	measures	_	_	I-Premise
218	in	_	_	I-Premise
219	patients	_	_	I-Premise
220	who	_	_	I-Premise
221	were	_	_	I-Premise
222	randomized	_	_	I-Premise
223	to	_	_	I-Premise
224	receive	_	_	I-Premise
225	innervated	_	_	I-Premise
226	free	_	_	I-Premise
227	TRAM	_	_	I-Premise
228	flaps	_	_	I-Premise
229	compared	_	_	I-Premise
230	with	_	_	I-Premise
231	those	_	_	I-Premise
232	receiving	_	_	I-Premise
233	noninnervated	_	_	I-Premise
234	flaps	_	_	I-Premise
235	.	_	_	I-Premise

236	This	_	_	B-Claim
237	study	_	_	I-Claim
238	demonstrates	_	_	I-Claim
239	that	_	_	I-Claim
240	innervation	_	_	I-Claim
241	of	_	_	I-Claim
242	free	_	_	I-Claim
243	TRAM	_	_	I-Claim
244	flaps	_	_	I-Claim
245	used	_	_	I-Claim
246	for	_	_	I-Claim
247	breast	_	_	I-Claim
248	reconstruction	_	_	I-Claim
249	not	_	_	I-Claim
250	only	_	_	I-Claim
251	improves	_	_	I-Claim
252	sensibility	_	_	I-Claim
253	but	_	_	I-Claim
254	also	_	_	I-Claim
255	has	_	_	I-Claim
256	a	_	_	I-Claim
257	positive	_	_	I-Claim
258	effect	_	_	I-Claim
259	on	_	_	I-Claim
260	patient-rated	_	_	I-Claim
261	quality	_	_	I-Claim
262	of	_	_	I-Claim
263	life	_	_	I-Claim
264	.	_	_	I-Claim


0	To	_	_	O
1	test	_	_	O
2	the	_	_	O
3	hypothesis	_	_	O
4	that	_	_	O
5	modulation	_	_	O
6	of	_	_	O
7	Bcl-2	_	_	O
8	with	_	_	O
9	13-cis	_	_	O
10	retinoic	_	_	O
11	acid	_	_	O
12	(	_	_	O
13	CRA	_	_	O
14	)	_	_	O
15	/interferon-alpha2b	_	_	O
16	(	_	_	O
17	IFN	_	_	O
18	)	_	_	O
19	with	_	_	O
20	paclitaxel	_	_	O
21	(	_	_	O
22	TAX	_	_	O
23	)	_	_	O
24	,	_	_	O
25	or	_	_	O
26	mitoxantrone	_	_	O
27	,	_	_	O
28	estramustine	_	_	O
29	and	_	_	O
30	vinorelbine	_	_	O
31	(	_	_	O
32	MEV	_	_	O
33	)	_	_	O
34	will	_	_	O
35	have	_	_	O
36	clinical	_	_	O
37	activity	_	_	O
38	in	_	_	O
39	men	_	_	O
40	with	_	_	O
41	metastatic	_	_	O
42	castrate-resistant	_	_	O
43	prostate	_	_	O
44	cancer	_	_	O
45	(	_	_	O
46	CRPC	_	_	O
47	)	_	_	O
48	.	_	_	O

49	70	_	_	O
50	patients	_	_	O
51	were	_	_	O
52	treated	_	_	O
53	with	_	_	O
54	either	_	_	O
55	MEV	_	_	O
56	(	_	_	O
57	Arm	_	_	O
58	A	_	_	O
59	)	_	_	O
60	in	_	_	O
61	a	_	_	O
62	3-week	_	_	O
63	cycle	_	_	O
64	or	_	_	O
65	CRA/IFN/TAX	_	_	O
66	with	_	_	O
67	an	_	_	O
68	8-week	_	_	O
69	cycle	_	_	O
70	(	_	_	O
71	Arm	_	_	O
72	B	_	_	O
73	)	_	_	O
74	.	_	_	O

75	Patients	_	_	O
76	were	_	_	O
77	assessed	_	_	O
78	for	_	_	O
79	response	_	_	O
80	,	_	_	O
81	toxicity	_	_	O
82	,	_	_	O
83	quality	_	_	O
84	of	_	_	O
85	life	_	_	O
86	(	_	_	O
87	QOL	_	_	O
88	)	_	_	O
89	,	_	_	O
90	and	_	_	O
91	the	_	_	O
92	effect	_	_	O
93	of	_	_	O
94	treatment	_	_	O
95	on	_	_	O
96	Bcl-2	_	_	O
97	levels	_	_	O
98	in	_	_	O
99	peripheral	_	_	O
100	blood	_	_	O
101	mononuclear	_	_	O
102	cells	_	_	O
103	(	_	_	O
104	PBMC	_	_	O
105	)	_	_	O
106	.	_	_	O

107	The	_	_	B-Premise
108	PSA	_	_	I-Premise
109	response	_	_	I-Premise
110	rates	_	_	I-Premise
111	were	_	_	I-Premise
112	50	_	_	I-Premise
113	%	_	_	I-Premise
114	and	_	_	I-Premise
115	23	_	_	I-Premise
116	%	_	_	I-Premise
117	,	_	_	I-Premise
118	measurable	_	_	I-Premise
119	disease	_	_	I-Premise
120	response	_	_	I-Premise
121	rates	_	_	I-Premise
122	(	_	_	I-Premise
123	CR+PR	_	_	I-Premise
124	)	_	_	I-Premise
125	14	_	_	I-Premise
126	%	_	_	I-Premise
127	and	_	_	I-Premise
128	15	_	_	I-Premise
129	%	_	_	I-Premise
130	,	_	_	I-Premise
131	and	_	_	I-Premise
132	median	_	_	I-Premise
133	overall	_	_	I-Premise
134	survival	_	_	I-Premise
135	19.4	_	_	I-Premise
136	months	_	_	I-Premise
137	and	_	_	I-Premise
138	13.9	_	_	I-Premise
139	months	_	_	I-Premise
140	on	_	_	I-Premise
141	Arm	_	_	I-Premise
142	A	_	_	I-Premise
143	and	_	_	I-Premise
144	Arm	_	_	I-Premise
145	B	_	_	I-Premise
146	respectively	_	_	I-Premise
147	.	_	_	I-Premise

148	Transient	_	_	B-Premise
149	grade	_	_	I-Premise
150	4	_	_	I-Premise
151	neutropenia	_	_	I-Premise
152	occurred	_	_	I-Premise
153	in	_	_	I-Premise
154	18	_	_	I-Premise
155	and	_	_	I-Premise
156	2	_	_	I-Premise
157	patients	_	_	I-Premise
158	,	_	_	I-Premise
159	and	_	_	I-Premise
160	grade	_	_	I-Premise
161	3	_	_	I-Premise
162	to	_	_	I-Premise
163	4	_	_	I-Premise
164	thrombosis	_	_	I-Premise
165	in	_	_	I-Premise
166	7	_	_	I-Premise
167	patients	_	_	I-Premise
168	and	_	_	I-Premise
169	1	_	_	I-Premise
170	patient	_	_	I-Premise
171	in	_	_	I-Premise
172	Arm	_	_	I-Premise
173	A	_	_	I-Premise
174	and	_	_	I-Premise
175	Arm	_	_	I-Premise
176	B	_	_	I-Premise
177	respectively	_	_	I-Premise
178	.	_	_	I-Premise

179	Patients	_	_	B-Premise
180	on	_	_	I-Premise
181	Arm	_	_	I-Premise
182	B	_	_	I-Premise
183	reported	_	_	I-Premise
184	a	_	_	I-Premise
185	clinically	_	_	I-Premise
186	significant	_	_	I-Premise
187	decline	_	_	I-Premise
188	in	_	_	I-Premise
189	QOL	_	_	I-Premise
190	between	_	_	I-Premise
191	baseline	_	_	I-Premise
192	and	_	_	I-Premise
193	week	_	_	I-Premise
194	9/10	_	_	I-Premise
195	(	_	_	I-Premise
196	.71	_	_	I-Premise
197	s.d	_	_	I-Premise
198	.	_	_	I-Premise

199	)	_	_	I-Premise
200	,	_	_	I-Premise
201	and	_	_	I-Premise
202	a	_	_	I-Premise
203	significantly	_	_	I-Premise
204	lower	_	_	I-Premise
205	level	_	_	I-Premise
206	of	_	_	I-Premise
207	QOL	_	_	I-Premise
208	than	_	_	I-Premise
209	Arm	_	_	I-Premise
210	A	_	_	I-Premise
211	(	_	_	I-Premise
212	p	_	_	I-Premise
213	=	_	_	I-Premise
214	0.01	_	_	I-Premise
215	)	_	_	I-Premise
216	.	_	_	I-Premise

217	As	_	_	B-Premise
218	hypothesized	_	_	I-Premise
219	,	_	_	I-Premise
220	Bcl-2	_	_	I-Premise
221	levels	_	_	I-Premise
222	decreased	_	_	I-Premise
223	with	_	_	I-Premise
224	CRA/IFN	_	_	I-Premise
225	therapy	_	_	I-Premise
226	only	_	_	I-Premise
227	in	_	_	I-Premise
228	Arm	_	_	I-Premise
229	B	_	_	I-Premise
230	(	_	_	I-Premise
231	p	_	_	I-Premise
232	=	_	_	I-Premise
233	0.03	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	Treatment	_	_	B-Claim
237	with	_	_	I-Claim
238	MEV	_	_	I-Claim
239	was	_	_	I-Claim
240	well	_	_	I-Claim
241	tolerated	_	_	I-Claim
242	and	_	_	I-Claim
243	demonstrated	_	_	I-Claim
244	clinical	_	_	I-Claim
245	activity	_	_	I-Claim
246	in	_	_	I-Claim
247	patients	_	_	I-Claim
248	with	_	_	I-Claim
249	CRPC	_	_	I-Claim
250	.	_	_	I-Claim

251	Given	_	_	B-Claim
252	the	_	_	I-Claim
253	adverse	_	_	I-Claim
254	effect	_	_	I-Claim
255	of	_	_	I-Claim
256	CRA/IFN/TAX	_	_	I-Claim
257	on	_	_	I-Claim
258	QOL	_	_	I-Claim
259	,	_	_	I-Claim
260	the	_	_	I-Claim
261	study	_	_	I-Claim
262	of	_	_	I-Claim
263	other	_	_	I-Claim
264	novel	_	_	I-Claim
265	agents	_	_	I-Claim
266	that	_	_	I-Claim
267	target	_	_	I-Claim
268	Bcl-2	_	_	I-Claim
269	family	_	_	I-Claim
270	proteins	_	_	I-Claim
271	is	_	_	I-Claim
272	warranted	_	_	I-Claim
273	.	_	_	I-Claim

274	The	_	_	O
275	feasibility	_	_	O
276	of	_	_	O
277	measuring	_	_	O
278	Bcl-2	_	_	O
279	protein	_	_	O
280	in	_	_	O
281	a	_	_	O
282	cooperative	_	_	O
283	group	_	_	O
284	setting	_	_	O
285	is	_	_	O
286	hypothesis	_	_	O
287	generating	_	_	O
288	and	_	_	O
289	supports	_	_	O
290	further	_	_	O
291	study	_	_	O
292	as	_	_	O
293	a	_	_	O
294	marker	_	_	O
295	for	_	_	O
296	Bcl-2	_	_	O
297	targeted	_	_	O
298	therapy	_	_	O
299	.	_	_	O


0	To	_	_	O
1	compare	_	_	O
2	phacoemulsification	_	_	O
3	alone	_	_	O
4	and	_	_	O
5	phacoemulsification	_	_	O
6	with	_	_	O
7	micro-bypass	_	_	O
8	stent	_	_	O
9	implantation	_	_	O
10	in	_	_	O
11	eyes	_	_	O
12	with	_	_	O
13	primary	_	_	O
14	open-angle	_	_	O
15	glaucoma	_	_	O
16	.	_	_	O

17	Instituto	_	_	O
18	di	_	_	O
19	Fisiopatologia	_	_	O
20	Clinica	_	_	O
21	,	_	_	O
22	Clinica	_	_	O
23	Oculistica	_	_	O
24	,	_	_	O
25	Universita	_	_	O
26	'	_	_	O
27	di	_	_	O
28	Torino	_	_	O
29	,	_	_	O
30	Torino	_	_	O
31	,	_	_	O
32	Italy	_	_	O
33	.	_	_	O

34	In	_	_	O
35	this	_	_	O
36	prospective	_	_	O
37	double-masked	_	_	O
38	randomized	_	_	O
39	clinical	_	_	O
40	trial	_	_	O
41	,	_	_	O
42	patients	_	_	O
43	had	_	_	O
44	phacoemulsification	_	_	O
45	alone	_	_	O
46	(	_	_	O
47	control	_	_	O
48	group	_	_	O
49	)	_	_	O
50	or	_	_	O
51	phacoemulsification	_	_	O
52	with	_	_	O
53	iStent	_	_	O
54	implantation	_	_	O
55	(	_	_	O
56	combined	_	_	O
57	group	_	_	O
58	)	_	_	O
59	.	_	_	O

60	Primary	_	_	O
61	outcomes	_	_	O
62	were	_	_	O
63	intraocular	_	_	O
64	pressure	_	_	O
65	(	_	_	O
66	IOP	_	_	O
67	)	_	_	O
68	and	_	_	O
69	reduction	_	_	O
70	in	_	_	O
71	medication	_	_	O
72	use	_	_	O
73	over	_	_	O
74	15	_	_	O
75	months	_	_	O
76	and	_	_	O
77	IOP	_	_	O
78	after	_	_	O
79	a	_	_	O
80	1-month	_	_	O
81	washout	_	_	O
82	of	_	_	O
83	ocular	_	_	O
84	hypotensive	_	_	O
85	agents	_	_	O
86	(	_	_	O
87	ie	_	_	O
88	,	_	_	O
89	16	_	_	O
90	months	_	_	O
91	postoperatively	_	_	O
92	)	_	_	O
93	.	_	_	O

94	The	_	_	O
95	baseline	_	_	O
96	IOP	_	_	O
97	was	_	_	O
98	similar	_	_	O
99	between	_	_	O
100	groups	_	_	O
101	(	_	_	O
102	combined	_	_	O
103	group	_	_	O
104	:	_	_	O
105	17.9	_	_	O
106	mm	_	_	O
107	Hg	_	_	O
108	+/-	_	_	O
109	2.6	_	_	O
110	[	_	_	O
111	SD	_	_	O
112	]	_	_	O
113	;	_	_	O
114	control	_	_	O
115	group	_	_	O
116	:	_	_	O
117	17.3	_	_	O
118	+/-	_	_	O
119	3.0	_	_	O
120	mm	_	_	O
121	Hg	_	_	O
122	)	_	_	O
123	(	_	_	O
124	P	_	_	O
125	=	_	_	O
126	.512	_	_	O
127	)	_	_	O
128	.	_	_	O

129	Three	_	_	O
130	patients	_	_	O
131	in	_	_	O
132	the	_	_	O
133	control	_	_	O
134	group	_	_	O
135	were	_	_	O
136	lost	_	_	O
137	to	_	_	O
138	follow-up	_	_	O
139	.	_	_	O

140	The	_	_	B-Premise
141	mean	_	_	I-Premise
142	IOP	_	_	I-Premise
143	was	_	_	I-Premise
144	14.8	_	_	I-Premise
145	+/-	_	_	I-Premise
146	1.2	_	_	I-Premise
147	mm	_	_	I-Premise
148	Hg	_	_	I-Premise
149	in	_	_	I-Premise
150	the	_	_	I-Premise
151	combined	_	_	I-Premise
152	group	_	_	I-Premise
153	and	_	_	I-Premise
154	15.7	_	_	I-Premise
155	+/-	_	_	I-Premise
156	1.1	_	_	I-Premise
157	mm	_	_	I-Premise
158	Hg	_	_	I-Premise
159	in	_	_	I-Premise
160	the	_	_	I-Premise
161	control	_	_	I-Premise
162	group	_	_	I-Premise
163	at	_	_	I-Premise
164	15	_	_	I-Premise
165	months	_	_	I-Premise
166	and	_	_	I-Premise
167	16.6	_	_	I-Premise
168	+/-	_	_	I-Premise
169	3.1	_	_	I-Premise
170	mm	_	_	I-Premise
171	Hg	_	_	I-Premise
172	and	_	_	I-Premise
173	19.2	_	_	I-Premise
174	+/-	_	_	I-Premise
175	3.5	_	_	I-Premise
176	mm	_	_	I-Premise
177	Hg	_	_	I-Premise
178	,	_	_	I-Premise
179	respectively	_	_	I-Premise
180	,	_	_	I-Premise
181	after	_	_	I-Premise
182	washout	_	_	I-Premise
183	;	_	_	I-Premise
184	the	_	_	B-Premise
185	IOP	_	_	I-Premise
186	was	_	_	I-Premise
187	statistically	_	_	I-Premise
188	significantly	_	_	I-Premise
189	lower	_	_	I-Premise
190	in	_	_	I-Premise
191	the	_	_	I-Premise
192	combined	_	_	I-Premise
193	group	_	_	I-Premise
194	than	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	control	_	_	I-Premise
198	group	_	_	I-Premise
199	at	_	_	I-Premise
200	both	_	_	I-Premise
201	time	_	_	I-Premise
202	points	_	_	I-Premise
203	(	_	_	I-Premise
204	P	_	_	I-Premise
205	=	_	_	I-Premise
206	.031	_	_	I-Premise
207	and	_	_	I-Premise
208	P	_	_	I-Premise
209	=	_	_	I-Premise
210	.042	_	_	I-Premise
211	,	_	_	I-Premise
212	respectively	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	At	_	_	B-Premise
216	15	_	_	I-Premise
217	months	_	_	I-Premise
218	,	_	_	I-Premise
219	the	_	_	I-Premise
220	mean	_	_	I-Premise
221	number	_	_	I-Premise
222	of	_	_	I-Premise
223	medications	_	_	I-Premise
224	was	_	_	I-Premise
225	lower	_	_	I-Premise
226	in	_	_	I-Premise
227	the	_	_	I-Premise
228	combined	_	_	I-Premise
229	group	_	_	I-Premise
230	than	_	_	I-Premise
231	in	_	_	I-Premise
232	the	_	_	I-Premise
233	control	_	_	I-Premise
234	group	_	_	I-Premise
235	(	_	_	I-Premise
236	0.4	_	_	I-Premise
237	+/-	_	_	I-Premise
238	0.7	_	_	I-Premise
239	and	_	_	I-Premise
240	1.3	_	_	I-Premise
241	+/-	_	_	I-Premise
242	1.0	_	_	I-Premise
243	,	_	_	I-Premise
244	respectively	_	_	I-Premise
245	;	_	_	I-Premise
246	P	_	_	I-Premise
247	=	_	_	I-Premise
248	.007	_	_	I-Premise
249	)	_	_	I-Premise
250	,	_	_	I-Premise
251	as	_	_	I-Premise
252	was	_	_	I-Premise
253	the	_	_	I-Premise
254	proportion	_	_	I-Premise
255	of	_	_	I-Premise
256	patients	_	_	I-Premise
257	on	_	_	I-Premise
258	ocular	_	_	I-Premise
259	hypotensive	_	_	I-Premise
260	medication	_	_	I-Premise
261	(	_	_	I-Premise
262	33	_	_	I-Premise
263	%	_	_	I-Premise
264	and	_	_	I-Premise
265	76	_	_	I-Premise
266	%	_	_	I-Premise
267	,	_	_	I-Premise
268	respectively	_	_	I-Premise
269	)	_	_	I-Premise
270	.	_	_	I-Premise

271	Phacoemulsification	_	_	B-Claim
272	with	_	_	I-Claim
273	stent	_	_	I-Claim
274	implantation	_	_	I-Claim
275	was	_	_	I-Claim
276	more	_	_	I-Claim
277	effective	_	_	I-Claim
278	in	_	_	I-Claim
279	controlling	_	_	I-Claim
280	IOP	_	_	I-Claim
281	than	_	_	I-Claim
282	phacoemulsification	_	_	I-Claim
283	alone	_	_	I-Claim
284	;	_	_	I-Claim
285	the	_	_	O
286	safety	_	_	O
287	profiles	_	_	O
288	were	_	_	O
289	similar	_	_	O
290	.	_	_	O


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	laser	_	_	O
8	peripheral	_	_	O
9	iridotomy	_	_	O
10	with	_	_	O
11	or	_	_	O
12	without	_	_	O
13	laser	_	_	O
14	peripheral	_	_	O
15	iridoplasty	_	_	O
16	in	_	_	O
17	the	_	_	O
18	treatment	_	_	O
19	of	_	_	O
20	eyes	_	_	O
21	with	_	_	O
22	synechial	_	_	O
23	primary	_	_	O
24	angle-closure	_	_	O
25	or	_	_	O
26	primary	_	_	O
27	angle-closure	_	_	O
28	glaucoma	_	_	O
29	.	_	_	O

30	Randomized	_	_	O
31	,	_	_	O
32	controlled	_	_	O
33	clinical	_	_	O
34	trial	_	_	O
35	.	_	_	O

36	Consecutive	_	_	O
37	patients	_	_	O
38	older	_	_	O
39	than	_	_	O
40	40	_	_	O
41	years	_	_	O
42	with	_	_	O
43	synechial	_	_	O
44	primary	_	_	O
45	angle-closure	_	_	O
46	or	_	_	O
47	primary	_	_	O
48	angle	_	_	O
49	closure	_	_	O
50	glaucoma	_	_	O
51	were	_	_	O
52	recruited	_	_	O
53	.	_	_	O

54	Eligible	_	_	O
55	patients	_	_	O
56	were	_	_	O
57	randomized	_	_	O
58	to	_	_	O
59	1	_	_	O
60	of	_	_	O
61	2	_	_	O
62	treatment	_	_	O
63	options	_	_	O
64	,	_	_	O
65	iridotomy	_	_	O
66	or	_	_	O
67	iridotomy	_	_	O
68	plus	_	_	O
69	iridoplasty	_	_	O
70	,	_	_	O
71	and	_	_	O
72	were	_	_	O
73	followed	_	_	O
74	up	_	_	O
75	for	_	_	O
76	1	_	_	O
77	year	_	_	O
78	.	_	_	O

79	Main	_	_	O
80	outcome	_	_	O
81	measures	_	_	O
82	were	_	_	O
83	intraocular	_	_	O
84	pressure	_	_	O
85	(	_	_	O
86	IOP	_	_	O
87	)	_	_	O
88	,	_	_	O
89	peripheral	_	_	O
90	anterior	_	_	O
91	synechiae	_	_	O
92	,	_	_	O
93	corneal	_	_	O
94	endothelial	_	_	O
95	cell	_	_	O
96	count	_	_	O
97	,	_	_	O
98	and	_	_	O
99	complications	_	_	O
100	.	_	_	O

101	Seventy-seven	_	_	O
102	eyes	_	_	O
103	(	_	_	O
104	77	_	_	O
105	patients	_	_	O
106	)	_	_	O
107	were	_	_	O
108	randomized	_	_	O
109	to	_	_	O
110	the	_	_	O
111	iridotomy	_	_	O
112	group	_	_	O
113	,	_	_	O
114	and	_	_	O
115	81	_	_	O
116	eyes	_	_	O
117	(	_	_	O
118	81	_	_	O
119	patients	_	_	O
120	)	_	_	O
121	were	_	_	O
122	randomized	_	_	O
123	to	_	_	O
124	the	_	_	O
125	iridotomy	_	_	O
126	plus	_	_	O
127	iridoplasty	_	_	O
128	group	_	_	O
129	.	_	_	O

130	Sixty-one	_	_	O
131	patients	_	_	O
132	(	_	_	O
133	79.2	_	_	O
134	%	_	_	O
135	)	_	_	O
136	in	_	_	O
137	the	_	_	O
138	iridotomy	_	_	O
139	and	_	_	O
140	65	_	_	O
141	patients	_	_	O
142	(	_	_	O
143	80.2	_	_	O
144	%	_	_	O
145	)	_	_	O
146	from	_	_	O
147	the	_	_	O
148	iridotomy	_	_	O
149	plus	_	_	O
150	iridoplasty	_	_	O
151	groups	_	_	O
152	completed	_	_	O
153	1	_	_	O
154	year	_	_	O
155	of	_	_	O
156	follow-up	_	_	O
157	.	_	_	O

158	There	_	_	O
159	were	_	_	O
160	no	_	_	O
161	significant	_	_	O
162	differences	_	_	O
163	between	_	_	O
164	the	_	_	O
165	groups	_	_	O
166	in	_	_	O
167	the	_	_	O
168	baseline	_	_	O
169	data	_	_	O
170	.	_	_	O

171	IOP	_	_	B-Premise
172	was	_	_	I-Premise
173	reduced	_	_	I-Premise
174	from	_	_	I-Premise
175	24.66	_	_	I-Premise
176	+/-	_	_	I-Premise
177	13.76	_	_	I-Premise
178	mm	_	_	I-Premise
179	Hg	_	_	I-Premise
180	to	_	_	I-Premise
181	19.03	_	_	I-Premise
182	+/-	_	_	I-Premise
183	6.21	_	_	I-Premise
184	mm	_	_	I-Premise
185	Hg	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	iridotomy	_	_	I-Premise
189	group	_	_	I-Premise
190	(	_	_	I-Premise
191	P	_	_	I-Premise
192	<	_	_	I-Premise
193	.001	_	_	I-Premise
194	)	_	_	I-Premise
195	and	_	_	I-Premise
196	from	_	_	I-Premise
197	27.96	_	_	I-Premise
198	+/-	_	_	I-Premise
199	13.06	_	_	I-Premise
200	mm	_	_	I-Premise
201	Hg	_	_	I-Premise
202	to	_	_	I-Premise
203	20.45	_	_	I-Premise
204	+/-	_	_	I-Premise
205	7.26	_	_	I-Premise
206	mm	_	_	I-Premise
207	Hg	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	iridotomy	_	_	I-Premise
211	plus	_	_	I-Premise
212	iridoplasty	_	_	I-Premise
213	group	_	_	I-Premise
214	(	_	_	I-Premise
215	P	_	_	I-Premise
216	<	_	_	I-Premise
217	.001	_	_	I-Premise
218	)	_	_	I-Premise
219	.	_	_	I-Premise

220	Extent	_	_	B-Premise
221	of	_	_	I-Premise
222	peripheral	_	_	I-Premise
223	anterior	_	_	I-Premise
224	synechiae	_	_	I-Premise
225	was	_	_	I-Premise
226	decreased	_	_	I-Premise
227	by	_	_	I-Premise
228	1	_	_	I-Premise
229	more	_	_	I-Premise
230	clock-hour	_	_	I-Premise
231	after	_	_	I-Premise
232	iridoplasty	_	_	I-Premise
233	compared	_	_	I-Premise
234	with	_	_	I-Premise
235	that	_	_	I-Premise
236	after	_	_	I-Premise
237	iridotomy	_	_	I-Premise
238	in	_	_	I-Premise
239	the	_	_	I-Premise
240	iridotomy	_	_	I-Premise
241	plus	_	_	I-Premise
242	iridoplasty	_	_	I-Premise
243	group	_	_	I-Premise
244	(	_	_	I-Premise
245	P	_	_	I-Premise
246	<	_	_	I-Premise
247	.001	_	_	I-Premise
248	)	_	_	I-Premise
249	.	_	_	I-Premise

250	There	_	_	B-Premise
251	was	_	_	I-Premise
252	no	_	_	I-Premise
253	significant	_	_	I-Premise
254	difference	_	_	I-Premise
255	in	_	_	I-Premise
256	IOP	_	_	I-Premise
257	,	_	_	I-Premise
258	medications	_	_	I-Premise
259	,	_	_	I-Premise
260	need	_	_	I-Premise
261	for	_	_	I-Premise
262	surgery	_	_	I-Premise
263	,	_	_	I-Premise
264	or	_	_	I-Premise
265	visual	_	_	I-Premise
266	function	_	_	I-Premise
267	between	_	_	I-Premise
268	groups	_	_	I-Premise
269	at	_	_	I-Premise
270	the	_	_	I-Premise
271	1-year	_	_	I-Premise
272	visit	_	_	I-Premise
273	.	_	_	I-Premise

274	In	_	_	B-Claim
275	eyes	_	_	I-Claim
276	with	_	_	I-Claim
277	synechial	_	_	I-Claim
278	primary	_	_	I-Claim
279	angle-closure	_	_	I-Claim
280	or	_	_	I-Claim
281	primary	_	_	I-Claim
282	angle-closure	_	_	I-Claim
283	glaucoma	_	_	I-Claim
284	,	_	_	I-Claim
285	both	_	_	I-Claim
286	iridotomy	_	_	I-Claim
287	alone	_	_	I-Claim
288	or	_	_	I-Claim
289	combined	_	_	I-Claim
290	with	_	_	I-Claim
291	iridoplasty	_	_	I-Claim
292	provide	_	_	I-Claim
293	a	_	_	I-Claim
294	significant	_	_	I-Claim
295	and	_	_	I-Claim
296	equivalent	_	_	I-Claim
297	reduction	_	_	I-Claim
298	in	_	_	I-Claim
299	IOP	_	_	I-Claim
300	.	_	_	I-Claim

301	There	_	_	B-Claim
302	is	_	_	I-Claim
303	also	_	_	I-Claim
304	a	_	_	I-Claim
305	possible	_	_	I-Claim
306	reduction	_	_	I-Claim
307	in	_	_	I-Claim
308	peripheral	_	_	I-Claim
309	anterior	_	_	I-Claim
310	synechiae	_	_	I-Claim
311	,	_	_	I-Claim
312	more	_	_	I-Claim
313	so	_	_	I-Claim
314	in	_	_	I-Claim
315	the	_	_	I-Claim
316	iridoplasty	_	_	I-Claim
317	group	_	_	I-Claim
318	.	_	_	I-Claim


0	Promising	_	_	O
1	results	_	_	O
2	in	_	_	O
3	a	_	_	O
4	randomized	_	_	O
5	phase	_	_	O
6	II	_	_	O
7	trial	_	_	O
8	with	_	_	O
9	the	_	_	O
10	hypoxic	_	_	O
11	cytotoxin	_	_	O
12	tirapazamine	_	_	O
13	(	_	_	O
14	TPZ	_	_	O
15	)	_	_	O
16	combined	_	_	O
17	with	_	_	O
18	cisplatin	_	_	O
19	(	_	_	O
20	CIS	_	_	O
21	)	_	_	O
22	and	_	_	O
23	radiation	_	_	O
24	led	_	_	O
25	to	_	_	O
26	this	_	_	O
27	phase	_	_	O
28	III	_	_	O
29	trial	_	_	O
30	.	_	_	O

31	Patients	_	_	O
32	with	_	_	O
33	previously	_	_	O
34	untreated	_	_	O
35	stage	_	_	O
36	III	_	_	O
37	or	_	_	O
38	IV	_	_	O
39	(	_	_	O
40	excluding	_	_	O
41	T1-2N1	_	_	O
42	and	_	_	O
43	M1	_	_	O
44	)	_	_	O
45	squamous	_	_	O
46	cell	_	_	O
47	carcinoma	_	_	O
48	of	_	_	O
49	the	_	_	O
50	oral	_	_	O
51	cavity	_	_	O
52	,	_	_	O
53	oropharynx	_	_	O
54	,	_	_	O
55	hypopharynx	_	_	O
56	,	_	_	O
57	or	_	_	O
58	larynx	_	_	O
59	were	_	_	O
60	randomly	_	_	O
61	assigned	_	_	O
62	to	_	_	O
63	receive	_	_	O
64	definitive	_	_	O
65	radiotherapy	_	_	O
66	(	_	_	O
67	70	_	_	O
68	Gy	_	_	O
69	in	_	_	O
70	7	_	_	O
71	weeks	_	_	O
72	)	_	_	O
73	concurrently	_	_	O
74	with	_	_	O
75	either	_	_	O
76	CIS	_	_	O
77	(	_	_	O
78	100	_	_	O
79	mg/m	_	_	O
80	(	_	_	O
81	2	_	_	O
82	)	_	_	O
83	)	_	_	O
84	on	_	_	O
85	day	_	_	O
86	1	_	_	O
87	of	_	_	O
88	weeks	_	_	O
89	1	_	_	O
90	,	_	_	O
91	4	_	_	O
92	,	_	_	O
93	and	_	_	O
94	7	_	_	O
95	or	_	_	O
96	CIS	_	_	O
97	(	_	_	O
98	75	_	_	O
99	mg/m	_	_	O
100	(	_	_	O
101	2	_	_	O
102	)	_	_	O
103	)	_	_	O
104	plus	_	_	O
105	TPZ	_	_	O
106	(	_	_	O
107	290	_	_	O
108	mg/m	_	_	O
109	(	_	_	O
110	2	_	_	O
111	)	_	_	O
112	/d	_	_	O
113	)	_	_	O
114	on	_	_	O
115	day	_	_	O
116	1	_	_	O
117	of	_	_	O
118	weeks	_	_	O
119	1	_	_	O
120	,	_	_	O
121	4	_	_	O
122	,	_	_	O
123	and	_	_	O
124	7	_	_	O
125	and	_	_	O
126	TPZ	_	_	O
127	alone	_	_	O
128	(	_	_	O
129	160	_	_	O
130	mg/m	_	_	O
131	(	_	_	O
132	2	_	_	O
133	)	_	_	O
134	/d	_	_	O
135	)	_	_	O
136	on	_	_	O
137	days	_	_	O
138	1	_	_	O
139	,	_	_	O
140	3	_	_	O
141	,	_	_	O
142	and	_	_	O
143	5	_	_	O
144	of	_	_	O
145	weeks	_	_	O
146	2	_	_	O
147	and	_	_	O
148	3	_	_	O
149	(	_	_	O
150	TPZ/CIS	_	_	O
151	)	_	_	O
152	.	_	_	O

153	The	_	_	O
154	primary	_	_	O
155	end	_	_	O
156	point	_	_	O
157	was	_	_	O
158	overall	_	_	O
159	survival	_	_	O
160	(	_	_	O
161	OS	_	_	O
162	)	_	_	O
163	.	_	_	O

164	The	_	_	O
165	planned	_	_	O
166	sample	_	_	O
167	size	_	_	O
168	was	_	_	O
169	850	_	_	O
170	,	_	_	O
171	estimated	_	_	O
172	to	_	_	O
173	result	_	_	O
174	in	_	_	O
175	334	_	_	O
176	deaths	_	_	O
177	,	_	_	O
178	which	_	_	O
179	would	_	_	O
180	provide	_	_	O
181	90	_	_	O
182	%	_	_	O
183	power	_	_	O
184	to	_	_	O
185	detect	_	_	O
186	a	_	_	O
187	difference	_	_	O
188	in	_	_	O
189	2-year	_	_	O
190	survival	_	_	O
191	rates	_	_	O
192	of	_	_	O
193	60	_	_	O
194	%	_	_	O
195	v	_	_	O
196	70	_	_	O
197	%	_	_	O
198	for	_	_	O
199	CIS	_	_	O
200	versus	_	_	O
201	TPZ/CIS	_	_	O
202	,	_	_	O
203	respectively	_	_	O
204	(	_	_	O
205	hazard	_	_	O
206	ratio	_	_	O
207	=	_	_	O
208	0.69	_	_	O
209	)	_	_	O
210	.	_	_	O

211	Eight	_	_	O
212	hundred	_	_	O
213	sixty-one	_	_	O
214	patients	_	_	O
215	were	_	_	O
216	accrued	_	_	O
217	from	_	_	O
218	89	_	_	O
219	sites	_	_	O
220	in	_	_	O
221	16	_	_	O
222	countries	_	_	O
223	.	_	_	O

224	In	_	_	B-Premise
225	an	_	_	I-Premise
226	intent-to-treat	_	_	I-Premise
227	analysis	_	_	I-Premise
228	,	_	_	I-Premise
229	the	_	_	I-Premise
230	2-year	_	_	I-Premise
231	OS	_	_	I-Premise
232	rates	_	_	I-Premise
233	were	_	_	I-Premise
234	65.7	_	_	I-Premise
235	%	_	_	I-Premise
236	for	_	_	I-Premise
237	CIS	_	_	I-Premise
238	and	_	_	I-Premise
239	66.2	_	_	I-Premise
240	%	_	_	I-Premise
241	for	_	_	I-Premise
242	TPZ/CIS	_	_	I-Premise
243	(	_	_	I-Premise
244	TPZ/CIS	_	_	I-Premise
245	--	_	_	I-Premise
246	CIS	_	_	I-Premise
247	:	_	_	I-Premise
248	95	_	_	I-Premise
249	%	_	_	I-Premise
250	CI	_	_	I-Premise
251	,	_	_	I-Premise
252	-5.9	_	_	I-Premise
253	%	_	_	I-Premise
254	to	_	_	I-Premise
255	6.9	_	_	I-Premise
256	%	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	There	_	_	B-Premise
260	were	_	_	I-Premise
261	no	_	_	I-Premise
262	significant	_	_	I-Premise
263	differences	_	_	I-Premise
264	in	_	_	I-Premise
265	failure-free	_	_	I-Premise
266	survival	_	_	I-Premise
267	,	_	_	I-Premise
268	time	_	_	I-Premise
269	to	_	_	I-Premise
270	locoregional	_	_	I-Premise
271	failure	_	_	I-Premise
272	,	_	_	I-Premise
273	or	_	_	I-Premise
274	quality	_	_	I-Premise
275	of	_	_	I-Premise
276	life	_	_	I-Premise
277	as	_	_	I-Premise
278	measured	_	_	I-Premise
279	by	_	_	I-Premise
280	Functional	_	_	I-Premise
281	Assessment	_	_	I-Premise
282	of	_	_	I-Premise
283	Cancer	_	_	I-Premise
284	Therapy-Head	_	_	I-Premise
285	and	_	_	I-Premise
286	Neck	_	_	I-Premise
287	.	_	_	I-Premise

288	We	_	_	B-Claim
289	found	_	_	I-Claim
290	no	_	_	I-Claim
291	evidence	_	_	I-Claim
292	that	_	_	I-Claim
293	the	_	_	I-Claim
294	addition	_	_	I-Claim
295	of	_	_	I-Claim
296	TPZ	_	_	I-Claim
297	to	_	_	I-Claim
298	chemoradiotherapy	_	_	I-Claim
299	,	_	_	I-Claim
300	in	_	_	I-Claim
301	patients	_	_	I-Claim
302	with	_	_	I-Claim
303	advanced	_	_	I-Claim
304	head	_	_	I-Claim
305	and	_	_	I-Claim
306	neck	_	_	I-Claim
307	cancer	_	_	I-Claim
308	not	_	_	I-Claim
309	selected	_	_	I-Claim
310	for	_	_	I-Claim
311	the	_	_	I-Claim
312	presence	_	_	I-Claim
313	of	_	_	I-Claim
314	hypoxia	_	_	I-Claim
315	,	_	_	I-Claim
316	improves	_	_	I-Claim
317	OS	_	_	I-Claim
318	.	_	_	I-Claim


0	To	_	_	O
1	examine	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	a	_	_	O
6	scapula-oriented	_	_	O
7	exercise	_	_	O
8	on	_	_	O
9	upper	_	_	O
10	limb	_	_	O
11	dysfunction	_	_	O
12	in	_	_	O
13	breast	_	_	O
14	cancer	_	_	O
15	survivors	_	_	O
16	.	_	_	O

17	A	_	_	O
18	prospective	_	_	O
19	randomized	_	_	O
20	,	_	_	O
21	controlled	_	_	O
22	pilot	_	_	O
23	trial	_	_	O
24	with	_	_	O
25	historical	_	_	O
26	control	_	_	O
27	.	_	_	O

28	Rehabilitation	_	_	O
29	department	_	_	O
30	at	_	_	O
31	a	_	_	O
32	university	_	_	O
33	hospital	_	_	O
34	.	_	_	O

35	Thirty-two	_	_	O
36	women	_	_	O
37	with	_	_	O
38	breast	_	_	O
39	cancer	_	_	O
40	were	_	_	O
41	randomly	_	_	O
42	assigned	_	_	O
43	to	_	_	O
44	scapula-oriented	_	_	O
45	exercise	_	_	O
46	group	_	_	O
47	(	_	_	O
48	n	_	_	O
49	=	_	_	O
50	16	_	_	O
51	)	_	_	O
52	and	_	_	O
53	general	_	_	O
54	exercise	_	_	O
55	group	_	_	O
56	(	_	_	O
57	n	_	_	O
58	=	_	_	O
59	16	_	_	O
60	)	_	_	O
61	.	_	_	O

62	An	_	_	O
63	historical	_	_	O
64	control	_	_	O
65	group	_	_	O
66	(	_	_	O
67	n	_	_	O
68	=	_	_	O
69	18	_	_	O
70	)	_	_	O
71	without	_	_	O
72	exercise	_	_	O
73	was	_	_	O
74	enrolled	_	_	O
75	from	_	_	O
76	breast	_	_	O
77	cancer	_	_	O
78	survivors	_	_	O
79	.	_	_	O

80	The	_	_	O
81	scapula-oriented	_	_	O
82	exercises	_	_	O
83	were	_	_	O
84	designed	_	_	O
85	focusing	_	_	O
86	on	_	_	O
87	scapulothoracic	_	_	O
88	movement	_	_	O
89	.	_	_	O

90	The	_	_	O
91	general	_	_	O
92	exercise	_	_	O
93	group	_	_	O
94	performed	_	_	O
95	body	_	_	O
96	conditioning	_	_	O
97	exercise	_	_	O
98	.	_	_	O

99	Exercise	_	_	O
100	therapies	_	_	O
101	were	_	_	O
102	performed	_	_	O
103	for	_	_	O
104	one	_	_	O
105	session	_	_	O
106	per	_	_	O
107	week	_	_	O
108	for	_	_	O
109	eight	_	_	O
110	weeks	_	_	O
111	.	_	_	O

112	Pain	_	_	O
113	and	_	_	O
114	physical	_	_	O
115	disabilities	_	_	O
116	related	_	_	O
117	to	_	_	O
118	upper	_	_	O
119	limb	_	_	O
120	dysfunction	_	_	O
121	,	_	_	O
122	quality	_	_	O
123	of	_	_	O
124	life	_	_	O
125	and	_	_	O
126	depression	_	_	O
127	were	_	_	O
128	used	_	_	O
129	as	_	_	O
130	subjective	_	_	O
131	outcomes	_	_	O
132	.	_	_	O

133	Objective	_	_	O
134	outcome	_	_	O
135	measures	_	_	O
136	included	_	_	O
137	shoulder	_	_	O
138	range	_	_	O
139	of	_	_	O
140	motion	_	_	O
141	and	_	_	O
142	strength	_	_	O
143	.	_	_	O

144	Outcomes	_	_	O
145	were	_	_	O
146	assessed	_	_	O
147	at	_	_	O
148	baseline	_	_	O
149	and	_	_	O
150	post	_	_	O
151	exercise	_	_	O
152	.	_	_	O

153	At	_	_	O
154	baseline	_	_	O
155	,	_	_	O
156	no	_	_	O
157	significant	_	_	O
158	difference	_	_	O
159	was	_	_	O
160	observed	_	_	O
161	among	_	_	O
162	the	_	_	O
163	three	_	_	O
164	groups	_	_	O
165	.	_	_	O

166	The	_	_	B-Premise
167	scapula-oriented	_	_	I-Premise
168	exercise	_	_	I-Premise
169	group	_	_	I-Premise
170	showed	_	_	I-Premise
171	improvements	_	_	I-Premise
172	in	_	_	I-Premise
173	pain	_	_	I-Premise
174	,	_	_	I-Premise
175	physical	_	_	I-Premise
176	function	_	_	I-Premise
177	,	_	_	I-Premise
178	social	_	_	I-Premise
179	function	_	_	I-Premise
180	,	_	_	I-Premise
181	and	_	_	I-Premise
182	global	_	_	I-Premise
183	quality	_	_	I-Premise
184	of	_	_	I-Premise
185	life	_	_	I-Premise
186	compared	_	_	I-Premise
187	with	_	_	I-Premise
188	baseline	_	_	I-Premise
189	,	_	_	I-Premise
190	whereas	_	_	I-Premise
191	the	_	_	I-Premise
192	general	_	_	I-Premise
193	exercise	_	_	I-Premise
194	group	_	_	I-Premise
195	showed	_	_	I-Premise
196	improved	_	_	I-Premise
197	fatigue	_	_	I-Premise
198	and	_	_	I-Premise
199	range	_	_	I-Premise
200	of	_	_	I-Premise
201	motion	_	_	I-Premise
202	.	_	_	I-Premise

203	The	_	_	B-Premise
204	change	_	_	I-Premise
205	in	_	_	I-Premise
206	global	_	_	I-Premise
207	quality	_	_	I-Premise
208	of	_	_	I-Premise
209	life	_	_	I-Premise
210	(	_	_	I-Premise
211	P	_	_	I-Premise
212	=	_	_	I-Premise
213	0.067	_	_	I-Premise
214	;	_	_	I-Premise
215	effect	_	_	I-Premise
216	size	_	_	I-Premise
217	,	_	_	I-Premise
218	0.33	_	_	I-Premise
219	)	_	_	I-Premise
220	and	_	_	I-Premise
221	strength	_	_	I-Premise
222	of	_	_	I-Premise
223	external	_	_	I-Premise
224	rotation	_	_	I-Premise
225	(	_	_	I-Premise
226	P	_	_	I-Premise
227	=	_	_	I-Premise
228	0.001	_	_	I-Premise
229	;	_	_	I-Premise
230	effect	_	_	I-Premise
231	size	_	_	I-Premise
232	,	_	_	I-Premise
233	0.55	_	_	I-Premise
234	)	_	_	I-Premise
235	were	_	_	I-Premise
236	significantly	_	_	I-Premise
237	greater	_	_	I-Premise
238	in	_	_	I-Premise
239	the	_	_	I-Premise
240	scapula-oriented	_	_	I-Premise
241	exercise	_	_	I-Premise
242	group	_	_	I-Premise
243	than	_	_	I-Premise
244	in	_	_	I-Premise
245	the	_	_	I-Premise
246	general	_	_	I-Premise
247	exercise	_	_	I-Premise
248	and	_	_	I-Premise
249	control	_	_	I-Premise
250	group	_	_	I-Premise
251	.	_	_	I-Premise

252	Scapula-oriented	_	_	B-Claim
253	exercise	_	_	I-Claim
254	had	_	_	I-Claim
255	beneficial	_	_	I-Claim
256	effects	_	_	I-Claim
257	on	_	_	I-Claim
258	pain	_	_	I-Claim
259	,	_	_	I-Claim
260	quality	_	_	I-Claim
261	of	_	_	I-Claim
262	life	_	_	I-Claim
263	and	_	_	I-Claim
264	aspects	_	_	I-Claim
265	of	_	_	I-Claim
266	strength	_	_	I-Claim
267	.	_	_	I-Claim

268	The	_	_	O
269	sample	_	_	O
270	size	_	_	O
271	required	_	_	O
272	in	_	_	O
273	a	_	_	O
274	larger	_	_	O
275	definitive	_	_	O
276	study	_	_	O
277	is	_	_	O
278	32	_	_	O
279	subjects	_	_	O
280	per	_	_	O
281	group	_	_	O
282	.	_	_	O


0	For	_	_	O
1	patients	_	_	O
2	undergoing	_	_	O
3	oncologic	_	_	O
4	surgery	_	_	O
5	,	_	_	O
6	the	_	_	O
7	quality	_	_	O
8	of	_	_	O
9	life	_	_	O
10	(	_	_	O
11	QoL	_	_	O
12	)	_	_	O
13	is	_	_	O
14	generally	_	_	O
15	accepted	_	_	O
16	as	_	_	O
17	an	_	_	O
18	important	_	_	O
19	outcome	_	_	O
20	parameter	_	_	O
21	in	_	_	O
22	addition	_	_	O
23	to	_	_	O
24	long-term	_	_	O
25	survival	_	_	O
26	,	_	_	O
27	mortality	_	_	O
28	and	_	_	O
29	complication	_	_	O
30	rates	_	_	O
31	.	_	_	O

32	This	_	_	O
33	study	_	_	O
34	focussed	_	_	O
35	on	_	_	O
36	the	_	_	O
37	QoL	_	_	O
38	in	_	_	O
39	patients	_	_	O
40	after	_	_	O
41	oesophagectomy	_	_	O
42	for	_	_	O
43	cancer	_	_	O
44	,	_	_	O
45	comparing	_	_	O
46	the	_	_	O
47	method	_	_	O
48	of	_	_	O
49	reconstruction	_	_	O
50	(	_	_	O
51	narrow	_	_	O
52	gastric	_	_	O
53	tube	_	_	O
54	vs	_	_	O
55	whole	_	_	O
56	stomach	_	_	O
57	)	_	_	O
58	.	_	_	O

59	In	_	_	O
60	a	_	_	O
61	prospective	_	_	O
62	randomised	_	_	O
63	single-centre	_	_	O
64	study	_	_	O
65	from	_	_	O
66	2007	_	_	O
67	to	_	_	O
68	2008	_	_	O
69	,	_	_	O
70	104	_	_	O
71	patients	_	_	O
72	underwent	_	_	O
73	oesophagectomy	_	_	O
74	for	_	_	O
75	cancer	_	_	O
76	.	_	_	O

77	To	_	_	O
78	assess	_	_	O
79	the	_	_	O
80	QoL	_	_	O
81	,	_	_	O
82	a	_	_	O
83	questionnaire	_	_	O
84	in	_	_	O
85	reference	_	_	O
86	to	_	_	O
87	the	_	_	O
88	EORTC-QLQ-C30	_	_	O
89	and	_	_	O
90	the	_	_	O
91	QLQ-OES24	_	_	O
92	was	_	_	O
93	administered	_	_	O
94	at	_	_	O
95	3	_	_	O
96	weeks	_	_	O
97	,	_	_	O
98	6	_	_	O
99	months	_	_	O
100	and	_	_	O
101	1	_	_	O
102	year	_	_	O
103	after	_	_	O
104	surgery	_	_	O
105	.	_	_	O

106	Clinical	_	_	O
107	data	_	_	O
108	were	_	_	O
109	collected	_	_	O
110	prospectively	_	_	O
111	,	_	_	O
112	and	_	_	O
113	follow-up	_	_	O
114	was	_	_	O
115	performed	_	_	O
116	regularly	_	_	O
117	.	_	_	O

118	There	_	_	B-Premise
119	were	_	_	I-Premise
120	no	_	_	I-Premise
121	significant	_	_	I-Premise
122	differences	_	_	I-Premise
123	between	_	_	I-Premise
124	the	_	_	I-Premise
125	narrow	_	_	I-Premise
126	gastric	_	_	I-Premise
127	tube	_	_	I-Premise
128	group	_	_	I-Premise
129	(	_	_	I-Premise
130	NGT	_	_	I-Premise
131	group	_	_	I-Premise
132	,	_	_	I-Premise
133	n=52	_	_	I-Premise
134	)	_	_	I-Premise
135	and	_	_	I-Premise
136	the	_	_	I-Premise
137	whole-stomach	_	_	I-Premise
138	group	_	_	I-Premise
139	(	_	_	I-Premise
140	WS	_	_	I-Premise
141	group	_	_	I-Premise
142	,	_	_	I-Premise
143	n=52	_	_	I-Premise
144	)	_	_	I-Premise
145	with	_	_	I-Premise
146	regard	_	_	I-Premise
147	to	_	_	I-Premise
148	patient	_	_	I-Premise
149	and	_	_	I-Premise
150	cancer	_	_	I-Premise
151	characteristics	_	_	I-Premise
152	,	_	_	I-Premise
153	operative	_	_	I-Premise
154	procedure	_	_	I-Premise
155	,	_	_	I-Premise
156	postoperative	_	_	I-Premise
157	intensive	_	_	I-Premise
158	care	_	_	I-Premise
159	unit	_	_	I-Premise
160	(	_	_	I-Premise
161	ICU	_	_	I-Premise
162	)	_	_	I-Premise
163	hospitalisation	_	_	I-Premise
164	,	_	_	I-Premise
165	and	_	_	I-Premise
166	overall	_	_	I-Premise
167	survival	_	_	I-Premise
168	at	_	_	I-Premise
169	1	_	_	I-Premise
170	year	_	_	I-Premise
171	.	_	_	I-Premise

172	Regarding	_	_	B-Premise
173	the	_	_	I-Premise
174	postoperative	_	_	I-Premise
175	complication	_	_	I-Premise
176	,	_	_	I-Premise
177	there	_	_	I-Premise
178	were	_	_	I-Premise
179	more	_	_	I-Premise
180	cases	_	_	I-Premise
181	of	_	_	I-Premise
182	postoperative	_	_	I-Premise
183	reflux	_	_	I-Premise
184	oesophagitis	_	_	I-Premise
185	and	_	_	I-Premise
186	impairment	_	_	I-Premise
187	of	_	_	I-Premise
188	pulmonary	_	_	I-Premise
189	function	_	_	I-Premise
190	in	_	_	I-Premise
191	the	_	_	I-Premise
192	WS	_	_	I-Premise
193	group	_	_	I-Premise
194	(	_	_	I-Premise
195	P	_	_	I-Premise
196	<	_	_	I-Premise
197	0.05	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	Regarding	_	_	B-Premise
201	the	_	_	I-Premise
202	QoL	_	_	I-Premise
203	investigation	_	_	I-Premise
204	,	_	_	I-Premise
205	the	_	_	I-Premise
206	scores	_	_	I-Premise
207	of	_	_	I-Premise
208	QoL	_	_	I-Premise
209	dropped	_	_	I-Premise
210	for	_	_	I-Premise
211	all	_	_	I-Premise
212	patients	_	_	I-Premise
213	at	_	_	I-Premise
214	3	_	_	I-Premise
215	weeks	_	_	I-Premise
216	after	_	_	I-Premise
217	surgery	_	_	I-Premise
218	.	_	_	I-Premise

219	Slowly	_	_	O
220	,	_	_	O
221	recovery	_	_	B-Premise
222	was	_	_	I-Premise
223	found	_	_	I-Premise
224	at	_	_	I-Premise
225	both	_	_	I-Premise
226	6	_	_	I-Premise
227	months	_	_	I-Premise
228	and	_	_	I-Premise
229	1	_	_	I-Premise
230	year	_	_	I-Premise
231	in	_	_	I-Premise
232	both	_	_	I-Premise
233	groups	_	_	I-Premise
234	.	_	_	I-Premise

235	Patients	_	_	B-Premise
236	in	_	_	I-Premise
237	the	_	_	I-Premise
238	NGT	_	_	I-Premise
239	group	_	_	I-Premise
240	reported	_	_	I-Premise
241	significantly	_	_	I-Premise
242	(	_	_	I-Premise
243	P	_	_	I-Premise
244	<	_	_	I-Premise
245	0.05	_	_	I-Premise
246	)	_	_	I-Premise
247	better	_	_	I-Premise
248	scores	_	_	I-Premise
249	of	_	_	I-Premise
250	QoL	_	_	I-Premise
251	at	_	_	I-Premise
252	both	_	_	I-Premise
253	6	_	_	I-Premise
254	months	_	_	I-Premise
255	and	_	_	I-Premise
256	1	_	_	I-Premise
257	year	_	_	I-Premise
258	.	_	_	I-Premise

259	Patients	_	_	B-Claim
260	who	_	_	I-Claim
261	underwent	_	_	I-Claim
262	gastric	_	_	I-Claim
263	tube	_	_	I-Claim
264	reconstruction	_	_	I-Claim
265	develop	_	_	I-Claim
266	less	_	_	I-Claim
267	postoperative	_	_	I-Claim
268	digestive	_	_	I-Claim
269	tract	_	_	I-Claim
270	complications	_	_	I-Claim
271	,	_	_	I-Claim
272	and	_	_	I-Claim
273	have	_	_	I-Claim
274	a	_	_	I-Claim
275	quicker	_	_	I-Claim
276	recovery	_	_	I-Claim
277	and	_	_	I-Claim
278	a	_	_	I-Claim
279	better	_	_	I-Claim
280	QoL	_	_	I-Claim
281	during	_	_	I-Claim
282	the	_	_	I-Claim
283	follow-up	_	_	I-Claim
284	period	_	_	I-Claim
285	.	_	_	I-Claim

286	Further	_	_	O
287	investigation	_	_	O
288	and	_	_	O
289	data	_	_	O
290	collection	_	_	O
291	will	_	_	O
292	allow	_	_	O
293	the	_	_	O
294	assessment	_	_	O
295	of	_	_	O
296	this	_	_	O
297	procedure	_	_	O
298	beyond	_	_	O
299	1	_	_	O
300	year	_	_	O
301	after	_	_	O
302	operation	_	_	O
303	.	_	_	O


0	The	_	_	O
1	Medical	_	_	O
2	Research	_	_	O
3	Council	_	_	O
4	CR07/National	_	_	O
5	Cancer	_	_	O
6	Institute	_	_	O
7	of	_	_	O
8	Canada	_	_	O
9	Clinical	_	_	O
10	Trials	_	_	O
11	Group	_	_	O
12	C016	_	_	O
13	(	_	_	O
14	MRC	_	_	O
15	CR07/NCIC	_	_	O
16	CTG	_	_	O
17	C016	_	_	O
18	)	_	_	O
19	trial	_	_	O
20	showed	_	_	O
21	that	_	_	O
22	,	_	_	O
23	in	_	_	O
24	patients	_	_	O
25	with	_	_	O
26	operable	_	_	O
27	rectal	_	_	O
28	cancer	_	_	O
29	,	_	_	O
30	short-course	_	_	O
31	preoperative	_	_	O
32	radiotherapy	_	_	O
33	(	_	_	O
34	PRE	_	_	O
35	)	_	_	O
36	reduced	_	_	O
37	the	_	_	O
38	rate	_	_	O
39	of	_	_	O
40	local	_	_	O
41	recurrence	_	_	O
42	compared	_	_	O
43	with	_	_	O
44	surgery	_	_	O
45	followed	_	_	O
46	by	_	_	O
47	selective	_	_	O
48	postoperative	_	_	O
49	chemoradiotherapy	_	_	O
50	for	_	_	O
51	patients	_	_	O
52	with	_	_	O
53	a	_	_	O
54	positive	_	_	O
55	circumferential	_	_	O
56	resection	_	_	O
57	margin	_	_	O
58	.	_	_	O

59	However	_	_	O
60	,	_	_	O
61	the	_	_	O
62	advantages	_	_	O
63	of	_	_	O
64	giving	_	_	O
65	PRE	_	_	O
66	to	_	_	O
67	all	_	_	O
68	patients	_	_	O
69	needs	_	_	O
70	to	_	_	O
71	be	_	_	O
72	balanced	_	_	O
73	against	_	_	O
74	any	_	_	O
75	negative	_	_	O
76	impact	_	_	O
77	on	_	_	O
78	patients	_	_	O
79	'	_	_	O
80	quality	_	_	O
81	of	_	_	O
82	life	_	_	O
83	.	_	_	O

84	All	_	_	O
85	1,350	_	_	O
86	patients	_	_	O
87	were	_	_	O
88	asked	_	_	O
89	to	_	_	O
90	complete	_	_	O
91	the	_	_	O
92	Medical	_	_	O
93	Outcomes	_	_	O
94	Study	_	_	O
95	Short-Form	_	_	O
96	36-item	_	_	O
97	(	_	_	O
98	MOS	_	_	O
99	SF-36	_	_	O
100	)	_	_	O
101	and	_	_	O
102	the	_	_	O
103	European	_	_	O
104	Organisation	_	_	O
105	for	_	_	O
106	Research	_	_	O
107	and	_	_	O
108	Treatment	_	_	O
109	of	_	_	O
110	Cancer	_	_	O
111	Quality	_	_	O
112	of	_	_	O
113	Life	_	_	O
114	Questionnaire	_	_	O
115	Colorectal	_	_	O
116	38-item	_	_	O
117	(	_	_	O
118	EORTC	_	_	O
119	QLQ-CR38	_	_	O
120	)	_	_	O
121	questionnaires	_	_	O
122	.	_	_	O

123	A	_	_	O
124	priori	_	_	O
125	hypotheses	_	_	O
126	related	_	_	O
127	to	_	_	O
128	the	_	_	O
129	impact	_	_	O
130	of	_	_	O
131	treatment	_	_	O
132	on	_	_	O
133	sexual	_	_	O
134	,	_	_	O
135	bowel	_	_	O
136	,	_	_	O
137	and	_	_	O
138	physical	_	_	O
139	function	_	_	O
140	and	_	_	O
141	general	_	_	O
142	health	_	_	O
143	.	_	_	O

144	Male	_	_	B-Premise
145	sexual	_	_	I-Premise
146	dysfunction	_	_	I-Premise
147	was	_	_	I-Premise
148	significantly	_	_	I-Premise
149	increased	_	_	I-Premise
150	following	_	_	I-Premise
151	surgery	_	_	I-Premise
152	(	_	_	I-Premise
153	P	_	_	I-Premise
154	<	_	_	I-Premise
155	.001	_	_	I-Premise
156	)	_	_	I-Premise
157	,	_	_	I-Premise
158	although	_	_	B-Premise
159	there	_	_	I-Premise
160	was	_	_	I-Premise
161	no	_	_	I-Premise
162	difference	_	_	I-Premise
163	between	_	_	I-Premise
164	treatment	_	_	I-Premise
165	arms	_	_	I-Premise
166	.	_	_	I-Premise

167	However	_	_	O
168	,	_	_	O
169	a	_	_	O
170	treatment	_	_	O
171	difference	_	_	O
172	had	_	_	O
173	emerged	_	_	O
174	at	_	_	O
175	6	_	_	O
176	months	_	_	O
177	(	_	_	O
178	PRE	_	_	O
179	patients	_	_	O
180	reporting	_	_	O
181	significantly	_	_	O
182	greater	_	_	O
183	dysfunction	_	_	O
184	;	_	_	O
185	P	_	_	O
186	=	_	_	O
187	.004	_	_	O
188	)	_	_	O
189	,	_	_	O
190	which	_	_	O
191	persisted	_	_	O
192	out	_	_	O
193	to	_	_	O
194	at	_	_	O
195	least	_	_	O
196	2	_	_	O
197	years	_	_	O
198	(	_	_	O
199	an	_	_	O
200	insufficient	_	_	O
201	number	_	_	O
202	of	_	_	O
203	female	_	_	O
204	patients	_	_	O
205	completed	_	_	O
206	the	_	_	O
207	sexual	_	_	O
208	dysfunction	_	_	O
209	questions	_	_	O
210	to	_	_	O
211	draw	_	_	O
212	firm	_	_	O
213	conclusions	_	_	O
214	)	_	_	O
215	.	_	_	O

216	Both	_	_	B-Premise
217	treatment	_	_	I-Premise
218	groups	_	_	I-Premise
219	reported	_	_	I-Premise
220	similar	_	_	I-Premise
221	levels	_	_	I-Premise
222	of	_	_	I-Premise
223	decreased	_	_	I-Premise
224	physical	_	_	I-Premise
225	function	_	_	I-Premise
226	at	_	_	I-Premise
227	3	_	_	I-Premise
228	months	_	_	I-Premise
229	,	_	_	I-Premise
230	but	_	_	B-Premise
231	thereafter	_	_	I-Premise
232	it	_	_	I-Premise
233	returned	_	_	I-Premise
234	to	_	_	I-Premise
235	baseline	_	_	I-Premise
236	levels	_	_	I-Premise
237	.	_	_	I-Premise

238	There	_	_	B-Premise
239	was	_	_	I-Premise
240	no	_	_	I-Premise
241	evidence	_	_	I-Premise
242	of	_	_	I-Premise
243	any	_	_	I-Premise
244	major	_	_	I-Premise
245	changes	_	_	I-Premise
246	between	_	_	I-Premise
247	treatments	_	_	I-Premise
248	or	_	_	I-Premise
249	time	_	_	I-Premise
250	points	_	_	I-Premise
251	in	_	_	I-Premise
252	terms	_	_	I-Premise
253	of	_	_	I-Premise
254	general	_	_	I-Premise
255	health	_	_	I-Premise
256	or	_	_	I-Premise
257	bowel	_	_	I-Premise
258	function	_	_	I-Premise
259	,	_	_	I-Premise
260	but	_	_	B-Premise
261	exploratory	_	_	I-Premise
262	analysis	_	_	I-Premise
263	indicated	_	_	I-Premise
264	a	_	_	I-Premise
265	significant	_	_	I-Premise
266	(	_	_	I-Premise
267	P	_	_	I-Premise
268	=	_	_	I-Premise
269	.006	_	_	I-Premise
270	at	_	_	I-Premise
271	2	_	_	I-Premise
272	years	_	_	I-Premise
273	)	_	_	I-Premise
274	increase	_	_	I-Premise
275	in	_	_	I-Premise
276	the	_	_	I-Premise
277	level	_	_	I-Premise
278	of	_	_	I-Premise
279	fecal	_	_	I-Premise
280	incontinence	_	_	I-Premise
281	with	_	_	I-Premise
282	PRE	_	_	I-Premise
283	.	_	_	I-Premise

284	These	_	_	B-Claim
285	results	_	_	I-Claim
286	from	_	_	I-Claim
287	a	_	_	I-Claim
288	large	_	_	I-Claim
289	randomized	_	_	I-Claim
290	trial	_	_	I-Claim
291	using	_	_	I-Claim
292	validated	_	_	I-Claim
293	patient-completed	_	_	I-Claim
294	questionnaires	_	_	I-Claim
295	show	_	_	I-Claim
296	that	_	_	I-Claim
297	,	_	_	I-Claim
298	for	_	_	I-Claim
299	males	_	_	I-Claim
300	,	_	_	I-Claim
301	the	_	_	I-Claim
302	main	_	_	I-Claim
303	adverse	_	_	I-Claim
304	effect	_	_	I-Claim
305	was	_	_	I-Claim
306	sexual	_	_	I-Claim
307	dysfunction	_	_	I-Claim
308	,	_	_	I-Claim
309	and	_	_	I-Claim
310	the	_	_	I-Claim
311	main	_	_	I-Claim
312	cause	_	_	I-Claim
313	of	_	_	I-Claim
314	this	_	_	I-Claim
315	was	_	_	I-Claim
316	surgery	_	_	I-Claim
317	,	_	_	I-Claim
318	but	_	_	O
319	that	_	_	O
320	PRE	_	_	B-Claim
321	also	_	_	I-Claim
322	affected	_	_	I-Claim
323	sexual	_	_	I-Claim
324	and	_	_	I-Claim
325	some	_	_	I-Claim
326	aspects	_	_	I-Claim
327	of	_	_	I-Claim
328	bowel	_	_	I-Claim
329	functioning	_	_	I-Claim
330	.	_	_	I-Claim


0	Fatigue	_	_	O
1	is	_	_	O
2	one	_	_	O
3	of	_	_	O
4	the	_	_	O
5	most	_	_	O
6	common	_	_	O
7	symptoms	_	_	O
8	experienced	_	_	O
9	by	_	_	O
10	patients	_	_	O
11	with	_	_	O
12	cancer	_	_	O
13	.	_	_	O

14	This	_	_	O
15	trial	_	_	O
16	was	_	_	O
17	developed	_	_	O
18	to	_	_	O
19	evaluate	_	_	O
20	the	_	_	O
21	efficacy	_	_	O
22	of	_	_	O
23	long-acting	_	_	O
24	methylphenidate	_	_	O
25	for	_	_	O
26	improving	_	_	O
27	cancer-related	_	_	O
28	fatigue	_	_	O
29	and	_	_	O
30	to	_	_	O
31	assess	_	_	O
32	its	_	_	O
33	toxicities	_	_	O
34	.	_	_	O

35	Adults	_	_	O
36	with	_	_	O
37	cancer	_	_	O
38	were	_	_	O
39	randomly	_	_	O
40	assigned	_	_	O
41	in	_	_	O
42	a	_	_	O
43	double-blinded	_	_	O
44	manner	_	_	O
45	to	_	_	O
46	receive	_	_	O
47	methylphenidate	_	_	O
48	(	_	_	O
49	target	_	_	O
50	dose	_	_	O
51	,	_	_	O
52	54	_	_	O
53	mg/d	_	_	O
54	)	_	_	O
55	or	_	_	O
56	placebo	_	_	O
57	for	_	_	O
58	4	_	_	O
59	weeks	_	_	O
60	.	_	_	O

61	The	_	_	O
62	Brief	_	_	O
63	Fatigue	_	_	O
64	Inventory	_	_	O
65	was	_	_	O
66	the	_	_	O
67	primary	_	_	O
68	outcome	_	_	O
69	measure	_	_	O
70	,	_	_	O
71	while	_	_	O
72	secondary	_	_	O
73	outcome	_	_	O
74	measures	_	_	O
75	included	_	_	O
76	a	_	_	O
77	Symptom	_	_	O
78	Experience	_	_	O
79	Diary	_	_	O
80	(	_	_	O
81	SED	_	_	O
82	)	_	_	O
83	,	_	_	O
84	the	_	_	O
85	Short	_	_	O
86	Form-36	_	_	O
87	(	_	_	O
88	SF-36	_	_	O
89	)	_	_	O
90	Vitality	_	_	O
91	Subscale	_	_	O
92	,	_	_	O
93	a	_	_	O
94	linear	_	_	O
95	analog	_	_	O
96	self-assessment	_	_	O
97	,	_	_	O
98	the	_	_	O
99	Pittsburgh	_	_	O
100	Sleep	_	_	O
101	Quality	_	_	O
102	Index	_	_	O
103	,	_	_	O
104	and	_	_	O
105	the	_	_	O
106	Subject	_	_	O
107	Global	_	_	O
108	Impression	_	_	O
109	of	_	_	O
110	Change	_	_	O
111	.	_	_	O

112	In	_	_	O
113	total	_	_	O
114	,	_	_	O
115	148	_	_	O
116	patients	_	_	O
117	were	_	_	O
118	enrolled	_	_	O
119	.	_	_	O

120	Using	_	_	B-Premise
121	an	_	_	I-Premise
122	area	_	_	I-Premise
123	under	_	_	I-Premise
124	the	_	_	I-Premise
125	serum	_	_	I-Premise
126	concentration-time	_	_	I-Premise
127	curve	_	_	I-Premise
128	analysis	_	_	I-Premise
129	,	_	_	I-Premise
130	there	_	_	I-Premise
131	was	_	_	I-Premise
132	no	_	_	I-Premise
133	evidence	_	_	I-Premise
134	that	_	_	I-Premise
135	methylphenidate	_	_	I-Premise
136	,	_	_	I-Premise
137	as	_	_	I-Premise
138	compared	_	_	I-Premise
139	with	_	_	I-Premise
140	placebo	_	_	I-Premise
141	,	_	_	I-Premise
142	improved	_	_	I-Premise
143	the	_	_	I-Premise
144	primary	_	_	I-Premise
145	end	_	_	I-Premise
146	point	_	_	I-Premise
147	of	_	_	I-Premise
148	cancer-related	_	_	I-Premise
149	fatigue	_	_	I-Premise
150	in	_	_	I-Premise
151	this	_	_	I-Premise
152	patient	_	_	I-Premise
153	population	_	_	I-Premise
154	(	_	_	I-Premise
155	P	_	_	I-Premise
156	=	_	_	I-Premise
157	.35	_	_	I-Premise
158	)	_	_	I-Premise
159	.	_	_	I-Premise

160	Comparisons	_	_	B-Premise
161	of	_	_	I-Premise
162	secondary	_	_	I-Premise
163	end	_	_	I-Premise
164	points	_	_	I-Premise
165	,	_	_	I-Premise
166	including	_	_	I-Premise
167	clinically	_	_	I-Premise
168	significant	_	_	I-Premise
169	changes	_	_	I-Premise
170	in	_	_	I-Premise
171	quality-of-life	_	_	I-Premise
172	variables	_	_	I-Premise
173	and	_	_	I-Premise
174	cancer-related	_	_	I-Premise
175	fatigue	_	_	I-Premise
176	change	_	_	I-Premise
177	from	_	_	I-Premise
178	baseline	_	_	I-Premise
179	,	_	_	I-Premise
180	were	_	_	I-Premise
181	similarly	_	_	I-Premise
182	negative	_	_	I-Premise
183	.	_	_	I-Premise

184	However	_	_	B-Premise
185	,	_	_	I-Premise
186	a	_	_	I-Premise
187	subset	_	_	I-Premise
188	analysis	_	_	I-Premise
189	suggested	_	_	I-Premise
190	that	_	_	I-Premise
191	patients	_	_	I-Premise
192	with	_	_	I-Premise
193	more	_	_	I-Premise
194	severe	_	_	I-Premise
195	fatigue	_	_	I-Premise
196	and/or	_	_	I-Premise
197	with	_	_	I-Premise
198	more	_	_	I-Premise
199	advanced	_	_	I-Premise
200	disease	_	_	I-Premise
201	did	_	_	I-Premise
202	have	_	_	I-Premise
203	some	_	_	I-Premise
204	fatigue	_	_	I-Premise
205	improvement	_	_	I-Premise
206	with	_	_	I-Premise
207	methylphenidate	_	_	I-Premise
208	(	_	_	I-Premise
209	eg	_	_	I-Premise
210	,	_	_	I-Premise
211	in	_	_	I-Premise
212	patients	_	_	I-Premise
213	with	_	_	I-Premise
214	stage	_	_	I-Premise
215	III	_	_	I-Premise
216	or	_	_	I-Premise
217	IV	_	_	I-Premise
218	disease	_	_	I-Premise
219	,	_	_	I-Premise
220	the	_	_	I-Premise
221	mean	_	_	I-Premise
222	improvement	_	_	I-Premise
223	in	_	_	I-Premise
224	usual	_	_	I-Premise
225	fatigue	_	_	I-Premise
226	was	_	_	I-Premise
227	19.7	_	_	I-Premise
228	with	_	_	I-Premise
229	methylphenidate	_	_	I-Premise
230	v	_	_	I-Premise
231	2.1	_	_	I-Premise
232	with	_	_	I-Premise
233	placebo	_	_	I-Premise
234	;	_	_	I-Premise
235	P	_	_	I-Premise
236	=	_	_	I-Premise
237	.02	_	_	I-Premise
238	)	_	_	I-Premise
239	.	_	_	I-Premise

240	There	_	_	B-Premise
241	was	_	_	I-Premise
242	a	_	_	I-Premise
243	significant	_	_	I-Premise
244	difference	_	_	I-Premise
245	in	_	_	I-Premise
246	self-reported	_	_	I-Premise
247	toxicities	_	_	I-Premise
248	(	_	_	I-Premise
249	SED	_	_	I-Premise
250	)	_	_	I-Premise
251	,	_	_	I-Premise
252	with	_	_	I-Premise
253	increased	_	_	I-Premise
254	levels	_	_	I-Premise
255	of	_	_	I-Premise
256	nervousness	_	_	I-Premise
257	and	_	_	I-Premise
258	appetite	_	_	I-Premise
259	loss	_	_	I-Premise
260	in	_	_	I-Premise
261	the	_	_	I-Premise
262	methylphenidate	_	_	I-Premise
263	arm	_	_	I-Premise
264	.	_	_	I-Premise

265	This	_	_	B-Claim
266	clinical	_	_	I-Claim
267	trial	_	_	I-Claim
268	was	_	_	I-Claim
269	unable	_	_	I-Claim
270	to	_	_	I-Claim
271	support	_	_	I-Claim
272	the	_	_	I-Claim
273	primary	_	_	I-Claim
274	prestudy	_	_	I-Claim
275	hypothesis	_	_	I-Claim
276	that	_	_	I-Claim
277	the	_	_	I-Claim
278	chosen	_	_	I-Claim
279	long-acting	_	_	I-Claim
280	methylphenidate	_	_	I-Claim
281	product	_	_	I-Claim
282	would	_	_	I-Claim
283	decrease	_	_	I-Claim
284	cancer-related	_	_	I-Claim
285	fatigue	_	_	I-Claim
286	.	_	_	I-Claim


0	To	_	_	O
1	observe	_	_	O
2	the	_	_	O
3	clinical	_	_	O
4	effectiveness	_	_	O
5	of	_	_	O
6	a	_	_	O
7	topical	_	_	O
8	application	_	_	O
9	of	_	_	O
10	Xiaozheng	_	_	O
11	Zhitong	_	_	O
12	:	_	_	O
13	Paste	_	_	O
14	(	_	_	O
15	,	_	_	O
16	XZP	_	_	O
17	)	_	_	O
18	in	_	_	O
19	alleviating	_	_	O
20	the	_	_	O
21	cancerous	_	_	O
22	pain	_	_	O
23	of	_	_	O
24	patients	_	_	O
25	with	_	_	O
26	middle/late	_	_	O
27	stage	_	_	O
28	cancer	_	_	O
29	By	_	_	O
30	:	_	_	O
31	adopting	_	_	O
32	a	_	_	O
33	random	_	_	O
34	number	_	_	O
35	table	_	_	O
36	,	_	_	O
37	124	_	_	O
38	patients	_	_	O
39	enrolled	_	_	O
40	were	_	_	O
41	randomized	_	_	O
42	into	_	_	O
43	the	_	_	O
44	treatment	_	_	O
45	group	_	_	O
46	(	_	_	O
47	64	_	_	O
48	patients	_	_	O
49	)	_	_	O
50	and	_	_	O
51	the	_	_	O
52	control	_	_	O
53	group	_	_	O
54	(	_	_	O
55	60	_	_	O
56	patients	_	_	O
57	)	_	_	O
58	.	_	_	O

59	In	_	_	O
60	addition	_	_	O
61	to	_	_	O
62	the	_	_	O
63	basic	_	_	O
64	therapy	_	_	O
65	[	_	_	O
66	including	_	_	O
67	the	_	_	O
68	three-ladder	_	_	O
69	(	_	_	O
70	3L	_	_	O
71	)	_	_	O
72	analgesia	_	_	O
73	]	_	_	O
74	used	_	_	O
75	in	_	_	O
76	both	_	_	O
77	groups	_	_	O
78	,	_	_	O
79	topical	_	_	O
80	application	_	_	O
81	of	_	_	O
82	XZP	_	_	O
83	was	_	_	O
84	given	_	_	O
85	to	_	_	O
86	patients	_	_	O
87	in	_	_	O
88	the	_	_	O
89	treatment	_	_	O
90	group	_	_	O
91	for	_	_	O
92	pain	_	_	O
93	alleviation	_	_	O
94	.	_	_	O

95	The	_	_	O
96	analgesic	_	_	O
97	efficacy	_	_	O
98	was	_	_	O
99	recorded	_	_	O
100	in	_	_	O
101	terms	_	_	O
102	of	_	_	O
103	pain	_	_	O
104	intensity	_	_	O
105	,	_	_	O
106	analgesia	_	_	O
107	initiating	_	_	O
108	time	_	_	O
109	and	_	_	O
110	sustaining	_	_	O
111	time	_	_	O
112	,	_	_	O
113	and	_	_	O
114	the	_	_	O
115	optimal	_	_	O
116	analgesic	_	_	O
117	effect	_	_	O
118	revealing	_	_	O
119	time	_	_	O
120	.	_	_	O

121	Meanwhile	_	_	O
122	,	_	_	O
123	the	_	_	O
124	quality	_	_	O
125	of	_	_	O
126	life	_	_	O
127	(	_	_	O
128	QOL	_	_	O
129	)	_	_	O
130	and	_	_	O
131	adverse	_	_	O
132	reactions	_	_	O
133	that	_	_	O
134	occurred	_	_	O
135	in	_	_	O
136	patients	_	_	O
137	were	_	_	O
138	recorded	_	_	O
139	as	_	_	O
140	well	_	_	O
141	.	_	_	O

142	The	_	_	B-Premise
143	total	_	_	I-Premise
144	effective	_	_	I-Premise
145	rate	_	_	I-Premise
146	in	_	_	I-Premise
147	the	_	_	I-Premise
148	treatment	_	_	I-Premise
149	group	_	_	I-Premise
150	was	_	_	I-Premise
151	:	_	_	I-Premise
152	84.38	_	_	I-Premise
153	%	_	_	I-Premise
154	(	_	_	I-Premise
155	54/64	_	_	I-Premise
156	)	_	_	I-Premise
157	,	_	_	I-Premise
158	and	_	_	I-Premise
159	in	_	_	I-Premise
160	the	_	_	I-Premise
161	control	_	_	I-Premise
162	group	_	_	I-Premise
163	it	_	_	I-Premise
164	was	_	_	I-Premise
165	88.33	_	_	I-Premise
166	%	_	_	I-Premise
167	(	_	_	I-Premise
168	53/60	_	_	I-Premise
169	)	_	_	I-Premise
170	,	_	_	I-Premise
171	showing	_	_	I-Premise
172	no	_	_	I-Premise
173	significant	_	_	I-Premise
174	difference	_	_	I-Premise
175	between	_	_	I-Premise
176	them	_	_	I-Premise
177	(	_	_	I-Premise
178	P	_	_	I-Premise
179	>	_	_	I-Premise
180	0.05	_	_	I-Premise
181	)	_	_	I-Premise
182	,	_	_	I-Premise
183	but	_	_	B-Premise
184	the	_	_	I-Premise
185	analgesia	_	_	I-Premise
186	initiating	_	_	I-Premise
187	time	_	_	I-Premise
188	and	_	_	I-Premise
189	the	_	_	I-Premise
190	optimal	_	_	I-Premise
191	analgesia	_	_	I-Premise
192	effect	_	_	I-Premise
193	revealing	_	_	I-Premise
194	time	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	treatment	_	_	I-Premise
198	group	_	_	I-Premise
199	were	_	_	I-Premise
200	significantly	_	_	I-Premise
201	shorter	_	_	I-Premise
202	(	_	_	I-Premise
203	both	_	_	I-Premise
204	P	_	_	I-Premise
205	<	_	_	I-Premise
206	0.01	_	_	I-Premise
207	)	_	_	I-Premise
208	.	_	_	I-Premise

209	Moreover	_	_	O
210	,	_	_	O
211	XZP	_	_	B-Premise
212	was	_	_	I-Premise
213	better	_	_	I-Premise
214	in	_	_	I-Premise
215	improving	_	_	I-Premise
216	patients	_	_	I-Premise
217	'	_	_	I-Premise
218	QOL	_	_	I-Premise
219	,	_	_	I-Premise
220	showing	_	_	I-Premise
221	more	_	_	I-Premise
222	significant	_	_	I-Premise
223	improvements	_	_	I-Premise
224	in	_	_	I-Premise
225	the	_	_	I-Premise
226	treatment	_	_	I-Premise
227	group	_	_	I-Premise
228	than	_	_	I-Premise
229	those	_	_	I-Premise
230	in	_	_	I-Premise
231	the	_	_	I-Premise
232	control	_	_	I-Premise
233	group	_	_	I-Premise
234	in	_	_	I-Premise
235	aspects	_	_	I-Premise
236	of	_	_	I-Premise
237	mental	_	_	I-Premise
238	condition	_	_	I-Premise
239	,	_	_	I-Premise
240	walking	_	_	I-Premise
241	capacity	_	_	I-Premise
242	,	_	_	I-Premise
243	working	_	_	I-Premise
244	capacity	_	_	I-Premise
245	,	_	_	I-Premise
246	social	_	_	I-Premise
247	acceptability	_	_	I-Premise
248	,	_	_	I-Premise
249	sleep	_	_	I-Premise
250	and	_	_	I-Premise
251	joy	_	_	I-Premise
252	of	_	_	I-Premise
253	living	_	_	I-Premise
254	(	_	_	I-Premise
255	P	_	_	I-Premise
256	<	_	_	I-Premise
257	0.05	_	_	I-Premise
258	or	_	_	I-Premise
259	P	_	_	I-Premise
260	<	_	_	I-Premise
261	0.01	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	Lower	_	_	B-Premise
265	incidence	_	_	I-Premise
266	of	_	_	I-Premise
267	adverse	_	_	I-Premise
268	reactions	_	_	I-Premise
269	,	_	_	I-Premise
270	such	_	_	I-Premise
271	as	_	_	I-Premise
272	nausea	_	_	I-Premise
273	,	_	_	I-Premise
274	vomiting	_	_	I-Premise
275	,	_	_	I-Premise
276	mouth	_	_	I-Premise
277	dryness	_	_	I-Premise
278	,	_	_	I-Premise
279	dizziness	_	_	I-Premise
280	,	_	_	I-Premise
281	etc.	_	_	I-Premise
282	,	_	_	I-Premise
283	especially	_	_	I-Premise
284	constipation	_	_	I-Premise
285	,	_	_	I-Premise
286	was	_	_	I-Premise
287	noted	_	_	I-Premise
288	in	_	_	I-Premise
289	the	_	_	I-Premise
290	treatment	_	_	I-Premise
291	group	_	_	I-Premise
292	(	_	_	I-Premise
293	P	_	_	I-Premise
294	<	_	_	I-Premise
295	0.05	_	_	I-Premise
296	or	_	_	I-Premise
297	P	_	_	I-Premise
298	<	_	_	I-Premise
299	0.01	_	_	I-Premise
300	)	_	_	I-Premise
301	.	_	_	I-Premise

302	Applying	_	_	B-Claim
303	an	_	_	I-Claim
304	external	_	_	I-Claim
305	compress	_	_	I-Claim
306	:	_	_	I-Claim
307	of	_	_	I-Claim
308	XZP	_	_	I-Claim
309	showed	_	_	I-Claim
310	a	_	_	I-Claim
311	synergistic	_	_	I-Claim
312	action	_	_	I-Claim
313	with	_	_	I-Claim
314	3L	_	_	I-Claim
315	analgesia	_	_	I-Claim
316	for	_	_	I-Claim
317	shortening	_	_	I-Claim
318	the	_	_	I-Claim
319	initiating	_	_	I-Claim
320	time	_	_	I-Claim
321	and	_	_	I-Claim
322	the	_	_	I-Claim
323	optimal	_	_	I-Claim
324	effect	_	_	I-Claim
325	revealing	_	_	I-Claim
326	time	_	_	I-Claim
327	,	_	_	I-Claim
328	and	_	_	I-Claim
329	could	_	_	I-Claim
330	evidently	_	_	I-Claim
331	enhance	_	_	I-Claim
332	patients	_	_	I-Claim
333	'	_	_	I-Claim
334	QOL	_	_	I-Claim
335	with	_	_	I-Claim
336	fewer	_	_	I-Claim
337	adverse	_	_	I-Claim
338	reactions	_	_	I-Claim
339	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	safety	_	_	O
4	and	_	_	O
5	efficacy	_	_	O
6	of	_	_	O
7	the	_	_	O
8	iStent	_	_	O
9	trabecular	_	_	O
10	micro-bypass	_	_	O
11	stent	_	_	O
12	(	_	_	O
13	Glaukos	_	_	O
14	Corporation	_	_	O
15	,	_	_	O
16	Laguna	_	_	O
17	Hills	_	_	O
18	,	_	_	O
19	CA	_	_	O
20	)	_	_	O
21	in	_	_	O
22	combination	_	_	O
23	with	_	_	O
24	cataract	_	_	O
25	surgery	_	_	O
26	in	_	_	O
27	subjects	_	_	O
28	with	_	_	O
29	mild	_	_	O
30	to	_	_	O
31	moderate	_	_	O
32	open-angle	_	_	O
33	glaucoma	_	_	O
34	.	_	_	O

35	Prospective	_	_	O
36	,	_	_	O
37	randomized	_	_	O
38	,	_	_	O
39	open-label	_	_	O
40	,	_	_	O
41	controlled	_	_	O
42	,	_	_	O
43	multicenter	_	_	O
44	clinical	_	_	O
45	trial	_	_	O
46	.	_	_	O

47	A	_	_	O
48	total	_	_	O
49	of	_	_	O
50	240	_	_	O
51	eyes	_	_	O
52	with	_	_	O
53	mild	_	_	O
54	to	_	_	O
55	moderate	_	_	O
56	open-angle	_	_	O
57	glaucoma	_	_	O
58	with	_	_	O
59	intraocular	_	_	O
60	pressure	_	_	O
61	(	_	_	O
62	IOP	_	_	O
63	)	_	_	O
64	=24	_	_	O
65	mmHg	_	_	O
66	controlled	_	_	O
67	on	_	_	O
68	1	_	_	O
69	to	_	_	O
70	3	_	_	O
71	medications	_	_	O
72	were	_	_	O
73	randomized	_	_	O
74	to	_	_	O
75	undergo	_	_	O
76	cataract	_	_	O
77	surgery	_	_	O
78	with	_	_	O
79	iStent	_	_	O
80	implantation	_	_	O
81	(	_	_	O
82	treatment	_	_	O
83	group	_	_	O
84	)	_	_	O
85	or	_	_	O
86	cataract	_	_	O
87	surgery	_	_	O
88	only	_	_	O
89	(	_	_	O
90	control	_	_	O
91	)	_	_	O
92	.	_	_	O

93	Fifty	_	_	O
94	additional	_	_	O
95	subjects	_	_	O
96	were	_	_	O
97	enrolled	_	_	O
98	to	_	_	O
99	undergo	_	_	O
100	cataract	_	_	O
101	surgery	_	_	O
102	with	_	_	O
103	iStent	_	_	O
104	implantation	_	_	O
105	under	_	_	O
106	protocol	_	_	O
107	expansion	_	_	O
108	.	_	_	O

109	Data	_	_	O
110	in	_	_	O
111	this	_	_	O
112	report	_	_	O
113	are	_	_	O
114	based	_	_	O
115	on	_	_	O
116	the	_	_	O
117	first	_	_	O
118	240	_	_	O
119	eyes	_	_	O
120	enrolled	_	_	O
121	.	_	_	O

122	Implantation	_	_	O
123	of	_	_	O
124	the	_	_	O
125	iStent	_	_	O
126	trabecular	_	_	O
127	micro-bypass	_	_	O
128	stent	_	_	O
129	in	_	_	O
130	conjunction	_	_	O
131	with	_	_	O
132	cataract	_	_	O
133	surgery	_	_	O
134	or	_	_	O
135	cataract	_	_	O
136	surgery	_	_	O
137	only	_	_	O
138	.	_	_	O

139	The	_	_	O
140	primary	_	_	O
141	efficacy	_	_	O
142	measure	_	_	O
143	was	_	_	O
144	unmedicated	_	_	O
145	IOP	_	_	O
146	≤21	_	_	O
147	mmHg	_	_	O
148	at	_	_	O
149	1	_	_	O
150	year	_	_	O
151	.	_	_	O

152	A	_	_	O
153	secondary	_	_	O
154	measure	_	_	O
155	was	_	_	O
156	unmedicated	_	_	O
157	IOP	_	_	O
158	reduction	_	_	O
159	≥20	_	_	O
160	%	_	_	O
161	at	_	_	O
162	1	_	_	O
163	year	_	_	O
164	.	_	_	O

165	Safety	_	_	O
166	measures	_	_	O
167	included	_	_	O
168	best-corrected	_	_	O
169	visual	_	_	O
170	acuity	_	_	O
171	(	_	_	O
172	BCVA	_	_	O
173	)	_	_	O
174	,	_	_	O
175	slit-lamp	_	_	O
176	observations	_	_	O
177	,	_	_	O
178	complications	_	_	O
179	,	_	_	O
180	and	_	_	O
181	adverse	_	_	O
182	events	_	_	O
183	.	_	_	O

184	The	_	_	O
185	study	_	_	O
186	met	_	_	O
187	the	_	_	O
188	primary	_	_	O
189	outcome	_	_	O
190	,	_	_	O
191	with	_	_	O
192	72	_	_	O
193	%	_	_	O
194	of	_	_	O
195	treatment	_	_	O
196	eyes	_	_	O
197	versus	_	_	O
198	50	_	_	O
199	%	_	_	O
200	of	_	_	O
201	control	_	_	O
202	eyes	_	_	O
203	achieving	_	_	O
204	the	_	_	O
205	criterion	_	_	O
206	(	_	_	O
207	P	_	_	O
208	<	_	_	O
209	0.001	_	_	O
210	)	_	_	O
211	.	_	_	O

212	At	_	_	B-Premise
213	1	_	_	I-Premise
214	year	_	_	I-Premise
215	,	_	_	I-Premise
216	IOP	_	_	I-Premise
217	in	_	_	I-Premise
218	both	_	_	I-Premise
219	treatment	_	_	I-Premise
220	groups	_	_	I-Premise
221	was	_	_	I-Premise
222	statistically	_	_	I-Premise
223	significantly	_	_	I-Premise
224	lower	_	_	I-Premise
225	from	_	_	I-Premise
226	baseline	_	_	I-Premise
227	values	_	_	I-Premise
228	.	_	_	I-Premise

229	Sixty-six	_	_	B-Premise
230	percent	_	_	I-Premise
231	of	_	_	I-Premise
232	treatment	_	_	I-Premise
233	eyes	_	_	I-Premise
234	versus	_	_	I-Premise
235	48	_	_	I-Premise
236	%	_	_	I-Premise
237	of	_	_	I-Premise
238	control	_	_	I-Premise
239	eyes	_	_	I-Premise
240	achieved	_	_	I-Premise
241	=20	_	_	I-Premise
242	%	_	_	I-Premise
243	IOP	_	_	I-Premise
244	reduction	_	_	I-Premise
245	without	_	_	I-Premise
246	medication	_	_	I-Premise
247	(	_	_	I-Premise
248	P	_	_	I-Premise
249	=	_	_	I-Premise
250	0.003	_	_	I-Premise
251	)	_	_	I-Premise
252	.	_	_	I-Premise

253	The	_	_	B-Premise
254	overall	_	_	I-Premise
255	incidence	_	_	I-Premise
256	of	_	_	I-Premise
257	adverse	_	_	I-Premise
258	events	_	_	I-Premise
259	was	_	_	I-Premise
260	similar	_	_	I-Premise
261	between	_	_	I-Premise
262	groups	_	_	I-Premise
263	with	_	_	I-Premise
264	no	_	_	I-Premise
265	unanticipated	_	_	I-Premise
266	adverse	_	_	I-Premise
267	device	_	_	I-Premise
268	effects	_	_	I-Premise
269	.	_	_	I-Premise

270	Pressure	_	_	B-Claim
271	reduction	_	_	I-Claim
272	on	_	_	I-Claim
273	fewer	_	_	I-Claim
274	medications	_	_	I-Claim
275	was	_	_	I-Claim
276	clinically	_	_	I-Claim
277	and	_	_	I-Claim
278	statistically	_	_	I-Claim
279	significantly	_	_	I-Claim
280	better	_	_	I-Claim
281	1	_	_	I-Claim
282	year	_	_	I-Claim
283	after	_	_	I-Claim
284	stent	_	_	I-Claim
285	plus	_	_	I-Claim
286	cataract	_	_	I-Claim
287	surgery	_	_	I-Claim
288	versus	_	_	I-Claim
289	cataract	_	_	I-Claim
290	surgery	_	_	I-Claim
291	alone	_	_	I-Claim
292	,	_	_	I-Claim
293	with	_	_	I-Claim
294	an	_	_	I-Claim
295	overall	_	_	I-Claim
296	safety	_	_	I-Claim
297	profile	_	_	I-Claim
298	similar	_	_	I-Claim
299	to	_	_	I-Claim
300	that	_	_	I-Claim
301	of	_	_	I-Claim
302	cataract	_	_	I-Claim
303	surgery	_	_	I-Claim
304	alone	_	_	I-Claim
305	.	_	_	I-Claim


0	Systematic	_	_	B-Claim
1	assessment	_	_	I-Claim
2	is	_	_	I-Claim
3	vital	_	_	I-Claim
4	to	_	_	I-Claim
5	palliative	_	_	I-Claim
6	care	_	_	I-Claim
7	,	_	_	O
8	but	_	_	O
9	documentation	_	_	O
10	confirming	_	_	O
11	completion	_	_	O
12	of	_	_	O
13	systematic	_	_	O
14	assessment	_	_	O
15	in	_	_	O
16	hospice	_	_	O
17	settings	_	_	O
18	is	_	_	O
19	often	_	_	O
20	inadequate	_	_	O
21	or	_	_	O
22	absent	_	_	O
23	.	_	_	O

24	The	_	_	O
25	objective	_	_	O
26	of	_	_	O
27	the	_	_	O
28	study	_	_	O
29	was	_	_	O
30	to	_	_	O
31	determine	_	_	O
32	the	_	_	O
33	efficacy	_	_	O
34	of	_	_	O
35	systematic	_	_	O
36	feedback	_	_	O
37	from	_	_	O
38	standardized	_	_	O
39	assessment	_	_	O
40	tools	_	_	O
41	for	_	_	O
42	hospice	_	_	O
43	patient-caregiver	_	_	O
44	dyads	_	_	O
45	in	_	_	O
46	improving	_	_	O
47	hospice	_	_	O
48	outcomes	_	_	O
49	compared	_	_	O
50	with	_	_	O
51	the	_	_	O
52	usual	_	_	O
53	clinical	_	_	O
54	practice	_	_	O
55	.	_	_	O

56	The	_	_	O
57	sample	_	_	O
58	of	_	_	O
59	patients	_	_	O
60	(	_	_	O
61	n	_	_	O
62	=	_	_	O
63	709	_	_	O
64	)	_	_	O
65	newly	_	_	O
66	admitted	_	_	O
67	to	_	_	O
68	hospice	_	_	O
69	home	_	_	O
70	care	_	_	O
71	in	_	_	O
72	2	_	_	O
73	hospices	_	_	O
74	had	_	_	O
75	designated	_	_	O
76	family	_	_	O
77	caregivers	_	_	O
78	.	_	_	O

79	The	_	_	O
80	interdisciplinary	_	_	O
81	teams	_	_	O
82	(	_	_	O
83	IDTs	_	_	O
84	)	_	_	O
85	caring	_	_	O
86	for	_	_	O
87	these	_	_	O
88	dyads	_	_	O
89	were	_	_	O
90	randomly	_	_	O
91	assigned	_	_	O
92	to	_	_	O
93	either	_	_	O
94	experimental	_	_	O
95	(	_	_	O
96	n	_	_	O
97	=	_	_	O
98	338	_	_	O
99	)	_	_	O
100	or	_	_	O
101	control	_	_	O
102	(	_	_	O
103	n	_	_	O
104	=	_	_	O
105	371	_	_	O
106	)	_	_	O
107	conditions	_	_	O
108	.	_	_	O

109	Data	_	_	O
110	were	_	_	O
111	collected	_	_	O
112	from	_	_	O
113	both	_	_	O
114	groups	_	_	O
115	of	_	_	O
116	dyads	_	_	O
117	using	_	_	O
118	standardized	_	_	O
119	assessments	_	_	O
120	on	_	_	O
121	admission	_	_	O
122	and	_	_	O
123	1	_	_	O
124	week	_	_	O
125	after	_	_	O
126	each	_	_	O
127	of	_	_	O
128	the	_	_	O
129	first	_	_	O
130	2	_	_	O
131	IDT	_	_	O
132	meetings	_	_	O
133	in	_	_	O
134	which	_	_	O
135	these	_	_	O
136	dyads	_	_	O
137	were	_	_	O
138	discussed	_	_	O
139	.	_	_	O

140	The	_	_	O
141	experimental	_	_	O
142	intervention	_	_	O
143	consisted	_	_	O
144	of	_	_	O
145	reporting	_	_	O
146	data	_	_	O
147	from	_	_	O
148	the	_	_	O
149	standardized	_	_	O
150	assessments	_	_	O
151	to	_	_	O
152	the	_	_	O
153	IDTs	_	_	O
154	.	_	_	O

155	Results	_	_	B-Premise
156	showed	_	_	I-Premise
157	improved	_	_	I-Premise
158	patient	_	_	I-Premise
159	depression	_	_	I-Premise
160	(	_	_	I-Premise
161	P	_	_	I-Premise
162	<	_	_	I-Premise
163	.001	_	_	I-Premise
164	)	_	_	I-Premise
165	as	_	_	I-Premise
166	a	_	_	I-Premise
167	result	_	_	I-Premise
168	of	_	_	I-Premise
169	the	_	_	I-Premise
170	intervention	_	_	I-Premise
171	and	_	_	I-Premise
172	improvement	_	_	I-Premise
173	in	_	_	I-Premise
174	both	_	_	I-Premise
175	groups	_	_	I-Premise
176	in	_	_	I-Premise
177	patients	_	_	I-Premise
178	'	_	_	I-Premise
179	quality	_	_	I-Premise
180	of	_	_	I-Premise
181	life	_	_	I-Premise
182	(	_	_	I-Premise
183	P	_	_	I-Premise
184	<	_	_	I-Premise
185	.001	_	_	I-Premise
186	)	_	_	I-Premise
187	.	_	_	I-Premise

188	No	_	_	B-Premise
189	other	_	_	I-Premise
190	patient	_	_	I-Premise
191	outcomes	_	_	I-Premise
192	(	_	_	I-Premise
193	symptom	_	_	I-Premise
194	distress	_	_	I-Premise
195	,	_	_	I-Premise
196	spiritual	_	_	I-Premise
197	needs	_	_	I-Premise
198	)	_	_	I-Premise
199	or	_	_	I-Premise
200	caregiver	_	_	I-Premise
201	outcomes	_	_	I-Premise
202	(	_	_	I-Premise
203	depression	_	_	I-Premise
204	,	_	_	I-Premise
205	support	_	_	I-Premise
206	,	_	_	I-Premise
207	spiritual	_	_	I-Premise
208	needs	_	_	I-Premise
209	)	_	_	I-Premise
210	were	_	_	I-Premise
211	significantly	_	_	I-Premise
212	different	_	_	I-Premise
213	.	_	_	I-Premise

214	Assessment	_	_	O
215	of	_	_	O
216	depression	_	_	O
217	added	_	_	O
218	to	_	_	O
219	usual	_	_	O
220	care	_	_	O
221	probably	_	_	O
222	had	_	_	O
223	an	_	_	O
224	effect	_	_	O
225	because	_	_	O
226	it	_	_	O
227	is	_	_	O
228	not	_	_	O
229	normally	_	_	O
230	a	_	_	O
231	focus	_	_	O
232	of	_	_	O
233	hospice	_	_	O
234	staff	_	_	O
235	.	_	_	O

236	Hospice	_	_	B-Premise
237	care	_	_	I-Premise
238	was	_	_	I-Premise
239	so	_	_	I-Premise
240	good	_	_	I-Premise
241	during	_	_	I-Premise
242	the	_	_	I-Premise
243	study	_	_	I-Premise
244	that	_	_	I-Premise
245	overall	_	_	I-Premise
246	quality	_	_	I-Premise
247	of	_	_	I-Premise
248	life	_	_	I-Premise
249	improved	_	_	I-Premise
250	as	_	_	I-Premise
251	a	_	_	I-Premise
252	result	_	_	I-Premise
253	of	_	_	I-Premise
254	standard	_	_	I-Premise
255	care	_	_	I-Premise
256	and	_	_	I-Premise
257	left	_	_	I-Premise
258	little	_	_	I-Premise
259	room	_	_	I-Premise
260	for	_	_	I-Premise
261	improvement	_	_	I-Premise
262	in	_	_	I-Premise
263	other	_	_	I-Premise
264	variables	_	_	I-Premise
265	.	_	_	I-Premise

266	Systematic	_	_	B-Claim
267	assessment	_	_	I-Claim
268	of	_	_	I-Claim
269	depression	_	_	I-Claim
270	is	_	_	I-Claim
271	needed	_	_	I-Claim
272	in	_	_	I-Claim
273	hospice	_	_	I-Claim
274	patients	_	_	I-Claim
275	.	_	_	I-Claim

276	No	_	_	O
277	caregiver	_	_	O
278	variables	_	_	O
279	changed	_	_	O
280	,	_	_	O
281	which	_	_	O
282	may	_	_	O
283	indicate	_	_	O
284	a	_	_	O
285	need	_	_	O
286	for	_	_	O
287	a	_	_	O
288	focus	_	_	O
289	on	_	_	O
290	caregivers	_	_	O
291	.	_	_	O


0	Serum	_	_	O
1	CA125	_	_	O
2	concentration	_	_	O
3	often	_	_	O
4	rises	_	_	O
5	several	_	_	O
6	months	_	_	O
7	before	_	_	O
8	clinical	_	_	O
9	or	_	_	O
10	symptomatic	_	_	O
11	relapse	_	_	O
12	in	_	_	O
13	women	_	_	O
14	with	_	_	O
15	ovarian	_	_	O
16	cancer	_	_	O
17	.	_	_	O

18	In	_	_	O
19	the	_	_	O
20	MRC	_	_	O
21	OV05/EORTC	_	_	O
22	55955	_	_	O
23	collaborative	_	_	O
24	trial	_	_	O
25	,	_	_	O
26	we	_	_	O
27	aimed	_	_	O
28	to	_	_	O
29	establish	_	_	O
30	the	_	_	O
31	benefits	_	_	O
32	of	_	_	O
33	early	_	_	O
34	treatment	_	_	O
35	on	_	_	O
36	the	_	_	O
37	basis	_	_	O
38	of	_	_	O
39	increased	_	_	O
40	CA125	_	_	O
41	concentrations	_	_	O
42	compared	_	_	O
43	with	_	_	O
44	delayed	_	_	O
45	treatment	_	_	O
46	on	_	_	O
47	the	_	_	O
48	basis	_	_	O
49	of	_	_	O
50	clinical	_	_	O
51	recurrence	_	_	O
52	.	_	_	O

53	Women	_	_	O
54	with	_	_	O
55	ovarian	_	_	O
56	cancer	_	_	O
57	in	_	_	O
58	complete	_	_	O
59	remission	_	_	O
60	after	_	_	O
61	first-line	_	_	O
62	platinum-based	_	_	O
63	chemotherapy	_	_	O
64	and	_	_	O
65	a	_	_	O
66	normal	_	_	O
67	CA125	_	_	O
68	concentration	_	_	O
69	were	_	_	O
70	registered	_	_	O
71	for	_	_	O
72	this	_	_	O
73	randomised	_	_	O
74	controlled	_	_	O
75	trial	_	_	O
76	.	_	_	O

77	Clinical	_	_	O
78	examination	_	_	O
79	and	_	_	O
80	CA125	_	_	O
81	measurement	_	_	O
82	were	_	_	O
83	done	_	_	O
84	every	_	_	O
85	3	_	_	O
86	months	_	_	O
87	.	_	_	O

88	Patients	_	_	O
89	and	_	_	O
90	investigators	_	_	O
91	were	_	_	O
92	masked	_	_	O
93	to	_	_	O
94	CA125	_	_	O
95	results	_	_	O
96	,	_	_	O
97	which	_	_	O
98	were	_	_	O
99	monitored	_	_	O
100	by	_	_	O
101	coordinating	_	_	O
102	centres	_	_	O
103	.	_	_	O

104	If	_	_	O
105	CA125	_	_	O
106	concentration	_	_	O
107	exceeded	_	_	O
108	twice	_	_	O
109	the	_	_	O
110	upper	_	_	O
111	limit	_	_	O
112	of	_	_	O
113	normal	_	_	O
114	,	_	_	O
115	patients	_	_	O
116	were	_	_	O
117	randomly	_	_	O
118	assigned	_	_	O
119	(	_	_	O
120	1:1	_	_	O
121	)	_	_	O
122	by	_	_	O
123	minimisation	_	_	O
124	to	_	_	O
125	early	_	_	O
126	or	_	_	O
127	delayed	_	_	O
128	chemotherapy	_	_	O
129	.	_	_	O

130	Patients	_	_	O
131	and	_	_	O
132	clinical	_	_	O
133	sites	_	_	O
134	were	_	_	O
135	informed	_	_	O
136	of	_	_	O
137	allocation	_	_	O
138	to	_	_	O
139	early	_	_	O
140	treatment	_	_	O
141	,	_	_	O
142	and	_	_	O
143	treatment	_	_	O
144	was	_	_	O
145	started	_	_	O
146	as	_	_	O
147	soon	_	_	O
148	as	_	_	O
149	possible	_	_	O
150	within	_	_	O
151	28	_	_	O
152	days	_	_	O
153	of	_	_	O
154	the	_	_	O
155	increased	_	_	O
156	CA125	_	_	O
157	measurement	_	_	O
158	.	_	_	O

159	Patients	_	_	O
160	assigned	_	_	O
161	to	_	_	O
162	delayed	_	_	O
163	treatment	_	_	O
164	continued	_	_	O
165	masked	_	_	O
166	CA125	_	_	O
167	measurements	_	_	O
168	,	_	_	O
169	with	_	_	O
170	treatment	_	_	O
171	commencing	_	_	O
172	at	_	_	O
173	clinical	_	_	O
174	or	_	_	O
175	symptomatic	_	_	O
176	relapse	_	_	O
177	.	_	_	O

178	All	_	_	O
179	patients	_	_	O
180	were	_	_	O
181	treated	_	_	O
182	according	_	_	O
183	to	_	_	O
184	standard	_	_	O
185	local	_	_	O
186	practice	_	_	O
187	.	_	_	O

188	The	_	_	O
189	primary	_	_	O
190	outcome	_	_	O
191	was	_	_	O
192	overall	_	_	O
193	survival	_	_	O
194	.	_	_	O

195	Analysis	_	_	O
196	was	_	_	O
197	by	_	_	O
198	intention	_	_	O
199	to	_	_	O
200	treat	_	_	O
201	.	_	_	O

202	This	_	_	O
203	study	_	_	O
204	is	_	_	O
205	registered	_	_	O
206	,	_	_	O
207	ISRCTN87786644	_	_	O
208	.	_	_	O

209	1442	_	_	O
210	patients	_	_	O
211	were	_	_	O
212	registered	_	_	O
213	for	_	_	O
214	the	_	_	O
215	trial	_	_	O
216	,	_	_	O
217	of	_	_	O
218	whom	_	_	O
219	529	_	_	O
220	were	_	_	O
221	randomly	_	_	O
222	assigned	_	_	O
223	to	_	_	O
224	treatment	_	_	O
225	groups	_	_	O
226	and	_	_	O
227	were	_	_	O
228	included	_	_	O
229	in	_	_	O
230	our	_	_	O
231	analysis	_	_	O
232	(	_	_	O
233	265	_	_	O
234	early	_	_	O
235	,	_	_	O
236	264	_	_	O
237	delayed	_	_	O
238	)	_	_	O
239	.	_	_	O

240	With	_	_	B-Premise
241	a	_	_	I-Premise
242	median	_	_	I-Premise
243	follow-up	_	_	I-Premise
244	of	_	_	I-Premise
245	56·9	_	_	I-Premise
246	months	_	_	I-Premise
247	(	_	_	I-Premise
248	IQR	_	_	I-Premise
249	37·4-81·8	_	_	I-Premise
250	)	_	_	I-Premise
251	from	_	_	I-Premise
252	randomisation	_	_	I-Premise
253	and	_	_	I-Premise
254	370	_	_	I-Premise
255	deaths	_	_	I-Premise
256	(	_	_	I-Premise
257	186	_	_	I-Premise
258	early	_	_	I-Premise
259	,	_	_	I-Premise
260	184	_	_	I-Premise
261	delayed	_	_	I-Premise
262	)	_	_	I-Premise
263	,	_	_	I-Premise
264	there	_	_	I-Premise
265	was	_	_	I-Premise
266	no	_	_	I-Premise
267	evidence	_	_	I-Premise
268	of	_	_	I-Premise
269	a	_	_	I-Premise
270	difference	_	_	I-Premise
271	in	_	_	I-Premise
272	overall	_	_	I-Premise
273	survival	_	_	I-Premise
274	between	_	_	I-Premise
275	early	_	_	I-Premise
276	and	_	_	I-Premise
277	delayed	_	_	I-Premise
278	treatment	_	_	I-Premise
279	(	_	_	I-Premise
280	HR	_	_	I-Premise
281	0·98	_	_	I-Premise
282	,	_	_	I-Premise
283	95	_	_	I-Premise
284	%	_	_	I-Premise
285	CI	_	_	I-Premise
286	0·80-1·20	_	_	I-Premise
287	,	_	_	I-Premise
288	p=0·85	_	_	I-Premise
289	)	_	_	I-Premise
290	.	_	_	I-Premise

291	Median	_	_	B-Premise
292	survival	_	_	I-Premise
293	from	_	_	I-Premise
294	randomisation	_	_	I-Premise
295	was	_	_	I-Premise
296	25·7	_	_	I-Premise
297	months	_	_	I-Premise
298	(	_	_	I-Premise
299	95	_	_	I-Premise
300	%	_	_	I-Premise
301	CI	_	_	I-Premise
302	23·0-27·9	_	_	I-Premise
303	)	_	_	I-Premise
304	for	_	_	I-Premise
305	patients	_	_	I-Premise
306	on	_	_	I-Premise
307	early	_	_	I-Premise
308	treatment	_	_	I-Premise
309	and	_	_	I-Premise
310	27·1	_	_	I-Premise
311	months	_	_	I-Premise
312	(	_	_	I-Premise
313	22·8-30·9	_	_	I-Premise
314	)	_	_	I-Premise
315	for	_	_	I-Premise
316	those	_	_	I-Premise
317	on	_	_	I-Premise
318	delayed	_	_	I-Premise
319	treatment	_	_	I-Premise
320	.	_	_	I-Premise

321	Our	_	_	B-Claim
322	findings	_	_	I-Claim
323	showed	_	_	I-Claim
324	no	_	_	I-Claim
325	evidence	_	_	I-Claim
326	of	_	_	I-Claim
327	a	_	_	I-Claim
328	survival	_	_	I-Claim
329	benefit	_	_	I-Claim
330	with	_	_	I-Claim
331	early	_	_	I-Claim
332	treatment	_	_	I-Claim
333	of	_	_	I-Claim
334	relapse	_	_	I-Claim
335	on	_	_	I-Claim
336	the	_	_	I-Claim
337	basis	_	_	I-Claim
338	of	_	_	I-Claim
339	a	_	_	I-Claim
340	raised	_	_	I-Claim
341	CA125	_	_	I-Claim
342	concentration	_	_	I-Claim
343	alone	_	_	I-Claim
344	,	_	_	I-Claim
345	and	_	_	B-Claim
346	therefore	_	_	I-Claim
347	the	_	_	I-Claim
348	value	_	_	I-Claim
349	of	_	_	I-Claim
350	routine	_	_	I-Claim
351	measurement	_	_	I-Claim
352	of	_	_	I-Claim
353	CA125	_	_	I-Claim
354	in	_	_	I-Claim
355	the	_	_	I-Claim
356	follow-up	_	_	I-Claim
357	of	_	_	I-Claim
358	patients	_	_	I-Claim
359	with	_	_	I-Claim
360	ovarian	_	_	I-Claim
361	cancer	_	_	I-Claim
362	who	_	_	I-Claim
363	attain	_	_	I-Claim
364	a	_	_	I-Claim
365	complete	_	_	I-Claim
366	response	_	_	I-Claim
367	after	_	_	I-Claim
368	first-line	_	_	I-Claim
369	treatment	_	_	I-Claim
370	is	_	_	I-Claim
371	not	_	_	I-Claim
372	proven	_	_	I-Claim
373	.	_	_	I-Claim


0	To	_	_	O
1	test	_	_	O
2	the	_	_	O
3	hypothesis	_	_	O
4	that	_	_	O
5	neodymium	_	_	B-Claim
6	:	_	_	I-Claim
7	yttrium-aluminum-garnet	_	_	I-Claim
8	(	_	_	I-Claim
9	Nd	_	_	I-Claim
10	:	_	_	I-Claim
11	YAG	_	_	I-Claim
12	)	_	_	I-Claim
13	laser	_	_	I-Claim
14	peripheral	_	_	I-Claim
15	iridotomy	_	_	I-Claim
16	(	_	_	I-Claim
17	LPI	_	_	I-Claim
18	)	_	_	I-Claim
19	significantly	_	_	I-Claim
20	reduces	_	_	I-Claim
21	the	_	_	I-Claim
22	incidence	_	_	I-Claim
23	of	_	_	I-Claim
24	conversion	_	_	I-Claim
25	from	_	_	I-Claim
26	pigment	_	_	I-Claim
27	dispersion	_	_	I-Claim
28	syndrome	_	_	I-Claim
29	(	_	_	I-Claim
30	PDS	_	_	I-Claim
31	)	_	_	I-Claim
32	with	_	_	I-Claim
33	ocular	_	_	I-Claim
34	hypertension	_	_	I-Claim
35	(	_	_	I-Claim
36	OHT	_	_	I-Claim
37	)	_	_	I-Claim
38	to	_	_	I-Claim
39	pigmentary	_	_	I-Claim
40	glaucoma	_	_	I-Claim
41	(	_	_	I-Claim
42	PG	_	_	I-Claim
43	)	_	_	I-Claim
44	.	_	_	I-Claim

45	Prospective	_	_	O
46	,	_	_	O
47	randomized	_	_	O
48	,	_	_	O
49	controlled	_	_	O
50	3-year	_	_	O
51	trial	_	_	O
52	.	_	_	O

53	One	_	_	O
54	hundred	_	_	O
55	sixteen	_	_	O
56	eyes	_	_	O
57	of	_	_	O
58	116	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	PDS	_	_	O
62	and	_	_	O
63	OHT	_	_	O
64	.	_	_	O

65	Patients	_	_	O
66	were	_	_	O
67	assigned	_	_	O
68	randomly	_	_	O
69	either	_	_	O
70	to	_	_	O
71	Nd	_	_	O
72	:	_	_	O
73	YAG	_	_	O
74	LPI	_	_	O
75	or	_	_	O
76	to	_	_	O
77	a	_	_	O
78	control	_	_	O
79	group	_	_	O
80	(	_	_	O
81	no	_	_	O
82	laser	_	_	O
83	)	_	_	O
84	.	_	_	O

85	The	_	_	O
86	primary	_	_	O
87	outcome	_	_	O
88	measure	_	_	O
89	was	_	_	O
90	conversion	_	_	O
91	to	_	_	O
92	PG	_	_	O
93	within	_	_	O
94	3	_	_	O
95	years	_	_	O
96	,	_	_	O
97	based	_	_	O
98	on	_	_	O
99	full-threshold	_	_	O
100	visual	_	_	O
101	field	_	_	O
102	(	_	_	O
103	VF	_	_	O
104	)	_	_	O
105	analysis	_	_	O
106	using	_	_	O
107	the	_	_	O
108	Ocular	_	_	O
109	Hypertension	_	_	O
110	Treatment	_	_	O
111	Study	_	_	O
112	criteria	_	_	O
113	.	_	_	O

114	Secondary	_	_	O
115	outcome	_	_	O
116	measures	_	_	O
117	were	_	_	O
118	whether	_	_	O
119	eyes	_	_	O
120	required	_	_	O
121	topical	_	_	O
122	antiglaucoma	_	_	O
123	medications	_	_	O
124	during	_	_	O
125	the	_	_	O
126	study	_	_	O
127	period	_	_	O
128	and	_	_	O
129	the	_	_	O
130	time	_	_	O
131	to	_	_	O
132	conversion	_	_	O
133	or	_	_	O
134	medication	_	_	O
135	.	_	_	O

136	Fifty-seven	_	_	O
137	patients	_	_	O
138	were	_	_	O
139	randomized	_	_	O
140	to	_	_	O
141	undergo	_	_	O
142	laser	_	_	O
143	treatment	_	_	O
144	and	_	_	O
145	59	_	_	O
146	were	_	_	O
147	randomized	_	_	O
148	to	_	_	O
149	no	_	_	O
150	laser	_	_	O
151	(	_	_	O
152	controls	_	_	O
153	)	_	_	O
154	.	_	_	O

155	Age	_	_	O
156	,	_	_	O
157	gender	_	_	O
158	,	_	_	O
159	spherical	_	_	O
160	equivalent	_	_	O
161	refraction	_	_	O
162	,	_	_	O
163	and	_	_	O
164	intraocular	_	_	O
165	pressure	_	_	O
166	at	_	_	O
167	baseline	_	_	O
168	were	_	_	O
169	similar	_	_	O
170	between	_	_	O
171	groups	_	_	O
172	.	_	_	O

173	Outcome	_	_	O
174	data	_	_	O
175	were	_	_	O
176	available	_	_	O
177	for	_	_	O
178	105	_	_	O
179	(	_	_	O
180	90	_	_	O
181	%	_	_	O
182	)	_	_	O
183	of	_	_	O
184	recruited	_	_	O
185	subjects	_	_	O
186	,	_	_	O
187	52	_	_	O
188	in	_	_	O
189	the	_	_	O
190	laser	_	_	O
191	treatment	_	_	O
192	group	_	_	O
193	and	_	_	O
194	53	_	_	O
195	in	_	_	O
196	the	_	_	O
197	no	_	_	O
198	laser	_	_	O
199	treatment	_	_	O
200	group	_	_	O
201	.	_	_	O

202	Patients	_	_	O
203	were	_	_	O
204	followed	_	_	O
205	up	_	_	O
206	for	_	_	O
207	a	_	_	O
208	median	_	_	O
209	of	_	_	O
210	35.9	_	_	O
211	months	_	_	O
212	(	_	_	O
213	range	_	_	O
214	,	_	_	O
215	10-36	_	_	O
216	months	_	_	O
217	)	_	_	O
218	in	_	_	O
219	the	_	_	O
220	laser	_	_	O
221	arm	_	_	O
222	and	_	_	O
223	35.9	_	_	O
224	months	_	_	O
225	(	_	_	O
226	range	_	_	O
227	,	_	_	O
228	1-36	_	_	O
229	months	_	_	O
230	)	_	_	O
231	in	_	_	O
232	the	_	_	O
233	control	_	_	O
234	arm	_	_	O
235	.	_	_	O

236	Eight	_	_	B-Premise
237	eyes	_	_	I-Premise
238	(	_	_	I-Premise
239	15	_	_	I-Premise
240	%	_	_	I-Premise
241	)	_	_	I-Premise
242	in	_	_	I-Premise
243	the	_	_	I-Premise
244	laser	_	_	I-Premise
245	group	_	_	I-Premise
246	and	_	_	I-Premise
247	3	_	_	I-Premise
248	eyes	_	_	I-Premise
249	(	_	_	I-Premise
250	6	_	_	I-Premise
251	%	_	_	I-Premise
252	)	_	_	I-Premise
253	in	_	_	I-Premise
254	the	_	_	I-Premise
255	control	_	_	I-Premise
256	group	_	_	I-Premise
257	converted	_	_	I-Premise
258	to	_	_	I-Premise
259	glaucoma	_	_	I-Premise
260	in	_	_	I-Premise
261	the	_	_	I-Premise
262	study	_	_	I-Premise
263	period	_	_	I-Premise
264	.	_	_	I-Premise

265	The	_	_	B-Premise
266	proportion	_	_	I-Premise
267	of	_	_	I-Premise
268	eyes	_	_	I-Premise
269	started	_	_	I-Premise
270	on	_	_	I-Premise
271	medical	_	_	I-Premise
272	treatment	_	_	I-Premise
273	was	_	_	I-Premise
274	similar	_	_	I-Premise
275	in	_	_	I-Premise
276	the	_	_	I-Premise
277	2	_	_	I-Premise
278	groups	_	_	I-Premise
279	:	_	_	I-Premise
280	8	_	_	I-Premise
281	eyes	_	_	I-Premise
282	(	_	_	I-Premise
283	15	_	_	I-Premise
284	%	_	_	I-Premise
285	)	_	_	I-Premise
286	in	_	_	I-Premise
287	the	_	_	I-Premise
288	laser	_	_	I-Premise
289	group	_	_	I-Premise
290	and	_	_	I-Premise
291	9	_	_	I-Premise
292	eyes	_	_	I-Premise
293	(	_	_	I-Premise
294	17	_	_	I-Premise
295	%	_	_	I-Premise
296	)	_	_	I-Premise
297	in	_	_	I-Premise
298	the	_	_	I-Premise
299	control	_	_	I-Premise
300	group	_	_	I-Premise
301	.	_	_	I-Premise

302	Survival	_	_	B-Claim
303	analyses	_	_	I-Claim
304	showed	_	_	I-Claim
305	no	_	_	I-Claim
306	evidence	_	_	I-Claim
307	of	_	_	I-Claim
308	any	_	_	I-Claim
309	difference	_	_	I-Claim
310	in	_	_	I-Claim
311	time	_	_	I-Claim
312	to	_	_	I-Claim
313	VF	_	_	I-Claim
314	progression	_	_	I-Claim
315	or	_	_	I-Claim
316	commencement	_	_	I-Claim
317	of	_	_	I-Claim
318	topical	_	_	I-Claim
319	therapy	_	_	I-Claim
320	between	_	_	I-Claim
321	the	_	_	I-Claim
322	2	_	_	I-Claim
323	groups	_	_	I-Claim
324	.	_	_	I-Claim

325	Cataract	_	_	B-Premise
326	extraction	_	_	I-Premise
327	was	_	_	I-Premise
328	performed	_	_	I-Premise
329	on	_	_	I-Premise
330	1	_	_	I-Premise
331	patient	_	_	I-Premise
332	in	_	_	I-Premise
333	the	_	_	I-Premise
334	laser	_	_	I-Premise
335	group	_	_	I-Premise
336	and	_	_	I-Premise
337	in	_	_	I-Premise
338	1	_	_	I-Premise
339	patient	_	_	I-Premise
340	in	_	_	I-Premise
341	the	_	_	I-Premise
342	control	_	_	I-Premise
343	group	_	_	I-Premise
344	during	_	_	I-Premise
345	the	_	_	I-Premise
346	study	_	_	I-Premise
347	period	_	_	I-Premise
348	(	_	_	I-Premise
349	laser	_	_	I-Premise
350	eye	_	_	I-Premise
351	at	_	_	I-Premise
352	18	_	_	I-Premise
353	months	_	_	I-Premise
354	;	_	_	I-Premise
355	control	_	_	I-Premise
356	eye	_	_	I-Premise
357	at	_	_	I-Premise
358	34	_	_	I-Premise
359	months	_	_	I-Premise
360	)	_	_	I-Premise
361	.	_	_	I-Premise

362	This	_	_	B-Claim
363	study	_	_	I-Claim
364	suggests	_	_	I-Claim
365	that	_	_	I-Claim
366	there	_	_	I-Claim
367	was	_	_	I-Claim
368	no	_	_	I-Claim
369	benefit	_	_	I-Claim
370	of	_	_	I-Claim
371	Nd	_	_	I-Claim
372	:	_	_	I-Claim
373	YAG	_	_	I-Claim
374	LPI	_	_	I-Claim
375	in	_	_	I-Claim
376	preventing	_	_	I-Claim
377	progression	_	_	I-Claim
378	from	_	_	I-Claim
379	PDS	_	_	I-Claim
380	with	_	_	I-Claim
381	OHT	_	_	I-Claim
382	to	_	_	I-Claim
383	PG	_	_	I-Claim
384	within	_	_	I-Claim
385	3	_	_	I-Claim
386	years	_	_	I-Claim
387	of	_	_	I-Claim
388	follow-up	_	_	I-Claim
389	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	scleral	_	_	O
6	flap	_	_	O
7	size	_	_	O
8	on	_	_	O
9	the	_	_	O
10	medium-term	_	_	O
11	intraocular	_	_	O
12	pressure	_	_	O
13	control	_	_	O
14	and	_	_	O
15	complication	_	_	O
16	rates	_	_	O
17	after	_	_	O
18	augmented	_	_	O
19	trabeculectomy	_	_	O
20	.	_	_	O

21	Prospective	_	_	O
22	randomized	_	_	O
23	clinical	_	_	O
24	trial	_	_	O
25	.	_	_	O

26	Glaucoma	_	_	O
27	patients	_	_	O
28	undergoing	_	_	O
29	primary	_	_	O
30	trabeculectomy	_	_	O
31	.	_	_	O

32	Exclusion	_	_	O
33	criteria	_	_	O
34	included	_	_	O
35	previous	_	_	O
36	ocular	_	_	O
37	surgery	_	_	O
38	apart	_	_	O
39	from	_	_	O
40	cataract	_	_	O
41	surgery	_	_	O
42	,	_	_	O
43	secondary	_	_	O
44	glaucoma	_	_	O
45	and	_	_	O
46	age	_	_	O
47	under	_	_	O
48	18	_	_	O
49	.	_	_	O

50	Patients	_	_	O
51	were	_	_	O
52	randomized	_	_	O
53	to	_	_	O
54	either	_	_	O
55	standard	_	_	O
56	trabeculectomy	_	_	O
57	(	_	_	O
58	4	_	_	O
59	×	_	_	O
60	4	_	_	O
61	mm	_	_	O
62	scleral	_	_	O
63	flap	_	_	O
64	)	_	_	O
65	or	_	_	O
66	microtrabeculectomy	_	_	O
67	(	_	_	O
68	2	_	_	O
69	×	_	_	O
70	2	_	_	O
71	mm	_	_	O
72	scleral	_	_	O
73	flap	_	_	O
74	)	_	_	O
75	,	_	_	O
76	both	_	_	O
77	with	_	_	O
78	adjustable	_	_	O
79	sutures	_	_	O
80	and	_	_	O
81	antimetabolites	_	_	O
82	.	_	_	O

83	Bleb	_	_	O
84	needling	_	_	O
85	was	_	_	O
86	performed	_	_	O
87	as	_	_	O
88	required	_	_	O
89	.	_	_	O

90	Patients	_	_	O
91	were	_	_	O
92	evaluated	_	_	O
93	at	_	_	O
94	day	_	_	O
95	1	_	_	O
96	,	_	_	O
97	weeks	_	_	O
98	1	_	_	O
99	,	_	_	O
100	3	_	_	O
101	,	_	_	O
102	6	_	_	O
103	and	_	_	O
104	months	_	_	O
105	3	_	_	O
106	,	_	_	O
107	6	_	_	O
108	,	_	_	O
109	12	_	_	O
110	,	_	_	O
111	18	_	_	O
112	and	_	_	O
113	24	_	_	O
114	postoperatively	_	_	O
115	.	_	_	O

116	Vision	_	_	O
117	,	_	_	O
118	intraocular	_	_	O
119	pressure	_	_	O
120	,	_	_	O
121	complications	_	_	O
122	and	_	_	O
123	failure	_	_	O
124	(	_	_	O
125	intraocular	_	_	O
126	pressure	_	_	O
127	≥	_	_	O
128	21	_	_	O
129	mmHg	_	_	O
130	or	_	_	O
131	not	_	_	O
132	reduced	_	_	O
133	by	_	_	O
134	≥20	_	_	O
135	%	_	_	O
136	from	_	_	O
137	baseline	_	_	O
138	,	_	_	O
139	intraocular	_	_	O
140	pressure	_	_	O
141	≤	_	_	O
142	5	_	_	O
143	mmHg	_	_	O
144	,	_	_	O
145	repeat	_	_	O
146	glaucoma	_	_	O
147	surgery	_	_	O
148	and	_	_	O
149	no	_	_	O
150	light	_	_	O
151	perception	_	_	O
152	vision	_	_	O
153	)	_	_	O
154	.	_	_	O

155	Forty-one	_	_	O
156	patients	_	_	O
157	were	_	_	O
158	recruited	_	_	O
159	;	_	_	O
160	20	_	_	O
161	had	_	_	O
162	standard	_	_	O
163	trabeculectomy	_	_	O
164	,	_	_	O
165	and	_	_	O
166	21	_	_	O
167	had	_	_	O
168	microtrabeculectomy	_	_	O
169	.	_	_	O

170	At	_	_	B-Premise
171	2	_	_	I-Premise
172	years	_	_	I-Premise
173	,	_	_	I-Premise
174	the	_	_	I-Premise
175	mean	_	_	I-Premise
176	intraocular	_	_	I-Premise
177	pressure	_	_	I-Premise
178	and	_	_	I-Premise
179	cumulative	_	_	I-Premise
180	probability	_	_	I-Premise
181	of	_	_	I-Premise
182	failure	_	_	I-Premise
183	was	_	_	I-Premise
184	12.4	_	_	I-Premise
185	±	_	_	I-Premise
186	4.6	_	_	I-Premise
187	mmHg	_	_	I-Premise
188	and	_	_	I-Premise
189	0.28	_	_	I-Premise
190	for	_	_	I-Premise
191	standard	_	_	I-Premise
192	trabeculectomy	_	_	I-Premise
193	,	_	_	I-Premise
194	and	_	_	I-Premise
195	11.5	_	_	I-Premise
196	±	_	_	I-Premise
197	3.6	_	_	I-Premise
198	mmHg	_	_	I-Premise
199	and	_	_	I-Premise
200	0.27	_	_	I-Premise
201	for	_	_	I-Premise
202	microtrabeculectomy	_	_	I-Premise
203	(	_	_	I-Premise
204	P	_	_	I-Premise
205	=	_	_	I-Premise
206	0.50	_	_	I-Premise
207	and	_	_	I-Premise
208	0.89	_	_	I-Premise
209	,	_	_	I-Premise
210	respectively	_	_	I-Premise
211	)	_	_	I-Premise
212	.	_	_	I-Premise

213	One	_	_	B-Premise
214	patient	_	_	I-Premise
215	in	_	_	I-Premise
216	each	_	_	I-Premise
217	group	_	_	I-Premise
218	required	_	_	I-Premise
219	Baerveldt	_	_	I-Premise
220	device	_	_	I-Premise
221	implantation	_	_	I-Premise
222	.	_	_	I-Premise

223	Vision	_	_	B-Premise
224	reduced	_	_	I-Premise
225	≥2	_	_	I-Premise
226	Snellen	_	_	I-Premise
227	lines	_	_	I-Premise
228	in	_	_	I-Premise
229	15	_	_	I-Premise
230	%	_	_	I-Premise
231	in	_	_	I-Premise
232	the	_	_	I-Premise
233	standard	_	_	I-Premise
234	trabeculectomy	_	_	I-Premise
235	group	_	_	I-Premise
236	and	_	_	I-Premise
237	25	_	_	I-Premise
238	%	_	_	I-Premise
239	in	_	_	I-Premise
240	the	_	_	I-Premise
241	microtrabeculectomy	_	_	I-Premise
242	group	_	_	I-Premise
243	,	_	_	I-Premise
244	mainly	_	_	I-Premise
245	from	_	_	I-Premise
246	cataract	_	_	I-Premise
247	(	_	_	I-Premise
248	P	_	_	I-Premise
249	=	_	_	I-Premise
250	0.48	_	_	I-Premise
251	)	_	_	I-Premise
252	.	_	_	I-Premise

253	Both	_	_	B-Claim
254	trabeculectomy	_	_	I-Claim
255	techniques	_	_	I-Claim
256	achieved	_	_	I-Claim
257	good	_	_	I-Claim
258	intraocular	_	_	I-Claim
259	pressure	_	_	I-Claim
260	reduction	_	_	I-Claim
261	and	_	_	I-Claim
262	had	_	_	I-Claim
263	similar	_	_	I-Claim
264	complication	_	_	I-Claim
265	rates	_	_	I-Claim
266	.	_	_	I-Claim

267	Scleral	_	_	B-Claim
268	flap	_	_	I-Claim
269	size	_	_	I-Claim
270	had	_	_	I-Claim
271	no	_	_	I-Claim
272	significant	_	_	I-Claim
273	effect	_	_	I-Claim
274	on	_	_	I-Claim
275	medium-term	_	_	I-Claim
276	intraocular	_	_	I-Claim
277	pressure	_	_	I-Claim
278	control	_	_	I-Claim
279	and	_	_	I-Claim
280	complication	_	_	I-Claim
281	profile	_	_	I-Claim
282	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	latanoprost	_	_	O
8	versus	_	_	O
9	timolol	_	_	O
10	in	_	_	O
11	pediatric	_	_	O
12	patients	_	_	O
13	with	_	_	O
14	glaucoma	_	_	O
15	.	_	_	O

16	Prospective	_	_	O
17	,	_	_	O
18	randomized	_	_	O
19	,	_	_	O
20	double-masked	_	_	O
21	,	_	_	O
22	12-week	_	_	O
23	,	_	_	O
24	multicenter	_	_	O
25	study	_	_	O
26	.	_	_	O

27	Individuals	_	_	O
28	aged	_	_	O
29	<	_	_	O
30	18	_	_	O
31	years	_	_	O
32	with	_	_	O
33	glaucoma	_	_	O
34	.	_	_	O

35	Stratified	_	_	O
36	by	_	_	O
37	age	_	_	O
38	,	_	_	O
39	diagnosis	_	_	O
40	,	_	_	O
41	and	_	_	O
42	intraocular	_	_	O
43	pressure	_	_	O
44	(	_	_	O
45	IOP	_	_	O
46	)	_	_	O
47	level	_	_	O
48	,	_	_	O
49	subjects	_	_	O
50	were	_	_	O
51	randomized	_	_	O
52	(	_	_	O
53	1:1	_	_	O
54	)	_	_	O
55	to	_	_	O
56	latanoprost	_	_	O
57	vehicle	_	_	O
58	at	_	_	O
59	8	_	_	O
60	am	_	_	O
61	and	_	_	O
62	latanoprost	_	_	O
63	0.005	_	_	O
64	%	_	_	O
65	at	_	_	O
66	8	_	_	O
67	pm	_	_	O
68	or	_	_	O
69	timolol	_	_	O
70	0.5	_	_	O
71	%	_	_	O
72	(	_	_	O
73	0.25	_	_	O
74	%	_	_	O
75	for	_	_	O
76	those	_	_	O
77	aged	_	_	O
78	<	_	_	O
79	3	_	_	O
80	years	_	_	O
81	)	_	_	O
82	twice	_	_	O
83	daily	_	_	O
84	(	_	_	O
85	8	_	_	O
86	am	_	_	O
87	,	_	_	O
88	8	_	_	O
89	pm	_	_	O
90	)	_	_	O
91	.	_	_	O

92	At	_	_	O
93	baseline	_	_	O
94	and	_	_	O
95	weeks	_	_	O
96	1	_	_	O
97	,	_	_	O
98	4	_	_	O
99	,	_	_	O
100	and	_	_	O
101	12	_	_	O
102	,	_	_	O
103	IOP	_	_	O
104	and	_	_	O
105	ocular	_	_	O
106	safety	_	_	O
107	were	_	_	O
108	assessed	_	_	O
109	and	_	_	O
110	adverse	_	_	O
111	events	_	_	O
112	were	_	_	O
113	recorded	_	_	O
114	.	_	_	O

115	Therapy	_	_	O
116	was	_	_	O
117	switched	_	_	O
118	to	_	_	O
119	open-label	_	_	O
120	latanoprost	_	_	O
121	pm	_	_	O
122	and	_	_	O
123	timolol	_	_	O
124	am	_	_	O
125	and	_	_	O
126	pm	_	_	O
127	for	_	_	O
128	uncontrolled	_	_	O
129	IOP	_	_	O
130	.	_	_	O

131	Mean	_	_	O
132	IOP	_	_	O
133	reduction	_	_	O
134	from	_	_	O
135	baseline	_	_	O
136	to	_	_	O
137	week	_	_	O
138	12	_	_	O
139	.	_	_	O

140	Latanoprost	_	_	O
141	was	_	_	O
142	considered	_	_	O
143	noninferior	_	_	O
144	to	_	_	O
145	timolol	_	_	O
146	if	_	_	O
147	the	_	_	O
148	lower	_	_	O
149	limit	_	_	O
150	of	_	_	O
151	the	_	_	O
152	95	_	_	O
153	%	_	_	O
154	confidence	_	_	O
155	interval	_	_	O
156	(	_	_	O
157	CI	_	_	O
158	)	_	_	O
159	of	_	_	O
160	the	_	_	O
161	difference	_	_	O
162	was	_	_	O
163	>	_	_	O
164	-3	_	_	O
165	mmHg	_	_	O
166	.	_	_	O

167	A	_	_	O
168	proportion	_	_	O
169	of	_	_	O
170	responders	_	_	O
171	(	_	_	O
172	subjects	_	_	O
173	with	_	_	O
174	15	_	_	O
175	%	_	_	O
176	IOP	_	_	O
177	reduction	_	_	O
178	at	_	_	O
179	weeks	_	_	O
180	4	_	_	O
181	and	_	_	O
182	12	_	_	O
183	)	_	_	O
184	were	_	_	O
185	evaluated	_	_	O
186	.	_	_	O

187	Analyses	_	_	O
188	were	_	_	O
189	performed	_	_	O
190	in	_	_	O
191	diagnosis	_	_	O
192	subgroups	_	_	O
193	:	_	_	O
194	primary	_	_	O
195	congenital	_	_	O
196	glaucoma	_	_	O
197	(	_	_	O
198	PCG	_	_	O
199	)	_	_	O
200	and	_	_	O
201	non-PCG	_	_	O
202	.	_	_	O

203	In	_	_	O
204	total	_	_	O
205	,	_	_	O
206	137	_	_	O
207	subjects	_	_	O
208	were	_	_	O
209	treated	_	_	O
210	(	_	_	O
211	safety	_	_	O
212	population	_	_	O
213	;	_	_	O
214	12-18	_	_	O
215	years	_	_	O
216	,	_	_	O
217	n=48	_	_	O
218	;	_	_	O
219	3-	_	_	O
220	<	_	_	O
221	12	_	_	O
222	years	_	_	O
223	,	_	_	O
224	n=55	_	_	O
225	;	_	_	O
226	0-	_	_	O
227	<	_	_	O
228	3	_	_	O
229	years	_	_	O
230	,	_	_	O
231	n=34	_	_	O
232	)	_	_	O
233	.	_	_	O

234	Mean	_	_	O
235	age	_	_	O
236	was	_	_	O
237	8.8±5.5	_	_	O
238	years	_	_	O
239	,	_	_	O
240	and	_	_	O
241	mean	_	_	O
242	baseline	_	_	O
243	IOP	_	_	O
244	was	_	_	O
245	27.7±6.17	_	_	O
246	mmHg	_	_	O
247	;	_	_	O
248	125	_	_	O
249	subjects	_	_	O
250	completed	_	_	O
251	the	_	_	O
252	study	_	_	O
253	,	_	_	O
254	and	_	_	O
255	107	_	_	O
256	subjects	_	_	O
257	were	_	_	O
258	in	_	_	O
259	the	_	_	O
260	per	_	_	O
261	protocol	_	_	O
262	population	_	_	O
263	.	_	_	O

264	Mean	_	_	B-Premise
265	IOP	_	_	I-Premise
266	reductions	_	_	I-Premise
267	for	_	_	I-Premise
268	latanoprost	_	_	I-Premise
269	and	_	_	I-Premise
270	timolol	_	_	I-Premise
271	at	_	_	I-Premise
272	week	_	_	I-Premise
273	12	_	_	I-Premise
274	were	_	_	I-Premise
275	7.2	_	_	I-Premise
276	and	_	_	I-Premise
277	5.7	_	_	I-Premise
278	mmHg	_	_	I-Premise
279	,	_	_	I-Premise
280	respectively	_	_	I-Premise
281	,	_	_	I-Premise
282	with	_	_	I-Premise
283	a	_	_	I-Premise
284	difference	_	_	I-Premise
285	of	_	_	I-Premise
286	1.5	_	_	I-Premise
287	mmHg	_	_	I-Premise
288	(	_	_	I-Premise
289	95	_	_	I-Premise
290	%	_	_	I-Premise
291	CI	_	_	I-Premise
292	,	_	_	I-Premise
293	-0.8	_	_	I-Premise
294	to	_	_	I-Premise
295	3.7	_	_	I-Premise
296	;	_	_	I-Premise
297	P=0.21	_	_	I-Premise
298	)	_	_	I-Premise
299	.	_	_	I-Premise

300	Responder	_	_	B-Premise
301	rates	_	_	I-Premise
302	were	_	_	I-Premise
303	60	_	_	I-Premise
304	%	_	_	I-Premise
305	for	_	_	I-Premise
306	latanoprost	_	_	I-Premise
307	and	_	_	I-Premise
308	52	_	_	I-Premise
309	%	_	_	I-Premise
310	for	_	_	I-Premise
311	timolol	_	_	I-Premise
312	(	_	_	I-Premise
313	P=0.33	_	_	I-Premise
314	)	_	_	I-Premise
315	.	_	_	I-Premise

316	Between-treatment	_	_	B-Premise
317	differences	_	_	I-Premise
318	in	_	_	I-Premise
319	mean	_	_	I-Premise
320	IOP	_	_	I-Premise
321	reduction	_	_	I-Premise
322	for	_	_	I-Premise
323	PCG	_	_	I-Premise
324	and	_	_	I-Premise
325	non-PCG	_	_	I-Premise
326	subgroups	_	_	I-Premise
327	were	_	_	I-Premise
328	0.6	_	_	I-Premise
329	mmHg	_	_	I-Premise
330	(	_	_	I-Premise
331	95	_	_	I-Premise
332	%	_	_	I-Premise
333	CI	_	_	I-Premise
334	,	_	_	I-Premise
335	-2.3	_	_	I-Premise
336	to	_	_	I-Premise
337	3.4	_	_	I-Premise
338	)	_	_	I-Premise
339	and	_	_	I-Premise
340	2.6	_	_	I-Premise
341	mmHg	_	_	I-Premise
342	(	_	_	I-Premise
343	95	_	_	I-Premise
344	%	_	_	I-Premise
345	CI	_	_	I-Premise
346	,	_	_	I-Premise
347	-0.8	_	_	I-Premise
348	to	_	_	I-Premise
349	6.1	_	_	I-Premise
350	)	_	_	I-Premise
351	,	_	_	I-Premise
352	respectively	_	_	I-Premise
353	.	_	_	I-Premise

354	Responder	_	_	B-Premise
355	rates	_	_	I-Premise
356	for	_	_	I-Premise
357	latanoprost	_	_	I-Premise
358	versus	_	_	I-Premise
359	timolol	_	_	I-Premise
360	were	_	_	I-Premise
361	50	_	_	I-Premise
362	%	_	_	I-Premise
363	versus	_	_	I-Premise
364	46	_	_	I-Premise
365	%	_	_	I-Premise
366	for	_	_	I-Premise
367	the	_	_	I-Premise
368	PCG	_	_	I-Premise
369	group	_	_	I-Premise
370	and	_	_	I-Premise
371	72	_	_	I-Premise
372	%	_	_	I-Premise
373	versus	_	_	I-Premise
374	57	_	_	I-Premise
375	%	_	_	I-Premise
376	for	_	_	I-Premise
377	the	_	_	I-Premise
378	non-PCG	_	_	I-Premise
379	group	_	_	I-Premise
380	.	_	_	I-Premise

381	Both	_	_	B-Claim
382	therapies	_	_	I-Claim
383	were	_	_	I-Claim
384	well	_	_	I-Claim
385	tolerated	_	_	I-Claim
386	.	_	_	I-Claim

387	Latanoprost	_	_	B-Claim
388	0.005	_	_	I-Claim
389	%	_	_	I-Claim
390	is	_	_	I-Claim
391	not	_	_	I-Claim
392	inferior	_	_	I-Claim
393	(	_	_	I-Claim
394	i.e.	_	_	I-Claim
395	,	_	_	I-Claim
396	is	_	_	I-Claim
397	either	_	_	I-Claim
398	more	_	_	I-Claim
399	or	_	_	I-Claim
400	similarly	_	_	I-Claim
401	effective	_	_	I-Claim
402	)	_	_	I-Claim
403	to	_	_	I-Claim
404	timolol	_	_	I-Claim
405	and	_	_	I-Claim
406	produces	_	_	I-Claim
407	clinically	_	_	I-Claim
408	relevant	_	_	I-Claim
409	IOP	_	_	I-Claim
410	reductions	_	_	I-Claim
411	across	_	_	I-Claim
412	pediatric	_	_	I-Claim
413	patients	_	_	I-Claim
414	with	_	_	I-Claim
415	and	_	_	I-Claim
416	without	_	_	I-Claim
417	PCG	_	_	I-Claim
418	.	_	_	I-Claim

419	Both	_	_	B-Claim
420	latanoprost	_	_	I-Claim
421	and	_	_	I-Claim
422	timolol	_	_	I-Claim
423	had	_	_	I-Claim
424	favorable	_	_	I-Claim
425	safety	_	_	I-Claim
426	profiles	_	_	I-Claim
427	over	_	_	I-Claim
428	the	_	_	I-Claim
429	duration	_	_	I-Claim
430	of	_	_	I-Claim
431	this	_	_	I-Claim
432	3-month	_	_	I-Claim
433	trial	_	_	I-Claim
434	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	is	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	safety	_	_	O
10	and	_	_	O
11	intraocular	_	_	O
12	pressure	_	_	O
13	(	_	_	O
14	IOP	_	_	O
15	)	_	_	O
16	-lowering	_	_	O
17	efficacy	_	_	O
18	of	_	_	O
19	travoprost/timolol	_	_	O
20	in	_	_	O
21	a	_	_	O
22	benzalkonium	_	_	O
23	chloride	_	_	O
24	(	_	_	O
25	BAK	_	_	O
26	)	_	_	O
27	-free	_	_	O
28	fixed	_	_	O
29	combination	_	_	O
30	preserved	_	_	O
31	with	_	_	O
32	polyquaternium-1	_	_	O
33	(	_	_	O
34	TRA/TIM	_	_	O
35	BAK-free	_	_	O
36	)	_	_	O
37	,	_	_	O
38	with	_	_	O
39	travoprost/timolol-fixed	_	_	O
40	combination	_	_	O
41	preserved	_	_	O
42	with	_	_	O
43	BAK	_	_	O
44	(	_	_	O
45	TRA/TIM	_	_	O
46	)	_	_	O
47	,	_	_	O
48	in	_	_	O
49	patients	_	_	O
50	with	_	_	O
51	open-angle	_	_	O
52	glaucoma	_	_	O
53	or	_	_	O
54	ocular	_	_	O
55	hypertension	_	_	O
56	.	_	_	O

57	In	_	_	O
58	this	_	_	O
59	prospective	_	_	O
60	randomized	_	_	O
61	controlled	_	_	O
62	trial	_	_	O
63	,	_	_	O
64	subjects	_	_	O
65	with	_	_	O
66	IOP	_	_	O
67	of	_	_	O
68	at	_	_	O
69	least	_	_	O
70	22	_	_	O
71	mm	_	_	O
72	Hg	_	_	O
73	in	_	_	O
74	one	_	_	O
75	or	_	_	O
76	both	_	_	O
77	eyes	_	_	O
78	at	_	_	O
79	0900	_	_	O
80	h	_	_	O
81	,	_	_	O
82	and	_	_	O
83	IOP	_	_	O
84	of	_	_	O
85	at	_	_	O
86	least	_	_	O
87	21	_	_	O
88	mm	_	_	O
89	Hg	_	_	O
90	in	_	_	O
91	one	_	_	O
92	or	_	_	O
93	both	_	_	O
94	eyes	_	_	O
95	at	_	_	O
96	1100	_	_	O
97	h	_	_	O
98	and	_	_	O
99	1600	_	_	O
100	h	_	_	O
101	at	_	_	O
102	two	_	_	O
103	eligibility	_	_	O
104	visits	_	_	O
105	were	_	_	O
106	randomly	_	_	O
107	assigned	_	_	O
108	to	_	_	O
109	receive	_	_	O
110	either	_	_	O
111	TRA/TIM	_	_	O
112	BAK-free	_	_	O
113	(	_	_	O
114	n=195	_	_	O
115	)	_	_	O
116	or	_	_	O
117	TRA/TIM	_	_	O
118	(	_	_	O
119	n=193	_	_	O
120	)	_	_	O
121	,	_	_	O
122	dosed	_	_	O
123	once	_	_	O
124	daily	_	_	O
125	in	_	_	O
126	the	_	_	O
127	morning	_	_	O
128	(	_	_	O
129	0900	_	_	O
130	h	_	_	O
131	)	_	_	O
132	for	_	_	O
133	6	_	_	O
134	weeks	_	_	O
135	.	_	_	O

136	IOP	_	_	O
137	was	_	_	O
138	assessed	_	_	O
139	at	_	_	O
140	0900	_	_	O
141	h	_	_	O
142	,	_	_	O
143	1100	_	_	O
144	h	_	_	O
145	,	_	_	O
146	and	_	_	O
147	1600	_	_	O
148	h	_	_	O
149	at	_	_	O
150	each	_	_	O
151	scheduled	_	_	O
152	visit	_	_	O
153	(	_	_	O
154	baseline	_	_	O
155	,	_	_	O
156	2	_	_	O
157	and	_	_	O
158	6	_	_	O
159	weeks	_	_	O
160	after	_	_	O
161	randomization	_	_	O
162	)	_	_	O
163	.	_	_	O

164	Mean	_	_	B-Premise
165	IOP	_	_	I-Premise
166	reduction	_	_	I-Premise
167	across	_	_	I-Premise
168	all	_	_	I-Premise
169	visits	_	_	I-Premise
170	and	_	_	I-Premise
171	time	_	_	I-Premise
172	points	_	_	I-Premise
173	was	_	_	I-Premise
174	8.0	_	_	I-Premise
175	mm	_	_	I-Premise
176	Hg	_	_	I-Premise
177	in	_	_	I-Premise
178	the	_	_	I-Premise
179	TRA/TIM	_	_	I-Premise
180	BAK-free	_	_	I-Premise
181	group	_	_	I-Premise
182	and	_	_	I-Premise
183	8.4	_	_	I-Premise
184	mm	_	_	I-Premise
185	Hg	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	TRA/TIM	_	_	I-Premise
189	group	_	_	I-Premise
190	(	_	_	I-Premise
191	P=0.0943	_	_	I-Premise
192	)	_	_	I-Premise
193	.	_	_	I-Premise

194	The	_	_	B-Premise
195	difference	_	_	I-Premise
196	in	_	_	I-Premise
197	mean	_	_	I-Premise
198	IOP	_	_	I-Premise
199	between	_	_	I-Premise
200	groups	_	_	I-Premise
201	ranged	_	_	I-Premise
202	from	_	_	I-Premise
203	0.2	_	_	I-Premise
204	to	_	_	I-Premise
205	0.7	_	_	I-Premise
206	mm	_	_	I-Premise
207	Hg	_	_	I-Premise
208	across	_	_	I-Premise
209	visits	_	_	I-Premise
210	and	_	_	I-Premise
211	time	_	_	I-Premise
212	points	_	_	I-Premise
213	,	_	_	I-Premise
214	with	_	_	I-Premise
215	a	_	_	I-Premise
216	mean	_	_	I-Premise
217	pooled	_	_	I-Premise
218	difference	_	_	I-Premise
219	of	_	_	I-Premise
220	0.4	_	_	I-Premise
221	mm	_	_	I-Premise
222	Hg	_	_	I-Premise
223	(	_	_	I-Premise
224	95	_	_	I-Premise
225	%	_	_	I-Premise
226	CI	_	_	I-Premise
227	:	_	_	I-Premise
228	-0.1	_	_	I-Premise
229	to	_	_	I-Premise
230	0.8	_	_	I-Premise
231	)	_	_	I-Premise
232	,	_	_	I-Premise
233	demonstrating	_	_	O
234	equivalence	_	_	O
235	of	_	_	O
236	the	_	_	O
237	two	_	_	O
238	formulations	_	_	O
239	.	_	_	O

240	The	_	_	B-Premise
241	most	_	_	I-Premise
242	common	_	_	I-Premise
243	drug-related	_	_	I-Premise
244	adverse	_	_	I-Premise
245	event	_	_	I-Premise
246	was	_	_	I-Premise
247	hyperemia	_	_	I-Premise
248	of	_	_	I-Premise
249	the	_	_	I-Premise
250	eye	_	_	I-Premise
251	(	_	_	I-Premise
252	ocular	_	_	I-Premise
253	hyperemia	_	_	I-Premise
254	and	_	_	I-Premise
255	conjunctival	_	_	I-Premise
256	hyperemia	_	_	I-Premise
257	combined	_	_	I-Premise
258	)	_	_	I-Premise
259	,	_	_	I-Premise
260	occurring	_	_	I-Premise
261	in	_	_	I-Premise
262	11.8	_	_	I-Premise
263	%	_	_	I-Premise
264	of	_	_	I-Premise
265	the	_	_	I-Premise
266	TRA/TIM	_	_	I-Premise
267	BAK-free	_	_	I-Premise
268	group	_	_	I-Premise
269	and	_	_	I-Premise
270	13.0	_	_	I-Premise
271	%	_	_	I-Premise
272	of	_	_	I-Premise
273	the	_	_	I-Premise
274	TRA/TIM	_	_	I-Premise
275	group	_	_	I-Premise
276	.	_	_	I-Premise

277	Travoprost/timolol	_	_	B-Claim
278	BAK-free	_	_	I-Claim
279	demonstrated	_	_	I-Claim
280	equivalence	_	_	I-Claim
281	to	_	_	I-Claim
282	travoprost/timolol	_	_	I-Claim
283	preserved	_	_	I-Claim
284	with	_	_	I-Claim
285	BAK	_	_	I-Claim
286	in	_	_	I-Claim
287	efficacy	_	_	I-Claim
288	.	_	_	I-Claim

289	No	_	_	B-Claim
290	clinically	_	_	I-Claim
291	relevant	_	_	I-Claim
292	differences	_	_	I-Claim
293	in	_	_	I-Claim
294	the	_	_	I-Claim
295	safety	_	_	I-Claim
296	profiles	_	_	I-Claim
297	of	_	_	I-Claim
298	travoprost/timolol	_	_	I-Claim
299	BAK-free	_	_	I-Claim
300	and	_	_	I-Claim
301	travoprost/timolol	_	_	I-Claim
302	preserved	_	_	I-Claim
303	with	_	_	I-Claim
304	BAK	_	_	I-Claim
305	were	_	_	I-Claim
306	identified	_	_	I-Claim
307	.	_	_	I-Claim


0	This	_	_	O
1	randomized	_	_	O
2	controlled	_	_	O
3	trial	_	_	O
4	assessed	_	_	O
5	the	_	_	O
6	effect	_	_	O
7	of	_	_	O
8	a	_	_	O
9	SMART	_	_	O
10	(	_	_	O
11	Stress	_	_	O
12	Management	_	_	O
13	and	_	_	O
14	Resiliency	_	_	O
15	Training	_	_	O
16	)	_	_	O
17	program	_	_	O
18	among	_	_	O
19	25	_	_	O
20	women	_	_	O
21	diagnosed	_	_	O
22	with	_	_	O
23	breast	_	_	O
24	cancer	_	_	O
25	.	_	_	O

26	Resilience	_	_	O
27	,	_	_	O
28	perceived	_	_	O
29	stress	_	_	O
30	,	_	_	O
31	anxiety	_	_	O
32	,	_	_	O
33	and	_	_	O
34	quality	_	_	O
35	of	_	_	O
36	life	_	_	O
37	improved	_	_	O
38	at	_	_	O
39	12	_	_	O
40	weeks	_	_	O
41	in	_	_	O
42	the	_	_	O
43	active	_	_	O
44	but	_	_	O
45	not	_	_	O
46	the	_	_	O
47	control	_	_	O
48	arm	_	_	O
49	.	_	_	O

50	A	_	_	O
51	brief	_	_	O
52	training	_	_	O
53	in	_	_	O
54	the	_	_	O
55	SMART	_	_	O
56	program	_	_	O
57	can	_	_	O
58	enhance	_	_	O
59	resilience	_	_	O
60	and	_	_	O
61	quality	_	_	O
62	of	_	_	O
63	life	_	_	O
64	and	_	_	O
65	decrease	_	_	O
66	stress	_	_	O
67	and	_	_	O
68	anxiety	_	_	O
69	.	_	_	O

70	Patients	_	_	O
71	with	_	_	O
72	breast	_	_	O
73	cancer	_	_	O
74	experience	_	_	O
75	stress	_	_	O
76	and	_	_	O
77	anxiety	_	_	O
78	related	_	_	O
79	to	_	_	O
80	their	_	_	O
81	diagnosis	_	_	O
82	,	_	_	O
83	with	_	_	O
84	resulting	_	_	O
85	lower	_	_	O
86	quality	_	_	O
87	of	_	_	O
88	life	_	_	O
89	.	_	_	O

90	The	_	_	O
91	purpose	_	_	O
92	of	_	_	O
93	this	_	_	O
94	study	_	_	O
95	was	_	_	O
96	to	_	_	O
97	assess	_	_	O
98	the	_	_	O
99	effect	_	_	O
100	of	_	_	O
101	a	_	_	O
102	SMART	_	_	O
103	(	_	_	O
104	Stress	_	_	O
105	Management	_	_	O
106	and	_	_	O
107	Resiliency	_	_	O
108	Training	_	_	O
109	)	_	_	O
110	program	_	_	O
111	for	_	_	O
112	increasing	_	_	O
113	resiliency	_	_	O
114	and	_	_	O
115	for	_	_	O
116	decreasing	_	_	O
117	stress	_	_	O
118	and	_	_	O
119	anxiety	_	_	O
120	among	_	_	O
121	mentors	_	_	O
122	who	_	_	O
123	themselves	_	_	O
124	were	_	_	O
125	previously	_	_	O
126	diagnosed	_	_	O
127	with	_	_	O
128	breast	_	_	O
129	cancer	_	_	O
130	.	_	_	O

131	The	_	_	O
132	program	_	_	O
133	consisted	_	_	O
134	of	_	_	O
135	two	_	_	O
136	90-minute	_	_	O
137	group	_	_	O
138	training	_	_	O
139	sessions	_	_	O
140	,	_	_	O
141	a	_	_	O
142	brief	_	_	O
143	individual	_	_	O
144	session	_	_	O
145	,	_	_	O
146	and	_	_	O
147	3	_	_	O
148	follow-up	_	_	O
149	telephone	_	_	O
150	calls	_	_	O
151	.	_	_	O

152	Twenty-four	_	_	O
153	mentors	_	_	O
154	at	_	_	O
155	Mayo	_	_	O
156	Clinic	_	_	O
157	in	_	_	O
158	Rochester	_	_	O
159	,	_	_	O
160	Minnesota	_	_	O
161	,	_	_	O
162	were	_	_	O
163	randomized	_	_	O
164	in	_	_	O
165	a	_	_	O
166	single-blind	_	_	O
167	,	_	_	O
168	wait-list	_	_	O
169	controlled	_	_	O
170	clinical	_	_	O
171	trial	_	_	O
172	to	_	_	O
173	either	_	_	O
174	the	_	_	O
175	SMART	_	_	O
176	intervention	_	_	O
177	or	_	_	O
178	a	_	_	O
179	control	_	_	O
180	group	_	_	O
181	for	_	_	O
182	12	_	_	O
183	weeks	_	_	O
184	.	_	_	O

185	Primary	_	_	O
186	outcome	_	_	O
187	measures	_	_	O
188	assessed	_	_	O
189	at	_	_	O
190	baseline	_	_	O
191	and	_	_	O
192	at	_	_	O
193	week	_	_	O
194	12	_	_	O
195	included	_	_	O
196	the	_	_	O
197	Connor	_	_	O
198	Davidson	_	_	O
199	Resilience	_	_	O
200	Scale	_	_	O
201	,	_	_	O
202	Perceived	_	_	O
203	Stress	_	_	O
204	Scale	_	_	O
205	,	_	_	O
206	Smith	_	_	O
207	Anxiety	_	_	O
208	Scale	_	_	O
209	,	_	_	O
210	and	_	_	O
211	Linear	_	_	O
212	Analog	_	_	O
213	Self	_	_	O
214	Assessment	_	_	O
215	Scale	_	_	O
216	.	_	_	O

217	Twenty	_	_	O
218	patients	_	_	O
219	completed	_	_	O
220	the	_	_	O
221	study	_	_	O
222	.	_	_	O

223	A	_	_	B-Premise
224	statistically	_	_	I-Premise
225	significant	_	_	I-Premise
226	improvement	_	_	I-Premise
227	in	_	_	I-Premise
228	resilience	_	_	I-Premise
229	,	_	_	I-Premise
230	perceived	_	_	I-Premise
231	stress	_	_	I-Premise
232	,	_	_	I-Premise
233	anxiety	_	_	I-Premise
234	,	_	_	I-Premise
235	and	_	_	I-Premise
236	overall	_	_	I-Premise
237	quality	_	_	I-Premise
238	of	_	_	I-Premise
239	life	_	_	I-Premise
240	at	_	_	I-Premise
241	12	_	_	I-Premise
242	weeks	_	_	I-Premise
243	,	_	_	I-Premise
244	compared	_	_	I-Premise
245	with	_	_	I-Premise
246	baseline	_	_	I-Premise
247	was	_	_	I-Premise
248	observed	_	_	I-Premise
249	in	_	_	I-Premise
250	the	_	_	I-Premise
251	study	_	_	I-Premise
252	arm	_	_	I-Premise
253	.	_	_	I-Premise

254	No	_	_	B-Premise
255	significant	_	_	I-Premise
256	difference	_	_	I-Premise
257	in	_	_	I-Premise
258	any	_	_	I-Premise
259	of	_	_	I-Premise
260	these	_	_	I-Premise
261	measures	_	_	I-Premise
262	was	_	_	I-Premise
263	noted	_	_	I-Premise
264	in	_	_	I-Premise
265	the	_	_	I-Premise
266	control	_	_	I-Premise
267	group	_	_	I-Premise
268	.	_	_	I-Premise

269	This	_	_	B-Claim
270	study	_	_	I-Claim
271	demonstrates	_	_	I-Claim
272	that	_	_	I-Claim
273	a	_	_	I-Claim
274	brief	_	_	I-Claim
275	,	_	_	I-Claim
276	predominantly	_	_	I-Claim
277	group-based	_	_	I-Claim
278	resilience	_	_	I-Claim
279	training	_	_	I-Claim
280	intervention	_	_	I-Claim
281	is	_	_	I-Claim
282	feasible	_	_	I-Claim
283	in	_	_	I-Claim
284	patients	_	_	I-Claim
285	with	_	_	I-Claim
286	previous	_	_	I-Claim
287	breast	_	_	I-Claim
288	cancer	_	_	I-Claim
289	;	_	_	I-Claim
290	also	_	_	I-Claim
291	,	_	_	I-Claim
292	it	_	_	I-Claim
293	may	_	_	I-Claim
294	be	_	_	I-Claim
295	efficacious	_	_	I-Claim
296	.	_	_	I-Claim


0	Molecular	_	_	O
1	markers	_	_	O
2	to	_	_	O
3	predict	_	_	O
4	response	_	_	O
5	to	_	_	O
6	5-fluorouracil	_	_	O
7	(	_	_	O
8	FU	_	_	O
9	)	_	_	O
10	-based	_	_	O
11	treatment	_	_	O
12	of	_	_	O
13	recurrent	_	_	O
14	or	_	_	O
15	metastasised	_	_	O
16	colorectal	_	_	O
17	cancer	_	_	O
18	(	_	_	O
19	mCRC	_	_	O
20	)	_	_	O
21	are	_	_	O
22	not	_	_	O
23	established	_	_	O
24	.	_	_	O

25	The	_	_	O
26	aim	_	_	O
27	of	_	_	O
28	this	_	_	O
29	trial	_	_	O
30	was	_	_	O
31	to	_	_	O
32	determine	_	_	O
33	the	_	_	O
34	value	_	_	O
35	of	_	_	O
36	thymidylate	_	_	O
37	synthase	_	_	O
38	(	_	_	O
39	TS	_	_	O
40	)	_	_	O
41	,	_	_	O
42	a	_	_	O
43	key	_	_	O
44	enzyme	_	_	O
45	of	_	_	O
46	DNA	_	_	O
47	synthesis	_	_	O
48	and	_	_	O
49	target	_	_	O
50	of	_	_	O
51	5-FU	_	_	O
52	,	_	_	O
53	to	_	_	O
54	predict	_	_	O
55	response	_	_	O
56	to	_	_	O
57	chemotherapy	_	_	O
58	of	_	_	O
59	mCRC	_	_	O
60	.	_	_	O

61	Tumour	_	_	O
62	tissue	_	_	O
63	was	_	_	O
64	obtained	_	_	O
65	from	_	_	O
66	168	_	_	O
67	patients	_	_	O
68	with	_	_	O
69	mCRC	_	_	O
70	for	_	_	O
71	relative	_	_	O
72	thymidylate	_	_	O
73	synthase	_	_	O
74	(	_	_	O
75	TS	_	_	O
76	)	_	_	O
77	mRNA	_	_	O
78	quantitation	_	_	O
79	.	_	_	O

80	Patients	_	_	O
81	were	_	_	O
82	randomised	_	_	O
83	to	_	_	O
84	receive	_	_	O
85	either	_	_	O
86	5-FU/folinic	_	_	O
87	acid	_	_	O
88	(	_	_	O
89	FA	_	_	O
90	,	_	_	O
91	FUFA	_	_	O
92	)	_	_	O
93	alone	_	_	O
94	or	_	_	O
95	in	_	_	O
96	combination	_	_	O
97	with	_	_	O
98	irinotecan	_	_	O
99	5-fluorouracil/folinic	_	_	O
100	acid	_	_	O
101	and	_	_	O
102	irinotecan	_	_	O
103	(	_	_	O
104	FOLFIRI	_	_	O
105	)	_	_	O
106	stratified	_	_	O
107	by	_	_	O
108	TS	_	_	O
109	(	_	_	O
110	low	_	_	O
111	versus	_	_	O
112	high	_	_	O
113	)	_	_	O
114	.	_	_	O

115	Primary	_	_	O
116	end-point	_	_	O
117	was	_	_	O
118	overall	_	_	O
119	response	_	_	O
120	to	_	_	O
121	first-line	_	_	O
122	treatment	_	_	O
123	among	_	_	O
124	TS	_	_	O
125	high	_	_	O
126	patients	_	_	O
127	.	_	_	O

128	All	_	_	O
129	parties	_	_	O
130	,	_	_	O
131	except	_	_	O
132	for	_	_	O
133	the	_	_	O
134	randomisation	_	_	O
135	centre	_	_	O
136	,	_	_	O
137	were	_	_	O
138	blinded	_	_	O
139	for	_	_	O
140	TS	_	_	O
141	status	_	_	O
142	.	_	_	O

143	Biopsies	_	_	O
144	(	_	_	O
145	n=168	_	_	O
146	)	_	_	O
147	were	_	_	O
148	taken	_	_	O
149	without	_	_	O
150	complications	_	_	O
151	.	_	_	O

152	TS	_	_	O
153	levels	_	_	O
154	were	_	_	O
155	available	_	_	O
156	for	_	_	O
157	147	_	_	O
158	patients	_	_	O
159	(	_	_	O
160	87.5	_	_	O
161	%	_	_	O
162	)	_	_	O
163	.	_	_	O

164	Analysing	_	_	B-Premise
165	response	_	_	I-Premise
166	to	_	_	I-Premise
167	FUFA	_	_	I-Premise
168	and	_	_	I-Premise
169	FOLFIRI	_	_	I-Premise
170	in	_	_	I-Premise
171	the	_	_	I-Premise
172	per	_	_	I-Premise
173	protocol	_	_	I-Premise
174	set	_	_	I-Premise
175	(	_	_	I-Premise
176	n=119	_	_	I-Premise
177	)	_	_	I-Premise
178	after	_	_	I-Premise
179	un-blinding	_	_	I-Premise
180	TS	_	_	I-Premise
181	in	_	_	I-Premise
182	the	_	_	I-Premise
183	data	_	_	I-Premise
184	base	_	_	I-Premise
185	revealed	_	_	I-Premise
186	a	_	_	I-Premise
187	trend	_	_	I-Premise
188	to	_	_	I-Premise
189	better	_	_	I-Premise
190	overall	_	_	I-Premise
191	response	_	_	I-Premise
192	to	_	_	I-Premise
193	FOLFIRI	_	_	I-Premise
194	(	_	_	I-Premise
195	9/19	_	_	I-Premise
196	,	_	_	I-Premise
197	47	_	_	I-Premise
198	%	_	_	I-Premise
199	)	_	_	I-Premise
200	in	_	_	I-Premise
201	TS	_	_	I-Premise
202	high	_	_	I-Premise
203	compared	_	_	I-Premise
204	to	_	_	I-Premise
205	FUFA	_	_	I-Premise
206	(	_	_	I-Premise
207	5/23	_	_	I-Premise
208	,	_	_	I-Premise
209	22	_	_	I-Premise
210	%	_	_	I-Premise
211	,	_	_	I-Premise
212	p=0.077	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	In	_	_	B-Premise
216	patients	_	_	I-Premise
217	with	_	_	I-Premise
218	biopsies	_	_	I-Premise
219	taken	_	_	I-Premise
220	from	_	_	I-Premise
221	liver	_	_	I-Premise
222	lesions	_	_	I-Premise
223	(	_	_	I-Premise
224	n=91	_	_	I-Premise
225	)	_	_	I-Premise
226	overall	_	_	I-Premise
227	response	_	_	I-Premise
228	to	_	_	I-Premise
229	FOLFIRI	_	_	I-Premise
230	and	_	_	I-Premise
231	FUFA	_	_	I-Premise
232	in	_	_	I-Premise
233	TS	_	_	I-Premise
234	high	_	_	I-Premise
235	was	_	_	I-Premise
236	53	_	_	I-Premise
237	%	_	_	I-Premise
238	(	_	_	I-Premise
239	9/17	_	_	I-Premise
240	)	_	_	I-Premise
241	and	_	_	I-Premise
242	18	_	_	I-Premise
243	%	_	_	I-Premise
244	(	_	_	I-Premise
245	3/17	_	_	I-Premise
246	)	_	_	I-Premise
247	,	_	_	I-Premise
248	respectively	_	_	I-Premise
249	(	_	_	I-Premise
250	p=0.035	_	_	I-Premise
251	)	_	_	I-Premise
252	.	_	_	I-Premise

253	In	_	_	B-Premise
254	patients	_	_	I-Premise
255	with	_	_	I-Premise
256	low	_	_	I-Premise
257	TS	_	_	I-Premise
258	,	_	_	I-Premise
259	no	_	_	I-Premise
260	remarkable	_	_	I-Premise
261	difference	_	_	I-Premise
262	in	_	_	I-Premise
263	overall	_	_	I-Premise
264	response	_	_	I-Premise
265	to	_	_	I-Premise
266	FOLFIRI	_	_	I-Premise
267	and	_	_	I-Premise
268	FUFA	_	_	I-Premise
269	was	_	_	I-Premise
270	observed	_	_	I-Premise
271	.	_	_	I-Premise

272	Taking	_	_	B-Claim
273	a	_	_	I-Claim
274	pre-treatment	_	_	I-Claim
275	biopsy	_	_	I-Claim
276	is	_	_	I-Claim
277	a	_	_	I-Claim
278	safe	_	_	I-Claim
279	and	_	_	I-Claim
280	feasible	_	_	I-Claim
281	procedure	_	_	I-Claim
282	in	_	_	I-Claim
283	mCRC	_	_	I-Claim
284	.	_	_	I-Claim

285	After	_	_	B-Claim
286	validation	_	_	I-Claim
287	of	_	_	I-Claim
288	our	_	_	I-Claim
289	data	_	_	I-Claim
290	in	_	_	I-Claim
291	a	_	_	I-Claim
292	larger	_	_	I-Claim
293	group	_	_	I-Claim
294	TS	_	_	I-Claim
295	determination	_	_	I-Claim
296	may	_	_	I-Claim
297	have	_	_	I-Claim
298	the	_	_	I-Claim
299	potential	_	_	I-Claim
300	to	_	_	I-Claim
301	better	_	_	I-Claim
302	help	_	_	I-Claim
303	direct	_	_	I-Claim
304	systemic	_	_	I-Claim
305	treatment	_	_	I-Claim
306	in	_	_	I-Claim
307	patients	_	_	I-Claim
308	with	_	_	I-Claim
309	primarily	_	_	I-Claim
310	non-resectable	_	_	I-Claim
311	mCRC	_	_	I-Claim
312	.	_	_	I-Claim


0	The	_	_	O
1	primary	_	_	O
2	objective	_	_	O
3	of	_	_	O
4	this	_	_	O
5	study	_	_	O
6	was	_	_	O
7	to	_	_	O
8	compare	_	_	O
9	the	_	_	O
10	response	_	_	O
11	rates	_	_	O
12	of	_	_	O
13	elderly	_	_	O
14	,	_	_	O
15	chemonaive	_	_	O
16	patients	_	_	O
17	with	_	_	O
18	advanced	_	_	O
19	non-small	_	_	O
20	cell	_	_	O
21	lung	_	_	O
22	cancer	_	_	O
23	(	_	_	O
24	NSCLC	_	_	O
25	)	_	_	O
26	treated	_	_	O
27	with	_	_	O
28	daily	_	_	O
29	oral	_	_	O
30	erlotinib	_	_	O
31	versus	_	_	O
32	oral	_	_	O
33	vinorelbine	_	_	O
34	.	_	_	O

35	Chemonaive	_	_	O
36	Taiwanese	_	_	O
37	patients	_	_	O
38	aged	_	_	O
39	70	_	_	O
40	years	_	_	O
41	or	_	_	O
42	older	_	_	O
43	who	_	_	O
44	had	_	_	O
45	advanced	_	_	O
46	NSCLC	_	_	O
47	were	_	_	O
48	randomized	_	_	O
49	to	_	_	O
50	receive	_	_	O
51	either	_	_	O
52	oral	_	_	O
53	erlotinib	_	_	O
54	150	_	_	O
55	mg	_	_	O
56	(	_	_	O
57	E	_	_	O
58	)	_	_	O
59	daily	_	_	O
60	or	_	_	O
61	oral	_	_	O
62	vinorelbine	_	_	O
63	60	_	_	O
64	mg/m	_	_	O
65	(	_	_	O
66	V	_	_	O
67	)	_	_	O
68	on	_	_	O
69	days	_	_	O
70	1	_	_	O
71	and	_	_	O
72	8	_	_	O
73	every	_	_	O
74	3	_	_	O
75	weeks	_	_	O
76	.	_	_	O

77	From	_	_	O
78	February	_	_	O
79	2007	_	_	O
80	to	_	_	O
81	July	_	_	O
82	2008	_	_	O
83	,	_	_	O
84	116	_	_	O
85	patients	_	_	O
86	were	_	_	O
87	enrolled	_	_	O
88	and	_	_	O
89	113	_	_	O
90	were	_	_	O
91	included	_	_	O
92	in	_	_	O
93	the	_	_	O
94	intent-to-treat	_	_	O
95	population	_	_	O
96	:	_	_	O
97	57	_	_	O
98	patients	_	_	O
99	in	_	_	O
100	the	_	_	O
101	E	_	_	O
102	group	_	_	O
103	and	_	_	O
104	56	_	_	O
105	patients	_	_	O
106	in	_	_	O
107	the	_	_	O
108	V	_	_	O
109	group	_	_	O
110	.	_	_	O

111	Objective	_	_	B-Premise
112	response	_	_	I-Premise
113	rates	_	_	I-Premise
114	were	_	_	I-Premise
115	22.8	_	_	I-Premise
116	%	_	_	I-Premise
117	(	_	_	I-Premise
118	13	_	_	I-Premise
119	of	_	_	I-Premise
120	57	_	_	I-Premise
121	)	_	_	I-Premise
122	in	_	_	I-Premise
123	E	_	_	I-Premise
124	and	_	_	I-Premise
125	8.9	_	_	I-Premise
126	%	_	_	I-Premise
127	(	_	_	I-Premise
128	5	_	_	I-Premise
129	of	_	_	I-Premise
130	56	_	_	I-Premise
131	)	_	_	I-Premise
132	in	_	_	I-Premise
133	V	_	_	I-Premise
134	(	_	_	I-Premise
135	p	_	_	I-Premise
136	=	_	_	I-Premise
137	0.0388	_	_	I-Premise
138	)	_	_	I-Premise
139	.	_	_	I-Premise

140	Median	_	_	B-Premise
141	progression-free	_	_	I-Premise
142	survival	_	_	I-Premise
143	(	_	_	I-Premise
144	PFS	_	_	I-Premise
145	)	_	_	I-Premise
146	was	_	_	I-Premise
147	4.57	_	_	I-Premise
148	months	_	_	I-Premise
149	in	_	_	I-Premise
150	E	_	_	I-Premise
151	and	_	_	I-Premise
152	2.53	_	_	I-Premise
153	months	_	_	I-Premise
154	in	_	_	I-Premise
155	V	_	_	I-Premise
156	(	_	_	I-Premise
157	p	_	_	I-Premise
158	=	_	_	I-Premise
159	0.0287	_	_	I-Premise
160	)	_	_	I-Premise
161	,	_	_	I-Premise
162	with	_	_	I-Premise
163	an	_	_	I-Premise
164	80.6	_	_	I-Premise
165	%	_	_	I-Premise
166	increase	_	_	I-Premise
167	in	_	_	I-Premise
168	median	_	_	I-Premise
169	PFS	_	_	I-Premise
170	for	_	_	I-Premise
171	E	_	_	I-Premise
172	compared	_	_	I-Premise
173	with	_	_	I-Premise
174	V.	_	_	I-Premise
175	Median	_	_	B-Premise
176	survival	_	_	I-Premise
177	time	_	_	I-Premise
178	was	_	_	I-Premise
179	11.67	_	_	I-Premise
180	months	_	_	I-Premise
181	in	_	_	I-Premise
182	E	_	_	I-Premise
183	and	_	_	I-Premise
184	9.3	_	_	I-Premise
185	months	_	_	I-Premise
186	in	_	_	I-Premise
187	V	_	_	I-Premise
188	(	_	_	I-Premise
189	p	_	_	I-Premise
190	=	_	_	I-Premise
191	0.6975	_	_	I-Premise
192	)	_	_	I-Premise
193	.	_	_	I-Premise

194	Toxicities	_	_	B-Premise
195	were	_	_	I-Premise
196	generally	_	_	I-Premise
197	mild	_	_	I-Premise
198	in	_	_	I-Premise
199	both	_	_	I-Premise
200	groups	_	_	I-Premise
201	.	_	_	I-Premise

202	Median	_	_	B-Premise
203	PFS	_	_	I-Premise
204	was	_	_	I-Premise
205	longest	_	_	I-Premise
206	for	_	_	I-Premise
207	epidermal	_	_	I-Premise
208	growth	_	_	I-Premise
209	factor	_	_	I-Premise
210	receptor	_	_	I-Premise
211	gene	_	_	I-Premise
212	(	_	_	I-Premise
213	EGFR	_	_	I-Premise
214	)	_	_	I-Premise
215	-mutated	_	_	I-Premise
216	patients	_	_	I-Premise
217	in	_	_	I-Premise
218	the	_	_	I-Premise
219	E	_	_	I-Premise
220	group	_	_	I-Premise
221	,	_	_	I-Premise
222	followed	_	_	I-Premise
223	by	_	_	I-Premise
224	EGFR-mutated	_	_	I-Premise
225	patients	_	_	I-Premise
226	in	_	_	I-Premise
227	V	_	_	I-Premise
228	,	_	_	I-Premise
229	EGFR	_	_	I-Premise
230	wild	_	_	I-Premise
231	type	_	_	I-Premise
232	in	_	_	I-Premise
233	E	_	_	I-Premise
234	,	_	_	I-Premise
235	and	_	_	I-Premise
236	EGFR	_	_	I-Premise
237	wild	_	_	I-Premise
238	type	_	_	I-Premise
239	in	_	_	I-Premise
240	V	_	_	I-Premise
241	(	_	_	I-Premise
242	p	_	_	I-Premise
243	=	_	_	I-Premise
244	0.0034	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	Overall	_	_	B-Premise
248	survival	_	_	I-Premise
249	was	_	_	I-Premise
250	longer	_	_	I-Premise
251	for	_	_	I-Premise
252	EGFR-mutated	_	_	I-Premise
253	patients	_	_	I-Premise
254	than	_	_	I-Premise
255	for	_	_	I-Premise
256	EGFR	_	_	I-Premise
257	wild-type	_	_	I-Premise
258	patients	_	_	I-Premise
259	(	_	_	I-Premise
260	p	_	_	I-Premise
261	<	_	_	I-Premise
262	0.0001	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	Erlotinib	_	_	B-Claim
266	is	_	_	I-Claim
267	highly	_	_	I-Claim
268	effective	_	_	I-Claim
269	compared	_	_	I-Claim
270	with	_	_	I-Claim
271	oral	_	_	I-Claim
272	vinorelbine	_	_	I-Claim
273	in	_	_	I-Claim
274	elderly	_	_	I-Claim
275	,	_	_	I-Claim
276	chemonaive	_	_	I-Claim
277	,	_	_	I-Claim
278	Taiwanese	_	_	I-Claim
279	patients	_	_	I-Claim
280	with	_	_	I-Claim
281	NSCLC	_	_	I-Claim
282	.	_	_	I-Claim

283	EGFR-mutated	_	_	B-Claim
284	patients	_	_	I-Claim
285	had	_	_	I-Claim
286	better	_	_	I-Claim
287	survival	_	_	I-Claim
288	than	_	_	I-Claim
289	those	_	_	I-Claim
290	with	_	_	I-Claim
291	EGFR	_	_	I-Claim
292	wild-type	_	_	I-Claim
293	disease	_	_	I-Claim
294	,	_	_	I-Claim
295	regardless	_	_	I-Claim
296	of	_	_	I-Claim
297	the	_	_	I-Claim
298	treatment	_	_	I-Claim
299	received	_	_	I-Claim
300	.	_	_	I-Claim


0	Few	_	_	O
1	intervention	_	_	O
2	programs	_	_	O
3	assist	_	_	O
4	patients	_	_	O
5	and	_	_	O
6	their	_	_	O
7	family	_	_	O
8	caregivers	_	_	O
9	to	_	_	O
10	manage	_	_	O
11	advanced	_	_	O
12	cancer	_	_	O
13	and	_	_	O
14	maintain	_	_	O
15	their	_	_	O
16	quality	_	_	O
17	of	_	_	O
18	life	_	_	O
19	(	_	_	O
20	QOL	_	_	O
21	)	_	_	O
22	.	_	_	O

23	This	_	_	O
24	study	_	_	O
25	examined	_	_	O
26	(	_	_	O
27	i	_	_	O
28	)	_	_	O
29	whether	_	_	O
30	patient-caregiver	_	_	O
31	dyads	_	_	O
32	(	_	_	O
33	i.e.	_	_	O
34	,	_	_	O
35	pairs	_	_	O
36	)	_	_	O
37	randomly	_	_	O
38	assigned	_	_	O
39	to	_	_	O
40	a	_	_	O
41	brief	_	_	O
42	or	_	_	O
43	extensive	_	_	O
44	dyadic	_	_	O
45	intervention	_	_	O
46	(	_	_	O
47	the	_	_	O
48	FOCUS	_	_	O
49	Program	_	_	O
50	)	_	_	O
51	had	_	_	O
52	better	_	_	O
53	outcomes	_	_	O
54	than	_	_	O
55	dyads	_	_	O
56	randomly	_	_	O
57	assigned	_	_	O
58	to	_	_	O
59	usual	_	_	O
60	care	_	_	O
61	and	_	_	O
62	(	_	_	O
63	ii	_	_	O
64	)	_	_	O
65	whether	_	_	O
66	patients	_	_	O
67	'	_	_	O
68	risk	_	_	O
69	for	_	_	O
70	distress	_	_	O
71	and	_	_	O
72	other	_	_	O
73	factors	_	_	O
74	moderated	_	_	O
75	the	_	_	O
76	effect	_	_	O
77	of	_	_	O
78	the	_	_	O
79	brief	_	_	O
80	or	_	_	O
81	extensive	_	_	O
82	program	_	_	O
83	on	_	_	O
84	outcomes	_	_	O
85	.	_	_	O

86	Advanced	_	_	O
87	cancer	_	_	O
88	patients	_	_	O
89	and	_	_	O
90	their	_	_	O
91	caregivers	_	_	O
92	(	_	_	O
93	N	_	_	O
94	=	_	_	O
95	484	_	_	O
96	dyads	_	_	O
97	)	_	_	O
98	were	_	_	O
99	stratified	_	_	O
100	by	_	_	O
101	patients	_	_	O
102	'	_	_	O
103	baseline	_	_	O
104	risk	_	_	O
105	for	_	_	O
106	distress	_	_	O
107	(	_	_	O
108	high	_	_	O
109	versus	_	_	O
110	low	_	_	O
111	)	_	_	O
112	,	_	_	O
113	cancer	_	_	O
114	type	_	_	O
115	(	_	_	O
116	lung	_	_	O
117	,	_	_	O
118	colorectal	_	_	O
119	,	_	_	O
120	breast	_	_	O
121	,	_	_	O
122	or	_	_	O
123	prostate	_	_	O
124	)	_	_	O
125	,	_	_	O
126	and	_	_	O
127	research	_	_	O
128	site	_	_	O
129	and	_	_	O
130	then	_	_	O
131	randomly	_	_	O
132	assigned	_	_	O
133	to	_	_	O
134	a	_	_	O
135	brief	_	_	O
136	(	_	_	O
137	three-session	_	_	O
138	)	_	_	O
139	or	_	_	O
140	extensive	_	_	O
141	(	_	_	O
142	six-session	_	_	O
143	)	_	_	O
144	intervention	_	_	O
145	or	_	_	O
146	control	_	_	O
147	.	_	_	O

148	The	_	_	O
149	interventions	_	_	O
150	offered	_	_	O
151	dyads	_	_	O
152	information	_	_	O
153	and	_	_	O
154	support	_	_	O
155	.	_	_	O

156	Intermediary	_	_	O
157	outcomes	_	_	O
158	were	_	_	O
159	appraisals	_	_	O
160	(	_	_	O
161	i.e.	_	_	O
162	,	_	_	O
163	appraisal	_	_	O
164	of	_	_	O
165	illness/caregiving	_	_	O
166	,	_	_	O
167	uncertainty	_	_	O
168	,	_	_	O
169	and	_	_	O
170	hopelessness	_	_	O
171	)	_	_	O
172	and	_	_	O
173	resources	_	_	O
174	(	_	_	O
175	i.e.	_	_	O
176	,	_	_	O
177	coping	_	_	O
178	,	_	_	O
179	interpersonal	_	_	O
180	relationships	_	_	O
181	,	_	_	O
182	and	_	_	O
183	self-efficacy	_	_	O
184	)	_	_	O
185	.	_	_	O

186	The	_	_	O
187	primary	_	_	O
188	outcome	_	_	O
189	was	_	_	O
190	QOL	_	_	O
191	.	_	_	O

192	Data	_	_	O
193	were	_	_	O
194	collected	_	_	O
195	prior	_	_	O
196	to	_	_	O
197	intervention	_	_	O
198	and	_	_	O
199	post-intervention	_	_	O
200	(	_	_	O
201	3	_	_	O
202	and	_	_	O
203	6	_	_	O
204	months	_	_	O
205	from	_	_	O
206	baseline	_	_	O
207	)	_	_	O
208	.	_	_	O

209	The	_	_	O
210	final	_	_	O
211	sample	_	_	O
212	was	_	_	O
213	302	_	_	O
214	dyads	_	_	O
215	.	_	_	O

216	Repeated	_	_	O
217	measures	_	_	O
218	MANCOVA	_	_	O
219	was	_	_	O
220	used	_	_	O
221	to	_	_	O
222	evaluate	_	_	O
223	outcomes	_	_	O
224	.	_	_	O

225	Significant	_	_	B-Premise
226	group	_	_	I-Premise
227	by	_	_	I-Premise
228	time	_	_	I-Premise
229	interactions	_	_	I-Premise
230	showed	_	_	I-Premise
231	that	_	_	I-Premise
232	there	_	_	I-Premise
233	was	_	_	I-Premise
234	an	_	_	I-Premise
235	improvement	_	_	I-Premise
236	in	_	_	I-Premise
237	dyads	_	_	I-Premise
238	'	_	_	I-Premise
239	coping	_	_	I-Premise
240	(	_	_	I-Premise
241	p	_	_	I-Premise
242	<	_	_	I-Premise
243	0.05	_	_	I-Premise
244	)	_	_	I-Premise
245	,	_	_	I-Premise
246	self-efficacy	_	_	I-Premise
247	(	_	_	I-Premise
248	p	_	_	I-Premise
249	<	_	_	I-Premise
250	0.05	_	_	I-Premise
251	)	_	_	I-Premise
252	,	_	_	I-Premise
253	and	_	_	I-Premise
254	social	_	_	I-Premise
255	QOL	_	_	I-Premise
256	(	_	_	I-Premise
257	p	_	_	I-Premise
258	<	_	_	I-Premise
259	0.01	_	_	I-Premise
260	)	_	_	I-Premise
261	and	_	_	I-Premise
262	in	_	_	I-Premise
263	caregivers	_	_	I-Premise
264	'	_	_	I-Premise
265	emotional	_	_	I-Premise
266	QOL	_	_	I-Premise
267	(	_	_	I-Premise
268	p	_	_	I-Premise
269	<	_	_	I-Premise
270	0.05	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	Effects	_	_	O
274	varied	_	_	O
275	by	_	_	O
276	intervention	_	_	O
277	dose	_	_	O
278	.	_	_	O

279	Most	_	_	O
280	effects	_	_	O
281	were	_	_	O
282	found	_	_	O
283	at	_	_	O
284	3	_	_	O
285	months	_	_	O
286	only	_	_	O
287	.	_	_	O

288	Risk	_	_	B-Premise
289	for	_	_	I-Premise
290	distress	_	_	I-Premise
291	accounted	_	_	I-Premise
292	for	_	_	I-Premise
293	very	_	_	I-Premise
294	few	_	_	I-Premise
295	moderation	_	_	I-Premise
296	effects	_	_	I-Premise
297	.	_	_	I-Premise

298	Both	_	_	B-Premise
299	brief	_	_	I-Premise
300	and	_	_	I-Premise
301	extensive	_	_	I-Premise
302	programs	_	_	I-Premise
303	had	_	_	I-Premise
304	positive	_	_	I-Premise
305	outcomes	_	_	I-Premise
306	for	_	_	I-Premise
307	patient-caregiver	_	_	I-Premise
308	dyads	_	_	I-Premise
309	,	_	_	I-Premise
310	but	_	_	B-Premise
311	few	_	_	I-Premise
312	sustained	_	_	I-Premise
313	effects	_	_	I-Premise
314	.	_	_	I-Premise

315	Patient-caregiver	_	_	B-Claim
316	dyads	_	_	I-Claim
317	benefit	_	_	I-Claim
318	when	_	_	I-Claim
319	viewed	_	_	I-Claim
320	as	_	_	I-Claim
321	the	_	_	I-Claim
322	'unit	_	_	I-Claim
323	of	_	_	I-Claim
324	care	_	_	I-Claim
325	'	_	_	I-Claim
326	.	_	_	I-Claim


0	The	_	_	O
1	phase	_	_	O
2	3	_	_	O
3	VISTA	_	_	O
4	study	_	_	O
5	in	_	_	O
6	transplant-ineligible	_	_	O
7	myeloma	_	_	O
8	patients	_	_	O
9	demonstrated	_	_	O
10	superior	_	_	O
11	efficacy	_	_	O
12	with	_	_	O
13	bortezomib-melphalan-prednisone	_	_	O
14	(	_	_	O
15	VMP	_	_	O
16	;	_	_	O
17	nine	_	_	O
18	6-wk	_	_	O
19	cycles	_	_	O
20	)	_	_	O
21	vs.	_	_	O
22	melphalan-prednisone	_	_	O
23	(	_	_	O
24	MP	_	_	O
25	)	_	_	O
26	but	_	_	O
27	also	_	_	O
28	increased	_	_	O
29	toxicity	_	_	O
30	.	_	_	O

31	Health-related	_	_	O
32	quality	_	_	O
33	of	_	_	O
34	life	_	_	O
35	(	_	_	O
36	HRQoL	_	_	O
37	;	_	_	O
38	exploratory	_	_	O
39	endpoint	_	_	O
40	)	_	_	O
41	was	_	_	O
42	evaluated	_	_	O
43	using	_	_	O
44	the	_	_	O
45	European	_	_	O
46	Organization	_	_	O
47	for	_	_	O
48	Research	_	_	O
49	and	_	_	O
50	Treatment	_	_	O
51	of	_	_	O
52	Cancer	_	_	O
53	(	_	_	O
54	EORTC	_	_	O
55	)	_	_	O
56	Quality	_	_	O
57	of	_	_	O
58	Life	_	_	O
59	Questionnaire	_	_	O
60	(	_	_	O
61	QLQ-C30	_	_	O
62	)	_	_	O
63	.	_	_	O

64	The	_	_	O
65	phase	_	_	O
66	3	_	_	O
67	VISTA	_	_	O
68	study	_	_	O
69	in	_	_	O
70	transplant-ineligible	_	_	O
71	myeloma	_	_	O
72	patients	_	_	O
73	demonstrated	_	_	O
74	superior	_	_	O
75	efficacy	_	_	O
76	with	_	_	O
77	bortezomib-melphalan-prednisone	_	_	O
78	(	_	_	O
79	VMP	_	_	O
80	;	_	_	O
81	nine	_	_	O
82	6-wk	_	_	O
83	cycles	_	_	O
84	)	_	_	O
85	vs.	_	_	O
86	melphalan-prednisone	_	_	O
87	(	_	_	O
88	MP	_	_	O
89	)	_	_	O
90	but	_	_	O
91	also	_	_	O
92	increased	_	_	O
93	toxicity	_	_	O
94	.	_	_	O

95	Health-related	_	_	O
96	quality	_	_	O
97	of	_	_	O
98	life	_	_	O
99	(	_	_	O
100	HRQoL	_	_	O
101	;	_	_	O
102	exploratory	_	_	O
103	endpoint	_	_	O
104	)	_	_	O
105	was	_	_	O
106	evaluated	_	_	O
107	using	_	_	O
108	the	_	_	O
109	European	_	_	O
110	Organization	_	_	O
111	for	_	_	O
112	Research	_	_	O
113	and	_	_	O
114	Treatment	_	_	O
115	of	_	_	O
116	Cancer	_	_	O
117	(	_	_	O
118	EORTC	_	_	O
119	)	_	_	O
120	Quality	_	_	O
121	of	_	_	O
122	Life	_	_	O
123	Questionnaire	_	_	O
124	(	_	_	O
125	QLQ-C30	_	_	O
126	)	_	_	O
127	.	_	_	O

128	EORTC	_	_	O
129	QLQ-C30	_	_	O
130	was	_	_	O
131	administered	_	_	O
132	at	_	_	O
133	screening	_	_	O
134	,	_	_	O
135	on	_	_	O
136	day	_	_	O
137	1	_	_	O
138	of	_	_	O
139	each	_	_	O
140	cycle	_	_	O
141	,	_	_	O
142	at	_	_	O
143	the	_	_	O
144	end-of-treatment	_	_	O
145	visit	_	_	O
146	,	_	_	O
147	and	_	_	O
148	every	_	_	O
149	8	_	_	O
150	wk	_	_	O
151	until	_	_	O
152	progression	_	_	O
153	.	_	_	O

154	EORTC	_	_	O
155	QLQ-C30	_	_	O
156	scores	_	_	O
157	were	_	_	O
158	evaluated	_	_	O
159	among	_	_	O
160	patients	_	_	O
161	with	_	_	O
162	a	_	_	O
163	valid	_	_	O
164	baseline	_	_	O
165	and	_	_	O
166	at	_	_	O
167	least	_	_	O
168	one	_	_	O
169	post-baseline	_	_	O
170	HRQoL	_	_	O
171	assessment	_	_	O
172	.	_	_	O

173	At	_	_	O
174	baseline	_	_	O
175	,	_	_	O
176	domain	_	_	O
177	scores	_	_	O
178	were	_	_	O
179	similar	_	_	O
180	between	_	_	O
181	arms	_	_	O
182	.	_	_	O

183	By	_	_	B-Premise
184	cycle	_	_	I-Premise
185	4	_	_	I-Premise
186	,	_	_	I-Premise
187	mean	_	_	I-Premise
188	differences	_	_	I-Premise
189	were	_	_	I-Premise
190	clinically	_	_	I-Premise
191	meaningful	_	_	I-Premise
192	for	_	_	I-Premise
193	most	_	_	I-Premise
194	domains	_	_	I-Premise
195	,	_	_	I-Premise
196	indicating	_	_	I-Premise
197	poorer	_	_	I-Premise
198	health	_	_	I-Premise
199	status	_	_	I-Premise
200	with	_	_	I-Premise
201	VMP	_	_	I-Premise
202	.	_	_	I-Premise

203	From	_	_	B-Premise
204	cycle	_	_	I-Premise
205	5	_	_	I-Premise
206	onwards	_	_	I-Premise
207	,	_	_	I-Premise
208	improvements	_	_	I-Premise
209	relative	_	_	I-Premise
210	to	_	_	I-Premise
211	baseline/MP	_	_	I-Premise
212	were	_	_	I-Premise
213	observed	_	_	I-Premise
214	for	_	_	I-Premise
215	all	_	_	I-Premise
216	domains	_	_	I-Premise
217	with	_	_	I-Premise
218	VMP	_	_	I-Premise
219	.	_	_	I-Premise

220	Mean	_	_	B-Premise
221	scores	_	_	I-Premise
222	were	_	_	I-Premise
223	generally	_	_	I-Premise
224	improved	_	_	I-Premise
225	by	_	_	I-Premise
226	the	_	_	I-Premise
227	end-of-treatment	_	_	I-Premise
228	assessment	_	_	I-Premise
229	vs.	_	_	I-Premise
230	baseline	_	_	I-Premise
231	in	_	_	I-Premise
232	both	_	_	I-Premise
233	arms	_	_	I-Premise
234	.	_	_	I-Premise

235	Among	_	_	B-Premise
236	responding	_	_	I-Premise
237	patients	_	_	I-Premise
238	,	_	_	I-Premise
239	mean	_	_	I-Premise
240	scores	_	_	I-Premise
241	generally	_	_	I-Premise
242	improved	_	_	I-Premise
243	from	_	_	I-Premise
244	time	_	_	I-Premise
245	of	_	_	I-Premise
246	response	_	_	I-Premise
247	to	_	_	I-Premise
248	end-of-treatment	_	_	I-Premise
249	assessment	_	_	I-Premise
250	,	_	_	I-Premise
251	substantially	_	_	I-Premise
252	driven	_	_	I-Premise
253	by	_	_	I-Premise
254	patients	_	_	I-Premise
255	achieving	_	_	I-Premise
256	complete	_	_	I-Premise
257	response	_	_	I-Premise
258	(	_	_	I-Premise
259	CR	_	_	I-Premise
260	)	_	_	I-Premise
261	.	_	_	I-Premise

262	Multivariate	_	_	B-Premise
263	analysis	_	_	I-Premise
264	showed	_	_	I-Premise
265	a	_	_	I-Premise
266	significant	_	_	I-Premise
267	impact	_	_	I-Premise
268	of	_	_	I-Premise
269	duration	_	_	I-Premise
270	of	_	_	I-Premise
271	response/CR	_	_	I-Premise
272	on	_	_	I-Premise
273	improving	_	_	I-Premise
274	global	_	_	I-Premise
275	health	_	_	I-Premise
276	status	_	_	I-Premise
277	,	_	_	I-Premise
278	pain	_	_	I-Premise
279	,	_	_	I-Premise
280	and	_	_	I-Premise
281	appetite	_	_	I-Premise
282	loss	_	_	I-Premise
283	scores	_	_	I-Premise
284	.	_	_	I-Premise

285	Analyses	_	_	B-Claim
286	by	_	_	I-Claim
287	bortezomib	_	_	I-Claim
288	dose	_	_	I-Claim
289	intensity	_	_	I-Claim
290	indicated	_	_	I-Claim
291	better	_	_	I-Claim
292	HRQoL	_	_	I-Claim
293	in	_	_	I-Claim
294	patients	_	_	I-Claim
295	receiving	_	_	I-Claim
296	lower	_	_	I-Claim
297	dose	_	_	I-Claim
298	intensity	_	_	I-Claim
299	.	_	_	I-Claim

300	These	_	_	B-Claim
301	findings	_	_	I-Claim
302	demonstrate	_	_	I-Claim
303	clinically	_	_	I-Claim
304	meaningful	_	_	I-Claim
305	,	_	_	I-Claim
306	transitory	_	_	I-Claim
307	HRQoL	_	_	I-Claim
308	decrements	_	_	I-Claim
309	with	_	_	I-Claim
310	VMP	_	_	I-Claim
311	and	_	_	I-Claim
312	relatively	_	_	I-Claim
313	lower	_	_	I-Claim
314	HRQoL	_	_	I-Claim
315	vs.	_	_	I-Claim
316	MP	_	_	I-Claim
317	during	_	_	I-Claim
318	early	_	_	I-Claim
319	treatment	_	_	I-Claim
320	cycles	_	_	I-Claim
321	,	_	_	I-Claim
322	associated	_	_	I-Claim
323	with	_	_	I-Claim
324	the	_	_	I-Claim
325	expected	_	_	I-Claim
326	additional	_	_	I-Claim
327	toxicities	_	_	I-Claim
328	.	_	_	I-Claim

329	However	_	_	B-Claim
330	,	_	_	I-Claim
331	HRQoL	_	_	I-Claim
332	is	_	_	I-Claim
333	not	_	_	I-Claim
334	compromised	_	_	I-Claim
335	in	_	_	I-Claim
336	the	_	_	I-Claim
337	long	_	_	I-Claim
338	term	_	_	I-Claim
339	,	_	_	I-Claim
340	recovering	_	_	I-Claim
341	by	_	_	I-Claim
342	the	_	_	I-Claim
343	end-of-treatment	_	_	I-Claim
344	visit	_	_	I-Claim
345	to	_	_	I-Claim
346	be	_	_	I-Claim
347	comparable	_	_	I-Claim
348	vs.	_	_	I-Claim
349	MP	_	_	I-Claim
350	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	prophylactic	_	_	O
6	swallowing	_	_	O
7	exercises	_	_	O
8	on	_	_	O
9	swallowing	_	_	O
10	function	_	_	O
11	in	_	_	O
12	patients	_	_	O
13	undergoing	_	_	O
14	chemoradiation	_	_	O
15	therapy	_	_	O
16	(	_	_	O
17	CRT	_	_	O
18	)	_	_	O
19	for	_	_	O
20	head	_	_	O
21	and	_	_	O
22	neck	_	_	O
23	cancer	_	_	O
24	.	_	_	O

25	Randomized	_	_	O
26	controlled	_	_	O
27	trial	_	_	O
28	.	_	_	O

29	Tertiary	_	_	O
30	care	_	_	O
31	,	_	_	O
32	academic	_	_	O
33	medical	_	_	O
34	center	_	_	O
35	.	_	_	O

36	Twenty-six	_	_	O
37	patients	_	_	O
38	with	_	_	O
39	head	_	_	O
40	and	_	_	O
41	neck	_	_	O
42	cancer	_	_	O
43	receiving	_	_	O
44	CRT	_	_	O
45	.	_	_	O

46	Patients	_	_	O
47	performed	_	_	O
48	5	_	_	O
49	targeted	_	_	O
50	swallowing	_	_	O
51	exercises	_	_	O
52	throughout	_	_	O
53	their	_	_	O
54	CRT	_	_	O
55	and	_	_	O
56	participated	_	_	O
57	in	_	_	O
58	weekly	_	_	O
59	swallowing	_	_	O
60	therapy	_	_	O
61	sessions	_	_	O
62	to	_	_	O
63	promote	_	_	O
64	adherence	_	_	O
65	and	_	_	O
66	accurate	_	_	O
67	technique	_	_	O
68	.	_	_	O

69	Controls	_	_	O
70	had	_	_	O
71	no	_	_	O
72	prophylactic	_	_	O
73	exercises	_	_	O
74	and	_	_	O
75	were	_	_	O
76	referred	_	_	O
77	for	_	_	O
78	swallowing	_	_	O
79	treatment	_	_	O
80	after	_	_	O
81	completion	_	_	O
82	of	_	_	O
83	CRT	_	_	O
84	if	_	_	O
85	indicated	_	_	O
86	.	_	_	O

87	Swallowing	_	_	O
88	function	_	_	O
89	was	_	_	O
90	assessed	_	_	O
91	with	_	_	O
92	the	_	_	O
93	Functional	_	_	O
94	Oral	_	_	O
95	Intake	_	_	O
96	Scale	_	_	O
97	(	_	_	O
98	FOIS	_	_	O
99	)	_	_	O
100	and	_	_	O
101	the	_	_	O
102	Performance	_	_	O
103	Status	_	_	O
104	Scale	_	_	O
105	for	_	_	O
106	Head	_	_	O
107	and	_	_	O
108	Neck	_	_	O
109	Cancer	_	_	O
110	Patients	_	_	O
111	(	_	_	O
112	PSS-H	_	_	O
113	&	_	_	O
114	N	_	_	O
115	)	_	_	O
116	at	_	_	O
117	baseline	_	_	O
118	,	_	_	O
119	immediately	_	_	O
120	after	_	_	O
121	CRT	_	_	O
122	,	_	_	O
123	and	_	_	O
124	at	_	_	O
125	3	_	_	O
126	,	_	_	O
127	6	_	_	O
128	,	_	_	O
129	9	_	_	O
130	,	_	_	O
131	and	_	_	O
132	12	_	_	O
133	months	_	_	O
134	after	_	_	O
135	CRT	_	_	O
136	.	_	_	O

137	There	_	_	B-Premise
138	were	_	_	I-Premise
139	no	_	_	I-Premise
140	statistically	_	_	I-Premise
141	significant	_	_	I-Premise
142	differences	_	_	I-Premise
143	in	_	_	I-Premise
144	FOIS	_	_	I-Premise
145	scores	_	_	I-Premise
146	between	_	_	I-Premise
147	intervention	_	_	I-Premise
148	and	_	_	I-Premise
149	control	_	_	I-Premise
150	patients	_	_	I-Premise
151	immediately	_	_	I-Premise
152	after	_	_	I-Premise
153	CRT	_	_	I-Premise
154	(	_	_	I-Premise
155	immediately	_	_	I-Premise
156	after	_	_	I-Premise
157	CRT	_	_	I-Premise
158	:	_	_	I-Premise
159	intervention	_	_	I-Premise
160	group	_	_	I-Premise
161	median	_	_	I-Premise
162	score	_	_	I-Premise
163	,	_	_	I-Premise
164	3	_	_	I-Premise
165	[	_	_	I-Premise
166	range	_	_	I-Premise
167	,	_	_	I-Premise
168	1-7	_	_	I-Premise
169	]	_	_	I-Premise
170	,	_	_	I-Premise
171	vs	_	_	I-Premise
172	median	_	_	I-Premise
173	control	_	_	I-Premise
174	score	_	_	I-Premise
175	,	_	_	I-Premise
176	4	_	_	I-Premise
177	[	_	_	I-Premise
178	range	_	_	I-Premise
179	,	_	_	I-Premise
180	1-6	_	_	I-Premise
181	]	_	_	I-Premise
182	(	_	_	I-Premise
183	P	_	_	I-Premise
184	=	_	_	I-Premise
185	.88	_	_	I-Premise
186	)	_	_	I-Premise
187	.	_	_	I-Premise

188	However	_	_	O
189	,	_	_	O
190	intervention	_	_	B-Premise
191	patients	_	_	I-Premise
192	had	_	_	I-Premise
193	significantly	_	_	I-Premise
194	better	_	_	I-Premise
195	scores	_	_	I-Premise
196	at	_	_	I-Premise
197	months	_	_	I-Premise
198	3	_	_	I-Premise
199	and	_	_	I-Premise
200	6	_	_	I-Premise
201	(	_	_	I-Premise
202	median	_	_	I-Premise
203	3-month	_	_	I-Premise
204	intervention	_	_	I-Premise
205	score	_	_	I-Premise
206	,	_	_	I-Premise
207	7	_	_	I-Premise
208	[	_	_	I-Premise
209	range	_	_	I-Premise
210	,	_	_	I-Premise
211	5-7	_	_	I-Premise
212	]	_	_	I-Premise
213	,	_	_	I-Premise
214	vs	_	_	I-Premise
215	median	_	_	I-Premise
216	control	_	_	I-Premise
217	score	_	_	I-Premise
218	,	_	_	I-Premise
219	5	_	_	I-Premise
220	[	_	_	I-Premise
221	range	_	_	I-Premise
222	,	_	_	I-Premise
223	3-7	_	_	I-Premise
224	]	_	_	I-Premise
225	[	_	_	I-Premise
226	P	_	_	I-Premise
227	=	_	_	I-Premise
228	.03	_	_	I-Premise
229	]	_	_	I-Premise
230	;	_	_	I-Premise
231	median	_	_	I-Premise
232	6-month	_	_	I-Premise
233	intervention	_	_	I-Premise
234	score	_	_	I-Premise
235	,	_	_	I-Premise
236	7	_	_	I-Premise
237	[	_	_	I-Premise
238	range	_	_	I-Premise
239	,	_	_	I-Premise
240	6-7	_	_	I-Premise
241	]	_	_	I-Premise
242	,	_	_	I-Premise
243	vs	_	_	I-Premise
244	median	_	_	I-Premise
245	control	_	_	I-Premise
246	score	_	_	I-Premise
247	,	_	_	I-Premise
248	6	_	_	I-Premise
249	[	_	_	I-Premise
250	range	_	_	I-Premise
251	,	_	_	I-Premise
252	3-7	_	_	I-Premise
253	]	_	_	I-Premise
254	[	_	_	I-Premise
255	P	_	_	I-Premise
256	=	_	_	I-Premise
257	.009	_	_	I-Premise
258	]	_	_	I-Premise
259	)	_	_	I-Premise
260	.	_	_	I-Premise

261	There	_	_	B-Premise
262	was	_	_	I-Premise
263	no	_	_	I-Premise
264	significant	_	_	I-Premise
265	difference	_	_	I-Premise
266	in	_	_	I-Premise
267	scores	_	_	I-Premise
268	at	_	_	I-Premise
269	months	_	_	I-Premise
270	9	_	_	I-Premise
271	and	_	_	I-Premise
272	12	_	_	I-Premise
273	(	_	_	I-Premise
274	P	_	_	I-Premise
275	=	_	_	I-Premise
276	.24	_	_	I-Premise
277	and	_	_	I-Premise
278	P	_	_	I-Premise
279	=	_	_	I-Premise
280	.93	_	_	I-Premise
281	,	_	_	I-Premise
282	respectively	_	_	I-Premise
283	)	_	_	I-Premise
284	.	_	_	I-Premise

285	The	_	_	B-Premise
286	same	_	_	I-Premise
287	pattern	_	_	I-Premise
288	between	_	_	I-Premise
289	intervention	_	_	I-Premise
290	and	_	_	I-Premise
291	control	_	_	I-Premise
292	patients	_	_	I-Premise
293	was	_	_	I-Premise
294	observed	_	_	I-Premise
295	for	_	_	I-Premise
296	scores	_	_	I-Premise
297	on	_	_	I-Premise
298	the	_	_	I-Premise
299	PSS-H	_	_	I-Premise
300	&	_	_	I-Premise
301	N	_	_	I-Premise
302	.	_	_	I-Premise

303	Patients	_	_	B-Claim
304	who	_	_	I-Claim
305	performed	_	_	I-Claim
306	prophylactic	_	_	I-Claim
307	swallowing	_	_	I-Claim
308	exercises	_	_	I-Claim
309	had	_	_	I-Claim
310	improved	_	_	I-Claim
311	swallowing	_	_	I-Claim
312	function	_	_	I-Claim
313	at	_	_	I-Claim
314	3	_	_	I-Claim
315	and	_	_	I-Claim
316	6	_	_	I-Claim
317	months	_	_	I-Claim
318	after	_	_	I-Claim
319	CRT	_	_	I-Claim
320	but	_	_	I-Claim
321	not	_	_	I-Claim
322	immediately	_	_	I-Claim
323	after	_	_	I-Claim
324	CRT	_	_	I-Claim
325	or	_	_	I-Claim
326	at	_	_	I-Claim
327	9	_	_	I-Claim
328	and	_	_	I-Claim
329	12	_	_	I-Claim
330	months	_	_	I-Claim
331	after	_	_	I-Claim
332	CRT	_	_	I-Claim
333	.	_	_	I-Claim

334	The	_	_	B-Claim
335	small	_	_	I-Claim
336	sample	_	_	I-Claim
337	size	_	_	I-Claim
338	may	_	_	I-Claim
339	have	_	_	I-Claim
340	limited	_	_	I-Claim
341	our	_	_	I-Claim
342	ability	_	_	I-Claim
343	to	_	_	I-Claim
344	detect	_	_	I-Claim
345	significant	_	_	I-Claim
346	differences	_	_	I-Claim
347	beyond	_	_	I-Claim
348	6	_	_	I-Claim
349	months	_	_	I-Claim
350	of	_	_	I-Claim
351	observation	_	_	I-Claim
352	as	_	_	I-Claim
353	well	_	_	I-Claim
354	as	_	_	I-Claim
355	additional	_	_	I-Claim
356	significant	_	_	I-Claim
357	differences	_	_	I-Claim
358	in	_	_	I-Claim
359	our	_	_	I-Claim
360	study	_	_	I-Claim
361	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	examined	_	_	O
3	whether	_	_	O
4	changes	_	_	O
5	in	_	_	O
6	self-efficacy	_	_	O
7	explain	_	_	O
8	the	_	_	O
9	effects	_	_	O
10	of	_	_	O
11	a	_	_	O
12	mailed	_	_	O
13	print	_	_	O
14	intervention	_	_	O
15	on	_	_	O
16	long-term	_	_	O
17	dietary	_	_	O
18	practices	_	_	O
19	of	_	_	O
20	breast	_	_	O
21	and	_	_	O
22	prostate	_	_	O
23	cancer	_	_	O
24	survivors	_	_	O
25	.	_	_	O

26	The	_	_	O
27	relationship	_	_	O
28	between	_	_	O
29	change	_	_	O
30	in	_	_	O
31	self-efficacy	_	_	O
32	and	_	_	O
33	long-term	_	_	O
34	physical	_	_	O
35	activity	_	_	O
36	(	_	_	O
37	PA	_	_	O
38	)	_	_	O
39	also	_	_	O
40	was	_	_	O
41	examined	_	_	O
42	.	_	_	O

43	Breast	_	_	O
44	and	_	_	O
45	prostate	_	_	O
46	cancer	_	_	O
47	survivors	_	_	O
48	(	_	_	O
49	N	_	_	O
50	=	_	_	O
51	543	_	_	O
52	)	_	_	O
53	from	_	_	O
54	39	_	_	O
55	US	_	_	O
56	states	_	_	O
57	and	_	_	O
58	two	_	_	O
59	Canadian	_	_	O
60	provinces	_	_	O
61	participated	_	_	O
62	in	_	_	O
63	the	_	_	O
64	FRESH	_	_	O
65	START	_	_	O
66	intervention	_	_	O
67	trial	_	_	O
68	.	_	_	O

69	Participants	_	_	O
70	were	_	_	O
71	randomly	_	_	O
72	assigned	_	_	O
73	to	_	_	O
74	receive	_	_	O
75	a	_	_	O
76	10-month	_	_	O
77	program	_	_	O
78	of	_	_	O
79	mailed	_	_	O
80	print	_	_	O
81	materials	_	_	O
82	on	_	_	O
83	diet	_	_	O
84	and	_	_	O
85	PA	_	_	O
86	available	_	_	O
87	in	_	_	O
88	the	_	_	O
89	public	_	_	O
90	domain	_	_	O
91	or	_	_	O
92	a	_	_	O
93	10-month	_	_	O
94	program	_	_	O
95	of	_	_	O
96	tailored	_	_	O
97	materials	_	_	O
98	designed	_	_	O
99	to	_	_	O
100	increase	_	_	O
101	fruit	_	_	O
102	and	_	_	O
103	vegetable	_	_	O
104	(	_	_	O
105	F	_	_	O
106	&	_	_	O
107	V	_	_	O
108	)	_	_	O
109	intake	_	_	O
110	,	_	_	O
111	decrease	_	_	O
112	fat	_	_	O
113	intake	_	_	O
114	,	_	_	O
115	and/or	_	_	O
116	increase	_	_	O
117	PA.	_	_	O
118	Changes	_	_	O
119	in	_	_	O
120	self-efficacy	_	_	O
121	for	_	_	O
122	F	_	_	O
123	&	_	_	O
124	V	_	_	O
125	intake	_	_	O
126	and	_	_	O
127	fat	_	_	O
128	restriction	_	_	O
129	were	_	_	O
130	analyzed	_	_	O
131	as	_	_	O
132	potential	_	_	O
133	mediators	_	_	O
134	of	_	_	O
135	the	_	_	O
136	intervention	_	_	O
137	's	_	_	O
138	effects	_	_	O
139	on	_	_	O
140	diet	_	_	O
141	at	_	_	O
142	2-year	_	_	O
143	follow-up	_	_	O
144	.	_	_	O

145	Because	_	_	O
146	we	_	_	O
147	previously	_	_	O
148	found	_	_	O
149	that	_	_	O
150	change	_	_	O
151	in	_	_	O
152	self-efficacy	_	_	O
153	for	_	_	O
154	PA	_	_	O
155	did	_	_	O
156	not	_	_	O
157	vary	_	_	O
158	by	_	_	O
159	group	_	_	O
160	assignment	_	_	O
161	,	_	_	O
162	the	_	_	O
163	relationship	_	_	O
164	between	_	_	O
165	change	_	_	O
166	in	_	_	O
167	self-efficacy	_	_	O
168	and	_	_	O
169	PA	_	_	O
170	at	_	_	O
171	2-year	_	_	O
172	follow-up	_	_	O
173	was	_	_	O
174	examined	_	_	O
175	across	_	_	O
176	study	_	_	O
177	conditions	_	_	O
178	.	_	_	O

179	Results	_	_	B-Claim
180	suggest	_	_	I-Claim
181	that	_	_	I-Claim
182	change	_	_	I-Claim
183	in	_	_	I-Claim
184	self-efficacy	_	_	I-Claim
185	for	_	_	I-Claim
186	fat	_	_	I-Claim
187	restriction	_	_	I-Claim
188	partially	_	_	I-Claim
189	explained	_	_	I-Claim
190	the	_	_	I-Claim
191	intervention	_	_	I-Claim
192	's	_	_	I-Claim
193	effect	_	_	I-Claim
194	on	_	_	I-Claim
195	fat	_	_	I-Claim
196	intake	_	_	I-Claim
197	(	_	_	I-Claim
198	mean	_	_	I-Claim
199	indirect	_	_	I-Claim
200	effect	_	_	I-Claim
201	=	_	_	I-Claim
202	-0.28	_	_	I-Claim
203	)	_	_	I-Claim
204	,	_	_	I-Claim
205	and	_	_	I-Claim
206	change	_	_	I-Claim
207	in	_	_	I-Claim
208	self-efficacy	_	_	I-Claim
209	for	_	_	I-Claim
210	F	_	_	I-Claim
211	&	_	_	I-Claim
212	V	_	_	I-Claim
213	consumption	_	_	I-Claim
214	partially	_	_	I-Claim
215	explained	_	_	I-Claim
216	the	_	_	I-Claim
217	intervention	_	_	I-Claim
218	's	_	_	I-Claim
219	effect	_	_	I-Claim
220	on	_	_	I-Claim
221	daily	_	_	I-Claim
222	F	_	_	I-Claim
223	&	_	_	I-Claim
224	V	_	_	I-Claim
225	intake	_	_	I-Claim
226	(	_	_	I-Claim
227	mean	_	_	I-Claim
228	indirect	_	_	I-Claim
229	effect	_	_	I-Claim
230	=	_	_	I-Claim
231	.11	_	_	I-Claim
232	)	_	_	I-Claim
233	.	_	_	I-Claim

234	Change	_	_	B-Premise
235	in	_	_	I-Premise
236	self-efficacy	_	_	I-Premise
237	for	_	_	I-Premise
238	fat	_	_	I-Premise
239	restriction	_	_	I-Premise
240	partially	_	_	I-Premise
241	accounted	_	_	I-Premise
242	for	_	_	I-Premise
243	the	_	_	I-Premise
244	intervention	_	_	I-Premise
245	's	_	_	I-Premise
246	impact	_	_	I-Premise
247	on	_	_	I-Premise
248	overall	_	_	I-Premise
249	diet	_	_	I-Premise
250	quality	_	_	I-Premise
251	among	_	_	I-Premise
252	men	_	_	I-Premise
253	only	_	_	I-Premise
254	(	_	_	I-Premise
255	mean	_	_	I-Premise
256	indirect	_	_	I-Premise
257	effect	_	_	I-Premise
258	=	_	_	I-Premise
259	0.60	_	_	I-Premise
260	)	_	_	I-Premise
261	.	_	_	I-Premise

262	Finally	_	_	O
263	,	_	_	O
264	change	_	_	O
265	in	_	_	O
266	self-efficacy	_	_	O
267	for	_	_	O
268	PA	_	_	O
269	predicted	_	_	O
270	PA	_	_	O
271	at	_	_	O
272	2-year	_	_	O
273	follow-up	_	_	O
274	.	_	_	O

275	Findings	_	_	B-Claim
276	suggest	_	_	I-Claim
277	that	_	_	I-Claim
278	self-efficacy	_	_	I-Claim
279	may	_	_	I-Claim
280	influence	_	_	I-Claim
281	long-term	_	_	I-Claim
282	maintenance	_	_	I-Claim
283	of	_	_	I-Claim
284	healthy	_	_	I-Claim
285	lifestyle	_	_	I-Claim
286	practices	_	_	I-Claim
287	among	_	_	I-Claim
288	cancer	_	_	I-Claim
289	survivors	_	_	I-Claim
290	.	_	_	I-Claim


0	Surgical	_	_	O
1	resection	_	_	O
2	is	_	_	O
3	regarded	_	_	O
4	as	_	_	O
5	the	_	_	O
6	only	_	_	O
7	curative	_	_	O
8	option	_	_	O
9	for	_	_	O
10	resectable	_	_	O
11	oesophageal	_	_	O
12	cancer	_	_	O
13	,	_	_	O
14	but	_	_	O
15	pulmonary	_	_	O
16	complications	_	_	O
17	occurring	_	_	O
18	in	_	_	O
19	more	_	_	O
20	than	_	_	O
21	half	_	_	O
22	of	_	_	O
23	patients	_	_	O
24	after	_	_	O
25	open	_	_	O
26	oesophagectomy	_	_	O
27	are	_	_	O
28	a	_	_	O
29	great	_	_	O
30	concern	_	_	O
31	.	_	_	O

32	We	_	_	O
33	assessed	_	_	O
34	whether	_	_	O
35	minimally	_	_	O
36	invasive	_	_	O
37	oesophagectomy	_	_	O
38	reduces	_	_	O
39	morbidity	_	_	O
40	compared	_	_	O
41	with	_	_	O
42	open	_	_	O
43	oesophagectomy	_	_	O
44	.	_	_	O

45	We	_	_	O
46	did	_	_	O
47	a	_	_	O
48	multicentre	_	_	O
49	,	_	_	O
50	open-label	_	_	O
51	,	_	_	O
52	randomised	_	_	O
53	controlled	_	_	O
54	trial	_	_	O
55	at	_	_	O
56	five	_	_	O
57	study	_	_	O
58	centres	_	_	O
59	in	_	_	O
60	three	_	_	O
61	countries	_	_	O
62	between	_	_	O
63	June	_	_	O
64	1	_	_	O
65	,	_	_	O
66	2009	_	_	O
67	,	_	_	O
68	and	_	_	O
69	March	_	_	O
70	31	_	_	O
71	,	_	_	O
72	2011	_	_	O
73	.	_	_	O

74	Patients	_	_	O
75	aged	_	_	O
76	18-75	_	_	O
77	years	_	_	O
78	with	_	_	O
79	resectable	_	_	O
80	cancer	_	_	O
81	of	_	_	O
82	the	_	_	O
83	oesophagus	_	_	O
84	or	_	_	O
85	gastro-oesophageal	_	_	O
86	junction	_	_	O
87	were	_	_	O
88	randomly	_	_	O
89	assigned	_	_	O
90	via	_	_	O
91	a	_	_	O
92	computer-generated	_	_	O
93	randomisation	_	_	O
94	sequence	_	_	O
95	to	_	_	O
96	receive	_	_	O
97	either	_	_	O
98	open	_	_	O
99	transthoracic	_	_	O
100	or	_	_	O
101	minimally	_	_	O
102	invasive	_	_	O
103	transthoracic	_	_	O
104	oesophagectomy	_	_	O
105	.	_	_	O

106	Randomisation	_	_	O
107	was	_	_	O
108	stratified	_	_	O
109	by	_	_	O
110	centre	_	_	O
111	.	_	_	O

112	Patients	_	_	O
113	,	_	_	O
114	and	_	_	O
115	investigators	_	_	O
116	undertaking	_	_	O
117	interventions	_	_	O
118	,	_	_	O
119	assessing	_	_	O
120	outcomes	_	_	O
121	,	_	_	O
122	and	_	_	O
123	analysing	_	_	O
124	data	_	_	O
125	,	_	_	O
126	were	_	_	O
127	not	_	_	O
128	masked	_	_	O
129	to	_	_	O
130	group	_	_	O
131	assignment	_	_	O
132	.	_	_	O

133	The	_	_	O
134	primary	_	_	O
135	outcome	_	_	O
136	was	_	_	O
137	pulmonary	_	_	O
138	infection	_	_	O
139	within	_	_	O
140	the	_	_	O
141	first	_	_	O
142	2	_	_	O
143	weeks	_	_	O
144	after	_	_	O
145	surgery	_	_	O
146	and	_	_	O
147	during	_	_	O
148	the	_	_	O
149	whole	_	_	O
150	stay	_	_	O
151	in	_	_	O
152	hospital	_	_	O
153	.	_	_	O

154	Analysis	_	_	O
155	was	_	_	O
156	by	_	_	O
157	intention	_	_	O
158	to	_	_	O
159	treat	_	_	O
160	.	_	_	O

161	This	_	_	O
162	trial	_	_	O
163	is	_	_	O
164	registered	_	_	O
165	with	_	_	O
166	the	_	_	O
167	Netherlands	_	_	O
168	Trial	_	_	O
169	Register	_	_	O
170	,	_	_	O
171	NTR	_	_	O
172	TC	_	_	O
173	2452	_	_	O
174	.	_	_	O

175	We	_	_	O
176	randomly	_	_	O
177	assigned	_	_	O
178	56	_	_	O
179	patients	_	_	O
180	to	_	_	O
181	the	_	_	O
182	open	_	_	O
183	oesophagectomy	_	_	O
184	group	_	_	O
185	and	_	_	O
186	59	_	_	O
187	to	_	_	O
188	the	_	_	O
189	minimally	_	_	O
190	invasive	_	_	O
191	oesophagectomy	_	_	O
192	group	_	_	O
193	.	_	_	O

194	16	_	_	B-Premise
195	(	_	_	I-Premise
196	29	_	_	I-Premise
197	%	_	_	I-Premise
198	)	_	_	I-Premise
199	patients	_	_	I-Premise
200	in	_	_	I-Premise
201	the	_	_	I-Premise
202	open	_	_	I-Premise
203	oesophagectomy	_	_	I-Premise
204	group	_	_	I-Premise
205	had	_	_	I-Premise
206	pulmonary	_	_	I-Premise
207	infection	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	first	_	_	I-Premise
211	2	_	_	I-Premise
212	weeks	_	_	I-Premise
213	compared	_	_	I-Premise
214	with	_	_	I-Premise
215	five	_	_	I-Premise
216	(	_	_	I-Premise
217	9	_	_	I-Premise
218	%	_	_	I-Premise
219	)	_	_	I-Premise
220	in	_	_	I-Premise
221	the	_	_	I-Premise
222	minimally	_	_	I-Premise
223	invasive	_	_	I-Premise
224	group	_	_	I-Premise
225	(	_	_	I-Premise
226	relative	_	_	I-Premise
227	risk	_	_	I-Premise
228	[	_	_	I-Premise
229	RR	_	_	I-Premise
230	]	_	_	I-Premise
231	0·30	_	_	I-Premise
232	,	_	_	I-Premise
233	95	_	_	I-Premise
234	%	_	_	I-Premise
235	CI	_	_	I-Premise
236	0·12-0·76	_	_	I-Premise
237	;	_	_	I-Premise
238	p=0·005	_	_	I-Premise
239	)	_	_	I-Premise
240	.	_	_	I-Premise

241	19	_	_	B-Premise
242	(	_	_	I-Premise
243	34	_	_	I-Premise
244	%	_	_	I-Premise
245	)	_	_	I-Premise
246	patients	_	_	I-Premise
247	in	_	_	I-Premise
248	the	_	_	I-Premise
249	open	_	_	I-Premise
250	oesophagectomy	_	_	I-Premise
251	group	_	_	I-Premise
252	had	_	_	I-Premise
253	pulmonary	_	_	I-Premise
254	infection	_	_	I-Premise
255	in-hospital	_	_	I-Premise
256	compared	_	_	I-Premise
257	with	_	_	I-Premise
258	seven	_	_	I-Premise
259	(	_	_	I-Premise
260	12	_	_	I-Premise
261	%	_	_	I-Premise
262	)	_	_	I-Premise
263	in	_	_	I-Premise
264	the	_	_	I-Premise
265	minimally	_	_	I-Premise
266	invasive	_	_	I-Premise
267	group	_	_	I-Premise
268	(	_	_	I-Premise
269	0·35	_	_	I-Premise
270	,	_	_	I-Premise
271	0·16-0·78	_	_	I-Premise
272	;	_	_	I-Premise
273	p=0·005	_	_	I-Premise
274	)	_	_	I-Premise
275	.	_	_	I-Premise

276	For	_	_	B-Premise
277	in-hospital	_	_	I-Premise
278	mortality	_	_	I-Premise
279	,	_	_	I-Premise
280	one	_	_	I-Premise
281	patient	_	_	I-Premise
282	in	_	_	I-Premise
283	the	_	_	I-Premise
284	open	_	_	I-Premise
285	oesophagectomy	_	_	I-Premise
286	group	_	_	I-Premise
287	died	_	_	I-Premise
288	from	_	_	I-Premise
289	anastomotic	_	_	I-Premise
290	leakage	_	_	I-Premise
291	and	_	_	I-Premise
292	two	_	_	I-Premise
293	in	_	_	I-Premise
294	the	_	_	I-Premise
295	minimally	_	_	I-Premise
296	invasive	_	_	I-Premise
297	group	_	_	I-Premise
298	from	_	_	I-Premise
299	aspiration	_	_	I-Premise
300	and	_	_	I-Premise
301	mediastinitis	_	_	I-Premise
302	after	_	_	I-Premise
303	anastomotic	_	_	I-Premise
304	leakage	_	_	I-Premise
305	.	_	_	I-Premise

306	These	_	_	B-Claim
307	findings	_	_	I-Claim
308	provide	_	_	I-Claim
309	evidence	_	_	I-Claim
310	for	_	_	I-Claim
311	the	_	_	I-Claim
312	short-term	_	_	I-Claim
313	benefits	_	_	I-Claim
314	of	_	_	I-Claim
315	minimally	_	_	I-Claim
316	invasive	_	_	I-Claim
317	oesophagectomy	_	_	I-Claim
318	for	_	_	I-Claim
319	patients	_	_	I-Claim
320	with	_	_	I-Claim
321	resectable	_	_	I-Claim
322	oesophageal	_	_	I-Claim
323	cancer	_	_	I-Claim
324	.	_	_	I-Claim


0	The	_	_	B-Claim
1	incidence	_	_	I-Claim
2	and	_	_	I-Claim
3	development	_	_	I-Claim
4	of	_	_	I-Claim
5	cancer	_	_	I-Claim
6	are	_	_	I-Claim
7	closely	_	_	I-Claim
8	related	_	_	I-Claim
9	to	_	_	I-Claim
10	dysfunction	_	_	I-Claim
11	of	_	_	I-Claim
12	immune	_	_	I-Claim
13	function	_	_	I-Claim
14	.	_	_	I-Claim

15	The	_	_	O
16	immune	_	_	O
17	system	_	_	O
18	can	_	_	O
19	not	_	_	O
20	identify	_	_	O
21	and	_	_	O
22	remove	_	_	O
23	malignant	_	_	O
24	and	_	_	O
25	mutant	_	_	O
26	cells	_	_	O
27	,	_	_	O
28	which	_	_	O
29	cause	_	_	O
30	tumor	_	_	O
31	cells	_	_	O
32	to	_	_	O
33	escape	_	_	O
34	from	_	_	O
35	surveillance	_	_	O
36	and	_	_	O
37	clearance	_	_	O
38	of	_	_	O
39	the	_	_	O
40	immune	_	_	O
41	system	_	_	O
42	.	_	_	O

43	Immunobiological	_	_	O
44	cancer	_	_	O
45	therapy	_	_	O
46	plays	_	_	O
47	an	_	_	O
48	important	_	_	O
49	role	_	_	O
50	in	_	_	O
51	strengthening	_	_	O
52	body	_	_	O
53	immunological	_	_	O
54	surveillance	_	_	O
55	function	_	_	O
56	and	_	_	O
57	killing	_	_	O
58	remaining	_	_	O
59	tumor	_	_	O
60	cells	_	_	O
61	in	_	_	O
62	the	_	_	O
63	body	_	_	O
64	.	_	_	O

65	We	_	_	O
66	investigated	_	_	O
67	the	_	_	O
68	role	_	_	O
69	of	_	_	O
70	DC/CIK	_	_	O
71	(	_	_	O
72	dendritic	_	_	O
73	cell/cytokine-induced	_	_	O
74	killer	_	_	O
75	cells	_	_	O
76	)	_	_	O
77	immunobiological	_	_	O
78	cancer	_	_	O
79	therapy	_	_	O
80	in	_	_	O
81	maintenance	_	_	O
82	therapy	_	_	O
83	of	_	_	O
84	advanced	_	_	O
85	non-small	_	_	O
86	cell	_	_	O
87	lung	_	_	O
88	cancer	_	_	O
89	.	_	_	O

90	When	_	_	O
91	60	_	_	O
92	cases	_	_	O
93	of	_	_	O
94	non-small	_	_	O
95	cell	_	_	O
96	lung	_	_	O
97	cancer	_	_	O
98	patients	_	_	O
99	in	_	_	O
100	stage	_	_	O
101	IIIb	_	_	O
102	and	_	_	O
103	IV	_	_	O
104	reached	_	_	O
105	stable	_	_	O
106	disease	_	_	O
107	after	_	_	O
108	treatment	_	_	O
109	with	_	_	O
110	4	_	_	O
111	cycles	_	_	O
112	of	_	_	O
113	a	_	_	O
114	two-drug	_	_	O
115	regimen	_	_	O
116	with	_	_	O
117	platinum	_	_	O
118	,	_	_	O
119	they	_	_	O
120	were	_	_	O
121	randomly	_	_	O
122	divided	_	_	O
123	into	_	_	O
124	two	_	_	O
125	groups	_	_	O
126	.	_	_	O

127	One	_	_	O
128	group	_	_	O
129	was	_	_	O
130	treated	_	_	O
131	with	_	_	O
132	DC/CIK	_	_	O
133	immunobiological	_	_	O
134	cancer	_	_	O
135	therapy	_	_	O
136	,	_	_	O
137	and	_	_	O
138	the	_	_	O
139	other	_	_	O
140	was	_	_	O
141	taken	_	_	O
142	as	_	_	O
143	a	_	_	O
144	control	_	_	O
145	group	_	_	O
146	.	_	_	O

147	Finally	_	_	O
148	,	_	_	O
149	cancer	_	_	O
150	progression	_	_	O
151	time	_	_	O
152	and	_	_	O
153	toxicity	_	_	O
154	reaction	_	_	O
155	of	_	_	O
156	the	_	_	O
157	two	_	_	O
158	groups	_	_	O
159	were	_	_	O
160	evaluated	_	_	O
161	.	_	_	O

162	DC/CIK	_	_	B-Premise
163	treatment	_	_	I-Premise
164	prolongs	_	_	I-Premise
165	progression-free	_	_	I-Premise
166	survival	_	_	I-Premise
167	(	_	_	I-Premise
168	3.20	_	_	I-Premise
169	months	_	_	I-Premise
170	[	_	_	I-Premise
171	95	_	_	I-Premise
172	%	_	_	I-Premise
173	CI	_	_	I-Premise
174	,	_	_	I-Premise
175	2.94-3.50	_	_	I-Premise
176	]	_	_	I-Premise
177	vs	_	_	I-Premise
178	2.56	_	_	I-Premise
179	months	_	_	I-Premise
180	[	_	_	I-Premise
181	95	_	_	I-Premise
182	%	_	_	I-Premise
183	CI	_	_	I-Premise
184	,	_	_	I-Premise
185	2.39-2.73	_	_	I-Premise
186	]	_	_	I-Premise
187	;	_	_	I-Premise
188	P	_	_	I-Premise
189	<	_	_	I-Premise
190	0.05	_	_	I-Premise
191	)	_	_	I-Premise
192	.	_	_	I-Premise

193	In	_	_	B-Premise
194	the	_	_	I-Premise
195	treatment	_	_	I-Premise
196	group	_	_	I-Premise
197	,	_	_	I-Premise
198	the	_	_	I-Premise
199	proportion	_	_	I-Premise
200	of	_	_	I-Premise
201	NK	_	_	I-Premise
202	cells	_	_	I-Premise
203	,	_	_	I-Premise
204	T-cell	_	_	I-Premise
205	subgroups	_	_	I-Premise
206	CD3+	_	_	I-Premise
207	,	_	_	I-Premise
208	CD4+	_	_	I-Premise
209	and	_	_	I-Premise
210	CD8+	_	_	I-Premise
211	had	_	_	I-Premise
212	a	_	_	I-Premise
213	significant	_	_	I-Premise
214	change	_	_	I-Premise
215	before	_	_	I-Premise
216	and	_	_	I-Premise
217	after	_	_	I-Premise
218	treatment	_	_	I-Premise
219	.	_	_	I-Premise

220	Liver	_	_	B-Premise
221	and	_	_	I-Premise
222	kidney	_	_	I-Premise
223	function	_	_	I-Premise
224	and	_	_	I-Premise
225	blood	_	_	I-Premise
226	tests	_	_	I-Premise
227	of	_	_	I-Premise
228	the	_	_	I-Premise
229	treatment	_	_	I-Premise
230	group	_	_	I-Premise
231	were	_	_	I-Premise
232	within	_	_	I-Premise
233	the	_	_	I-Premise
234	normal	_	_	I-Premise
235	range	_	_	I-Premise
236	before	_	_	I-Premise
237	and	_	_	I-Premise
238	after	_	_	I-Premise
239	treatment	_	_	I-Premise
240	.	_	_	I-Premise

241	In	_	_	B-Premise
242	the	_	_	I-Premise
243	treatment	_	_	I-Premise
244	group	_	_	I-Premise
245	,	_	_	I-Premise
246	1	_	_	I-Premise
247	case	_	_	I-Premise
248	suffered	_	_	I-Premise
249	from	_	_	I-Premise
250	chest	_	_	I-Premise
251	distress	_	_	I-Premise
252	,	_	_	I-Premise
253	3	_	_	I-Premise
254	cases	_	_	I-Premise
255	suffered	_	_	I-Premise
256	from	_	_	I-Premise
257	acratia	_	_	I-Premise
258	,	_	_	I-Premise
259	and	_	_	I-Premise
260	4	_	_	I-Premise
261	cases	_	_	I-Premise
262	suffered	_	_	I-Premise
263	from	_	_	I-Premise
264	pyrexia	_	_	I-Premise
265	.	_	_	I-Premise

266	DC/CIK	_	_	B-Claim
267	treatment	_	_	I-Claim
268	had	_	_	I-Claim
269	potential	_	_	I-Claim
270	benefit	_	_	I-Claim
271	for	_	_	I-Claim
272	patients	_	_	I-Claim
273	with	_	_	I-Claim
274	advanced	_	_	I-Claim
275	non-small	_	_	I-Claim
276	cell	_	_	I-Claim
277	lung	_	_	I-Claim
278	cancer	_	_	I-Claim
279	compared	_	_	I-Claim
280	with	_	_	I-Claim
281	the	_	_	I-Claim
282	control	_	_	I-Claim
283	group	_	_	I-Claim
284	and	_	_	I-Claim
285	had	_	_	I-Claim
286	no	_	_	I-Claim
287	obvious	_	_	I-Claim
288	side	_	_	I-Claim
289	effects	_	_	I-Claim
290	.	_	_	I-Claim

291	DC/CIK	_	_	B-Claim
292	treatment	_	_	I-Claim
293	is	_	_	I-Claim
294	a	_	_	I-Claim
295	safe	_	_	I-Claim
296	and	_	_	I-Claim
297	effective	_	_	I-Claim
298	method	_	_	I-Claim
299	for	_	_	I-Claim
300	maintenance	_	_	I-Claim
301	therapy	_	_	I-Claim
302	of	_	_	I-Claim
303	advanced	_	_	I-Claim
304	non-small	_	_	I-Claim
305	cell	_	_	I-Claim
306	lung	_	_	I-Claim
307	cancer	_	_	I-Claim
308	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	the	_	_	O
4	study	_	_	O
5	is	_	_	O
6	to	_	_	O
7	demonstrate	_	_	O
8	that	_	_	O
9	intrapatient	_	_	O
10	dose	_	_	O
11	escalation	_	_	O
12	of	_	_	O
13	carboplatin	_	_	O
14	would	_	_	O
15	improve	_	_	O
16	the	_	_	O
17	outcome	_	_	O
18	in	_	_	O
19	ovarian	_	_	O
20	cancer	_	_	O
21	compared	_	_	O
22	with	_	_	O
23	flat	_	_	O
24	dosing	_	_	O
25	.	_	_	O

26	Patients	_	_	O
27	with	_	_	O
28	untreated	_	_	O
29	stage	_	_	O
30	IC-IV	_	_	O
31	ovarian	_	_	O
32	cancer	_	_	O
33	received	_	_	O
34	six	_	_	O
35	cycles	_	_	O
36	of	_	_	O
37	carboplatin	_	_	O
38	area	_	_	O
39	under	_	_	O
40	the	_	_	O
41	curve	_	_	O
42	6	_	_	O
43	(	_	_	O
44	AUC	_	_	O
45	6	_	_	O
46	)	_	_	O
47	3	_	_	O
48	weekly	_	_	O
49	either	_	_	O
50	with	_	_	O
51	no	_	_	O
52	dose	_	_	O
53	modification	_	_	O
54	except	_	_	O
55	for	_	_	O
56	toxicity	_	_	O
57	(	_	_	O
58	Arm	_	_	O
59	A	_	_	O
60	)	_	_	O
61	or	_	_	O
62	with	_	_	O
63	dose	_	_	O
64	escalations	_	_	O
65	in	_	_	O
66	cycles	_	_	O
67	2-6	_	_	O
68	based	_	_	O
69	on	_	_	O
70	nadir	_	_	O
71	neutrophil	_	_	O
72	and	_	_	O
73	platelet	_	_	O
74	counts	_	_	O
75	(	_	_	O
76	Arm	_	_	O
77	B	_	_	O
78	)	_	_	O
79	.	_	_	O

80	The	_	_	O
81	primary	_	_	O
82	end-point	_	_	O
83	was	_	_	O
84	progression-free	_	_	O
85	survival	_	_	O
86	(	_	_	O
87	PFS	_	_	O
88	)	_	_	O
89	.	_	_	O

90	Nine	_	_	O
91	hundred	_	_	O
92	and	_	_	O
93	sixty-four	_	_	O
94	patients	_	_	O
95	were	_	_	O
96	recruited	_	_	O
97	from	_	_	O
98	71	_	_	O
99	centers	_	_	O
100	.	_	_	O

101	Dose	_	_	O
102	escalation	_	_	O
103	was	_	_	O
104	achieved	_	_	O
105	in	_	_	O
106	77	_	_	O
107	%	_	_	O
108	of	_	_	O
109	patients	_	_	O
110	who	_	_	O
111	had	_	_	O
112	≥1	_	_	O
113	cycle	_	_	O
114	.	_	_	O

115	The	_	_	B-Premise
116	median	_	_	I-Premise
117	AUCs	_	_	I-Premise
118	(	_	_	I-Premise
119	cycle	_	_	I-Premise
120	2-6	_	_	I-Premise
121	)	_	_	I-Premise
122	received	_	_	I-Premise
123	were	_	_	I-Premise
124	6.0	_	_	I-Premise
125	(	_	_	I-Premise
126	Arm	_	_	I-Premise
127	A	_	_	I-Premise
128	)	_	_	I-Premise
129	and	_	_	I-Premise
130	7.2	_	_	I-Premise
131	(	_	_	I-Premise
132	Arm	_	_	I-Premise
133	B	_	_	I-Premise
134	)	_	_	I-Premise
135	(	_	_	I-Premise
136	P	_	_	I-Premise
137	<	_	_	I-Premise
138	0.001	_	_	I-Premise
139	)	_	_	I-Premise
140	.	_	_	I-Premise

141	Grade	_	_	B-Premise
142	3/4	_	_	I-Premise
143	non-hematological	_	_	I-Premise
144	toxicity	_	_	I-Premise
145	was	_	_	I-Premise
146	higher	_	_	I-Premise
147	in	_	_	I-Premise
148	Arm	_	_	I-Premise
149	B	_	_	I-Premise
150	(	_	_	I-Premise
151	31	_	_	I-Premise
152	%	_	_	I-Premise
153	versus	_	_	I-Premise
154	22	_	_	I-Premise
155	%	_	_	I-Premise
156	P	_	_	I-Premise
157	=	_	_	I-Premise
158	0.001	_	_	I-Premise
159	)	_	_	I-Premise
160	.	_	_	I-Premise

161	The	_	_	B-Premise
162	median	_	_	I-Premise
163	PFS	_	_	I-Premise
164	was	_	_	I-Premise
165	12.1	_	_	I-Premise
166	months	_	_	I-Premise
167	in	_	_	I-Premise
168	Arm	_	_	I-Premise
169	A	_	_	I-Premise
170	and	_	_	I-Premise
171	B	_	_	I-Premise
172	[	_	_	I-Premise
173	hazard	_	_	I-Premise
174	ratio	_	_	I-Premise
175	(	_	_	I-Premise
176	HR	_	_	I-Premise
177	)	_	_	I-Premise
178	0.99	_	_	I-Premise
179	;	_	_	I-Premise
180	95	_	_	I-Premise
181	%	_	_	I-Premise
182	confidence	_	_	I-Premise
183	interval	_	_	I-Premise
184	(	_	_	I-Premise
185	CI	_	_	I-Premise
186	)	_	_	I-Premise
187	0.85-1.15	_	_	I-Premise
188	;	_	_	I-Premise
189	P	_	_	I-Premise
190	=	_	_	I-Premise
191	0.93	_	_	I-Premise
192	]	_	_	I-Premise
193	.	_	_	I-Premise

194	The	_	_	B-Premise
195	median	_	_	I-Premise
196	overall	_	_	I-Premise
197	survival	_	_	I-Premise
198	(	_	_	I-Premise
199	OS	_	_	I-Premise
200	)	_	_	I-Premise
201	was	_	_	I-Premise
202	34.1	_	_	I-Premise
203	and	_	_	I-Premise
204	30.7	_	_	I-Premise
205	months	_	_	I-Premise
206	in	_	_	I-Premise
207	Arms	_	_	I-Premise
208	A	_	_	I-Premise
209	and	_	_	I-Premise
210	B	_	_	I-Premise
211	,	_	_	I-Premise
212	respectively	_	_	I-Premise
213	(	_	_	I-Premise
214	HR	_	_	I-Premise
215	0.98	_	_	I-Premise
216	;	_	_	I-Premise
217	95	_	_	I-Premise
218	%	_	_	I-Premise
219	CI	_	_	I-Premise
220	0.81-1.18	_	_	I-Premise
221	,	_	_	I-Premise
222	P	_	_	I-Premise
223	=	_	_	I-Premise
224	0.82	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	In	_	_	B-Premise
228	multivariate	_	_	I-Premise
229	analysis	_	_	I-Premise
230	,	_	_	I-Premise
231	baseline	_	_	I-Premise
232	neutrophil	_	_	I-Premise
233	(	_	_	I-Premise
234	P	_	_	I-Premise
235	<	_	_	I-Premise
236	0.001	_	_	I-Premise
237	)	_	_	I-Premise
238	,	_	_	I-Premise
239	baseline	_	_	I-Premise
240	platelet	_	_	I-Premise
241	counts	_	_	I-Premise
242	(	_	_	I-Premise
243	P	_	_	I-Premise
244	<	_	_	I-Premise
245	0.001	_	_	I-Premise
246	)	_	_	I-Premise
247	and	_	_	I-Premise
248	the	_	_	I-Premise
249	difference	_	_	I-Premise
250	between	_	_	I-Premise
251	white	_	_	I-Premise
252	blood	_	_	I-Premise
253	cell	_	_	I-Premise
254	(	_	_	I-Premise
255	WBC	_	_	I-Premise
256	)	_	_	I-Premise
257	and	_	_	I-Premise
258	neutrophil	_	_	I-Premise
259	count	_	_	I-Premise
260	(	_	_	I-Premise
261	P	_	_	I-Premise
262	=	_	_	I-Premise
263	0.009	_	_	I-Premise
264	)	_	_	I-Premise
265	had	_	_	I-Premise
266	a	_	_	I-Premise
267	significant	_	_	I-Premise
268	adverse	_	_	I-Premise
269	prognostic	_	_	I-Premise
270	value	_	_	I-Premise
271	.	_	_	I-Premise

272	Intrapatient	_	_	B-Claim
273	dose	_	_	I-Claim
274	escalation	_	_	I-Claim
275	of	_	_	I-Claim
276	carboplatin	_	_	I-Claim
277	based	_	_	I-Claim
278	on	_	_	I-Claim
279	nadir	_	_	I-Claim
280	blood	_	_	I-Claim
281	counts	_	_	I-Claim
282	is	_	_	I-Claim
283	feasible	_	_	I-Claim
284	and	_	_	I-Claim
285	safe	_	_	I-Claim
286	.	_	_	I-Claim

287	However	_	_	B-Claim
288	,	_	_	I-Claim
289	it	_	_	I-Claim
290	provided	_	_	I-Claim
291	no	_	_	I-Claim
292	improvement	_	_	I-Claim
293	in	_	_	I-Claim
294	PFS	_	_	I-Claim
295	or	_	_	I-Claim
296	OS	_	_	I-Claim
297	compared	_	_	I-Claim
298	with	_	_	I-Claim
299	flat	_	_	I-Claim
300	dosing	_	_	I-Claim
301	.	_	_	I-Claim

302	Baseline	_	_	O
303	neutrophils	_	_	O
304	over-ride	_	_	O
305	nadir	_	_	O
306	counts	_	_	O
307	in	_	_	O
308	prognostic	_	_	O
309	significance	_	_	O
310	.	_	_	O

311	These	_	_	O
312	data	_	_	O
313	may	_	_	O
314	have	_	_	O
315	wider	_	_	O
316	implications	_	_	O
317	particularly	_	_	O
318	in	_	_	O
319	respect	_	_	O
320	of	_	_	O
321	the	_	_	O
322	management	_	_	O
323	of	_	_	O
324	chemotherapy-induced	_	_	O
325	neutropenia	_	_	O
326	.	_	_	O


0	Two	_	_	O
1	million	_	_	O
2	people	_	_	O
3	across	_	_	O
4	the	_	_	O
5	U.K.	_	_	O
6	are	_	_	O
7	living	_	_	O
8	with	_	_	O
9	cancer	_	_	O
10	,	_	_	O
11	often	_	_	O
12	experienced	_	_	O
13	as	_	_	O
14	a	_	_	O
15	long-term	_	_	O
16	condition	_	_	O
17	.	_	_	O

18	They	_	_	O
19	may	_	_	O
20	have	_	_	O
21	unmet	_	_	O
22	needs	_	_	O
23	after	_	_	O
24	active	_	_	O
25	treatment	_	_	O
26	.	_	_	O

27	Rehabilitation	_	_	O
28	aims	_	_	O
29	to	_	_	O
30	address	_	_	O
31	these	_	_	O
32	needs	_	_	O
33	,	_	_	O
34	maximize	_	_	O
35	psychological	_	_	O
36	and	_	_	O
37	physical	_	_	O
38	function	_	_	O
39	,	_	_	O
40	and	_	_	O
41	enable	_	_	O
42	minimum	_	_	O
43	dependency	_	_	O
44	regardless	_	_	O
45	of	_	_	O
46	life	_	_	O
47	expectancy	_	_	O
48	.	_	_	O

49	We	_	_	O
50	aimed	_	_	O
51	to	_	_	O
52	test	_	_	O
53	,	_	_	O
54	in	_	_	O
55	a	_	_	O
56	randomized	_	_	O
57	controlled	_	_	O
58	trial	_	_	O
59	,	_	_	O
60	the	_	_	O
61	clinical	_	_	O
62	and	_	_	O
63	cost	_	_	O
64	effectiveness	_	_	O
65	of	_	_	O
66	a	_	_	O
67	rehabilitation	_	_	O
68	intervention	_	_	O
69	for	_	_	O
70	patients	_	_	O
71	with	_	_	O
72	advanced	_	_	O
73	,	_	_	O
74	recurrent	_	_	O
75	cancer	_	_	O
76	.	_	_	O

77	We	_	_	O
78	conducted	_	_	O
79	a	_	_	O
80	two-arm	_	_	O
81	,	_	_	O
82	wait-list	_	_	O
83	control	_	_	O
84	,	_	_	O
85	randomized	_	_	O
86	trial	_	_	O
87	of	_	_	O
88	a	_	_	O
89	complex	_	_	O
90	rehabilitation	_	_	O
91	intervention	_	_	O
92	delivered	_	_	O
93	by	_	_	O
94	a	_	_	O
95	hospice-based	_	_	O
96	multidisciplinary	_	_	O
97	team	_	_	O
98	vs.	_	_	O
99	usual	_	_	O
100	care	_	_	O
101	for	_	_	O
102	active	_	_	O
103	,	_	_	O
104	progressive	_	_	O
105	,	_	_	O
106	recurrent	_	_	O
107	hematological	_	_	O
108	and	_	_	O
109	breast	_	_	O
110	malignancies	_	_	O
111	,	_	_	O
112	with	_	_	O
113	a	_	_	O
114	follow-up	_	_	O
115	at	_	_	O
116	three	_	_	O
117	months	_	_	O
118	.	_	_	O

119	The	_	_	O
120	primary	_	_	O
121	outcome	_	_	O
122	was	_	_	O
123	the	_	_	O
124	psychological	_	_	O
125	subscale	_	_	O
126	of	_	_	O
127	the	_	_	O
128	Supportive	_	_	O
129	Care	_	_	O
130	Needs	_	_	O
131	Survey	_	_	O
132	(	_	_	O
133	SCNS	_	_	O
134	)	_	_	O
135	.	_	_	O

136	Secondary	_	_	O
137	outcomes	_	_	O
138	were	_	_	O
139	other	_	_	O
140	domains	_	_	O
141	of	_	_	O
142	the	_	_	O
143	SCNS	_	_	O
144	,	_	_	O
145	psychological	_	_	O
146	status	_	_	O
147	,	_	_	O
148	continuity	_	_	O
149	of	_	_	O
150	care	_	_	O
151	,	_	_	O
152	quality	_	_	O
153	of	_	_	O
154	life	_	_	O
155	,	_	_	O
156	and	_	_	O
157	resource	_	_	O
158	use	_	_	O
159	.	_	_	O

160	Forty-one	_	_	O
161	participants	_	_	O
162	were	_	_	O
163	enrolled	_	_	O
164	and	_	_	O
165	36	_	_	O
166	completed	_	_	O
167	the	_	_	O
168	trial	_	_	O
169	.	_	_	O

170	The	_	_	B-Premise
171	primary	_	_	I-Premise
172	outcome	_	_	I-Premise
173	was	_	_	I-Premise
174	significantly	_	_	I-Premise
175	lower	_	_	I-Premise
176	in	_	_	I-Premise
177	the	_	_	I-Premise
178	intervention	_	_	I-Premise
179	arm	_	_	I-Premise
180	(	_	_	I-Premise
181	adjusted	_	_	I-Premise
182	difference	_	_	I-Premise
183	-16.8	_	_	I-Premise
184	,	_	_	I-Premise
185	95	_	_	I-Premise
186	%	_	_	I-Premise
187	CI	_	_	I-Premise
188	-28.34	_	_	I-Premise
189	to	_	_	I-Premise
190	-5.3	_	_	I-Premise
191	;	_	_	I-Premise
192	P	_	_	I-Premise
193	=	_	_	I-Premise
194	0.006	_	_	I-Premise
195	)	_	_	I-Premise
196	.	_	_	I-Premise

197	The	_	_	B-Premise
198	SCNS	_	_	I-Premise
199	physical	_	_	I-Premise
200	and	_	_	I-Premise
201	patient	_	_	I-Premise
202	care	_	_	I-Premise
203	subscales	_	_	I-Premise
204	(	_	_	I-Premise
205	-14.2	_	_	I-Premise
206	,	_	_	I-Premise
207	95	_	_	I-Premise
208	%	_	_	I-Premise
209	CI	_	_	I-Premise
210	-26.2	_	_	I-Premise
211	to	_	_	I-Premise
212	-2.2	_	_	I-Premise
213	;	_	_	I-Premise
214	P	_	_	I-Premise
215	=	_	_	I-Premise
216	0.02	_	_	I-Premise
217	and	_	_	I-Premise
218	-7.4	_	_	I-Premise
219	,	_	_	I-Premise
220	95	_	_	I-Premise
221	%	_	_	I-Premise
222	CI	_	_	I-Premise
223	-13.7	_	_	I-Premise
224	to	_	_	I-Premise
225	-1.1	_	_	I-Premise
226	;	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	0.02	_	_	I-Premise
230	,	_	_	I-Premise
231	respectively	_	_	I-Premise
232	)	_	_	I-Premise
233	and	_	_	I-Premise
234	self-reported	_	_	I-Premise
235	health	_	_	I-Premise
236	state	_	_	I-Premise
237	(	_	_	I-Premise
238	12.8	_	_	I-Premise
239	,	_	_	I-Premise
240	95	_	_	I-Premise
241	%	_	_	I-Premise
242	CI	_	_	I-Premise
243	3.2	_	_	I-Premise
244	to	_	_	I-Premise
245	22.4	_	_	I-Premise
246	;	_	_	I-Premise
247	P	_	_	I-Premise
248	=	_	_	I-Premise
249	0.01	_	_	I-Premise
250	)	_	_	I-Premise
251	also	_	_	I-Premise
252	differed	_	_	I-Premise
253	significantly	_	_	I-Premise
254	.	_	_	I-Premise

255	The	_	_	B-Premise
256	incremental	_	_	I-Premise
257	cost-effectiveness	_	_	I-Premise
258	ratio	_	_	I-Premise
259	was	_	_	I-Premise
260	£19,390	_	_	I-Premise
261	per	_	_	I-Premise
262	quality-adjusted	_	_	I-Premise
263	life	_	_	I-Premise
264	year	_	_	I-Premise
265	.	_	_	I-Premise

266	This	_	_	B-Claim
267	intervention	_	_	I-Claim
268	significantly	_	_	I-Claim
269	reduced	_	_	I-Claim
270	the	_	_	I-Claim
271	unmet	_	_	I-Claim
272	needs	_	_	I-Claim
273	of	_	_	I-Claim
274	cancer	_	_	I-Claim
275	survivors	_	_	I-Claim
276	and	_	_	I-Claim
277	it	_	_	I-Claim
278	is	_	_	I-Claim
279	likely	_	_	I-Claim
280	that	_	_	I-Claim
281	it	_	_	I-Claim
282	is	_	_	I-Claim
283	cost-effective	_	_	I-Claim
284	.	_	_	I-Claim

285	Despite	_	_	B-Claim
286	small	_	_	I-Claim
287	numbers	_	_	I-Claim
288	,	_	_	I-Claim
289	the	_	_	I-Claim
290	main	_	_	I-Claim
291	effect	_	_	I-Claim
292	size	_	_	I-Claim
293	was	_	_	I-Claim
294	robust	_	_	I-Claim
295	.	_	_	I-Claim

296	We	_	_	B-Claim
297	recommend	_	_	I-Claim
298	implementation	_	_	I-Claim
299	alongside	_	_	I-Claim
300	evaluation	_	_	I-Claim
301	in	_	_	I-Claim
302	wider	_	_	I-Claim
303	clinical	_	_	I-Claim
304	settings	_	_	I-Claim
305	and	_	_	I-Claim
306	patient	_	_	I-Claim
307	populations	_	_	I-Claim
308	.	_	_	I-Claim


0	To	_	_	O
1	study	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	Fuzheng	_	_	O
6	Jianpi	_	_	O
7	Decoction	_	_	O
8	(	_	_	O
9	FJD	_	_	O
10	)	_	_	O
11	combined	_	_	O
12	chemotherapy	_	_	O
13	on	_	_	O
14	the	_	_	O
15	quality	_	_	O
16	of	_	_	O
17	life	_	_	O
18	(	_	_	O
19	QOL	_	_	O
20	)	_	_	O
21	and	_	_	O
22	the	_	_	O
23	survival	_	_	O
24	time	_	_	O
25	of	_	_	O
26	children	_	_	O
27	with	_	_	O
28	solid	_	_	O
29	tumor	_	_	O
30	.	_	_	O

31	Recruited	_	_	O
32	were	_	_	O
33	167	_	_	O
34	solid	_	_	O
35	tumor	_	_	O
36	children	_	_	O
37	patients	_	_	O
38	at	_	_	O
39	Department	_	_	O
40	of	_	_	O
41	Tumor	_	_	O
42	,	_	_	O
43	Beijing	_	_	O
44	Children	_	_	O
45	's	_	_	O
46	Hospital	_	_	O
47	.	_	_	O

48	They	_	_	O
49	were	_	_	O
50	randomly	_	_	O
51	assigned	_	_	O
52	to	_	_	O
53	the	_	_	O
54	treatment	_	_	O
55	group	_	_	O
56	(	_	_	O
57	83	_	_	O
58	cases	_	_	O
59	)	_	_	O
60	and	_	_	O
61	the	_	_	O
62	control	_	_	O
63	group	_	_	O
64	(	_	_	O
65	84	_	_	O
66	cases	_	_	O
67	)	_	_	O
68	according	_	_	O
69	to	_	_	O
70	the	_	_	O
71	random	_	_	O
72	digit	_	_	O
73	table	_	_	O
74	.	_	_	O

75	All	_	_	O
76	had	_	_	O
77	chemotherapy	_	_	O
78	.	_	_	O

79	Those	_	_	O
80	in	_	_	O
81	the	_	_	O
82	treatment	_	_	O
83	group	_	_	O
84	additionally	_	_	O
85	took	_	_	O
86	FJD	_	_	O
87	,	_	_	O
88	50	_	_	O
89	-100	_	_	O
90	mL	_	_	O
91	each	_	_	O
92	time	_	_	O
93	,	_	_	O
94	twice	_	_	O
95	daily	_	_	O
96	.	_	_	O

97	After	_	_	O
98	chemotherapy	_	_	O
99	those	_	_	O
100	in	_	_	O
101	the	_	_	O
102	treatment	_	_	O
103	group	_	_	O
104	took	_	_	O
105	modified	_	_	O
106	FJD	_	_	O
107	.	_	_	O

108	The	_	_	O
109	WBC	_	_	O
110	,	_	_	O
111	Hb	_	_	O
112	,	_	_	O
113	and	_	_	O
114	PLT	_	_	O
115	were	_	_	O
116	detected	_	_	O
117	in	_	_	O
118	all	_	_	O
119	patients	_	_	O
120	before	_	_	O
121	treatment	_	_	O
122	,	_	_	O
123	6	_	_	O
124	months	_	_	O
125	after	_	_	O
126	treatment	_	_	O
127	,	_	_	O
128	and	_	_	O
129	1	_	_	O
130	year	_	_	O
131	after	_	_	O
132	treatment	_	_	O
133	.	_	_	O

134	The	_	_	O
135	1-	_	_	O
136	,	_	_	O
137	2-	_	_	O
138	,	_	_	O
139	and	_	_	O
140	3-year	_	_	O
141	QOL	_	_	O
142	,	_	_	O
143	3-year	_	_	O
144	survival	_	_	O
145	rate	_	_	O
146	,	_	_	O
147	and	_	_	O
148	the	_	_	O
149	survival	_	_	O
150	life	_	_	O
151	of	_	_	O
152	dead	_	_	O
153	children	_	_	O
154	patients	_	_	O
155	were	_	_	O
156	observed	_	_	O
157	.	_	_	O

158	Compared	_	_	B-Premise
159	with	_	_	I-Premise
160	the	_	_	I-Premise
161	control	_	_	I-Premise
162	group	_	_	I-Premise
163	of	_	_	I-Premise
164	the	_	_	I-Premise
165	same	_	_	I-Premise
166	period	_	_	I-Premise
167	,	_	_	I-Premise
168	the	_	_	I-Premise
169	6-month	_	_	I-Premise
170	and	_	_	I-Premise
171	1-year	_	_	I-Premise
172	WBC	_	_	I-Premise
173	and	_	_	I-Premise
174	Hb	_	_	I-Premise
175	increased	_	_	I-Premise
176	,	_	_	I-Premise
177	the	_	_	I-Premise
178	1-year	_	_	I-Premise
179	PLT	_	_	I-Premise
180	increased	_	_	I-Premise
181	in	_	_	I-Premise
182	the	_	_	I-Premise
183	treatment	_	_	I-Premise
184	group	_	_	I-Premise
185	,	_	_	I-Premise
186	showing	_	_	I-Premise
187	statistical	_	_	I-Premise
188	difference	_	_	I-Premise
189	(	_	_	I-Premise
190	P	_	_	I-Premise
191	<	_	_	I-Premise
192	0.05	_	_	I-Premise
193	,	_	_	I-Premise
194	P	_	_	I-Premise
195	<	_	_	I-Premise
196	0.01	_	_	I-Premise
197	)	_	_	I-Premise
198	.	_	_	I-Premise

199	Compared	_	_	B-Premise
200	with	_	_	I-Premise
201	1-year	_	_	I-Premise
202	treatment	_	_	I-Premise
203	in	_	_	I-Premise
204	the	_	_	I-Premise
205	treatment	_	_	I-Premise
206	group	_	_	I-Premise
207	,	_	_	I-Premise
208	the	_	_	I-Premise
209	2-and	_	_	I-Premise
210	3-year	_	_	I-Premise
211	psychological	_	_	I-Premise
212	functions	_	_	I-Premise
213	and	_	_	I-Premise
214	the	_	_	I-Premise
215	general	_	_	I-Premise
216	symptoms	_	_	I-Premise
217	scores	_	_	I-Premise
218	decreased	_	_	I-Premise
219	(	_	_	I-Premise
220	P	_	_	I-Premise
221	<	_	_	I-Premise
222	0.05	_	_	I-Premise
223	,	_	_	I-Premise
224	P	_	_	I-Premise
225	<	_	_	I-Premise
226	0.01	_	_	I-Premise
227	)	_	_	I-Premise
228	.	_	_	I-Premise

229	Compared	_	_	B-Premise
230	with	_	_	I-Premise
231	the	_	_	I-Premise
232	control	_	_	I-Premise
233	group	_	_	I-Premise
234	of	_	_	I-Premise
235	the	_	_	I-Premise
236	same	_	_	I-Premise
237	period	_	_	I-Premise
238	,	_	_	I-Premise
239	the	_	_	I-Premise
240	2-and	_	_	I-Premise
241	3-year	_	_	I-Premise
242	somatic	_	_	I-Premise
243	functions	_	_	I-Premise
244	,	_	_	I-Premise
245	psychological	_	_	I-Premise
246	functions	_	_	I-Premise
247	,	_	_	I-Premise
248	and	_	_	I-Premise
249	the	_	_	I-Premise
250	general	_	_	I-Premise
251	symptoms	_	_	I-Premise
252	scores	_	_	I-Premise
253	decreased	_	_	I-Premise
254	in	_	_	I-Premise
255	the	_	_	I-Premise
256	treatment	_	_	I-Premise
257	group	_	_	I-Premise
258	;	_	_	I-Premise
259	the	_	_	B-Premise
260	2-year	_	_	I-Premise
261	somatic	_	_	I-Premise
262	functions	_	_	I-Premise
263	and	_	_	I-Premise
264	psychological	_	_	I-Premise
265	functions	_	_	I-Premise
266	decreased	_	_	I-Premise
267	in	_	_	I-Premise
268	the	_	_	I-Premise
269	treatment	_	_	I-Premise
270	group	_	_	I-Premise
271	;	_	_	I-Premise
272	the	_	_	B-Premise
273	3-year	_	_	I-Premise
274	psychological	_	_	I-Premise
275	functions	_	_	I-Premise
276	and	_	_	I-Premise
277	the	_	_	I-Premise
278	general	_	_	I-Premise
279	symptoms	_	_	I-Premise
280	scores	_	_	I-Premise
281	decreased	_	_	I-Premise
282	in	_	_	I-Premise
283	the	_	_	I-Premise
284	treatment	_	_	I-Premise
285	group	_	_	I-Premise
286	,	_	_	I-Premise
287	all	_	_	I-Premise
288	with	_	_	I-Premise
289	statistical	_	_	I-Premise
290	difference	_	_	I-Premise
291	(	_	_	I-Premise
292	all	_	_	I-Premise
293	P	_	_	I-Premise
294	<	_	_	I-Premise
295	0.05	_	_	I-Premise
296	)	_	_	I-Premise
297	.	_	_	I-Premise

298	Compared	_	_	B-Premise
299	with	_	_	I-Premise
300	the	_	_	I-Premise
301	control	_	_	I-Premise
302	group	_	_	I-Premise
303	,	_	_	I-Premise
304	the	_	_	I-Premise
305	death	_	_	I-Premise
306	number	_	_	I-Premise
307	decreased	_	_	I-Premise
308	,	_	_	I-Premise
309	the	_	_	I-Premise
310	survival	_	_	I-Premise
311	rate	_	_	I-Premise
312	increased	_	_	I-Premise
313	,	_	_	I-Premise
314	the	_	_	I-Premise
315	life	_	_	I-Premise
316	span	_	_	I-Premise
317	of	_	_	I-Premise
318	dead	_	_	I-Premise
319	children	_	_	I-Premise
320	was	_	_	I-Premise
321	prolonged	_	_	I-Premise
322	in	_	_	I-Premise
323	the	_	_	I-Premise
324	treatment	_	_	I-Premise
325	group	_	_	I-Premise
326	,	_	_	I-Premise
327	showing	_	_	I-Premise
328	statistical	_	_	I-Premise
329	difference	_	_	I-Premise
330	(	_	_	I-Premise
331	P	_	_	I-Premise
332	<	_	_	I-Premise
333	0.05	_	_	I-Premise
334	)	_	_	I-Premise
335	.	_	_	I-Premise

336	FJD	_	_	B-Claim
337	combined	_	_	I-Claim
338	chemotherapy	_	_	I-Claim
339	could	_	_	I-Claim
340	effectively	_	_	I-Claim
341	improve	_	_	I-Claim
342	the	_	_	I-Claim
343	QOL	_	_	I-Claim
344	of	_	_	I-Claim
345	solid	_	_	I-Claim
346	tumor	_	_	I-Claim
347	children	_	_	I-Claim
348	patients	_	_	I-Claim
349	,	_	_	I-Claim
350	elevate	_	_	I-Claim
351	their	_	_	I-Claim
352	survival	_	_	I-Claim
353	rate	_	_	I-Claim
354	,	_	_	I-Claim
355	and	_	_	I-Claim
356	prolong	_	_	I-Claim
357	their	_	_	I-Claim
358	life	_	_	I-Claim
359	spans	_	_	I-Claim
360	.	_	_	I-Claim


0	Chemoradiotherapy	_	_	O
1	(	_	_	O
2	CRT	_	_	O
3	)	_	_	O
4	-induced	_	_	O
5	oral	_	_	O
6	mucositis	_	_	O
7	(	_	_	O
8	OM	_	_	O
9	)	_	_	O
10	adversely	_	_	O
11	affects	_	_	O
12	a	_	_	O
13	patient	_	_	O
14	's	_	_	O
15	oral	_	_	O
16	functions	_	_	O
17	and	_	_	O
18	quality	_	_	O
19	of	_	_	O
20	life	_	_	O
21	(	_	_	O
22	QOL	_	_	O
23	)	_	_	O
24	.	_	_	O

25	Low-level	_	_	O
26	laser	_	_	O
27	therapy	_	_	O
28	(	_	_	O
29	LLLT	_	_	O
30	)	_	_	O
31	showed	_	_	O
32	some	_	_	O
33	preventive	_	_	O
34	and	_	_	O
35	curative	_	_	O
36	effects	_	_	O
37	against	_	_	O
38	clinically	_	_	O
39	reported	_	_	O
40	objective	_	_	O
41	measures	_	_	O
42	of	_	_	O
43	OM	_	_	O
44	in	_	_	O
45	few	_	_	O
46	trials	_	_	O
47	including	_	_	O
48	our	_	_	O
49	recently	_	_	O
50	published	_	_	O
51	study	_	_	O
52	.	_	_	O

53	There	_	_	O
54	is	_	_	O
55	dearth	_	_	O
56	of	_	_	O
57	evidence	_	_	O
58	regarding	_	_	O
59	the	_	_	O
60	effects	_	_	O
61	of	_	_	O
62	LLLT	_	_	O
63	on	_	_	O
64	patient	_	_	O
65	's	_	_	O
66	subjective	_	_	O
67	experience	_	_	O
68	of	_	_	O
69	OM	_	_	O
70	and	_	_	O
71	QOL	_	_	O
72	.	_	_	O

73	Hence	_	_	O
74	,	_	_	O
75	we	_	_	O
76	did	_	_	O
77	this	_	_	O
78	study	_	_	O
79	to	_	_	O
80	evaluate	_	_	O
81	the	_	_	O
82	effects	_	_	O
83	of	_	_	O
84	LLLT	_	_	O
85	on	_	_	O
86	a	_	_	O
87	patient	_	_	O
88	's	_	_	O
89	reported	_	_	O
90	measures	_	_	O
91	of	_	_	O
92	OM	_	_	O
93	and	_	_	O
94	QOL	_	_	O
95	in	_	_	O
96	head	_	_	O
97	and	_	_	O
98	neck	_	_	O
99	cancer	_	_	O
100	(	_	_	O
101	HNC	_	_	O
102	)	_	_	O
103	patients	_	_	O
104	receiving	_	_	O
105	CRT	_	_	O
106	.	_	_	O

107	This	_	_	O
108	triple	_	_	O
109	blinded	_	_	O
110	study	_	_	O
111	randomized	_	_	O
112	220	_	_	O
113	HNC	_	_	O
114	patients	_	_	O
115	scheduled	_	_	O
116	for	_	_	O
117	CRT	_	_	O
118	(	_	_	O
119	three	_	_	O
120	weekly	_	_	O
121	Cisplatin	_	_	O
122	+	_	_	O
123	RT	_	_	O
124	=	_	_	O
125	66	_	_	O
126	Gray	_	_	O
127	(	_	_	O
128	2	_	_	O
129	Gy/session	_	_	O
130	)	_	_	O
131	,	_	_	O
132	five	_	_	O
133	fractions/week	_	_	O
134	for	_	_	O
135	6.5	_	_	O
136	weeks	_	_	O
137	,	_	_	O
138	total	_	_	O
139	33	_	_	O
140	fractions	_	_	O
141	)	_	_	O
142	into	_	_	O
143	laser	_	_	O
144	(	_	_	O
145	110	_	_	O
146	)	_	_	O
147	and	_	_	O
148	placebo	_	_	O
149	(	_	_	O
150	110	_	_	O
151	)	_	_	O
152	groups	_	_	O
153	.	_	_	O

154	The	_	_	O
155	laser	_	_	O
156	group	_	_	O
157	received	_	_	O
158	LLLT	_	_	O
159	(	_	_	O
160	Technomed	_	_	O
161	Electronics	_	_	O
162	Advanced	_	_	O
163	Laser	_	_	O
164	Therapy	_	_	O
165	1000	_	_	O
166	,	_	_	O
167	He-Ne	_	_	O
168	,	_	_	O
169	λ	_	_	O
170	=	_	_	O
171	632.8	_	_	O
172	nm	_	_	O
173	,	_	_	O
174	power	_	_	O
175	density	_	_	O
176	=	_	_	O
177	24	_	_	O
178	mW/cm	_	_	O
179	(	_	_	O
180	2	_	_	O
181	)	_	_	O
182	,	_	_	O
183	dosage	_	_	O
184	=	_	_	O
185	3.0	_	_	O
186	J	_	_	O
187	at	_	_	O
188	each	_	_	O
189	point	_	_	O
190	,	_	_	O
191	total	_	_	O
192	dose/session	_	_	O
193	=	_	_	O
194	36-40	_	_	O
195	J	_	_	O
196	,	_	_	O
197	spot	_	_	O
198	size	_	_	O
199	1	_	_	O
200	cm	_	_	O
201	(	_	_	O
202	2	_	_	O
203	)	_	_	O
204	,	_	_	O
205	irradiation	_	_	O
206	time/point	_	_	O
207	125	_	_	O
208	s	_	_	O
209	)	_	_	O
210	before	_	_	O
211	each	_	_	O
212	radiation	_	_	O
213	session	_	_	O
214	,	_	_	O
215	while	_	_	O
216	the	_	_	O
217	placebo	_	_	O
218	group	_	_	O
219	did	_	_	O
220	not	_	_	O
221	receive	_	_	O
222	laser	_	_	O
223	therapy	_	_	O
224	.	_	_	O

225	Methodology	_	_	O
226	was	_	_	O
227	similar	_	_	O
228	to	_	_	O
229	our	_	_	O
230	recently	_	_	O
231	published	_	_	O
232	study	_	_	O
233	(	_	_	O
234	Gautam	_	_	O
235	et	_	_	O
236	al	_	_	O
237	.	_	_	O

238	Radiother	_	_	O
239	Oncol	_	_	O
240	104:349-354	_	_	O
241	,	_	_	O
242	2012	_	_	O
243	)	_	_	O
244	.	_	_	O

245	In	_	_	O
246	this	_	_	O
247	part	_	_	O
248	of	_	_	O
249	our	_	_	O
250	study	_	_	O
251	,	_	_	O
252	a	_	_	O
253	blinded	_	_	O
254	assessor	_	_	O
255	collected	_	_	O
256	subjective	_	_	O
257	outcomes	_	_	O
258	of	_	_	O
259	the	_	_	O
260	patient	_	_	O
261	's	_	_	O
262	reported	_	_	O
263	measures	_	_	O
264	of	_	_	O
265	OM	_	_	O
266	using	_	_	O
267	Oral	_	_	O
268	Mucositis	_	_	O
269	Weekly	_	_	O
270	Questionnaire-Head	_	_	O
271	and	_	_	O
272	Neck	_	_	O
273	(	_	_	O
274	OMWQ-HN	_	_	O
275	)	_	_	O
276	and	_	_	O
277	QOL	_	_	O
278	using	_	_	O
279	Functional	_	_	O
280	Assessment	_	_	O
281	of	_	_	O
282	Cancer	_	_	O
283	Treatment-Head	_	_	O
284	and	_	_	O
285	Neck	_	_	O
286	(	_	_	O
287	FACT-HN	_	_	O
288	)	_	_	O
289	Questionnaire	_	_	O
290	.	_	_	O

291	Data	_	_	O
292	were	_	_	O
293	analyzed	_	_	O
294	using	_	_	O
295	repeated	_	_	O
296	measure	_	_	O
297	ANOVA	_	_	O
298	through	_	_	O
299	general	_	_	O
300	linear	_	_	O
301	model	_	_	O
302	.	_	_	O

303	Statistical	_	_	O
304	significance	_	_	O
305	was	_	_	O
306	kept	_	_	O
307	at	_	_	O
308	p	_	_	O
309	<	_	_	O
310	0.05	_	_	O
311	.	_	_	O

312	Results	_	_	B-Premise
313	analysis	_	_	I-Premise
314	revealed	_	_	I-Premise
315	that	_	_	I-Premise
316	OMWQ-HN	_	_	I-Premise
317	(	_	_	I-Premise
318	F	_	_	I-Premise
319	=	_	_	I-Premise
320	12.199	_	_	I-Premise
321	,	_	_	I-Premise
322	df	_	_	I-Premise
323	=	_	_	I-Premise
324	6,1314	_	_	I-Premise
325	,	_	_	I-Premise
326	p	_	_	I-Premise
327	<	_	_	I-Premise
328	0.001	_	_	I-Premise
329	)	_	_	I-Premise
330	and	_	_	I-Premise
331	FACT-HN	_	_	I-Premise
332	(	_	_	I-Premise
333	p	_	_	I-Premise
334	<	_	_	I-Premise
335	0.05	_	_	I-Premise
336	)	_	_	I-Premise
337	scores	_	_	I-Premise
338	were	_	_	I-Premise
339	significantly	_	_	I-Premise
340	lower	_	_	I-Premise
341	in	_	_	I-Premise
342	LLLT	_	_	I-Premise
343	than	_	_	I-Premise
344	placebo	_	_	I-Premise
345	group	_	_	I-Premise
346	patients	_	_	I-Premise
347	.	_	_	I-Premise

348	Also	_	_	O
349	,	_	_	O
350	a	_	_	B-Premise
351	significant	_	_	I-Premise
352	reduction	_	_	I-Premise
353	(	_	_	I-Premise
354	p	_	_	I-Premise
355	<	_	_	I-Premise
356	0.001	_	_	I-Premise
357	)	_	_	I-Premise
358	in	_	_	I-Premise
359	incidence	_	_	I-Premise
360	of	_	_	I-Premise
361	severe	_	_	I-Premise
362	OM	_	_	I-Premise
363	,	_	_	I-Premise
364	need	_	_	I-Premise
365	for	_	_	I-Premise
366	opioid	_	_	I-Premise
367	analgesics	_	_	I-Premise
368	,	_	_	I-Premise
369	and	_	_	I-Premise
370	total	_	_	I-Premise
371	parenteral	_	_	I-Premise
372	nutrition	_	_	I-Premise
373	was	_	_	I-Premise
374	observed	_	_	I-Premise
375	.	_	_	I-Premise

376	LLLT	_	_	B-Claim
377	was	_	_	I-Claim
378	effective	_	_	I-Claim
379	in	_	_	I-Claim
380	improving	_	_	I-Claim
381	the	_	_	I-Claim
382	patient	_	_	I-Claim
383	's	_	_	I-Claim
384	subjective	_	_	I-Claim
385	experience	_	_	I-Claim
386	of	_	_	I-Claim
387	OM	_	_	I-Claim
388	and	_	_	I-Claim
389	QOL	_	_	I-Claim
390	in	_	_	I-Claim
391	HNC	_	_	I-Claim
392	patients	_	_	I-Claim
393	receiving	_	_	I-Claim
394	CRT	_	_	I-Claim
395	.	_	_	I-Claim


0	Behavioral	_	_	O
1	symptoms	_	_	O
2	are	_	_	O
3	common	_	_	O
4	in	_	_	O
5	breast	_	_	O
6	cancer	_	_	O
7	survivors	_	_	O
8	,	_	_	O
9	including	_	_	O
10	disturbances	_	_	O
11	in	_	_	O
12	energy	_	_	O
13	,	_	_	O
14	sleep	_	_	O
15	,	_	_	O
16	and	_	_	O
17	mood	_	_	O
18	,	_	_	O
19	though	_	_	O
20	few	_	_	O
21	risk	_	_	O
22	factors	_	_	O
23	for	_	_	O
24	these	_	_	O
25	negative	_	_	O
26	outcomes	_	_	O
27	have	_	_	O
28	been	_	_	O
29	identified	_	_	O
30	.	_	_	O

31	Our	_	_	O
32	study	_	_	O
33	examined	_	_	O
34	intrusive	_	_	O
35	thoughts	_	_	O
36	as	_	_	O
37	a	_	_	O
38	predictor	_	_	O
39	of	_	_	O
40	lingering	_	_	O
41	symptoms	_	_	O
42	in	_	_	O
43	breast	_	_	O
44	cancer	_	_	O
45	survivors	_	_	O
46	in	_	_	O
47	the	_	_	O
48	year	_	_	O
49	following	_	_	O
50	treatment	_	_	O
51	.	_	_	O

52	Data	_	_	O
53	come	_	_	O
54	from	_	_	O
55	the	_	_	O
56	Moving	_	_	O
57	Beyond	_	_	O
58	Cancer	_	_	O
59	psychoeducational	_	_	O
60	intervention	_	_	O
61	trial	_	_	O
62	,	_	_	O
63	aimed	_	_	O
64	at	_	_	O
65	easing	_	_	O
66	the	_	_	O
67	transition	_	_	O
68	from	_	_	O
69	patient	_	_	O
70	to	_	_	O
71	survivor	_	_	O
72	.	_	_	O

73	Women	_	_	O
74	(	_	_	O
75	n	_	_	O
76	=	_	_	O
77	558	_	_	O
78	)	_	_	O
79	completed	_	_	O
80	psychosocial	_	_	O
81	questionnaires	_	_	O
82	within	_	_	O
83	4	_	_	O
84	weeks	_	_	O
85	posttreatment	_	_	O
86	and	_	_	O
87	again	_	_	O
88	2	_	_	O
89	,	_	_	O
90	6	_	_	O
91	,	_	_	O
92	and	_	_	O
93	12	_	_	O
94	months	_	_	O
95	later	_	_	O
96	.	_	_	O

97	We	_	_	O
98	examined	_	_	O
99	intrusive	_	_	O
100	thoughts	_	_	O
101	about	_	_	O
102	cancer	_	_	O
103	at	_	_	O
104	the	_	_	O
105	baseline	_	_	O
106	assessment	_	_	O
107	as	_	_	O
108	a	_	_	O
109	predictor	_	_	O
110	of	_	_	O
111	fatigue	_	_	O
112	,	_	_	O
113	sleep	_	_	O
114	problems	_	_	O
115	,	_	_	O
116	pain	_	_	O
117	,	_	_	O
118	breast	_	_	O
119	cancer-specific	_	_	O
120	symptoms	_	_	O
121	,	_	_	O
122	depressive	_	_	O
123	symptoms	_	_	O
124	,	_	_	O
125	negative	_	_	O
126	affect	_	_	O
127	,	_	_	O
128	and	_	_	O
129	quality	_	_	O
130	of	_	_	O
131	life	_	_	O
132	using	_	_	O
133	growth	_	_	O
134	curve	_	_	O
135	modeling	_	_	O
136	,	_	_	O
137	controlling	_	_	O
138	for	_	_	O
139	study	_	_	O
140	condition	_	_	O
141	and	_	_	O
142	other	_	_	O
143	covariates	_	_	O
144	.	_	_	O

145	Intrusive	_	_	B-Premise
146	thoughts	_	_	I-Premise
147	were	_	_	I-Premise
148	associated	_	_	I-Premise
149	with	_	_	I-Premise
150	higher	_	_	I-Premise
151	levels	_	_	I-Premise
152	of	_	_	I-Premise
153	all	_	_	I-Premise
154	symptoms	_	_	I-Premise
155	at	_	_	I-Premise
156	baseline	_	_	I-Premise
157	and	_	_	I-Premise
158	at	_	_	I-Premise
159	the	_	_	I-Premise
160	12-month	_	_	I-Premise
161	assessment	_	_	I-Premise
162	.	_	_	I-Premise

163	Intrusive	_	_	B-Premise
164	thoughts	_	_	I-Premise
165	also	_	_	I-Premise
166	influenced	_	_	I-Premise
167	the	_	_	I-Premise
168	trajectory	_	_	I-Premise
169	of	_	_	I-Premise
170	pain	_	_	I-Premise
171	,	_	_	I-Premise
172	depressive	_	_	I-Premise
173	symptoms	_	_	I-Premise
174	,	_	_	I-Premise
175	negative	_	_	I-Premise
176	affect	_	_	I-Premise
177	,	_	_	I-Premise
178	and	_	_	I-Premise
179	physical	_	_	I-Premise
180	functioning	_	_	I-Premise
181	over	_	_	I-Premise
182	time	_	_	I-Premise
183	;	_	_	I-Premise
184	women	_	_	B-Premise
185	with	_	_	I-Premise
186	higher	_	_	I-Premise
187	intrusions	_	_	I-Premise
188	at	_	_	I-Premise
189	baseline	_	_	I-Premise
190	started	_	_	I-Premise
191	worse	_	_	I-Premise
192	and	_	_	I-Premise
193	improved	_	_	I-Premise
194	over	_	_	I-Premise
195	time	_	_	I-Premise
196	,	_	_	I-Premise
197	whereas	_	_	I-Premise
198	those	_	_	I-Premise
199	with	_	_	I-Premise
200	lower	_	_	I-Premise
201	intrusions	_	_	I-Premise
202	remained	_	_	I-Premise
203	at	_	_	I-Premise
204	a	_	_	I-Premise
205	constant	_	_	I-Premise
206	,	_	_	I-Premise
207	lower	_	_	I-Premise
208	level	_	_	I-Premise
209	over	_	_	I-Premise
210	time	_	_	I-Premise
211	.	_	_	I-Premise

212	Intrusions	_	_	B-Premise
213	were	_	_	I-Premise
214	not	_	_	I-Premise
215	associated	_	_	I-Premise
216	with	_	_	I-Premise
217	the	_	_	I-Premise
218	trajectory	_	_	I-Premise
219	of	_	_	I-Premise
220	fatigue	_	_	I-Premise
221	,	_	_	I-Premise
222	sleep	_	_	I-Premise
223	,	_	_	I-Premise
224	breast	_	_	I-Premise
225	cancer-specific	_	_	I-Premise
226	symptoms	_	_	I-Premise
227	,	_	_	I-Premise
228	or	_	_	I-Premise
229	mental	_	_	I-Premise
230	functioning	_	_	I-Premise
231	;	_	_	I-Premise
232	women	_	_	B-Premise
233	with	_	_	I-Premise
234	higher	_	_	I-Premise
235	intrusions	_	_	I-Premise
236	at	_	_	I-Premise
237	baseline	_	_	I-Premise
238	started	_	_	I-Premise
239	worse	_	_	I-Premise
240	and	_	_	I-Premise
241	remained	_	_	I-Premise
242	worse	_	_	I-Premise
243	over	_	_	I-Premise
244	time	_	_	I-Premise
245	.	_	_	I-Premise

246	Intrusive	_	_	B-Claim
247	thoughts	_	_	I-Claim
248	are	_	_	I-Claim
249	associated	_	_	I-Claim
250	with	_	_	I-Claim
251	enduring	_	_	I-Claim
252	elevations	_	_	I-Claim
253	in	_	_	I-Claim
254	behavioral	_	_	I-Claim
255	symptoms	_	_	I-Claim
256	and	_	_	I-Claim
257	impaired	_	_	I-Claim
258	quality	_	_	I-Claim
259	of	_	_	I-Claim
260	life	_	_	I-Claim
261	in	_	_	I-Claim
262	the	_	_	I-Claim
263	year	_	_	I-Claim
264	after	_	_	I-Claim
265	breast	_	_	I-Claim
266	cancer	_	_	I-Claim
267	treatment	_	_	I-Claim
268	and	_	_	I-Claim
269	may	_	_	I-Claim
270	be	_	_	I-Claim
271	a	_	_	I-Claim
272	risk	_	_	I-Claim
273	factor	_	_	I-Claim
274	for	_	_	I-Claim
275	poor	_	_	I-Claim
276	outcomes	_	_	I-Claim
277	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	dose-volume	_	_	O
3	histogram	_	_	O
4	variables	_	_	O
5	for	_	_	O
6	the	_	_	O
7	internal	_	_	O
8	and	_	_	O
9	external	_	_	O
10	urinary	_	_	O
11	sphincters	_	_	O
12	(	_	_	O
13	IUS/EUS	_	_	O
14	)	_	_	O
15	with	_	_	O
16	urinary	_	_	O
17	quality	_	_	O
18	of	_	_	O
19	life	_	_	O
20	after	_	_	O
21	prostate	_	_	O
22	brachytherapy	_	_	O
23	.	_	_	O

24	Subjects	_	_	O
25	were	_	_	O
26	42	_	_	O
27	consecutive	_	_	O
28	men	_	_	O
29	from	_	_	O
30	a	_	_	O
31	prospective	_	_	O
32	study	_	_	O
33	of	_	_	O
34	brachytherapy	_	_	O
35	as	_	_	O
36	monotherapy	_	_	O
37	with	_	_	O
38	(	_	_	O
39	125	_	_	O
40	)	_	_	O
41	I	_	_	O
42	for	_	_	O
43	intermediate-risk	_	_	O
44	localized	_	_	O
45	prostate	_	_	O
46	cancer	_	_	O
47	.	_	_	O

48	No	_	_	O
49	patient	_	_	O
50	received	_	_	O
51	hormonal	_	_	O
52	therapy	_	_	O
53	.	_	_	O

54	Preplanning	_	_	O
55	constraints	_	_	O
56	included	_	_	O
57	prostate	_	_	O
58	V100	_	_	O
59	higher	_	_	O
60	than	_	_	O
61	95	_	_	O
62	%	_	_	O
63	,	_	_	O
64	V150	_	_	O
65	lower	_	_	O
66	than	_	_	O
67	60	_	_	O
68	%	_	_	O
69	,	_	_	O
70	and	_	_	O
71	V200	_	_	O
72	lower	_	_	O
73	than	_	_	O
74	20	_	_	O
75	%	_	_	O
76	and	_	_	O
77	rectal	_	_	O
78	R100	_	_	O
79	less	_	_	O
80	than	_	_	O
81	1cm	_	_	O
82	(	_	_	O
83	3	_	_	O
84	)	_	_	O
85	.	_	_	O

86	Patients	_	_	O
87	completed	_	_	O
88	the	_	_	O
89	Expanded	_	_	O
90	Prostate	_	_	O
91	Cancer	_	_	O
92	Index	_	_	O
93	Composite	_	_	O
94	quality-of-life	_	_	O
95	questionnaire	_	_	O
96	before	_	_	O
97	and	_	_	O
98	at	_	_	O
99	1	_	_	O
100	,	_	_	O
101	4	_	_	O
102	,	_	_	O
103	8	_	_	O
104	,	_	_	O
105	and	_	_	O
106	12	_	_	O
107	months	_	_	O
108	after	_	_	O
109	implantation	_	_	O
110	,	_	_	O
111	and	_	_	O
112	urinary	_	_	O
113	domain	_	_	O
114	scores	_	_	O
115	were	_	_	O
116	analyzed	_	_	O
117	.	_	_	O

118	All	_	_	O
119	structures	_	_	O
120	including	_	_	O
121	the	_	_	O
122	IUS	_	_	O
123	and	_	_	O
124	EUS	_	_	O
125	were	_	_	O
126	contoured	_	_	O
127	on	_	_	O
128	T2-weighted	_	_	O
129	MRI	_	_	O
130	at	_	_	O
131	day	_	_	O
132	30	_	_	O
133	,	_	_	O
134	and	_	_	O
135	doses	_	_	O
136	received	_	_	O
137	were	_	_	O
138	calculated	_	_	O
139	from	_	_	O
140	identification	_	_	O
141	of	_	_	O
142	seeds	_	_	O
143	on	_	_	O
144	CT.	_	_	O
145	Spearman	_	_	O
146	's	_	_	O
147	(	_	_	O
148	nonparametric	_	_	O
149	)	_	_	O
150	rank	_	_	O
151	correlation	_	_	O
152	coefficient	_	_	O
153	(	_	_	O
154	ρ	_	_	O
155	)	_	_	O
156	was	_	_	O
157	used	_	_	O
158	for	_	_	O
159	statistical	_	_	O
160	analyses	_	_	O
161	.	_	_	O

162	Overall	_	_	O
163	urinary	_	_	O
164	morbidity	_	_	O
165	was	_	_	O
166	worst	_	_	O
167	at	_	_	O
168	1	_	_	O
169	month	_	_	O
170	after	_	_	O
171	the	_	_	O
172	implant	_	_	O
173	.	_	_	O

174	Urinary	_	_	B-Premise
175	function	_	_	I-Premise
176	declined	_	_	I-Premise
177	when	_	_	I-Premise
178	the	_	_	I-Premise
179	IUS	_	_	I-Premise
180	V285	_	_	I-Premise
181	was	_	_	I-Premise
182	0.4	_	_	I-Premise
183	%	_	_	I-Premise
184	(	_	_	I-Premise
185	ρ=-0.32	_	_	I-Premise
186	,	_	_	I-Premise
187	p=0.04	_	_	I-Premise
188	)	_	_	I-Premise
189	;	_	_	I-Premise
190	bother	_	_	B-Premise
191	worsened	_	_	I-Premise
192	when	_	_	I-Premise
193	the	_	_	I-Premise
194	IUS	_	_	I-Premise
195	V35	_	_	I-Premise
196	was	_	_	I-Premise
197	99	_	_	I-Premise
198	%	_	_	I-Premise
199	(	_	_	I-Premise
200	ρ=-0.31	_	_	I-Premise
201	,	_	_	I-Premise
202	p=0.05	_	_	I-Premise
203	)	_	_	I-Premise
204	or	_	_	I-Premise
205	the	_	_	I-Premise
206	EUS	_	_	I-Premise
207	V240	_	_	I-Premise
208	was	_	_	I-Premise
209	63	_	_	I-Premise
210	%	_	_	I-Premise
211	(	_	_	I-Premise
212	ρ=-0.31	_	_	I-Premise
213	,	_	_	I-Premise
214	p=0.05	_	_	I-Premise
215	)	_	_	I-Premise
216	;	_	_	I-Premise
217	irritation	_	_	B-Premise
218	increased	_	_	I-Premise
219	when	_	_	I-Premise
220	the	_	_	I-Premise
221	IUS	_	_	I-Premise
222	V35	_	_	I-Premise
223	was	_	_	I-Premise
224	95	_	_	I-Premise
225	%	_	_	I-Premise
226	(	_	_	I-Premise
227	ρ=-0.37	_	_	I-Premise
228	,	_	_	I-Premise
229	p=0.02	_	_	I-Premise
230	)	_	_	I-Premise
231	and	_	_	I-Premise
232	the	_	_	I-Premise
233	EUS	_	_	I-Premise
234	V265	_	_	I-Premise
235	was	_	_	I-Premise
236	24	_	_	I-Premise
237	%	_	_	I-Premise
238	(	_	_	I-Premise
239	ρ=-0.32	_	_	I-Premise
240	,	_	_	I-Premise
241	p=0.04	_	_	I-Premise
242	)	_	_	I-Premise
243	;	_	_	I-Premise
244	and	_	_	O
245	urgency	_	_	B-Premise
246	worsened	_	_	I-Premise
247	when	_	_	I-Premise
248	the	_	_	I-Premise
249	IUS	_	_	I-Premise
250	V35	_	_	I-Premise
251	was	_	_	I-Premise
252	99.5	_	_	I-Premise
253	%	_	_	I-Premise
254	(	_	_	I-Premise
255	ρ=-0.38	_	_	I-Premise
256	,	_	_	I-Premise
257	p=0.02	_	_	I-Premise
258	)	_	_	I-Premise
259	.	_	_	I-Premise

260	Incontinence	_	_	B-Premise
261	did	_	_	I-Premise
262	not	_	_	I-Premise
263	correlate	_	_	I-Premise
264	with	_	_	I-Premise
265	EUS	_	_	I-Premise
266	or	_	_	I-Premise
267	IUS	_	_	I-Premise
268	dose	_	_	I-Premise
269	.	_	_	I-Premise

270	Doses	_	_	B-Claim
271	to	_	_	I-Claim
272	the	_	_	I-Claim
273	IUS	_	_	I-Claim
274	and	_	_	I-Claim
275	EUS	_	_	I-Claim
276	on	_	_	I-Claim
277	MRI/CT	_	_	I-Claim
278	predicted	_	_	I-Claim
279	worse	_	_	I-Claim
280	urinary	_	_	I-Claim
281	function	_	_	I-Claim
282	,	_	_	I-Claim
283	with	_	_	I-Claim
284	greater	_	_	I-Claim
285	bother	_	_	I-Claim
286	,	_	_	I-Claim
287	irritative	_	_	I-Claim
288	symptoms	_	_	I-Claim
289	,	_	_	I-Claim
290	and	_	_	I-Claim
291	urgency	_	_	I-Claim
292	.	_	_	I-Claim

293	Incorporating	_	_	B-Claim
294	MRI-based	_	_	I-Claim
295	dose-volume	_	_	I-Claim
296	histogram	_	_	I-Claim
297	analysis	_	_	I-Claim
298	into	_	_	I-Claim
299	the	_	_	I-Claim
300	treatment	_	_	I-Claim
301	planning	_	_	I-Claim
302	process	_	_	I-Claim
303	may	_	_	I-Claim
304	reduce	_	_	I-Claim
305	acute	_	_	I-Claim
306	urinary	_	_	I-Claim
307	morbidity	_	_	I-Claim
308	after	_	_	I-Claim
309	brachytherapy	_	_	I-Claim
310	.	_	_	I-Claim


0	Maintenance	_	_	O
1	therapy	_	_	O
2	can	_	_	O
3	delay	_	_	O
4	progression	_	_	O
5	and	_	_	O
6	prolong	_	_	O
7	survival	_	_	O
8	in	_	_	O
9	metastatic	_	_	O
10	non-small-cell	_	_	O
11	lung	_	_	O
12	cancer	_	_	O
13	(	_	_	O
14	mNSCLC	_	_	O
15	)	_	_	O
16	.	_	_	O

17	As	_	_	O
18	treatment	_	_	O
19	for	_	_	O
20	mNSCLC	_	_	O
21	is	_	_	O
22	non-curative	_	_	O
23	,	_	_	O
24	its	_	_	O
25	impact	_	_	O
26	on	_	_	O
27	patient	_	_	O
28	health-related	_	_	O
29	quality	_	_	O
30	of	_	_	O
31	life	_	_	O
32	(	_	_	O
33	HRQoL	_	_	O
34	)	_	_	O
35	is	_	_	O
36	an	_	_	O
37	important	_	_	O
38	consideration	_	_	O
39	.	_	_	O

40	SATURN	_	_	O
41	(	_	_	O
42	Sequential	_	_	O
43	Tarceva	_	_	O
44	in	_	_	O
45	Unresectable	_	_	O
46	NSCLC	_	_	O
47	)	_	_	O
48	was	_	_	O
49	a	_	_	O
50	randomised	_	_	O
51	,	_	_	O
52	double-blind	_	_	O
53	,	_	_	O
54	placebo-controlled	_	_	O
55	,	_	_	O
56	multicentre	_	_	O
57	study	_	_	O
58	investigating	_	_	O
59	the	_	_	O
60	impact	_	_	O
61	of	_	_	O
62	erlotinib	_	_	O
63	maintenance	_	_	O
64	therapy	_	_	O
65	on	_	_	O
66	HRQoL	_	_	O
67	in	_	_	O
68	patients	_	_	O
69	with	_	_	O
70	locally	_	_	O
71	advanced	_	_	O
72	or	_	_	O
73	recurrent	_	_	O
74	NSCLC	_	_	O
75	.	_	_	O

76	Eligible	_	_	O
77	patients	_	_	O
78	who	_	_	O
79	had	_	_	O
80	previously	_	_	O
81	completed	_	_	O
82	four	_	_	O
83	cycles	_	_	O
84	of	_	_	O
85	platinum-based	_	_	O
86	chemotherapy	_	_	O
87	were	_	_	O
88	randomised	_	_	O
89	1:1	_	_	O
90	to	_	_	O
91	receive	_	_	O
92	erlotinib	_	_	O
93	150	_	_	O
94	mg/day	_	_	O
95	or	_	_	O
96	placebo	_	_	O
97	until	_	_	O
98	disease	_	_	O
99	progression	_	_	O
100	,	_	_	O
101	unacceptable	_	_	O
102	toxicity	_	_	O
103	or	_	_	O
104	death	_	_	O
105	.	_	_	O

106	Patient	_	_	O
107	HRQoL	_	_	O
108	was	_	_	O
109	assessed	_	_	O
110	using	_	_	O
111	the	_	_	O
112	Functional	_	_	O
113	Assessment	_	_	O
114	of	_	_	O
115	Cancer	_	_	O
116	Therapy-Lung	_	_	O
117	questionnaire	_	_	O
118	,	_	_	O
119	in	_	_	O
120	terms	_	_	O
121	of	_	_	O
122	time	_	_	O
123	to	_	_	O
124	symptom	_	_	O
125	progression	_	_	O
126	(	_	_	O
127	TSP	_	_	O
128	)	_	_	O
129	,	_	_	O
130	time	_	_	O
131	to	_	_	O
132	deterioration	_	_	O
133	(	_	_	O
134	TTD	_	_	O
135	)	_	_	O
136	in	_	_	O
137	Trial	_	_	O
138	Outcome	_	_	O
139	Index	_	_	O
140	(	_	_	O
141	TOI	_	_	O
142	)	_	_	O
143	and	_	_	O
144	TTD	_	_	O
145	.	_	_	O

146	Exploratory	_	_	O
147	analysis	_	_	O
148	was	_	_	O
149	based	_	_	O
150	on	_	_	O
151	time	_	_	O
152	to	_	_	O
153	analgesia	_	_	O
154	and	_	_	O
155	appearance	_	_	O
156	of	_	_	O
157	key	_	_	O
158	symptoms	_	_	O
159	(	_	_	O
160	pain	_	_	O
161	,	_	_	O
162	cough	_	_	O
163	and	_	_	O
164	dyspnoea	_	_	O
165	)	_	_	O
166	.	_	_	O

167	Compared	_	_	B-Premise
168	with	_	_	I-Premise
169	placebo	_	_	I-Premise
170	,	_	_	I-Premise
171	erlotinib	_	_	I-Premise
172	maintenance	_	_	I-Premise
173	therapy	_	_	I-Premise
174	prolonged	_	_	I-Premise
175	progression-free	_	_	I-Premise
176	and	_	_	I-Premise
177	overall	_	_	I-Premise
178	survival	_	_	I-Premise
179	by	_	_	I-Premise
180	41	_	_	I-Premise
181	%	_	_	I-Premise
182	and	_	_	I-Premise
183	23	_	_	I-Premise
184	%	_	_	I-Premise
185	,	_	_	I-Premise
186	respectively	_	_	I-Premise
187	.	_	_	I-Premise

188	At	_	_	O
189	baseline	_	_	O
190	,	_	_	O
191	HRQoL	_	_	O
192	measures	_	_	O
193	were	_	_	O
194	comparable	_	_	O
195	between	_	_	O
196	the	_	_	O
197	two	_	_	O
198	treatment	_	_	O
199	groups	_	_	O
200	.	_	_	O

201	Maintenance	_	_	B-Premise
202	therapy	_	_	I-Premise
203	with	_	_	I-Premise
204	erlotinib	_	_	I-Premise
205	did	_	_	I-Premise
206	not	_	_	I-Premise
207	impact	_	_	I-Premise
208	on	_	_	I-Premise
209	deterioration	_	_	I-Premise
210	in	_	_	I-Premise
211	HRQoL	_	_	I-Premise
212	:	_	_	I-Premise
213	TSP	_	_	I-Premise
214	(	_	_	I-Premise
215	hazard	_	_	I-Premise
216	ratio	_	_	I-Premise
217	[	_	_	I-Premise
218	HR	_	_	I-Premise
219	]	_	_	I-Premise
220	=0.91	_	_	I-Premise
221	[	_	_	I-Premise
222	95	_	_	I-Premise
223	%	_	_	I-Premise
224	confidence	_	_	I-Premise
225	interval	_	_	I-Premise
226	(	_	_	I-Premise
227	CI	_	_	I-Premise
228	)	_	_	I-Premise
229	0.74-1.12	_	_	I-Premise
230	]	_	_	I-Premise
231	;	_	_	I-Premise
232	n=785	_	_	I-Premise
233	)	_	_	I-Premise
234	,	_	_	I-Premise
235	TTD	_	_	I-Premise
236	in	_	_	I-Premise
237	TOI	_	_	I-Premise
238	(	_	_	I-Premise
239	HR=1.06	_	_	I-Premise
240	[	_	_	I-Premise
241	95	_	_	I-Premise
242	%	_	_	I-Premise
243	CI	_	_	I-Premise
244	0.87-1.31	_	_	I-Premise
245	]	_	_	I-Premise
246	;	_	_	I-Premise
247	n=781	_	_	I-Premise
248	)	_	_	I-Premise
249	and	_	_	I-Premise
250	TTD	_	_	I-Premise
251	in	_	_	I-Premise
252	HRQoL	_	_	I-Premise
253	(	_	_	I-Premise
254	HR=0.96	_	_	I-Premise
255	[	_	_	I-Premise
256	95	_	_	I-Premise
257	%	_	_	I-Premise
258	CI	_	_	I-Premise
259	0.79-1.16	_	_	I-Premise
260	]	_	_	I-Premise
261	;	_	_	I-Premise
262	n=776	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	Time	_	_	B-Premise
266	to	_	_	I-Premise
267	pain	_	_	I-Premise
268	and	_	_	I-Premise
269	time	_	_	I-Premise
270	to	_	_	I-Premise
271	analgesic	_	_	I-Premise
272	use	_	_	I-Premise
273	were	_	_	I-Premise
274	significantly	_	_	I-Premise
275	delayed	_	_	I-Premise
276	in	_	_	I-Premise
277	patients	_	_	I-Premise
278	receiving	_	_	I-Premise
279	erlotinib	_	_	I-Premise
280	compared	_	_	I-Premise
281	with	_	_	I-Premise
282	placebo	_	_	I-Premise
283	(	_	_	I-Premise
284	HR=0.61	_	_	I-Premise
285	[	_	_	I-Premise
286	95	_	_	I-Premise
287	%	_	_	I-Premise
288	CI	_	_	I-Premise
289	0.42-0.88	_	_	I-Premise
290	]	_	_	I-Premise
291	;	_	_	I-Premise
292	p=0.0080	_	_	I-Premise
293	and	_	_	I-Premise
294	HR=0.66	_	_	I-Premise
295	[	_	_	I-Premise
296	95	_	_	I-Premise
297	%	_	_	I-Premise
298	CI	_	_	I-Premise
299	0.46-0.94	_	_	I-Premise
300	]	_	_	I-Premise
301	;	_	_	I-Premise
302	p=0.0199	_	_	I-Premise
303	,	_	_	I-Premise
304	respectively	_	_	I-Premise
305	)	_	_	I-Premise
306	.	_	_	I-Premise

307	A	_	_	B-Premise
308	non-significant	_	_	I-Premise
309	trend	_	_	I-Premise
310	towards	_	_	I-Premise
311	delayed	_	_	I-Premise
312	time	_	_	I-Premise
313	to	_	_	I-Premise
314	cough	_	_	I-Premise
315	and	_	_	I-Premise
316	time	_	_	I-Premise
317	to	_	_	I-Premise
318	dyspnoea	_	_	I-Premise
319	(	_	_	I-Premise
320	HR=0.77	_	_	I-Premise
321	[	_	_	I-Premise
322	95	_	_	I-Premise
323	%	_	_	I-Premise
324	CI	_	_	I-Premise
325	0.49-1.21	_	_	I-Premise
326	]	_	_	I-Premise
327	and	_	_	I-Premise
328	HR=0.75	_	_	I-Premise
329	[	_	_	I-Premise
330	95	_	_	I-Premise
331	%	_	_	I-Premise
332	CI	_	_	I-Premise
333	0.48-1.17	_	_	I-Premise
334	]	_	_	I-Premise
335	,	_	_	I-Premise
336	respectively	_	_	I-Premise
337	)	_	_	I-Premise
338	was	_	_	I-Premise
339	also	_	_	I-Premise
340	observed	_	_	I-Premise
341	.	_	_	I-Premise

342	Erlotinib	_	_	B-Claim
343	maintenance	_	_	I-Claim
344	therapy	_	_	I-Claim
345	significantly	_	_	I-Claim
346	extends	_	_	I-Claim
347	progression-free	_	_	I-Claim
348	survival	_	_	I-Claim
349	without	_	_	I-Claim
350	compromising	_	_	I-Claim
351	patient	_	_	I-Claim
352	HRQoL	_	_	I-Claim
353	in	_	_	I-Claim
354	comparison	_	_	I-Claim
355	with	_	_	I-Claim
356	placebo	_	_	I-Claim
357	,	_	_	I-Claim
358	with	_	_	I-Claim
359	some	_	_	I-Claim
360	improvement	_	_	I-Claim
361	in	_	_	I-Claim
362	symptoms	_	_	I-Claim
363	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	was	_	_	O
3	designed	_	_	O
4	to	_	_	O
5	evaluate	_	_	O
6	efficacy	_	_	O
7	,	_	_	O
8	toxicity	_	_	O
9	,	_	_	O
10	and	_	_	O
11	adverse	_	_	O
12	effects	_	_	O
13	of	_	_	O
14	combination	_	_	O
15	of	_	_	O
16	chemotherapy	_	_	O
17	drugs	_	_	O
18	and	_	_	O
19	intraperitoneal	_	_	O
20	perfusion	_	_	O
21	of	_	_	O
22	verapamil	_	_	O
23	in	_	_	O
24	the	_	_	O
25	treatment	_	_	O
26	of	_	_	O
27	malignant	_	_	O
28	ascites	_	_	O
29	.	_	_	O

30	Seventy-two	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	malignant	_	_	O
34	ascites	_	_	O
35	were	_	_	O
36	divided	_	_	O
37	into	_	_	O
38	two	_	_	O
39	study	_	_	O
40	groups	_	_	O
41	.	_	_	O

42	Patients	_	_	O
43	in	_	_	O
44	control	_	_	O
45	group	_	_	O
46	(	_	_	O
47	31	_	_	O
48	cases	_	_	O
49	)	_	_	O
50	received	_	_	O
51	conventional	_	_	O
52	chemotherapy	_	_	O
53	,	_	_	O
54	whereas	_	_	O
55	patients	_	_	O
56	in	_	_	O
57	the	_	_	O
58	combined	_	_	O
59	treatment	_	_	O
60	group	_	_	O
61	(	_	_	O
62	41	_	_	O
63	cases	_	_	O
64	)	_	_	O
65	were	_	_	O
66	given	_	_	O
67	verapamil	_	_	O
68	intraperitoneally	_	_	O
69	in	_	_	O
70	addition	_	_	O
71	to	_	_	O
72	chemotherapy	_	_	O
73	drugs	_	_	O
74	.	_	_	O

75	Thirty	_	_	O
76	days	_	_	O
77	after	_	_	O
78	the	_	_	O
79	treatment	_	_	O
80	,	_	_	O
81	efficacy	_	_	O
82	,	_	_	O
83	toxicity	_	_	O
84	,	_	_	O
85	and	_	_	O
86	adverse	_	_	O
87	effects	_	_	O
88	were	_	_	O
89	assessed	_	_	O
90	in	_	_	O
91	both	_	_	O
92	study	_	_	O
93	groups	_	_	O
94	.	_	_	O

95	The	_	_	B-Premise
96	treatment	_	_	I-Premise
97	of	_	_	I-Premise
98	control	_	_	I-Premise
99	group	_	_	I-Premise
100	led	_	_	I-Premise
101	to	_	_	I-Premise
102	1	_	_	I-Premise
103	case	_	_	I-Premise
104	of	_	_	I-Premise
105	complete	_	_	I-Premise
106	remission	_	_	I-Premise
107	and	_	_	I-Premise
108	2	_	_	I-Premise
109	cases	_	_	I-Premise
110	of	_	_	I-Premise
111	partial	_	_	I-Premise
112	remission	_	_	I-Premise
113	,	_	_	I-Premise
114	making	_	_	I-Premise
115	the	_	_	I-Premise
116	rate	_	_	I-Premise
117	of	_	_	I-Premise
118	efficacy	_	_	I-Premise
119	(	_	_	I-Premise
120	complete	_	_	I-Premise
121	+	_	_	I-Premise
122	partial	_	_	I-Premise
123	remission	_	_	I-Premise
124	)	_	_	I-Premise
125	of	_	_	I-Premise
126	9.7	_	_	I-Premise
127	%	_	_	I-Premise
128	.	_	_	I-Premise

129	The	_	_	B-Premise
130	combined	_	_	I-Premise
131	treatment	_	_	I-Premise
132	group	_	_	I-Premise
133	demonstrated	_	_	I-Premise
134	13	_	_	I-Premise
135	cases	_	_	I-Premise
136	of	_	_	I-Premise
137	complete	_	_	I-Premise
138	remission	_	_	I-Premise
139	and	_	_	I-Premise
140	22	_	_	I-Premise
141	cases	_	_	I-Premise
142	of	_	_	I-Premise
143	partial	_	_	I-Premise
144	remission	_	_	I-Premise
145	.	_	_	I-Premise

146	Thus	_	_	O
147	,	_	_	O
148	the	_	_	B-Premise
149	rate	_	_	I-Premise
150	of	_	_	I-Premise
151	efficacy	_	_	I-Premise
152	was	_	_	I-Premise
153	significantly	_	_	I-Premise
154	higher	_	_	I-Premise
155	in	_	_	I-Premise
156	the	_	_	I-Premise
157	combined	_	_	I-Premise
158	treatment	_	_	I-Premise
159	group	_	_	I-Premise
160	(	_	_	I-Premise
161	85.36	_	_	I-Premise
162	%	_	_	I-Premise
163	;	_	_	I-Premise
164	p	_	_	I-Premise
165	<	_	_	I-Premise
166	0.05	_	_	I-Premise
167	vs.	_	_	I-Premise
168	control	_	_	I-Premise
169	group	_	_	I-Premise
170	)	_	_	I-Premise
171	.	_	_	I-Premise

172	Using	_	_	O
173	KPS	_	_	O
174	scores	_	_	O
175	,	_	_	O
176	changes	_	_	O
177	in	_	_	O
178	quality	_	_	O
179	of	_	_	O
180	life	_	_	O
181	were	_	_	O
182	compared	_	_	O
183	before	_	_	O
184	and	_	_	O
185	after	_	_	O
186	the	_	_	O
187	treatment	_	_	O
188	.	_	_	O

189	The	_	_	B-Premise
190	quality	_	_	I-Premise
191	of	_	_	I-Premise
192	life	_	_	I-Premise
193	improved	_	_	I-Premise
194	in	_	_	I-Premise
195	control	_	_	I-Premise
196	group	_	_	I-Premise
197	by	_	_	I-Premise
198	13.7	_	_	I-Premise
199	%	_	_	I-Premise
200	,	_	_	I-Premise
201	while	_	_	I-Premise
202	combined	_	_	I-Premise
203	treatment	_	_	I-Premise
204	group	_	_	I-Premise
205	showed	_	_	I-Premise
206	improvement	_	_	I-Premise
207	of	_	_	I-Premise
208	83.5	_	_	I-Premise
209	%	_	_	I-Premise
210	(	_	_	I-Premise
211	p	_	_	I-Premise
212	<	_	_	I-Premise
213	0.05	_	_	I-Premise
214	vs.	_	_	I-Premise
215	control	_	_	I-Premise
216	group	_	_	I-Premise
217	)	_	_	I-Premise
218	.	_	_	I-Premise

219	Further	_	_	O
220	,	_	_	O
221	cumulative	_	_	B-Premise
222	survival	_	_	I-Premise
223	rate	_	_	I-Premise
224	was	_	_	I-Premise
225	also	_	_	I-Premise
226	significantly	_	_	I-Premise
227	higher	_	_	I-Premise
228	in	_	_	I-Premise
229	the	_	_	I-Premise
230	combined	_	_	I-Premise
231	treatment	_	_	I-Premise
232	group	_	_	I-Premise
233	.	_	_	I-Premise

234	Treatment	_	_	B-Premise
235	toxicity	_	_	I-Premise
236	and	_	_	I-Premise
237	the	_	_	I-Premise
238	rate	_	_	I-Premise
239	of	_	_	I-Premise
240	adverse	_	_	I-Premise
241	effects	_	_	I-Premise
242	and	_	_	I-Premise
243	intestinal	_	_	I-Premise
244	adhesion	_	_	I-Premise
245	were	_	_	I-Premise
246	not	_	_	I-Premise
247	significantly	_	_	I-Premise
248	different	_	_	I-Premise
249	between	_	_	I-Premise
250	study	_	_	I-Premise
251	groups	_	_	I-Premise
252	.	_	_	I-Premise

253	Intraperitoneal	_	_	B-Claim
254	perfusion	_	_	I-Claim
255	of	_	_	I-Claim
256	verapamil	_	_	I-Claim
257	enhances	_	_	I-Claim
258	the	_	_	I-Claim
259	efficacy	_	_	I-Claim
260	of	_	_	I-Claim
261	chemotherapy	_	_	I-Claim
262	drugs	_	_	I-Claim
263	,	_	_	I-Claim
264	prolongs	_	_	I-Claim
265	survival	_	_	I-Claim
266	,	_	_	I-Claim
267	and	_	_	I-Claim
268	improves	_	_	I-Claim
269	the	_	_	I-Claim
270	quality	_	_	I-Claim
271	of	_	_	I-Claim
272	life	_	_	I-Claim
273	.	_	_	I-Claim

274	Intraperitoneal	_	_	B-Claim
275	administration	_	_	I-Claim
276	limits	_	_	I-Claim
277	cardiotoxicity	_	_	I-Claim
278	of	_	_	I-Claim
279	verapamil	_	_	I-Claim
280	.	_	_	I-Claim


0	In	_	_	O
1	a	_	_	O
2	phase	_	_	O
3	3	_	_	O
4	trial	_	_	O
5	comparing	_	_	O
6	the	_	_	O
7	efficacy	_	_	O
8	and	_	_	O
9	safety	_	_	O
10	of	_	_	O
11	axitinib	_	_	O
12	versus	_	_	O
13	sorafenib	_	_	O
14	as	_	_	O
15	second-line	_	_	O
16	treatment	_	_	O
17	for	_	_	O
18	metastatic	_	_	O
19	renal	_	_	O
20	cell	_	_	O
21	carcinoma	_	_	O
22	,	_	_	O
23	patients	_	_	O
24	given	_	_	O
25	axitinib	_	_	O
26	had	_	_	O
27	a	_	_	O
28	longer	_	_	O
29	progression-free	_	_	O
30	survival	_	_	O
31	(	_	_	O
32	PFS	_	_	O
33	)	_	_	O
34	.	_	_	O

35	Here	_	_	O
36	,	_	_	O
37	we	_	_	O
38	report	_	_	O
39	overall	_	_	O
40	survival	_	_	O
41	and	_	_	O
42	updated	_	_	O
43	efficacy	_	_	O
44	,	_	_	O
45	quality	_	_	O
46	of	_	_	O
47	life	_	_	O
48	,	_	_	O
49	and	_	_	O
50	safety	_	_	O
51	results	_	_	O
52	.	_	_	O

53	Eligible	_	_	O
54	patients	_	_	O
55	had	_	_	O
56	clear	_	_	O
57	cell	_	_	O
58	metastatic	_	_	O
59	renal	_	_	O
60	cell	_	_	O
61	carcinoma	_	_	O
62	,	_	_	O
63	progressive	_	_	O
64	disease	_	_	O
65	after	_	_	O
66	one	_	_	O
67	approved	_	_	O
68	systemic	_	_	O
69	treatment	_	_	O
70	,	_	_	O
71	and	_	_	O
72	an	_	_	O
73	Eastern	_	_	O
74	Cooperative	_	_	O
75	Oncology	_	_	O
76	Group	_	_	O
77	performance	_	_	O
78	status	_	_	O
79	(	_	_	O
80	ECOG	_	_	O
81	PS	_	_	O
82	)	_	_	O
83	of	_	_	O
84	0-1	_	_	O
85	.	_	_	O

86	723	_	_	O
87	patients	_	_	O
88	were	_	_	O
89	stratified	_	_	O
90	by	_	_	O
91	ECOG	_	_	O
92	PS	_	_	O
93	and	_	_	O
94	previous	_	_	O
95	treatment	_	_	O
96	and	_	_	O
97	randomly	_	_	O
98	allocated	_	_	O
99	(	_	_	O
100	1:1	_	_	O
101	)	_	_	O
102	to	_	_	O
103	receive	_	_	O
104	axitinib	_	_	O
105	(	_	_	O
106	5	_	_	O
107	mg	_	_	O
108	twice	_	_	O
109	daily	_	_	O
110	;	_	_	O
111	n=361	_	_	O
112	)	_	_	O
113	or	_	_	O
114	sorafenib	_	_	O
115	(	_	_	O
116	400	_	_	O
117	mg	_	_	O
118	twice	_	_	O
119	daily	_	_	O
120	;	_	_	O
121	n=362	_	_	O
122	)	_	_	O
123	.	_	_	O

124	The	_	_	O
125	primary	_	_	O
126	endpoint	_	_	O
127	was	_	_	O
128	PFS	_	_	O
129	assessed	_	_	O
130	by	_	_	O
131	a	_	_	O
132	masked	_	_	O
133	,	_	_	O
134	independent	_	_	O
135	radiology	_	_	O
136	review	_	_	O
137	committee	_	_	O
138	.	_	_	O

139	We	_	_	O
140	assessed	_	_	O
141	patient-reported	_	_	O
142	outcomes	_	_	O
143	using	_	_	O
144	validated	_	_	O
145	questionnaires	_	_	O
146	.	_	_	O

147	Baseline	_	_	O
148	characteristics	_	_	O
149	and	_	_	O
150	development	_	_	O
151	of	_	_	O
152	hypertension	_	_	O
153	on	_	_	O
154	treatment	_	_	O
155	were	_	_	O
156	studied	_	_	O
157	as	_	_	O
158	prognostic	_	_	O
159	factors	_	_	O
160	.	_	_	O

161	Efficacy	_	_	O
162	was	_	_	O
163	assessed	_	_	O
164	in	_	_	O
165	the	_	_	O
166	intention-to-treat	_	_	O
167	population	_	_	O
168	,	_	_	O
169	and	_	_	O
170	safety	_	_	O
171	was	_	_	O
172	assessed	_	_	O
173	in	_	_	O
174	patients	_	_	O
175	who	_	_	O
176	received	_	_	O
177	at	_	_	O
178	least	_	_	O
179	one	_	_	O
180	dose	_	_	O
181	of	_	_	O
182	the	_	_	O
183	study	_	_	O
184	drug	_	_	O
185	.	_	_	O

186	Median	_	_	B-Premise
187	overall	_	_	I-Premise
188	survival	_	_	I-Premise
189	was	_	_	I-Premise
190	20.1	_	_	I-Premise
191	months	_	_	I-Premise
192	(	_	_	I-Premise
193	95	_	_	I-Premise
194	%	_	_	I-Premise
195	CI	_	_	I-Premise
196	16.7-23.4	_	_	I-Premise
197	)	_	_	I-Premise
198	with	_	_	I-Premise
199	axitinib	_	_	I-Premise
200	and	_	_	I-Premise
201	19.2	_	_	I-Premise
202	months	_	_	I-Premise
203	(	_	_	I-Premise
204	17.5-22.3	_	_	I-Premise
205	)	_	_	I-Premise
206	with	_	_	I-Premise
207	sorafenib	_	_	I-Premise
208	(	_	_	I-Premise
209	hazard	_	_	I-Premise
210	ratio	_	_	I-Premise
211	[	_	_	I-Premise
212	HR	_	_	I-Premise
213	]	_	_	I-Premise
214	0.969	_	_	I-Premise
215	,	_	_	I-Premise
216	95	_	_	I-Premise
217	%	_	_	I-Premise
218	CI	_	_	I-Premise
219	0.800-1.174	_	_	I-Premise
220	;	_	_	I-Premise
221	one-sided	_	_	I-Premise
222	p=0.3744	_	_	I-Premise
223	)	_	_	I-Premise
224	.	_	_	I-Premise

225	Median	_	_	B-Premise
226	investigator-assessed	_	_	I-Premise
227	PFS	_	_	I-Premise
228	was	_	_	I-Premise
229	8.3	_	_	I-Premise
230	months	_	_	I-Premise
231	(	_	_	I-Premise
232	95	_	_	I-Premise
233	%	_	_	I-Premise
234	CI	_	_	I-Premise
235	6.7-9.2	_	_	I-Premise
236	)	_	_	I-Premise
237	with	_	_	I-Premise
238	axitinib	_	_	I-Premise
239	and	_	_	I-Premise
240	5·7	_	_	I-Premise
241	months	_	_	I-Premise
242	(	_	_	I-Premise
243	4.7-6.5	_	_	I-Premise
244	)	_	_	I-Premise
245	with	_	_	I-Premise
246	sorafenib	_	_	I-Premise
247	(	_	_	I-Premise
248	HR	_	_	I-Premise
249	0.656	_	_	I-Premise
250	,	_	_	I-Premise
251	95	_	_	I-Premise
252	%	_	_	I-Premise
253	CI	_	_	I-Premise
254	0.552-0.779	_	_	I-Premise
255	;	_	_	I-Premise
256	one-sided	_	_	I-Premise
257	p	_	_	I-Premise
258	<	_	_	I-Premise
259	0.0001	_	_	I-Premise
260	)	_	_	I-Premise
261	.	_	_	I-Premise

262	Patient-reported	_	_	B-Premise
263	outcomes	_	_	I-Premise
264	scores	_	_	I-Premise
265	were	_	_	I-Premise
266	similar	_	_	I-Premise
267	in	_	_	I-Premise
268	the	_	_	I-Premise
269	treatment	_	_	I-Premise
270	groups	_	_	I-Premise
271	at	_	_	I-Premise
272	baseline	_	_	I-Premise
273	,	_	_	I-Premise
274	were	_	_	I-Premise
275	maintained	_	_	I-Premise
276	during	_	_	I-Premise
277	treatment	_	_	I-Premise
278	,	_	_	I-Premise
279	but	_	_	B-Premise
280	decreased	_	_	I-Premise
281	at	_	_	I-Premise
282	end-of-treatment	_	_	I-Premise
283	.	_	_	I-Premise

284	Common	_	_	B-Premise
285	grade	_	_	I-Premise
286	3	_	_	I-Premise
287	or	_	_	I-Premise
288	higher	_	_	I-Premise
289	treatment-related	_	_	I-Premise
290	adverse	_	_	I-Premise
291	events	_	_	I-Premise
292	were	_	_	I-Premise
293	hypertension	_	_	I-Premise
294	(	_	_	I-Premise
295	60	_	_	I-Premise
296	[	_	_	I-Premise
297	17	_	_	I-Premise
298	%	_	_	I-Premise
299	]	_	_	I-Premise
300	)	_	_	I-Premise
301	,	_	_	I-Premise
302	diarrhoea	_	_	I-Premise
303	(	_	_	I-Premise
304	40	_	_	I-Premise
305	[	_	_	I-Premise
306	11	_	_	I-Premise
307	%	_	_	I-Premise
308	]	_	_	I-Premise
309	)	_	_	I-Premise
310	,	_	_	I-Premise
311	and	_	_	I-Premise
312	fatigue	_	_	I-Premise
313	(	_	_	I-Premise
314	37	_	_	I-Premise
315	[	_	_	I-Premise
316	10	_	_	I-Premise
317	%	_	_	I-Premise
318	]	_	_	I-Premise
319	)	_	_	I-Premise
320	in	_	_	I-Premise
321	359	_	_	I-Premise
322	axitinib-treated	_	_	I-Premise
323	patients	_	_	I-Premise
324	and	_	_	I-Premise
325	hand-foot	_	_	I-Premise
326	syndrome	_	_	I-Premise
327	(	_	_	I-Premise
328	61	_	_	I-Premise
329	[	_	_	I-Premise
330	17	_	_	I-Premise
331	%	_	_	I-Premise
332	]	_	_	I-Premise
333	)	_	_	I-Premise
334	,	_	_	I-Premise
335	hypertension	_	_	I-Premise
336	(	_	_	I-Premise
337	43	_	_	I-Premise
338	[	_	_	I-Premise
339	12	_	_	I-Premise
340	%	_	_	I-Premise
341	]	_	_	I-Premise
342	)	_	_	I-Premise
343	,	_	_	I-Premise
344	and	_	_	I-Premise
345	diarrhoea	_	_	I-Premise
346	(	_	_	I-Premise
347	27	_	_	I-Premise
348	[	_	_	I-Premise
349	8	_	_	I-Premise
350	%	_	_	I-Premise
351	]	_	_	I-Premise
352	)	_	_	I-Premise
353	in	_	_	I-Premise
354	355	_	_	I-Premise
355	sorafenib-treated	_	_	I-Premise
356	patients	_	_	I-Premise
357	.	_	_	I-Premise

358	In	_	_	B-Premise
359	a	_	_	I-Premise
360	post-hoc	_	_	I-Premise
361	12-week	_	_	I-Premise
362	landmark	_	_	I-Premise
363	analysis	_	_	I-Premise
364	,	_	_	I-Premise
365	median	_	_	I-Premise
366	overall	_	_	I-Premise
367	survival	_	_	I-Premise
368	was	_	_	I-Premise
369	longer	_	_	I-Premise
370	in	_	_	I-Premise
371	patients	_	_	I-Premise
372	with	_	_	I-Premise
373	a	_	_	I-Premise
374	diastolic	_	_	I-Premise
375	blood	_	_	I-Premise
376	pressure	_	_	I-Premise
377	of	_	_	I-Premise
378	90	_	_	I-Premise
379	mm	_	_	I-Premise
380	Hg	_	_	I-Premise
381	or	_	_	I-Premise
382	greater	_	_	I-Premise
383	than	_	_	I-Premise
384	in	_	_	I-Premise
385	those	_	_	I-Premise
386	with	_	_	I-Premise
387	a	_	_	I-Premise
388	diastolic	_	_	I-Premise
389	blood	_	_	I-Premise
390	pressure	_	_	I-Premise
391	of	_	_	I-Premise
392	less	_	_	I-Premise
393	than	_	_	I-Premise
394	90	_	_	I-Premise
395	mm	_	_	I-Premise
396	Hg	_	_	I-Premise
397	:	_	_	I-Premise
398	20.7	_	_	I-Premise
399	months	_	_	I-Premise
400	(	_	_	I-Premise
401	95	_	_	I-Premise
402	%	_	_	I-Premise
403	CI	_	_	I-Premise
404	18.4-24.6	_	_	I-Premise
405	)	_	_	I-Premise
406	versus	_	_	I-Premise
407	12.9	_	_	I-Premise
408	months	_	_	I-Premise
409	(	_	_	I-Premise
410	10.1-20.4	_	_	I-Premise
411	)	_	_	I-Premise
412	in	_	_	I-Premise
413	the	_	_	I-Premise
414	axitinib	_	_	I-Premise
415	group	_	_	I-Premise
416	(	_	_	I-Premise
417	p=0.0116	_	_	I-Premise
418	)	_	_	I-Premise
419	,	_	_	I-Premise
420	and	_	_	I-Premise
421	20.2	_	_	I-Premise
422	months	_	_	I-Premise
423	(	_	_	I-Premise
424	17.1-32.0	_	_	I-Premise
425	)	_	_	I-Premise
426	versus	_	_	I-Premise
427	14.8	_	_	I-Premise
428	months	_	_	I-Premise
429	(	_	_	I-Premise
430	12.0-17.7	_	_	I-Premise
431	)	_	_	I-Premise
432	in	_	_	I-Premise
433	the	_	_	I-Premise
434	sorafenib	_	_	I-Premise
435	group	_	_	I-Premise
436	(	_	_	I-Premise
437	one-sided	_	_	I-Premise
438	p=0.0020	_	_	I-Premise
439	)	_	_	I-Premise
440	.	_	_	I-Premise

441	Although	_	_	O
442	overall	_	_	B-Claim
443	survival	_	_	I-Claim
444	,	_	_	I-Claim
445	a	_	_	I-Claim
446	secondary	_	_	I-Claim
447	endpoint	_	_	I-Claim
448	for	_	_	I-Claim
449	the	_	_	I-Claim
450	study	_	_	I-Claim
451	,	_	_	I-Claim
452	did	_	_	I-Claim
453	not	_	_	I-Claim
454	differ	_	_	I-Claim
455	between	_	_	I-Claim
456	the	_	_	I-Claim
457	two	_	_	I-Claim
458	groups	_	_	I-Claim
459	,	_	_	I-Claim
460	investigator-assessed	_	_	B-Claim
461	PFS	_	_	I-Claim
462	remained	_	_	I-Claim
463	longer	_	_	I-Claim
464	in	_	_	I-Claim
465	the	_	_	I-Claim
466	axitinib	_	_	I-Claim
467	group	_	_	I-Claim
468	compared	_	_	I-Claim
469	with	_	_	I-Claim
470	the	_	_	I-Claim
471	sorafenib	_	_	I-Claim
472	group	_	_	I-Claim
473	.	_	_	I-Claim

474	These	_	_	B-Claim
475	results	_	_	I-Claim
476	establish	_	_	I-Claim
477	axitinib	_	_	I-Claim
478	as	_	_	I-Claim
479	a	_	_	I-Claim
480	second-line	_	_	I-Claim
481	treatment	_	_	I-Claim
482	option	_	_	I-Claim
483	for	_	_	I-Claim
484	patients	_	_	I-Claim
485	with	_	_	I-Claim
486	metastatic	_	_	I-Claim
487	renal	_	_	I-Claim
488	cell	_	_	I-Claim
489	carcinoma	_	_	I-Claim
490	.	_	_	I-Claim


0	There	_	_	O
1	is	_	_	O
2	a	_	_	O
3	paucity	_	_	O
4	of	_	_	O
5	methodologically	_	_	O
6	robust	_	_	O
7	vocational	_	_	O
8	rehabilitation	_	_	O
9	(	_	_	O
10	VR	_	_	O
11	)	_	_	O
12	intervention	_	_	O
13	trials	_	_	O
14	.	_	_	O

15	This	_	_	O
16	study	_	_	O
17	assessed	_	_	O
18	the	_	_	O
19	feasibility	_	_	O
20	and	_	_	O
21	acceptability	_	_	O
22	of	_	_	O
23	a	_	_	O
24	VR	_	_	O
25	trial	_	_	O
26	of	_	_	O
27	women	_	_	O
28	with	_	_	O
29	breast	_	_	O
30	cancer	_	_	O
31	to	_	_	O
32	inform	_	_	O
33	the	_	_	O
34	development	_	_	O
35	of	_	_	O
36	a	_	_	O
37	larger	_	_	O
38	interventional	_	_	O
39	study	_	_	O
40	.	_	_	O

41	Women	_	_	O
42	were	_	_	O
43	recruited	_	_	O
44	in	_	_	O
45	Scotland	_	_	O
46	and	_	_	O
47	randomised	_	_	O
48	to	_	_	O
49	either	_	_	O
50	a	_	_	O
51	case	_	_	O
52	management	_	_	O
53	VR	_	_	O
54	service	_	_	O
55	or	_	_	O
56	to	_	_	O
57	usual	_	_	O
58	care	_	_	O
59	.	_	_	O

60	Data	_	_	O
61	were	_	_	O
62	collected	_	_	O
63	on	_	_	O
64	eligibility	_	_	O
65	,	_	_	O
66	recruitment	_	_	O
67	and	_	_	O
68	attrition	_	_	O
69	rates	_	_	O
70	to	_	_	O
71	assess	_	_	O
72	trial	_	_	O
73	feasibility	_	_	O
74	,	_	_	O
75	and	_	_	O
76	interviews	_	_	O
77	conducted	_	_	O
78	to	_	_	O
79	determine	_	_	O
80	trial	_	_	O
81	acceptability	_	_	O
82	.	_	_	O

83	Sick	_	_	O
84	leave	_	_	O
85	days	_	_	O
86	(	_	_	O
87	primary	_	_	O
88	outcome	_	_	O
89	)	_	_	O
90	were	_	_	O
91	self-reported	_	_	O
92	via	_	_	O
93	postal	_	_	O
94	questionnaire	_	_	O
95	every	_	_	O
96	4	_	_	O
97	weeks	_	_	O
98	during	_	_	O
99	the	_	_	O
100	first	_	_	O
101	6	_	_	O
102	months	_	_	O
103	post-surgery	_	_	O
104	and	_	_	O
105	at	_	_	O
106	12	_	_	O
107	months	_	_	O
108	.	_	_	O

109	Secondary	_	_	O
110	outcome	_	_	O
111	measures	_	_	O
112	were	_	_	O
113	change	_	_	O
114	in	_	_	O
115	employment	_	_	O
116	pattern	_	_	O
117	,	_	_	O
118	quality	_	_	O
119	of	_	_	O
120	life	_	_	O
121	and	_	_	O
122	fatigue	_	_	O
123	.	_	_	O

124	Of	_	_	O
125	the	_	_	O
126	1,114	_	_	O
127	women	_	_	O
128	assessed	_	_	O
129	for	_	_	O
130	eligibility	_	_	O
131	,	_	_	O
132	163	_	_	O
133	(	_	_	O
134	15	_	_	O
135	%	_	_	O
136	)	_	_	O
137	were	_	_	O
138	eligible	_	_	O
139	.	_	_	O

140	The	_	_	O
141	main	_	_	O
142	reason	_	_	O
143	for	_	_	O
144	ineligibility	_	_	O
145	was	_	_	O
146	age	_	_	O
147	(	_	_	O
148	>	_	_	O
149	65	_	_	O
150	years	_	_	O
151	,	_	_	O
152	n	_	_	O
153	=	_	_	O
154	637	_	_	O
155	,	_	_	O
156	67	_	_	O
157	%	_	_	O
158	)	_	_	O
159	.	_	_	O

160	Of	_	_	O
161	those	_	_	O
162	eligible	_	_	O
163	,	_	_	O
164	111	_	_	O
165	(	_	_	O
166	68	_	_	O
167	%	_	_	O
168	)	_	_	O
169	received	_	_	O
170	study	_	_	O
171	information	_	_	O
172	,	_	_	O
173	of	_	_	O
174	which	_	_	O
175	23	_	_	O
176	(	_	_	O
177	21	_	_	O
178	%	_	_	O
179	)	_	_	O
180	consented	_	_	O
181	to	_	_	O
182	participate	_	_	O
183	in	_	_	O
184	the	_	_	O
185	study	_	_	O
186	.	_	_	O

187	Data	_	_	O
188	for	_	_	O
189	18	_	_	O
190	(	_	_	O
191	78	_	_	O
192	%	_	_	O
193	)	_	_	O
194	women	_	_	O
195	were	_	_	O
196	analysed	_	_	O
197	(	_	_	O
198	intervention	_	_	O
199	:	_	_	O
200	n	_	_	O
201	=	_	_	O
202	7	_	_	O
203	;	_	_	O
204	control	_	_	O
205	:	_	_	O
206	n	_	_	O
207	=	_	_	O
208	11	_	_	O
209	)	_	_	O
210	.	_	_	O

211	Participants	_	_	B-Premise
212	in	_	_	I-Premise
213	the	_	_	I-Premise
214	intervention	_	_	I-Premise
215	group	_	_	I-Premise
216	reported	_	_	I-Premise
217	,	_	_	I-Premise
218	on	_	_	I-Premise
219	average	_	_	I-Premise
220	,	_	_	I-Premise
221	53	_	_	I-Premise
222	fewer	_	_	I-Premise
223	days	_	_	I-Premise
224	of	_	_	I-Premise
225	sick	_	_	I-Premise
226	leave	_	_	I-Premise
227	over	_	_	I-Premise
228	the	_	_	I-Premise
229	first	_	_	I-Premise
230	6	_	_	I-Premise
231	months	_	_	I-Premise
232	post-surgery	_	_	I-Premise
233	than	_	_	I-Premise
234	those	_	_	I-Premise
235	in	_	_	I-Premise
236	the	_	_	I-Premise
237	control	_	_	I-Premise
238	group	_	_	I-Premise
239	;	_	_	I-Premise
240	however	_	_	B-Premise
241	,	_	_	I-Premise
242	this	_	_	I-Premise
243	difference	_	_	I-Premise
244	was	_	_	I-Premise
245	not	_	_	I-Premise
246	statistically	_	_	I-Premise
247	significant	_	_	I-Premise
248	(	_	_	I-Premise
249	p	_	_	I-Premise
250	=	_	_	I-Premise
251	0.122	_	_	I-Premise
252	;	_	_	I-Premise
253	95	_	_	I-Premise
254	%	_	_	I-Premise
255	confidence	_	_	I-Premise
256	interval	_	_	I-Premise
257	-15.8	_	_	I-Premise
258	,	_	_	I-Premise
259	122.0	_	_	I-Premise
260	)	_	_	I-Premise
261	.	_	_	I-Premise

262	No	_	_	B-Premise
263	statistically	_	_	I-Premise
264	significant	_	_	I-Premise
265	differences	_	_	I-Premise
266	were	_	_	I-Premise
267	found	_	_	I-Premise
268	for	_	_	I-Premise
269	secondary	_	_	I-Premise
270	outcomes	_	_	I-Premise
271	.	_	_	I-Premise

272	Interviews	_	_	B-Premise
273	with	_	_	I-Premise
274	trial	_	_	I-Premise
275	participants	_	_	I-Premise
276	indicated	_	_	I-Premise
277	that	_	_	I-Premise
278	trial	_	_	I-Premise
279	procedures	_	_	I-Premise
280	,	_	_	I-Premise
281	including	_	_	I-Premise
282	recruitment	_	_	I-Premise
283	,	_	_	I-Premise
284	randomisation	_	_	I-Premise
285	and	_	_	I-Premise
286	research	_	_	I-Premise
287	instruments	_	_	I-Premise
288	,	_	_	I-Premise
289	were	_	_	I-Premise
290	acceptable	_	_	I-Premise
291	.	_	_	I-Premise

292	Conducting	_	_	B-Claim
293	a	_	_	I-Claim
294	pragmatic	_	_	I-Claim
295	trial	_	_	I-Claim
296	of	_	_	I-Claim
297	effectiveness	_	_	I-Claim
298	of	_	_	I-Claim
299	a	_	_	I-Claim
300	VR	_	_	I-Claim
301	intervention	_	_	I-Claim
302	among	_	_	I-Claim
303	cancer	_	_	I-Claim
304	survivors	_	_	I-Claim
305	is	_	_	I-Claim
306	both	_	_	I-Claim
307	feasible	_	_	I-Claim
308	and	_	_	I-Claim
309	acceptable	_	_	I-Claim
310	,	_	_	I-Claim
311	but	_	_	B-Claim
312	more	_	_	I-Claim
313	research	_	_	I-Claim
314	about	_	_	I-Claim
315	the	_	_	I-Claim
316	exact	_	_	I-Claim
317	components	_	_	I-Claim
318	of	_	_	I-Claim
319	a	_	_	I-Claim
320	VR	_	_	I-Claim
321	intervention	_	_	I-Claim
322	and	_	_	I-Claim
323	choice	_	_	I-Claim
324	of	_	_	I-Claim
325	outcomes	_	_	I-Claim
326	to	_	_	I-Claim
327	measure	_	_	I-Claim
328	effectiveness	_	_	I-Claim
329	is	_	_	I-Claim
330	required	_	_	I-Claim
331	.	_	_	I-Claim

332	VR	_	_	B-Claim
333	to	_	_	I-Claim
334	assist	_	_	I-Claim
335	breast	_	_	I-Claim
336	cancer	_	_	I-Claim
337	patients	_	_	I-Claim
338	in	_	_	I-Claim
339	the	_	_	I-Claim
340	return	_	_	I-Claim
341	to	_	_	I-Claim
342	work	_	_	I-Claim
343	process	_	_	I-Claim
344	is	_	_	I-Claim
345	an	_	_	I-Claim
346	important	_	_	I-Claim
347	component	_	_	I-Claim
348	of	_	_	I-Claim
349	cancer	_	_	I-Claim
350	survivorship	_	_	I-Claim
351	plans	_	_	I-Claim
352	.	_	_	I-Claim


0	Major	_	_	O
1	depressive	_	_	O
2	disorder	_	_	O
3	develops	_	_	O
4	in	_	_	O
5	up	_	_	O
6	to	_	_	O
7	half	_	_	O
8	the	_	_	O
9	patients	_	_	O
10	undergoing	_	_	O
11	treatment	_	_	O
12	for	_	_	O
13	head	_	_	O
14	and	_	_	O
15	neck	_	_	O
16	cancer	_	_	O
17	,	_	_	O
18	resulting	_	_	O
19	in	_	_	O
20	significant	_	_	O
21	morbidity	_	_	O
22	;	_	_	O
23	therefore	_	_	O
24	,	_	_	O
25	preventing	_	_	O
26	depression	_	_	O
27	during	_	_	O
28	cancer	_	_	O
29	treatment	_	_	O
30	may	_	_	O
31	be	_	_	O
32	of	_	_	O
33	great	_	_	O
34	benefit	_	_	O
35	.	_	_	O

36	To	_	_	O
37	determine	_	_	O
38	whether	_	_	O
39	prophylactic	_	_	O
40	use	_	_	O
41	of	_	_	O
42	the	_	_	O
43	antidepressant	_	_	O
44	escitalopram	_	_	O
45	oxalate	_	_	O
46	would	_	_	O
47	decrease	_	_	O
48	the	_	_	O
49	incidence	_	_	O
50	of	_	_	O
51	depression	_	_	O
52	in	_	_	O
53	patients	_	_	O
54	receiving	_	_	O
55	primary	_	_	O
56	therapy	_	_	O
57	for	_	_	O
58	head	_	_	O
59	and	_	_	O
60	neck	_	_	O
61	cancer	_	_	O
62	.	_	_	O

63	A	_	_	O
64	randomized	_	_	O
65	,	_	_	O
66	double-blind	_	_	O
67	,	_	_	O
68	placebo-controlled	_	_	O
69	trial	_	_	O
70	of	_	_	O
71	escitalopram	_	_	O
72	vs	_	_	O
73	placebo	_	_	O
74	was	_	_	O
75	conducted	_	_	O
76	in	_	_	O
77	a	_	_	O
78	group	_	_	O
79	of	_	_	O
80	nondepressed	_	_	O
81	patients	_	_	O
82	diagnosed	_	_	O
83	as	_	_	O
84	having	_	_	O
85	head	_	_	O
86	and	_	_	O
87	neck	_	_	O
88	cancer	_	_	O
89	who	_	_	O
90	were	_	_	O
91	about	_	_	O
92	to	_	_	O
93	enter	_	_	O
94	cancer	_	_	O
95	treatment	_	_	O
96	.	_	_	O

97	Patients	_	_	O
98	were	_	_	O
99	stratified	_	_	O
100	by	_	_	O
101	sex	_	_	O
102	,	_	_	O
103	site	_	_	O
104	,	_	_	O
105	stage	_	_	O
106	(	_	_	O
107	early	_	_	O
108	vs	_	_	O
109	advanced	_	_	O
110	)	_	_	O
111	,	_	_	O
112	and	_	_	O
113	primary	_	_	O
114	modality	_	_	O
115	of	_	_	O
116	treatment	_	_	O
117	(	_	_	O
118	radiation	_	_	O
119	vs	_	_	O
120	surgery	_	_	O
121	)	_	_	O
122	.	_	_	O

123	The	_	_	O
124	primary	_	_	O
125	outcome	_	_	O
126	measure	_	_	O
127	was	_	_	O
128	the	_	_	O
129	number	_	_	O
130	of	_	_	O
131	participants	_	_	O
132	who	_	_	O
133	developed	_	_	O
134	moderate	_	_	O
135	or	_	_	O
136	greater	_	_	O
137	depression	_	_	O
138	(	_	_	O
139	scores	_	_	O
140	on	_	_	O
141	the	_	_	O
142	Quick	_	_	O
143	Inventory	_	_	O
144	of	_	_	O
145	Depressive	_	_	O
146	Symptomology-Self	_	_	O
147	Rated	_	_	O
148	of	_	_	O
149	≥11	_	_	O
150	)	_	_	O
151	.	_	_	O

152	From	_	_	O
153	January	_	_	O
154	6	_	_	O
155	,	_	_	O
156	2008	_	_	O
157	,	_	_	O
158	to	_	_	O
159	December	_	_	O
160	28	_	_	O
161	,	_	_	O
162	2011	_	_	O
163	,	_	_	O
164	148	_	_	O
165	patients	_	_	O
166	were	_	_	O
167	randomized	_	_	O
168	.	_	_	O

169	Significantly	_	_	B-Premise
170	fewer	_	_	I-Premise
171	patients	_	_	I-Premise
172	receiving	_	_	I-Premise
173	escitalopram	_	_	I-Premise
174	developed	_	_	I-Premise
175	depression	_	_	I-Premise
176	(	_	_	I-Premise
177	24.6	_	_	I-Premise
178	%	_	_	I-Premise
179	in	_	_	I-Premise
180	the	_	_	I-Premise
181	placebo	_	_	I-Premise
182	group	_	_	I-Premise
183	vs	_	_	I-Premise
184	10.0	_	_	I-Premise
185	%	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	escitalopram	_	_	I-Premise
189	group	_	_	I-Premise
190	;	_	_	I-Premise
191	stratified	_	_	I-Premise
192	log-rank	_	_	I-Premise
193	test	_	_	I-Premise
194	,	_	_	I-Premise
195	P	_	_	I-Premise
196	=	_	_	I-Premise
197	.04	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	A	_	_	O
201	Cox	_	_	O
202	proportional	_	_	O
203	hazards	_	_	O
204	regression	_	_	O
205	model	_	_	O
206	compared	_	_	O
207	the	_	_	O
208	2	_	_	O
209	treatment	_	_	O
210	groups	_	_	O
211	after	_	_	O
212	controlling	_	_	O
213	for	_	_	O
214	age	_	_	O
215	,	_	_	O
216	baseline	_	_	O
217	smoking	_	_	O
218	status	_	_	O
219	,	_	_	O
220	and	_	_	O
221	stratification	_	_	O
222	variables	_	_	O
223	.	_	_	O

224	The	_	_	B-Premise
225	hazard	_	_	I-Premise
226	ratio	_	_	I-Premise
227	of	_	_	I-Premise
228	0.37	_	_	I-Premise
229	(	_	_	I-Premise
230	95	_	_	I-Premise
231	%	_	_	I-Premise
232	CI	_	_	I-Premise
233	,	_	_	I-Premise
234	0.14-0.96	_	_	I-Premise
235	)	_	_	I-Premise
236	demonstrated	_	_	I-Premise
237	an	_	_	I-Premise
238	advantage	_	_	I-Premise
239	of	_	_	I-Premise
240	escitalopram	_	_	I-Premise
241	(	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	.04	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	Patients	_	_	B-Premise
248	undergoing	_	_	I-Premise
249	radiotherapy	_	_	I-Premise
250	as	_	_	I-Premise
251	the	_	_	I-Premise
252	initial	_	_	I-Premise
253	modality	_	_	I-Premise
254	were	_	_	I-Premise
255	significantly	_	_	I-Premise
256	more	_	_	I-Premise
257	likely	_	_	I-Premise
258	to	_	_	I-Premise
259	develop	_	_	I-Premise
260	depression	_	_	I-Premise
261	than	_	_	I-Premise
262	those	_	_	I-Premise
263	undergoing	_	_	I-Premise
264	surgery	_	_	I-Premise
265	(	_	_	I-Premise
266	radiotherapy	_	_	I-Premise
267	compared	_	_	I-Premise
268	with	_	_	I-Premise
269	surgery	_	_	I-Premise
270	group	_	_	I-Premise
271	;	_	_	I-Premise
272	hazard	_	_	I-Premise
273	ratio	_	_	I-Premise
274	,	_	_	I-Premise
275	3.6	_	_	I-Premise
276	;	_	_	I-Premise
277	95	_	_	I-Premise
278	%	_	_	I-Premise
279	CI	_	_	I-Premise
280	,	_	_	I-Premise
281	1.38-9.40	_	_	I-Premise
282	;	_	_	I-Premise
283	P	_	_	I-Premise
284	=	_	_	I-Premise
285	.009	_	_	I-Premise
286	)	_	_	I-Premise
287	.	_	_	I-Premise

288	Patients	_	_	B-Premise
289	in	_	_	I-Premise
290	the	_	_	I-Premise
291	escitalopram	_	_	I-Premise
292	group	_	_	I-Premise
293	who	_	_	I-Premise
294	completed	_	_	I-Premise
295	the	_	_	I-Premise
296	study	_	_	I-Premise
297	and	_	_	I-Premise
298	were	_	_	I-Premise
299	not	_	_	I-Premise
300	depressed	_	_	I-Premise
301	rated	_	_	I-Premise
302	their	_	_	I-Premise
303	overall	_	_	I-Premise
304	quality	_	_	I-Premise
305	of	_	_	I-Premise
306	life	_	_	I-Premise
307	as	_	_	I-Premise
308	significantly	_	_	I-Premise
309	better	_	_	I-Premise
310	for	_	_	I-Premise
311	3	_	_	I-Premise
312	consecutive	_	_	I-Premise
313	months	_	_	I-Premise
314	after	_	_	I-Premise
315	cessation	_	_	I-Premise
316	of	_	_	I-Premise
317	drug	_	_	I-Premise
318	use	_	_	I-Premise
319	.	_	_	I-Premise

320	In	_	_	B-Claim
321	nondepressed	_	_	I-Claim
322	patients	_	_	I-Claim
323	undergoing	_	_	I-Claim
324	treatment	_	_	I-Claim
325	for	_	_	I-Claim
326	head	_	_	I-Claim
327	and	_	_	I-Claim
328	neck	_	_	I-Claim
329	cancer	_	_	I-Claim
330	,	_	_	I-Claim
331	prophylactic	_	_	I-Claim
332	escitalopram	_	_	I-Claim
333	reduced	_	_	I-Claim
334	the	_	_	I-Claim
335	risk	_	_	I-Claim
336	of	_	_	I-Claim
337	developing	_	_	I-Claim
338	depression	_	_	I-Claim
339	by	_	_	I-Claim
340	more	_	_	I-Claim
341	than	_	_	I-Claim
342	50	_	_	I-Claim
343	%	_	_	I-Claim
344	.	_	_	I-Claim

345	In	_	_	B-Claim
346	nondepressed	_	_	I-Claim
347	patients	_	_	I-Claim
348	who	_	_	I-Claim
349	completed	_	_	I-Claim
350	the	_	_	I-Claim
351	trial	_	_	I-Claim
352	,	_	_	I-Claim
353	quality	_	_	I-Claim
354	of	_	_	I-Claim
355	life	_	_	I-Claim
356	was	_	_	I-Claim
357	also	_	_	I-Claim
358	significantly	_	_	I-Claim
359	better	_	_	I-Claim
360	for	_	_	I-Claim
361	3	_	_	I-Claim
362	consecutive	_	_	I-Claim
363	months	_	_	I-Claim
364	after	_	_	I-Claim
365	cessation	_	_	I-Claim
366	of	_	_	I-Claim
367	drug	_	_	I-Claim
368	use	_	_	I-Claim
369	in	_	_	I-Claim
370	the	_	_	I-Claim
371	escitalopram	_	_	I-Claim
372	group	_	_	I-Claim
373	.	_	_	I-Claim

374	These	_	_	B-Claim
375	findings	_	_	I-Claim
376	have	_	_	I-Claim
377	important	_	_	I-Claim
378	implications	_	_	I-Claim
379	for	_	_	I-Claim
380	the	_	_	I-Claim
381	treatment	_	_	I-Claim
382	of	_	_	I-Claim
383	patients	_	_	I-Claim
384	with	_	_	I-Claim
385	head	_	_	I-Claim
386	and	_	_	I-Claim
387	neck	_	_	I-Claim
388	cancer	_	_	I-Claim
389	.	_	_	I-Claim


0	Many	_	_	O
1	patients	_	_	O
2	with	_	_	O
3	cancer	_	_	O
4	experience	_	_	O
5	depression	_	_	O
6	and	_	_	O
7	anxiety	_	_	O
8	,	_	_	O
9	and	_	_	O
10	an	_	_	O
11	associated	_	_	O
12	decrease	_	_	O
13	in	_	_	O
14	quality	_	_	O
15	of	_	_	O
16	life	_	_	O
17	(	_	_	O
18	QOL	_	_	O
19	)	_	_	O
20	during	_	_	O
21	radiation	_	_	O
22	therapy	_	_	O
23	(	_	_	O
24	RT	_	_	O
25	)	_	_	O
26	.	_	_	O

27	The	_	_	O
28	main	_	_	O
29	objective	_	_	O
30	of	_	_	O
31	the	_	_	O
32	study	_	_	O
33	was	_	_	O
34	to	_	_	O
35	determine	_	_	O
36	the	_	_	O
37	benefits	_	_	O
38	of	_	_	O
39	psychosocial	_	_	O
40	interventions	_	_	O
41	for	_	_	O
42	cancer	_	_	O
43	patients	_	_	O
44	who	_	_	O
45	received	_	_	O
46	RT	_	_	O
47	.	_	_	O

48	Patients	_	_	O
49	with	_	_	O
50	cancer	_	_	O
51	(	_	_	O
52	n	_	_	O
53	=	_	_	O
54	178	_	_	O
55	)	_	_	O
56	who	_	_	O
57	agreed	_	_	O
58	to	_	_	O
59	participate	_	_	O
60	in	_	_	O
61	the	_	_	O
62	study	_	_	O
63	were	_	_	O
64	randomized	_	_	O
65	to	_	_	O
66	the	_	_	O
67	intervention	_	_	O
68	arm	_	_	O
69	(	_	_	O
70	n	_	_	O
71	=	_	_	O
72	89	_	_	O
73	)	_	_	O
74	or	_	_	O
75	the	_	_	O
76	control	_	_	O
77	arm	_	_	O
78	(	_	_	O
79	n	_	_	O
80	=	_	_	O
81	89	_	_	O
82	)	_	_	O
83	.	_	_	O

84	Patients	_	_	O
85	in	_	_	O
86	the	_	_	O
87	intervention	_	_	O
88	group	_	_	O
89	received	_	_	O
90	psychosocial	_	_	O
91	care	_	_	O
92	during	_	_	O
93	RT	_	_	O
94	,	_	_	O
95	whereas	_	_	O
96	the	_	_	O
97	control	_	_	O
98	group	_	_	O
99	received	_	_	O
100	RT	_	_	O
101	only	_	_	O
102	.	_	_	O

103	The	_	_	O
104	benefits	_	_	O
105	of	_	_	O
106	the	_	_	O
107	intervention	_	_	O
108	were	_	_	O
109	evaluated	_	_	O
110	using	_	_	O
111	the	_	_	O
112	Zung	_	_	O
113	Self-rating	_	_	O
114	Depression	_	_	O
115	Scale	_	_	O
116	(	_	_	O
117	SDS	_	_	O
118	)	_	_	O
119	to	_	_	O
120	measure	_	_	O
121	depression	_	_	O
122	,	_	_	O
123	the	_	_	O
124	Self-rating	_	_	O
125	Anxiety	_	_	O
126	Scale	_	_	O
127	(	_	_	O
128	SAS	_	_	O
129	)	_	_	O
130	to	_	_	O
131	assess	_	_	O
132	anxiety	_	_	O
133	,	_	_	O
134	and	_	_	O
135	the	_	_	O
136	European	_	_	O
137	Organization	_	_	O
138	for	_	_	O
139	Research	_	_	O
140	and	_	_	O
141	Treatment	_	_	O
142	of	_	_	O
143	Cancer	_	_	O
144	Quality	_	_	O
145	of	_	_	O
146	Life	_	_	O
147	Questionnaire-Core	_	_	O
148	30	_	_	O
149	(	_	_	O
150	EORTC	_	_	O
151	QLQ-C30	_	_	O
152	)	_	_	O
153	to	_	_	O
154	survey	_	_	O
155	health-related	_	_	O
156	QOL	_	_	O
157	.	_	_	O

158	The	_	_	O
159	association	_	_	O
160	between	_	_	O
161	intervention	_	_	O
162	and	_	_	O
163	survival	_	_	O
164	was	_	_	O
165	also	_	_	O
166	assessed	_	_	O
167	.	_	_	O

168	Patients	_	_	B-Premise
169	randomly	_	_	I-Premise
170	assigned	_	_	I-Premise
171	to	_	_	I-Premise
172	the	_	_	I-Premise
173	intervention	_	_	I-Premise
174	arm	_	_	I-Premise
175	showed	_	_	I-Premise
176	significant	_	_	I-Premise
177	improvements	_	_	I-Premise
178	on	_	_	I-Premise
179	symptoms	_	_	I-Premise
180	of	_	_	I-Premise
181	depression	_	_	I-Premise
182	(	_	_	I-Premise
183	p	_	_	I-Premise
184	<	_	_	I-Premise
185	0.05	_	_	I-Premise
186	)	_	_	I-Premise
187	and	_	_	I-Premise
188	anxiety	_	_	I-Premise
189	(	_	_	I-Premise
190	p	_	_	I-Premise
191	<	_	_	I-Premise
192	0.05	_	_	I-Premise
193	)	_	_	I-Premise
194	,	_	_	I-Premise
195	health-related	_	_	I-Premise
196	QOL	_	_	I-Premise
197	(	_	_	I-Premise
198	p	_	_	I-Premise
199	<	_	_	I-Premise
200	0.05	_	_	I-Premise
201	)	_	_	I-Premise
202	(	_	_	I-Premise
203	i.e	_	_	I-Premise
204	.	_	_	I-Premise

205	better	_	_	I-Premise
206	global	_	_	I-Premise
207	health	_	_	I-Premise
208	status	_	_	I-Premise
209	,	_	_	I-Premise
210	and	_	_	I-Premise
211	physical	_	_	I-Premise
212	and	_	_	I-Premise
213	emotional	_	_	I-Premise
214	functioning	_	_	I-Premise
215	,	_	_	I-Premise
216	and	_	_	I-Premise
217	less	_	_	I-Premise
218	insomnia	_	_	I-Premise
219	)	_	_	I-Premise
220	when	_	_	I-Premise
221	compared	_	_	I-Premise
222	with	_	_	I-Premise
223	controls	_	_	I-Premise
224	.	_	_	I-Premise

225	In	_	_	B-Claim
226	the	_	_	I-Claim
227	subset	_	_	I-Claim
228	analysis	_	_	I-Claim
229	,	_	_	I-Claim
230	female	_	_	I-Claim
231	patients	_	_	I-Claim
232	,	_	_	I-Claim
233	those	_	_	I-Claim
234	that	_	_	I-Claim
235	received	_	_	I-Claim
236	high	_	_	I-Claim
237	dose	_	_	I-Claim
238	irradiation	_	_	I-Claim
239	,	_	_	I-Claim
240	and	_	_	I-Claim
241	those	_	_	I-Claim
242	that	_	_	I-Claim
243	underwent	_	_	I-Claim
244	adjuvant	_	_	I-Claim
245	chemotherapy	_	_	I-Claim
246	could	_	_	I-Claim
247	benefit	_	_	I-Claim
248	more	_	_	I-Claim
249	from	_	_	I-Claim
250	psychosocial	_	_	I-Claim
251	intervention	_	_	I-Claim
252	.	_	_	I-Claim

253	There	_	_	B-Premise
254	was	_	_	I-Premise
255	no	_	_	I-Premise
256	difference	_	_	I-Premise
257	between	_	_	I-Premise
258	the	_	_	I-Premise
259	two	_	_	I-Premise
260	groups	_	_	I-Premise
261	in	_	_	I-Premise
262	disease-free	_	_	I-Premise
263	survival	_	_	I-Premise
264	(	_	_	I-Premise
265	DFS	_	_	I-Premise
266	)	_	_	I-Premise
267	(	_	_	I-Premise
268	2-year	_	_	I-Premise
269	DFS	_	_	I-Premise
270	79.8	_	_	I-Premise
271	%	_	_	I-Premise
272	in	_	_	I-Premise
273	the	_	_	I-Premise
274	intervention	_	_	I-Premise
275	arm	_	_	I-Premise
276	and	_	_	I-Premise
277	76.4	_	_	I-Premise
278	%	_	_	I-Premise
279	in	_	_	I-Premise
280	the	_	_	I-Premise
281	control	_	_	I-Premise
282	arm	_	_	I-Premise
283	;	_	_	I-Premise
284	p	_	_	I-Premise
285	=	_	_	I-Premise
286	0.527	_	_	I-Premise
287	)	_	_	I-Premise
288	and	_	_	I-Premise
289	overall	_	_	I-Premise
290	survival	_	_	I-Premise
291	(	_	_	I-Premise
292	OS	_	_	I-Premise
293	)	_	_	I-Premise
294	(	_	_	I-Premise
295	2-year	_	_	I-Premise
296	OS	_	_	I-Premise
297	83.1	_	_	I-Premise
298	%	_	_	I-Premise
299	in	_	_	I-Premise
300	the	_	_	I-Premise
301	intervention	_	_	I-Premise
302	arm	_	_	I-Premise
303	and	_	_	I-Premise
304	84.3	_	_	I-Premise
305	%	_	_	I-Premise
306	in	_	_	I-Premise
307	the	_	_	I-Premise
308	control	_	_	I-Premise
309	arm	_	_	I-Premise
310	;	_	_	I-Premise
311	p	_	_	I-Premise
312	=	_	_	I-Premise
313	0.925	_	_	I-Premise
314	)	_	_	I-Premise
315	.	_	_	I-Premise

316	Psychosocial	_	_	B-Claim
317	intervention	_	_	I-Claim
318	is	_	_	I-Claim
319	a	_	_	I-Claim
320	cost-effective	_	_	I-Claim
321	approach	_	_	I-Claim
322	that	_	_	I-Claim
323	can	_	_	I-Claim
324	improve	_	_	I-Claim
325	a	_	_	I-Claim
326	patient	_	_	I-Claim
327	's	_	_	I-Claim
328	mood	_	_	I-Claim
329	and	_	_	I-Claim
330	QOL	_	_	I-Claim
331	both	_	_	I-Claim
332	during	_	_	I-Claim
333	and	_	_	I-Claim
334	after	_	_	I-Claim
335	RT	_	_	I-Claim
336	.	_	_	I-Claim

337	However	_	_	B-Claim
338	,	_	_	I-Claim
339	the	_	_	I-Claim
340	intervention	_	_	I-Claim
341	was	_	_	I-Claim
342	not	_	_	I-Claim
343	found	_	_	I-Claim
344	to	_	_	I-Claim
345	reduce	_	_	I-Claim
346	the	_	_	I-Claim
347	risk	_	_	I-Claim
348	of	_	_	I-Claim
349	cancer	_	_	I-Claim
350	recurrence	_	_	I-Claim
351	and	_	_	I-Claim
352	death	_	_	I-Claim
353	.	_	_	I-Claim


0	Surgical	_	_	O
1	resection	_	_	O
2	enhances	_	_	O
3	long-term	_	_	O
4	survival	_	_	O
5	after	_	_	O
6	lung	_	_	O
7	cancer	_	_	O
8	,	_	_	O
9	but	_	_	O
10	survivors	_	_	O
11	face	_	_	O
12	functional	_	_	O
13	deficits	_	_	O
14	and	_	_	O
15	report	_	_	O
16	on	_	_	O
17	poor	_	_	O
18	quality	_	_	O
19	of	_	_	O
20	life	_	_	O
21	long	_	_	O
22	time	_	_	O
23	after	_	_	O
24	surgery	_	_	O
25	.	_	_	O

26	This	_	_	O
27	study	_	_	O
28	evaluated	_	_	O
29	short	_	_	O
30	and	_	_	O
31	long-term	_	_	O
32	effects	_	_	O
33	of	_	_	O
34	supervised	_	_	O
35	group	_	_	O
36	exercise	_	_	O
37	training	_	_	O
38	on	_	_	O
39	health-related	_	_	O
40	quality	_	_	O
41	of	_	_	O
42	life	_	_	O
43	and	_	_	O
44	physical	_	_	O
45	performance	_	_	O
46	in	_	_	O
47	patients	_	_	O
48	,	_	_	O
49	who	_	_	O
50	were	_	_	O
51	radically	_	_	O
52	operated	_	_	O
53	for	_	_	O
54	lung	_	_	O
55	cancer	_	_	O
56	.	_	_	O

57	A	_	_	O
58	randomized	_	_	O
59	,	_	_	O
60	assessor-blinded	_	_	O
61	,	_	_	O
62	controlled	_	_	O
63	trial	_	_	O
64	was	_	_	O
65	performed	_	_	O
66	on	_	_	O
67	78	_	_	O
68	patients	_	_	O
69	undergoing	_	_	O
70	lung	_	_	O
71	cancer	_	_	O
72	surgery	_	_	O
73	.	_	_	O

74	The	_	_	O
75	intervention	_	_	O
76	group	_	_	O
77	(	_	_	O
78	IG	_	_	O
79	,	_	_	O
80	n=41	_	_	O
81	)	_	_	O
82	participated	_	_	O
83	in	_	_	O
84	supervised	_	_	O
85	out-patient	_	_	O
86	exercise	_	_	O
87	training	_	_	O
88	sessions	_	_	O
89	,	_	_	O
90	one	_	_	O
91	hour	_	_	O
92	once	_	_	O
93	a	_	_	O
94	week	_	_	O
95	for	_	_	O
96	ten	_	_	O
97	weeks	_	_	O
98	.	_	_	O

99	The	_	_	O
100	sessions	_	_	O
101	were	_	_	O
102	based	_	_	O
103	on	_	_	O
104	aerobic	_	_	O
105	exercises	_	_	O
106	with	_	_	O
107	target	_	_	O
108	intensity	_	_	O
109	of	_	_	O
110	60-80	_	_	O
111	%	_	_	O
112	of	_	_	O
113	work	_	_	O
114	capacity	_	_	O
115	,	_	_	O
116	resistance	_	_	O
117	training	_	_	O
118	and	_	_	O
119	dyspnoea	_	_	O
120	management	_	_	O
121	.	_	_	O

122	The	_	_	O
123	control	_	_	O
124	group	_	_	O
125	(	_	_	O
126	CG	_	_	O
127	,	_	_	O
128	n=37	_	_	O
129	)	_	_	O
130	received	_	_	O
131	one	_	_	O
132	individual	_	_	O
133	instruction	_	_	O
134	in	_	_	O
135	exercise	_	_	O
136	training	_	_	O
137	.	_	_	O

138	Measurements	_	_	O
139	consisted	_	_	O
140	of	_	_	O
141	:	_	_	O
142	health-related	_	_	O
143	quality	_	_	O
144	of	_	_	O
145	life	_	_	O
146	(	_	_	O
147	SF36	_	_	O
148	)	_	_	O
149	,	_	_	O
150	six	_	_	O
151	minute	_	_	O
152	walk	_	_	O
153	test	_	_	O
154	(	_	_	O
155	6MWT	_	_	O
156	)	_	_	O
157	and	_	_	O
158	lung	_	_	O
159	function	_	_	O
160	(	_	_	O
161	spirometry	_	_	O
162	)	_	_	O
163	,	_	_	O
164	assessed	_	_	O
165	three	_	_	O
166	weeks	_	_	O
167	after	_	_	O
168	surgery	_	_	O
169	and	_	_	O
170	after	_	_	O
171	four	_	_	O
172	and	_	_	O
173	twelve	_	_	O
174	months	_	_	O
175	.	_	_	O

176	Both	_	_	O
177	groups	_	_	O
178	were	_	_	O
179	comparable	_	_	O
180	at	_	_	O
181	baseline	_	_	O
182	on	_	_	O
183	demographic	_	_	O
184	characteristic	_	_	O
185	and	_	_	O
186	outcome	_	_	O
187	values	_	_	O
188	.	_	_	O

189	We	_	_	B-Premise
190	found	_	_	I-Premise
191	a	_	_	I-Premise
192	statistically	_	_	I-Premise
193	significant	_	_	I-Premise
194	effect	_	_	I-Premise
195	after	_	_	I-Premise
196	four	_	_	I-Premise
197	months	_	_	I-Premise
198	in	_	_	I-Premise
199	the	_	_	I-Premise
200	bodily	_	_	I-Premise
201	pain	_	_	I-Premise
202	domain	_	_	I-Premise
203	of	_	_	I-Premise
204	SF36	_	_	I-Premise
205	,	_	_	I-Premise
206	with	_	_	I-Premise
207	an	_	_	I-Premise
208	estimated	_	_	I-Premise
209	mean	_	_	I-Premise
210	difference	_	_	I-Premise
211	(	_	_	I-Premise
212	EMD	_	_	I-Premise
213	)	_	_	I-Premise
214	of	_	_	I-Premise
215	15.3	_	_	I-Premise
216	(	_	_	I-Premise
217	95	_	_	I-Premise
218	%	_	_	I-Premise
219	CI:4	_	_	I-Premise
220	to	_	_	I-Premise
221	26.6	_	_	I-Premise
222	,	_	_	I-Premise
223	p=0.01	_	_	I-Premise
224	)	_	_	I-Premise
225	and	_	_	I-Premise
226	a	_	_	I-Premise
227	trend	_	_	I-Premise
228	in	_	_	I-Premise
229	favour	_	_	I-Premise
230	of	_	_	I-Premise
231	the	_	_	I-Premise
232	intervention	_	_	I-Premise
233	for	_	_	I-Premise
234	role	_	_	I-Premise
235	physical	_	_	I-Premise
236	functioning	_	_	I-Premise
237	(	_	_	I-Premise
238	EMD	_	_	I-Premise
239	12.04	_	_	I-Premise
240	,	_	_	I-Premise
241	95	_	_	I-Premise
242	%	_	_	I-Premise
243	CI	_	_	I-Premise
244	:	_	_	I-Premise
245	-1	_	_	I-Premise
246	to	_	_	I-Premise
247	25.1	_	_	I-Premise
248	,	_	_	I-Premise
249	p=0.07	_	_	I-Premise
250	)	_	_	I-Premise
251	and	_	_	I-Premise
252	physical	_	_	I-Premise
253	component	_	_	I-Premise
254	summary	_	_	I-Premise
255	(	_	_	I-Premise
256	EMD	_	_	I-Premise
257	3.76	_	_	I-Premise
258	,	_	_	I-Premise
259	95	_	_	I-Premise
260	%	_	_	I-Premise
261	CI	_	_	I-Premise
262	:	_	_	I-Premise
263	-0.1	_	_	I-Premise
264	to	_	_	I-Premise
265	7.6	_	_	I-Premise
266	,	_	_	I-Premise
267	p=0.06	_	_	I-Premise
268	)	_	_	I-Premise
269	.	_	_	I-Premise

270	At	_	_	B-Premise
271	12	_	_	I-Premise
272	months	_	_	I-Premise
273	,	_	_	I-Premise
274	the	_	_	I-Premise
275	tendency	_	_	I-Premise
276	was	_	_	I-Premise
277	reversed	_	_	I-Premise
278	,	_	_	I-Premise
279	with	_	_	I-Premise
280	the	_	_	I-Premise
281	CG	_	_	I-Premise
282	presenting	_	_	I-Premise
283	overall	_	_	I-Premise
284	slightly	_	_	I-Premise
285	better	_	_	I-Premise
286	measures	_	_	I-Premise
287	.	_	_	I-Premise

288	We	_	_	B-Claim
289	found	_	_	I-Claim
290	no	_	_	I-Claim
291	effect	_	_	I-Claim
292	of	_	_	I-Claim
293	the	_	_	I-Claim
294	intervention	_	_	I-Claim
295	on	_	_	I-Claim
296	6MWT	_	_	I-Claim
297	or	_	_	I-Claim
298	lung	_	_	I-Claim
299	volumes	_	_	I-Claim
300	at	_	_	I-Claim
301	any	_	_	I-Claim
302	time-point	_	_	I-Claim
303	.	_	_	I-Claim

304	Supervised	_	_	B-Claim
305	compared	_	_	I-Claim
306	to	_	_	I-Claim
307	unsupervised	_	_	I-Claim
308	exercise	_	_	I-Claim
309	training	_	_	I-Claim
310	resulted	_	_	I-Claim
311	in	_	_	I-Claim
312	no	_	_	I-Claim
313	improvement	_	_	I-Claim
314	in	_	_	I-Claim
315	health-related	_	_	I-Claim
316	quality	_	_	I-Claim
317	of	_	_	I-Claim
318	life	_	_	I-Claim
319	,	_	_	I-Claim
320	except	_	_	B-Claim
321	for	_	_	I-Claim
322	the	_	_	I-Claim
323	bodily	_	_	I-Claim
324	pain	_	_	I-Claim
325	domain	_	_	I-Claim
326	,	_	_	I-Claim
327	four	_	_	I-Claim
328	months	_	_	I-Claim
329	after	_	_	I-Claim
330	lung	_	_	I-Claim
331	cancer	_	_	I-Claim
332	surgery	_	_	I-Claim
333	.	_	_	I-Claim

334	No	_	_	B-Claim
335	effects	_	_	I-Claim
336	of	_	_	I-Claim
337	the	_	_	I-Claim
338	intervention	_	_	I-Claim
339	were	_	_	I-Claim
340	found	_	_	I-Claim
341	for	_	_	I-Claim
342	any	_	_	I-Claim
343	outcome	_	_	I-Claim
344	after	_	_	I-Claim
345	one	_	_	I-Claim
346	year	_	_	I-Claim
347	.	_	_	I-Claim


0	In	_	_	B-Claim
1	patients	_	_	I-Claim
2	with	_	_	I-Claim
3	chronic	_	_	I-Claim
4	hepatitis	_	_	I-Claim
5	B	_	_	I-Claim
6	,	_	_	I-Claim
7	tenofovir	_	_	I-Claim
8	disoproxil	_	_	I-Claim
9	fumarate	_	_	I-Claim
10	(	_	_	I-Claim
11	TDF	_	_	I-Claim
12	)	_	_	I-Claim
13	plus	_	_	I-Claim
14	pegylated	_	_	I-Claim
15	interferon	_	_	I-Claim
16	(	_	_	I-Claim
17	PEG-IFN	_	_	I-Claim
18	)	_	_	I-Claim
19	for	_	_	I-Claim
20	48-weeks	_	_	I-Claim
21	results	_	_	I-Claim
22	in	_	_	I-Claim
23	higher	_	_	I-Claim
24	rates	_	_	I-Claim
25	of	_	_	I-Claim
26	hepatitis	_	_	I-Claim
27	B	_	_	I-Claim
28	surface	_	_	I-Claim
29	antigen	_	_	I-Claim
30	(	_	_	I-Claim
31	HBsAg	_	_	I-Claim
32	)	_	_	I-Claim
33	loss	_	_	I-Claim
34	than	_	_	I-Claim
35	either	_	_	I-Claim
36	monotherapy	_	_	I-Claim
37	.	_	_	I-Claim

38	To	_	_	O
39	identify	_	_	O
40	baseline	_	_	O
41	and	_	_	O
42	on-treatment	_	_	O
43	factors	_	_	O
44	associated	_	_	O
45	with	_	_	O
46	HBsAg	_	_	O
47	loss	_	_	O
48	at	_	_	O
49	Week	_	_	O
50	72	_	_	O
51	and	_	_	O
52	provide	_	_	O
53	a	_	_	O
54	model	_	_	O
55	for	_	_	O
56	predicting	_	_	O
57	HBsAg	_	_	O
58	loss	_	_	O
59	in	_	_	O
60	patients	_	_	O
61	receiving	_	_	O
62	combination	_	_	O
63	therapy	_	_	O
64	for	_	_	O
65	48	_	_	O
66	weeks	_	_	O
67	.	_	_	O

68	A	_	_	O
69	secondary	_	_	O
70	analysis	_	_	O
71	of	_	_	O
72	data	_	_	O
73	from	_	_	O
74	an	_	_	O
75	open-label	_	_	O
76	study	_	_	O
77	where	_	_	O
78	patients	_	_	O
79	were	_	_	O
80	randomised	_	_	O
81	to	_	_	O
82	TDF	_	_	O
83	(	_	_	O
84	300	_	_	O
85	mg/day	_	_	O
86	,	_	_	O
87	oral	_	_	O
88	)	_	_	O
89	plus	_	_	O
90	PEG-IFN	_	_	O
91	(	_	_	O
92	PI	_	_	O
93	,	_	_	O
94	180	_	_	O
95	μg/week	_	_	O
96	,	_	_	O
97	subcutaneous	_	_	O
98	)	_	_	O
99	for	_	_	O
100	48	_	_	O
101	weeks	_	_	O
102	(	_	_	O
103	TDF/PI-48w	_	_	O
104	)	_	_	O
105	;	_	_	O
106	TDF	_	_	O
107	plus	_	_	O
108	PEG-IFN	_	_	O
109	for	_	_	O
110	16	_	_	O
111	weeks	_	_	O
112	,	_	_	O
113	TDF	_	_	O
114	for	_	_	O
115	32	_	_	O
116	weeks	_	_	O
117	(	_	_	O
118	TDF/PI-16w+TDF-32w	_	_	O
119	)	_	_	O
120	;	_	_	O
121	TDF	_	_	O
122	for	_	_	O
123	120	_	_	O
124	weeks	_	_	O
125	(	_	_	O
126	TDF-120w	_	_	O
127	)	_	_	O
128	or	_	_	O
129	PEG-IFN	_	_	O
130	for	_	_	O
131	48	_	_	O
132	weeks	_	_	O
133	(	_	_	O
134	PI-48w	_	_	O
135	)	_	_	O
136	.	_	_	O

137	Logistic	_	_	O
138	regression	_	_	O
139	methods	_	_	O
140	were	_	_	O
141	used	_	_	O
142	to	_	_	O
143	identify	_	_	O
144	models	_	_	O
145	that	_	_	O
146	best	_	_	O
147	predicted	_	_	O
148	HBsAg	_	_	O
149	loss	_	_	O
150	at	_	_	O
151	Week	_	_	O
152	72	_	_	O
153	.	_	_	O

154	Rates	_	_	B-Premise
155	of	_	_	I-Premise
156	HBsAg	_	_	I-Premise
157	loss	_	_	I-Premise
158	at	_	_	I-Premise
159	Week	_	_	I-Premise
160	72	_	_	I-Premise
161	were	_	_	I-Premise
162	significantly	_	_	I-Premise
163	higher	_	_	I-Premise
164	in	_	_	I-Premise
165	the	_	_	I-Premise
166	TDF/PI-48w	_	_	I-Premise
167	group	_	_	I-Premise
168	(	_	_	I-Premise
169	6.5	_	_	I-Premise
170	%	_	_	I-Premise
171	)	_	_	I-Premise
172	than	_	_	I-Premise
173	in	_	_	I-Premise
174	the	_	_	I-Premise
175	TDF/PI-16w+TDF-32w	_	_	I-Premise
176	(	_	_	I-Premise
177	0.5	_	_	I-Premise
178	%	_	_	I-Premise
179	)	_	_	I-Premise
180	,	_	_	I-Premise
181	TDF-120w	_	_	I-Premise
182	(	_	_	I-Premise
183	0	_	_	I-Premise
184	%	_	_	I-Premise
185	)	_	_	I-Premise
186	and	_	_	I-Premise
187	PI-48w	_	_	I-Premise
188	(	_	_	I-Premise
189	2.2	_	_	I-Premise
190	%	_	_	I-Premise
191	)	_	_	I-Premise
192	groups	_	_	I-Premise
193	(	_	_	I-Premise
194	P	_	_	I-Premise
195	=	_	_	I-Premise
196	0.09	_	_	I-Premise
197	)	_	_	I-Premise
198	.	_	_	I-Premise

199	The	_	_	O
200	only	_	_	O
201	baseline	_	_	O
202	factor	_	_	O
203	associated	_	_	O
204	with	_	_	O
205	response	_	_	O
206	was	_	_	O
207	genotype	_	_	O
208	A.	_	_	O
209	HBsAg	_	_	B-Premise
210	decline	_	_	I-Premise
211	at	_	_	I-Premise
212	Week	_	_	I-Premise
213	12	_	_	I-Premise
214	or	_	_	I-Premise
215	24	_	_	I-Premise
216	of	_	_	I-Premise
217	treatment	_	_	I-Premise
218	was	_	_	I-Premise
219	associated	_	_	I-Premise
220	with	_	_	I-Premise
221	HBsAg	_	_	I-Premise
222	loss	_	_	I-Premise
223	at	_	_	I-Premise
224	Week	_	_	I-Premise
225	72	_	_	I-Premise
226	(	_	_	I-Premise
227	P	_	_	I-Premise
228	<	_	_	I-Premise
229	0.001	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	HBsAg	_	_	B-Premise
233	decline	_	_	I-Premise
234	>	_	_	I-Premise
235	3.5	_	_	I-Premise
236	log10	_	_	I-Premise
237	IU/mL	_	_	I-Premise
238	at	_	_	I-Premise
239	Week	_	_	I-Premise
240	24	_	_	I-Premise
241	in	_	_	I-Premise
242	the	_	_	I-Premise
243	TDF/PI-48w	_	_	I-Premise
244	group	_	_	I-Premise
245	resulted	_	_	I-Premise
246	in	_	_	I-Premise
247	a	_	_	I-Premise
248	positive	_	_	I-Premise
249	predictive	_	_	I-Premise
250	value	_	_	I-Premise
251	of	_	_	I-Premise
252	85	_	_	I-Premise
253	%	_	_	I-Premise
254	and	_	_	I-Premise
255	a	_	_	I-Premise
256	negative	_	_	I-Premise
257	predictive	_	_	I-Premise
258	value	_	_	I-Premise
259	of	_	_	I-Premise
260	99	_	_	I-Premise
261	%	_	_	I-Premise
262	for	_	_	I-Premise
263	HBsAg	_	_	I-Premise
264	loss	_	_	I-Premise
265	at	_	_	I-Premise
266	Week	_	_	I-Premise
267	72	_	_	I-Premise
268	.	_	_	I-Premise

269	HBsAg	_	_	B-Claim
270	decline	_	_	I-Claim
271	at	_	_	I-Claim
272	Week	_	_	I-Claim
273	24	_	_	I-Claim
274	of	_	_	I-Claim
275	TDF	_	_	I-Claim
276	plus	_	_	I-Claim
277	PEG-IFN	_	_	I-Claim
278	combination	_	_	I-Claim
279	therapy	_	_	I-Claim
280	may	_	_	I-Claim
281	identify	_	_	I-Claim
282	patients	_	_	I-Claim
283	who	_	_	I-Claim
284	,	_	_	I-Claim
285	after	_	_	I-Claim
286	completing	_	_	I-Claim
287	48	_	_	I-Claim
288	weeks	_	_	I-Claim
289	of	_	_	I-Claim
290	treatment	_	_	I-Claim
291	,	_	_	I-Claim
292	have	_	_	I-Claim
293	a	_	_	I-Claim
294	better	_	_	I-Claim
295	chance	_	_	I-Claim
296	of	_	_	I-Claim
297	achieving	_	_	I-Claim
298	HBsAg	_	_	I-Claim
299	loss	_	_	I-Claim
300	at	_	_	I-Claim
301	Week	_	_	I-Claim
302	72	_	_	I-Claim
303	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	selective	_	_	O
6	laser	_	_	O
7	trabeculoplasty	_	_	O
8	(	_	_	O
9	SLT	_	_	O
10	)	_	_	O
11	and	_	_	O
12	travoprost	_	_	O
13	on	_	_	O
14	24-hour	_	_	O
15	IOP	_	_	O
16	fluctuations	_	_	O
17	in	_	_	O
18	primary	_	_	O
19	open-angle	_	_	O
20	glaucoma	_	_	O
21	(	_	_	O
22	POAG	_	_	O
23	)	_	_	O
24	and	_	_	O
25	normal-tension	_	_	O
26	glaucoma	_	_	O
27	(	_	_	O
28	NTG	_	_	O
29	)	_	_	O
30	.	_	_	O

31	Sixty	_	_	O
32	eyes	_	_	O
33	were	_	_	O
34	included	_	_	O
35	.	_	_	O

36	Sixteen	_	_	O
37	and	_	_	O
38	14	_	_	O
39	eyes	_	_	O
40	of	_	_	O
41	POAG	_	_	O
42	patients	_	_	O
43	were	_	_	O
44	randomized	_	_	O
45	to	_	_	O
46	receive	_	_	O
47	360°	_	_	O
48	SLT	_	_	O
49	or	_	_	O
50	0.004	_	_	O
51	%	_	_	O
52	travoprost	_	_	O
53	,	_	_	O
54	respectively	_	_	O
55	.	_	_	O

56	Fourteen	_	_	O
57	and	_	_	O
58	16	_	_	O
59	eyes	_	_	O
60	of	_	_	O
61	NTG	_	_	O
62	patients	_	_	O
63	were	_	_	O
64	randomized	_	_	O
65	to	_	_	O
66	receive	_	_	O
67	either	_	_	O
68	SLT	_	_	O
69	or	_	_	O
70	travoprost	_	_	O
71	,	_	_	O
72	respectively	_	_	O
73	.	_	_	O

74	The	_	_	O
75	24-hour	_	_	O
76	IOP	_	_	O
77	data	_	_	O
78	were	_	_	O
79	collected	_	_	O
80	before	_	_	O
81	treatment	_	_	O
82	and	_	_	O
83	6	_	_	O
84	to	_	_	O
85	8	_	_	O
86	weeks	_	_	O
87	after	_	_	O
88	treatment	_	_	O
89	.	_	_	O

90	IOP	_	_	O
91	was	_	_	O
92	measured	_	_	O
93	at	_	_	O
94	2	_	_	O
95	hours	_	_	O
96	intervals	_	_	O
97	in	_	_	O
98	the	_	_	O
99	sitting	_	_	O
100	position	_	_	O
101	during	_	_	O
102	daytime	_	_	O
103	(	_	_	O
104	9	_	_	O
105	AM	_	_	O
106	to	_	_	O
107	7	_	_	O
108	PM	_	_	O
109	)	_	_	O
110	and	_	_	O
111	in	_	_	O
112	the	_	_	O
113	supine	_	_	O
114	position	_	_	O
115	during	_	_	O
116	nighttime	_	_	O
117	(	_	_	O
118	9	_	_	O
119	PM	_	_	O
120	to	_	_	O
121	7	_	_	O
122	AM	_	_	O
123	)	_	_	O
124	.	_	_	O

125	Main	_	_	O
126	outcome	_	_	O
127	measure	_	_	O
128	was	_	_	O
129	the	_	_	O
130	percentage	_	_	O
131	of	_	_	O
132	eyes	_	_	O
133	that	_	_	O
134	achieved	_	_	O
135	posttreatment	_	_	O
136	24-hour	_	_	O
137	IOP	_	_	O
138	fluctuations	_	_	O
139	<	_	_	O
140	3	_	_	O
141	mm	_	_	O
142	Hg	_	_	O
143	.	_	_	O

144	Success	_	_	O
145	in	_	_	O
146	fluctuation	_	_	O
147	reduction	_	_	O
148	was	_	_	O
149	defined	_	_	O
150	as	_	_	O
151	at	_	_	O
152	least	_	_	O
153	a	_	_	O
154	50	_	_	O
155	%	_	_	O
156	reduction	_	_	O
157	in	_	_	O
158	these	_	_	O
159	fluctuations	_	_	O
160	.	_	_	O

161	Fifty-eight	_	_	O
162	eyes	_	_	O
163	were	_	_	O
164	analyzed	_	_	O
165	.	_	_	O

166	Overall	_	_	O
167	,	_	_	O
168	eyes	_	_	B-Premise
169	in	_	_	I-Premise
170	the	_	_	I-Premise
171	SLT	_	_	I-Premise
172	and	_	_	I-Premise
173	the	_	_	I-Premise
174	travoprost	_	_	I-Premise
175	groups	_	_	I-Premise
176	achieved	_	_	I-Premise
177	a	_	_	I-Premise
178	significant	_	_	I-Premise
179	reduction	_	_	I-Premise
180	in	_	_	I-Premise
181	IOP	_	_	I-Premise
182	compared	_	_	I-Premise
183	with	_	_	I-Premise
184	the	_	_	I-Premise
185	baseline	_	_	I-Premise
186	IOP	_	_	I-Premise
187	values	_	_	I-Premise
188	(	_	_	I-Premise
189	-3.7	_	_	I-Premise
190	mm	_	_	I-Premise
191	Hg	_	_	I-Premise
192	[	_	_	I-Premise
193	P	_	_	I-Premise
194	=	_	_	I-Premise
195	0.002	_	_	I-Premise
196	]	_	_	I-Premise
197	vs	_	_	I-Premise
198	-4.1	_	_	I-Premise
199	mm	_	_	I-Premise
200	Hg	_	_	I-Premise
201	[	_	_	I-Premise
202	P	_	_	I-Premise
203	<	_	_	I-Premise
204	0.001	_	_	I-Premise
205	]	_	_	I-Premise
206	,	_	_	I-Premise
207	respectively	_	_	I-Premise
208	)	_	_	I-Premise
209	.	_	_	I-Premise

210	There	_	_	O
211	was	_	_	O
212	no	_	_	O
213	significant	_	_	O
214	difference	_	_	O
215	in	_	_	O
216	IOP	_	_	O
217	reduction	_	_	O
218	in	_	_	O
219	both	_	_	O
220	groups	_	_	O
221	according	_	_	O
222	to	_	_	O
223	type	_	_	O
224	of	_	_	O
225	glaucoma	_	_	O
226	.	_	_	O

227	During	_	_	O
228	the	_	_	O
229	diurnal	_	_	O
230	period	_	_	O
231	,	_	_	O
232	100	_	_	O
233	%	_	_	O
234	of	_	_	O
235	POAG	_	_	O
236	eyes	_	_	O
237	in	_	_	O
238	the	_	_	O
239	travoprost	_	_	O
240	group	_	_	O
241	achieved	_	_	O
242	posttreatment	_	_	O
243	IOP	_	_	O
244	fluctuations	_	_	O
245	<	_	_	O
246	3	_	_	O
247	mm	_	_	O
248	Hg	_	_	O
249	,	_	_	O
250	and	_	_	O
251	87	_	_	O
252	%	_	_	O
253	of	_	_	O
254	eyes	_	_	O
255	in	_	_	O
256	the	_	_	O
257	SLT	_	_	O
258	group	_	_	O
259	achieved	_	_	O
260	the	_	_	O
261	same	_	_	O
262	level	_	_	O
263	of	_	_	O
264	fluctuations	_	_	O
265	(	_	_	O
266	P	_	_	O
267	<	_	_	O
268	0.001	_	_	O
269	)	_	_	O
270	.	_	_	O

271	Ninety-six	_	_	B-Premise
272	percent	_	_	I-Premise
273	of	_	_	I-Premise
274	NTG	_	_	I-Premise
275	eyes	_	_	I-Premise
276	in	_	_	I-Premise
277	the	_	_	I-Premise
278	travoprost	_	_	I-Premise
279	group	_	_	I-Premise
280	,	_	_	I-Premise
281	and	_	_	I-Premise
282	82	_	_	I-Premise
283	%	_	_	I-Premise
284	of	_	_	I-Premise
285	eyes	_	_	I-Premise
286	in	_	_	I-Premise
287	the	_	_	I-Premise
288	SLT	_	_	I-Premise
289	group	_	_	I-Premise
290	had	_	_	I-Premise
291	IOP	_	_	I-Premise
292	fluctuations	_	_	I-Premise
293	<	_	_	I-Premise
294	3	_	_	I-Premise
295	mm	_	_	I-Premise
296	Hg	_	_	I-Premise
297	(	_	_	I-Premise
298	P	_	_	I-Premise
299	=	_	_	I-Premise
300	0.01	_	_	I-Premise
301	)	_	_	I-Premise
302	.	_	_	I-Premise

303	Success	_	_	B-Premise
304	in	_	_	I-Premise
305	fluctuation	_	_	I-Premise
306	reduction	_	_	I-Premise
307	was	_	_	I-Premise
308	75	_	_	I-Premise
309	%	_	_	I-Premise
310	and	_	_	I-Premise
311	92	_	_	I-Premise
312	%	_	_	I-Premise
313	for	_	_	I-Premise
314	the	_	_	I-Premise
315	SLT	_	_	I-Premise
316	and	_	_	I-Premise
317	travoprost	_	_	I-Premise
318	groups	_	_	I-Premise
319	,	_	_	I-Premise
320	respectively	_	_	I-Premise
321	(	_	_	I-Premise
322	P	_	_	I-Premise
323	=	_	_	I-Premise
324	0.005	_	_	I-Premise
325	)	_	_	I-Premise
326	.	_	_	I-Premise

327	The	_	_	B-Claim
328	effect	_	_	I-Claim
329	of	_	_	I-Claim
330	travoprost	_	_	I-Claim
331	on	_	_	I-Claim
332	IOP	_	_	I-Claim
333	reduction	_	_	I-Claim
334	in	_	_	I-Claim
335	POAG	_	_	I-Claim
336	and	_	_	I-Claim
337	NTG	_	_	I-Claim
338	patients	_	_	I-Claim
339	was	_	_	I-Claim
340	significant	_	_	I-Claim
341	both	_	_	I-Claim
342	during	_	_	I-Claim
343	the	_	_	I-Claim
344	daytime	_	_	I-Claim
345	and	_	_	I-Claim
346	the	_	_	I-Claim
347	nighttime	_	_	I-Claim
348	,	_	_	I-Claim
349	while	_	_	O
350	the	_	_	B-Claim
351	SLT	_	_	I-Claim
352	's	_	_	I-Claim
353	effect	_	_	I-Claim
354	was	_	_	I-Claim
355	significant	_	_	I-Claim
356	only	_	_	I-Claim
357	during	_	_	I-Claim
358	the	_	_	I-Claim
359	nighttime	_	_	I-Claim
360	.	_	_	I-Claim

361	Both	_	_	B-Claim
362	travoprost	_	_	I-Claim
363	and	_	_	I-Claim
364	SLT	_	_	I-Claim
365	can	_	_	I-Claim
366	significantly	_	_	I-Claim
367	reduce	_	_	I-Claim
368	the	_	_	I-Claim
369	IOP	_	_	I-Claim
370	in	_	_	I-Claim
371	patients	_	_	I-Claim
372	with	_	_	I-Claim
373	POAG	_	_	I-Claim
374	and	_	_	I-Claim
375	NTG	_	_	I-Claim
376	.	_	_	I-Claim

377	Based	_	_	O
378	on	_	_	O
379	habitual	_	_	O
380	positions	_	_	O
381	,	_	_	O
382	travoprost	_	_	B-Claim
383	better	_	_	I-Claim
384	controls	_	_	I-Claim
385	IOP	_	_	I-Claim
386	fluctuations	_	_	I-Claim
387	than	_	_	I-Claim
388	SLT	_	_	I-Claim
389	,	_	_	I-Claim
390	especially	_	_	I-Claim
391	during	_	_	I-Claim
392	the	_	_	I-Claim
393	daytime	_	_	I-Claim
394	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	outcomes	_	_	O
4	of	_	_	O
5	microcatheter-assisted	_	_	O
6	circumferential	_	_	O
7	trabeculotomy	_	_	O
8	to	_	_	O
9	standard	_	_	O
10	rigid	_	_	O
11	probe	_	_	O
12	trabeculotomy	_	_	O
13	in	_	_	O
14	childhood	_	_	O
15	glaucomas	_	_	O
16	.	_	_	O

17	Eyes	_	_	O
18	of	_	_	O
19	children	_	_	O
20	requiring	_	_	O
21	trabeculotomy	_	_	O
22	for	_	_	O
23	primary	_	_	O
24	congenital	_	_	O
25	or	_	_	O
26	secondary	_	_	O
27	paediatric	_	_	O
28	glaucoma	_	_	O
29	were	_	_	O
30	randomized	_	_	O
31	to	_	_	O
32	undergo	_	_	O
33	either	_	_	O
34	trabeculotomy	_	_	O
35	using	_	_	O
36	the	_	_	O
37	Glaucolight	_	_	O
38	illuminated	_	_	O
39	microcatheter	_	_	O
40	,	_	_	O
41	or	_	_	O
42	a	_	_	O
43	rigid	_	_	O
44	probe	_	_	O
45	trabeculotomy	_	_	O
46	.	_	_	O

47	Complete	_	_	O
48	success	_	_	O
49	was	_	_	O
50	defined	_	_	O
51	as	_	_	O
52	an	_	_	O
53	intraocular	_	_	O
54	pressure	_	_	O
55	(	_	_	O
56	IOP	_	_	O
57	)	_	_	O
58	of	_	_	O
59	<	_	_	O
60	18	_	_	O
61	mmHg	_	_	O
62	without	_	_	O
63	medications	_	_	O
64	.	_	_	O

65	A	_	_	O
66	total	_	_	O
67	of	_	_	O
68	62	_	_	O
69	eyes	_	_	O
70	of	_	_	O
71	62	_	_	O
72	patients	_	_	O
73	were	_	_	O
74	included	_	_	O
75	.	_	_	O

76	Of	_	_	O
77	these	_	_	O
78	30	_	_	O
79	eyes	_	_	O
80	of	_	_	O
81	30	_	_	O
82	patients	_	_	O
83	aged	_	_	O
84	5.6	_	_	O
85	±	_	_	O
86	4.8	_	_	O
87	months	_	_	O
88	underwent	_	_	O
89	microcatheter-assisted	_	_	O
90	trabeculotomy	_	_	O
91	,	_	_	O
92	with	_	_	O
93	15	_	_	O
94	eyes	_	_	O
95	(	_	_	O
96	50	_	_	O
97	%	_	_	O
98	)	_	_	O
99	having	_	_	O
100	a	_	_	O
101	complete	_	_	O
102	360°	_	_	O
103	cut	_	_	O
104	,	_	_	O
105	while	_	_	O
106	15	_	_	O
107	eyes	_	_	O
108	(	_	_	O
109	50	_	_	O
110	%	_	_	O
111	)	_	_	O
112	had	_	_	O
113	an	_	_	O
114	incomplete	_	_	O
115	cut	_	_	O
116	ranging	_	_	O
117	from	_	_	O
118	250	_	_	O
119	to	_	_	O
120	350	_	_	O
121	degrees	_	_	O
122	.	_	_	O

123	The	_	_	O
124	rigid	_	_	O
125	probe	_	_	O
126	trabeculotomy	_	_	O
127	group	_	_	O
128	included	_	_	O
129	32	_	_	O
130	eyes	_	_	O
131	of	_	_	O
132	32	_	_	O
133	patients	_	_	O
134	aged	_	_	O
135	4.4	_	_	O
136	±	_	_	O
137	3.8	_	_	O
138	months	_	_	O
139	.	_	_	O

140	At	_	_	B-Premise
141	the	_	_	I-Premise
142	end	_	_	I-Premise
143	of	_	_	I-Premise
144	the	_	_	I-Premise
145	2-year	_	_	I-Premise
146	follow-up	_	_	I-Premise
147	period	_	_	I-Premise
148	,	_	_	I-Premise
149	the	_	_	I-Premise
150	complete	_	_	I-Premise
151	success	_	_	I-Premise
152	and	_	_	I-Premise
153	the	_	_	I-Premise
154	failure	_	_	I-Premise
155	rates	_	_	I-Premise
156	were	_	_	I-Premise
157	67	_	_	I-Premise
158	%	_	_	I-Premise
159	and	_	_	I-Premise
160	15	_	_	I-Premise
161	%	_	_	I-Premise
162	,	_	_	I-Premise
163	respectively	_	_	I-Premise
164	,	_	_	I-Premise
165	in	_	_	I-Premise
166	the	_	_	I-Premise
167	microcatheter-assisted	_	_	I-Premise
168	group	_	_	I-Premise
169	versus	_	_	I-Premise
170	47	_	_	I-Premise
171	%	_	_	I-Premise
172	and	_	_	I-Premise
173	50	_	_	I-Premise
174	%	_	_	I-Premise
175	in	_	_	I-Premise
176	the	_	_	I-Premise
177	rigid	_	_	I-Premise
178	probe	_	_	I-Premise
179	trabeculotomy	_	_	I-Premise
180	group	_	_	I-Premise
181	(	_	_	I-Premise
182	p	_	_	I-Premise
183	=	_	_	I-Premise
184	0.006	_	_	I-Premise
185	)	_	_	I-Premise
186	.	_	_	I-Premise

187	There	_	_	B-Premise
188	was	_	_	I-Premise
189	a	_	_	I-Premise
190	tendency	_	_	I-Premise
191	towards	_	_	I-Premise
192	lower	_	_	I-Premise
193	IOP	_	_	I-Premise
194	in	_	_	I-Premise
195	the	_	_	I-Premise
196	microcatheter	_	_	I-Premise
197	group	_	_	I-Premise
198	at	_	_	I-Premise
199	1	_	_	I-Premise
200	,	_	_	I-Premise
201	3	_	_	I-Premise
202	,	_	_	I-Premise
203	6	_	_	I-Premise
204	,	_	_	I-Premise
205	12	_	_	I-Premise
206	and	_	_	I-Premise
207	24	_	_	I-Premise
208	months	_	_	I-Premise
209	postoperatively	_	_	I-Premise
210	,	_	_	I-Premise
211	with	_	_	I-Premise
212	the	_	_	I-Premise
213	difference	_	_	I-Premise
214	in	_	_	I-Premise
215	IOP	_	_	I-Premise
216	reaching	_	_	I-Premise
217	statistical	_	_	I-Premise
218	significance	_	_	I-Premise
219	at	_	_	I-Premise
220	6	_	_	I-Premise
221	months	_	_	I-Premise
222	(	_	_	I-Premise
223	p	_	_	I-Premise
224	=	_	_	I-Premise
225	0.004	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	The	_	_	B-Premise
229	mean	_	_	I-Premise
230	survival	_	_	I-Premise
231	time	_	_	I-Premise
232	was	_	_	I-Premise
233	significantly	_	_	I-Premise
234	longer	_	_	I-Premise
235	for	_	_	I-Premise
236	the	_	_	I-Premise
237	microcatheter	_	_	I-Premise
238	group	_	_	I-Premise
239	(	_	_	I-Premise
240	p	_	_	I-Premise
241	=	_	_	I-Premise
242	0.01	_	_	I-Premise
243	)	_	_	I-Premise
244	.	_	_	I-Premise

245	At	_	_	B-Claim
246	2	_	_	I-Claim
247	years	_	_	I-Claim
248	postoperatively	_	_	I-Claim
249	,	_	_	I-Claim
250	microcatheter-assisted	_	_	I-Claim
251	trabeculotomy	_	_	I-Claim
252	still	_	_	I-Claim
253	yielded	_	_	I-Claim
254	superior	_	_	I-Claim
255	results	_	_	I-Claim
256	in	_	_	I-Claim
257	terms	_	_	I-Claim
258	of	_	_	I-Claim
259	IOP	_	_	I-Claim
260	control	_	_	I-Claim
261	and	_	_	I-Claim
262	success	_	_	I-Claim
263	rates	_	_	I-Claim
264	in	_	_	I-Claim
265	children	_	_	I-Claim
266	with	_	_	I-Claim
267	primary	_	_	I-Claim
268	congenital	_	_	I-Claim
269	glaucoma	_	_	I-Claim
270	.	_	_	I-Claim

271	The	_	_	B-Premise
272	need	_	_	I-Premise
273	for	_	_	I-Premise
274	reoperation	_	_	I-Premise
275	for	_	_	I-Premise
276	glaucoma	_	_	I-Premise
277	was	_	_	I-Premise
278	significantly	_	_	I-Premise
279	lower	_	_	I-Premise
280	in	_	_	I-Premise
281	the	_	_	I-Premise
282	microcatheter	_	_	I-Premise
283	group	_	_	I-Premise
284	.	_	_	I-Premise


0	We	_	_	O
1	aimed	_	_	O
2	to	_	_	O
3	compare	_	_	O
4	a	_	_	O
5	combined	_	_	O
6	oral	_	_	O
7	contraceptive	_	_	O
8	(	_	_	O
9	COC	_	_	O
10	)	_	_	O
11	plus	_	_	O
12	the	_	_	O
13	antiandrogen	_	_	O
14	spironolactone	_	_	O
15	with	_	_	O
16	the	_	_	O
17	insulin	_	_	O
18	sensitizer	_	_	O
19	metformin	_	_	O
20	in	_	_	O
21	women	_	_	O
22	with	_	_	O
23	polycystic	_	_	O
24	ovary	_	_	O
25	syndrome	_	_	O
26	(	_	_	O
27	PCOS	_	_	O
28	)	_	_	O
29	.	_	_	O

30	We	_	_	O
31	conducted	_	_	O
32	a	_	_	O
33	randomized	_	_	O
34	,	_	_	O
35	parallel	_	_	O
36	,	_	_	O
37	open-label	_	_	O
38	,	_	_	O
39	clinical	_	_	O
40	trial	_	_	O
41	comparing	_	_	O
42	COC	_	_	O
43	(	_	_	O
44	30	_	_	O
45	μg	_	_	O
46	of	_	_	O
47	ethinylestradiol	_	_	O
48	and	_	_	O
49	150	_	_	O
50	μg	_	_	O
51	of	_	_	O
52	desogestrel	_	_	O
53	)	_	_	O
54	plus	_	_	O
55	spironolactone	_	_	O
56	(	_	_	O
57	100	_	_	O
58	mg/day	_	_	O
59	)	_	_	O
60	with	_	_	O
61	metformin	_	_	O
62	(	_	_	O
63	850	_	_	O
64	mg	_	_	O
65	b.i.d	_	_	O
66	.	_	_	O
67	)	_	_	O

68	for	_	_	O
69	one	_	_	O
70	year	_	_	O
71	in	_	_	O
72	women	_	_	O
73	with	_	_	O
74	PCOS	_	_	O
75	(	_	_	O
76	EudraCT2008-004531-38	_	_	O
77	)	_	_	O
78	.	_	_	O

79	The	_	_	O
80	composite	_	_	O
81	primary	_	_	O
82	outcome	_	_	O
83	included	_	_	O
84	efficacy	_	_	O
85	(	_	_	O
86	amelioration	_	_	O
87	of	_	_	O
88	hirsutism	_	_	O
89	,	_	_	O
90	androgen	_	_	O
91	excess	_	_	O
92	and	_	_	O
93	menstrual	_	_	O
94	dysfunction	_	_	O
95	)	_	_	O
96	and	_	_	O
97	cardiometabolic	_	_	O
98	safety	_	_	O
99	(	_	_	O
100	changes	_	_	O
101	in	_	_	O
102	the	_	_	O
103	frequencies	_	_	O
104	of	_	_	O
105	disorders	_	_	O
106	of	_	_	O
107	glucose	_	_	O
108	tolerance	_	_	O
109	,	_	_	O
110	dyslipidemia	_	_	O
111	and	_	_	O
112	hypertension	_	_	O
113	)	_	_	O
114	.	_	_	O

115	A	_	_	O
116	complete	_	_	O
117	anthropometric	_	_	O
118	,	_	_	O
119	biochemical	_	_	O
120	,	_	_	O
121	hormonal	_	_	O
122	and	_	_	O
123	metabolic	_	_	O
124	evaluation	_	_	O
125	was	_	_	O
126	conducted	_	_	O
127	every	_	_	O
128	three	_	_	O
129	months	_	_	O
130	and	_	_	O
131	data	_	_	O
132	were	_	_	O
133	submitted	_	_	O
134	to	_	_	O
135	intention-to-treat	_	_	O
136	analyses	_	_	O
137	.	_	_	O

138	Twenty-four	_	_	O
139	patients	_	_	O
140	were	_	_	O
141	assigned	_	_	O
142	to	_	_	O
143	COC	_	_	O
144	plus	_	_	O
145	spironolactone	_	_	O
146	and	_	_	O
147	22	_	_	O
148	patients	_	_	O
149	to	_	_	O
150	metformin	_	_	O
151	.	_	_	O

152	Compared	_	_	B-Premise
153	with	_	_	I-Premise
154	metformin	_	_	I-Premise
155	,	_	_	I-Premise
156	COC	_	_	I-Premise
157	plus	_	_	I-Premise
158	spironolactone	_	_	I-Premise
159	caused	_	_	I-Premise
160	larger	_	_	I-Premise
161	decreases	_	_	I-Premise
162	in	_	_	I-Premise
163	hirsutism	_	_	I-Premise
164	score	_	_	I-Premise
165	(	_	_	I-Premise
166	mean	_	_	I-Premise
167	difference	_	_	I-Premise
168	4.6	_	_	I-Premise
169	points	_	_	I-Premise
170	,	_	_	I-Premise
171	95	_	_	I-Premise
172	%	_	_	I-Premise
173	CI	_	_	I-Premise
174	:	_	_	I-Premise
175	2.6-6.7	_	_	I-Premise
176	)	_	_	I-Premise
177	,	_	_	I-Premise
178	total	_	_	I-Premise
179	testosterone	_	_	I-Premise
180	(	_	_	I-Premise
181	1.1	_	_	I-Premise
182	nmol/L	_	_	I-Premise
183	,	_	_	I-Premise
184	0.4-1.7	_	_	I-Premise
185	)	_	_	I-Premise
186	,	_	_	I-Premise
187	free	_	_	I-Premise
188	testosterone	_	_	I-Premise
189	(	_	_	I-Premise
190	25	_	_	I-Premise
191	pmol/L	_	_	I-Premise
192	,	_	_	I-Premise
193	12-39	_	_	I-Premise
194	)	_	_	I-Premise
195	,	_	_	I-Premise
196	androstenedione	_	_	I-Premise
197	(	_	_	I-Premise
198	5.5	_	_	I-Premise
199	nmol/L	_	_	I-Premise
200	,	_	_	I-Premise
201	1.8-9.2	_	_	I-Premise
202	)	_	_	I-Premise
203	and	_	_	I-Premise
204	dehydroepiandrosterone	_	_	I-Premise
205	sulfate	_	_	I-Premise
206	(	_	_	I-Premise
207	2.7	_	_	I-Premise
208	μmol/L	_	_	I-Premise
209	,	_	_	I-Premise
210	1.4-4.0	_	_	I-Premise
211	)	_	_	I-Premise
212	.	_	_	I-Premise

213	Menstrual	_	_	B-Premise
214	dysfunction	_	_	I-Premise
215	was	_	_	I-Premise
216	less	_	_	I-Premise
217	frequent	_	_	I-Premise
218	with	_	_	I-Premise
219	COC	_	_	I-Premise
220	plus	_	_	I-Premise
221	spironolactone	_	_	I-Premise
222	(	_	_	I-Premise
223	OR	_	_	I-Premise
224	:	_	_	I-Premise
225	0.06	_	_	I-Premise
226	,	_	_	I-Premise
227	95	_	_	I-Premise
228	%	_	_	I-Premise
229	CI	_	_	I-Premise
230	:	_	_	I-Premise
231	0.02-0.23	_	_	I-Premise
232	)	_	_	I-Premise
233	.	_	_	I-Premise

234	No	_	_	B-Premise
235	differences	_	_	I-Premise
236	were	_	_	I-Premise
237	found	_	_	I-Premise
238	in	_	_	I-Premise
239	frequencies	_	_	I-Premise
240	of	_	_	I-Premise
241	abnormal	_	_	I-Premise
242	glucose	_	_	I-Premise
243	tolerance	_	_	I-Premise
244	(	_	_	I-Premise
245	OR	_	_	I-Premise
246	:	_	_	I-Premise
247	1.7	_	_	I-Premise
248	,	_	_	I-Premise
249	95	_	_	I-Premise
250	%	_	_	I-Premise
251	CI	_	_	I-Premise
252	:	_	_	I-Premise
253	0.7-4.4	_	_	I-Premise
254	)	_	_	I-Premise
255	,	_	_	I-Premise
256	dyslipidemia	_	_	I-Premise
257	(	_	_	I-Premise
258	OR	_	_	I-Premise
259	:	_	_	I-Premise
260	0.6	_	_	I-Premise
261	,	_	_	I-Premise
262	95	_	_	I-Premise
263	%	_	_	I-Premise
264	CI	_	_	I-Premise
265	:	_	_	I-Premise
266	0.2-1.8	_	_	I-Premise
267	)	_	_	I-Premise
268	or	_	_	I-Premise
269	hypertension	_	_	I-Premise
270	(	_	_	I-Premise
271	OR	_	_	I-Premise
272	:	_	_	I-Premise
273	0.3	_	_	I-Premise
274	,	_	_	I-Premise
275	95	_	_	I-Premise
276	%	_	_	I-Premise
277	CI	_	_	I-Premise
278	:	_	_	I-Premise
279	0.5-2.0	_	_	I-Premise
280	)	_	_	I-Premise
281	.	_	_	I-Premise

282	No	_	_	B-Premise
283	major	_	_	I-Premise
284	adverse	_	_	I-Premise
285	events	_	_	I-Premise
286	occurred	_	_	I-Premise
287	and	_	_	I-Premise
288	biochemical	_	_	I-Premise
289	markers	_	_	I-Premise
290	were	_	_	I-Premise
291	similarly	_	_	I-Premise
292	safe	_	_	I-Premise
293	with	_	_	I-Premise
294	both	_	_	I-Premise
295	treatments	_	_	I-Premise
296	.	_	_	I-Premise

297	COC	_	_	B-Claim
298	plus	_	_	I-Claim
299	spironolactone	_	_	I-Claim
300	was	_	_	I-Claim
301	more	_	_	I-Claim
302	effective	_	_	I-Claim
303	than	_	_	I-Claim
304	metformin	_	_	I-Claim
305	for	_	_	I-Claim
306	symptoms	_	_	I-Claim
307	of	_	_	I-Claim
308	PCOS	_	_	I-Claim
309	showing	_	_	I-Claim
310	similar	_	_	I-Claim
311	safety	_	_	I-Claim
312	and	_	_	I-Claim
313	overall	_	_	I-Claim
314	neutral	_	_	I-Claim
315	effects	_	_	I-Claim
316	on	_	_	I-Claim
317	cardiometabolic	_	_	I-Claim
318	risk	_	_	I-Claim
319	factors	_	_	I-Claim
320	.	_	_	I-Claim


0	Extranodal	_	_	O
1	natural	_	_	O
2	killer/T-cell	_	_	O
3	lymphoma	_	_	O
4	,	_	_	O
5	nasal	_	_	O
6	type	_	_	O
7	(	_	_	O
8	ENKTL	_	_	O
9	)	_	_	O
10	is	_	_	O
11	a	_	_	O
12	rare	_	_	O
13	subtype	_	_	O
14	of	_	_	O
15	lymphoma	_	_	O
16	that	_	_	O
17	is	_	_	O
18	often	_	_	O
19	associated	_	_	O
20	with	_	_	O
21	poor	_	_	O
22	clinical	_	_	O
23	prognosis	_	_	O
24	.	_	_	O

25	Several	_	_	O
26	studies	_	_	O
27	have	_	_	O
28	shown	_	_	O
29	that	_	_	O
30	hepatitis	_	_	O
31	B	_	_	O
32	virus	_	_	O
33	(	_	_	O
34	HBV	_	_	O
35	)	_	_	O
36	infection	_	_	O
37	may	_	_	O
38	be	_	_	O
39	associated	_	_	O
40	with	_	_	O
41	increased	_	_	O
42	risk	_	_	O
43	of	_	_	O
44	B-cell	_	_	O
45	non-Hodgkin	_	_	O
46	lymphoma	_	_	O
47	;	_	_	O
48	however	_	_	O
49	,	_	_	O
50	because	_	_	O
51	of	_	_	O
52	the	_	_	O
53	rarity	_	_	O
54	of	_	_	O
55	ENKTL	_	_	O
56	,	_	_	O
57	little	_	_	O
58	is	_	_	O
59	known	_	_	O
60	about	_	_	O
61	its	_	_	O
62	association	_	_	O
63	with	_	_	O
64	HBV	_	_	O
65	.	_	_	O

66	Our	_	_	O
67	study	_	_	O
68	aimed	_	_	O
69	to	_	_	O
70	assess	_	_	O
71	whether	_	_	O
72	HBV	_	_	O
73	infection	_	_	O
74	was	_	_	O
75	associated	_	_	O
76	with	_	_	O
77	increased	_	_	O
78	odds	_	_	O
79	of	_	_	O
80	ENKTL	_	_	O
81	.	_	_	O

82	We	_	_	O
83	conducted	_	_	O
84	a	_	_	O
85	hospital-based	_	_	O
86	case-control	_	_	O
87	study	_	_	O
88	including	_	_	O
89	417	_	_	O
90	ENKTL	_	_	O
91	cases	_	_	O
92	and	_	_	O
93	488	_	_	O
94	age-	_	_	O
95	and	_	_	O
96	sex-matched	_	_	O
97	subjects	_	_	O
98	with	_	_	O
99	nonmalignant	_	_	O
100	diseases	_	_	O
101	unrelated	_	_	O
102	to	_	_	O
103	HBV	_	_	O
104	infection	_	_	O
105	.	_	_	O

106	Multivariable	_	_	O
107	unconditional	_	_	O
108	logistic	_	_	O
109	regression	_	_	O
110	analyses	_	_	O
111	were	_	_	O
112	performed	_	_	O
113	to	_	_	O
114	estimate	_	_	O
115	adjusted	_	_	O
116	odds	_	_	O
117	ratios	_	_	O
118	[	_	_	O
119	AOR	_	_	O
120	]	_	_	O
121	and	_	_	O
122	their	_	_	O
123	corresponding	_	_	O
124	95	_	_	O
125	%	_	_	O
126	confidence	_	_	O
127	intervals	_	_	O
128	(	_	_	O
129	CI	_	_	O
130	)	_	_	O
131	.	_	_	O

132	The	_	_	B-Premise
133	results	_	_	I-Premise
134	of	_	_	I-Premise
135	the	_	_	I-Premise
136	multivariable	_	_	I-Premise
137	analysis	_	_	I-Premise
138	showed	_	_	I-Premise
139	that	_	_	I-Premise
140	after	_	_	I-Premise
141	adjustment	_	_	I-Premise
142	for	_	_	I-Premise
143	a	_	_	I-Premise
144	set	_	_	I-Premise
145	of	_	_	I-Premise
146	known	_	_	I-Premise
147	risk	_	_	I-Premise
148	factors	_	_	I-Premise
149	,	_	_	I-Premise
150	patients	_	_	I-Premise
151	previously	_	_	I-Premise
152	infected	_	_	I-Premise
153	with	_	_	I-Premise
154	HBV	_	_	I-Premise
155	(	_	_	I-Premise
156	HBsAg-seronegative/anti-HBc-seropositive	_	_	I-Premise
157	)	_	_	I-Premise
158	and	_	_	I-Premise
159	naturally	_	_	I-Premise
160	immune	_	_	I-Premise
161	to	_	_	I-Premise
162	HBV	_	_	I-Premise
163	(	_	_	I-Premise
164	anti-HBs-seropositive/anti-HBc-seropositive	_	_	I-Premise
165	)	_	_	I-Premise
166	were	_	_	I-Premise
167	at	_	_	I-Premise
168	significantly	_	_	I-Premise
169	greater	_	_	I-Premise
170	odds	_	_	I-Premise
171	of	_	_	I-Premise
172	being	_	_	I-Premise
173	diagnosed	_	_	I-Premise
174	with	_	_	I-Premise
175	ENKTL	_	_	I-Premise
176	(	_	_	I-Premise
177	AOR	_	_	I-Premise
178	,	_	_	I-Premise
179	1.497	_	_	I-Premise
180	;	_	_	I-Premise
181	95	_	_	I-Premise
182	%	_	_	I-Premise
183	CI	_	_	I-Premise
184	1.098-2.042	_	_	I-Premise
185	,	_	_	I-Premise
186	P=0.033	_	_	I-Premise
187	and	_	_	I-Premise
188	AOR	_	_	I-Premise
189	,	_	_	I-Premise
190	1.871	_	_	I-Premise
191	;	_	_	I-Premise
192	95	_	_	I-Premise
193	%	_	_	I-Premise
194	CI	_	_	I-Premise
195	1.302-2.689	_	_	I-Premise
196	,	_	_	I-Premise
197	P=0.001	_	_	I-Premise
198	,	_	_	I-Premise
199	respectively	_	_	I-Premise
200	)	_	_	I-Premise
201	.	_	_	I-Premise

202	After	_	_	B-Premise
203	adjusting	_	_	I-Premise
204	for	_	_	I-Premise
205	other	_	_	I-Premise
206	factors	_	_	I-Premise
207	,	_	_	I-Premise
208	significantly	_	_	I-Premise
209	greater	_	_	I-Premise
210	odds	_	_	I-Premise
211	of	_	_	I-Premise
212	being	_	_	I-Premise
213	diagnosed	_	_	I-Premise
214	with	_	_	I-Premise
215	ENKTL	_	_	I-Premise
216	were	_	_	I-Premise
217	observed	_	_	I-Premise
218	among	_	_	I-Premise
219	cases	_	_	I-Premise
220	who	_	_	I-Premise
221	reported	_	_	I-Premise
222	ever	_	_	I-Premise
223	drinking	_	_	I-Premise
224	alcohol	_	_	I-Premise
225	(	_	_	I-Premise
226	AOR	_	_	I-Premise
227	,	_	_	I-Premise
228	1.675	_	_	I-Premise
229	;	_	_	I-Premise
230	95	_	_	I-Premise
231	%	_	_	I-Premise
232	CI	_	_	I-Premise
233	1.054-2.660	_	_	I-Premise
234	,	_	_	I-Premise
235	P=0.029	_	_	I-Premise
236	)	_	_	I-Premise
237	.	_	_	I-Premise

238	The	_	_	B-Premise
239	odds	_	_	I-Premise
240	of	_	_	I-Premise
241	ENKTL	_	_	I-Premise
242	diagnosis	_	_	I-Premise
243	were	_	_	I-Premise
244	not	_	_	I-Premise
245	significantly	_	_	I-Premise
246	associated	_	_	I-Premise
247	with	_	_	I-Premise
248	ABO	_	_	I-Premise
249	blood	_	_	I-Premise
250	type	_	_	I-Premise
251	,	_	_	I-Premise
252	cigarette	_	_	I-Premise
253	smoking	_	_	I-Premise
254	status	_	_	I-Premise
255	or	_	_	I-Premise
256	family	_	_	I-Premise
257	history	_	_	I-Premise
258	of	_	_	I-Premise
259	cancer	_	_	I-Premise
260	.	_	_	I-Premise

261	The	_	_	B-Claim
262	results	_	_	I-Claim
263	of	_	_	I-Claim
264	our	_	_	I-Claim
265	study	_	_	I-Claim
266	suggest	_	_	I-Claim
267	that	_	_	I-Claim
268	patients	_	_	I-Claim
269	previously	_	_	I-Claim
270	infected	_	_	I-Claim
271	with	_	_	I-Claim
272	HBV	_	_	I-Claim
273	and	_	_	I-Claim
274	naturally	_	_	I-Claim
275	immune	_	_	I-Claim
276	to	_	_	I-Claim
277	HBV	_	_	I-Claim
278	were	_	_	I-Claim
279	at	_	_	I-Claim
280	greater	_	_	I-Claim
281	odds	_	_	I-Claim
282	of	_	_	I-Claim
283	being	_	_	I-Claim
284	diagnosed	_	_	I-Claim
285	with	_	_	I-Claim
286	ENKTL	_	_	I-Claim
287	.	_	_	I-Claim


0	Antiretroviral	_	_	O
1	treatment	_	_	O
2	(	_	_	O
3	ART	_	_	O
4	)	_	_	O
5	interruptions	_	_	O
6	increase	_	_	O
7	the	_	_	O
8	risk	_	_	O
9	of	_	_	O
10	severe	_	_	O
11	morbidity/mortality	_	_	O
12	in	_	_	O
13	human	_	_	O
14	immunodeficiency	_	_	O
15	virus	_	_	O
16	(	_	_	O
17	HIV	_	_	O
18	)	_	_	O
19	-infected	_	_	O
20	individuals	_	_	O
21	from	_	_	O
22	subSaharan	_	_	O
23	Africa	_	_	O
24	.	_	_	O

25	We	_	_	O
26	aimed	_	_	O
27	to	_	_	O
28	determine	_	_	O
29	whether	_	_	O
30	the	_	_	O
31	risk	_	_	O
32	is	_	_	O
33	further	_	_	O
34	increased	_	_	O
35	among	_	_	O
36	HIV-hepatitis	_	_	O
37	B	_	_	O
38	virus	_	_	O
39	(	_	_	O
40	HBV	_	_	O
41	)	_	_	O
42	co-infected	_	_	O
43	patients	_	_	O
44	in	_	_	O
45	this	_	_	O
46	setting	_	_	O
47	.	_	_	O

48	In	_	_	O
49	this	_	_	O
50	sub-analysis	_	_	O
51	of	_	_	O
52	a	_	_	O
53	randomized-control	_	_	O
54	trial	_	_	O
55	,	_	_	O
56	632	_	_	O
57	participants	_	_	O
58	from	_	_	O
59	Côte	_	_	O
60	d'Ivoire	_	_	O
61	randomized	_	_	O
62	to	_	_	O
63	receive	_	_	O
64	continuous-ART	_	_	O
65	(	_	_	O
66	C-ART	_	_	O
67	)	_	_	O
68	,	_	_	O
69	structured	_	_	O
70	ART	_	_	O
71	interruptions	_	_	O
72	of	_	_	O
73	2-months	_	_	O
74	off	_	_	O
75	,	_	_	O
76	4-months	_	_	O
77	on	_	_	O
78	(	_	_	O
79	2/4-ART	_	_	O
80	)	_	_	O
81	,	_	_	O
82	and	_	_	O
83	CD4-guided	_	_	O
84	ART	_	_	O
85	interruptions	_	_	O
86	(	_	_	O
87	CD4GT	_	_	O
88	,	_	_	O
89	interruption	_	_	O
90	at	_	_	O
91	350/mm3	_	_	O
92	and	_	_	O
93	reintroduction	_	_	O
94	at	_	_	O
95	250/mm3	_	_	O
96	)	_	_	O
97	were	_	_	O
98	analyzed	_	_	O
99	.	_	_	O

100	Incidence	_	_	O
101	rates	_	_	O
102	(	_	_	O
103	IR	_	_	O
104	)	_	_	O
105	of	_	_	O
106	serious	_	_	O
107	HIV-	_	_	O
108	and	_	_	O
109	non-HIV-related	_	_	O
110	morbidity	_	_	O
111	were	_	_	O
112	compared	_	_	O
113	between	_	_	O
114	patients	_	_	O
115	stratified	_	_	O
116	on	_	_	O
117	hepatitis	_	_	O
118	B	_	_	O
119	surface	_	_	O
120	antigen	_	_	O
121	(	_	_	O
122	HBsAg	_	_	O
123	)	_	_	O
124	status	_	_	O
125	.	_	_	O

126	Overall	_	_	O
127	,	_	_	O
128	65	_	_	O
129	(	_	_	O
130	10.3	_	_	O
131	%	_	_	O
132	)	_	_	O
133	were	_	_	O
134	HBsAg-positive	_	_	O
135	,	_	_	O
136	29	_	_	O
137	(	_	_	O
138	44.6	_	_	O
139	%	_	_	O
140	)	_	_	O
141	of	_	_	O
142	whom	_	_	O
143	had	_	_	O
144	HBV-DNA	_	_	O
145	levels	_	_	O
146	>	_	_	O
147	10,000	_	_	O
148	copies/mL	_	_	O
149	.	_	_	O

150	After	_	_	B-Premise
151	a	_	_	I-Premise
152	median	_	_	I-Premise
153	2.0	_	_	I-Premise
154	year	_	_	I-Premise
155	(	_	_	I-Premise
156	range	_	_	I-Premise
157	=	_	_	I-Premise
158	0.2-3.1	_	_	I-Premise
159	)	_	_	I-Premise
160	follow-up	_	_	I-Premise
161	,	_	_	I-Premise
162	≥	_	_	I-Premise
163	1	_	_	I-Premise
164	serious	_	_	I-Premise
165	HIV-related	_	_	I-Premise
166	events	_	_	I-Premise
167	occurred	_	_	I-Premise
168	in	_	_	I-Premise
169	101	_	_	I-Premise
170	HIV	_	_	I-Premise
171	mono-infected	_	_	I-Premise
172	and	_	_	I-Premise
173	15	_	_	I-Premise
174	HIV-HBV	_	_	I-Premise
175	co-infected	_	_	I-Premise
176	patients	_	_	I-Premise
177	(	_	_	I-Premise
178	IR	_	_	I-Premise
179	=	_	_	I-Premise
180	10.0	_	_	I-Premise
181	versus	_	_	I-Premise
182	13.2/100	_	_	I-Premise
183	person/years	_	_	I-Premise
184	,	_	_	I-Premise
185	respectively	_	_	I-Premise
186	,	_	_	I-Premise
187	P	_	_	I-Premise
188	=	_	_	I-Premise
189	0.3	_	_	I-Premise
190	)	_	_	I-Premise
191	,	_	_	O
192	whereas	_	_	O
193	the	_	_	O
194	highest	_	_	O
195	incidence	_	_	O
196	was	_	_	O
197	observed	_	_	O
198	in	_	_	O
199	co-infected	_	_	O
200	patients	_	_	O
201	with	_	_	O
202	baseline	_	_	O
203	HBV-replication	_	_	O
204	>	_	_	O
205	10,000	_	_	O
206	copies/mL	_	_	O
207	(	_	_	O
208	IR	_	_	O
209	=	_	_	O
210	24.0/100	_	_	O
211	person/years	_	_	O
212	,	_	_	O
213	P	_	_	O
214	versus	_	_	O
215	HIV	_	_	O
216	mono-infected	_	_	O
217	=	_	_	O
218	0.002	_	_	O
219	)	_	_	O
220	.	_	_	O

221	Incidence	_	_	B-Premise
222	of	_	_	I-Premise
223	bacterial	_	_	I-Premise
224	infections	_	_	I-Premise
225	was	_	_	I-Premise
226	also	_	_	I-Premise
227	highest	_	_	I-Premise
228	in	_	_	I-Premise
229	the	_	_	I-Premise
230	co-infected	_	_	I-Premise
231	group	_	_	I-Premise
232	with	_	_	I-Premise
233	HBV-replication	_	_	I-Premise
234	>	_	_	I-Premise
235	10,000	_	_	I-Premise
236	copies/mL	_	_	I-Premise
237	(	_	_	I-Premise
238	IR	_	_	I-Premise
239	=	_	_	I-Premise
240	12.9	_	_	I-Premise
241	versus	_	_	I-Premise
242	3.3/100	_	_	I-Premise
243	person/years	_	_	I-Premise
244	in	_	_	I-Premise
245	HIV	_	_	I-Premise
246	mono-infected	_	_	I-Premise
247	patients	_	_	I-Premise
248	,	_	_	I-Premise
249	P	_	_	I-Premise
250	=	_	_	I-Premise
251	0.001	_	_	I-Premise
252	)	_	_	I-Premise
253	.	_	_	I-Premise

254	The	_	_	B-Premise
255	relative	_	_	I-Premise
256	effect	_	_	I-Premise
257	of	_	_	I-Premise
258	CD4GT	_	_	I-Premise
259	or	_	_	I-Premise
260	2/4-ART	_	_	I-Premise
261	versus	_	_	I-Premise
262	C-ART	_	_	I-Premise
263	was	_	_	I-Premise
264	not	_	_	I-Premise
265	different	_	_	I-Premise
266	between	_	_	I-Premise
267	infection	_	_	I-Premise
268	groups	_	_	I-Premise
269	(	_	_	I-Premise
270	P	_	_	I-Premise
271	for	_	_	I-Premise
272	interaction	_	_	I-Premise
273	=	_	_	I-Premise
274	0.4	_	_	I-Premise
275	)	_	_	I-Premise
276	.	_	_	I-Premise

277	No	_	_	B-Premise
278	increase	_	_	I-Premise
279	in	_	_	I-Premise
280	the	_	_	I-Premise
281	incidence	_	_	I-Premise
282	of	_	_	I-Premise
283	non-HIV-related	_	_	I-Premise
284	morbidity	_	_	I-Premise
285	was	_	_	I-Premise
286	observed	_	_	I-Premise
287	for	_	_	I-Premise
288	co-infected	_	_	I-Premise
289	patients	_	_	I-Premise
290	(	_	_	I-Premise
291	P	_	_	I-Premise
292	=	_	_	I-Premise
293	0.5	_	_	I-Premise
294	)	_	_	I-Premise
295	,	_	_	I-Premise
296	even	_	_	I-Premise
297	at	_	_	I-Premise
298	HBV-replication	_	_	I-Premise
299	levels	_	_	I-Premise
300	>	_	_	I-Premise
301	10,000	_	_	I-Premise
302	copies/mL	_	_	I-Premise
303	(	_	_	I-Premise
304	P	_	_	I-Premise
305	=	_	_	I-Premise
306	0.7	_	_	I-Premise
307	)	_	_	I-Premise
308	.	_	_	I-Premise

309	In	_	_	B-Claim
310	conclusion	_	_	I-Claim
311	,	_	_	I-Claim
312	co-infected	_	_	I-Claim
313	patients	_	_	I-Claim
314	with	_	_	I-Claim
315	elevated	_	_	I-Claim
316	HBV-replication	_	_	I-Claim
317	at	_	_	I-Claim
318	ART-initiation	_	_	I-Claim
319	are	_	_	I-Claim
320	more	_	_	I-Claim
321	susceptible	_	_	I-Claim
322	to	_	_	I-Claim
323	HIV-related	_	_	I-Claim
324	morbidity	_	_	I-Claim
325	,	_	_	I-Claim
326	especially	_	_	I-Claim
327	invasive	_	_	I-Claim
328	bacterial	_	_	I-Claim
329	diseases	_	_	I-Claim
330	,	_	_	I-Claim
331	during	_	_	I-Claim
332	treatment	_	_	I-Claim
333	interruption	_	_	I-Claim
334	.	_	_	I-Claim


0	The	_	_	O
1	authors	_	_	O
2	tested	_	_	O
3	the	_	_	O
4	hypothesis	_	_	O
5	that	_	_	O
6	a	_	_	O
7	valsartan/cilnidipine	_	_	B-Claim
8	combination	_	_	I-Claim
9	would	_	_	I-Claim
10	suppress	_	_	I-Claim
11	the	_	_	I-Claim
12	home	_	_	I-Claim
13	morning	_	_	I-Claim
14	blood	_	_	I-Claim
15	pressure	_	_	I-Claim
16	(	_	_	I-Claim
17	BP	_	_	I-Claim
18	)	_	_	I-Claim
19	surge	_	_	I-Claim
20	(	_	_	I-Claim
21	HMBPS	_	_	I-Claim
22	)	_	_	I-Claim
23	more	_	_	I-Claim
24	effectively	_	_	I-Claim
25	than	_	_	I-Claim
26	a	_	_	I-Claim
27	valsartan/hydrochlorothiazide	_	_	I-Claim
28	combination	_	_	I-Claim
29	in	_	_	I-Claim
30	patients	_	_	I-Claim
31	with	_	_	I-Claim
32	morning	_	_	I-Claim
33	hypertension	_	_	I-Claim
34	,	_	_	O
35	defined	_	_	O
36	as	_	_	O
37	systolic	_	_	O
38	BP	_	_	O
39	(	_	_	O
40	SBP	_	_	O
41	)	_	_	O
42	≥135	_	_	O
43	mm	_	_	O
44	Hg	_	_	O
45	or	_	_	O
46	diastolic	_	_	O
47	BP	_	_	O
48	≥85	_	_	O
49	mm	_	_	O
50	Hg	_	_	O
51	assessed	_	_	O
52	by	_	_	O
53	a	_	_	O
54	self-measuring	_	_	O
55	information	_	_	O
56	and	_	_	O
57	communication	_	_	O
58	technology-based	_	_	O
59	home	_	_	O
60	BP	_	_	O
61	monitoring	_	_	O
62	device	_	_	O
63	more	_	_	O
64	than	_	_	O
65	three	_	_	O
66	times	_	_	O
67	before	_	_	O
68	either	_	_	O
69	combination	_	_	O
70	's	_	_	O
71	administration	_	_	O
72	.	_	_	O

73	This	_	_	O
74	was	_	_	O
75	an	_	_	O
76	8-week	_	_	O
77	prospective	_	_	O
78	,	_	_	O
79	multicenter	_	_	O
80	,	_	_	O
81	randomized	_	_	O
82	,	_	_	O
83	open-label	_	_	O
84	clinical	_	_	O
85	trial	_	_	O
86	.	_	_	O

87	The	_	_	O
88	HMBPS	_	_	O
89	,	_	_	O
90	which	_	_	O
91	is	_	_	O
92	a	_	_	O
93	new	_	_	O
94	index	_	_	O
95	,	_	_	O
96	was	_	_	O
97	defined	_	_	O
98	as	_	_	O
99	the	_	_	O
100	mean	_	_	O
101	morning	_	_	O
102	SBP	_	_	O
103	minus	_	_	O
104	the	_	_	O
105	mean	_	_	O
106	nocturnal	_	_	O
107	SBP	_	_	O
108	,	_	_	O
109	both	_	_	O
110	measured	_	_	O
111	on	_	_	O
112	the	_	_	O
113	same	_	_	O
114	day	_	_	O
115	.	_	_	O

116	The	_	_	O
117	authors	_	_	O
118	randomly	_	_	O
119	allocated	_	_	O
120	129	_	_	O
121	patients	_	_	O
122	to	_	_	O
123	the	_	_	O
124	valsartan/cilnidipine	_	_	O
125	(	_	_	O
126	63	_	_	O
127	patients	_	_	O
128	;	_	_	O
129	mean	_	_	O
130	68.4	_	_	O
131	years	_	_	O
132	)	_	_	O
133	or	_	_	O
134	valsartan/hydrochlorothiazide	_	_	O
135	(	_	_	O
136	66	_	_	O
137	patients	_	_	O
138	;	_	_	O
139	mean	_	_	O
140	67.3	_	_	O
141	years	_	_	O
142	)	_	_	O
143	combination	_	_	O
144	groups	_	_	O
145	,	_	_	O
146	and	_	_	O
147	the	_	_	O
148	baseline	_	_	O
149	HMBPS	_	_	O
150	values	_	_	O
151	were	_	_	O
152	17.4	_	_	O
153	mm	_	_	O
154	Hg	_	_	O
155	vs	_	_	O
156	16.9	_	_	O
157	mm	_	_	O
158	Hg	_	_	O
159	,	_	_	O
160	respectively	_	_	O
161	(	_	_	O
162	P	_	_	O
163	=	_	_	O
164	.820	_	_	O
165	)	_	_	O
166	.	_	_	O

167	At	_	_	B-Premise
168	the	_	_	I-Premise
169	end	_	_	I-Premise
170	of	_	_	I-Premise
171	the	_	_	I-Premise
172	treatment	_	_	I-Premise
173	period	_	_	I-Premise
174	,	_	_	I-Premise
175	the	_	_	I-Premise
176	changes	_	_	I-Premise
177	in	_	_	I-Premise
178	nocturnal	_	_	I-Premise
179	SBP	_	_	I-Premise
180	and	_	_	I-Premise
181	morning	_	_	I-Premise
182	SBP	_	_	I-Premise
183	from	_	_	I-Premise
184	baseline	_	_	I-Premise
185	were	_	_	I-Premise
186	significant	_	_	I-Premise
187	in	_	_	I-Premise
188	both	_	_	I-Premise
189	the	_	_	I-Premise
190	valsartan/cilnidipine	_	_	I-Premise
191	and	_	_	I-Premise
192	valsartan/hydrochlorothiazide	_	_	I-Premise
193	groups	_	_	I-Premise
194	(	_	_	I-Premise
195	P	_	_	I-Premise
196	<	_	_	I-Premise
197	.001	_	_	I-Premise
198	)	_	_	I-Premise
199	:	_	_	I-Premise
200	-5.0	_	_	I-Premise
201	vs	_	_	I-Premise
202	-10.0	_	_	I-Premise
203	mm	_	_	I-Premise
204	Hg	_	_	I-Premise
205	(	_	_	I-Premise
206	P	_	_	I-Premise
207	=	_	_	I-Premise
208	.035	_	_	I-Premise
209	)	_	_	I-Premise
210	and	_	_	I-Premise
211	-10.7	_	_	I-Premise
212	vs	_	_	I-Premise
213	-13.6	_	_	I-Premise
214	mm	_	_	I-Premise
215	Hg	_	_	I-Premise
216	(	_	_	I-Premise
217	P	_	_	I-Premise
218	=	_	_	I-Premise
219	.142	_	_	I-Premise
220	)	_	_	I-Premise
221	,	_	_	I-Premise
222	respectively	_	_	I-Premise
223	.	_	_	I-Premise

224	HMBPS	_	_	B-Premise
225	was	_	_	I-Premise
226	significantly	_	_	I-Premise
227	decreased	_	_	I-Premise
228	from	_	_	I-Premise
229	baseline	_	_	I-Premise
230	in	_	_	I-Premise
231	both	_	_	I-Premise
232	groups	_	_	I-Premise
233	(	_	_	I-Premise
234	P	_	_	I-Premise
235	<	_	_	I-Premise
236	.001	_	_	I-Premise
237	)	_	_	I-Premise
238	,	_	_	I-Premise
239	but	_	_	I-Premise
240	there	_	_	I-Premise
241	was	_	_	I-Premise
242	no	_	_	I-Premise
243	significant	_	_	I-Premise
244	difference	_	_	I-Premise
245	between	_	_	I-Premise
246	the	_	_	I-Premise
247	two	_	_	I-Premise
248	groups	_	_	I-Premise
249	:	_	_	I-Premise
250	14.4	_	_	I-Premise
251	mm	_	_	I-Premise
252	Hg	_	_	I-Premise
253	vs	_	_	I-Premise
254	14.0	_	_	I-Premise
255	mm	_	_	I-Premise
256	Hg	_	_	I-Premise
257	,	_	_	I-Premise
258	respectively	_	_	I-Premise
259	(	_	_	I-Premise
260	P	_	_	I-Premise
261	=	_	_	I-Premise
262	.892	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	Valsartan/cilnidipine	_	_	B-Claim
266	could	_	_	I-Claim
267	not	_	_	I-Claim
268	significantly	_	_	I-Claim
269	suppress	_	_	I-Claim
270	HMBPS	_	_	I-Claim
271	compared	_	_	I-Claim
272	with	_	_	I-Claim
273	valsartan/hydrochlorothiazide	_	_	I-Claim
274	.	_	_	I-Claim

275	Large-scale	_	_	O
276	randomized	_	_	O
277	controlled	_	_	O
278	studies	_	_	O
279	are	_	_	O
280	needed	_	_	O
281	to	_	_	O
282	assess	_	_	O
283	how	_	_	O
284	reducing	_	_	O
285	HMBPS	_	_	O
286	will	_	_	O
287	affect	_	_	O
288	future	_	_	O
289	cardiovascular	_	_	O
290	outcomes	_	_	O
291	.	_	_	O

292	The	_	_	O
293	information	_	_	O
294	and	_	_	O
295	communication	_	_	O
296	technology-based	_	_	O
297	home	_	_	O
298	BP	_	_	O
299	monitoring	_	_	O
300	device	_	_	O
301	may	_	_	O
302	become	_	_	O
303	an	_	_	O
304	alternative	_	_	O
305	to	_	_	O
306	ambulatory	_	_	O
307	BP	_	_	O
308	monitoring	_	_	O
309	,	_	_	O
310	which	_	_	O
311	has	_	_	O
312	been	_	_	O
313	a	_	_	O
314	gold	_	_	O
315	standard	_	_	O
316	to	_	_	O
317	measure	_	_	O
318	nocturnal	_	_	O
319	BP	_	_	O
320	and	_	_	O
321	the	_	_	O
322	morning	_	_	O
323	BP	_	_	O
324	surge	_	_	O
325	.	_	_	O


0	The	_	_	B-Claim
1	efficacy	_	_	I-Claim
2	of	_	_	I-Claim
3	switching	_	_	I-Claim
4	to	_	_	I-Claim
5	tenofovir	_	_	I-Claim
6	disoproxil	_	_	I-Claim
7	fumarate	_	_	I-Claim
8	(	_	_	I-Claim
9	TDF	_	_	I-Claim
10	)	_	_	I-Claim
11	monotherapy	_	_	I-Claim
12	from	_	_	I-Claim
13	lamivudine	_	_	I-Claim
14	(	_	_	I-Claim
15	LAM	_	_	I-Claim
16	)	_	_	I-Claim
17	plus	_	_	I-Claim
18	adefovir	_	_	I-Claim
19	dipivoxil	_	_	I-Claim
20	(	_	_	I-Claim
21	ADV	_	_	I-Claim
22	)	_	_	I-Claim
23	combination	_	_	I-Claim
24	therapy	_	_	I-Claim
25	(	_	_	I-Claim
26	stable	_	_	I-Claim
27	switching	_	_	I-Claim
28	)	_	_	I-Claim
29	in	_	_	I-Claim
30	patients	_	_	I-Claim
31	with	_	_	I-Claim
32	LAM-resistant	_	_	I-Claim
33	chronic	_	_	I-Claim
34	hepatitis	_	_	I-Claim
35	B	_	_	I-Claim
36	(	_	_	I-Claim
37	CHB	_	_	I-Claim
38	)	_	_	I-Claim
39	and	_	_	I-Claim
40	undetectable	_	_	I-Claim
41	hepatitis	_	_	I-Claim
42	B	_	_	I-Claim
43	virus	_	_	I-Claim
44	(	_	_	I-Claim
45	HBV	_	_	I-Claim
46	)	_	_	I-Claim
47	DNA	_	_	I-Claim
48	is	_	_	I-Claim
49	not	_	_	I-Claim
50	clear	_	_	I-Claim
51	.	_	_	I-Claim

52	In	_	_	O
53	this	_	_	O
54	non-inferiority	_	_	O
55	trial	_	_	O
56	,	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	LAM-resistant	_	_	O
60	CHB	_	_	O
61	and	_	_	O
62	undetectable	_	_	O
63	serum	_	_	O
64	HBV	_	_	O
65	DNA	_	_	O
66	(	_	_	O
67	<	_	_	O
68	20	_	_	O
69	IU/mL	_	_	O
70	)	_	_	O
71	for	_	_	O
72	>	_	_	O
73	6	_	_	O
74	months	_	_	O
75	after	_	_	O
76	initiating	_	_	O
77	LAM+ADV	_	_	O
78	combination	_	_	O
79	therapy	_	_	O
80	were	_	_	O
81	randomized	_	_	O
82	(	_	_	O
83	1:2	_	_	O
84	)	_	_	O
85	either	_	_	O
86	to	_	_	O
87	continue	_	_	O
88	the	_	_	O
89	combination	_	_	O
90	therapy	_	_	O
91	(	_	_	O
92	LAM+ADV	_	_	O
93	group	_	_	O
94	,	_	_	O
95	n	_	_	O
96	=	_	_	O
97	58	_	_	O
98	)	_	_	O
99	or	_	_	O
100	switched	_	_	O
101	to	_	_	O
102	TDF	_	_	O
103	monotherapy	_	_	O
104	(	_	_	O
105	TDF	_	_	O
106	group	_	_	O
107	,	_	_	O
108	n	_	_	O
109	=	_	_	O
110	111	_	_	O
111	)	_	_	O
112	.	_	_	O

113	They	_	_	O
114	were	_	_	O
115	followed-up	_	_	O
116	with	_	_	O
117	serum	_	_	O
118	biochemistry	_	_	O
119	tests	_	_	O
120	and	_	_	O
121	HBV	_	_	O
122	DNA	_	_	O
123	measurement	_	_	O
124	at	_	_	O
125	12-week	_	_	O
126	intervals	_	_	O
127	for	_	_	O
128	96	_	_	O
129	weeks	_	_	O
130	.	_	_	O

131	The	_	_	O
132	primary	_	_	O
133	endpoint	_	_	O
134	of	_	_	O
135	this	_	_	O
136	study	_	_	O
137	was	_	_	O
138	the	_	_	O
139	proportion	_	_	O
140	of	_	_	O
141	patients	_	_	O
142	with	_	_	O
143	viral	_	_	O
144	reactivation	_	_	O
145	at	_	_	O
146	week	_	_	O
147	96	_	_	O
148	.	_	_	O

149	Patients	_	_	O
150	with	_	_	O
151	CHB	_	_	O
152	enrolled	_	_	O
153	in	_	_	O
154	this	_	_	O
155	study	_	_	O
156	(	_	_	O
157	n	_	_	O
158	=	_	_	O
159	169	_	_	O
160	)	_	_	O
161	included	_	_	O
162	74	_	_	O
163	patients	_	_	O
164	with	_	_	O
165	compensated	_	_	O
166	liver	_	_	O
167	cirrhosis	_	_	O
168	.	_	_	O

169	In	_	_	O
170	total	_	_	O
171	,	_	_	O
172	9	_	_	O
173	patients	_	_	O
174	(	_	_	O
175	4	_	_	O
176	in	_	_	O
177	the	_	_	O
178	LAM+ADV	_	_	O
179	group	_	_	O
180	and	_	_	O
181	5	_	_	O
182	in	_	_	O
183	the	_	_	O
184	TDF	_	_	O
185	group	_	_	O
186	)	_	_	O
187	dropped-out	_	_	O
188	from	_	_	O
189	the	_	_	O
190	study	_	_	O
191	.	_	_	O

192	After	_	_	B-Premise
193	a	_	_	I-Premise
194	mean	_	_	I-Premise
195	follow-up	_	_	I-Premise
196	period	_	_	I-Premise
197	of	_	_	I-Premise
198	96	_	_	I-Premise
199	weeks	_	_	I-Premise
200	,	_	_	I-Premise
201	the	_	_	I-Premise
202	proportion	_	_	I-Premise
203	of	_	_	I-Premise
204	HBV	_	_	I-Premise
205	reactivation	_	_	I-Premise
206	observed	_	_	I-Premise
207	was	_	_	I-Premise
208	6.8	_	_	I-Premise
209	%	_	_	I-Premise
210	(	_	_	I-Premise
211	4/58	_	_	I-Premise
212	)	_	_	I-Premise
213	in	_	_	I-Premise
214	the	_	_	I-Premise
215	LAM+ADV	_	_	I-Premise
216	group	_	_	I-Premise
217	and	_	_	I-Premise
218	4.5	_	_	I-Premise
219	%	_	_	I-Premise
220	(	_	_	I-Premise
221	5/111	_	_	I-Premise
222	)	_	_	I-Premise
223	in	_	_	I-Premise
224	the	_	_	I-Premise
225	TDF	_	_	I-Premise
226	group	_	_	I-Premise
227	by	_	_	I-Premise
228	using	_	_	I-Premise
229	intention-to-treat	_	_	I-Premise
230	analysis	_	_	I-Premise
231	(	_	_	I-Premise
232	difference	_	_	I-Premise
233	,	_	_	I-Premise
234	-2.3	_	_	I-Premise
235	%	_	_	I-Premise
236	;	_	_	I-Premise
237	95	_	_	I-Premise
238	%	_	_	I-Premise
239	CI	_	_	I-Premise
240	,	_	_	I-Premise
241	-9.84-5.24	_	_	I-Premise
242	%	_	_	I-Premise
243	)	_	_	I-Premise
244	.	_	_	I-Premise

245	None	_	_	B-Premise
246	of	_	_	I-Premise
247	the	_	_	I-Premise
248	subjects	_	_	I-Premise
249	in	_	_	I-Premise
250	either	_	_	I-Premise
251	group	_	_	I-Premise
252	experienced	_	_	I-Premise
253	viral	_	_	I-Premise
254	reactivation	_	_	I-Premise
255	based	_	_	I-Premise
256	on	_	_	I-Premise
257	per	_	_	I-Premise
258	protocol	_	_	I-Premise
259	analysis	_	_	I-Premise
260	.	_	_	I-Premise

261	No	_	_	B-Premise
262	serious	_	_	I-Premise
263	adverse	_	_	I-Premise
264	reactions	_	_	I-Premise
265	were	_	_	I-Premise
266	observed	_	_	I-Premise
267	.	_	_	I-Premise

268	In	_	_	B-Premise
269	the	_	_	I-Premise
270	subgroup	_	_	I-Premise
271	analysis	_	_	I-Premise
272	for	_	_	I-Premise
273	estimated	_	_	I-Premise
274	glomerular	_	_	I-Premise
275	filtration	_	_	I-Premise
276	rate	_	_	I-Premise
277	(	_	_	I-Premise
278	eGFR	_	_	I-Premise
279	)	_	_	I-Premise
280	before	_	_	I-Premise
281	and	_	_	I-Premise
282	after	_	_	I-Premise
283	treatment	_	_	I-Premise
284	,	_	_	I-Premise
285	decreased	_	_	I-Premise
286	eGFR	_	_	I-Premise
287	was	_	_	I-Premise
288	observed	_	_	I-Premise
289	only	_	_	I-Premise
290	in	_	_	I-Premise
291	the	_	_	I-Premise
292	TDF	_	_	I-Premise
293	group	_	_	I-Premise
294	with	_	_	I-Premise
295	cirrhosis	_	_	I-Premise
296	(	_	_	I-Premise
297	85.22	_	_	I-Premise
298	vs.	_	_	I-Premise
299	79.83	_	_	I-Premise
300	mL/min/1.73	_	_	I-Premise
301	m2	_	_	I-Premise
302	,	_	_	I-Premise
303	p	_	_	I-Premise
304	=	_	_	I-Premise
305	0.000	_	_	I-Premise
306	)	_	_	I-Premise
307	.	_	_	I-Premise

308	Stable	_	_	B-Claim
309	switching	_	_	I-Claim
310	to	_	_	I-Claim
311	TDF	_	_	I-Claim
312	monotherapy	_	_	I-Claim
313	yielded	_	_	I-Claim
314	non-inferior	_	_	I-Claim
315	results	_	_	I-Claim
316	at	_	_	I-Claim
317	96	_	_	I-Claim
318	weeks	_	_	I-Claim
319	compared	_	_	I-Claim
320	to	_	_	I-Claim
321	the	_	_	I-Claim
322	results	_	_	I-Claim
323	obtained	_	_	I-Claim
324	with	_	_	I-Claim
325	LAM+ADV	_	_	I-Claim
326	combination	_	_	I-Claim
327	therapy	_	_	I-Claim
328	in	_	_	I-Claim
329	patients	_	_	I-Claim
330	with	_	_	I-Claim
331	LAM-resistant	_	_	I-Claim
332	CHB	_	_	I-Claim
333	and	_	_	I-Claim
334	undetectable	_	_	I-Claim
335	HBV	_	_	I-Claim
336	DNA	_	_	I-Claim
337	.	_	_	I-Claim

338	However	_	_	B-Claim
339	,	_	_	I-Claim
340	TDF	_	_	I-Claim
341	monotherapy	_	_	I-Claim
342	in	_	_	I-Claim
343	patients	_	_	I-Claim
344	with	_	_	I-Claim
345	cirrhosis	_	_	I-Claim
346	requires	_	_	I-Claim
347	close	_	_	I-Claim
348	attention	_	_	I-Claim
349	with	_	_	I-Claim
350	respect	_	_	I-Claim
351	to	_	_	I-Claim
352	renal	_	_	I-Claim
353	function	_	_	I-Claim
354	.	_	_	I-Claim


0	High	_	_	O
1	blood	_	_	O
2	pressure	_	_	O
3	(	_	_	O
4	BP	_	_	O
5	)	_	_	O
6	is	_	_	O
7	a	_	_	O
8	common	_	_	O
9	chronic	_	_	O
10	disease	_	_	O
11	needs	_	_	O
12	long	_	_	O
13	life	_	_	O
14	drug	_	_	O
15	consumption	_	_	O
16	to	_	_	O
17	control	_	_	O
18	.	_	_	O

19	Spironolactone	_	_	B-Claim
20	could	_	_	I-Claim
21	be	_	_	I-Claim
22	used	_	_	I-Claim
23	as	_	_	I-Claim
24	the	_	_	I-Claim
25	fourth-line	_	_	I-Claim
26	therapy	_	_	I-Claim
27	in	_	_	I-Claim
28	patients	_	_	I-Claim
29	with	_	_	I-Claim
30	resistant	_	_	I-Claim
31	hypertension	_	_	I-Claim
32	.	_	_	I-Claim

33	However	_	_	O
34	,	_	_	O
35	there	_	_	O
36	is	_	_	O
37	no	_	_	O
38	study	_	_	O
39	to	_	_	O
40	determine	_	_	O
41	the	_	_	O
42	effects	_	_	O
43	of	_	_	O
44	low	_	_	O
45	dose	_	_	O
46	spironolactone	_	_	O
47	as	_	_	O
48	a	_	_	O
49	first	_	_	O
50	line	_	_	O
51	therapy	_	_	O
52	in	_	_	O
53	treatment	_	_	O
54	of	_	_	O
55	essential	_	_	O
56	hypertension	_	_	O
57	.	_	_	O

58	The	_	_	O
59	aim	_	_	O
60	of	_	_	O
61	this	_	_	O
62	study	_	_	O
63	is	_	_	O
64	to	_	_	O
65	investigate	_	_	O
66	the	_	_	O
67	effect	_	_	O
68	of	_	_	O
69	low	_	_	O
70	dose	_	_	O
71	spironolactone	_	_	O
72	monotherapy	_	_	O
73	in	_	_	O
74	management	_	_	O
75	of	_	_	O
76	essential	_	_	O
77	hypertension	_	_	O
78	.	_	_	O

79	In	_	_	O
80	this	_	_	O
81	double	_	_	O
82	blind	_	_	O
83	randomized	_	_	O
84	clinical	_	_	O
85	trial	_	_	O
86	,	_	_	O
87	40	_	_	O
88	patients	_	_	O
89	who	_	_	O
90	had	_	_	O
91	stage	_	_	O
92	I	_	_	O
93	essential	_	_	O
94	hypertension	_	_	O
95	were	_	_	O
96	randomly	_	_	O
97	divided	_	_	O
98	into	_	_	O
99	two	_	_	O
100	groups	_	_	O
101	:	_	_	O
102	intervention	_	_	O
103	group	_	_	O
104	received	_	_	O
105	spironolactone	_	_	O
106	25	_	_	O
107	milligram	_	_	O
108	once	_	_	O
109	daily	_	_	O
110	for	_	_	O
111	one	_	_	O
112	month	_	_	O
113	and	_	_	O
114	control	_	_	O
115	group	_	_	O
116	received	_	_	O
117	placebo	_	_	O
118	once	_	_	O
119	daily	_	_	O
120	.	_	_	O

121	At	_	_	O
122	the	_	_	O
123	baseline	_	_	O
124	and	_	_	O
125	after	_	_	O
126	one	_	_	O
127	month	_	_	O
128	,	_	_	O
129	24-hour	_	_	O
130	BP	_	_	O
131	holter-monitoring	_	_	O
132	and	_	_	O
133	serum	_	_	O
134	potassium	_	_	O
135	assay	_	_	O
136	were	_	_	O
137	done	_	_	O
138	.	_	_	O

139	Systolic	_	_	B-Premise
140	BP	_	_	I-Premise
141	was	_	_	I-Premise
142	reduced	_	_	I-Premise
143	from	_	_	I-Premise
144	143.5	_	_	I-Premise
145	±	_	_	I-Premise
146	8.2	_	_	I-Premise
147	mmHg	_	_	I-Premise
148	to	_	_	I-Premise
149	137.10	_	_	I-Premise
150	±	_	_	I-Premise
151	7.57	_	_	I-Premise
152	mmHg	_	_	I-Premise
153	in	_	_	I-Premise
154	the	_	_	I-Premise
155	intervention	_	_	I-Premise
156	group	_	_	I-Premise
157	,	_	_	I-Premise
158	while	_	_	I-Premise
159	it	_	_	I-Premise
160	did	_	_	I-Premise
161	not	_	_	I-Premise
162	change	_	_	I-Premise
163	significantly	_	_	I-Premise
164	in	_	_	I-Premise
165	control	_	_	I-Premise
166	(	_	_	I-Premise
167	between	_	_	I-Premise
168	group	_	_	I-Premise
169	treatment	_	_	I-Premise
170	difference	_	_	I-Premise
171	=	_	_	I-Premise
172	-4.5	_	_	I-Premise
173	mmHg	_	_	I-Premise
174	,	_	_	I-Premise
175	p	_	_	I-Premise
176	=	_	_	I-Premise
177	0.004	_	_	I-Premise
178	)	_	_	I-Premise
179	.	_	_	I-Premise

180	There	_	_	B-Premise
181	was	_	_	I-Premise
182	no	_	_	I-Premise
183	significant	_	_	I-Premise
184	reduction	_	_	I-Premise
185	of	_	_	I-Premise
186	diastolic	_	_	I-Premise
187	BP	_	_	I-Premise
188	in	_	_	I-Premise
189	the	_	_	I-Premise
190	intervention	_	_	I-Premise
191	group	_	_	I-Premise
192	in	_	_	I-Premise
193	comparison	_	_	I-Premise
194	to	_	_	I-Premise
195	placebo	_	_	I-Premise
196	group	_	_	I-Premise
197	(	_	_	I-Premise
198	between	_	_	I-Premise
199	group	_	_	I-Premise
200	treatment	_	_	I-Premise
201	difference	_	_	I-Premise
202	=	_	_	I-Premise
203	-1.3	_	_	I-Premise
204	mmHg	_	_	I-Premise
205	,	_	_	I-Premise
206	p	_	_	I-Premise
207	=	_	_	I-Premise
208	0.099	_	_	I-Premise
209	)	_	_	I-Premise
210	.	_	_	I-Premise

211	Short	_	_	B-Claim
212	course	_	_	I-Claim
213	monotherapy	_	_	I-Claim
214	with	_	_	I-Claim
215	low	_	_	I-Claim
216	dose	_	_	I-Claim
217	spironolactone	_	_	I-Claim
218	is	_	_	I-Claim
219	effective	_	_	I-Claim
220	in	_	_	I-Claim
221	reducing	_	_	I-Claim
222	systolic	_	_	I-Claim
223	BP	_	_	I-Claim
224	in	_	_	I-Claim
225	patients	_	_	I-Claim
226	with	_	_	I-Claim
227	stage	_	_	I-Claim
228	I	_	_	I-Claim
229	essential	_	_	I-Claim
230	hypertension	_	_	I-Claim
231	.	_	_	I-Claim


0	The	_	_	O
1	oral	_	_	O
2	Toll-like	_	_	O
3	receptor	_	_	O
4	(	_	_	O
5	TLR	_	_	O
6	)	_	_	O
7	7	_	_	O
8	agonist	_	_	O
9	GS-9620	_	_	O
10	has	_	_	O
11	antiviral	_	_	O
12	effects	_	_	O
13	in	_	_	O
14	woodchuck	_	_	O
15	and	_	_	O
16	chimpanzee	_	_	O
17	models	_	_	O
18	of	_	_	O
19	chronic	_	_	O
20	hepatitis	_	_	O
21	B	_	_	O
22	virus	_	_	O
23	(	_	_	O
24	HBV	_	_	O
25	)	_	_	O
26	infection	_	_	O
27	.	_	_	O

28	We	_	_	O
29	investigated	_	_	O
30	,	_	_	O
31	in	_	_	O
32	a	_	_	O
33	clinical	_	_	O
34	trial	_	_	O
35	,	_	_	O
36	the	_	_	O
37	capacity	_	_	O
38	of	_	_	O
39	this	_	_	O
40	agent	_	_	O
41	to	_	_	O
42	reconstitute	_	_	O
43	protective	_	_	O
44	immunity	_	_	O
45	in	_	_	O
46	patients	_	_	O
47	with	_	_	O
48	chronic	_	_	O
49	HBV	_	_	O
50	infection	_	_	O
51	.	_	_	O

52	We	_	_	O
53	performed	_	_	O
54	a	_	_	O
55	prospective	_	_	O
56	study	_	_	O
57	of	_	_	O
58	28	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	suppression	_	_	O
62	of	_	_	O
63	HBV	_	_	O
64	infection	_	_	O
65	by	_	_	O
66	nucleos	_	_	O
67	(	_	_	O
68	t	_	_	O
69	)	_	_	O
70	ide	_	_	O
71	analogue	_	_	O
72	therapy	_	_	O
73	and	_	_	O
74	who	_	_	O
75	tested	_	_	O
76	negative	_	_	O
77	for	_	_	O
78	hepatitis	_	_	O
79	B	_	_	O
80	e	_	_	O
81	antigen	_	_	O
82	at	_	_	O
83	4	_	_	O
84	medical	_	_	O
85	centers	_	_	O
86	in	_	_	O
87	Italy	_	_	O
88	.	_	_	O

89	Patients	_	_	O
90	were	_	_	O
91	randomly	_	_	O
92	assigned	_	_	O
93	(	_	_	O
94	1:3:3:3	_	_	O
95	)	_	_	O
96	to	_	_	O
97	groups	_	_	O
98	given	_	_	O
99	placebo	_	_	O
100	or	_	_	O
101	different	_	_	O
102	doses	_	_	O
103	of	_	_	O
104	GS-9620	_	_	O
105	(	_	_	O
106	1	_	_	O
107	,	_	_	O
108	2	_	_	O
109	,	_	_	O
110	and	_	_	O
111	4	_	_	O
112	mg	_	_	O
113	,	_	_	O
114	weekly	_	_	O
115	for	_	_	O
116	12	_	_	O
117	weeks	_	_	O
118	)	_	_	O
119	.	_	_	O

120	We	_	_	O
121	added	_	_	O
122	data	_	_	O
123	from	_	_	O
124	8	_	_	O
125	patients	_	_	O
126	receiving	_	_	O
127	nucleos	_	_	O
128	(	_	_	O
129	t	_	_	O
130	)	_	_	O
131	ide	_	_	O
132	analogue	_	_	O
133	therapy	_	_	O
134	to	_	_	O
135	the	_	_	O
136	placebo	_	_	O
137	group	_	_	O
138	(	_	_	O
139	controls	_	_	O
140	)	_	_	O
141	;	_	_	O
142	13	_	_	O
143	treatment-naïve	_	_	O
144	patients	_	_	O
145	with	_	_	O
146	chronic	_	_	O
147	HBV	_	_	O
148	infection	_	_	O
149	and	_	_	O
150	15	_	_	O
151	subjects	_	_	O
152	who	_	_	O
153	spontaneously	_	_	O
154	recovered	_	_	O
155	from	_	_	O
156	an	_	_	O
157	acute	_	_	O
158	HBV	_	_	O
159	infection	_	_	O
160	served	_	_	O
161	as	_	_	O
162	additional	_	_	O
163	controls	_	_	O
164	.	_	_	O

165	Peripheral	_	_	O
166	blood	_	_	O
167	mononuclear	_	_	O
168	cells	_	_	O
169	were	_	_	O
170	collected	_	_	O
171	at	_	_	O
172	baseline	_	_	O
173	,	_	_	O
174	during	_	_	O
175	administration	_	_	O
176	of	_	_	O
177	GS-9620	_	_	O
178	or	_	_	O
179	placebo	_	_	O
180	,	_	_	O
181	and	_	_	O
182	12	_	_	O
183	weeks	_	_	O
184	afterward	_	_	O
185	.	_	_	O

186	Phenotype	_	_	O
187	and	_	_	O
188	function	_	_	O
189	of	_	_	O
190	natural	_	_	O
191	killer	_	_	O
192	(	_	_	O
193	NK	_	_	O
194	)	_	_	O
195	and	_	_	O
196	HBV-specific	_	_	O
197	T	_	_	O
198	cells	_	_	O
199	were	_	_	O
200	analyzed	_	_	O
201	by	_	_	O
202	flow	_	_	O
203	cytometry	_	_	O
204	.	_	_	O

205	T	_	_	O
206	cells	_	_	O
207	were	_	_	O
208	expanded	_	_	O
209	by	_	_	O
210	incubation	_	_	O
211	with	_	_	O
212	peptides	_	_	O
213	from	_	_	O
214	the	_	_	O
215	entire	_	_	O
216	HBV	_	_	O
217	proteome	_	_	O
218	and	_	_	O
219	studied	_	_	O
220	after	_	_	O
221	overnight	_	_	O
222	or	_	_	O
223	10	_	_	O
224	days	_	_	O
225	culture	_	_	O
226	.	_	_	O

227	NK-cell	_	_	O
228	inhibition	_	_	O
229	of	_	_	O
230	T-cell	_	_	O
231	responses	_	_	O
232	was	_	_	O
233	measured	_	_	O
234	by	_	_	O
235	assessing	_	_	O
236	cytokine	_	_	O
237	production	_	_	O
238	by	_	_	O
239	T	_	_	O
240	cells	_	_	O
241	stimulated	_	_	O
242	with	_	_	O
243	peptides	_	_	O
244	in	_	_	O
245	the	_	_	O
246	presence	_	_	O
247	or	_	_	O
248	absence	_	_	O
249	of	_	_	O
250	NK	_	_	O
251	cells	_	_	O
252	.	_	_	O

253	T	_	_	B-Premise
254	cells	_	_	I-Premise
255	collected	_	_	I-Premise
256	at	_	_	I-Premise
257	baseline	_	_	I-Premise
258	before	_	_	I-Premise
259	addition	_	_	I-Premise
260	of	_	_	I-Premise
261	GS-9620	_	_	I-Premise
262	,	_	_	I-Premise
263	when	_	_	I-Premise
264	patients	_	_	I-Premise
265	were	_	_	I-Premise
266	receiving	_	_	I-Premise
267	only	_	_	I-Premise
268	nucleos	_	_	I-Premise
269	(	_	_	I-Premise
270	t	_	_	I-Premise
271	)	_	_	I-Premise
272	ide	_	_	I-Premise
273	therapy	_	_	I-Premise
274	,	_	_	I-Premise
275	had	_	_	I-Premise
276	greater	_	_	I-Premise
277	responses	_	_	I-Premise
278	to	_	_	I-Premise
279	HBV	_	_	I-Premise
280	than	_	_	I-Premise
281	T	_	_	I-Premise
282	cells	_	_	I-Premise
283	from	_	_	I-Premise
284	treatment-naïve	_	_	I-Premise
285	patients	_	_	I-Premise
286	,	_	_	I-Premise
287	based	_	_	I-Premise
288	on	_	_	I-Premise
289	cytokine	_	_	I-Premise
290	production	_	_	I-Premise
291	in	_	_	I-Premise
292	response	_	_	I-Premise
293	to	_	_	I-Premise
294	HBV	_	_	I-Premise
295	peptides	_	_	I-Premise
296	.	_	_	I-Premise

297	However	_	_	B-Premise
298	,	_	_	I-Premise
299	during	_	_	I-Premise
300	or	_	_	I-Premise
301	after	_	_	I-Premise
302	administration	_	_	I-Premise
303	of	_	_	I-Premise
304	GS-9620	_	_	I-Premise
305	,	_	_	I-Premise
306	T	_	_	I-Premise
307	cells	_	_	I-Premise
308	produced	_	_	I-Premise
309	higher	_	_	I-Premise
310	levels	_	_	I-Premise
311	of	_	_	I-Premise
312	cytokines	_	_	I-Premise
313	compared	_	_	I-Premise
314	to	_	_	I-Premise
315	baseline	_	_	I-Premise
316	.	_	_	I-Premise

317	NK-cell	_	_	B-Premise
318	activation	_	_	I-Premise
319	and	_	_	I-Premise
320	function	_	_	I-Premise
321	increased	_	_	I-Premise
322	after	_	_	I-Premise
323	patients	_	_	I-Premise
324	were	_	_	I-Premise
325	given	_	_	I-Premise
326	GS-9620	_	_	I-Premise
327	,	_	_	I-Premise
328	but	_	_	I-Premise
329	the	_	_	I-Premise
330	ability	_	_	I-Premise
331	of	_	_	I-Premise
332	NK	_	_	I-Premise
333	cells	_	_	I-Premise
334	to	_	_	I-Premise
335	suppress	_	_	I-Premise
336	T-cell	_	_	I-Premise
337	responses	_	_	I-Premise
338	was	_	_	I-Premise
339	lower	_	_	I-Premise
340	during	_	_	I-Premise
341	GS-9620	_	_	I-Premise
342	therapy	_	_	I-Premise
343	than	_	_	I-Premise
344	before	_	_	I-Premise
345	.	_	_	I-Premise

346	Changes	_	_	B-Premise
347	in	_	_	I-Premise
348	T-cell	_	_	I-Premise
349	or	_	_	I-Premise
350	NK-cell	_	_	I-Premise
351	function	_	_	I-Premise
352	did	_	_	I-Premise
353	not	_	_	I-Premise
354	correlate	_	_	I-Premise
355	with	_	_	I-Premise
356	levels	_	_	I-Premise
357	of	_	_	I-Premise
358	hepatitis	_	_	I-Premise
359	B	_	_	I-Premise
360	surface	_	_	I-Premise
361	antigen	_	_	I-Premise
362	.	_	_	I-Premise

363	Serum	_	_	B-Premise
364	levels	_	_	I-Premise
365	of	_	_	I-Premise
366	hepatitis	_	_	I-Premise
367	B	_	_	I-Premise
368	surface	_	_	I-Premise
369	antigen	_	_	I-Premise
370	did	_	_	I-Premise
371	not	_	_	I-Premise
372	decrease	_	_	I-Premise
373	significantly	_	_	I-Premise
374	compared	_	_	I-Premise
375	to	_	_	I-Premise
376	baseline	_	_	I-Premise
377	in	_	_	I-Premise
378	patients	_	_	I-Premise
379	given	_	_	I-Premise
380	any	_	_	I-Premise
381	dose	_	_	I-Premise
382	of	_	_	I-Premise
383	GS-9620	_	_	I-Premise
384	.	_	_	I-Premise

385	Twelve	_	_	B-Claim
386	weeks	_	_	I-Claim
387	administration	_	_	I-Claim
388	of	_	_	I-Claim
389	GS-9620	_	_	I-Claim
390	had	_	_	I-Claim
391	no	_	_	I-Claim
392	significant	_	_	I-Claim
393	effect	_	_	I-Claim
394	on	_	_	I-Claim
395	serum	_	_	I-Claim
396	hepatitis	_	_	I-Claim
397	B	_	_	I-Claim
398	surface	_	_	I-Claim
399	antigen	_	_	I-Claim
400	levels	_	_	I-Claim
401	,	_	_	I-Claim
402	but	_	_	I-Claim
403	did	_	_	I-Claim
404	appear	_	_	I-Claim
405	to	_	_	I-Claim
406	increase	_	_	I-Claim
407	T-cell	_	_	I-Claim
408	and	_	_	I-Claim
409	NK-cell	_	_	I-Claim
410	responses	_	_	I-Claim
411	and	_	_	I-Claim
412	reduce	_	_	I-Claim
413	the	_	_	I-Claim
414	ability	_	_	I-Claim
415	of	_	_	I-Claim
416	NK	_	_	I-Claim
417	to	_	_	I-Claim
418	suppress	_	_	I-Claim
419	T	_	_	I-Claim
420	cells	_	_	I-Claim
421	.	_	_	I-Claim

422	GS-9620	_	_	B-Claim
423	might	_	_	I-Claim
424	therefore	_	_	I-Claim
425	be	_	_	I-Claim
426	included	_	_	I-Claim
427	in	_	_	I-Claim
428	therapies	_	_	I-Claim
429	to	_	_	I-Claim
430	increase	_	_	I-Claim
431	the	_	_	I-Claim
432	immune	_	_	I-Claim
433	response	_	_	I-Claim
434	to	_	_	I-Claim
435	HBV	_	_	I-Claim
436	.	_	_	I-Claim


0	Intradialytic	_	_	O
1	hypotension	_	_	O
2	(	_	_	O
3	IDH	_	_	O
4	)	_	_	O
5	is	_	_	O
6	an	_	_	O
7	important	_	_	O
8	cause	_	_	O
9	of	_	_	O
10	morbidity	_	_	O
11	and	_	_	O
12	mortality	_	_	O
13	among	_	_	O
14	hemodialysis	_	_	O
15	patients	_	_	O
16	.	_	_	O

17	We	_	_	O
18	used	_	_	O
19	an	_	_	O
20	immersion	_	_	O
21	model	_	_	O
22	to	_	_	O
23	evaluate	_	_	O
24	the	_	_	O
25	role	_	_	O
26	of	_	_	O
27	reduced	_	_	O
28	effective	_	_	O
29	circulating	_	_	O
30	volume	_	_	O
31	,	_	_	O
32	and	_	_	O
33	to	_	_	O
34	examine	_	_	O
35	whether	_	_	O
36	facilitated	_	_	O
37	refilling	_	_	O
38	can	_	_	O
39	prevent	_	_	O
40	IDH	_	_	O
41	.	_	_	O

42	Ten	_	_	O
43	male	_	_	O
44	hemodialysis	_	_	O
45	patients	_	_	O
46	who	_	_	O
47	had	_	_	O
48	frequent	_	_	O
49	episodes	_	_	O
50	of	_	_	O
51	IDH	_	_	O
52	were	_	_	O
53	randomized	_	_	O
54	to	_	_	O
55	a	_	_	O
56	mid-week	_	_	O
57	wet	_	_	O
58	or	_	_	O
59	dry	_	_	O
60	hemodialysis	_	_	O
61	session	_	_	O
62	,	_	_	O
63	and	_	_	O
64	subsequently	_	_	O
65	underwent	_	_	O
66	the	_	_	O
67	other	_	_	O
68	session	_	_	O
69	in	_	_	O
70	a	_	_	O
71	crossover	_	_	O
72	manner	_	_	O
73	.	_	_	O

74	The	_	_	O
75	wet	_	_	O
76	sessions	_	_	O
77	were	_	_	O
78	performed	_	_	O
79	while	_	_	O
80	immersed	_	_	O
81	up	_	_	O
82	to	_	_	O
83	the	_	_	O
84	neck	_	_	O
85	in	_	_	O
86	a	_	_	O
87	34	_	_	O
88	to	_	_	O
89	35°C	_	_	O
90	bath	_	_	O
91	,	_	_	O
92	and	_	_	O
93	the	_	_	O
94	dry	_	_	O
95	session	_	_	O
96	was	_	_	O
97	standard	_	_	O
98	hemodialysis	_	_	O
99	.	_	_	O

100	Ultrafiltration	_	_	O
101	goals	_	_	O
102	were	_	_	O
103	determined	_	_	O
104	as	_	_	O
105	the	_	_	O
106	mean	_	_	O
107	ultrafiltration	_	_	O
108	during	_	_	O
109	the	_	_	O
110	10	_	_	O
111	sessions	_	_	O
112	preceding	_	_	O
113	the	_	_	O
114	first	_	_	O
115	study	_	_	O
116	session	_	_	O
117	±	_	_	O
118	10	_	_	O
119	%	_	_	O
120	.	_	_	O

121	Mean	_	_	O
122	ultrafiltration	_	_	O
123	was	_	_	O
124	similar	_	_	O
125	for	_	_	O
126	the	_	_	O
127	wet	_	_	O
128	and	_	_	O
129	dry	_	_	O
130	sessions	_	_	O
131	(	_	_	O
132	2.99	_	_	O
133	±	_	_	O
134	0.64	_	_	O
135	kg	_	_	O
136	vs.	_	_	O
137	2.96	_	_	O
138	±	_	_	O
139	0.74	_	_	O
140	kg	_	_	O
141	)	_	_	O
142	.	_	_	O

143	Symptomatic	_	_	B-Premise
144	hypotension	_	_	I-Premise
145	did	_	_	I-Premise
146	not	_	_	I-Premise
147	develop	_	_	I-Premise
148	in	_	_	I-Premise
149	any	_	_	I-Premise
150	of	_	_	I-Premise
151	the	_	_	I-Premise
152	patients	_	_	I-Premise
153	during	_	_	I-Premise
154	the	_	_	I-Premise
155	wet	_	_	I-Premise
156	session	_	_	I-Premise
157	,	_	_	I-Premise
158	compared	_	_	I-Premise
159	to	_	_	I-Premise
160	4	_	_	I-Premise
161	(	_	_	I-Premise
162	40	_	_	I-Premise
163	%	_	_	I-Premise
164	)	_	_	I-Premise
165	during	_	_	I-Premise
166	the	_	_	I-Premise
167	dry	_	_	I-Premise
168	session	_	_	I-Premise
169	.	_	_	I-Premise

170	Systolic	_	_	B-Premise
171	blood	_	_	I-Premise
172	pressure	_	_	I-Premise
173	adjusted	_	_	I-Premise
174	to	_	_	I-Premise
175	ultrafiltration	_	_	I-Premise
176	was	_	_	I-Premise
177	stable	_	_	I-Premise
178	during	_	_	I-Premise
179	the	_	_	I-Premise
180	wet	_	_	I-Premise
181	session	_	_	I-Premise
182	,	_	_	I-Premise
183	0.22	_	_	I-Premise
184	mmHg/15	_	_	I-Premise
185	min	_	_	I-Premise
186	(	_	_	I-Premise
187	95	_	_	I-Premise
188	%	_	_	I-Premise
189	CI	_	_	I-Premise
190	-0.27	_	_	I-Premise
191	to	_	_	I-Premise
192	0.70	_	_	I-Premise
193	)	_	_	I-Premise
194	,	_	_	I-Premise
195	P	_	_	I-Premise
196	=	_	_	I-Premise
197	0.38	_	_	I-Premise
198	,	_	_	I-Premise
199	and	_	_	I-Premise
200	significantly	_	_	I-Premise
201	decreased	_	_	I-Premise
202	during	_	_	I-Premise
203	the	_	_	I-Premise
204	dry	_	_	I-Premise
205	session	_	_	I-Premise
206	,	_	_	I-Premise
207	-0.68	_	_	I-Premise
208	mmHg/15	_	_	I-Premise
209	min	_	_	I-Premise
210	(	_	_	I-Premise
211	95	_	_	I-Premise
212	%	_	_	I-Premise
213	CI	_	_	I-Premise
214	-1.24	_	_	I-Premise
215	to	_	_	I-Premise
216	-0.11	_	_	I-Premise
217	)	_	_	I-Premise
218	,	_	_	I-Premise
219	P	_	_	I-Premise
220	=	_	_	I-Premise
221	0.02	_	_	I-Premise
222	.	_	_	I-Premise

223	Diastolic	_	_	B-Premise
224	blood	_	_	I-Premise
225	pressure	_	_	I-Premise
226	did	_	_	I-Premise
227	not	_	_	I-Premise
228	change	_	_	I-Premise
229	during	_	_	I-Premise
230	the	_	_	I-Premise
231	sessions	_	_	I-Premise
232	.	_	_	I-Premise

233	Mean	_	_	B-Premise
234	atrial	_	_	I-Premise
235	natriuretic	_	_	I-Premise
236	peptide	_	_	I-Premise
237	significantly	_	_	I-Premise
238	increased	_	_	I-Premise
239	in	_	_	I-Premise
240	the	_	_	I-Premise
241	wet	_	_	I-Premise
242	session	_	_	I-Premise
243	,	_	_	I-Premise
244	by	_	_	I-Premise
245	31.36	_	_	I-Premise
246	pgr/mL	_	_	I-Premise
247	(	_	_	I-Premise
248	95	_	_	I-Premise
249	%	_	_	I-Premise
250	CI	_	_	I-Premise
251	8.73-53.99	_	_	I-Premise
252	)	_	_	I-Premise
253	,	_	_	I-Premise
254	P	_	_	I-Premise
255	=	_	_	I-Premise
256	0.007	_	_	I-Premise
257	,	_	_	I-Premise
258	and	_	_	I-Premise
259	slightly	_	_	I-Premise
260	and	_	_	I-Premise
261	insignificantly	_	_	I-Premise
262	decreased	_	_	I-Premise
263	in	_	_	I-Premise
264	the	_	_	I-Premise
265	dry	_	_	I-Premise
266	session	_	_	I-Premise
267	,	_	_	I-Premise
268	by	_	_	I-Premise
269	21.66	_	_	I-Premise
270	pgr/mL	_	_	I-Premise
271	(	_	_	I-Premise
272	95	_	_	I-Premise
273	%	_	_	I-Premise
274	CI	_	_	I-Premise
275	-52.59	_	_	I-Premise
276	to	_	_	I-Premise
277	9.25	_	_	I-Premise
278	)	_	_	I-Premise
279	,	_	_	I-Premise
280	P	_	_	I-Premise
281	=	_	_	I-Premise
282	0.167	_	_	I-Premise
283	.	_	_	I-Premise

284	Aldosterone	_	_	B-Premise
285	blood	_	_	I-Premise
286	levels	_	_	I-Premise
287	did	_	_	I-Premise
288	not	_	_	I-Premise
289	change	_	_	I-Premise
290	.	_	_	I-Premise

291	Reduced	_	_	B-Claim
292	effective	_	_	I-Claim
293	circulating	_	_	I-Claim
294	volume	_	_	I-Claim
295	is	_	_	I-Claim
296	a	_	_	I-Claim
297	major	_	_	I-Claim
298	cause	_	_	I-Claim
299	for	_	_	I-Claim
300	IDH	_	_	I-Claim
301	,	_	_	I-Claim
302	which	_	_	I-Claim
303	can	_	_	I-Claim
304	be	_	_	I-Claim
305	prevented	_	_	I-Claim
306	using	_	_	I-Claim
307	head-out	_	_	I-Claim
308	water	_	_	I-Claim
309	immersion	_	_	I-Claim
310	facilitated	_	_	I-Claim
311	redistribution	_	_	I-Claim
312	.	_	_	I-Claim


0	To	_	_	O
1	report	_	_	O
2	1-year	_	_	O
3	treatment	_	_	O
4	outcomes	_	_	O
5	in	_	_	O
6	the	_	_	O
7	Primary	_	_	O
8	Tube	_	_	O
9	Versus	_	_	O
10	Trabeculectomy	_	_	O
11	(	_	_	O
12	PTVT	_	_	O
13	)	_	_	O
14	Study	_	_	O
15	.	_	_	O

16	Two	_	_	O
17	hundred	_	_	O
18	forty-two	_	_	O
19	eyes	_	_	O
20	of	_	_	O
21	242	_	_	O
22	patients	_	_	O
23	with	_	_	O
24	medically	_	_	O
25	uncontrolled	_	_	O
26	glaucoma	_	_	O
27	and	_	_	O
28	no	_	_	O
29	previous	_	_	O
30	incisional	_	_	O
31	ocular	_	_	O
32	surgery	_	_	O
33	,	_	_	O
34	including	_	_	O
35	125	_	_	O
36	in	_	_	O
37	the	_	_	O
38	tube	_	_	O
39	group	_	_	O
40	and	_	_	O
41	117	_	_	O
42	in	_	_	O
43	the	_	_	O
44	trabeculectomy	_	_	O
45	group	_	_	O
46	.	_	_	O

47	Patients	_	_	O
48	were	_	_	O
49	enrolled	_	_	O
50	at	_	_	O
51	16	_	_	O
52	clinical	_	_	O
53	centers	_	_	O
54	and	_	_	O
55	assigned	_	_	O
56	randomly	_	_	O
57	to	_	_	O
58	treatment	_	_	O
59	with	_	_	O
60	a	_	_	O
61	tube	_	_	O
62	shunt	_	_	O
63	(	_	_	O
64	350-mm2	_	_	O
65	Baerveldt	_	_	O
66	glaucoma	_	_	O
67	implant	_	_	O
68	)	_	_	O
69	or	_	_	O
70	trabeculectomy	_	_	O
71	with	_	_	O
72	mitomycin	_	_	O
73	C	_	_	O
74	(	_	_	O
75	MMC	_	_	O
76	;	_	_	O
77	0.4	_	_	O
78	mg/ml	_	_	O
79	for	_	_	O
80	2	_	_	O
81	minutes	_	_	O
82	)	_	_	O
83	.	_	_	O

84	Intraocular	_	_	O
85	pressure	_	_	O
86	(	_	_	O
87	IOP	_	_	O
88	)	_	_	O
89	,	_	_	O
90	glaucoma	_	_	O
91	medical	_	_	O
92	therapy	_	_	O
93	,	_	_	O
94	visual	_	_	O
95	acuity	_	_	O
96	,	_	_	O
97	visual	_	_	O
98	fields	_	_	O
99	,	_	_	O
100	surgical	_	_	O
101	complications	_	_	O
102	,	_	_	O
103	and	_	_	O
104	failure	_	_	O
105	(	_	_	O
106	IOP	_	_	O
107	of	_	_	O
108	more	_	_	O
109	than	_	_	O
110	21	_	_	O
111	mmHg	_	_	O
112	or	_	_	O
113	reduced	_	_	O
114	by	_	_	O
115	less	_	_	O
116	than	_	_	O
117	20	_	_	O
118	%	_	_	O
119	from	_	_	O
120	baseline	_	_	O
121	,	_	_	O
122	IOP	_	_	O
123	of	_	_	O
124	5	_	_	O
125	mmHg	_	_	O
126	or	_	_	O
127	less	_	_	O
128	,	_	_	O
129	reoperation	_	_	O
130	for	_	_	O
131	glaucoma	_	_	O
132	,	_	_	O
133	or	_	_	O
134	loss	_	_	O
135	of	_	_	O
136	light	_	_	O
137	perception	_	_	O
138	vision	_	_	O
139	)	_	_	O
140	.	_	_	O

141	The	_	_	B-Premise
142	cumulative	_	_	I-Premise
143	probability	_	_	I-Premise
144	of	_	_	I-Premise
145	failure	_	_	I-Premise
146	during	_	_	I-Premise
147	the	_	_	I-Premise
148	first	_	_	I-Premise
149	year	_	_	I-Premise
150	of	_	_	I-Premise
151	follow-up	_	_	I-Premise
152	was	_	_	I-Premise
153	17.3	_	_	I-Premise
154	%	_	_	I-Premise
155	in	_	_	I-Premise
156	the	_	_	I-Premise
157	tube	_	_	I-Premise
158	group	_	_	I-Premise
159	and	_	_	I-Premise
160	7.9	_	_	I-Premise
161	%	_	_	I-Premise
162	in	_	_	I-Premise
163	the	_	_	I-Premise
164	trabeculectomy	_	_	I-Premise
165	group	_	_	I-Premise
166	(	_	_	I-Premise
167	P	_	_	I-Premise
168	=	_	_	I-Premise
169	0.01	_	_	I-Premise
170	;	_	_	I-Premise
171	hazard	_	_	I-Premise
172	ratio	_	_	I-Premise
173	,	_	_	I-Premise
174	2.59	_	_	I-Premise
175	;	_	_	I-Premise
176	95	_	_	I-Premise
177	%	_	_	I-Premise
178	confidence	_	_	I-Premise
179	interval	_	_	I-Premise
180	,	_	_	I-Premise
181	1.20-5.60	_	_	I-Premise
182	)	_	_	I-Premise
183	.	_	_	I-Premise

184	Mean	_	_	B-Premise
185	±	_	_	I-Premise
186	standard	_	_	I-Premise
187	deviation	_	_	I-Premise
188	IOP	_	_	I-Premise
189	was	_	_	I-Premise
190	13.8±4.1	_	_	I-Premise
191	mmHg	_	_	I-Premise
192	in	_	_	I-Premise
193	the	_	_	I-Premise
194	tube	_	_	I-Premise
195	group	_	_	I-Premise
196	and	_	_	I-Premise
197	12.4±4.4	_	_	I-Premise
198	mmHg	_	_	I-Premise
199	in	_	_	I-Premise
200	the	_	_	I-Premise
201	trabeculectomy	_	_	I-Premise
202	group	_	_	I-Premise
203	at	_	_	I-Premise
204	1	_	_	I-Premise
205	year	_	_	I-Premise
206	(	_	_	I-Premise
207	P	_	_	I-Premise
208	=	_	_	I-Premise
209	0.01	_	_	I-Premise
210	)	_	_	I-Premise
211	,	_	_	I-Premise
212	and	_	_	I-Premise
213	the	_	_	I-Premise
214	number	_	_	I-Premise
215	of	_	_	I-Premise
216	glaucoma	_	_	I-Premise
217	medications	_	_	I-Premise
218	was	_	_	I-Premise
219	2.1±1.4	_	_	I-Premise
220	in	_	_	I-Premise
221	the	_	_	I-Premise
222	tube	_	_	I-Premise
223	group	_	_	I-Premise
224	and	_	_	I-Premise
225	0.9±1.4	_	_	I-Premise
226	in	_	_	I-Premise
227	the	_	_	I-Premise
228	trabeculectomy	_	_	I-Premise
229	group	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	<	_	_	I-Premise
233	0.001	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	Postoperative	_	_	B-Premise
237	complications	_	_	I-Premise
238	developed	_	_	I-Premise
239	in	_	_	I-Premise
240	36	_	_	I-Premise
241	patients	_	_	I-Premise
242	(	_	_	I-Premise
243	29	_	_	I-Premise
244	%	_	_	I-Premise
245	)	_	_	I-Premise
246	in	_	_	I-Premise
247	the	_	_	I-Premise
248	tube	_	_	I-Premise
249	group	_	_	I-Premise
250	and	_	_	I-Premise
251	48	_	_	I-Premise
252	patients	_	_	I-Premise
253	(	_	_	I-Premise
254	41	_	_	I-Premise
255	%	_	_	I-Premise
256	)	_	_	I-Premise
257	in	_	_	I-Premise
258	the	_	_	I-Premise
259	trabeculectomy	_	_	I-Premise
260	group	_	_	I-Premise
261	(	_	_	I-Premise
262	P	_	_	I-Premise
263	=	_	_	I-Premise
264	0.06	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	Serious	_	_	B-Premise
268	complications	_	_	I-Premise
269	requiring	_	_	I-Premise
270	reoperation	_	_	I-Premise
271	or	_	_	I-Premise
272	producing	_	_	I-Premise
273	a	_	_	I-Premise
274	loss	_	_	I-Premise
275	of	_	_	I-Premise
276	2	_	_	I-Premise
277	Snellen	_	_	I-Premise
278	lines	_	_	I-Premise
279	or	_	_	I-Premise
280	more	_	_	I-Premise
281	occurred	_	_	I-Premise
282	in	_	_	I-Premise
283	1	_	_	I-Premise
284	patient	_	_	I-Premise
285	(	_	_	I-Premise
286	1	_	_	I-Premise
287	%	_	_	I-Premise
288	)	_	_	I-Premise
289	in	_	_	I-Premise
290	the	_	_	I-Premise
291	tube	_	_	I-Premise
292	group	_	_	I-Premise
293	and	_	_	I-Premise
294	8	_	_	I-Premise
295	patients	_	_	I-Premise
296	(	_	_	I-Premise
297	7	_	_	I-Premise
298	%	_	_	I-Premise
299	)	_	_	I-Premise
300	in	_	_	I-Premise
301	the	_	_	I-Premise
302	trabeculectomy	_	_	I-Premise
303	group	_	_	I-Premise
304	(	_	_	I-Premise
305	P	_	_	I-Premise
306	=	_	_	I-Premise
307	0.03	_	_	I-Premise
308	)	_	_	I-Premise
309	.	_	_	I-Premise

310	Trabeculectomy	_	_	B-Claim
311	with	_	_	I-Claim
312	MMC	_	_	I-Claim
313	had	_	_	I-Claim
314	a	_	_	I-Claim
315	higher	_	_	I-Claim
316	surgical	_	_	I-Claim
317	success	_	_	I-Claim
318	rate	_	_	I-Claim
319	than	_	_	I-Claim
320	tube	_	_	I-Claim
321	shunt	_	_	I-Claim
322	implantation	_	_	I-Claim
323	after	_	_	I-Claim
324	1	_	_	I-Claim
325	year	_	_	I-Claim
326	in	_	_	I-Claim
327	the	_	_	I-Claim
328	PTVT	_	_	I-Claim
329	Study	_	_	I-Claim
330	.	_	_	I-Claim

331	Lower	_	_	B-Claim
332	IOP	_	_	I-Claim
333	with	_	_	I-Claim
334	use	_	_	I-Claim
335	of	_	_	I-Claim
336	fewer	_	_	I-Claim
337	glaucoma	_	_	I-Claim
338	medications	_	_	I-Claim
339	was	_	_	I-Claim
340	achieved	_	_	I-Claim
341	after	_	_	I-Claim
342	trabeculectomy	_	_	I-Claim
343	with	_	_	I-Claim
344	MMC	_	_	I-Claim
345	compared	_	_	I-Claim
346	with	_	_	I-Claim
347	tube	_	_	I-Claim
348	shunt	_	_	I-Claim
349	surgery	_	_	I-Claim
350	during	_	_	I-Claim
351	the	_	_	I-Claim
352	first	_	_	I-Claim
353	year	_	_	I-Claim
354	of	_	_	I-Claim
355	follow-up	_	_	I-Claim
356	.	_	_	I-Claim

357	The	_	_	B-Claim
358	frequency	_	_	I-Claim
359	of	_	_	I-Claim
360	serious	_	_	I-Claim
361	complications	_	_	I-Claim
362	producing	_	_	I-Claim
363	vision	_	_	I-Claim
364	loss	_	_	I-Claim
365	or	_	_	I-Claim
366	requiring	_	_	I-Claim
367	reoperation	_	_	I-Claim
368	was	_	_	I-Claim
369	lower	_	_	I-Claim
370	after	_	_	I-Claim
371	tube	_	_	I-Claim
372	shunt	_	_	I-Claim
373	surgery	_	_	I-Claim
374	relative	_	_	I-Claim
375	to	_	_	I-Claim
376	trabeculectomy	_	_	I-Claim
377	with	_	_	I-Claim
378	MMC	_	_	I-Claim
379	.	_	_	I-Claim


0	Despite	_	_	O
1	the	_	_	O
2	lack	_	_	O
3	of	_	_	O
4	evidence	_	_	O
5	,	_	_	O
6	a	_	_	O
7	growing	_	_	O
8	number	_	_	O
9	of	_	_	O
10	people	_	_	O
11	are	_	_	O
12	using	_	_	O
13	herbal	_	_	O
14	medicine	_	_	O
15	to	_	_	O
16	attenuate	_	_	O
17	the	_	_	O
18	burden	_	_	O
19	of	_	_	O
20	diabetes	_	_	O
21	.	_	_	O

22	There	_	_	O
23	is	_	_	O
24	an	_	_	O
25	urgent	_	_	O
26	need	_	_	O
27	to	_	_	O
28	investigate	_	_	O
29	the	_	_	O
30	clinical	_	_	O
31	potential	_	_	O
32	of	_	_	O
33	herbs	_	_	O
34	.	_	_	O

35	Preliminary	_	_	O
36	observations	_	_	O
37	suggest	_	_	O
38	that	_	_	O
39	American	_	_	O
40	ginseng	_	_	O
41	(	_	_	O
42	Panax	_	_	O
43	quinquefolius	_	_	O
44	[	_	_	O
45	AG	_	_	O
46	]	_	_	O
47	)	_	_	O
48	may	_	_	O
49	reduce	_	_	O
50	postprandial	_	_	O
51	glycemia	_	_	O
52	.	_	_	O

53	Thus	_	_	O
54	,	_	_	O
55	we	_	_	O
56	aimed	_	_	O
57	to	_	_	O
58	evaluate	_	_	O
59	the	_	_	O
60	efficacy	_	_	O
61	and	_	_	O
62	safety	_	_	O
63	of	_	_	O
64	AG	_	_	O
65	as	_	_	O
66	an	_	_	O
67	add-on	_	_	O
68	therapy	_	_	O
69	in	_	_	O
70	individuals	_	_	O
71	with	_	_	O
72	type	_	_	O
73	2	_	_	O
74	diabetes	_	_	O
75	(	_	_	O
76	T2DM	_	_	O
77	)	_	_	O
78	controlled	_	_	O
79	by	_	_	O
80	conventional	_	_	O
81	treatment	_	_	O
82	.	_	_	O

83	24	_	_	O
84	individuals	_	_	O
85	living	_	_	O
86	with	_	_	O
87	T2DM	_	_	O
88	completed	_	_	O
89	the	_	_	O
90	study	_	_	O
91	(	_	_	O
92	F	_	_	O
93	:	_	_	O
94	M	_	_	O
95	=	_	_	O
96	11:13	_	_	O
97	;	_	_	O
98	age	_	_	O
99	=	_	_	O
100	64	_	_	O
101	±	_	_	O
102	7	_	_	O
103	year	_	_	O
104	;	_	_	O
105	BMI	_	_	O
106	=	_	_	O
107	27.8	_	_	O
108	±	_	_	O
109	4.6	_	_	O
110	kg/m2	_	_	O
111	;	_	_	O
112	HbA1c	_	_	O
113	=	_	_	O
114	7.1	_	_	O
115	±	_	_	O
116	1.2	_	_	O
117	%	_	_	O
118	)	_	_	O
119	.	_	_	O

120	Utilizing	_	_	O
121	a	_	_	O
122	double-blind	_	_	O
123	,	_	_	O
124	cross-over	_	_	O
125	design	_	_	O
126	,	_	_	O
127	the	_	_	O
128	participants	_	_	O
129	were	_	_	O
130	randomized	_	_	O
131	to	_	_	O
132	receive	_	_	O
133	either	_	_	O
134	1	_	_	O
135	g/meal	_	_	O
136	(	_	_	O
137	3	_	_	O
138	g/day	_	_	O
139	)	_	_	O
140	of	_	_	O
141	AG	_	_	O
142	extract	_	_	O
143	or	_	_	O
144	placebo	_	_	O
145	for	_	_	O
146	8	_	_	O
147	weeks	_	_	O
148	while	_	_	O
149	maintaining	_	_	O
150	their	_	_	O
151	original	_	_	O
152	treatment	_	_	O
153	.	_	_	O

154	Following	_	_	O
155	a	_	_	O
156	≥	_	_	O
157	4-week	_	_	O
158	washout	_	_	O
159	period	_	_	O
160	,	_	_	O
161	the	_	_	O
162	participants	_	_	O
163	were	_	_	O
164	crossed	_	_	O
165	over	_	_	O
166	to	_	_	O
167	the	_	_	O
168	opposite	_	_	O
169	8-week	_	_	O
170	treatment	_	_	O
171	arm	_	_	O
172	.	_	_	O

173	The	_	_	O
174	primary	_	_	O
175	objective	_	_	O
176	was	_	_	O
177	HbA1c	_	_	O
178	,	_	_	O
179	and	_	_	O
180	secondary	_	_	O
181	endpoints	_	_	O
182	included	_	_	O
183	fasting	_	_	O
184	blood	_	_	O
185	glucose	_	_	O
186	and	_	_	O
187	insulin	_	_	O
188	,	_	_	O
189	blood	_	_	O
190	pressure	_	_	O
191	,	_	_	O
192	plasma	_	_	O
193	lipids	_	_	O
194	,	_	_	O
195	serum	_	_	O
196	nitrates/nitrites	_	_	O
197	(	_	_	O
198	NOx	_	_	O
199	)	_	_	O
200	,	_	_	O
201	and	_	_	O
202	plasominogen-activating	_	_	O
203	factor-1	_	_	O
204	(	_	_	O
205	PAI-1	_	_	O
206	)	_	_	O
207	.	_	_	O

208	Safety	_	_	O
209	parameters	_	_	O
210	included	_	_	O
211	liver	_	_	O
212	and	_	_	O
213	kidney	_	_	O
214	function	_	_	O
215	.	_	_	O

216	Compared	_	_	B-Premise
217	to	_	_	I-Premise
218	placebo	_	_	I-Premise
219	,	_	_	I-Premise
220	AG	_	_	I-Premise
221	significantly	_	_	I-Premise
222	reduced	_	_	I-Premise
223	HbA1c	_	_	I-Premise
224	(	_	_	I-Premise
225	-	_	_	I-Premise
226	0.29	_	_	I-Premise
227	%	_	_	I-Premise
228	;	_	_	I-Premise
229	p	_	_	I-Premise
230	=	_	_	I-Premise
231	0.041	_	_	I-Premise
232	)	_	_	I-Premise
233	and	_	_	I-Premise
234	fasting	_	_	I-Premise
235	blood	_	_	I-Premise
236	glucose	_	_	I-Premise
237	(	_	_	I-Premise
238	-	_	_	I-Premise
239	0.71	_	_	I-Premise
240	mmol/L	_	_	I-Premise
241	;	_	_	I-Premise
242	p	_	_	I-Premise
243	=	_	_	I-Premise
244	0.008	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	Furthermore	_	_	O
248	,	_	_	O
249	AG	_	_	B-Premise
250	lowered	_	_	I-Premise
251	systolic	_	_	I-Premise
252	blood	_	_	I-Premise
253	pressure	_	_	I-Premise
254	(	_	_	I-Premise
255	-	_	_	I-Premise
256	5.6	_	_	I-Premise
257	±	_	_	I-Premise
258	2.7	_	_	I-Premise
259	mmHg	_	_	I-Premise
260	;	_	_	I-Premise
261	p	_	_	I-Premise
262	<	_	_	I-Premise
263	0.001	_	_	I-Premise
264	)	_	_	I-Premise
265	,	_	_	I-Premise
266	increased	_	_	I-Premise
267	NOx	_	_	I-Premise
268	(	_	_	I-Premise
269	+	_	_	I-Premise
270	1.85	_	_	I-Premise
271	±	_	_	I-Premise
272	2.13	_	_	I-Premise
273	µmol/L	_	_	I-Premise
274	;	_	_	I-Premise
275	p	_	_	I-Premise
276	<	_	_	I-Premise
277	0.03	_	_	I-Premise
278	)	_	_	I-Premise
279	,	_	_	I-Premise
280	and	_	_	I-Premise
281	produced	_	_	I-Premise
282	a	_	_	I-Premise
283	mean	_	_	I-Premise
284	percent	_	_	I-Premise
285	end-difference	_	_	I-Premise
286	of	_	_	I-Premise
287	-	_	_	I-Premise
288	12.3	_	_	I-Premise
289	±	_	_	I-Premise
290	3.9	_	_	I-Premise
291	%	_	_	I-Premise
292	in	_	_	I-Premise
293	LDL-C	_	_	I-Premise
294	and	_	_	I-Premise
295	-	_	_	I-Premise
296	13.9	_	_	I-Premise
297	±	_	_	I-Premise
298	5.8	_	_	I-Premise
299	%	_	_	I-Premise
300	in	_	_	I-Premise
301	LDL-C/HDL	_	_	I-Premise
302	.	_	_	I-Premise

303	The	_	_	O
304	safety	_	_	O
305	profiles	_	_	O
306	were	_	_	O
307	unaffected	_	_	O
308	.	_	_	O

309	AG	_	_	B-Claim
310	extract	_	_	I-Claim
311	added	_	_	I-Claim
312	to	_	_	I-Claim
313	conventional	_	_	I-Claim
314	treatment	_	_	I-Claim
315	provided	_	_	I-Claim
316	an	_	_	I-Claim
317	effective	_	_	I-Claim
318	and	_	_	I-Claim
319	safe	_	_	I-Claim
320	adjunct	_	_	I-Claim
321	in	_	_	I-Claim
322	the	_	_	I-Claim
323	management	_	_	I-Claim
324	of	_	_	I-Claim
325	T2DM	_	_	I-Claim
326	.	_	_	I-Claim

327	Larger	_	_	B-Claim
328	studies	_	_	I-Claim
329	using	_	_	I-Claim
330	physiologically	_	_	I-Claim
331	standardized	_	_	I-Claim
332	ginseng	_	_	I-Claim
333	preparations	_	_	I-Claim
334	are	_	_	I-Claim
335	warranted	_	_	I-Claim
336	to	_	_	I-Claim
337	substantiate	_	_	I-Claim
338	the	_	_	I-Claim
339	present	_	_	I-Claim
340	findings	_	_	I-Claim
341	and	_	_	I-Claim
342	to	_	_	I-Claim
343	demonstrate	_	_	I-Claim
344	therapeutic	_	_	I-Claim
345	effectiveness	_	_	I-Claim
346	of	_	_	I-Claim
347	AG	_	_	I-Claim
348	.	_	_	I-Claim


0	We	_	_	O
1	investigated	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	high-Ca	_	_	O
6	fat-free	_	_	O
7	milk	_	_	O
8	phase	_	_	O
9	(	_	_	O
10	MD	_	_	O
11	)	_	_	O
12	(	_	_	O
13	prescription	_	_	O
14	of	_	_	O
15	approximately	_	_	O
16	1500	_	_	O
17	mg	_	_	O
18	of	_	_	O
19	Ca/d	_	_	O
20	)	_	_	O
21	v.	_	_	O
22	low-Ca	_	_	O
23	phase	_	_	O
24	(	_	_	O
25	CD	_	_	O
26	)	_	_	O
27	(	_	_	O
28	prescription	_	_	O
29	of	_	_	O
30	approximately	_	_	O
31	800	_	_	O
32	mg	_	_	O
33	of	_	_	O
34	Ca/d	_	_	O
35	)	_	_	O
36	in	_	_	O
37	an	_	_	O
38	energy-restricted	_	_	O
39	diet	_	_	O
40	on	_	_	O
41	the	_	_	O
42	metabolic	_	_	O
43	syndrome	_	_	O
44	(	_	_	O
45	MetS	_	_	O
46	)	_	_	O
47	and	_	_	O
48	cardiometabolic	_	_	O
49	measures	_	_	O
50	in	_	_	O
51	individuals	_	_	O
52	with	_	_	O
53	type	_	_	O
54	2	_	_	O
55	diabetes	_	_	O
56	mellitus	_	_	O
57	(	_	_	O
58	T2DM	_	_	O
59	)	_	_	O
60	and	_	_	O
61	low	_	_	O
62	habitual	_	_	O
63	Ca	_	_	O
64	consumption	_	_	O
65	(	_	_	O
66	<	_	_	O
67	600	_	_	O
68	mg/d	_	_	O
69	)	_	_	O
70	.	_	_	O

71	In	_	_	O
72	this	_	_	O
73	randomised	_	_	O
74	cross-over	_	_	O
75	design	_	_	O
76	,	_	_	O
77	fourteen	_	_	O
78	adults	_	_	O
79	with	_	_	O
80	T2DM	_	_	O
81	(	_	_	O
82	49·5	_	_	O
83	(	_	_	O
84	sd	_	_	O
85	8·6	_	_	O
86	)	_	_	O
87	years	_	_	O
88	,	_	_	O
89	BMI	_	_	O
90	29·4	_	_	O
91	(	_	_	O
92	sd	_	_	O
93	4·5	_	_	O
94	)	_	_	O
95	kg/m2	_	_	O
96	)	_	_	O
97	consumed	_	_	O
98	either	_	_	O
99	MD	_	_	O
100	or	_	_	O
101	CD	_	_	O
102	for	_	_	O
103	12	_	_	O
104	weeks	_	_	O
105	,	_	_	O
106	with	_	_	O
107	a	_	_	O
108	washout	_	_	O
109	of	_	_	O
110	18	_	_	O
111	weeks	_	_	O
112	between	_	_	O
113	phases	_	_	O
114	.	_	_	O

115	A	_	_	O
116	breakfast	_	_	O
117	shake	_	_	O
118	containing	_	_	O
119	700	_	_	O
120	mg	_	_	O
121	(	_	_	O
122	MD	_	_	O
123	)	_	_	O
124	or	_	_	O
125	6·4	_	_	O
126	mg	_	_	O
127	(	_	_	O
128	CD	_	_	O
129	)	_	_	O
130	of	_	_	O
131	Ca	_	_	O
132	was	_	_	O
133	consumed	_	_	O
134	in	_	_	O
135	the	_	_	O
136	laboratory	_	_	O
137	.	_	_	O

138	In	_	_	O
139	addition	_	_	O
140	,	_	_	O
141	energy-restricted	_	_	O
142	diets	_	_	O
143	were	_	_	O
144	prescribed	_	_	O
145	(	_	_	O
146	800	_	_	O
147	mg	_	_	O
148	of	_	_	O
149	dietary	_	_	O
150	Ca/d	_	_	O
151	)	_	_	O
152	.	_	_	O

153	Waist	_	_	O
154	circumference	_	_	O
155	(	_	_	O
156	WC	_	_	O
157	)	_	_	O
158	,	_	_	O
159	fasting	_	_	O
160	glucose	_	_	O
161	,	_	_	O
162	fasting	_	_	O
163	TAG	_	_	O
164	,	_	_	O
165	systolic	_	_	O
166	(	_	_	O
167	SBP	_	_	O
168	)	_	_	O
169	and	_	_	O
170	diastolic	_	_	O
171	blood	_	_	O
172	pressure	_	_	O
173	(	_	_	O
174	DBP	_	_	O
175	)	_	_	O
176	,	_	_	O
177	fasting	_	_	O
178	total	_	_	O
179	cholesterol	_	_	O
180	,	_	_	O
181	fasting	_	_	O
182	LDL-cholesterol	_	_	O
183	,	_	_	O
184	fasting	_	_	O
185	HDL-cholesterol	_	_	O
186	,	_	_	O
187	HDL	_	_	O
188	:	_	_	O
189	LDL	_	_	O
190	ratio	_	_	O
191	,	_	_	O
192	HDL	_	_	O
193	:	_	_	O
194	TAG	_	_	O
195	ratio	_	_	O
196	and	_	_	O
197	lipid	_	_	O
198	accumulation	_	_	O
199	product	_	_	O
200	(	_	_	O
201	LAP	_	_	O
202	)	_	_	O
203	index	_	_	O
204	were	_	_	O
205	assessed	_	_	O
206	at	_	_	O
207	baseline	_	_	O
208	and	_	_	O
209	after	_	_	O
210	each	_	_	O
211	phase	_	_	O
212	.	_	_	O

213	Ca	_	_	B-Premise
214	consumption	_	_	I-Premise
215	during	_	_	I-Premise
216	the	_	_	I-Premise
217	study	_	_	I-Premise
218	was	_	_	I-Premise
219	equivalent	_	_	I-Premise
220	to	_	_	I-Premise
221	1200	_	_	I-Premise
222	mg/d	_	_	I-Premise
223	during	_	_	I-Premise
224	MD	_	_	I-Premise
225	and	_	_	I-Premise
226	525	_	_	I-Premise
227	mg/d	_	_	I-Premise
228	during	_	_	I-Premise
229	CD	_	_	I-Premise
230	.	_	_	I-Premise

231	There	_	_	B-Premise
232	was	_	_	I-Premise
233	a	_	_	I-Premise
234	greater	_	_	I-Premise
235	reduction	_	_	I-Premise
236	in	_	_	I-Premise
237	WC	_	_	I-Premise
238	,	_	_	I-Premise
239	SBP	_	_	I-Premise
240	,	_	_	I-Premise
241	DBP	_	_	I-Premise
242	and	_	_	I-Premise
243	LAP	_	_	I-Premise
244	index	_	_	I-Premise
245	after	_	_	I-Premise
246	MD	_	_	I-Premise
247	compared	_	_	I-Premise
248	with	_	_	I-Premise
249	CD	_	_	I-Premise
250	.	_	_	I-Premise

251	HDL	_	_	B-Premise
252	:	_	_	I-Premise
253	LDL	_	_	I-Premise
254	ratio	_	_	I-Premise
255	increased	_	_	I-Premise
256	and	_	_	I-Premise
257	total	_	_	I-Premise
258	cholesterol	_	_	I-Premise
259	,	_	_	I-Premise
260	LDL-cholesterol	_	_	I-Premise
261	,	_	_	I-Premise
262	SBP	_	_	I-Premise
263	,	_	_	I-Premise
264	DBP	_	_	I-Premise
265	and	_	_	I-Premise
266	LAP	_	_	I-Premise
267	index	_	_	I-Premise
268	decreased	_	_	I-Premise
269	only	_	_	I-Premise
270	in	_	_	I-Premise
271	MD	_	_	I-Premise
272	.	_	_	I-Premise

273	The	_	_	B-Premise
274	consumption	_	_	I-Premise
275	of	_	_	I-Premise
276	approximately	_	_	I-Premise
277	1200	_	_	I-Premise
278	mg	_	_	I-Premise
279	of	_	_	I-Premise
280	Ca/d	_	_	I-Premise
281	(	_	_	I-Premise
282	700	_	_	I-Premise
283	mg	_	_	I-Premise
284	from	_	_	I-Premise
285	fat-free	_	_	I-Premise
286	milk+500mg	_	_	I-Premise
287	from	_	_	I-Premise
288	other	_	_	I-Premise
289	dietary	_	_	I-Premise
290	sources	_	_	I-Premise
291	)	_	_	I-Premise
292	associated	_	_	I-Premise
293	with	_	_	I-Premise
294	an	_	_	I-Premise
295	energy-restricted	_	_	I-Premise
296	diet	_	_	I-Premise
297	decreased	_	_	I-Premise
298	some	_	_	I-Premise
299	of	_	_	I-Premise
300	the	_	_	I-Premise
301	MetS	_	_	I-Premise
302	components	_	_	I-Premise
303	and	_	_	I-Premise
304	cardiometabolic	_	_	I-Premise
305	measures	_	_	I-Premise
306	in	_	_	I-Premise
307	adults	_	_	I-Premise
308	with	_	_	I-Premise
309	T2DM	_	_	I-Premise
310	.	_	_	I-Premise


0	Observational	_	_	B-Claim
1	data	_	_	I-Claim
2	support	_	_	I-Claim
3	a	_	_	I-Claim
4	role	_	_	I-Claim
5	for	_	_	I-Claim
6	vitamin	_	_	I-Claim
7	D	_	_	I-Claim
8	in	_	_	I-Claim
9	type	_	_	I-Claim
10	2	_	_	I-Claim
11	diabetes	_	_	I-Claim
12	,	_	_	I-Claim
13	but	_	_	B-Claim
14	evidence	_	_	I-Claim
15	from	_	_	I-Claim
16	trials	_	_	I-Claim
17	is	_	_	I-Claim
18	inconclusive	_	_	I-Claim
19	.	_	_	I-Claim

20	To	_	_	O
21	evaluate	_	_	O
22	the	_	_	O
23	effect	_	_	O
24	of	_	_	O
25	vitamin	_	_	O
26	D	_	_	O
27	supplementation	_	_	O
28	on	_	_	O
29	β-cell	_	_	O
30	function	_	_	O
31	and	_	_	O
32	hemoglobin	_	_	O
33	A1c	_	_	O
34	(	_	_	O
35	HbA1c	_	_	O
36	)	_	_	O
37	in	_	_	O
38	patients	_	_	O
39	with	_	_	O
40	well-controlled	_	_	O
41	type	_	_	O
42	2	_	_	O
43	diabetes	_	_	O
44	.	_	_	O

45	Double-blind	_	_	O
46	,	_	_	O
47	randomized	_	_	O
48	,	_	_	O
49	placebo-controlled	_	_	O
50	clinical	_	_	O
51	trial	_	_	O
52	.	_	_	O

53	Tufts	_	_	O
54	Medical	_	_	O
55	Center	_	_	O
56	,	_	_	O
57	Boston	_	_	O
58	,	_	_	O
59	MA	_	_	O
60	;	_	_	O
61	VA	_	_	O
62	Medical	_	_	O
63	Center	_	_	O
64	,	_	_	O
65	Cincinnati	_	_	O
66	,	_	_	O
67	OH	_	_	O
68	.	_	_	O

69	A	_	_	O
70	total	_	_	O
71	of	_	_	O
72	127	_	_	O
73	patients	_	_	O
74	(	_	_	O
75	mean	_	_	O
76	age	_	_	O
77	,	_	_	O
78	60	_	_	O
79	years	_	_	O
80	)	_	_	O
81	with	_	_	O
82	stable	_	_	O
83	(	_	_	O
84	HbA1c	_	_	O
85	≤7.5	_	_	O
86	%	_	_	O
87	)	_	_	O
88	diabetes	_	_	O
89	managed	_	_	O
90	with	_	_	O
91	lifestyle	_	_	O
92	only	_	_	O
93	or	_	_	O
94	lifestyle	_	_	O
95	plus	_	_	O
96	metformin	_	_	O
97	.	_	_	O

98	Subjects	_	_	O
99	were	_	_	O
100	given	_	_	O
101	4000	_	_	O
102	units	_	_	O
103	of	_	_	O
104	vitamin	_	_	O
105	D3	_	_	O
106	(	_	_	O
107	cholecalciferol	_	_	O
108	)	_	_	O
109	daily	_	_	O
110	or	_	_	O
111	placebo	_	_	O
112	for	_	_	O
113	48	_	_	O
114	weeks	_	_	O
115	.	_	_	O

116	Insulin	_	_	O
117	secretion	_	_	O
118	rate	_	_	O
119	(	_	_	O
120	ISR	_	_	O
121	)	_	_	O
122	was	_	_	O
123	estimated	_	_	O
124	from	_	_	O
125	peripheral	_	_	O
126	plasma	_	_	O
127	C-peptide	_	_	O
128	levels	_	_	O
129	after	_	_	O
130	a	_	_	O
131	3-hour	_	_	O
132	75-g	_	_	O
133	oral	_	_	O
134	glucose	_	_	O
135	tolerance	_	_	O
136	test	_	_	O
137	done	_	_	O
138	at	_	_	O
139	baseline	_	_	O
140	and	_	_	O
141	week	_	_	O
142	24	_	_	O
143	.	_	_	O

144	Changes	_	_	O
145	in	_	_	O
146	HbA1c	_	_	O
147	were	_	_	O
148	assessed	_	_	O
149	at	_	_	O
150	16	_	_	O
151	,	_	_	O
152	24	_	_	O
153	,	_	_	O
154	36	_	_	O
155	,	_	_	O
156	and	_	_	O
157	48	_	_	O
158	weeks	_	_	O
159	.	_	_	O

160	Baseline	_	_	O
161	mean	_	_	O
162	plasma	_	_	O
163	25-hydroxyvitamin	_	_	O
164	D	_	_	O
165	[	_	_	O
166	25	_	_	O
167	(	_	_	O
168	OH	_	_	O
169	)	_	_	O
170	D	_	_	O
171	]	_	_	O
172	concentration	_	_	O
173	was	_	_	O
174	26.6	_	_	O
175	ng/mL	_	_	O
176	,	_	_	O
177	mean	_	_	O
178	HbA1c	_	_	O
179	was	_	_	O
180	6.6	_	_	O
181	%	_	_	O
182	,	_	_	O
183	and	_	_	O
184	78	_	_	O
185	%	_	_	O
186	of	_	_	O
187	patients	_	_	O
188	were	_	_	O
189	on	_	_	O
190	metformin	_	_	O
191	.	_	_	O

192	At	_	_	B-Premise
193	week	_	_	I-Premise
194	24	_	_	I-Premise
195	,	_	_	I-Premise
196	mean	_	_	I-Premise
197	25	_	_	I-Premise
198	(	_	_	I-Premise
199	OH	_	_	I-Premise
200	)	_	_	I-Premise
201	D	_	_	I-Premise
202	changed	_	_	I-Premise
203	by	_	_	I-Premise
204	20.5	_	_	I-Premise
205	and	_	_	I-Premise
206	-1.6	_	_	I-Premise
207	ng/mL	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	vitamin	_	_	I-Premise
211	D	_	_	I-Premise
212	and	_	_	I-Premise
213	placebo	_	_	I-Premise
214	groups	_	_	I-Premise
215	,	_	_	I-Premise
216	respectively	_	_	I-Premise
217	(	_	_	I-Premise
218	P	_	_	I-Premise
219	<	_	_	I-Premise
220	0.001	_	_	I-Premise
221	)	_	_	I-Premise
222	.	_	_	I-Premise

223	The	_	_	B-Premise
224	vitamin	_	_	I-Premise
225	D	_	_	I-Premise
226	and	_	_	I-Premise
227	placebo	_	_	I-Premise
228	groups	_	_	I-Premise
229	did	_	_	I-Premise
230	not	_	_	I-Premise
231	differ	_	_	I-Premise
232	in	_	_	I-Premise
233	change	_	_	I-Premise
234	in	_	_	I-Premise
235	ISR	_	_	I-Premise
236	or	_	_	I-Premise
237	HbA1c	_	_	I-Premise
238	.	_	_	I-Premise

239	Among	_	_	B-Premise
240	patients	_	_	I-Premise
241	treated	_	_	I-Premise
242	with	_	_	I-Premise
243	lifestyle	_	_	I-Premise
244	only	_	_	I-Premise
245	(	_	_	I-Premise
246	n	_	_	I-Premise
247	=	_	_	I-Premise
248	28	_	_	I-Premise
249	)	_	_	I-Premise
250	,	_	_	I-Premise
251	vitamin	_	_	I-Premise
252	D	_	_	I-Premise
253	supplementation	_	_	I-Premise
254	reduced	_	_	I-Premise
255	HbA1c	_	_	I-Premise
256	compared	_	_	I-Premise
257	with	_	_	I-Premise
258	placebo	_	_	I-Premise
259	(	_	_	I-Premise
260	-0.1	_	_	I-Premise
261	%	_	_	I-Premise
262	vs	_	_	I-Premise
263	0.3	_	_	I-Premise
264	%	_	_	I-Premise
265	,	_	_	I-Premise
266	respectively	_	_	I-Premise
267	;	_	_	I-Premise
268	P	_	_	I-Premise
269	=	_	_	I-Premise
270	0.034	_	_	I-Premise
271	)	_	_	I-Premise
272	at	_	_	I-Premise
273	week	_	_	I-Premise
274	24	_	_	I-Premise
275	.	_	_	I-Premise

276	This	_	_	O
277	result	_	_	O
278	was	_	_	O
279	not	_	_	O
280	observed	_	_	O
281	at	_	_	O
282	the	_	_	O
283	other	_	_	O
284	time	_	_	O
285	points	_	_	O
286	and	_	_	O
287	could	_	_	O
288	be	_	_	O
289	due	_	_	O
290	to	_	_	O
291	chance	_	_	O
292	.	_	_	O

293	Vitamin	_	_	B-Premise
294	D3	_	_	I-Premise
295	at	_	_	I-Premise
296	4000	_	_	I-Premise
297	IU/d	_	_	I-Premise
298	did	_	_	I-Premise
299	not	_	_	I-Premise
300	change	_	_	I-Premise
301	ISR	_	_	I-Premise
302	or	_	_	I-Premise
303	HbA1c	_	_	I-Premise
304	in	_	_	I-Premise
305	patients	_	_	I-Premise
306	with	_	_	I-Premise
307	well-controlled	_	_	I-Premise
308	type	_	_	I-Premise
309	2	_	_	I-Premise
310	diabetes	_	_	I-Premise
311	on	_	_	I-Premise
312	metformin	_	_	I-Premise
313	not	_	_	I-Premise
314	selected	_	_	I-Premise
315	for	_	_	I-Premise
316	vitamin	_	_	I-Premise
317	D	_	_	I-Premise
318	deficiency	_	_	I-Premise
319	.	_	_	I-Premise


0	To	_	_	O
1	determine	_	_	O
2	predictors	_	_	O
3	of	_	_	O
4	serious	_	_	O
5	adverse	_	_	O
6	events	_	_	O
7	(	_	_	O
8	SAEs	_	_	O
9	)	_	_	O
10	involving	_	_	O
11	syncope	_	_	O
12	,	_	_	O
13	hypotension	_	_	O
14	,	_	_	O
15	and	_	_	O
16	falls	_	_	O
17	,	_	_	O
18	with	_	_	O
19	particular	_	_	O
20	attention	_	_	O
21	to	_	_	O
22	age	_	_	O
23	,	_	_	O
24	in	_	_	O
25	the	_	_	O
26	Systolic	_	_	O
27	Blood	_	_	O
28	Pressure	_	_	O
29	Intervention	_	_	O
30	Trial	_	_	O
31	.	_	_	O

32	Academic	_	_	O
33	and	_	_	O
34	private	_	_	O
35	practices	_	_	O
36	across	_	_	O
37	the	_	_	O
38	United	_	_	O
39	States	_	_	O
40	(	_	_	O
41	N	_	_	O
42	=	_	_	O
43	102	_	_	O
44	)	_	_	O
45	.	_	_	O

46	Adults	_	_	O
47	aged	_	_	O
48	50	_	_	O
49	and	_	_	O
50	older	_	_	O
51	with	_	_	O
52	a	_	_	O
53	systolic	_	_	O
54	blood	_	_	O
55	pressure	_	_	O
56	(	_	_	O
57	SBP	_	_	O
58	)	_	_	O
59	of	_	_	O
60	130	_	_	O
61	to	_	_	O
62	180	_	_	O
63	mmHg	_	_	O
64	at	_	_	O
65	high	_	_	O
66	risk	_	_	O
67	of	_	_	O
68	cardiovascular	_	_	O
69	disease	_	_	O
70	events	_	_	O
71	,	_	_	O
72	but	_	_	O
73	without	_	_	O
74	diabetes	_	_	O
75	,	_	_	O
76	history	_	_	O
77	of	_	_	O
78	stroke	_	_	O
79	,	_	_	O
80	symptomatic	_	_	O
81	heart	_	_	O
82	failure	_	_	O
83	or	_	_	O
84	ejection	_	_	O
85	fraction	_	_	O
86	less	_	_	O
87	than	_	_	O
88	35	_	_	O
89	%	_	_	O
90	,	_	_	O
91	dementia	_	_	O
92	,	_	_	O
93	or	_	_	O
94	standing	_	_	O
95	SBP	_	_	O
96	less	_	_	O
97	than	_	_	O
98	110	_	_	O
99	mmHg	_	_	O
100	(	_	_	O
101	N	_	_	O
102	=	_	_	O
103	9,361	_	_	O
104	)	_	_	O
105	.	_	_	O

106	Treatment	_	_	O
107	of	_	_	O
108	SBP	_	_	O
109	to	_	_	O
110	a	_	_	O
111	goal	_	_	O
112	of	_	_	O
113	less	_	_	O
114	than	_	_	O
115	120	_	_	O
116	mmHg	_	_	O
117	or	_	_	O
118	140	_	_	O
119	mmHg	_	_	O
120	.	_	_	O

121	Outcomes	_	_	O
122	were	_	_	O
123	SAEs	_	_	O
124	involving	_	_	O
125	syncope	_	_	O
126	,	_	_	O
127	hypotension	_	_	O
128	,	_	_	O
129	and	_	_	O
130	falls	_	_	O
131	.	_	_	O

132	Predictors	_	_	O
133	were	_	_	O
134	treatment	_	_	O
135	assignment	_	_	O
136	,	_	_	O
137	demographic	_	_	O
138	characteristics	_	_	O
139	,	_	_	O
140	comorbidities	_	_	O
141	,	_	_	O
142	baseline	_	_	O
143	measurements	_	_	O
144	,	_	_	O
145	and	_	_	O
146	baseline	_	_	O
147	use	_	_	O
148	of	_	_	O
149	cardiovascular	_	_	O
150	medications	_	_	O
151	.	_	_	O

152	One	_	_	O
153	hundred	_	_	O
154	seventy-two	_	_	O
155	(	_	_	O
156	1.8	_	_	O
157	%	_	_	O
158	)	_	_	O
159	participants	_	_	O
160	had	_	_	O
161	SAEs	_	_	O
162	involving	_	_	O
163	syncope	_	_	O
164	,	_	_	O
165	155	_	_	O
166	(	_	_	O
167	1.6	_	_	O
168	%	_	_	O
169	)	_	_	O
170	hypotension	_	_	O
171	,	_	_	O
172	and	_	_	O
173	203	_	_	O
174	(	_	_	O
175	2.2	_	_	O
176	%	_	_	O
177	)	_	_	O
178	falls	_	_	O
179	.	_	_	O

180	Randomization	_	_	B-Premise
181	to	_	_	I-Premise
182	intensive	_	_	I-Premise
183	SBP	_	_	I-Premise
184	control	_	_	I-Premise
185	was	_	_	I-Premise
186	associated	_	_	I-Premise
187	with	_	_	I-Premise
188	greater	_	_	I-Premise
189	risk	_	_	I-Premise
190	of	_	_	I-Premise
191	an	_	_	I-Premise
192	SAE	_	_	I-Premise
193	involving	_	_	I-Premise
194	hypotension	_	_	I-Premise
195	(	_	_	I-Premise
196	hazard	_	_	I-Premise
197	ratio	_	_	I-Premise
198	(	_	_	I-Premise
199	HR	_	_	I-Premise
200	)	_	_	I-Premise
201	=	_	_	I-Premise
202	1.67	_	_	I-Premise
203	,	_	_	I-Premise
204	95	_	_	I-Premise
205	%	_	_	I-Premise
206	confidence	_	_	I-Premise
207	interval	_	_	I-Premise
208	(	_	_	I-Premise
209	CI	_	_	I-Premise
210	)	_	_	I-Premise
211	=	_	_	I-Premise
212	1.21-2.32	_	_	I-Premise
213	,	_	_	I-Premise
214	P	_	_	I-Premise
215	=	_	_	I-Premise
216	.002	_	_	I-Premise
217	)	_	_	I-Premise
218	,	_	_	I-Premise
219	and	_	_	I-Premise
220	possibly	_	_	I-Premise
221	syncope	_	_	I-Premise
222	(	_	_	I-Premise
223	HR	_	_	I-Premise
224	=	_	_	I-Premise
225	1.32	_	_	I-Premise
226	,	_	_	I-Premise
227	95	_	_	I-Premise
228	%	_	_	I-Premise
229	CI	_	_	I-Premise
230	=	_	_	I-Premise
231	0.98-1.79	_	_	I-Premise
232	,	_	_	I-Premise
233	P	_	_	I-Premise
234	=	_	_	I-Premise
235	.07	_	_	I-Premise
236	)	_	_	I-Premise
237	,	_	_	I-Premise
238	but	_	_	I-Premise
239	not	_	_	I-Premise
240	falls	_	_	I-Premise
241	(	_	_	I-Premise
242	HR	_	_	I-Premise
243	=	_	_	I-Premise
244	0.98	_	_	I-Premise
245	,	_	_	I-Premise
246	95	_	_	I-Premise
247	%	_	_	I-Premise
248	CI	_	_	I-Premise
249	=	_	_	I-Premise
250	0.75-1.29	_	_	I-Premise
251	,	_	_	I-Premise
252	P	_	_	I-Premise
253	=	_	_	I-Premise
254	.90	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	Risk	_	_	B-Premise
258	of	_	_	I-Premise
259	all	_	_	I-Premise
260	three	_	_	I-Premise
261	outcomes	_	_	I-Premise
262	was	_	_	I-Premise
263	higher	_	_	I-Premise
264	for	_	_	I-Premise
265	participants	_	_	I-Premise
266	with	_	_	I-Premise
267	chronic	_	_	I-Premise
268	kidney	_	_	I-Premise
269	disease	_	_	I-Premise
270	or	_	_	I-Premise
271	frailty	_	_	I-Premise
272	.	_	_	I-Premise

273	Older	_	_	B-Premise
274	age	_	_	I-Premise
275	was	_	_	I-Premise
276	also	_	_	I-Premise
277	associated	_	_	I-Premise
278	with	_	_	I-Premise
279	greater	_	_	I-Premise
280	risk	_	_	I-Premise
281	of	_	_	I-Premise
282	syncope	_	_	I-Premise
283	,	_	_	I-Premise
284	hypotension	_	_	I-Premise
285	,	_	_	I-Premise
286	and	_	_	I-Premise
287	falls	_	_	I-Premise
288	,	_	_	I-Premise
289	but	_	_	I-Premise
290	there	_	_	I-Premise
291	was	_	_	I-Premise
292	no	_	_	I-Premise
293	age-by-treatment	_	_	I-Premise
294	interaction	_	_	I-Premise
295	for	_	_	I-Premise
296	any	_	_	I-Premise
297	of	_	_	I-Premise
298	the	_	_	I-Premise
299	SAE	_	_	I-Premise
300	outcomes	_	_	I-Premise
301	.	_	_	I-Premise

302	Participants	_	_	B-Claim
303	randomized	_	_	I-Claim
304	to	_	_	I-Claim
305	intensive	_	_	I-Claim
306	SBP	_	_	I-Claim
307	control	_	_	I-Claim
308	had	_	_	I-Claim
309	greater	_	_	I-Claim
310	risk	_	_	I-Claim
311	of	_	_	I-Claim
312	hypotension	_	_	I-Claim
313	and	_	_	I-Claim
314	possibly	_	_	I-Claim
315	syncope	_	_	I-Claim
316	,	_	_	I-Claim
317	but	_	_	I-Claim
318	not	_	_	I-Claim
319	falls	_	_	I-Claim
320	.	_	_	I-Claim

321	The	_	_	O
322	greater	_	_	O
323	risk	_	_	O
324	of	_	_	O
325	developing	_	_	O
326	these	_	_	O
327	events	_	_	O
328	associated	_	_	O
329	with	_	_	O
330	intensive	_	_	O
331	treatment	_	_	O
332	did	_	_	O
333	not	_	_	O
334	vary	_	_	O
335	according	_	_	O
336	to	_	_	O
337	age	_	_	O
338	.	_	_	O


0	Multiple	_	_	B-Claim
1	studies	_	_	I-Claim
2	have	_	_	I-Claim
3	evaluated	_	_	I-Claim
4	the	_	_	I-Claim
5	hypoglycemic	_	_	I-Claim
6	effect	_	_	I-Claim
7	of	_	_	I-Claim
8	cinnamon	_	_	I-Claim
9	in	_	_	I-Claim
10	patients	_	_	I-Claim
11	with	_	_	I-Claim
12	diabetes	_	_	I-Claim
13	mellitus	_	_	I-Claim
14	(	_	_	I-Claim
15	DM	_	_	I-Claim
16	)	_	_	I-Claim
17	type	_	_	I-Claim
18	II	_	_	I-Claim
19	,	_	_	I-Claim
20	with	_	_	I-Claim
21	conflicting	_	_	I-Claim
22	results	_	_	I-Claim
23	.	_	_	I-Claim

24	Differences	_	_	O
25	in	_	_	O
26	Baseline	_	_	O
27	Body	_	_	O
28	Mass	_	_	O
29	Index	_	_	O
30	(	_	_	O
31	BMI	_	_	O
32	)	_	_	O
33	of	_	_	O
34	patients	_	_	O
35	may	_	_	O
36	be	_	_	O
37	able	_	_	O
38	to	_	_	O
39	explain	_	_	O
40	the	_	_	O
41	observed	_	_	O
42	differences	_	_	O
43	in	_	_	O
44	the	_	_	O
45	results	_	_	O
46	.	_	_	O

47	This	_	_	O
48	study	_	_	O
49	was	_	_	O
50	designed	_	_	O
51	to	_	_	O
52	evaluate	_	_	O
53	the	_	_	O
54	effect	_	_	O
55	of	_	_	O
56	cinnamon	_	_	O
57	supplementation	_	_	O
58	on	_	_	O
59	anthropometric	_	_	O
60	,	_	_	O
61	glycemic	_	_	O
62	and	_	_	O
63	lipid	_	_	O
64	outcomes	_	_	O
65	of	_	_	O
66	patients	_	_	O
67	with	_	_	O
68	DM	_	_	O
69	type	_	_	O
70	II	_	_	O
71	based	_	_	O
72	on	_	_	O
73	their	_	_	O
74	baseline	_	_	O
75	BMI	_	_	O
76	.	_	_	O

77	The	_	_	O
78	study	_	_	O
79	was	_	_	O
80	designed	_	_	O
81	as	_	_	O
82	a	_	_	O
83	triple-blind	_	_	O
84	placebo-controlled	_	_	O
85	randomized	_	_	O
86	clinical	_	_	O
87	trial	_	_	O
88	,	_	_	O
89	using	_	_	O
90	a	_	_	O
91	parallel	_	_	O
92	design	_	_	O
93	.	_	_	O

94	One	_	_	O
95	hundred	_	_	O
96	and	_	_	O
97	forty	_	_	O
98	patients	_	_	O
99	referred	_	_	O
100	to	_	_	O
101	Diabetes	_	_	O
102	Clinic	_	_	O
103	of	_	_	O
104	Yazd	_	_	O
105	University	_	_	O
106	of	_	_	O
107	Medical	_	_	O
108	Sciences	_	_	O
109	with	_	_	O
110	diagnosis	_	_	O
111	of	_	_	O
112	DM	_	_	O
113	type	_	_	O
114	II	_	_	O
115	were	_	_	O
116	randomly	_	_	O
117	assigned	_	_	O
118	in	_	_	O
119	four	_	_	O
120	groups	_	_	O
121	:	_	_	O
122	cinnamon	_	_	O
123	(	_	_	O
124	BMI	_	_	O
125	≥	_	_	O
126	27	_	_	O
127	,	_	_	O
128	BMI	_	_	O
129	<	_	_	O
130	27	_	_	O
131	)	_	_	O
132	and	_	_	O
133	Placebo	_	_	O
134	(	_	_	O
135	BMI	_	_	O
136	≥	_	_	O
137	27	_	_	O
138	,	_	_	O
139	BMI	_	_	O
140	<	_	_	O
141	27	_	_	O
142	)	_	_	O
143	.	_	_	O

144	Patients	_	_	O
145	received	_	_	O
146	cinnamon	_	_	O
147	bark	_	_	O
148	powder	_	_	O
149	or	_	_	O
150	placebo	_	_	O
151	in	_	_	O
152	500	_	_	O
153	mg	_	_	O
154	capsules	_	_	O
155	twice	_	_	O
156	daily	_	_	O
157	for	_	_	O
158	3	_	_	O
159	months	_	_	O
160	.	_	_	O

161	Anthropometric	_	_	O
162	,	_	_	O
163	glycemic	_	_	O
164	and	_	_	O
165	lipid	_	_	O
166	outcomes	_	_	O
167	were	_	_	O
168	measured	_	_	O
169	before	_	_	O
170	and	_	_	O
171	after	_	_	O
172	the	_	_	O
173	intervention	_	_	O
174	.	_	_	O

175	Cinnamon	_	_	B-Premise
176	supplementation	_	_	I-Premise
177	led	_	_	I-Premise
178	to	_	_	I-Premise
179	improvement	_	_	I-Premise
180	of	_	_	I-Premise
181	all	_	_	I-Premise
182	anthropometric	_	_	I-Premise
183	(	_	_	I-Premise
184	BMI	_	_	I-Premise
185	,	_	_	I-Premise
186	body	_	_	I-Premise
187	fat	_	_	I-Premise
188	,	_	_	I-Premise
189	and	_	_	I-Premise
190	visceral	_	_	I-Premise
191	fat	_	_	I-Premise
192	)	_	_	I-Premise
193	,	_	_	I-Premise
194	glycemic	_	_	I-Premise
195	(	_	_	I-Premise
196	FPG	_	_	I-Premise
197	,	_	_	I-Premise
198	2hpp	_	_	I-Premise
199	,	_	_	I-Premise
200	HbA1C	_	_	I-Premise
201	,	_	_	I-Premise
202	Fasting	_	_	I-Premise
203	Insulin	_	_	I-Premise
204	,	_	_	I-Premise
205	and	_	_	I-Premise
206	Insulin	_	_	I-Premise
207	Resistance	_	_	I-Premise
208	)	_	_	I-Premise
209	,	_	_	I-Premise
210	and	_	_	I-Premise
211	lipids	_	_	I-Premise
212	(	_	_	I-Premise
213	Cholesterol	_	_	I-Premise
214	Total	_	_	I-Premise
215	,	_	_	I-Premise
216	LDL-c	_	_	I-Premise
217	and	_	_	I-Premise
218	HDL-c	_	_	I-Premise
219	)	_	_	I-Premise
220	outcomes	_	_	I-Premise
221	(	_	_	I-Premise
222	except	_	_	I-Premise
223	for	_	_	I-Premise
224	triglycerides	_	_	I-Premise
225	level	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	All	_	_	B-Premise
229	observed	_	_	I-Premise
230	changes	_	_	I-Premise
231	(	_	_	I-Premise
232	except	_	_	I-Premise
233	for	_	_	I-Premise
234	Cholesterol	_	_	I-Premise
235	Total	_	_	I-Premise
236	and	_	_	I-Premise
237	LDL-c	_	_	I-Premise
238	)	_	_	I-Premise
239	were	_	_	I-Premise
240	significantly	_	_	I-Premise
241	more	_	_	I-Premise
242	prominent	_	_	I-Premise
243	in	_	_	I-Premise
244	patients	_	_	I-Premise
245	with	_	_	I-Premise
246	higher	_	_	I-Premise
247	baseline	_	_	I-Premise
248	BMI	_	_	I-Premise
249	(	_	_	I-Premise
250	BMI	_	_	I-Premise
251	≥	_	_	I-Premise
252	27	_	_	I-Premise
253	)	_	_	I-Premise
254	.	_	_	I-Premise

255	Based	_	_	B-Claim
256	on	_	_	I-Claim
257	the	_	_	I-Claim
258	study	_	_	I-Claim
259	findings	_	_	I-Claim
260	,	_	_	I-Claim
261	cinnamon	_	_	I-Claim
262	may	_	_	I-Claim
263	improve	_	_	I-Claim
264	anthropometric	_	_	I-Claim
265	parameters	_	_	I-Claim
266	,	_	_	I-Claim
267	glycemic	_	_	I-Claim
268	indices	_	_	I-Claim
269	and	_	_	I-Claim
270	lipid	_	_	I-Claim
271	profile	_	_	I-Claim
272	of	_	_	I-Claim
273	patients	_	_	I-Claim
274	with	_	_	I-Claim
275	type	_	_	I-Claim
276	II	_	_	I-Claim
277	diabetes	_	_	I-Claim
278	.	_	_	I-Claim

279	These	_	_	B-Claim
280	benefits	_	_	I-Claim
281	are	_	_	I-Claim
282	significantly	_	_	I-Claim
283	more	_	_	I-Claim
284	prominent	_	_	I-Claim
285	in	_	_	I-Claim
286	patients	_	_	I-Claim
287	with	_	_	I-Claim
288	higher	_	_	I-Claim
289	baseline	_	_	I-Claim
290	BMI	_	_	I-Claim
291	(	_	_	I-Claim
292	BMI	_	_	I-Claim
293	≥	_	_	I-Claim
294	27	_	_	I-Claim
295	)	_	_	I-Claim
296	.	_	_	I-Claim


0	KAMUT	_	_	B-Claim
1	khorasan	_	_	I-Claim
2	is	_	_	I-Claim
3	an	_	_	I-Claim
4	ancient	_	_	I-Claim
5	grain	_	_	I-Claim
6	with	_	_	I-Claim
7	widely	_	_	I-Claim
8	acclaimed	_	_	I-Claim
9	health	_	_	I-Claim
10	benefits	_	_	I-Claim
11	.	_	_	I-Claim

12	The	_	_	O
13	aim	_	_	O
14	of	_	_	O
15	this	_	_	O
16	study	_	_	O
17	was	_	_	O
18	to	_	_	O
19	investigate	_	_	O
20	the	_	_	O
21	effects	_	_	O
22	of	_	_	O
23	a	_	_	O
24	replacement	_	_	O
25	diet	_	_	O
26	with	_	_	O
27	ancient	_	_	O
28	khorasan	_	_	O
29	wheat	_	_	O
30	products	_	_	O
31	in	_	_	O
32	patients	_	_	O
33	with	_	_	O
34	NAFLD	_	_	O
35	,	_	_	O
36	in	_	_	O
37	comparison	_	_	O
38	to	_	_	O
39	a	_	_	O
40	similar	_	_	O
41	replacement	_	_	O
42	diet	_	_	O
43	with	_	_	O
44	control	_	_	O
45	products	_	_	O
46	made	_	_	O
47	from	_	_	O
48	organic	_	_	O
49	semi-whole-grain	_	_	O
50	modern	_	_	O
51	wheat	_	_	O
52	.	_	_	O

53	Forty	_	_	O
54	NAFLD	_	_	O
55	patients	_	_	O
56	(	_	_	O
57	12	_	_	O
58	M/28	_	_	O
59	F	_	_	O
60	;	_	_	O
61	age	_	_	O
62	55.2	_	_	O
63	±	_	_	O
64	10.4	_	_	O
65	years	_	_	O
66	)	_	_	O
67	with	_	_	O
68	mild	_	_	O
69	to	_	_	O
70	moderate	_	_	O
71	liver	_	_	O
72	steatosis	_	_	O
73	were	_	_	O
74	included	_	_	O
75	.	_	_	O

76	The	_	_	O
77	experimental	_	_	O
78	design	_	_	O
79	was	_	_	O
80	a	_	_	O
81	randomized	_	_	O
82	,	_	_	O
83	double-blind	_	_	O
84	,	_	_	O
85	parallel-arm	_	_	O
86	study	_	_	O
87	with	_	_	O
88	20	_	_	O
89	participants	_	_	O
90	assigned	_	_	O
91	to	_	_	O
92	consume	_	_	O
93	either	_	_	O
94	KAMUT	_	_	O
95	khorasan	_	_	O
96	or	_	_	O
97	control	_	_	O
98	wheat	_	_	O
99	products	_	_	O
100	(	_	_	O
101	pasta	_	_	O
102	,	_	_	O
103	bread	_	_	O
104	,	_	_	O
105	crackers	_	_	O
106	,	_	_	O
107	biscuits	_	_	O
108	)	_	_	O
109	over	_	_	O
110	a	_	_	O
111	3-month	_	_	O
112	period	_	_	O
113	.	_	_	O

114	Anthropometric	_	_	O
115	measurements	_	_	O
116	,	_	_	O
117	blood	_	_	O
118	analyses	_	_	O
119	,	_	_	O
120	and	_	_	O
121	ultrasonography	_	_	O
122	examination	_	_	O
123	were	_	_	O
124	performed	_	_	O
125	at	_	_	O
126	both	_	_	O
127	the	_	_	O
128	beginning	_	_	O
129	and	_	_	O
130	end	_	_	O
131	of	_	_	O
132	each	_	_	O
133	dietary	_	_	O
134	intervention	_	_	O
135	.	_	_	O

136	After	_	_	B-Premise
137	the	_	_	I-Premise
138	implementation	_	_	I-Premise
139	of	_	_	I-Premise
140	a	_	_	I-Premise
141	general	_	_	I-Premise
142	linear	_	_	I-Premise
143	model	_	_	I-Premise
144	for	_	_	I-Premise
145	repeated	_	_	I-Premise
146	measurements	_	_	I-Premise
147	adjusted	_	_	I-Premise
148	for	_	_	I-Premise
149	baseline	_	_	I-Premise
150	demographic	_	_	I-Premise
151	details	_	_	I-Premise
152	,	_	_	I-Premise
153	risk	_	_	I-Premise
154	factors	_	_	I-Premise
155	,	_	_	I-Premise
156	and	_	_	I-Premise
157	medication	_	_	I-Premise
158	,	_	_	I-Premise
159	alanine	_	_	I-Premise
160	aminotransferase	_	_	I-Premise
161	(	_	_	I-Premise
162	ALT	_	_	I-Premise
163	)	_	_	I-Premise
164	was	_	_	I-Premise
165	significantly	_	_	I-Premise
166	reduced	_	_	I-Premise
167	by	_	_	I-Premise
168	12	_	_	I-Premise
169	%	_	_	I-Premise
170	,	_	_	I-Premise
171	aspartate	_	_	I-Premise
172	aminotransferase	_	_	I-Premise
173	(	_	_	I-Premise
174	AST	_	_	I-Premise
175	)	_	_	I-Premise
176	by	_	_	I-Premise
177	14	_	_	I-Premise
178	%	_	_	I-Premise
179	,	_	_	I-Premise
180	alkaline	_	_	I-Premise
181	phosphatase	_	_	I-Premise
182	(	_	_	I-Premise
183	ALP	_	_	I-Premise
184	)	_	_	I-Premise
185	by	_	_	I-Premise
186	8	_	_	I-Premise
187	%	_	_	I-Premise
188	,	_	_	I-Premise
189	and	_	_	I-Premise
190	cholesterol	_	_	I-Premise
191	by	_	_	I-Premise
192	6	_	_	I-Premise
193	%	_	_	I-Premise
194	only	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	khorasan	_	_	I-Premise
198	group	_	_	I-Premise
199	(	_	_	I-Premise
200	p	_	_	I-Premise
201	<	_	_	I-Premise
202	0.05	_	_	I-Premise
203	for	_	_	I-Premise
204	all	_	_	I-Premise
205	)	_	_	I-Premise
206	.	_	_	I-Premise

207	Similarly	_	_	O
208	,	_	_	O
209	significant	_	_	B-Premise
210	reductions	_	_	I-Premise
211	in	_	_	I-Premise
212	circulating	_	_	I-Premise
213	proinflammatory	_	_	I-Premise
214	tumor	_	_	I-Premise
215	necrosis	_	_	I-Premise
216	factor-alpha	_	_	I-Premise
217	by	_	_	I-Premise
218	50	_	_	I-Premise
219	%	_	_	I-Premise
220	,	_	_	I-Premise
221	interleukin	_	_	I-Premise
222	l-receptor	_	_	I-Premise
223	antagonist-alpha	_	_	I-Premise
224	by	_	_	I-Premise
225	37	_	_	I-Premise
226	%	_	_	I-Premise
227	,	_	_	I-Premise
228	interleukin-8	_	_	I-Premise
229	by	_	_	I-Premise
230	24	_	_	I-Premise
231	%	_	_	I-Premise
232	,	_	_	I-Premise
233	and	_	_	I-Premise
234	interferon	_	_	I-Premise
235	gamma	_	_	I-Premise
236	by	_	_	I-Premise
237	24	_	_	I-Premise
238	%	_	_	I-Premise
239	were	_	_	I-Premise
240	evident	_	_	I-Premise
241	only	_	_	I-Premise
242	in	_	_	I-Premise
243	participants	_	_	I-Premise
244	who	_	_	I-Premise
245	consumed	_	_	I-Premise
246	the	_	_	I-Premise
247	khorasan	_	_	I-Premise
248	products	_	_	I-Premise
249	(	_	_	I-Premise
250	p	_	_	I-Premise
251	<	_	_	I-Premise
252	0.05	_	_	I-Premise
253	for	_	_	I-Premise
254	all	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	Finally	_	_	O
258	,	_	_	O
259	significant	_	_	B-Premise
260	improvements	_	_	I-Premise
261	in	_	_	I-Premise
262	the	_	_	I-Premise
263	liver	_	_	I-Premise
264	steatosis	_	_	I-Premise
265	grading	_	_	I-Premise
266	,	_	_	I-Premise
267	Doppler	_	_	I-Premise
268	perfusion	_	_	I-Premise
269	index	_	_	I-Premise
270	values	_	_	I-Premise
271	,	_	_	I-Premise
272	and	_	_	I-Premise
273	reactive	_	_	I-Premise
274	oxygen	_	_	I-Premise
275	species	_	_	I-Premise
276	(	_	_	I-Premise
277	ROS	_	_	I-Premise
278	)	_	_	I-Premise
279	production	_	_	I-Premise
280	were	_	_	I-Premise
281	evident	_	_	I-Premise
282	after	_	_	I-Premise
283	consumption	_	_	I-Premise
284	of	_	_	I-Premise
285	both	_	_	I-Premise
286	the	_	_	I-Premise
287	khorasan	_	_	I-Premise
288	and	_	_	I-Premise
289	control	_	_	I-Premise
290	products	_	_	I-Premise
291	.	_	_	I-Premise

292	This	_	_	B-Claim
293	study	_	_	I-Claim
294	suggests	_	_	I-Claim
295	that	_	_	I-Claim
296	a	_	_	I-Claim
297	short-term	_	_	I-Claim
298	replacement	_	_	I-Claim
299	diet	_	_	I-Claim
300	with	_	_	I-Claim
301	ancient	_	_	I-Claim
302	KAMUT	_	_	I-Claim
303	khorasan	_	_	I-Claim
304	products	_	_	I-Claim
305	is	_	_	I-Claim
306	most	_	_	I-Claim
307	effective	_	_	I-Claim
308	in	_	_	I-Claim
309	reducing	_	_	I-Claim
310	metabolic	_	_	I-Claim
311	risk	_	_	I-Claim
312	factors	_	_	I-Claim
313	and	_	_	I-Claim
314	ameliorating	_	_	I-Claim
315	the	_	_	I-Claim
316	liver	_	_	I-Claim
317	profile	_	_	I-Claim
318	in	_	_	I-Claim
319	patients	_	_	I-Claim
320	with	_	_	I-Claim
321	NAFLD	_	_	I-Claim
322	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	review	_	_	O
5	is	_	_	O
6	to	_	_	O
7	correlate	_	_	O
8	predictions	_	_	O
9	based	_	_	O
10	on	_	_	O
11	pre-clinical	_	_	O
12	data	_	_	O
13	with	_	_	O
14	outcomes	_	_	O
15	from	_	_	O
16	clinical	_	_	O
17	trials	_	_	O
18	that	_	_	O
19	examine	_	_	O
20	the	_	_	O
21	effects	_	_	O
22	of	_	_	O
23	incretin-based	_	_	O
24	diabetes	_	_	O
25	treatments	_	_	O
26	on	_	_	O
27	the	_	_	O
28	kidney	_	_	O
29	.	_	_	O

30	The	_	_	O
31	incretin-based	_	_	O
32	treatments	_	_	O
33	include	_	_	O
34	agonists	_	_	O
35	of	_	_	O
36	the	_	_	O
37	glucagon-like	_	_	O
38	peptide	_	_	O
39	1	_	_	O
40	receptor	_	_	O
41	(	_	_	O
42	GLP-1R	_	_	O
43	)	_	_	O
44	and	_	_	O
45	inhibitors	_	_	O
46	of	_	_	O
47	the	_	_	O
48	enzyme	_	_	O
49	,	_	_	O
50	dipeptidyl	_	_	O
51	peptidase-4	_	_	O
52	(	_	_	O
53	DPP-4	_	_	O
54	)	_	_	O
55	.	_	_	O

56	In	_	_	O
57	addition	_	_	O
58	,	_	_	O
59	what	_	_	O
60	is	_	_	O
61	known	_	_	O
62	about	_	_	O
63	the	_	_	O
64	incretin-based	_	_	O
65	therapies	_	_	O
66	will	_	_	O
67	be	_	_	O
68	compared	_	_	O
69	to	_	_	O
70	what	_	_	O
71	is	_	_	O
72	known	_	_	O
73	about	_	_	O
74	the	_	_	O
75	renal	_	_	O
76	effects	_	_	O
77	of	_	_	O
78	SGLT2	_	_	O
79	inhibitors	_	_	O
80	.	_	_	O

81	Large-scale	_	_	O
82	clinical	_	_	O
83	trials	_	_	O
84	have	_	_	O
85	shown	_	_	O
86	that	_	_	O
87	SGLT2	_	_	O
88	inhibitors	_	_	O
89	reduce	_	_	O
90	albuminuria	_	_	O
91	and	_	_	O
92	preserve	_	_	O
93	estimated	_	_	O
94	glomerular	_	_	O
95	filtration	_	_	O
96	rate	_	_	O
97	(	_	_	O
98	eGFR	_	_	O
99	)	_	_	O
100	in	_	_	O
101	patients	_	_	O
102	with	_	_	O
103	diabetic	_	_	O
104	nephropathy	_	_	O
105	.	_	_	O

106	A	_	_	O
107	concise	_	_	O
108	and	_	_	O
109	plausible	_	_	O
110	hemodynamic	_	_	O
111	mechanism	_	_	O
112	is	_	_	O
113	supported	_	_	O
114	by	_	_	O
115	pre-clinical	_	_	O
116	research	_	_	O
117	on	_	_	O
118	the	_	_	O
119	physiology	_	_	O
120	and	_	_	O
121	pharmacology	_	_	O
122	of	_	_	O
123	SGLT2	_	_	O
124	.	_	_	O

125	Large-scale	_	_	B-Premise
126	clinical	_	_	I-Premise
127	trials	_	_	I-Premise
128	have	_	_	I-Premise
129	shown	_	_	I-Premise
130	that	_	_	I-Premise
131	incretin-based	_	_	I-Premise
132	therapies	_	_	I-Premise
133	mitigate	_	_	I-Premise
134	albuminuria	_	_	I-Premise
135	but	_	_	B-Premise
136	have	_	_	I-Premise
137	not	_	_	I-Premise
138	shown	_	_	I-Premise
139	beneficial	_	_	I-Premise
140	effects	_	_	I-Premise
141	on	_	_	I-Premise
142	eGFR	_	_	I-Premise
143	.	_	_	I-Premise

144	Research	_	_	B-Premise
145	on	_	_	I-Premise
146	the	_	_	I-Premise
147	incretin-based	_	_	I-Premise
148	therapies	_	_	I-Premise
149	has	_	_	I-Premise
150	yielded	_	_	I-Premise
151	a	_	_	I-Premise
152	diverse	_	_	I-Premise
153	array	_	_	I-Premise
154	of	_	_	I-Premise
155	direct	_	_	I-Premise
156	effects	_	_	I-Premise
157	throughout	_	_	I-Premise
158	the	_	_	I-Premise
159	body	_	_	I-Premise
160	,	_	_	I-Premise
161	which	_	_	I-Premise
162	fuels	_	_	I-Premise
163	speculation	_	_	I-Premise
164	as	_	_	I-Premise
165	to	_	_	I-Premise
166	how	_	_	I-Premise
167	these	_	_	I-Premise
168	drugs	_	_	I-Premise
169	might	_	_	I-Premise
170	benefit	_	_	I-Premise
171	the	_	_	I-Premise
172	diabetic	_	_	I-Premise
173	kidney	_	_	I-Premise
174	and	_	_	I-Premise
175	affect	_	_	I-Premise
176	its	_	_	I-Premise
177	function	_	_	I-Premise
178	(	_	_	I-Premise
179	s	_	_	I-Premise
180	)	_	_	I-Premise
181	.	_	_	I-Premise

182	But	_	_	B-Premise
183	in	_	_	I-Premise
184	vivo	_	_	I-Premise
185	experiments	_	_	I-Premise
186	have	_	_	I-Premise
187	yet	_	_	I-Premise
188	to	_	_	I-Premise
189	confirm	_	_	I-Premise
190	that	_	_	I-Premise
191	the	_	_	I-Premise
192	proposed	_	_	I-Premise
193	mechanisms	_	_	I-Premise
194	underlying	_	_	I-Premise
195	emergent	_	_	I-Premise
196	phenomena	_	_	I-Premise
197	,	_	_	I-Premise
198	such	_	_	I-Premise
199	as	_	_	I-Premise
200	proximal	_	_	I-Premise
201	tubular	_	_	I-Premise
202	fluid	_	_	I-Premise
203	reabsorption	_	_	I-Premise
204	,	_	_	I-Premise
205	are	_	_	I-Premise
206	the	_	_	I-Premise
207	ones	_	_	I-Premise
208	predicted	_	_	I-Premise
209	by	_	_	I-Premise
210	cell	_	_	I-Premise
211	and	_	_	I-Premise
212	molecular	_	_	I-Premise
213	experiments	_	_	I-Premise
214	.	_	_	I-Premise

215	There	_	_	B-Claim
216	may	_	_	I-Claim
217	be	_	_	I-Claim
218	salutary	_	_	I-Claim
219	effects	_	_	I-Claim
220	of	_	_	I-Claim
221	incretin-based	_	_	I-Claim
222	treatments	_	_	I-Claim
223	on	_	_	I-Claim
224	the	_	_	I-Claim
225	diabetic	_	_	I-Claim
226	kidney	_	_	I-Claim
227	,	_	_	I-Claim
228	but	_	_	B-Claim
229	the	_	_	I-Claim
230	system	_	_	I-Claim
231	is	_	_	I-Claim
232	complex	_	_	I-Claim
233	and	_	_	I-Claim
234	not	_	_	I-Claim
235	amenable	_	_	I-Claim
236	to	_	_	I-Claim
237	simple	_	_	I-Claim
238	explanation	_	_	I-Claim
239	or	_	_	I-Claim
240	prior	_	_	I-Claim
241	prediction	_	_	I-Claim
242	.	_	_	I-Claim

243	This	_	_	B-Claim
244	contrasts	_	_	I-Claim
245	with	_	_	I-Claim
246	the	_	_	I-Claim
247	renal	_	_	I-Claim
248	effects	_	_	I-Claim
249	of	_	_	I-Claim
250	SGLT2	_	_	I-Claim
251	inhibitors	_	_	I-Claim
252	,	_	_	I-Claim
253	which	_	_	I-Claim
254	can	_	_	I-Claim
255	be	_	_	I-Claim
256	explained	_	_	I-Claim
257	concisely	_	_	I-Claim
258	.	_	_	I-Claim


0	Fracture	_	_	B-Claim
1	risk	_	_	I-Claim
2	is	_	_	I-Claim
3	increased	_	_	I-Claim
4	in	_	_	I-Claim
5	individuals	_	_	I-Claim
6	with	_	_	I-Claim
7	type	_	_	I-Claim
8	2	_	_	I-Claim
9	diabetes	_	_	I-Claim
10	(	_	_	I-Claim
11	T2D	_	_	I-Claim
12	)	_	_	I-Claim
13	.	_	_	I-Claim

14	The	_	_	O
15	pathophysiological	_	_	O
16	mechanisms	_	_	O
17	accentuating	_	_	O
18	fracture	_	_	O
19	risk	_	_	O
20	in	_	_	O
21	T2D	_	_	O
22	are	_	_	O
23	convoluted	_	_	O
24	,	_	_	O
25	incorporating	_	_	O
26	factors	_	_	O
27	such	_	_	O
28	as	_	_	O
29	hyperglycaemia	_	_	O
30	,	_	_	O
31	insulinopenia	_	_	O
32	,	_	_	O
33	and	_	_	O
34	antidiabetic	_	_	O
35	drugs	_	_	O
36	.	_	_	O

37	The	_	_	O
38	objectives	_	_	O
39	of	_	_	O
40	this	_	_	O
41	study	_	_	O
42	were	_	_	O
43	to	_	_	O
44	assess	_	_	O
45	whether	_	_	O
46	different	_	_	O
47	insulin	_	_	O
48	regimens	_	_	O
49	,	_	_	O
50	metformin	_	_	O
51	and	_	_	O
52	rosiglitazone	_	_	O
53	influence	_	_	O
54	bone	_	_	O
55	metabolism	_	_	O
56	.	_	_	O

57	We	_	_	O
58	explored	_	_	O
59	if	_	_	O
60	the	_	_	O
61	concentration	_	_	O
62	of	_	_	O
63	metformin	_	_	O
64	and	_	_	O
65	rosiglitazone	_	_	O
66	in	_	_	O
67	blood	_	_	O
68	or	_	_	O
69	improved	_	_	O
70	glycaemic	_	_	O
71	control	_	_	O
72	altered	_	_	O
73	bone	_	_	O
74	turnover	_	_	O
75	.	_	_	O

76	Two-year	_	_	O
77	clinical	_	_	O
78	trial	_	_	O
79	designed	_	_	O
80	to	_	_	O
81	investigate	_	_	O
82	effects	_	_	O
83	of	_	_	O
84	antidiabetic	_	_	O
85	treatment	_	_	O
86	in	_	_	O
87	371	_	_	O
88	T2D	_	_	O
89	patients	_	_	O
90	.	_	_	O

91	Participants	_	_	O
92	were	_	_	O
93	randomized	_	_	O
94	to	_	_	O
95	short	_	_	O
96	or	_	_	O
97	long-acting	_	_	O
98	human	_	_	O
99	insulin	_	_	O
100	(	_	_	O
101	non-blinded	_	_	O
102	)	_	_	O
103	and	_	_	O
104	then	_	_	O
105	further	_	_	O
106	randomized	_	_	O
107	to	_	_	O
108	metformin	_	_	O
109	+	_	_	O
110	placebo	_	_	O
111	,	_	_	O
112	rosiglitazone	_	_	O
113	+	_	_	O
114	placebo	_	_	O
115	,	_	_	O
116	metformin	_	_	O
117	+	_	_	O
118	rosiglitazone	_	_	O
119	or	_	_	O
120	placebo	_	_	O
121	+	_	_	O
122	placebo	_	_	O
123	(	_	_	O
124	blinded	_	_	O
125	)	_	_	O
126	.	_	_	O

127	Fasting	_	_	O
128	bone	_	_	O
129	turnover	_	_	O
130	markers	_	_	O
131	(	_	_	O
132	BTM	_	_	O
133	)	_	_	O
134	representing	_	_	O
135	bone	_	_	O
136	resorption	_	_	O
137	(	_	_	O
138	CTX	_	_	O
139	)	_	_	O
140	and	_	_	O
141	formation	_	_	O
142	(	_	_	O
143	PINP	_	_	O
144	)	_	_	O
145	including	_	_	O
146	HbA1c	_	_	O
147	were	_	_	O
148	measured	_	_	O
149	at	_	_	O
150	baseline	_	_	O
151	and	_	_	O
152	after	_	_	O
153	3	_	_	O
154	,	_	_	O
155	12	_	_	O
156	and	_	_	O
157	24	_	_	O
158	months	_	_	O
159	.	_	_	O

160	Trough	_	_	O
161	steady-state	_	_	O
162	plasma	_	_	O
163	concentrations	_	_	O
164	of	_	_	O
165	metformin	_	_	O
166	and	_	_	O
167	rosiglitazone	_	_	O
168	were	_	_	O
169	measured	_	_	O
170	after	_	_	O
171	3	_	_	O
172	,	_	_	O
173	6	_	_	O
174	and	_	_	O
175	9	_	_	O
176	months	_	_	O
177	of	_	_	O
178	treatment	_	_	O
179	.	_	_	O

180	Associations	_	_	O
181	between	_	_	O
182	treatments	_	_	O
183	and	_	_	O
184	BTMs	_	_	O
185	during	_	_	O
186	the	_	_	O
187	follow-up	_	_	O
188	of	_	_	O
189	the	_	_	O
190	trial	_	_	O
191	were	_	_	O
192	analysed	_	_	O
193	in	_	_	O
194	mixed-effects	_	_	O
195	models	_	_	O
196	that	_	_	O
197	included	_	_	O
198	adjustments	_	_	O
199	for	_	_	O
200	age	_	_	O
201	,	_	_	O
202	gender	_	_	O
203	,	_	_	O
204	BMI	_	_	O
205	,	_	_	O
206	renal	_	_	O
207	function	_	_	O
208	and	_	_	O
209	repeated	_	_	O
210	measures	_	_	O
211	of	_	_	O
212	HbA1c	_	_	O
213	.	_	_	O

214	BTMs	_	_	B-Premise
215	increased	_	_	I-Premise
216	from	_	_	I-Premise
217	baseline	_	_	I-Premise
218	to	_	_	I-Premise
219	month	_	_	I-Premise
220	12	_	_	I-Premise
221	and	_	_	I-Premise
222	remained	_	_	I-Premise
223	higher	_	_	I-Premise
224	at	_	_	I-Premise
225	month	_	_	I-Premise
226	24	_	_	I-Premise
227	,	_	_	I-Premise
228	with	_	_	I-Premise
229	CTX	_	_	I-Premise
230	and	_	_	I-Premise
231	PINP	_	_	I-Premise
232	increasing	_	_	I-Premise
233	28.5	_	_	I-Premise
234	%	_	_	I-Premise
235	and	_	_	I-Premise
236	23.0	_	_	I-Premise
237	%	_	_	I-Premise
238	(	_	_	I-Premise
239	all	_	_	I-Premise
240	:	_	_	I-Premise
241	p	_	_	I-Premise
242	<	_	_	I-Premise
243	0.001	_	_	I-Premise
244	)	_	_	I-Premise
245	,	_	_	I-Premise
246	respectively	_	_	I-Premise
247	.	_	_	I-Premise

248	Allocation	_	_	B-Premise
249	of	_	_	I-Premise
250	insulin	_	_	I-Premise
251	regimens	_	_	I-Premise
252	was	_	_	I-Premise
253	not	_	_	I-Premise
254	associated	_	_	I-Premise
255	with	_	_	I-Premise
256	different	_	_	I-Premise
257	levels	_	_	I-Premise
258	of	_	_	I-Premise
259	BTMs	_	_	I-Premise
260	.	_	_	I-Premise

261	Metformin	_	_	B-Premise
262	and	_	_	I-Premise
263	metformin	_	_	I-Premise
264	+	_	_	I-Premise
265	rosiglitazone	_	_	I-Premise
266	but	_	_	I-Premise
267	not	_	_	I-Premise
268	rosiglitazone	_	_	I-Premise
269	alone	_	_	I-Premise
270	were	_	_	I-Premise
271	associated	_	_	I-Premise
272	with	_	_	I-Premise
273	lower	_	_	I-Premise
274	bone	_	_	I-Premise
275	formation	_	_	I-Premise
276	(	_	_	I-Premise
277	PINP	_	_	I-Premise
278	)	_	_	I-Premise
279	.	_	_	I-Premise

280	Neither	_	_	B-Premise
281	metformin	_	_	I-Premise
282	nor	_	_	I-Premise
283	rosiglitazone	_	_	I-Premise
284	plasma	_	_	I-Premise
285	concentrations	_	_	I-Premise
286	was	_	_	I-Premise
287	associated	_	_	I-Premise
288	with	_	_	I-Premise
289	BTMs	_	_	I-Premise
290	.	_	_	I-Premise

291	HbA1c	_	_	B-Premise
292	was	_	_	I-Premise
293	inversely	_	_	I-Premise
294	associated	_	_	I-Premise
295	with	_	_	I-Premise
296	CTX	_	_	I-Premise
297	but	_	_	I-Premise
298	not	_	_	I-Premise
299	P1NP	_	_	I-Premise
300	.	_	_	I-Premise

301	The	_	_	B-Claim
302	choice	_	_	I-Claim
303	of	_	_	I-Claim
304	insulin	_	_	I-Claim
305	treatment	_	_	I-Claim
306	is	_	_	I-Claim
307	not	_	_	I-Claim
308	influencing	_	_	I-Claim
309	BTMs	_	_	I-Claim
310	,	_	_	I-Claim
311	metformin	_	_	B-Claim
312	treatment	_	_	I-Claim
313	may	_	_	I-Claim
314	decrease	_	_	I-Claim
315	BTMs	_	_	I-Claim
316	,	_	_	I-Claim
317	and	_	_	O
318	improvement	_	_	B-Claim
319	of	_	_	I-Claim
320	glycaemic	_	_	I-Claim
321	control	_	_	I-Claim
322	may	_	_	I-Claim
323	influence	_	_	I-Claim
324	bone	_	_	I-Claim
325	resorption	_	_	I-Claim
326	activity	_	_	I-Claim
327	.	_	_	I-Claim


0	An	_	_	O
1	open	_	_	O
2	,	_	_	O
3	randomized	_	_	O
4	study	_	_	O
5	was	_	_	O
6	performed	_	_	O
7	to	_	_	O
8	assess	_	_	O
9	the	_	_	O
10	effects	_	_	O
11	of	_	_	O
12	supportive	_	_	O
13	pamidronate	_	_	O
14	treatment	_	_	O
15	on	_	_	O
16	morbidity	_	_	O
17	from	_	_	O
18	bone	_	_	O
19	metastases	_	_	O
20	in	_	_	O
21	breast	_	_	O
22	cancer	_	_	O
23	patients	_	_	O
24	.	_	_	O

25	Eighty-one	_	_	O
26	pamidronate	_	_	O
27	patients	_	_	O
28	and	_	_	O
29	80	_	_	O
30	control	_	_	O
31	patients	_	_	O
32	were	_	_	O
33	monitored	_	_	O
34	for	_	_	O
35	a	_	_	O
36	median	_	_	O
37	of	_	_	O
38	18	_	_	O
39	and	_	_	O
40	21	_	_	O
41	months	_	_	O
42	,	_	_	O
43	respectively	_	_	O
44	,	_	_	O
45	for	_	_	O
46	events	_	_	O
47	of	_	_	O
48	skeletal	_	_	O
49	morbidity	_	_	O
50	and	_	_	O
51	the	_	_	O
52	radiologic	_	_	O
53	course	_	_	O
54	of	_	_	O
55	metastatic	_	_	O
56	bone	_	_	O
57	disease	_	_	O
58	.	_	_	O

59	The	_	_	O
60	oral	_	_	O
61	pamidronate	_	_	O
62	dose	_	_	O
63	was	_	_	O
64	600	_	_	O
65	mg/d	_	_	O
66	(	_	_	O
67	high	_	_	O
68	dose	_	_	O
69	[	_	_	O
70	HD	_	_	O
71	]	_	_	O
72	)	_	_	O
73	during	_	_	O
74	the	_	_	O
75	earliest	_	_	O
76	study	_	_	O
77	years	_	_	O
78	,	_	_	O
79	then	_	_	O
80	changed	_	_	O
81	to	_	_	O
82	300	_	_	O
83	mg/d	_	_	O
84	(	_	_	O
85	low	_	_	O
86	dose	_	_	O
87	[	_	_	O
88	LD	_	_	O
89	]	_	_	O
90	)	_	_	O
91	because	_	_	O
92	of	_	_	O
93	gastrointestinal	_	_	O
94	toxicity	_	_	O
95	.	_	_	O

96	Twenty-nine	_	_	O
97	of	_	_	O
98	81	_	_	O
99	pamidronate	_	_	O
100	(	_	_	O
101	HD/LD	_	_	O
102	)	_	_	O
103	patients	_	_	O
104	first	_	_	O
105	received	_	_	O
106	600	_	_	O
107	mg/d	_	_	O
108	and	_	_	O
109	were	_	_	O
110	then	_	_	O
111	changed	_	_	O
112	to	_	_	O
113	300	_	_	O
114	mg/d	_	_	O
115	;	_	_	O
116	52	_	_	O
117	of	_	_	O
118	81	_	_	O
119	pamidronate	_	_	O
120	LD	_	_	O
121	patients	_	_	O
122	received	_	_	O
123	300	_	_	O
124	mg/d	_	_	O
125	throughout	_	_	O
126	the	_	_	O
127	study	_	_	O
128	.	_	_	O

129	Tumor	_	_	O
130	treatment	_	_	O
131	was	_	_	O
132	unrestricted	_	_	O
133	.	_	_	O

134	An	_	_	O
135	overall	_	_	O
136	intent-to-treat	_	_	O
137	analysis	_	_	O
138	was	_	_	O
139	performed	_	_	O
140	.	_	_	O

141	In	_	_	B-Premise
142	the	_	_	I-Premise
143	pamidronate	_	_	I-Premise
144	group	_	_	I-Premise
145	,	_	_	I-Premise
146	the	_	_	I-Premise
147	occurrence	_	_	I-Premise
148	of	_	_	I-Premise
149	hypercalcemia	_	_	I-Premise
150	,	_	_	I-Premise
151	severe	_	_	I-Premise
152	bone	_	_	I-Premise
153	pain	_	_	I-Premise
154	,	_	_	I-Premise
155	and	_	_	I-Premise
156	symptomatic	_	_	I-Premise
157	impending	_	_	I-Premise
158	fractures	_	_	I-Premise
159	decreased	_	_	I-Premise
160	by	_	_	I-Premise
161	65	_	_	I-Premise
162	%	_	_	I-Premise
163	,	_	_	I-Premise
164	30	_	_	I-Premise
165	%	_	_	I-Premise
166	,	_	_	I-Premise
167	and	_	_	I-Premise
168	50	_	_	I-Premise
169	%	_	_	I-Premise
170	,	_	_	I-Premise
171	respectively	_	_	I-Premise
172	;	_	_	I-Premise
173	event-rates	_	_	I-Premise
174	of	_	_	I-Premise
175	systemic	_	_	I-Premise
176	treatment	_	_	I-Premise
177	and	_	_	I-Premise
178	radiotherapy	_	_	I-Premise
179	decreased	_	_	I-Premise
180	by	_	_	I-Premise
181	35	_	_	I-Premise
182	%	_	_	I-Premise
183	(	_	_	I-Premise
184	P	_	_	I-Premise
185	<	_	_	I-Premise
186	or	_	_	I-Premise
187	=	_	_	I-Premise
188	.02	_	_	I-Premise
189	)	_	_	I-Premise
190	.	_	_	I-Premise

191	The	_	_	B-Premise
192	event-free	_	_	I-Premise
193	period	_	_	I-Premise
194	(	_	_	I-Premise
195	EFP	_	_	I-Premise
196	)	_	_	I-Premise
197	,	_	_	I-Premise
198	radiologic	_	_	I-Premise
199	course	_	_	I-Premise
200	of	_	_	I-Premise
201	disease	_	_	I-Premise
202	,	_	_	I-Premise
203	and	_	_	I-Premise
204	survival	_	_	I-Premise
205	did	_	_	I-Premise
206	not	_	_	I-Premise
207	improve	_	_	I-Premise
208	.	_	_	I-Premise

209	Subgroup	_	_	B-Claim
210	analyses	_	_	I-Claim
211	suggested	_	_	I-Claim
212	a	_	_	I-Claim
213	dose-dependent	_	_	I-Claim
214	treatment	_	_	I-Claim
215	effect	_	_	I-Claim
216	.	_	_	I-Claim

217	Compared	_	_	B-Premise
218	with	_	_	I-Premise
219	their	_	_	I-Premise
220	controls	_	_	I-Premise
221	,	_	_	I-Premise
222	in	_	_	I-Premise
223	pamidronate	_	_	I-Premise
224	HD/LD	_	_	I-Premise
225	patients	_	_	I-Premise
226	,	_	_	I-Premise
227	events	_	_	I-Premise
228	occurred	_	_	I-Premise
229	60	_	_	I-Premise
230	%	_	_	I-Premise
231	to	_	_	I-Premise
232	90	_	_	I-Premise
233	%	_	_	I-Premise
234	less	_	_	I-Premise
235	frequently	_	_	I-Premise
236	(	_	_	I-Premise
237	P	_	_	I-Premise
238	<	_	_	I-Premise
239	or	_	_	I-Premise
240	=	_	_	I-Premise
241	.03	_	_	I-Premise
242	)	_	_	I-Premise
243	and	_	_	I-Premise
244	the	_	_	I-Premise
245	EFP	_	_	I-Premise
246	was	_	_	I-Premise
247	prolonged	_	_	I-Premise
248	(	_	_	I-Premise
249	P	_	_	I-Premise
250	=	_	_	I-Premise
251	.002	_	_	I-Premise
252	)	_	_	I-Premise
253	.	_	_	I-Premise

254	In	_	_	B-Premise
255	pamidronate	_	_	I-Premise
256	LD	_	_	I-Premise
257	patients	_	_	I-Premise
258	,	_	_	I-Premise
259	event-rates	_	_	I-Premise
260	decreased	_	_	I-Premise
261	by	_	_	I-Premise
262	15	_	_	I-Premise
263	%	_	_	I-Premise
264	to	_	_	I-Premise
265	45	_	_	I-Premise
266	%	_	_	I-Premise
267	(	_	_	I-Premise
268	P	_	_	I-Premise
269	<	_	_	I-Premise
270	or	_	_	I-Premise
271	=	_	_	I-Premise
272	.04	_	_	I-Premise
273	)	_	_	I-Premise
274	.	_	_	I-Premise

275	Gastrointestinal	_	_	B-Premise
276	toxicity	_	_	I-Premise
277	of	_	_	I-Premise
278	pamidronate	_	_	I-Premise
279	caused	_	_	I-Premise
280	a	_	_	I-Premise
281	23	_	_	I-Premise
282	%	_	_	I-Premise
283	drop-out	_	_	I-Premise
284	rate	_	_	I-Premise
285	,	_	_	I-Premise
286	but	_	_	B-Claim
287	other	_	_	I-Claim
288	cancer-associated	_	_	I-Claim
289	factors	_	_	I-Claim
290	seemed	_	_	I-Claim
291	to	_	_	I-Claim
292	contribute	_	_	I-Claim
293	to	_	_	I-Claim
294	this	_	_	I-Claim
295	toxicity	_	_	I-Claim
296	.	_	_	I-Claim

297	Pamidronate	_	_	B-Claim
298	treatment	_	_	I-Claim
299	of	_	_	I-Claim
300	breast	_	_	I-Claim
301	cancer	_	_	I-Claim
302	patients	_	_	I-Claim
303	efficaciously	_	_	I-Claim
304	reduced	_	_	I-Claim
305	skeletal	_	_	I-Claim
306	morbidity	_	_	I-Claim
307	.	_	_	I-Claim

308	The	_	_	B-Claim
309	effect	_	_	I-Claim
310	appeared	_	_	I-Claim
311	to	_	_	I-Claim
312	be	_	_	I-Claim
313	dose-dependent	_	_	I-Claim
314	.	_	_	I-Claim

315	Further	_	_	B-Claim
316	research	_	_	I-Claim
317	on	_	_	I-Claim
318	dose	_	_	I-Claim
319	and	_	_	I-Claim
320	mode	_	_	I-Claim
321	of	_	_	I-Claim
322	treatment	_	_	I-Claim
323	is	_	_	I-Claim
324	mandatory	_	_	I-Claim
325	.	_	_	I-Claim


0	The	_	_	O
1	impact	_	_	O
2	of	_	_	O
3	the	_	_	O
4	side	_	_	O
5	effects	_	_	O
6	of	_	_	O
7	megestrol	_	_	O
8	acetate	_	_	O
9	on	_	_	O
10	the	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	of	_	_	O
15	noncachectic	_	_	O
16	women	_	_	O
17	with	_	_	O
18	advanced	_	_	O
19	breast	_	_	O
20	cancer	_	_	O
21	was	_	_	O
22	studied	_	_	O
23	in	_	_	O
24	a	_	_	O
25	dose-response	_	_	O
26	clinical	_	_	O
27	trial	_	_	O
28	of	_	_	O
29	the	_	_	O
30	Cancer	_	_	O
31	and	_	_	O
32	Leukemia	_	_	O
33	Group	_	_	O
34	B	_	_	O
35	(	_	_	O
36	CALGB	_	_	O
37	8741	_	_	O
38	)	_	_	O
39	.	_	_	O

40	Side	_	_	O
41	effects	_	_	O
42	of	_	_	O
43	appetite	_	_	O
44	increase	_	_	O
45	and	_	_	O
46	weight	_	_	O
47	gain	_	_	O
48	at	_	_	O
49	higher	_	_	O
50	doses	_	_	O
51	were	_	_	O
52	predicted	_	_	O
53	to	_	_	O
54	have	_	_	O
55	a	_	_	O
56	negative	_	_	O
57	effect	_	_	O
58	on	_	_	O
59	quality	_	_	O
60	of	_	_	O
61	life	_	_	O
62	.	_	_	O

63	Stage	_	_	O
64	IV	_	_	O
65	breast	_	_	O
66	cancer	_	_	O
67	patients	_	_	O
68	were	_	_	O
69	randomized	_	_	O
70	to	_	_	O
71	receive	_	_	O
72	either	_	_	O
73	160	_	_	O
74	,	_	_	O
75	800	_	_	O
76	,	_	_	O
77	or	_	_	O
78	1,600	_	_	O
79	mg/d	_	_	O
80	of	_	_	O
81	megestrol	_	_	O
82	acetate	_	_	O
83	.	_	_	O

84	Quality	_	_	O
85	of	_	_	O
86	life	_	_	O
87	was	_	_	O
88	assessed	_	_	O
89	in	_	_	O
90	131	_	_	O
91	patients	_	_	O
92	at	_	_	O
93	trial	_	_	O
94	entry	_	_	O
95	and	_	_	O
96	at	_	_	O
97	1	_	_	O
98	and	_	_	O
99	3	_	_	O
100	months	_	_	O
101	while	_	_	O
102	on	_	_	O
103	treatment	_	_	O
104	,	_	_	O
105	by	_	_	O
106	telephone	_	_	O
107	interview	_	_	O
108	,	_	_	O
109	using	_	_	O
110	the	_	_	O
111	following	_	_	O
112	measures	_	_	O
113	:	_	_	O
114	the	_	_	O
115	Functional	_	_	O
116	Living	_	_	O
117	Index-Cancer	_	_	O
118	(	_	_	O
119	FLIC	_	_	O
120	)	_	_	O
121	,	_	_	O
122	Rand	_	_	O
123	Functional	_	_	O
124	Limitations	_	_	O
125	Scale	_	_	O
126	,	_	_	O
127	Rand	_	_	O
128	Mental	_	_	O
129	Health	_	_	O
130	Inventory	_	_	O
131	(	_	_	O
132	MHI	_	_	O
133	)	_	_	O
134	,	_	_	O
135	the	_	_	O
136	Body	_	_	O
137	Image	_	_	O
138	Subscale	_	_	O
139	,	_	_	O
140	and	_	_	O
141	linear	_	_	O
142	analog	_	_	O
143	scales	_	_	O
144	of	_	_	O
145	drug	_	_	O
146	side	_	_	O
147	effects	_	_	O
148	.	_	_	O

149	At	_	_	B-Premise
150	3	_	_	I-Premise
151	months	_	_	I-Premise
152	,	_	_	I-Premise
153	women	_	_	I-Premise
154	treated	_	_	I-Premise
155	with	_	_	I-Premise
156	160	_	_	I-Premise
157	mg/d	_	_	I-Premise
158	reported	_	_	I-Premise
159	less	_	_	I-Premise
160	severe	_	_	I-Premise
161	side	_	_	I-Premise
162	effects	_	_	I-Premise
163	(	_	_	I-Premise
164	P	_	_	I-Premise
165	<	_	_	I-Premise
166	.0005	_	_	I-Premise
167	)	_	_	I-Premise
168	,	_	_	I-Premise
169	better	_	_	I-Premise
170	physical	_	_	I-Premise
171	functioning	_	_	I-Premise
172	(	_	_	I-Premise
173	FLS	_	_	I-Premise
174	,	_	_	I-Premise
175	P	_	_	I-Premise
176	<	_	_	I-Premise
177	.0005	_	_	I-Premise
178	)	_	_	I-Premise
179	,	_	_	I-Premise
180	less	_	_	I-Premise
181	psychologic	_	_	I-Premise
182	distress	_	_	I-Premise
183	(	_	_	I-Premise
184	MHI	_	_	I-Premise
185	,	_	_	I-Premise
186	P	_	_	I-Premise
187	=	_	_	I-Premise
188	.008	_	_	I-Premise
189	)	_	_	I-Premise
190	,	_	_	I-Premise
191	and	_	_	I-Premise
192	an	_	_	I-Premise
193	improvement	_	_	I-Premise
194	in	_	_	I-Premise
195	overall	_	_	I-Premise
196	quality	_	_	I-Premise
197	of	_	_	I-Premise
198	life	_	_	I-Premise
199	(	_	_	I-Premise
200	FLIC	_	_	I-Premise
201	,	_	_	I-Premise
202	P	_	_	I-Premise
203	=	_	_	I-Premise
204	.003	_	_	I-Premise
205	)	_	_	I-Premise
206	from	_	_	I-Premise
207	the	_	_	I-Premise
208	time	_	_	I-Premise
209	of	_	_	I-Premise
210	study	_	_	I-Premise
211	entry	_	_	I-Premise
212	as	_	_	I-Premise
213	compared	_	_	I-Premise
214	with	_	_	I-Premise
215	those	_	_	I-Premise
216	treated	_	_	I-Premise
217	with	_	_	I-Premise
218	1,600	_	_	I-Premise
219	mg/d	_	_	I-Premise
220	.	_	_	I-Premise

221	Patients	_	_	B-Premise
222	who	_	_	I-Premise
223	received	_	_	I-Premise
224	the	_	_	I-Premise
225	800-mg/d	_	_	I-Premise
226	dose	_	_	I-Premise
227	fell	_	_	I-Premise
228	between	_	_	I-Premise
229	the	_	_	I-Premise
230	low-	_	_	I-Premise
231	and	_	_	I-Premise
232	high-dose	_	_	I-Premise
233	arms	_	_	I-Premise
234	in	_	_	I-Premise
235	reported	_	_	I-Premise
236	intensity	_	_	I-Premise
237	of	_	_	I-Premise
238	drug	_	_	I-Premise
239	side	_	_	I-Premise
240	effects	_	_	I-Premise
241	,	_	_	I-Premise
242	but	_	_	B-Premise
243	responded	_	_	I-Premise
244	similarly	_	_	I-Premise
245	to	_	_	I-Premise
246	those	_	_	I-Premise
247	in	_	_	I-Premise
248	the	_	_	I-Premise
249	160-mg/d	_	_	I-Premise
250	group	_	_	I-Premise
251	in	_	_	I-Premise
252	terms	_	_	I-Premise
253	of	_	_	I-Premise
254	physical	_	_	I-Premise
255	functioning	_	_	I-Premise
256	,	_	_	I-Premise
257	psychologic	_	_	I-Premise
258	distress	_	_	I-Premise
259	,	_	_	I-Premise
260	and	_	_	I-Premise
261	overall	_	_	I-Premise
262	quality	_	_	I-Premise
263	of	_	_	I-Premise
264	life	_	_	I-Premise
265	.	_	_	I-Premise

266	Unless	_	_	B-Claim
267	additional	_	_	I-Claim
268	follow-up	_	_	I-Claim
269	data	_	_	I-Claim
270	demonstrate	_	_	I-Claim
271	a	_	_	I-Claim
272	survival	_	_	I-Claim
273	advantage	_	_	I-Claim
274	at	_	_	I-Claim
275	higher	_	_	I-Claim
276	doses	_	_	I-Claim
277	,	_	_	I-Claim
278	the	_	_	I-Claim
279	160-mg/d	_	_	I-Claim
280	dose	_	_	I-Claim
281	is	_	_	I-Claim
282	optimal	_	_	I-Claim
283	,	_	_	I-Claim
284	achieving	_	_	I-Claim
285	maximal	_	_	I-Claim
286	treatment	_	_	I-Claim
287	effect	_	_	I-Claim
288	with	_	_	I-Claim
289	the	_	_	I-Claim
290	fewest	_	_	I-Claim
291	side	_	_	I-Claim
292	effects	_	_	I-Claim
293	and	_	_	I-Claim
294	better	_	_	I-Claim
295	quality	_	_	I-Claim
296	of	_	_	I-Claim
297	life	_	_	I-Claim
298	.	_	_	I-Claim


0	Latanoprost	_	_	O
1	,	_	_	O
2	a	_	_	O
3	new	_	_	O
4	prostaglandin	_	_	O
5	analogue	_	_	O
6	,	_	_	O
7	was	_	_	O
8	compared	_	_	O
9	with	_	_	O
10	timolol	_	_	O
11	for	_	_	O
12	ocular	_	_	O
13	hypotensive	_	_	O
14	efficacy	_	_	O
15	and	_	_	O
16	side	_	_	O
17	effects	_	_	O
18	.	_	_	O

19	In	_	_	O
20	a	_	_	O
21	multicenter	_	_	O
22	,	_	_	O
23	randomized	_	_	O
24	,	_	_	O
25	double-masked	_	_	O
26	,	_	_	O
27	parallel	_	_	O
28	group	_	_	O
29	study	_	_	O
30	,	_	_	O
31	268	_	_	O
32	patients	_	_	O
33	with	_	_	O
34	ocular	_	_	O
35	hypertension	_	_	O
36	or	_	_	O
37	early	_	_	O
38	primary	_	_	O
39	open-angle	_	_	O
40	glaucoma	_	_	O
41	received	_	_	O
42	either	_	_	O
43	0.005	_	_	O
44	%	_	_	O
45	latanoprost	_	_	O
46	once	_	_	O
47	daily	_	_	O
48	or	_	_	O
49	0.5	_	_	O
50	%	_	_	O
51	timolol	_	_	O
52	twice	_	_	O
53	daily	_	_	O
54	for	_	_	O
55	6	_	_	O
56	months	_	_	O
57	.	_	_	O

58	All	_	_	O
59	except	_	_	O
60	ten	_	_	O
61	patients	_	_	O
62	from	_	_	O
63	each	_	_	O
64	group	_	_	O
65	successfully	_	_	O
66	completed	_	_	O
67	the	_	_	O
68	study	_	_	O
69	.	_	_	O

70	Intraocular	_	_	B-Premise
71	pressure	_	_	I-Premise
72	(	_	_	I-Premise
73	IOP	_	_	I-Premise
74	)	_	_	I-Premise
75	was	_	_	I-Premise
76	significantly	_	_	I-Premise
77	(	_	_	I-Premise
78	P	_	_	I-Premise
79	<	_	_	I-Premise
80	0.001	_	_	I-Premise
81	)	_	_	I-Premise
82	reduced	_	_	I-Premise
83	and	_	_	I-Premise
84	maintained	_	_	I-Premise
85	by	_	_	I-Premise
86	both	_	_	I-Premise
87	medications	_	_	I-Premise
88	without	_	_	I-Premise
89	evidence	_	_	I-Premise
90	of	_	_	I-Premise
91	a	_	_	I-Premise
92	long-term	_	_	I-Premise
93	drift	_	_	I-Premise
94	over	_	_	I-Premise
95	6	_	_	I-Premise
96	months	_	_	I-Premise
97	.	_	_	I-Premise

98	Comparing	_	_	B-Premise
99	6-month	_	_	I-Premise
100	with	_	_	I-Premise
101	baseline	_	_	I-Premise
102	diurnal	_	_	I-Premise
103	IOP	_	_	I-Premise
104	values	_	_	I-Premise
105	,	_	_	I-Premise
106	the	_	_	I-Premise
107	IOP	_	_	I-Premise
108	reduction	_	_	I-Premise
109	(	_	_	I-Premise
110	mean	_	_	I-Premise
111	+/-	_	_	I-Premise
112	standard	_	_	I-Premise
113	deviation	_	_	I-Premise
114	)	_	_	I-Premise
115	achieved	_	_	I-Premise
116	with	_	_	I-Premise
117	latanoprost	_	_	I-Premise
118	(	_	_	I-Premise
119	-6.7	_	_	I-Premise
120	+/-	_	_	I-Premise
121	3.4	_	_	I-Premise
122	mmHg	_	_	I-Premise
123	)	_	_	I-Premise
124	was	_	_	I-Premise
125	significantly	_	_	I-Premise
126	(	_	_	I-Premise
127	P	_	_	I-Premise
128	<	_	_	I-Premise
129	0.001	_	_	I-Premise
130	)	_	_	I-Premise
131	greater	_	_	I-Premise
132	than	_	_	I-Premise
133	that	_	_	I-Premise
134	produced	_	_	I-Premise
135	with	_	_	I-Premise
136	timolol	_	_	I-Premise
137	(	_	_	I-Premise
138	4.9	_	_	I-Premise
139	+/-	_	_	I-Premise
140	2.9	_	_	I-Premise
141	mmHg	_	_	I-Premise
142	)	_	_	I-Premise
143	.	_	_	I-Premise

144	Four	_	_	O
145	patients	_	_	O
146	treated	_	_	O
147	with	_	_	O
148	timolol	_	_	O
149	and	_	_	O
150	none	_	_	O
151	treated	_	_	O
152	with	_	_	O
153	latanoprost	_	_	O
154	were	_	_	O
155	withdrawn	_	_	O
156	from	_	_	O
157	the	_	_	O
158	study	_	_	O
159	because	_	_	O
160	of	_	_	O
161	inadequate	_	_	O
162	IOP	_	_	O
163	control	_	_	O
164	.	_	_	O

165	Pulse	_	_	B-Premise
166	rate	_	_	I-Premise
167	was	_	_	I-Premise
168	significantly	_	_	I-Premise
169	reduced	_	_	I-Premise
170	with	_	_	I-Premise
171	timolol	_	_	I-Premise
172	,	_	_	I-Premise
173	but	_	_	I-Premise
174	not	_	_	I-Premise
175	with	_	_	I-Premise
176	latanoprost	_	_	I-Premise
177	.	_	_	I-Premise

178	Slightly	_	_	B-Premise
179	more	_	_	I-Premise
180	conjunctival	_	_	I-Premise
181	hyperemia	_	_	I-Premise
182	appeared	_	_	I-Premise
183	in	_	_	I-Premise
184	latanoprost-treated	_	_	I-Premise
185	compared	_	_	I-Premise
186	with	_	_	I-Premise
187	timolol-treated	_	_	I-Premise
188	eyes	_	_	I-Premise
189	.	_	_	I-Premise

190	Fewer	_	_	B-Claim
191	subjective	_	_	I-Claim
192	side	_	_	I-Claim
193	effects	_	_	I-Claim
194	occurred	_	_	I-Claim
195	in	_	_	I-Claim
196	latanoprost-treated	_	_	I-Claim
197	eyes	_	_	I-Claim
198	.	_	_	I-Claim

199	Both	_	_	B-Premise
200	eyes	_	_	I-Premise
201	of	_	_	I-Premise
202	a	_	_	I-Premise
203	patient	_	_	I-Premise
204	with	_	_	I-Premise
205	a	_	_	I-Premise
206	characteristic	_	_	I-Premise
207	,	_	_	I-Premise
208	concentric	_	_	I-Premise
209	iris	_	_	I-Premise
210	heterochromia	_	_	I-Premise
211	(	_	_	I-Premise
212	darker	_	_	I-Premise
213	centrally	_	_	I-Premise
214	)	_	_	I-Premise
215	at	_	_	I-Premise
216	baseline	_	_	I-Premise
217	showed	_	_	I-Premise
218	a	_	_	I-Premise
219	definite	_	_	I-Premise
220	,	_	_	I-Premise
221	photographically	_	_	I-Premise
222	documented	_	_	I-Premise
223	increase	_	_	I-Premise
224	in	_	_	I-Premise
225	pigmentation	_	_	I-Premise
226	during	_	_	I-Premise
227	latanoprost	_	_	I-Premise
228	treatment	_	_	I-Premise
229	,	_	_	I-Premise
230	making	_	_	I-Premise
231	the	_	_	I-Premise
232	irides	_	_	I-Premise
233	uniformly	_	_	I-Premise
234	darker	_	_	I-Premise
235	.	_	_	I-Premise

236	Three	_	_	O
237	additional	_	_	O
238	patients	_	_	O
239	treated	_	_	O
240	with	_	_	O
241	latanoprost	_	_	O
242	were	_	_	O
243	suspects	_	_	O
244	for	_	_	O
245	this	_	_	O
246	color	_	_	O
247	change	_	_	O
248	.	_	_	O

249	Otherwise	_	_	O
250	,	_	_	O
251	no	_	_	B-Claim
252	significant	_	_	I-Claim
253	difference	_	_	I-Claim
254	between	_	_	I-Claim
255	treatment	_	_	I-Claim
256	groups	_	_	I-Claim
257	occurred	_	_	I-Claim
258	visual	_	_	I-Claim
259	acuity	_	_	I-Claim
260	,	_	_	I-Claim
261	slit-lamp	_	_	I-Claim
262	examination	_	_	I-Claim
263	,	_	_	I-Claim
264	blood	_	_	I-Claim
265	pressure	_	_	I-Claim
266	,	_	_	I-Claim
267	and	_	_	I-Claim
268	laboratory	_	_	I-Claim
269	values	_	_	I-Claim
270	.	_	_	I-Claim

271	Latanoprost	_	_	B-Claim
272	has	_	_	I-Claim
273	the	_	_	I-Claim
274	potential	_	_	I-Claim
275	for	_	_	I-Claim
276	becoming	_	_	I-Claim
277	a	_	_	I-Claim
278	new	_	_	I-Claim
279	first-line	_	_	I-Claim
280	treatment	_	_	I-Claim
281	for	_	_	I-Claim
282	glaucoma	_	_	I-Claim
283	.	_	_	I-Claim


0	The	_	_	B-Claim
1	extent	_	_	I-Claim
2	to	_	_	I-Claim
3	which	_	_	I-Claim
4	chemotherapy	_	_	I-Claim
5	may	_	_	I-Claim
6	relieve	_	_	I-Claim
7	tumour-related	_	_	I-Claim
8	symptoms	_	_	I-Claim
9	,	_	_	I-Claim
10	improve	_	_	I-Claim
11	quality	_	_	I-Claim
12	of	_	_	I-Claim
13	life	_	_	I-Claim
14	and	_	_	I-Claim
15	prolong	_	_	I-Claim
16	survival	_	_	I-Claim
17	in	_	_	I-Claim
18	patients	_	_	I-Claim
19	with	_	_	I-Claim
20	gastric	_	_	I-Claim
21	cancer	_	_	I-Claim
22	is	_	_	I-Claim
23	not	_	_	I-Claim
24	known	_	_	I-Claim
25	in	_	_	I-Claim
26	spite	_	_	I-Claim
27	of	_	_	I-Claim
28	the	_	_	I-Claim
29	extensive	_	_	I-Claim
30	use	_	_	I-Claim
31	of	_	_	I-Claim
32	this	_	_	I-Claim
33	treatment	_	_	I-Claim
34	modality	_	_	I-Claim
35	.	_	_	I-Claim

36	The	_	_	O
37	aim	_	_	O
38	of	_	_	O
39	this	_	_	O
40	study	_	_	O
41	was	_	_	O
42	to	_	_	O
43	estimate	_	_	O
44	any	_	_	O
45	gain	_	_	O
46	in	_	_	O
47	the	_	_	O
48	quantity	_	_	O
49	and	_	_	O
50	quality	_	_	O
51	of	_	_	O
52	life	_	_	O
53	produced	_	_	O
54	by	_	_	O
55	chemotherapy	_	_	O
56	in	_	_	O
57	these	_	_	O
58	patients	_	_	O
59	.	_	_	O

60	Between	_	_	O
61	January	_	_	O
62	1991	_	_	O
63	and	_	_	O
64	February	_	_	O
65	1995	_	_	O
66	,	_	_	O
67	61	_	_	O
68	patients	_	_	O
69	with	_	_	O
70	gastric	_	_	O
71	cancer	_	_	O
72	were	_	_	O
73	randomized	_	_	O
74	to	_	_	O
75	either	_	_	O
76	chemotherapy	_	_	O
77	in	_	_	O
78	addition	_	_	O
79	to	_	_	O
80	best	_	_	O
81	supportive	_	_	O
82	care	_	_	O
83	or	_	_	O
84	to	_	_	O
85	best	_	_	O
86	supportive	_	_	O
87	care	_	_	O
88	.	_	_	O

89	Chemotherapy	_	_	O
90	was	_	_	O
91	allowed	_	_	O
92	in	_	_	O
93	the	_	_	O
94	latter	_	_	O
95	group	_	_	O
96	if	_	_	O
97	the	_	_	O
98	supportive	_	_	O
99	measures	_	_	O
100	did	_	_	O
101	not	_	_	O
102	lead	_	_	O
103	to	_	_	O
104	palliation	_	_	O
105	.	_	_	O

106	Chemotherapy	_	_	O
107	was	_	_	O
108	the	_	_	O
109	ELF-regimen	_	_	O
110	consisting	_	_	O
111	of	_	_	O
112	5-fluorouracil	_	_	O
113	,	_	_	O
114	leucovorin	_	_	O
115	and	_	_	O
116	etoposide	_	_	O
117	,	_	_	O
118	or	_	_	O
119	,	_	_	O
120	in	_	_	O
121	elderly	_	_	O
122	patients	_	_	O
123	with	_	_	O
124	poor	_	_	O
125	performance	_	_	O
126	,	_	_	O
127	a	_	_	O
128	5-fluorouracil/leucovorin	_	_	O
129	regimen	_	_	O
130	(	_	_	O
131	FLv	_	_	O
132	)	_	_	O
133	.	_	_	O

134	Quality	_	_	O
135	of	_	_	O
136	life	_	_	O
137	was	_	_	O
138	evaluated	_	_	O
139	with	_	_	O
140	the	_	_	O
141	EORTC-QLQ-C30	_	_	O
142	instrument	_	_	O
143	.	_	_	O

144	More	_	_	B-Premise
145	patients	_	_	I-Premise
146	in	_	_	I-Premise
147	the	_	_	I-Premise
148	chemotherapy	_	_	I-Premise
149	group	_	_	I-Premise
150	(	_	_	I-Premise
151	45	_	_	I-Premise
152	%	_	_	I-Premise
153	,	_	_	I-Premise
154	14/31	_	_	I-Premise
155	)	_	_	I-Premise
156	had	_	_	I-Premise
157	an	_	_	I-Premise
158	improved	_	_	I-Premise
159	or	_	_	I-Premise
160	prolonged	_	_	I-Premise
161	high	_	_	I-Premise
162	quality	_	_	I-Premise
163	of	_	_	I-Premise
164	life	_	_	I-Premise
165	for	_	_	I-Premise
166	a	_	_	I-Premise
167	minimum	_	_	I-Premise
168	period	_	_	I-Premise
169	of	_	_	I-Premise
170	4	_	_	I-Premise
171	months	_	_	I-Premise
172	compared	_	_	I-Premise
173	to	_	_	I-Premise
174	those	_	_	I-Premise
175	in	_	_	I-Premise
176	the	_	_	I-Premise
177	best	_	_	I-Premise
178	supportive	_	_	I-Premise
179	care	_	_	I-Premise
180	group	_	_	I-Premise
181	(	_	_	I-Premise
182	20	_	_	I-Premise
183	%	_	_	I-Premise
184	,	_	_	I-Premise
185	6/30	_	_	I-Premise
186	,	_	_	I-Premise
187	P	_	_	I-Premise
188	<	_	_	I-Premise
189	0.05	_	_	I-Premise
190	)	_	_	I-Premise
191	.	_	_	I-Premise

192	A	_	_	B-Premise
193	similar	_	_	I-Premise
194	difference	_	_	I-Premise
195	was	_	_	I-Premise
196	seen	_	_	I-Premise
197	in	_	_	I-Premise
198	the	_	_	I-Premise
199	treating	_	_	I-Premise
200	physician	_	_	I-Premise
201	's	_	_	I-Premise
202	evaluation	_	_	I-Premise
203	of	_	_	I-Premise
204	whether	_	_	I-Premise
205	the	_	_	I-Premise
206	patient	_	_	I-Premise
207	was	_	_	I-Premise
208	subjectively	_	_	I-Premise
209	improved	_	_	I-Premise
210	or	_	_	I-Premise
211	continued	_	_	I-Premise
212	to	_	_	I-Premise
213	do	_	_	I-Premise
214	well	_	_	I-Premise
215	for	_	_	I-Premise
216	at	_	_	I-Premise
217	least	_	_	I-Premise
218	4	_	_	I-Premise
219	months	_	_	I-Premise
220	(	_	_	I-Premise
221	17/31	_	_	I-Premise
222	,	_	_	I-Premise
223	55	_	_	I-Premise
224	%	_	_	I-Premise
225	versus	_	_	I-Premise
226	6/30	_	_	I-Premise
227	,	_	_	I-Premise
228	20	_	_	I-Premise
229	%	_	_	I-Premise
230	,	_	_	I-Premise
231	P	_	_	I-Premise
232	<	_	_	I-Premise
233	0.01	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	Overall	_	_	B-Premise
237	survival	_	_	I-Premise
238	was	_	_	I-Premise
239	longer	_	_	I-Premise
240	in	_	_	I-Premise
241	the	_	_	I-Premise
242	chemotherapy	_	_	I-Premise
243	group	_	_	I-Premise
244	(	_	_	I-Premise
245	median	_	_	I-Premise
246	8	_	_	I-Premise
247	vs.	_	_	I-Premise
248	5	_	_	I-Premise
249	months	_	_	I-Premise
250	)	_	_	I-Premise
251	although	_	_	B-Premise
252	the	_	_	I-Premise
253	difference	_	_	I-Premise
254	was	_	_	I-Premise
255	not	_	_	I-Premise
256	statistically	_	_	I-Premise
257	significant	_	_	I-Premise
258	(	_	_	I-Premise
259	P	_	_	I-Premise
260	=	_	_	I-Premise
261	0.12	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	After	_	_	B-Premise
265	corrections	_	_	I-Premise
266	for	_	_	I-Premise
267	imbalances	_	_	I-Premise
268	in	_	_	I-Premise
269	pretreatment	_	_	I-Premise
270	characteristics	_	_	I-Premise
271	,	_	_	I-Premise
272	chemotherapy	_	_	I-Premise
273	treatment	_	_	I-Premise
274	was	_	_	I-Premise
275	,	_	_	I-Premise
276	however	_	_	I-Premise
277	,	_	_	I-Premise
278	associated	_	_	I-Premise
279	with	_	_	I-Premise
280	a	_	_	I-Premise
281	survival	_	_	I-Premise
282	benefit	_	_	I-Premise
283	(	_	_	I-Premise
284	P	_	_	I-Premise
285	=	_	_	I-Premise
286	0.003	_	_	I-Premise
287	)	_	_	I-Premise
288	.	_	_	I-Premise

289	Also	_	_	B-Premise
290	,	_	_	I-Premise
291	the	_	_	I-Premise
292	quality-adjusted	_	_	I-Premise
293	survival	_	_	I-Premise
294	time	_	_	I-Premise
295	and	_	_	I-Premise
296	time	_	_	I-Premise
297	to	_	_	I-Premise
298	disease	_	_	I-Premise
299	progression	_	_	I-Premise
300	were	_	_	I-Premise
301	longer	_	_	I-Premise
302	for	_	_	I-Premise
303	patients	_	_	I-Premise
304	randomized	_	_	I-Premise
305	to	_	_	I-Premise
306	chemotherapy	_	_	I-Premise
307	(	_	_	I-Premise
308	median	_	_	I-Premise
309	5	_	_	I-Premise
310	vs.	_	_	I-Premise
311	2	_	_	I-Premise
312	months	_	_	I-Premise
313	,	_	_	I-Premise
314	P	_	_	I-Premise
315	=	_	_	I-Premise
316	0.03	_	_	I-Premise
317	)	_	_	I-Premise
318	.	_	_	I-Premise

319	The	_	_	B-Claim
320	results	_	_	I-Claim
321	show	_	_	I-Claim
322	that	_	_	I-Claim
323	chemotherapy	_	_	I-Claim
324	can	_	_	I-Claim
325	add	_	_	I-Claim
326	to	_	_	I-Claim
327	both	_	_	I-Claim
328	quantity	_	_	I-Claim
329	and	_	_	I-Claim
330	quality	_	_	I-Claim
331	of	_	_	I-Claim
332	life	_	_	I-Claim
333	in	_	_	I-Claim
334	advanced	_	_	I-Claim
335	gastric	_	_	I-Claim
336	cancer	_	_	I-Claim
337	.	_	_	I-Claim

338	The	_	_	B-Claim
339	number	_	_	I-Claim
340	of	_	_	I-Claim
341	patients	_	_	I-Claim
342	who	_	_	I-Claim
343	benefit	_	_	I-Claim
344	from	_	_	I-Claim
345	treatment	_	_	I-Claim
346	is	_	_	I-Claim
347	,	_	_	I-Claim
348	however	_	_	I-Claim
349	,	_	_	I-Claim
350	still	_	_	I-Claim
351	rather	_	_	I-Claim
352	limited	_	_	I-Claim
353	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	whether	_	_	O
3	the	_	_	O
4	administration	_	_	O
5	of	_	_	O
6	recombinant	_	_	O
7	human	_	_	O
8	erythropoietin	_	_	O
9	(	_	_	O
10	r-HuEPO	_	_	O
11	)	_	_	O
12	would	_	_	O
13	increase	_	_	O
14	the	_	_	O
15	hematocrit	_	_	O
16	,	_	_	O
17	reduce	_	_	O
18	the	_	_	O
19	requirement	_	_	O
20	for	_	_	O
21	transfusion	_	_	O
22	,	_	_	O
23	and	_	_	O
24	improve	_	_	O
25	the	_	_	O
26	quality	_	_	O
27	of	_	_	O
28	life	_	_	O
29	in	_	_	O
30	anemic	_	_	O
31	cancer	_	_	O
32	patients	_	_	O
33	receiving	_	_	O
34	myelosuppressive	_	_	O
35	,	_	_	O
36	cisplatin-based	_	_	O
37	chemotherapy	_	_	O
38	.	_	_	O

39	One	_	_	O
40	hundred	_	_	O
41	thirty-two	_	_	O
42	anemic	_	_	O
43	cancer	_	_	O
44	patients	_	_	O
45	receiving	_	_	O
46	cyclic	_	_	O
47	,	_	_	O
48	cisplatin-containing	_	_	O
49	,	_	_	O
50	myelosuppressive	_	_	O
51	chemotherapy	_	_	O
52	were	_	_	O
53	evaluated	_	_	O
54	.	_	_	O

55	Patients	_	_	O
56	received	_	_	O
57	either	_	_	O
58	r-HuEPO	_	_	O
59	(	_	_	O
60	150	_	_	O
61	U/kg	_	_	O
62	)	_	_	O
63	or	_	_	O
64	placebo	_	_	O
65	,	_	_	O
66	subcutaneously	_	_	O
67	,	_	_	O
68	three	_	_	O
69	times	_	_	O
70	a	_	_	O
71	week	_	_	O
72	for	_	_	O
73	3	_	_	O
74	months	_	_	O
75	.	_	_	O

76	Responses	_	_	O
77	were	_	_	O
78	assessed	_	_	O
79	by	_	_	O
80	measuring	_	_	O
81	changes	_	_	O
82	in	_	_	O
83	hemoglobin/hematocrit	_	_	O
84	,	_	_	O
85	transfusion	_	_	O
86	requirement	_	_	O
87	,	_	_	O
88	and	_	_	O
89	quality	_	_	O
90	of	_	_	O
91	life	_	_	O
92	.	_	_	O

93	The	_	_	B-Premise
94	mean	_	_	I-Premise
95	hematocrit	_	_	I-Premise
96	increased	_	_	I-Premise
97	by	_	_	I-Premise
98	6.0	_	_	I-Premise
99	percentage	_	_	I-Premise
100	points	_	_	I-Premise
101	in	_	_	I-Premise
102	the	_	_	I-Premise
103	r-HuEPO	_	_	I-Premise
104	group	_	_	I-Premise
105	versus	_	_	I-Premise
106	1.3	_	_	I-Premise
107	in	_	_	I-Premise
108	the	_	_	I-Premise
109	placebo	_	_	I-Premise
110	group	_	_	I-Premise
111	.	_	_	I-Premise

112	A	_	_	B-Premise
113	decrease	_	_	I-Premise
114	in	_	_	I-Premise
115	transfusion	_	_	I-Premise
116	requirement	_	_	I-Premise
117	did	_	_	I-Premise
118	not	_	_	I-Premise
119	reach	_	_	I-Premise
120	significance	_	_	I-Premise
121	over	_	_	I-Premise
122	all	_	_	I-Premise
123	3	_	_	I-Premise
124	months	_	_	I-Premise
125	,	_	_	I-Premise
126	but	_	_	I-Premise
127	there	_	_	I-Premise
128	was	_	_	I-Premise
129	a	_	_	I-Premise
130	significant	_	_	I-Premise
131	reduction	_	_	I-Premise
132	in	_	_	I-Premise
133	the	_	_	I-Premise
134	percentage	_	_	I-Premise
135	of	_	_	I-Premise
136	patients	_	_	I-Premise
137	transfused	_	_	I-Premise
138	in	_	_	I-Premise
139	the	_	_	I-Premise
140	second	_	_	I-Premise
141	and	_	_	I-Premise
142	third	_	_	I-Premise
143	months	_	_	I-Premise
144	(	_	_	I-Premise
145	27	_	_	I-Premise
146	%	_	_	I-Premise
147	r-HuEPO	_	_	I-Premise
148	vs.	_	_	I-Premise
149	56	_	_	I-Premise
150	%	_	_	I-Premise
151	placebo	_	_	I-Premise
152	)	_	_	I-Premise
153	and	_	_	I-Premise
154	a	_	_	I-Premise
155	trend	_	_	I-Premise
156	toward	_	_	I-Premise
157	reduction	_	_	I-Premise
158	in	_	_	I-Premise
159	the	_	_	I-Premise
160	mean	_	_	I-Premise
161	total	_	_	I-Premise
162	number	_	_	I-Premise
163	of	_	_	I-Premise
164	units	_	_	I-Premise
165	transfused	_	_	I-Premise
166	(	_	_	I-Premise
167	1.20	_	_	I-Premise
168	units	_	_	I-Premise
169	r-HuEPO	_	_	I-Premise
170	vs.	_	_	I-Premise
171	2.02	_	_	I-Premise
172	units	_	_	I-Premise
173	placebo	_	_	I-Premise
174	)	_	_	I-Premise
175	,	_	_	I-Premise
176	suggesting	_	_	I-Premise
177	a	_	_	I-Premise
178	lag	_	_	I-Premise
179	of	_	_	I-Premise
180	1	_	_	I-Premise
181	month	_	_	I-Premise
182	before	_	_	I-Premise
183	r-HuEPO	_	_	I-Premise
184	can	_	_	I-Premise
185	affect	_	_	I-Premise
186	the	_	_	I-Premise
187	transfusion	_	_	I-Premise
188	requirement	_	_	I-Premise
189	.	_	_	I-Premise

190	Pretreatment	_	_	B-Premise
191	serum	_	_	I-Premise
192	erythropoietin	_	_	I-Premise
193	levels	_	_	I-Premise
194	were	_	_	I-Premise
195	lower	_	_	I-Premise
196	in	_	_	I-Premise
197	responders	_	_	I-Premise
198	than	_	_	I-Premise
199	in	_	_	I-Premise
200	nonresponders	_	_	I-Premise
201	(	_	_	I-Premise
202	73.5	_	_	I-Premise
203	IU/L	_	_	I-Premise
204	and	_	_	I-Premise
205	86.3	_	_	I-Premise
206	IU/L	_	_	I-Premise
207	means	_	_	I-Premise
208	,	_	_	I-Premise
209	respectively	_	_	I-Premise
210	)	_	_	I-Premise
211	.	_	_	I-Premise

212	However	_	_	B-Premise
213	,	_	_	I-Premise
214	the	_	_	I-Premise
215	magnitude	_	_	I-Premise
216	of	_	_	I-Premise
217	this	_	_	I-Premise
218	difference	_	_	I-Premise
219	was	_	_	I-Premise
220	not	_	_	I-Premise
221	helpful	_	_	I-Premise
222	in	_	_	I-Premise
223	defining	_	_	I-Premise
224	which	_	_	I-Premise
225	patients	_	_	I-Premise
226	were	_	_	I-Premise
227	likely	_	_	I-Premise
228	to	_	_	I-Premise
229	respond	_	_	I-Premise
230	.	_	_	I-Premise

231	There	_	_	B-Premise
232	was	_	_	I-Premise
233	a	_	_	I-Premise
234	significant	_	_	I-Premise
235	improvement	_	_	I-Premise
236	in	_	_	I-Premise
237	overall	_	_	I-Premise
238	quality	_	_	I-Premise
239	of	_	_	I-Premise
240	life	_	_	I-Premise
241	between	_	_	I-Premise
242	the	_	_	I-Premise
243	two	_	_	I-Premise
244	treatment	_	_	I-Premise
245	arms	_	_	I-Premise
246	in	_	_	I-Premise
247	favor	_	_	I-Premise
248	of	_	_	I-Premise
249	the	_	_	I-Premise
250	r-HuEPO-treated	_	_	I-Premise
251	group	_	_	I-Premise
252	.	_	_	I-Premise

253	There	_	_	B-Premise
254	were	_	_	I-Premise
255	no	_	_	I-Premise
256	significant	_	_	I-Premise
257	adverse	_	_	I-Premise
258	effects	_	_	I-Premise
259	associated	_	_	I-Premise
260	with	_	_	I-Premise
261	r-HuEPO	_	_	I-Premise
262	.	_	_	I-Premise

263	r-HuEPO	_	_	B-Claim
264	is	_	_	I-Claim
265	safe	_	_	I-Claim
266	and	_	_	I-Claim
267	can	_	_	I-Claim
268	cause	_	_	I-Claim
269	a	_	_	I-Claim
270	significant	_	_	I-Claim
271	improvement	_	_	I-Claim
272	in	_	_	I-Claim
273	the	_	_	I-Claim
274	hematocrit	_	_	I-Claim
275	and	_	_	I-Claim
276	quality	_	_	I-Claim
277	of	_	_	I-Claim
278	life	_	_	I-Claim
279	of	_	_	I-Claim
280	anemic	_	_	I-Claim
281	cancer	_	_	I-Claim
282	patients	_	_	I-Claim
283	receiving	_	_	I-Claim
284	myelosuppressive	_	_	I-Claim
285	,	_	_	I-Claim
286	cisplatin-based	_	_	I-Claim
287	chemotherapy	_	_	I-Claim
288	.	_	_	I-Claim

289	After	_	_	B-Claim
290	1	_	_	I-Claim
291	month	_	_	I-Claim
292	of	_	_	I-Claim
293	r-HuEPO	_	_	I-Claim
294	,	_	_	I-Claim
295	there	_	_	I-Claim
296	is	_	_	I-Claim
297	also	_	_	I-Claim
298	a	_	_	I-Claim
299	reduction	_	_	I-Claim
300	in	_	_	I-Claim
301	transfusion	_	_	I-Claim
302	requirement	_	_	I-Claim
303	.	_	_	I-Claim


0	The	_	_	O
1	effectiveness	_	_	O
2	of	_	_	O
3	a	_	_	O
4	Pain	_	_	O
5	Education	_	_	O
6	Program	_	_	O
7	in	_	_	O
8	cancer	_	_	O
9	patients	_	_	O
10	with	_	_	O
11	chronic	_	_	O
12	pain	_	_	O
13	offered	_	_	O
14	by	_	_	O
15	nurses	_	_	O
16	was	_	_	O
17	investigated	_	_	O
18	in	_	_	O
19	a	_	_	O
20	randomized	_	_	O
21	controlled	_	_	O
22	clinical	_	_	O
23	trial	_	_	O
24	.	_	_	O

25	A	_	_	O
26	multi-method	_	_	O
27	approach	_	_	O
28	was	_	_	O
29	used	_	_	O
30	in	_	_	O
31	which	_	_	O
32	verbal	_	_	O
33	instruction	_	_	O
34	,	_	_	O
35	written	_	_	O
36	material	_	_	O
37	,	_	_	O
38	an	_	_	O
39	audio	_	_	O
40	cassette	_	_	O
41	tape	_	_	O
42	,	_	_	O
43	and	_	_	O
44	the	_	_	O
45	use	_	_	O
46	of	_	_	O
47	a	_	_	O
48	pain	_	_	O
49	diary	_	_	O
50	were	_	_	O
51	combined	_	_	O
52	to	_	_	O
53	inform	_	_	O
54	and	_	_	O
55	instruct	_	_	O
56	patients	_	_	O
57	about	_	_	O
58	pain	_	_	O
59	and	_	_	O
60	pain	_	_	O
61	management	_	_	O
62	.	_	_	O

63	The	_	_	O
64	Pain	_	_	O
65	Education	_	_	O
66	Program	_	_	O
67	was	_	_	O
68	tailored	_	_	O
69	to	_	_	O
70	the	_	_	O
71	needs	_	_	O
72	of	_	_	O
73	the	_	_	O
74	individual	_	_	O
75	patient	_	_	O
76	and	_	_	O
77	consisted	_	_	O
78	of	_	_	O
79	three	_	_	O
80	elements	_	_	O
81	:	_	_	O
82	(	_	_	O
83	1	_	_	O
84	)	_	_	O
85	educating	_	_	O
86	patients	_	_	O
87	about	_	_	O
88	the	_	_	O
89	basic	_	_	O
90	principles	_	_	O
91	regarding	_	_	O
92	pain	_	_	O
93	and	_	_	O
94	pain	_	_	O
95	management	_	_	O
96	;	_	_	O
97	(	_	_	O
98	2	_	_	O
99	)	_	_	O
100	instructing	_	_	O
101	patients	_	_	O
102	how	_	_	O
103	to	_	_	O
104	report	_	_	O
105	their	_	_	O
106	pain	_	_	O
107	in	_	_	O
108	a	_	_	O
109	pain	_	_	O
110	diary	_	_	O
111	;	_	_	O
112	and	_	_	O
113	(	_	_	O
114	3	_	_	O
115	)	_	_	O
116	instructing	_	_	O
117	patients	_	_	O
118	how	_	_	O
119	to	_	_	O
120	communicate	_	_	O
121	about	_	_	O
122	pain	_	_	O
123	and	_	_	O
124	how	_	_	O
125	to	_	_	O
126	contact	_	_	O
127	health	_	_	O
128	care	_	_	O
129	providers	_	_	O
130	.	_	_	O

131	Following	_	_	O
132	pretesting	_	_	O
133	in	_	_	O
134	313	_	_	O
135	patients	_	_	O
136	,	_	_	O
137	patients	_	_	O
138	who	_	_	O
139	needed	_	_	O
140	district	_	_	O
141	nursing	_	_	O
142	and	_	_	O
143	who	_	_	O
144	did	_	_	O
145	not	_	_	O
146	need	_	_	O
147	district	_	_	O
148	nursing	_	_	O
149	at	_	_	O
150	home	_	_	O
151	were	_	_	O
152	randomly	_	_	O
153	assigned	_	_	O
154	to	_	_	O
155	a	_	_	O
156	control	_	_	O
157	or	_	_	O
158	intervention	_	_	O
159	group	_	_	O
160	.	_	_	O

161	Intervention	_	_	O
162	group	_	_	O
163	patients	_	_	O
164	received	_	_	O
165	the	_	_	O
166	Pain	_	_	O
167	Education	_	_	O
168	Program	_	_	O
169	in	_	_	O
170	the	_	_	O
171	hospital	_	_	O
172	,	_	_	O
173	and	_	_	O
174	3	_	_	O
175	and	_	_	O
176	7	_	_	O
177	days	_	_	O
178	postdischarge	_	_	O
179	by	_	_	O
180	telephone	_	_	O
181	;	_	_	O
182	this	_	_	O
183	was	_	_	O
184	done	_	_	O
185	by	_	_	O
186	nurses	_	_	O
187	who	_	_	O
188	were	_	_	O
189	specially	_	_	O
190	trained	_	_	O
191	as	_	_	O
192	pain	_	_	O
193	counselors	_	_	O
194	.	_	_	O

195	Follow-up	_	_	O
196	assessments	_	_	O
197	were	_	_	O
198	at	_	_	O
199	2	_	_	O
200	,	_	_	O
201	4	_	_	O
202	and	_	_	O
203	8	_	_	O
204	weeks	_	_	O
205	postdischarge	_	_	O
206	.	_	_	O

207	Results	_	_	O
208	of	_	_	O
209	the	_	_	O
210	pretest	_	_	O
211	showed	_	_	O
212	that	_	_	O
213	many	_	_	O
214	patients	_	_	O
215	lacked	_	_	O
216	knowledge	_	_	O
217	about	_	_	O
218	pain	_	_	O
219	and	_	_	O
220	pain	_	_	O
221	management	_	_	O
222	.	_	_	O

223	The	_	_	O
224	majority	_	_	O
225	of	_	_	O
226	pain	_	_	O
227	topics	_	_	O
228	had	_	_	O
229	to	_	_	O
230	be	_	_	O
231	discussed	_	_	O
232	.	_	_	O

233	The	_	_	B-Claim
234	Pain	_	_	I-Claim
235	Education	_	_	I-Claim
236	Program	_	_	I-Claim
237	proved	_	_	I-Claim
238	to	_	_	I-Claim
239	be	_	_	I-Claim
240	feasible	_	_	I-Claim
241	:	_	_	I-Claim
242	75.0	_	_	B-Premise
243	%	_	_	I-Premise
244	of	_	_	I-Premise
245	the	_	_	I-Premise
246	patients	_	_	I-Premise
247	had	_	_	I-Premise
248	read	_	_	I-Premise
249	the	_	_	I-Premise
250	entire	_	_	I-Premise
251	pain	_	_	I-Premise
252	brochure	_	_	I-Premise
253	,	_	_	I-Premise
254	55.7	_	_	I-Premise
255	%	_	_	I-Premise
256	had	_	_	I-Premise
257	listened	_	_	I-Premise
258	to	_	_	I-Premise
259	the	_	_	I-Premise
260	audio	_	_	I-Premise
261	cassette	_	_	I-Premise
262	,	_	_	I-Premise
263	and	_	_	I-Premise
264	85.6	_	_	I-Premise
265	%	_	_	I-Premise
266	of	_	_	I-Premise
267	pain	_	_	I-Premise
268	scores	_	_	I-Premise
269	were	_	_	I-Premise
270	completed	_	_	I-Premise
271	in	_	_	I-Premise
272	the	_	_	I-Premise
273	pain	_	_	I-Premise
274	diary	_	_	I-Premise
275	.	_	_	I-Premise

276	Results	_	_	B-Claim
277	showed	_	_	I-Claim
278	a	_	_	I-Claim
279	significant	_	_	I-Claim
280	increase	_	_	I-Claim
281	in	_	_	I-Claim
282	pain	_	_	I-Claim
283	knowledge	_	_	I-Claim
284	in	_	_	I-Claim
285	patients	_	_	I-Claim
286	who	_	_	I-Claim
287	received	_	_	I-Claim
288	the	_	_	I-Claim
289	Pain	_	_	I-Claim
290	Education	_	_	I-Claim
291	Program	_	_	I-Claim
292	and	_	_	I-Claim
293	a	_	_	I-Claim
294	significant	_	_	I-Claim
295	decrease	_	_	I-Claim
296	in	_	_	I-Claim
297	pain	_	_	I-Claim
298	intensity	_	_	I-Claim
299	.	_	_	I-Claim

300	However	_	_	B-Premise
301	,	_	_	I-Premise
302	pain	_	_	I-Premise
303	relief	_	_	I-Premise
304	was	_	_	I-Premise
305	mainly	_	_	I-Premise
306	found	_	_	I-Premise
307	in	_	_	I-Premise
308	the	_	_	I-Premise
309	intervention	_	_	I-Premise
310	group	_	_	I-Premise
311	patients	_	_	I-Premise
312	without	_	_	I-Premise
313	district	_	_	I-Premise
314	nursing	_	_	I-Premise
315	.	_	_	I-Premise

316	It	_	_	B-Claim
317	can	_	_	I-Claim
318	be	_	_	I-Claim
319	concluded	_	_	I-Claim
320	that	_	_	I-Claim
321	the	_	_	I-Claim
322	tailored	_	_	I-Claim
323	Pain	_	_	I-Claim
324	Education	_	_	I-Claim
325	Program	_	_	I-Claim
326	is	_	_	I-Claim
327	effective	_	_	I-Claim
328	for	_	_	I-Claim
329	cancer	_	_	I-Claim
330	patients	_	_	I-Claim
331	in	_	_	I-Claim
332	chronic	_	_	I-Claim
333	pain	_	_	I-Claim
334	.	_	_	I-Claim

335	The	_	_	B-Claim
336	use	_	_	I-Claim
337	of	_	_	I-Claim
338	the	_	_	I-Claim
339	Pain	_	_	I-Claim
340	Education	_	_	I-Claim
341	Program	_	_	I-Claim
342	by	_	_	I-Claim
343	nurses	_	_	I-Claim
344	should	_	_	I-Claim
345	be	_	_	I-Claim
346	seriously	_	_	I-Claim
347	considered	_	_	I-Claim
348	on	_	_	I-Claim
349	oncology	_	_	I-Claim
350	units	_	_	I-Claim
351	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	tolerability	_	_	O
6	of	_	_	O
7	'Casodex	_	_	O
8	'	_	_	O
9	monotherapy	_	_	O
10	(	_	_	O
11	150	_	_	O
12	mg	_	_	O
13	daily	_	_	O
14	)	_	_	O
15	for	_	_	O
16	metastatic	_	_	O
17	and	_	_	O
18	locally	_	_	O
19	advanced	_	_	O
20	prostate	_	_	O
21	cancer	_	_	O
22	.	_	_	O

23	A	_	_	O
24	total	_	_	O
25	of	_	_	O
26	1,453	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	either	_	_	O
30	confirmed	_	_	O
31	metastatic	_	_	O
32	disease	_	_	O
33	(	_	_	O
34	M1	_	_	O
35	)	_	_	O
36	,	_	_	O
37	or	_	_	O
38	T3/T4	_	_	O
39	non-metastatic	_	_	O
40	disease	_	_	O
41	with	_	_	O
42	elevated	_	_	O
43	prostate-specific	_	_	O
44	antigen	_	_	O
45	(	_	_	O
46	M0	_	_	O
47	)	_	_	O
48	were	_	_	O
49	recruited	_	_	O
50	into	_	_	O
51	one	_	_	O
52	of	_	_	O
53	two	_	_	O
54	identical	_	_	O
55	,	_	_	O
56	multicentre	_	_	O
57	,	_	_	O
58	randomised	_	_	O
59	studies	_	_	O
60	to	_	_	O
61	compare	_	_	O
62	'Casodex	_	_	O
63	'	_	_	O
64	150	_	_	O
65	mg/day	_	_	O
66	with	_	_	O
67	castration	_	_	O
68	.	_	_	O

69	The	_	_	O
70	protocols	_	_	O
71	allowed	_	_	O
72	for	_	_	O
73	combined	_	_	O
74	analysis	_	_	O
75	.	_	_	O

76	At	_	_	B-Premise
77	a	_	_	I-Premise
78	median	_	_	I-Premise
79	follow-up	_	_	I-Premise
80	period	_	_	I-Premise
81	of	_	_	I-Premise
82	approximately	_	_	I-Premise
83	100	_	_	I-Premise
84	weeks	_	_	I-Premise
85	for	_	_	I-Premise
86	both	_	_	I-Premise
87	studies	_	_	I-Premise
88	,	_	_	I-Premise
89	'Casodex	_	_	I-Premise
90	'	_	_	I-Premise
91	150	_	_	I-Premise
92	mg	_	_	I-Premise
93	was	_	_	I-Premise
94	found	_	_	I-Premise
95	to	_	_	I-Premise
96	be	_	_	I-Premise
97	less	_	_	I-Premise
98	effective	_	_	I-Premise
99	than	_	_	I-Premise
100	castration	_	_	I-Premise
101	in	_	_	I-Premise
102	patients	_	_	I-Premise
103	with	_	_	I-Premise
104	metastatic	_	_	I-Premise
105	disease	_	_	I-Premise
106	(	_	_	I-Premise
107	M1	_	_	I-Premise
108	)	_	_	I-Premise
109	at	_	_	I-Premise
110	entry	_	_	I-Premise
111	(	_	_	I-Premise
112	hazard	_	_	I-Premise
113	ratio	_	_	I-Premise
114	of	_	_	I-Premise
115	1.30	_	_	I-Premise
116	for	_	_	I-Premise
117	time	_	_	I-Premise
118	to	_	_	I-Premise
119	death	_	_	I-Premise
120	)	_	_	I-Premise
121	with	_	_	I-Premise
122	a	_	_	I-Premise
123	difference	_	_	I-Premise
124	in	_	_	I-Premise
125	median	_	_	I-Premise
126	survival	_	_	I-Premise
127	of	_	_	I-Premise
128	6	_	_	I-Premise
129	weeks	_	_	I-Premise
130	.	_	_	I-Premise

131	In	_	_	B-Premise
132	symptomatic	_	_	I-Premise
133	M1	_	_	I-Premise
134	patients	_	_	I-Premise
135	,	_	_	I-Premise
136	'Casodex	_	_	I-Premise
137	'	_	_	I-Premise
138	was	_	_	I-Premise
139	associated	_	_	I-Premise
140	with	_	_	I-Premise
141	a	_	_	I-Premise
142	statistically	_	_	I-Premise
143	significant	_	_	I-Premise
144	improvement	_	_	I-Premise
145	in	_	_	I-Premise
146	subjective	_	_	I-Premise
147	response	_	_	I-Premise
148	(	_	_	I-Premise
149	70	_	_	I-Premise
150	%	_	_	I-Premise
151	)	_	_	I-Premise
152	compared	_	_	I-Premise
153	with	_	_	I-Premise
154	castration	_	_	I-Premise
155	(	_	_	I-Premise
156	58	_	_	I-Premise
157	%	_	_	I-Premise
158	)	_	_	I-Premise
159	.	_	_	I-Premise

160	Analysis	_	_	B-Premise
161	of	_	_	I-Premise
162	a	_	_	I-Premise
163	validated	_	_	I-Premise
164	quality-of-life	_	_	I-Premise
165	questionnaire	_	_	I-Premise
166	proved	_	_	I-Premise
167	an	_	_	I-Premise
168	advantage	_	_	I-Premise
169	for	_	_	I-Premise
170	'Casodex	_	_	I-Premise
171	'	_	_	I-Premise
172	in	_	_	I-Premise
173	sexual	_	_	I-Premise
174	interest	_	_	I-Premise
175	and	_	_	I-Premise
176	physical	_	_	I-Premise
177	capacity	_	_	I-Premise
178	.	_	_	I-Premise

179	'Casodex	_	_	B-Premise
180	'	_	_	I-Premise
181	had	_	_	I-Premise
182	a	_	_	I-Premise
183	substantially	_	_	I-Premise
184	lower	_	_	I-Premise
185	incidence	_	_	I-Premise
186	of	_	_	I-Premise
187	hot	_	_	I-Premise
188	flushes	_	_	I-Premise
189	compared	_	_	I-Premise
190	to	_	_	I-Premise
191	castration	_	_	I-Premise
192	(	_	_	I-Premise
193	6-13	_	_	I-Premise
194	%	_	_	I-Premise
195	compared	_	_	I-Premise
196	with	_	_	I-Premise
197	39-44	_	_	I-Premise
198	%	_	_	I-Premise
199	)	_	_	I-Premise
200	and	_	_	I-Premise
201	the	_	_	I-Premise
202	most	_	_	I-Premise
203	commonly	_	_	I-Premise
204	reported	_	_	I-Premise
205	adverse	_	_	I-Premise
206	events	_	_	I-Premise
207	were	_	_	I-Premise
208	those	_	_	I-Premise
209	expected	_	_	I-Premise
210	for	_	_	I-Premise
211	a	_	_	I-Premise
212	potent	_	_	I-Premise
213	antiandrogen	_	_	I-Premise
214	.	_	_	I-Premise

215	However	_	_	O
216	,	_	_	O
217	in	_	_	B-Claim
218	patients	_	_	I-Claim
219	with	_	_	I-Claim
220	M0	_	_	I-Claim
221	disease	_	_	I-Claim
222	at	_	_	I-Claim
223	entry	_	_	I-Claim
224	,	_	_	I-Claim
225	the	_	_	I-Claim
226	data	_	_	I-Claim
227	are	_	_	I-Claim
228	still	_	_	I-Claim
229	immature	_	_	I-Claim
230	with	_	_	I-Claim
231	only	_	_	I-Claim
232	13	_	_	I-Claim
233	%	_	_	I-Claim
234	of	_	_	I-Claim
235	M0	_	_	I-Claim
236	patients	_	_	I-Claim
237	having	_	_	I-Claim
238	died	_	_	I-Claim
239	.	_	_	I-Claim

240	An	_	_	B-Claim
241	initial	_	_	I-Claim
242	analysis	_	_	I-Claim
243	of	_	_	I-Claim
244	this	_	_	I-Claim
245	immature	_	_	I-Claim
246	data	_	_	I-Claim
247	has	_	_	I-Claim
248	suggested	_	_	I-Claim
249	that	_	_	I-Claim
250	the	_	_	I-Claim
251	results	_	_	I-Claim
252	in	_	_	I-Claim
253	these	_	_	I-Claim
254	patients	_	_	I-Claim
255	may	_	_	I-Claim
256	be	_	_	I-Claim
257	different	_	_	I-Claim
258	to	_	_	I-Claim
259	those	_	_	I-Claim
260	obtained	_	_	I-Claim
261	in	_	_	I-Claim
262	patients	_	_	I-Claim
263	with	_	_	I-Claim
264	M1	_	_	I-Claim
265	disease	_	_	I-Claim
266	.	_	_	I-Claim

267	A	_	_	O
268	further	_	_	O
269	survival	_	_	O
270	analysis	_	_	O
271	in	_	_	O
272	patients	_	_	O
273	with	_	_	O
274	M0	_	_	O
275	disease	_	_	O
276	is	_	_	O
277	therefore	_	_	O
278	planned	_	_	O
279	when	_	_	O
280	the	_	_	O
281	data	_	_	O
282	are	_	_	O
283	more	_	_	O
284	mature	_	_	O
285	.	_	_	O

286	'Casodex	_	_	B-Claim
287	'	_	_	I-Claim
288	150	_	_	I-Claim
289	mg	_	_	I-Claim
290	is	_	_	I-Claim
291	less	_	_	I-Claim
292	effective	_	_	I-Claim
293	than	_	_	I-Claim
294	castration	_	_	I-Claim
295	in	_	_	I-Claim
296	patients	_	_	I-Claim
297	with	_	_	I-Claim
298	M1	_	_	I-Claim
299	disease	_	_	I-Claim
300	.	_	_	I-Claim

301	However	_	_	O
302	,	_	_	O
303	'Casodex	_	_	B-Claim
304	'	_	_	I-Claim
305	has	_	_	I-Claim
306	shown	_	_	I-Claim
307	a	_	_	I-Claim
308	benefit	_	_	I-Claim
309	in	_	_	I-Claim
310	terms	_	_	I-Claim
311	of	_	_	I-Claim
312	quality	_	_	I-Claim
313	of	_	_	I-Claim
314	life	_	_	I-Claim
315	and	_	_	I-Claim
316	subjective	_	_	I-Claim
317	response	_	_	I-Claim
318	when	_	_	I-Claim
319	compared	_	_	I-Claim
320	to	_	_	I-Claim
321	castration	_	_	I-Claim
322	and	_	_	I-Claim
323	has	_	_	I-Claim
324	an	_	_	I-Claim
325	acceptable	_	_	I-Claim
326	tolerability	_	_	I-Claim
327	profile	_	_	I-Claim
328	.	_	_	I-Claim

329	Thus	_	_	B-Claim
330	'Casodex	_	_	I-Claim
331	'	_	_	I-Claim
332	150	_	_	I-Claim
333	mg	_	_	I-Claim
334	monotherapy	_	_	I-Claim
335	is	_	_	I-Claim
336	an	_	_	I-Claim
337	option	_	_	I-Claim
338	for	_	_	I-Claim
339	patients	_	_	I-Claim
340	with	_	_	I-Claim
341	M1	_	_	I-Claim
342	prostate	_	_	I-Claim
343	cancer	_	_	I-Claim
344	for	_	_	I-Claim
345	whom	_	_	I-Claim
346	surgical	_	_	I-Claim
347	or	_	_	I-Claim
348	medical	_	_	I-Claim
349	castration	_	_	I-Claim
350	is	_	_	I-Claim
351	not	_	_	I-Claim
352	indicated	_	_	I-Claim
353	or	_	_	I-Claim
354	is	_	_	I-Claim
355	not	_	_	I-Claim
356	acceptable	_	_	I-Claim
357	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	the	_	_	O
4	present	_	_	O
5	trial	_	_	O
6	was	_	_	O
7	to	_	_	O
8	evaluate	_	_	O
9	the	_	_	O
10	effects	_	_	O
11	of	_	_	O
12	chemotherapy	_	_	O
13	on	_	_	O
14	the	_	_	O
15	quality	_	_	O
16	of	_	_	O
17	life	_	_	O
18	and	_	_	O
19	survival	_	_	O
20	of	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	advanced	_	_	O
24	non-small	_	_	O
25	cell	_	_	O
26	lung	_	_	O
27	cancer	_	_	O
28	(	_	_	O
29	NSCLC	_	_	O
30	)	_	_	O
31	(	_	_	O
32	stage	_	_	O
33	IIIB	_	_	O
34	or	_	_	O
35	IV	_	_	O
36	)	_	_	O
37	.	_	_	O

38	In	_	_	O
39	a	_	_	O
40	controlled	_	_	O
41	multicentre	_	_	O
42	trial	_	_	O
43	,	_	_	O
44	patients	_	_	O
45	were	_	_	O
46	randomised	_	_	O
47	to	_	_	O
48	receive	_	_	O
49	supportive	_	_	O
50	care	_	_	O
51	only	_	_	O
52	or	_	_	O
53	supportive	_	_	O
54	care	_	_	O
55	plus	_	_	O
56	chemotherapy	_	_	O
57	.	_	_	O

58	Chemotherapy	_	_	O
59	consisted	_	_	O
60	of	_	_	O
61	intravenous	_	_	O
62	(	_	_	O
63	i.v	_	_	O
64	.	_	_	O
65	)	_	_	O

66	carboplatin	_	_	O
67	300	_	_	O
68	mg/m2	_	_	O
69	on	_	_	O
70	day	_	_	O
71	1	_	_	O
72	and	_	_	O
73	etoposide	_	_	O
74	120	_	_	O
75	mg/m2	_	_	O
76	orally	_	_	O
77	on	_	_	O
78	days	_	_	O
79	1-5	_	_	O
80	every	_	_	O
81	4	_	_	O
82	weeks	_	_	O
83	for	_	_	O
84	a	_	_	O
85	maximum	_	_	O
86	of	_	_	O
87	eight	_	_	O
88	courses	_	_	O
89	.	_	_	O

90	Quality	_	_	O
91	of	_	_	O
92	life	_	_	O
93	was	_	_	O
94	measured	_	_	O
95	at	_	_	O
96	randomisation	_	_	O
97	and	_	_	O
98	prior	_	_	O
99	to	_	_	O
100	each	_	_	O
101	treatment	_	_	O
102	course	_	_	O
103	and	_	_	O
104	at	_	_	O
105	corresponding	_	_	O
106	4-week	_	_	O
107	intervals	_	_	O
108	in	_	_	O
109	the	_	_	O
110	control	_	_	O
111	arm	_	_	O
112	,	_	_	O
113	using	_	_	O
114	the	_	_	O
115	EORTC	_	_	O
116	QLQ-C30	_	_	O
117	+	_	_	O
118	LC13	_	_	O
119	questionnaire	_	_	O
120	.	_	_	O

121	48	_	_	O
122	patients	_	_	O
123	were	_	_	O
124	randomised	_	_	O
125	(	_	_	O
126	supportive	_	_	O
127	care	_	_	O
128	26	_	_	O
129	,	_	_	O
130	chemotherapy	_	_	O
131	22	_	_	O
132	)	_	_	O
133	,	_	_	O
134	being	_	_	O
135	eligible	_	_	O
136	for	_	_	O
137	comparative	_	_	O
138	analyses	_	_	O
139	.	_	_	O

140	Another	_	_	O
141	102	_	_	O
142	patients	_	_	O
143	,	_	_	O
144	97	_	_	O
145	of	_	_	O
146	which	_	_	O
147	received	_	_	O
148	chemotherapy	_	_	O
149	,	_	_	O
150	were	_	_	O
151	subsequently	_	_	O
152	included	_	_	O
153	in	_	_	O
154	the	_	_	O
155	study	_	_	O
156	on	_	_	O
157	an	_	_	O
158	individual	_	_	O
159	treatment	_	_	O
160	preference	_	_	O
161	basis	_	_	O
162	.	_	_	O

163	Data	_	_	O
164	from	_	_	O
165	these	_	_	O
166	patients	_	_	O
167	were	_	_	O
168	used	_	_	O
169	for	_	_	O
170	confirmative	_	_	O
171	purposes	_	_	O
172	.	_	_	O

173	Patients	_	_	B-Premise
174	in	_	_	I-Premise
175	the	_	_	I-Premise
176	chemotherapy	_	_	I-Premise
177	group	_	_	I-Premise
178	reported	_	_	I-Premise
179	better	_	_	I-Premise
180	overall	_	_	I-Premise
181	physical	_	_	I-Premise
182	functioning	_	_	I-Premise
183	and	_	_	I-Premise
184	symptom	_	_	I-Premise
185	control	_	_	I-Premise
186	compared	_	_	I-Premise
187	with	_	_	I-Premise
188	the	_	_	I-Premise
189	supportive	_	_	I-Premise
190	care	_	_	I-Premise
191	group	_	_	I-Premise
192	.	_	_	I-Premise

193	Group	_	_	B-Premise
194	differences	_	_	I-Premise
195	were	_	_	I-Premise
196	smaller	_	_	I-Premise
197	within	_	_	I-Premise
198	the	_	_	I-Premise
199	psychosocial	_	_	I-Premise
200	domain	_	_	I-Premise
201	,	_	_	I-Premise
202	although	_	_	B-Premise
203	trends	_	_	I-Premise
204	were	_	_	I-Premise
205	seen	_	_	I-Premise
206	in	_	_	I-Premise
207	favour	_	_	I-Premise
208	of	_	_	I-Premise
209	the	_	_	I-Premise
210	chemotherapy	_	_	I-Premise
211	group	_	_	I-Premise
212	.	_	_	I-Premise

213	No	_	_	B-Premise
214	significant	_	_	I-Premise
215	differences	_	_	I-Premise
216	were	_	_	I-Premise
217	seen	_	_	I-Premise
218	in	_	_	I-Premise
219	favour	_	_	I-Premise
220	of	_	_	I-Premise
221	the	_	_	I-Premise
222	supportive	_	_	I-Premise
223	care	_	_	I-Premise
224	group	_	_	I-Premise
225	,	_	_	I-Premise
226	except	_	_	B-Premise
227	for	_	_	I-Premise
228	hair	_	_	I-Premise
229	loss	_	_	I-Premise
230	.	_	_	I-Premise

231	Median	_	_	B-Premise
232	survival	_	_	I-Premise
233	times	_	_	I-Premise
234	were	_	_	I-Premise
235	29	_	_	I-Premise
236	weeks	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	chemotherapy	_	_	I-Premise
240	group	_	_	I-Premise
241	versus	_	_	I-Premise
242	11	_	_	I-Premise
243	weeks	_	_	I-Premise
244	in	_	_	I-Premise
245	the	_	_	I-Premise
246	supportive	_	_	I-Premise
247	care	_	_	I-Premise
248	group	_	_	I-Premise
249	,	_	_	I-Premise
250	and	_	_	I-Premise
251	1-year	_	_	I-Premise
252	survival	_	_	I-Premise
253	rates	_	_	I-Premise
254	were	_	_	I-Premise
255	28	_	_	I-Premise
256	%	_	_	I-Premise
257	versus	_	_	I-Premise
258	8	_	_	I-Premise
259	%	_	_	I-Premise
260	.	_	_	I-Premise

261	Quality	_	_	B-Premise
262	of	_	_	I-Premise
263	life	_	_	I-Premise
264	and	_	_	I-Premise
265	survival	_	_	I-Premise
266	outcomes	_	_	I-Premise
267	were	_	_	I-Premise
268	similar	_	_	I-Premise
269	in	_	_	I-Premise
270	the	_	_	I-Premise
271	randomised	_	_	I-Premise
272	and	_	_	I-Premise
273	non-randomised	_	_	I-Premise
274	patients	_	_	I-Premise
275	receiving	_	_	I-Premise
276	chemotherapy	_	_	I-Premise
277	.	_	_	I-Premise

278	No	_	_	B-Premise
279	treatment-related	_	_	I-Premise
280	deaths	_	_	I-Premise
281	occurred	_	_	I-Premise
282	.	_	_	I-Premise

283	In	_	_	B-Claim
284	conclusion	_	_	I-Claim
285	,	_	_	I-Claim
286	treatment	_	_	I-Claim
287	with	_	_	I-Claim
288	carboplatin	_	_	I-Claim
289	and	_	_	I-Claim
290	etoposide	_	_	I-Claim
291	can	_	_	I-Claim
292	improve	_	_	I-Claim
293	both	_	_	I-Claim
294	the	_	_	I-Claim
295	quality	_	_	I-Claim
296	of	_	_	I-Claim
297	life	_	_	I-Claim
298	and	_	_	I-Claim
299	the	_	_	I-Claim
300	survival	_	_	I-Claim
301	of	_	_	I-Claim
302	patients	_	_	I-Claim
303	with	_	_	I-Claim
304	advanced	_	_	I-Claim
305	NSCLC	_	_	I-Claim
306	.	_	_	I-Claim

